Plunkett's Biotech & Genetics Industry Almanac 2003-2004 (Plunkett's Biotech & Genetics Industry Almanac)

Customer Support Information Plunkett's Biotech & Genetics Industry Almanac 2003-2004 Please register your book immedia...

Author: Jack W. Plunkett

99 downloads 4210 Views 4MB Size Report

This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form

DOWNLOAD PDF

Customer Support Information Plunkett's Biotech & Genetics Industry Almanac 2003-2004 Please register your book immediately… if you did not purchase it directly from Plunkett Research, Ltd. This will enable us to fulfill your replacement request if you have a damaged product, or your requests for assistance. Also it will enable us to notify you of future editions, so that you may purchase them from the source of your choice.

If you are an actual purchaser but did not receive a FREE CD-ROM version with your book… you may request it by returning this form. ____ YES, please register me as a purchaser of the book. I did not buy it directly from Plunkett Research, Ltd. ____ YES, please send me a free CD-ROM version of the book. I am an actual purchaser, but I did not receive one with my book. (Proof of purchase may be required.) Customer Name ____________________________________________________ Title ______________________________________________________________ Organization _______________________________________________________ Address ___________________________________________________________ City_______________________________State________Zip_________________ Country (if other than USA) ___________________________________________ Phone_________________________Fax ________________________________ E-mail ____________________________________________________________

Mail or Fax to:

Plunkett Research, Ltd.

Attn: FREE CD-ROM and/or Registration P.O. Drawer 541737, Houston, TX 77254-1737 USA 713.932.0000 Fax 713.932.7080 www.plunkettresearch.com

PLUNKETT’S BIOTECH & GENETICS INDUSTRY ALMANAC 2003-2004 The Only Comprehensive Guide to Biotech Companies and Trends

Jack W. Plunkett Published by: Plunkett Research, Ltd., Houston, Texas www.plunkettresearch.com

PLUNKETT’S BIOTECH & GENETICS INDUSTRY ALMANAC 2003-2004 Editor and Publisher: Jack W. Plunkett Executive Editor and Database Manager: Martha Burgher Plunkett

Web Page Design: Darren Smith

Senior Editors and Researchers: Elisa Gabbert Ghazal Siddiqi

Cover Design: Kim Paxson, Just Graphics Junction, TX

Editors, Researchers and Assistants: Christie Manck Ray Marumahoko Mariya Paterwic Suzanne Zarosky

Special Thanks to: Burrill & Company San Francisco, CA Food and Drug Administration U.S. Dept. of Health and Human Services National Human Genome Research Institute U.S. National Institutes of Health Patent and Trademark Office U.S. Department of Commerce Pharmaceutical Research and Manufacturers of America Washington, D.C.

Information Technology Director: Alex Preskovsky E-Commerce Manager: Robert Daniel

Plunkett Research, Ltd. P. O. Drawer 541737, Houston, Texas 77254 USA Phone: 713.932.0000 Fax: 713.932.7080 www.plunkettresearch.com

Copyright  2003 by Plunkett Research, Ltd. All rights reserved. No part of this book may be reproduced or transmitted in any form by any means, electronic or mechanical, including by photocopying or by any information storage or retrieval system, without the written permission of the publisher.

Published by: Plunkett Research, Ltd. P. O. Drawer 541737 Houston, Texas 77254-1737 USA Phone: 713.932.0000 Fax: 713.932.7080 Internet: www.plunkettresearch.com ISBN # 1-891775-98-7 Disclaimer of liability for use and results of use: The editors and publishers assume no responsibility for your own success in making an investment or business decision, in seeking or keeping any job, in succeeding at any firm or in obtaining any amount or type of benefits or wages. Your own results and the job stability or financial stability of any company depend on influences outside of our control. All risks are assumed by the reader. Investigate any potential employer or business relationship carefully and carefully verify past and present finances, present business conditions and the level of compensation and benefits currently paid. Each company's details are taken from sources deemed reliable; however, their accuracy is not guaranteed. The editors and publishers assume no liability, beyond the actual payment received from a reader, for any direct, indirect, incidental or consequential, special or exemplary damages, and they do not guarantee, warrant nor make any representation regarding the use of this material. Trademarks or tradenames are used without symbols and only in a descriptive sense, and this use is not authorized by, associated with or sponsored by the trademarks’ owners. Ranks and ratings are presented as an introductory and general glance at corporations, based on our research and our knowledge of businesses and the industries in which they operate. The reader should use caution.

PLUNKETT'S BIOTECH & GENETICS INDUSTRY ALMANAC 2003-2004 CONTENTS A Short Biotech & Genetics Glossary Introduction How To Use This Book Chapter 1: Major Trends & Technologies Affecting the Biotech & Genetics Industry Chapter 2: Biotech & Genetics Industry Statistics Chapter 3: Biotech & Genetics Industry Contacts Addresses, Telephone Numbers and World Wide Web Sites Chapter 4: THE BIOTECH & GENETICS 400: Who They Are and How They Were Chosen Industry List, With Codes Index of Rankings Within Industry Groups (The Biotech & Genetics 400 grouped by industry and ranked for sales and profits) Alphabetical Index Index of Headquarters Location by State Index of Headquarters Location by Country Index by Regions Where the Biotech & Genetics 400 Have Locations Index by Firms With International Operations Individual Profiles on each of THE BIOTECH & GENETICS 400 Appendix: Biotech Research Techniques & Genetic Illustrations Additional Indexes Index of Hot Spots for Advancement for Women/Minorities Index of Subsidiaries, Brand Names and Selected Affiliations List of Major Tables and Charts Biotechnology Industry Profile, 2001: U.S., Europe and Canada Total R&D Investments by Research-Based Pharmaceutical Companies: 1970-2001 Domestic R&D as a Percentage of Sales, U.S. Research-Based Pharmaceutical Companies: 1970-2001 Annual Percent Change in U.S. Research & Development by Research-Based Pharmaceutical Companies: 1980-2001 U.S. Biotech Industry Financing, 2001 U.S. Biotech Industry Fundraising, 1996-Third Quarter 2002 Top 20 Global Biotech and Pharmaceutical Companies, 2001 Major Biotechnology Company Consolidations, 1st through 3rd Quarter 2002 The U.S. Drug Discovery, Development and Approval Process Total U.S. Biotechnology Patents Granted Per Year, 1985-2000 Continued on Next Page

i 1 3 7 25 41 53 54 55 64 67 71 72 78 81 477 498 500

26 27 28 29 30 31 32 33 34 35

Continued from Previous Page New U.S. Biotech Drug and Vaccine and Indication Approvals, 1982-2001 U.S. Drug Development Times U.S. FDA Approval Times for New Drugs, 1987-2001 Average Salaries in the U.S. Pharmaceutical and Biotechnology Industries: 2002 Global Agricultural Biotech At A Glance, 2001 List of Illustrations Andenovirus Amino Acid Antibody Base Pair Blastocyst Chromosome Cytogenetic Map DNA DNA Replication Enzyme Gene Microarray Technology Nucleotide Protein RNA

36 37 38 39 40

481 482 482 483 484 485 486 487 488 489 489 490 491 493 494


www,plunkettresearch.com

A Short Biotech & Genetics Industry Glossary 510 K: The application filed with the FDA for a new medical device to show that the apparatus is “substantially equivalent” to one that is already marketed. ADME: Absorption, Distribution, Metabolism and Excretion. In clinical trials, the bodily processes studied to determine the extent and duration of systemic exposure to a drug. AE (Adverse Event): In clinical trials, a condition not observed at baseline or worsened if present at baseline. Sometimes called Treatment Emergent Signs and Symptoms (TESS). Amino Acid: Any of a class of 20 molecules that combine to form proteins. ANDA (Abbreviated New Drug Application): An application filed with the FDA for a drug showing that the substance is the same as an existing, previously approved drug (i.e., a generic version). Angiogenesis: Blood vessel formation, typically in the growth of malignant tissue. Antibody: A protein produced by white blood cells in response to a foreign substance (see “Antigen”). Each antibody can bind only to one specific antigen. Antigen: A foreign substance that causes the immune system to create an antibody (see “Antibody”). Antisense Technology: The use of RNA-like oligonucleotides that bind to RNA and inhibit the expression of a gene. Apoptosis : A normal cellular process leading to the termination of a cell’s life. Applied Research: The application of compounds, processes, materials or other items discovered during “basic research” to practical uses. The goal is to move discoveries along to the final development phase. Array: An orderly arrangement, such as a rectangular matrix of data. In some laboratory

systems, such as microarrays, multiple detectors (probes) are positioned in an array in order to best do research. See “Microarray” below. Assay: A laboratory test to identify and/or measure the amount of a particular substance in a sample. Types of assays include: endpoint assay, in which a single measurement is made at a fixed time; kinetic assay, in which increasing amounts of a product are formed with time and are monitored at multiple points; microbiological assay, which is a measurement of the concentration of antimicrobials in biological material; and immunological assay, in which an analysis or measurement is based on antigen-antibody reactions. Baseline : A set of data used in clinical studies for control or comparison. Basic Research: Attempts to discover compounds, materials, processes or other items that may be largely or entirely new and/or unique. Basic research may start with a theoretical concept that has yet to be proven. The goal is to create discoveries that can be moved along to “applied research.” Basic research is sometimes referred to as “blue sky” research. Bioavailability: In pharmaceuticals, the rate and extent to which a drug is absorbed or is otherwise available to the treatment site in the body. Bioequivalence: In pharmaceuticals, the demonstration that a drug’s rate and extent of absorption are not significantly different from those of an existing drug that is already approved by the FDA. Bioinformatics: Computer-simulated generation and testing of new chemical compounds for possible drug use. This method is much faster and more costeffective than manual methods. Biologic: Any virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic or analogous product or arsphenamine or one of its derivatives (or any other trivalent organic arsenic compound) applicable to the prevention, treatment or cure of disease or injury. Biopharmaceuticals : That portion of the pharmaceutical industry focused on the use of biotechnology to create new drugs.

Copyright@2003 Plunkett Research, Ltd., All Rights Reserved



Biotechnology: A set of powerful tools that employ living organisms (or parts of organisms) to make or modify products, improve plants or animals (including humans) or develop microorganisms for specific uses. Early uses of biotechnology included traditional animal and plant breeding techniques and the use of yeast in making bread, beer, wine and cheese. Today, biotechnology is most commonly thought of to include the development of human medical therapies and processes using recombinant DNA, cell fusion, other genetic techniques and bioremediation. Blastocyst - A fertilized embryo, aged four to eleven days, which consists of multiplying cells both outside and inside a cavity. It is the blastocyst that embeds itself in the uterine wall and ultimately develops into a fetus. Blastocysts are utilized outside the womb during the process of stem cell cultivation. CANDA (Computer-Assisted New Drug Application): An electronic submission of a new drug application (NDA) to the FDA. CAPLA (Computer-Assisted Product License Application): An electronic submission of a biological product license application (PLA) to the FDA. CBER (Center for Biologics Evaluation and Research): The branch of the FDA responsible for the regulation of biological products, including blood, vaccines, therapeutics and related drugs and devices, to ensure purity, potency, safety, availability and effectiveness. www.fda.gov/cber CDER (Center for Drug Evaluation and Research): The branch of the FDA responsible for the regulation of drug products. www.fda.gov/cder CDRH (Center for Devices and Radiological Health): The branch of the FDA responsible for the regulation of medical devices. www.fda.gov/cdrh Chromosome : A structure that contains genes and is found in the nucleus of a cell. Chromosomes are found in pairs. Class I Device: An FDA classification of medical devices. General controls are sufficient to ensure safety and efficacy.

Class II Device : An FDA classification of medical devices. Performance standards and special controls are sufficient to ensure safety and efficacy. Class III Device: An FDA classification of medical devices. Pre-market approval is required to ensure safety and efficacy, unless the device is substantially equivalent to a currently marketed device. (See “510 K” above.) Clone : A group of identical genes, cells or organisms derived from one ancestor; an identical copy. “Dolly” the sheep is a famous case of cloning a replica of an animal. (Also see "Cloning-Reproductive" and "Cloning-Therapeutic.") Cloning-Reproductive: A method of reproducing an exact copy of an animal, or potentially an exact copy of a human being. A scientist removes the nucleus from a donor's unfertilized egg, inserts a nucleus from the animal to be copied and then stimulates the nucleus to begin dividing to form an embryo. In the case of a mammal, such as a human, the embryo would then be implanted in the uterus of a host female. Also see "Cloning-Therapeutic." Cloning-Therapeutic : A method of reproducing exact copies of cells needed for research or for the development of replacement tissue or organs. A scientist removes the nucleus from a donor's unfertilized egg, inserts a nucleus from the animal, or human, whose cells are to be copied and then stimulates the nucleus to begin dividing to form an embryo. However, the embryo is never allowed to grow to any significant stage of development. Instead, it is allowed to grow for a few hours or days and stem cells are then removed from it for use in regenerating tissue. Also see "CloningReproductive." Combinatorial Chemistry: After researchers determine which protein is involved in a specific disease, they use combinatorial chemistry to find the molecule that controls the protein. This advanced computer technique enables scientists to use automatic fluid handlers to mix chemicals under specific test condit ions at extremely high speed. Combinatorial chemistry can generate thousands of chemical compound variations in a few hours. Previously, traditional chemistry methods could have required several weeks to do the same work.




Complementary-DNA: cDNA, also called “copy DNA,” is a sequence acquired by copying a messenger RNA (mRNA) molecule back into DNA. In contrast to the original DNA, mRNA codes for an expressed protein without non-coding DNA sequences (“introns”). Therefore, a cDNA probe can also be used to find the specific gene in a complex DNA sample from another organism with different non-coding sequences. Coordinator: In clinical trials, the person at an investigative site who handles the administrative responsibilities of a clinical trial acts as a liaison between the investigative site and the sponsor and reviews data and records during a monitoring visit. CPMP (Committee on Proprietary Medicinal Products): A committee, composed of two people from each EU member state (see “EU” below) that is responsible for the scientific evaluation and assessment of marketing applications for medicinal products in the EU. The CPMP is the major body involved in the harmonization of pharmaceutical regulations within the EU and receives administrative support from the European Medicines Evaluation Agency. (See “EMEA” below.) CRA (Clinical Research Associate): An individual responsible for monitoring clinical trial data to ensure compliance with study protocol and FDA GCP regulations. CRF (Case Report Form): In clinic al trials, a standard document used by clinicians to record and report subject data pertinent to the study protocol. CRO (Contract Research Organization): An independent organization that contracts with a sponsor of a clinical investigation to conduct part of the work on a clinical study. Drug makers and medical device makers frequently outsource work to CROs. CRT (Case Report Tabulation): In clinical trials, a tabular listing of all data collected on study case report forms. Development: The phase of research and development in which researchers attempt to create new products from the results of discoveries and applications created during basic and applied research.

Device: In medical product development, according to the FDA, an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related article, including any component, part or accessory, that 1) is recognized in the official National Formulary or United States Pharmacopoeia or any supplement to them, 2) is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease, in man or animals or 3) is intended to affect the structure of the body of man or animals and does not achieve any of its principal intended purposes through chemical action within or on the body of man or animals and is not dependent upon being metabolized for the achievement of any of its principal intended purposes. Diagnostic Radioisotope Facility: In medicine, the use of radioactive isotopes (radiopharmaceuticals) as tracers or indicators to detect an abnormal condition or disease in the body. Distributor: Distributors do not manufacture but may be involved in sales, marketing, warehousing or shipping of drugs and/or medical devices. In medicine, distributors are subject to medical device incident reporting, record keeping, tracking and registration and certification requirements under the Safe Medical Devices Act (see “SMDA” below). DMB (Data Monitoring Board): A committee that monitors the progress of a clinical trial and carefully observes the safety data. DNA: (Deoxyribonucleic Acid): The carrier of the genetic information that cells need to replicate and to produce proteins. DNA Chip: The DNA microchip is a revolutionary tool used to identify mutations in genes like BRCA1 and BRCA2. The chip, which consists of a small glass plate encased in plastic, is manufactured using a process similar to the one used to make computer microchips. On the surface, each chip conta ins synthetic single stranded DNA sequences identical to a normal gene. Drug Utilization Review: A quantitative assessment of patient drug use and physicians’ patterns of prescribing drugs in an effort to determine the usefulness of drug therapy.




DSMB (Data and Safety Monitoring Board): See “DMB” above.

FD&C Act (Food, Drug and Cosmetic Act): The federal body of law that governs the manufacture, sale and distribution of food, drugs and cosmetics.

EC (European Community): See “EU” below. EFGCP (European Forum for Good Clinical Practices): The organization dedicated to finding common ground in Europe on the implementation of Good Clinical Practices. (See “GCP” below.) www.efgcp.org ELA (Establishment License Application): An ELA is required for the approval of a biologic (see “Biologic” above). It permits a specific facility to manufacture a biological product for commercial purposes. (Compare to “PLA” below.) EMEA (European Medicines Evaluation Agency): The European agency responsible for supervising and coordinating applications for marketing medicinal products in the European Union (see “EU” below and “CPMP” above). The EMEA is headquartered in the U.K. www.eudraportal.eudra.org Endpoint: A clinical or laboratory measurement used to assess safety, efficacy or other trial objectives of a test article in a clinical trial. Enzyme : A protein that acts as a catalyst, affecting the chemical reactions in cells. EST (Expressed Sequence Tags): Small pieces of DNA sequence (usually 200 to 500 nucleotides long) that are generated by sequencing either one or both ends of an expressed gene. The idea is to sequence bits of DNA that represent genes expressed in certain cells, tissues or organs from different organisms and use these tags to fish a gene out of a portion of chromosomal DNA by matching base pairs. (See "Gene Expression" below.)

FDA (Food and Drug Administration): The U.S. government agency responsible for the enforcement of the FD&C Act (see above), ensuring industry compliance with laws regulating products in commerce. The FDA’s mission is to protect the public from harm and encourage technological advances that hold the promise of benefiting society. www.fda.gov Follow-On: Refers to the offering of additional stock shares as a form of financing; typically occurs after a company has had an initial public offering (IPO). Functional Genomics: The process of attempting to convert the molecular information represented by DNA into an understanding of gene functions and effects. To address gene function and expression specifically, the recovery and identification of mutant and over-expressed phenotypes can be employed. Functional genomics also entails research on the protein function (“proteomics”) or, even more broadly, the whole metabolism (“metabolomics”) of an organism. Functional Proteomics: The study of the function of all of the proteins encoded by an organism's entire genome. GCP (Good Clinical Practices): FDA regulations and guidelines that define the responsibilities of the key figures involved in a clinical trial, including the sponsor, the investigator, the monitor and the Institutional Review Board. (See “IRB” below.) Gene: A working subunit of DNA; the carrier of inheritable traits.

Etiology: The study of diseases.

Gene Chips : See “DNA Chip” above.

EU (European Union): Previously known as the European Community (EC), the EU is a consolidation of different European countries (Member States) functioning as one body to facilitate trade. There are currently 15 member states: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, The Netherlands, Portugal, Spain, Sweden and the United Kingdom. http://erupa.eu.int

Gene Expression: The term used to describe the transcription of the information contained within the DNA (the repository of genetic information) into messenger RNA (mRNA) molecules that are then translated into the proteins that perform most of the critical functions of cells. Scientists study the kinds and amounts of mRNA produced by a cell to learn which genes are expressed, which in turn provides insights into how the cell responds to its changing needs.




Gene Knock-Out: The inhibition of gene expression through various scientific methods. Gene Therapy: Treatment based on the alteration of existing genes. (Also see “High Throughput Screening” below.) Genetic Code : The sequence of nucleotides, determining the sequence of amino acids in protein synthesis. Genetically Modified (GM): Bioengineered food that is designed to resist herbicides and pests, and has higher nutritional value than non-engineered food and/or lasts longer on the shelf. An example of GM food is a soybean that has been specially modified to be impervious to the application of a specific pesticide. Genetics : The study of the process of heredity. Genome : The genetic material (composed of DNA) in the chromosomes of a living organism. Genomics : The study of genes, their role in diseases and our ability to manipulate them. Genotype : The genetic constitution of an organism. GLP (Good Laboratory Practices): A collection of regulations and guidelines to be used in laboratories where research is conducted on drugs, biologics or devices that are intended for submission to the FDA. GMP (Good Manufacturing Practices): A collection of regulations and guidelines to be used in manufacturing drugs, biologics and medical devices. High Throughput Screening (HTP): HTP screening makes use of techniques that allow for a fast and simple test on the presence or absence of a desirable structure, such as a specific DNA sequence. HTP screening often uses DNA chips or microarrays and automated data processing for the large-scale screening, for instance to identify new targets for drug development. IDE (Investigational New Device Exemption): An IDE must be filed with the FDA prior to initiating clinical trials of medical devices considered to pose a significant risk to human subjects.

Imaging: In medicine, the viewing of the body’s organs through external, high-tech means. This reduces the need for broad, exploratory surgery. These advances, along with new types of surgical instruments, have made minimally invasive surgery possible. Imaging includes: MRI (Magnetic Resonance Imaging), CT (Computed Tomography or “CAT scan”) and MEG (magnetoencephalography), improved x-ray technology, mammography, ultrasound and angiography. Immunoassay: Types of immunological assays include agglutination, complement fixation, precipitation, immunodiffusion, and electrophoretic assays. Each type of assay utilizes either a particular type of antibody or a specific support medium (such as a gel) to determine the amount of antigen present. In Vitro: Laboratory experiments conducted in the test tube, or otherwise, without using live animals and/or humans. In Vivo: Laboratory experiments conducted with live animals and/or humans. IND (Investigational New Drug Exemption): An IND must be filed with the FDA prior to initiating clinical trials of drugs or biologics. Indication: Refers to a specific disease, illness or condition for which a drug is approved as a treatment. Typically, a new drug is first approved for one indication. Then, an application to the FDA is later made for approval of additional indications. Informatics: See "Bioinformatics" above. Informed Consent: Must be obtained in writing from people who agree to be clinical trial subjects prior to their enrollment in the study. The document must explain the risks associated with the study and treatment and describe alternative therapy available to the patient. A copy of the document must also be provided to the patient. Insertion Mutants : Mutants of genes that are obtained by inserting DNA, for instance through mobile DNA sequences. Furthermore, in plant research, the capacity of the bacterium Agrpbacterium to introduce DNA into the plant genome is employed to induce mutants. In both cases, mutations lead to lacking or changing gene functions that are revealed by aberrant phenotypes.




Insertion mutant isolation, and subsequent identification and analysis are employed in model plants such as Arabiopsis and in crop plants such as maize and rice. Interferon: A type of biological response modifier (a substance that can improve the body’s natural response to disease). Investigator: In clinical trials, clinicians who agree to supervise the use of an investigational drug, device or biologic in humans. Responsibilities of the investigator include administering the drug, observing and testing the patient, collecting data and the care and welfare of the patient. Responsibilities of the investigator are defined in FDA regulations. IRB (Institutional Review Board): This group of individuals is found in most medical institutions. The main function of the IRB is to review protocols for ethical consideration (to ensure the rights of the patients). Secondly, the IRB evaluates the benefit-torisk ratio of a new drug to see that the risk is acceptable for patient exposure. Responsibilities of the IRB are defined in FDA regulations. ISO 9000, 9001, 9002: Standards set by the International Organization for Standardization for quality procedures. ISO 9000, 9001 and 9002 are the quality certifications for manufacturing. Ligand: Any atom or molecule attached to a central atom in a complex compound. Mass Spectrometry: Usage of analytical devices that can determine the mass (or molecular weight) of proteins and nucleic acids, the sequence of protein molecules, the chemical organization of almost all substances and the identification of gram-negative and gram-positive microorganisms. Medical Device : See “Device” above. Metabolomics : The study of low molecular weight materials produced during genomic expression within a cell. Such studies can lead to a better understanding of how changes within genes and proteins affect the function of cells. Microarray: A Microarray analyzes fragments of genes called Expressed Sequence Tags (ESTs). Minuscule amounts of hundreds or thousands of these ESTs are sprayed onto a single microscope slide by a

robotic process within the microarray. Next the genetic messenger molecules, which signal the production of proteins, from a particular cell are labeled with fluorescent tags and allowed to hybridize, or bind, to the ESTs on the slide whose sequences are complementary to the those of the messengers. After a scanner measures the fluorescence of each sample on the slide, scientists can determine how active the genes represented by the ESTs are in the cell. Strong fluorescence indicates that many of the cell's messengers hybridized to the EST and, therefore, that the gene is very active in the cell. Conversely, no fluorescence indicates that none of the messenger molecules hybridized to the EST and that the gene is inactive in the cell. The results of microarrays lead to knowledge about the genetic makeup of a patient's tissues. For example, they can be used to analyze the genetic nature of a tumor. Monoclonal Antibodies: Substances that can locate and bind to cancer cells wherever they are in the body. Nanotechnology: The science of designing, building or utilizing unique structures that are smaller than 100 nanometers. (A nanometer is one billionth of a meter.) Nanotechnology involves microscopic structures that might be no larger than the width of some cell membranes. NDA (New Drug Application): An application requesting FDA approval, after completion of Phase III studies, to market a new drug for human use in interstate commerce. Clinical trial results generally account for approximately 80% of the NDA. NIH (National Institutes of He alth): A branch of the U.S. Public Health Service that conducts experimental research. www.nih.gov Nonclinical Studies: In vitro (laboratory) or in vivo (animal) pharmacology, toxicology and pharmacokinetic studies that support the testing of a product in humans. Usually at least two or more species are evaluated prior to Phase I clinical trials. Nonclinical studies continue throughout all phases of research to evaluate long-term safety issues. Nucleic Acid: A large molecule composed of nucleotides. Nutraceutical: Nutrient + pharmaceutical – a food or part of a food that has been isolated and sold in a




medicinal form and claims to offer benefits such as the treatment or prevention of disease. Nutrigenomics : The study of how food interacts with genes. Oncogene : A unit of DNA that normally directs cell growth, but which can also promote or allow the uncontrolled growth of cancer. Orphan Drug: A drug, biologic or antibiotic designated by the FDA as providing therapeutic benefit for an indication (disease or condition) affecting less than 200,000 people in the U.S. Companies that market orphan drugs are granted a period of market exclusivity in return for the limited commercial potential of the drug. OTC: (Over-the-Counter) Over-the-counter drug products are FDA-regulated products that do not require a physician’s prescription. Some examples include aspirin, sunscreen, nasal spray and sunglasses. Pharmacodynamics: The study of reactions between drugs and living systems. It can be thought of as the study of what a drug does to the body. Pharmacoeconomics : The study of the costs and benefits associated with various treatments. Pharmacogenetics : The investigation of the different reactions of human beings to drugs and the underlying genetic predispositions. The differences in reaction are mainly caused by mutations in certain enzymes responsible for drug metabolization. As a result, the degradation of the active substance can lead to harmful by-products, or the drug might have no effect at all. Pharmacogenomics: The use of the knowledge of the DNA sequences for the development of new drugs. Pharmacokinetics (PK): The study of the processes of bodily absorption, distribution, metabolism and excretion of compounds and medicines. It can be thought of as the study of what the body does to a drug. (See “ADME” above.) Phase I Clinical Trials: Studies in this phase include initial introduction of the investigational drug into humans. These studies are closely monitored and are usually conducted in healthy volunteers. Phase I trials

are conducted after the completion of extensive nonclinical or pre-clinical trials not involving humans. Phase I studies include the determination of clinical pharmacology, bioavailability, drug interactions and side effects associated with increasing doses of the drug. Phase II Clinical Trials: Phase II studies include randomized, masked, controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication(s). During Phase II trials, the minimum effective dose and dosing intervals should be determined. Phase III Clinical Trials : These studies consist of controlled and uncontrolled trials that are performed after preliminary evidence of effectiveness of the drug has been established. They are conducted to document the safety and efficacy of the drug, as well as to determine adequate directions (labeling) for use by the physician. A specific patient population needs to be clearly identified from the results of these studies. Trials during Phase III are conducted in a large number of patients to determine the frequency of adverse events and to obtain data regarding intolerance. Phase IV Clinical Trials : These studies are conducted after approval of the drug has been obtained to gather data supporting new or revised labeling, marketing or advertising claims. Phenomics : The study of how an organism's structure responds to such things as toxins or drugs. Phenotype : Observable characteristics of an organism produced by the organism’s genotype interacting with the environment. Phylogenetic Systematics : The field of biology that deals with identifying and understanding the evolutionary relationships among the many different kinds of life on earth, both living (extant) and dead (extinct). PIPE: Private Investment, Public Equity. A type of financing whereby a private investor or mutual fund buys common stock for a company at a discount to the current market value per share. Pivotal Studies: In clinical trials, a Phase III trial that is designed specifically to support approval of a product. These studies are well controlled (usually by




placebo) and are generally designed with input from the FDA so that they will provide data that is adequate to support approval of the product. Two pivotal studies are required for drug product approval, but usually only one study is required for biologics.

For example, a sheet of paper can stop an alpha particle, a beta particle can penetrate tissues in the body and a gamma ray can penetrate concrete. The varying penetration capabilities allow radioisotopes to be used in different ways. (Also called radioactive isotope or radionuclide.)

PLA (Product License Agreement): Required for the approval of a biologic, a PLA permits a manufacturer to produce a biological product for commercial purposes. (Compare to “ELA” above).

Receptor: Proteins in or on a cell that selectively bind a specific substance called a ligand. (See “Ligand” above.)

Platform or Technology Platform Companies: Firms hoping to profit by providing information systems, software, databases and related support to biopharmaceutical companies. PMA (Pre -Market Approval): PMA is required for the approval of a new medical device or a device that is to be used for life-sustaining or life-supporting purposes, is implanted in the human body or presents potential risk of illness or injury. Positional Cloning : The identification and cloning of a specific gene, with chromosomal location as the only source of information about the gene. Post-Marketing Surveillance : The FDA’s ongoing safety monitoring of marketed drugs. Preclinical Studies: See “Nonclinical Studies” above. Protein: A large, complex molecule made up of amino acids. Proteome : The genetic material (composed of amino acids) in the chromosomes of a living organism. Proteomics : The study of gene expression at the protein level, by the identification and characterization of proteins present in a biological sample. QOL (Quality of Life): In medicine, an endpoint of therapeutic assessment used to adjust measures of effectiveness for clinical decision-making. Typically, QOL endpoints measure the improvement of a patient’s day-to-day living as a result of specific therapy. Radioisotope : Radioisotopes have varying properties that allow them to penetrate objects at different rates.

Recombination: The natural process of breaking and rejoining DNA strands to produce new combinations of genes. Reporter Gene : A gene that is inserted into DNA by researchers in order to indicate when a linked gene is successfully expressed or when signal transduction has taken place in a cell. RNA (ribonucleic acid): A macromolecule found in the nucleus and cytoplasm of cells; vital in protein synthesis. Single Nucleotide Polymorphisms: (SNPs) The most common type of genetic variation. SNPs are stable mutations consisting of a change at a single base in a DNA molecule. SNPs can be detected by HTP analyses, for instance with gene chips, and they are then mapped by DNA sequencing. SMDA (Safe Medical Devices Act): This Act became law in 1990 and amends the Food, Drug and Cosmetic Act to impose additional regulations on medical devices. SNP: See “Single -Nucleotide Polymorphism” above. Sponsor: The individual or company that assumes responsibility for the investigation of a new drug, including compliance with the FD&C Act and regulations. The sponsor may be an individual, partnership, corporation or governmental agency and may be a manufacturer, scientific institution or investigator regularly and lawfully engaged in the investigation of new drugs. The sponsor assumes most of the legal and financial responsibility of the clinical trial. Stem Cells: Found in human bone marrow, the blood stream and the umbilical cord, stem cells can be replicated indefinitely and can turn into any type of mature blood cell, including platelets, white blood




cells or red blood cells. Also referred to as pluripotent cells. Study Coordinator: See “Coordinator” above. Summary Plan Description: A description of an employee's entire benefit package as required by selffunded plans. Systems Biology: The use of combinations of advanced computer hardware, software and database technologies to take a systemic approach to biological research. Advanced technologies will enable scientists to view genetic predisposition by integrating information about entire biological systems, from DNA to proteins to cells to tissues. T Cell: White blood cell that carries out immune system responses. Target: The proteins involved in a specific disease. Drug compounds stick to specific targets in order to have the greatest positive effect and cut down on the incidence of side effects. Taste Masking: The creation of a barrier between a drug molecule and taste receptors so the drug is easier to take. It masks bitter or unpleasant tastes. TESS: See “AE” above. Toxicogenomics: The study of the relationship between responses to toxic substances and the resulting genetic changes. Trial Coordinator: See “Coordinator” above. Validation of Data: The procedure carried out to ensure that the data contained in a final clinical trial report match the original observations. WHO (World Health Organization): Assists governments in strengthening health services, furnishing technical assistance and aid in emergencies, working on the prevention and control of epidemics and promoting cooperation among different countries to improve nutrition, housing, sanitation, recreation and other aspects of environmental hygiene. Any country that is a member of the United Nations may become a member of the WHO by accepting its constitution. The WHO currently has 191 member states. www.who.int Copyright@2003 Plunkett Research, Ltd., All Rights Reserved



INTRODUCTION

PLUNKETT'S BIOTECH & GENETICS INDUSTRY ALMANAC 2003-2004, the second edition of our guide to the biotech and genetics field, is designed as a general source for researchers of all types. The data and areas of interest covered are intentionally broad, ranging from the costs and effectiveness of biotech and genetics engineering and research, to emerging technology, to an in-depth look at the 400 major firms (which we call “THE BIOTECH & GENETICS 400”) within the many sectors that make up the biotech and genetics industry. This reference book is designed to be a general source for researchers. It is especially intended to assist with market research, strategic planning, employment searches, contact or prospect list creation (be sure to see the export capabilities of the accompanying CD-ROM that is available to book and eBook buyers) and financial research, and as a data resource for executives and students of all types. PLUNKETT'S BIOTECH & GENETICS INDUSTRY ALMANAC takes a more rounded approach for the general reader. This book presents a complete overview of the biotech and genetics field (see “How To Use This Book”). For example, stem cells and tissue engineering are discussed, as well as the recent overall drop in biotech financing, the

outlook for manufacturers of related drugs and medical products within the scope of the industry. THE BIOTECH & GENETICS 400 is our unique grouping of the biggest, most successful corporations in all segments of the biotech and genetics industry. Tens of thousands of pieces of information, gathered from a wide variety of sources, have been researched and are presented in a unique form that can be easily understood. This section includes thorough indexes to THE BIOTECH & GENETICS 400, by geography, industry, sales, brand names, subsidiary names and many other topics. (See Chapter 4.) Especially helpful is the way in which PLUNKETT’S BIOTECH & GENETICS INDUSTRY ALMANAC enables readers who have no business background to readily compare the financial records and growth plans of biotech and genetics companies and major industry groups. You’ll see the mid-term financial record of each firm, along with the impact of earnings, sale s and strategic plans on each company’s potential to fuel growth, to create new technologies and to provide lucrative and lasting investment and employment opportunities. No other source provides this book’s easy-tounderstand discussions of growth, expenditures, technologies, corporations, research and many other items of great importance. The information within is crucial to people of all types who may be studying

Copyright©2003 Plunkett Research, Ltd., All Rights Reserved



this, one of the newest, most dynamic and most exciting industries in the world today.

•

This volume is intended to be a general guide to a quickly growing industry. That means that researchers should look to this book for an overview and, when conducting in-depth research, should contact the specific corporations or industry associations in question for the very latest changes and data. Where possible, we have listed contact names, toll-free telephone numbers and World Wide Web site addresses for the companies, government agencies and industry associations involved so that the reader may get further details without unnecessary delay.

•

Tables of industry data and statistics used in this book include the latest numbers available at the time of printing, generally through the end of 2001 or 2002.

•

We have used exhaustive efforts to locate and fairly present accurate and complete data. However, when using this book or any other source for business and industry information, the reader should use caution and diligence by conducting further research where it seems appropriate. We wish you success in your endeavors, and we trust that your experience with this book will be both satisfactory and productive.

By scanning the data groups and the unique indexes, you can find the best information to fit your personal research needs. The best major growth companies in biotech and genetics are profiled and then ranked using several different groups of specific criteria . Which firms are the biggest employers? Which biotech and genetics companies earn the most profits? These things and much more are easy to find. In addition to individual company profiles, an overview of biotech and genetic technology and its trends is provided. This book’s job is to help you sort through easy-to-understand summaries of today’s technologies, pharmaceuticals and trends in a quick and effective manner. Whatever your purpose for researching the biotech and genetics field, you’ll find this book to be a valuable guide. Nonetheless, as is true with all resources, this volume has limitations that the reader should be aware of: •

Financial data and other corporate information can change quickly. A book of this type can be no more current than the data that was available as of the time of editing. Consequently, the financial picture, management and ownership of the firm(s) you are studying may have changed since the date of this book. For example, this almanac includes the most up-to-date sales figures and profits available to the editors as of late 2002. That means that we have typically used corporate financial data as of mid-2002.

•

Corporate mergers, acquisitions and downsizing are occurring at a very rapid rate. Such events may have created significant change, subsequent to the publishing of this book, within a company you are studying.

•

Some of the companies in THE BIOTECH & GENETICS 400 are so large in scope and in variety of business endeavors conducted within a parent organization that we have been unable to completely list all subsidiaries, affiliations, divisions and activities within a firm’s corporate structure.

Jack W. Plunkett Houston, Texas January 2003




HOW TO USE THIS BOOK

The two primary sections of this book are devoted first to the biotech and genetics industry as a whole and then to the “Individual Data Listings” for THE BIOTECH & GENETICS 400. If time permits, you should begin your research in the front chapters of this book. Also, you will find lengthy indexes in Chapter 4 and in the back of the book. THE BIOTECH & GENETICS INDUSTRY Glossary: A short list of biotech and genetic industry terms. Chapter 1: Major Trends and Technologies Affecting the Biotech & Genetics Industry. This chapter presents an encapsulated view of the major trends that are creating rapid changes in the biotech and genetics industry today. These trends include the use by bioinformatics experts of vast genetics databases, systems biology, stem cell controversies and new developments at the FDA.

Chapter 2: Biotech & Genetics Statistics. This chapter contains charts and tables tracking the industry’s statistics. Chapter 3: Important Biotech & Genetics Industry Contacts – Addresses, Telephone Numbers and World Wide Web Sites. This chapter covers contacts for important government agencies and industry associations. Included are numerous web site addresses. Appendix: Biotech Research Techniques & Genetic Illustrations. This chapter in the back of this book presents in-depth information on the groundbreaking research performed over the past several years, including the different methods of studying DNA. This chapter also contains simple, easily understood illustrations of the complex biotech and genetic models currently under study. These models include human chromosomes, DNA chains, amino acids and RNA, to name a few.




THE BIOTECH & GENETICS 400 Chapter 4: THE BIOTECH & GENETICS 400: Who They Are and How They Were Chosen. The companies compared in this book were carefully selected from the biotech and genetics industry, primarily in the United States with 48 major foreign firms also included. For a complete description, see THE BIOTECH & GENETICS 400 indexes in this chapter. Individual Data Listings: Look at one of the companies in THE BIOTECH & GENETICS 400’s Individual Data Listings. You’ll find the following information fields: Company Name: The company profiles are in alphabetical order by company name. If you don’t find the company you are looking for, it may be a subsidiary or division of one of the firms covered in this book. Try looking it up in the Index by Subsidiaries, Brand Names and Selected Affiliations in the back of the book. Ranks: Industry Group Code: An NAIC code used to group companies within like segments. (See Chapter 4 for a list of codes.) Ranks Within This Company’s Industry Group: Ranks, within this firm’s segment only, for annual sales and annual profits, with 1 being the highest rank. Business Activities: A grid arranged into five major industry categories and several sub-categories. A “Y” indicates that the firm operates within that sub-category. A complete Index by Industry is included in the beginning of Chapter 4. Types of Business: A listing of the primary types of business specialties conducted by the firm. Brands/Divisions/Affiliations: Major brand names, operating divisions or subsidiaries of the firm, as well as major corporate affiliations—such as another firm that owns a significant portion of the stock. A complete Index of Subsidiaries, Brand Names and Selected Affiliations is in the back of the book. Contacts: The names and titles up to 27 top officers of the company are listed, including human resources contacts.

Address: The firm’s full headquarters address and telephone number, plus toll-free and fax numbers where available. Also provided are web site addresses. Financials: Annual Sales (2002 or the latest fiscal year available to the editors, plus up to four previous years): These are stated in thousands of dollars (add three zeros if you want the full number). This figure represents consolidated worldwide sales from all operations. 2002 figures may be estimates or may be for only part of the year—partial year figures will be appropriately footnoted. Annual Profits (2002 or the latest fiscal year available to the editors, plus up to four previous years): These are stated in thousands of dollars (add three zeros if you want the full number). This figure represents consolidated, after-tax net profit from all operations. 2002 figures may be estimates or may be for only part of the year—partial year figures will be appropriately footnoted. Total Number of Employees: The approximate total number of employees, worldwide, as of 2002 (or the latest data available to the editors). Apparent Salaries/Benefits: A “Y” in appropriate fields indicates “Yes.” Due to wide variations in the manner in which corporations report benefits to the U.S. Government’s regulatory bodies, not all plans will have been uncovered during our effort to research this data. Also, the availability of such plans to employees will vary according to the qualifications that employees must meet to become eligible. For example, some benefit plans may be available only to salaried workers—others only to employees who work more than 1,000 hours yearly. Benefits that are available to employees of the main or parent company may not be available to employees of the subsidiaries. NOTE: Generally, employees covered by wealthbuilding benefit plans do not fully own (“vest in”) funds contributed on their behalf by the employer until as many as five years of service with that employer have passed. Pension Plan: The firm offers a pension plan to qualified employees. The type and generosity of these plans vary widely from firm to firm. Caution: Some employers refer to plans as “pension” or “retirement” plans when they are actually 401(k) savings plans that require a contribution by the employee. True pension plans are rarely offered. ESOP Stock Plan (Employees’ Stock Ownership Plan): This type of plan is in wide use. Typically, the




plan borrows money from a bank and uses those funds to purchase a large block of the corporation’s stock. The corporation makes contributions to the plan over a period of time, and the stock purchase loan is eventually paid off. The value of the plan grows significantly as long as the market price of the stock holds up. Qualified employees are allocated a share of the plan based on their length of service and their level of salary. Savings Plan, 401(k): Under this type of plan, employees make a tax-deferred deposit into an account. In the best plans, the company makes annual matching donations to the employees’ accounts, typically in some proportion to deposits made by the employees themselves. A good plan will match onehalf of employee deposits of up to 6% of wages. For example, an employee earning $30,000 yearly might deposit $1,800 (6%) into the plan. The company will match one-half of the employee’s deposit, or $900. The plan grows on a tax-deferred basis, similar to an IRA. A very generous plan will match 100% of employee deposits. However, some plans do not call for the employer to make a matching deposit at all. Other plans call for a matching contribution to be made at the discretion of the firm’s board of directors. Actual terms of these plans vary widely from firm to firm. Generally, these savings plans allow employees to deposit as much as 15% of salary into the plan on a tax-deferred basis. However, the portion that the company uses to calculate its matching deposit is generally limited to a maximum of 6%. Stock Purchase Plan: Qualified employees may purchase the company’s common stock at a price below its market value under a specific plan. Typically, the employee is limited to investing a small percentage of wages in this plan. These pla ns usually offer a 15% discount, but the discount may range from 5 to 15%. Some of these plans allow for deposits to be made through regular monthly payroll deductions. Profit Sharing: Qualified employees are awarded an annual amount equal to some portion of a company’s profits. In a very generous plan, the pool of money awarded to employees would be 15% of profits. Typically, this money is deposited into a long-term retirement account. Caution: Some employers refer to plans as “profit sharing” when they are actually 401(k) savings plans. True profit sharing plans are rarely offered. Highest Executive Salary: The highest executive salary paid, typically a 2001 amount (or the latest

year available to the editors) and typically paid to the Chief Executive Officer. Highest Executive Bonus: The apparent bonus, if any, paid to the above person. Second Highest Executive Salary: The nexthighest executive salary paid, typically a 2001 amount (or the latest year available to the editors) and typically paid to the President or Chief Operating Officer. Second Highest Executive Bonus: The apparent bonus, if any, paid to the above person. Competitive Advantage: A brief statement regarding an outstanding feature that gives the firm an edge in the marketplace. Other Thoughts: Stock Ticker: When available, the unique stock market symbol used to identify this firm’s common stock for trading and tracking purposes. Apparent Women Officers or Directors: It is difficult to obtain this information on an exact basis, and employers generally do not disclose the data in a public way. However, we have indicated what our best efforts reveal to be the apparent number of women who either are in the posts of corporate officers or sit on the board of directors. There is a wide variance from company to company. Hot Spot for Advancement for Women/ Minorities: A “Y” in appropriate fields indicates “Yes.” These are firms that either have posted a far aboveaverage number of women and/or minorities to high posts or that have a good record of going out of their way to recruit, train, promote and retain women or minorities. (See the Index of Hot Spots For Women and Minorities in the back of the book.) Growth Plans/ Special Features: Listed here are observations regarding the firm’s strategy, hiring plans, plans for growth and product development, along with general information regarding a company’s business and prospects. Locations: A “Y” in the appropriate field indicates “Yes.” Primary locations outside of the headquarters, categorized by regions of the United States and by international locations. A complete index by locations is also in the front of this chapter.







Chapter 1 MAJOR TRENDS AND TECHNOLOGIES AFFECTING THE BIOTECH & GENETICS INDUSTRY Trends Affecting the Biotechnology and Genetics Industry: 1) Investors lose patience while financing declines and biotech stocks plummet. 2) Profits are elusive and many startups are out of cash. Meanwhile, mature global drug companies lose market share to generics as blockbuster patents expire. 3) Slow approval processing, new leadership and restructuring at the FDA. 4) Dozens of new drugs that initially seemed promising lead to vast disappointments when they fail in Phase II or III trials. 5) The field of Molecular Diagnostics leaps ahead. 6) A new era of regenerative medicine begins. 7) Biosecurity receives new attention and immense funding. 8) A personalized approach to medicine gains traction.

9) Systems biology will lead to faster, more costeffective drug development. 10) Total cost of patients’ pharmaceuticals soars in the U.S. and leads to calls for price controls and government aid for seniors. 11) Stem cell and cloning controversies abound in the U.S. while research in these fields flourishes overseas. 12) Cloning techniques advance, especially for therapeutic uses. 13) Nanotechnology (the creation of very tiny devices) and information technologies converge with biotechnology. 14) Partnerships and collaboration among biotech startups, major drug manufacturers and the research departments at major universities are at an all-time high. 15) Agricultural biotechnology has scored tremendous breakthroughs, but genetically engineered foods cause great controversy and are snubbed by European nations.




The State of the Industry in 2003-2004: Despite exponential advances in biopharmaceutical knowledge and technology, companies enduring the task of getting new drugs to market continue to face long timeframes, daunting costs and immense risks. Although the number of new drug applications submitted to the FDA tripled from 1996 through 2001, the number of new drugs receiving final approval remains small. Of every 1,000 experimental drug compounds in some form of preclinical testing, only one actually makes it to clinical trials. Then, only one in five of those drugs makes it to market. The amount of time required to develop a new drug and get it to market has not lessened, and development costs continue to rise rapidly for biopharmaceutical firms. According to the Tufts Center for the Study of Drug Development at Tufts University, the cost of developing a new drug and getting it to market now averages $802 million, up from about $500 million in 1996. (Averaged into these figures are the costs of developing and testing drugs that never reach the market.) The average time elapsed from the synthesis of a new chemical compound to its introduction to the market remains 12 to 14 years—the same timeframe that drug makers have dealt with for the past decade. As a result of these costs and the lengthy time-to-market, young biotech companies face a harsh financial reality: commercial profits take years and years to emerge from promising beginnings in the laboratory. However, advances in systems biology (the use of a combination of state-of-the-art technologies, such as molecular diagnostics, advanced computers and extremely deep, efficient genetic databases) will eventually lead to more efficient, faster drug development at reduced costs. Much of this advance will stem from the use of technology to efficiently target the genetic causes of and develop novel cures for niche diseases. For example, in May 2001 the FDA gave approval for Novartis’ new drug Gleevec (a revolutionary and highly effective treatment for patients suffering from chronic myeloid leukemia) after an astonishingly brief two and one-half months in the approval process had passed (compared to a more typical six years). This fast track approval, which promptly began saving lives, was possible because of two factors in addition to the FDA’s cooperation: 1) Novartis mounted a targeted approach to this niche disease. Its research determined that a specific

genetic malfunction causes the disease, and its drug specifically blocks the protein that causes the genetic malfunction. 2) Thanks to its use of advanced genetic research techniques, Novartis was so convinced of the effectiveness of this drug that it invested heavily and quickly in its development. Internet Research Tip: For extensive commentary and analysis on the true costs of developing new drugs see: Tufts Center for the Study of Drug Development http://csdd.tufts.edu

1) Investors lose patience while financing declines and biotech stocks plummet. In the most recent economic boom, particularly during late 1999 and much of 2000, venture capitalists and investment bankers bet heavily on biotech, which they saw as a promising technologybased alternative to investing in information technologies such as the Internet. A veritable frenzy of new financing poured into biotech startup companies and initial public offerings (IPOs) in 2000, which funded very aggressive research, development and marketing plans. New investments in U.S. biotech firms totaled about $32 billion in 2000—more than had been invested during the previous six years combined. The level of funding dropped quickly thereafter, largely as a result of the infotech industry crash of March 2000. New U.S. biotech capital totaled only $12 billion in 2001, and about $10 to $12 billion in 2002. Future levels of new funding will depend to a large extent on the ability of young biotech firms to get their new drugs successfully through Phase III trials and into the marketplace. Much of the investment burden will be borne by mature, glo bal drug firms that partner with or acquire smaller biotech companies. New drugs and profitable drug companies take a long, long time to develop. Historically, the years of operation required to reach profitability at leading biopharmaceutical firms ranges from, for example, six years at Amgen to 10 years for Chiron and 15 years for Cephalon. These timeframes do not fit the requirements of many investors.




Key Food & Drug Administration (FDA) terms relating to human clinical trials and approval stages: Phase I—Small-scale human trials to determine safety. Typically include 20 to 60 patients and are six months to one year in length. Phase II—Preliminary trials on a drug’s safety/efficacy. Typically include 100 to 500 patients and are one and one-half to two years in length. Phase III—Large-scale controlled trials for efficacy/safety; also the last stage before a request for approval for commercial distribution is made to the FDA. Typically include 1,000 to 7,500 patients and are three to five years in length. Phase IV—Follow-up trials after a drug is released to the public. NDA (New Drug Application)—A document submitted to the FDA that states the results of clinical trials and asks permission to market the drug to the public. PMA (Pre Market Approval)—An application to the FDA seeking permission to sell a medical device (rather than a drug) that is implanted, life-sustaining or life-supporting. Source: Plunkett Research, Ltd.

2) Profits are elusive and many startups are out of cash. Meanwhile, mature global drug companies lose market share to generics as blockbuster patents expire. Restructuring, mergers and bankruptcies will be regular occurrences at smaller firms, as their cash hoards from IPOs or initial rounds of venture capital dry up. Many of these companies are unable to achieve meaningful levels of revenues, and some of them are incurring immense annual losses due to the costs of research, development and regulatory requirements. At the major pharmaceutical firms, such as Bristol-Myers Squibb, Merck & Co., Eli Lilly and Schering-Plough, profits are subdued because many blockbuster drugs have lost their patent protection and face vast competition from generic versions. In the U.S., generic drugs now hold about a 50% market share. This puts pressure on these major, global drug firms to develop new avenues for profits. One such avenue will be partnerships with and investments in young biotech companies, but profits from such

ventures will, in most cases, be slow to appear. At the same time, these giant firms are investing billions inhouse on biotech research and development projects. In 2001, publicly held drug firms in the U.S. invested over $15 billion in research and development—double the amount invested in 1994. Nonetheless, the industry launched only 24 new drugs. Meanwhile, management scandals at ImClone and Elan, along with a heightened emphasis on corporate accountability in general, put pressure on CEOs and dampened the enthusiasm of investors despite the extraordinary long-term promise of the biotech era. 3) Slow approval processing, new leadership and restructuring at the FDA. New drug approval times slowed dramatically during 2001 and 2002, and the agency is in a state of reorganization. The FDA finally has a new chief after 21 months with no one in the top office. At the same time, the FDA has suffered a crisis in its finances that further complicated things. The results were hard on the drug industry. After dropping to as little as 11.7 months during 1998, the average amount of time required for approval of a new drug soared to 18.8 months during 2002. 4) Dozens of new drugs that initially seem promising lead to vast disappointments when they fail in Phase II or III trials. Many drugs seem effective in the small patient populations studie d in Phase I trials, but prove to have dangerous side effects or limited efficacy when tested on hundreds or thousands of patients. Unfortunately, in the first 10 months of 2002 alone, 30 biotech drugs that made it all the way through development and Phase I trials later showed unacceptable results in Phase II or III. 5) The field of Molecular Diagnostics leaps ahead. Diagnosing the individual patient at the genetic level will lead to predictive medicine and ultimately preventative medicine as an individual’s predisposition to be at risk for certain diseases, based on his or her genetic makeup, is revealed. The booming field of molecular diagnostics includes gene-based testing of patients and the use of immunoassays to determine the presence of specific antigens. This field will grow very rapidly as




scientists develop hundreds of new gene-based and protein-based assays that will enable physicians to determine how to best treat patients based on their genetic makeup and the presence in their bodies of specific infectious agents. Companies with superior technologies to watch in this area include Diagnostic Products Corporation, Orchid Biosciences and Abbott Laboratories. (See “Backgrounder—The Biotechnology Revolution of the Early 21ST Century” that follows later in this chapter.) 6) We are entering a new era of regenerative medicine. Many firms are conducting product development and research in the areas of skin replacement, vascular tissue replacement, bone graft and regeneration and stem cells, as well as transgenic organs harvested from pigs for use in humans. At its highest and most promising level, regenerative medicine may eventually utilize human stem cells to create virtually any type of replacement organ or tissue. (See “Backgrounder—The Biotechnology Revolution of the Early 21 ST Century” that follows later in this chapter.) 7) Biosecurity receives new attention and immense funding. Both in U.S. domestic and military uses, biosecurity is receiving more emphasis in an effort to thwart bioterrorism and to combat bioweapons on the battlefield. The U.S. Government is investing about $40 billion yearly in this effort, including the purchase of millions of doses of smallpox vaccine. Internet Research Tip: For an excellent “Science Primer” on genetics and basic biotechnology techniques, see: National Center for Biotechnology Information www.ncbi.nlm.nih.gov 8) A personalized approach to medicine gains traction. Perlegen Sciences, Inc. of Mountain View, California has decoded the genomes of about two dozen people. Each person’s genetic makeup took about 10 days and $1.5 million to complete. Meanwhile, a highly successful biologist entrepreneur, J. Craig Ventner, has announced that he

is seeking people who are willing to pay about $500,000 each to have their personal DNA (deoxyribonucleic acid) sequenced. He recognizes that the costs are currently limiting the number of people who can be studied, and he states that the eventual goal is a $1,000 personal genome. Ventner, former head of Celera Genomics, is on the board of a relatively new firm named U.S. Genomics. This new company was founded by researcher Eugene Chan. Chan has developed what he calls the GeneMachine, with the intent to sequence personal genomes in about 45 minutes for about $1,000. A Washington, D.C.-based firm called Alphagenetics plans to offer $1,000 personal profiles that predict how a person will respond to certain foods, based on the study of about 300 specific genes. The point to such a profile is “nutrigenomics,” the study of how food interacts with genes. For example, people with certain genetic makeups face a higher risk of heart disease and should therefore eat fewer foods containing harmful cholesterol. Other firms are already selling at-home DNA testing kits. Meanwhile, organizations ranging from the Mayo Clinic to drug giant GlaxoSmithKline are experimenting with personalized drugs that are designed to provide appropriate therapies based on the patient’s personal genetic makeup. The holy grail in all of this activity is for physicians to be able to receive a genetic model of a patient’s DNA, determine from there whether a particular drug will work effectively without daunting side effects and thus prescribe the drug that is most likely to effect the desired cure. 9) Systems biology will lead to faster, more costeffective drug development. Advanced technologies will enable scientists to view genetic predisposition by integrating information about entire biological systems, from DNA to proteins to cells to tissues. Integrating information from evolving bioinformatics databases into patient therapies and individual care will accelerate the ability to cure and prevent disease. For example, in January 2002 the FDA approved the Visys PathVision HER-2 new Probe, a diagnostic tool developed by Abbott Laboratories. This test helps determine whether a patient has the HER-2 protein, a marker for a certain type of breast cancer. Patients can thus be identified who should be treated




with the revolutionary breast cancer drug Herceptin, manufactured by biotech leader Genentech. At the drug development level, benefits of a systems biology approach will include: • Faster selection of the most promising novel protein targets • Better, targeted trial patient selection • Better analysis of trial patient response • Safer drugs with fewer side effects • Faster time to market Commentary: The challenges facing the biopharmaceuticals industry from 2003-2010 • Working with government to develop methods to (safely and effectively) speed approval of new drugs. • Working with the investment community to build confidence and foster patience on the part of investors for the lengthy timeframe required for commercialization of promising new compounds. • Working with civic, government, religious and academic leaders to deal with ethical questions centered on stem cells and other new technologies in a manner that will enable research and development to move forward. • Overcoming, through research, the technical obstacles to therapeutic cloning. • Enhancing sales and distribution channels so that they educate patients, payors and physicians about new drugs in a cost-effective manner. • Emphasizing fair and appropriate pricing models that will enable payors (both private and public) to afford new drugs and diagnostics while providing ample profit incentives to the industry. • Developing appropriate standards that fully realize the potential of systems biology (that is, the use of advanced information technology and the resources of genetic databases) in a manner that will create the synergies necessary to accelerate and lower the total cost of new drug development. • When a large stable of new biopharma drugs becomes available, fostering payor acceptance, diagnostic practices and physician practices that will harness the full potential of genetically-targeted, personalized medicine. Source: Plunkett Research, Ltd.

10) Total cost of patients’ pharmaceuticals soars in the U.S. and leads to calls for price controls and government aid for seniors. Factors leading to soaring drug costs in the American health care system: • Chronic illnesses are increasing as the population ages. • The drug industry is making an intensified sales effort. Direct-to-consumer advertising and legions of sales professionals calling on physicians increase demand for the newest, most expensive drugs. • Convoluted and uncoordinated lists of drug "formularies" (available drugs, their uses and their interactions) require increased administrative work to sort through, thus forcing costs upward. • Physicians continue to prescribe name-brand drugs when a generic equivalent may be available at a fraction of the cost. • Research budgets are escalating rapidly. Breakthroughs in research and development are creating significant new drug therapies, allowing a wide range of popular treatments that were not previously available. An excellent example is the rampant use of antidepressants such as Prozac. Meanwhile, major drug companies face the loss of patent protection on dozens of leading drugs— they are counting on expensive research, partnerships and acquisitions to replace those marquis drugs. • “Lifestyle” drug use is increasing, as shown by the popularity of such drugs as Viagra (for the treatment of sexual dysfunction), Propecia (for the treatment of male baldness) and Botox (for the treatment of facial wrinkles). Overall, the drug industry is one of the world's most profitable industries. Among the Fortune 500 companies in 2001, pharmaceutical firms ranked first in return on revenues at 18.5% (health care ranked 20th at only 3.3%). About 20% of pharmaceutical revenue is redirected toward discovering new medicines, well above the average of 4% reinvested in research and development in most industries. Advanced technology has allowed drug companies to saturate their development programs with smarter, more promising drugs. R&D budgets are staggering. Pfizer invested $4.9 billion in R&D in 2001, and Merck invested $2.6 billion.




Until recently, pharmaceutical research was focused primarily on curing life-threatening or severely debilitating illnesses. But a current generation of drugs, commonly referred to as “lifestyle drugs,” is economically and socially transforming the U.S. pharmaceutical industry. These lifestyle drugs target a variety of medical conditions, ranging from the painful to the inconvenient. Hundreds of millions of dollars are being poured into research for drugs to treat obesity, impotence, memory loss, depression and arthritis. Drug companies also continue to develop new treatments for hair loss and skin wrinkles in an effort to capture their share of the huge anti-aging market aimed at the baby-boomer generation. Thankfully, as the pressure and demand for new and improved treatments intensifies, so does the ability of modern technology. In addition to expediting the process and lowering the costs of drug discovery and development, advanced pharmaceutical technology promises to increase the number of diseases that are treatable with drugs, enhance the effectiveness of those drugs and increase the ability to predict disease, not just the ability to react to it. New technology aided by very fast computers will help control the cost of drug development. For example, development of new chemical compounds for potential drugs was previously a tiresome process that could easily require a full week of a laboratory worker’s effort, at a cost of $5,000 to $10,000 per compound. Now chemists can test thousands of drugs in one day, automatically. (See “combinatorial chemistry” below.) Consumers' voracious appetites for new drugs continue to grow. Insurance companies may raise copayments for drugs, strike deals with drug companies and employ pharmacy benefit management tactics in an effort to fend off rising pharmaceutical costs. Also, as new drugs hit the market, they initially have no generic equivalent, which consequently forces costs upward. In coming years, taming pharmaceutical costs will be one of the biggest challenges facing the health care system. Managed care must be able to determine which promising new drugs can deliver meaningful clinical benefits proportionate to their costs. At the same time, if the FDA can improve its inhouse handling of drug reviews, the incubation period required to develop, test, review and

commercialize a new drug could be substantially reduced. 11) Stem cell and cloning controversies abound in the U.S. while research in these fields flourishes overseas. During the 1980s, a biologist at Stanford University, Irving L. Weissman, was the first to isolate the stem cell that builds human blood (the mammalian hematopoietic cell). Later, Weissman isolated a stem cell in a laboratory mouse and went on to co-found SysTemix, Inc. (now part of drug giant Novartis) and StemCells, Inc. to continue this work in a commercial manner. In November 1998, two different university-based groups of researchers announced that they had accomplished the first isolation and characterization of the human embryonic stem cell (ESC). One group was led by James A. Thomson at the University of Wisconsin at Madison. The second was led by John D. Gearhart at the Johns Hopkins University School of Medicine at Baltimore. The ESC is among the most versatile basic building blocks in the human body. Embryos, when first conceived, begin creating small numbers of ESCs, and these cells eventually differentiate and develop into the 200+ cell types that make up the distinct tissues and organs of the human body, from bones to brains. If scientists can reproduce and then guide the development of these basic ESCs, then they could theoretically grow replacement organs and tissues in the laboratory— even such complicated tissue as brain cells or heart cells. Ethical and regulatory difficulties have arisen from the fact that the only source for human embryonic stem cells is, logically enough, human embryos. A laboratory can obtain these cells in one of three ways: 1) By inserting a patient’s DNA into an egg and thus producing a blastocyst that is a clone of the patient—which is then destroyed after only a few days of development. 2) By harvesting stem cells from aborted fetuses. 3) By harvesting stem cells from embryos that are left over and unused after an in vitro fertilization of a hopeful mother. (Artificial in vitro fertilization requires the creation of a large number of test tube embryos per instance, but only one of these embryos is used in the final process.) A rich source of similar but non-embryonic stem cells is bone marrow. Doctors have been performing bone marrow transplants in humans for years. This procedure essentially harnesses the healing power of




stem cells, which proliferate to create healthy new blood cells in the recipient. Several other nonembryonic stem cell sources have great promise—see below. In the fall of 2001, a small biotech company called Advanced Cell Technology announced the first cloning of a human embryo. The announcement set off yet another firestorm of rhetoric and debate on the scientific and ethical questions that cloning and related stem cell technology inspire. While medical researchers laud the seemingly infinite possibilities stem cells promise for fighting disease and the aging process, conservative theologians, policy makers and pro-life groups decry the harvest of cells from aborted fetuses and the possibility of cloning as an ethical and moral abomination. Congress, under the Bush Administration, has banned the use of Federal funding for the creation of new embryonic stem cell lines. This action was taken in spite of impassioned testimony regarding the healing potential of stem cells by physicians, researchers and celebrities, such as actor Michael J. Fox on behalf of research for Parkinson's disease, actor Christopher Reeve for spinal injury study and former first lady Nancy Reagan on behalf of Alzheimer's research. Stem cell research has been underway for years at biotech companies including Stem Cells, Inc., Geron and ViaCell. One company, Osiris Therapeutics, has been at work long enough to have several clinical trial programs in progress. The potential benefits are staggering. Through stem cell therapies, neurological disorders could be reversed with the growth of healthy cells in the brain. Injured cells in the spinal column could be regenerated and function fully again. Damaged organs such as hearts, livers and kidneys could be infused with healthy cells. Stem cell (and cloning) research activity is brisk in certain nations outside the U.S. To begin with, certain institutions around the world have stem cell lines in place, and some make them available for purchase. Groups that own existing lines include the National University of Singapore, Monash University in Australia and Hadassah Medical Centre in Israel. More importantly, several Asian nations, including Singapore, South Korea, Japan and China are investing intensely in biotech research centered on cloning and the development of stem cell therapies. The global lead in the development of stem cell therapies may eventually pass to China, where the Chinese Ministry of Science and Technology readily sees the commercial potential and is

enthusiastically funding research. In addition to funding from the Chinese government, investments in labs and research are being backed by Chinese universities, private companies, venture capitalists and Hong Kong investors. Meanwhile, back in the U.S., in December 2002 Stanford University announced plans to develop a privately funded library of human stem cell lines, which means it will be able to operate outside of the restrictions placed on federally-funded ESC research and development. It is the first U.S. university to take this path. Potential methods of developing “post-embryonic” stem cells without the use of human embryos: • Parthenogenesis—manipulation of unfertilized eggs. • Adult Stem Cells—harvesting of stem cells from bone marrow or brain tissue. • Other Cells—harvesting of stem cells from human placentas or other cells. • De-Differentiation—use of the nucleus of an existing cell, such as a skin cell, that is altered by an egg that has had its own nucleus removed. • Transdifferentiation—making a skin cell dedifferentiate back to its primordial state so that it can then morph into a useable organ cell, such as heart tissue. ESCs (typically harvested from five-day-old human embryos which are destroyed during the process) are used because of their ability to evolve into any cell or tissue in the body. Their versatility is undeniable, yet the implications of the death of the embryo are at the heart of the ethical and moral concerns. Meanwhile, scientists have discovered that there are stem cells in existence in many diverse places in the adult human body, and they are thus succeeding in creating stem cells without embryos, from “postembryonic” cells. Such cells are already showing the ability to differentiate and function in animal and human recipients. Best of all, these types of stem cells are not plagued by problems found in the use of ESCs, such as the tendency to form tumors when ESCs develop into differentiated cells. For scientists, the biggest challenge at present may be to discover the exact process by which stem cells are signaled to differentiate. (Differentiation is the molecular programming that causes stem cells to grow into specific types of tissue such as heart tissue




or brain tissue.) Another immense challenge lies in the fact that broad use of therapeutic cloning may require immense numbers of human eggs in which to grow blastocysts. The clearest path to therapeutic cloning may lie in “autologous transplantation.” In this method, a tiny amount of a patient’s muscle or other tissue would be harvested. This sample’s genetic material would then be de-differentiated, that is, it would be reduced to a simple, unprogrammed state. The patient’s DNA sample would then be inserted into an egg to grow a blastocyst. The blastocyst would be manipulated so that its stem cells would differentiate into the desired type of tissue, such as heart tissue. That newly grown tissue would then be transplanted to the patient’s body. Many obstacles must be overcome before such a transplant can become commonplace, but the potential is definitely there to completely revolutionize healing through such regenerative, stem cell-based processes. One type of bone marrow stem cell, recently discovered by scientists at the University of Minnesota, appears to have a wide range of differentiation capability, which means it may become the first cell type that is widely used to grow useful replacement tissue in the laboratory. (See “Cloning” below.) 12) Cloning techniques advance, especially for therapeutic uses. Cloning is a controversial technology, especially in the United States. While, as of mid December 2002, no one has successfully cloned a primate (such as a human being), large domestic animals have in fact been cloned. Reproductive cloning of a human being is illegal in the U.S. Nonetheless, an odd sect called the Raelians claimed, in late December 2002, that they had successfully arranged for the cloning of a human being that had led to a live birth, and that they had several other host mothers carrying human clone fetuses. This claim was unsubstantiated. No doubt, other groups, particularly overseas, will claim to be cloning humans, and eventually it will happen. Unfortunately, the successful birth of a cloned human baby doesn’t necessarily mean that a healthy adult human will result. To date, cloned animals have tended to develop severe health problems. For example, a U.S. firm, Advanced Cell Technology, reports that it has engineered the birth of cloned cows

that appeared healthy at first but developed severe health problems after a few years. Nonetheless, cloning has uses in regenerative medicine that can be vital in treating many types of disease, because cloning can be used to create a source of stem cells. It is instructive to note that there are two distinct types of embryonic cloning: reproductive cloning and therapeutic cloning. While they have similar beginnings, the desired end results are vastly different. Reproductive cloning is a method of reproducing an exact copy of an anima l—or potentially an exact copy of a human being. A scientist would remove the nucleus from a donor's unfertilized egg, insert a nucleus from the animal, or human, to be copied, and then stimulate the nucleus to begin dividing to form an embryo. In the case of a mammal, such as a human, the embryo would then be implanted in the uterus of a host female for gestation and birth. On the other hand, therapeutic cloning is a method of reproducing exact copies of cells needed for research or for the development of replacement tissue. In this case, once again a scientist removes the nucleus from a donor's unfertilized egg, inserts a nucleus from the animal, or human, whose cells are to be copied, and then stimulates the nucleus to begin dividing to form an embryo. However, in therapeutic use, the embryo would never be allowed to grow to any significant stage of development. Instead, it would be allowed to grow for a few hours or days, and stem cells would then be removed from it for use in regenerating tissue. 13) Nanotechnology (the creation of very tiny devices) and information technologies converge with biotechnology. Technologies that have been developed for the biotech market are now leveraging into uses in entirely new areas, such as molecular electronics. For example, tapping the true potential of proteomics will require computing projects that will be among the largest ever attempted by private industry. Biotechnology has become the most demanding commercial use for computer power. In August 2000, computer giant IBM established a specialized division centered on serving the bioinformatics market: IBM Life Sciences, www3.ibm.com/solutions/lifesciences. Eventually, the biotech industry will be one of the largest revenue producers for IBM. NuTec Sciences,




www.nutecsciences.com, an Atlanta-based firm, is working with IBM to assemble what it calls the world’s largest privately owned computer cluster: 1,250 IBM pSeries 640 servers linked for parallel processing capable of 7.5 trillion calculations per second. An ancillary result of this computer-based activity will be the development of new, convergent technologies and uses. 14) Partnerships and collaboration among biotech startups, major drug manufacturers and the research departments at major universities are at an all-time high. Small to mid-size biotech firms will continue to look to mature, global pharmaceutical companies for cash, marketing muscle, distribution channels and regulatory expertise. Despite the problems in the ImClone partnership with Bristol-Myers Squibb, major partnerships and acquisitions continue to be signed at a rapid clip. Good examples are the agreement between Millennium Pharmaceuticals and Abbott Laboratories to develop new diagnostics for obesity and diabetes, and the Isis Pharmaceuticals deal to do research into new drugs for inflammatory and metabolic diseases. 15) Agricultural biotechnology has scored tremendous breakthroughs, but genetically engineered foods cause great controversy and are snubbed by European nations. The biotech era technology of “molecular farming” will soon lead to broad commercialization of human drug therapies that are grown via agricultural methods. For example , scientists can manipulate plants into growing certain human proteins (instead of natural plant proteins) by inserting human genes into plants such as corn. The growth in plants of transgenic protein therapies for humans may become widespread. Such drug development methods may prove to be extremely cost-effective. At the same time, hundreds of antibodies produced in farm animals with biotech means, for use in human drug therapies, are currently under development or clinical trials. Meanwhile, genetically modified (GM) foods offer tremendous promise in agriculture—particularly in low-income/high-population-growth nations like China and India. Although scientists have been able to engineer highly desirable traits in GM seeds for crops (such as

disease-resistance and insect-resistance), such modified foods face stiff resistance among many consumers, particularly in Europe. (See Plunkett’s Food Industry Almanac.)

Technologies: HapMap Project. Now that the Human Genome Project has yielded excellent results, public funds are launching a new effort called the HapMap (Haplotype Map) Project. Funded with $100 million from the U.S. National Institutes of Health, similar agencies in China, Canada, Japan and the U.K., as well as corporate and non-profit sponsors, the project is slated to be completed in 2004 or 2005. HapMap will focus on the small percentage of DNA that varies from one individual to another. Blood samples will be collected from four different ethic populations in the nations of China, Nigeria, Japan and the U.S. Haplotypes, the building blocks of single nucleotide polymorphisms, or SNPs (see SNPs later in this chapter), are inherited and may affect diseases such as hypertension and diabetes. These haplotypes will be codified and studied in an effort to identify blocks of DNA that contain common variations in the human genome. The study will show how such variations are shared by many people and is intended to provide a shortcut to identifying which inherited gene sequences are most likely to promote whic h diseases. For additional information, see www.genome.gov/research. Biopharmaceuticals. “Biopharma,” the development and marketing of pharmaceuticals based on biotechnology, is a young, rapidly growing business. In 1982, Genentech received FDA approval to market the first genetically engineered drug for human use, a brand of insulin. Today, approximately 200 new biotech-based drugs and vaccines are on the commercial market, and most of them were approved only within the past five years. The good news is that these drugs are creating highly effective therapies for wide varieties of diseases, and they are having a significant impact on the cure rates and lifestyles of patients. The bad news is that these therapie s can be extremely expensive. Many cost in the range of $10,000 or more per treatment, and the cost can be above $100,000 for a small number of these therapies.




Genomics. The study of genes, as a resource for the commercial development of new drugs, received a significant boost from computer technology in the late 1970s. Frederick Sanger, a chemist, and Walter Gilbert, a biochemist, developed what is known as DNA sequencing technology, receiving a Nobel Prize in 1980 for their effort. In the same way that computer technology enabled the rapid growth of the Internet industry, computerization has been the catalyst for the booming biotech industry. For example, Sanger and Gilbert’s computerized DNA sequencing technology enables scientists to collect massive amounts of data on human genes at high speed, analyzing how certain genes are connected with specific diseases. Using this technology, the gene responsible for Parkinson’s disease was mapped in only nine days—a stark contrast to the nine years required to determine the gene connected with cystic fibrosis. Genomics, the mapping/analysis of genes and their uses, is the basic building block of the biopharma business. Pharmacogenomics is the study of genomics for the purpose of creating new pharmaceuticals. Today there is intense debate as to the actual number of genes in a human being, thought to be from 35,000 to 75,000. Genes are made up of DNA. Genes reside on densely packed fibers called chromosomes. The genetic information encoded in a gene is copied into RNA (ribonucleic acid—closely related to DNA) and then used to assemble proteins. You can think of DNA as a blueprint and RNA as the builder. The human body contains about 75 trillion cells. Each cell contains about 46 chromosomes, arranged in 23 pairs. Each chromosome is a strand of DNA. Each strand of DNA is composed of thousands of segments representing different genes. The sum total of all the DNA contained in all 46 chromosomes is called the human genome . Internet Research Tip: For a superior, easy-to-understand, illustrated resource on genetics and molecular biology, see: http://vector.cshl.org/dnaftb/15/concept/. Gene Tests. As specific disease genes are found, complementary gene tests are developed to screen for the gene in humans who suspect they may be at risk for developing the disease. These tests are usually patented and then licensed by the owners of the disease gene patent. Royalties are due the patent

holders each time the tests are administered, and only licensed entities can conduct the tests. Gene Mapping. This process, including such efforts as the well-known Human Genome Project, uses gene-sequencing computers to analyze genetic samples to determine the exact genetic makeup of the human body. Proteomics. Proteomics is the study of the proteins that a gene produces. Proteins do the work of the cell. A complete set of genetic information is contained in each cell. This information provides a specific set of instructions to the body. The body carries out these instructions via proteins. Genes encode for proteins. All living organisms are composed largely of proteins. They have three main cellular functions: 1) enzymes are proteins, 2) proteins provide cell structure and 3) proteins are involved in cell signaling and cell communication functions. Proteins are important to researchers because they are the link between genes and pharmaceutical development. They indicate which genes are expressed or are being used. They are important for understanding gene function. They also have unique shapes or structures. Understanding these structures and how potential pharmaceuticals will bind to them is a key element in drug design. Proteomic researchers seek to determine the unique role of each of the 500,000 or so proteins in the human body, as well as the relationships that such proteins have with each other and with various diseases. Microarrays enable the high-speed analysis of these proteins and the discovery of SNPs (see below). SNPs (“Snips”). The holy grail of genomics is the search for single nucleotide polymorphisms (SNPs). These are DNA sequence variations that occur when a single nucleotide (A, T, C or G) in the genome sequence is altered. For example an SNP might change the DNA sequence AAGGCTAA to ATGGCTAA (see the Appendix). SNPs occur every 100 to 1,000 bases along the 3 billion-base human genome. SNPs can occur in both coding (gene) and noncoding regions of the genome. Many SNPs have no effect on cell function, but scientists believe others could predispose people to diseases or influence their response to a drug. Variations in DNA sequence can have a major impact on how humans respond to disease; environmental insults such as bacteria, viruses, toxins and chemicals; drugs and other therapies. This makes




SNPs of great value for biomedical research and for developing pharmaceutical products or medical diagnostics. Scientists believe SNP maps will help them identify the multiple genes associated with such complex diseases as cancer, diabetes, vascular disease and some forms of mental illness. These associations are difficult to establish with conventional gene-hunting methods because a single altered gene may make only a small contribution to the disease. In April 1999, 10 large pharmaceutical companies and the U.K. Wellcome Trust philanthropy announced the establishment of a non-profit foundation to find and map at least 300,000 common SNPs. Their goal is to generate a widely accepted, high-quality, extensive, publicly available map using SNPs as markers, evenly distributed throughout the human genome. The consortium plans to patent all the SNPs found, but they will not enforce the patents. This will be done only as a measure to prevent others from patenting the same information. Information found by the consortium is being made freely available via the NIH's NCBI public Database of Single Nucleotide Polymorphisms.

a cancer patient’s tumor. That biopsy would be placed into microarray equipment. There, the microarray would arrange hundreds or thousands of microscopic dots of tumor material onto glass laboratory slides. Lasers would scan the slides, and computer software would compare the contents of the slides to vast databases, in order to determine the exact genes in the tumor. Such information may be extremely useful in treating the patient. Initially, genetic information scanned from microarrays has been used to create giant bioinformatics databases. Ideally, such databases could then analyze the genetic blueprint of a patient’s tumor in order to assist a physician in determining the drugs that would best treat the specific genes that have become mutant cancerous material, and thereby have the best opportunity to cure the patient.

Combinatorial Chemistry. After researchers determine which protein is involved in a specific disease, they use combinatorial chemistry to find the molecule that controls the protein. High-throughput screening techniques (see below) enable scientists to use automatic fluid handlers to mix chemicals under specific test conditions at extremely high speed. Combinatorial chemistry can generate thousands of chemical compound variations in a few hours. Previously, traditional chemistry methods could have required several weeks or even months to do the same work. High-throughput screening enables automated, computerized machines to screen as many as 100,000 chemical compounds daily, seeking potential molecules as drug candidates.

Gene Therapies. Generally, biopharma researchers have focused on replacing defective, disease-causing genes with healthy genes that have been engineered in the laboratory. New, healthy genes may be carried into the patient by benign viruses injected into the body or by other advanced delivery methods. (Viruses make effective gene carriers because they are efficie nt at infecting cells.) The healthy genes enable the patient to produce a supply of new, healthy proteins, thereby dissipating the disease at its root. As genomics and proteomics enable scientists to map genes and discover their related proteins, more and more gene therapies will be developed and tested.

DNA Chips. Several semiconductor (chip) platforms have been developed to facilitate molecular biology research. For example, industry leader Affymetrix has developed chips programmed to act like living cells. These chips can run thousands of tests in short order to help scientists determine a specific gene’s expression. Microarrays . In the laboratory, scientists use microarrays to map the DNA of a patient’s tissues. For example, a physician may take a small biopsy of

Bioinformatics. This is the use of specially designed computer software to store, sort and analyze the vast amounts of genetic and molecular data that are produced by computerized research techniques. This is, in many ways, a merger of computer science with biology.

Vaccines. Biopharma companies have developed vaccines that carry specific proteins that can stimulate the human immune system to have a desired response against a specific infectious disease. For example, biotech vaccines that fight hepatitis B have been introduced. Vaccines are under development at various firms for such diseases as herpes and tuberculosis. Additional DNA therapies that are somewhat related to vaccines are being developed to fight specific cancers and such immune system diseases as AIDS.




Agricultural Biotech. This sector became a significant commercial industry during the 1980s. It was fostered both by startups and by large chemical or seed companies. All of these players were focused on developing genetically engineered seeds and plants that had higher yields, better nutritional qualities and/or resistance to diseases or insects. Additional traits of plants that may be genetically modified include resistance to temperature and moisture extremes. At the same time, researchers are modifying the structural makeup of some plants in order to alter leaves, stems, branches, roots or seed structures. The ability to modify the nutritional makeup of plants can have highly desirable effects. For example, Mycogen, an affiliate of Dow AgroSciences, has developed sunflower seeds with higher levels of desirable oleic and linoleic acids. While many areas of biotech are controversial, agricultural biotech is presently the largest target for consumer backlash and government intervention into the marketplace. There are currently dozens of agbio food products on the market. These range from fruits to vegetables to nuts. There is significant potential for rapid development of new products, thanks to the same technologies that are pushing development of human gene therapies. The market for genetically engineered seeds has already reached the $50 billion+ stage, but consumer resistance to food products containing material grown in this manner is suddenly fierce, and the near-term outlook for the market is cloudy at best. In the fall of 2000, a relatively small quantity of taco shells were found to have been manufactured with cornmeal made from genetically engineered corn known as StarLink. Unfortunately, StarLink was intended for hog feed rather than human foods. Consumer interest in agbio regulation soared in the U.S. as a result. In 2000 alone, there were over 30 acts of antibiotech terrorism around the world, including the firebombing of a biotech lab at the University of Michigan. Also in 2000, a U.S. trade representative, Charlene Barshefsky, quietly signed a new section of the Convention on Biological Diversity that may allow member countries of the World Trade Organization to stop the importation of any biological product at any time.

develop a disease in the future, based on his/her genetic makeup today; the potential to harvest replacement organs and tissues from animals or from cloned human genetic material; and the ability to genetically alter the basic foods that we eat are only a handful of the implications of biotech that must be dealt with by socie ty. (Don’t forget the implications of Dolly the cloned sheep, created by Scottish scientists in 1997. Will humans be cloned next?) Watch for intense, impassioned discussion of such issues and a raft of governmental regulation as new technologies and therapies emerge. The biggest single issue may be privacy. Who should have access to your personal genetic records? Where should they be stored? How should they be accessed? Can you be denied employment or insurance coverage due to your genetic makeup? One interesting startup company attempting to deal with some of these issues is GeneSage, www.genesage.com. This San Francisco company was co-founded by Paul Billings, formerly a professor of medicine at Harvard and Stanford. GeneSage’s purpose is to provide genetic information and services online, with the ultimate goal of creating a secure online area where consumers can store their personal genetic information and genetic test results. Internet Research Tip: For official ELSI (Ethical, Legal and Social Issues) information, check out: www.ornl.gov/hgmis/research.elsi.htm.

Ethical Issues. Significant issues of an ethical nature face the biotech industry as it moves forward. The ability to determine an individual’s propensity to Copyright©2003 Plunkett Research, Ltd., All Rights Reserved



BACKGROUNDER— THE BIOTECHNOLOGY REVOLUTION OF THE EARLY 21ST CENTURY A Short History of Biotechnology: The field of biotechnology can trace its true beginnings back to the dawn of civilization, when early man discovered the ability to ferment grains to make alcoholic beverages and learned of the usefulness of cross-pollinating crops in order to create new hybrid strains—the earliest form of genetic engineering. In ancient China, people are thought to have harvested mold from soybean curd to use as an antibiotic as early as 500 B.C. Cells were first described as a concept by Robert Hooke in 1663 A.D., and in the late 1800s Gregor Mendel conducted experiments that became the basis of modern theories about heredity. Alexander Fleming discovered the first commercial antibiotic, penicillin, in 1928. The modern, more common concept of “biotech” could reasonably be said to have its beginnings shortly after World War II. In 1953, scientists James Watson and Frances Crick conceived the “double helix” model of DNA and thus encouraged a rash of scientists to consider the further implications of human DNA. The Watson/Crick three-dimensional model began to unlock the mysteries of heredity and the methods by which replication of genetic material took place within cells. Significant steps toward biotech drugs occurred in the early 1970s. In 1973, Dr. Stanley N. Cohen, a Stanford University genetics professor, and Dr. Herb Boyer, a biochemist, genetic engineer and educator at UC-San Francisco, introduced the concept of genesplicing and created the first form of recombinant DNA. In 1974, Cesar Milstein and Georges Kohler created monoclonal antibodies, cells that clone over and over again to create large quantities of a specific antibody. Many of today’s top biotech drugs are monoclonal antibodies. These two discoveries created the building blocks (recombinant DNA and monoclonal antibodies) of the first modern commercial biotech drugs. Boyer and Cohen’s gene-splicing technique enabled scientists to cut genetic material from the cells of one organism and paste it into another organism. This is important because the genetic material they moved from one place to another tells a cell how to make a particular protein. The organism

on the receiving end of the gene-splicing technique would then be able to make that protein. Over time, scientists perfected the technique of splicing material that enabled cells to create proteins that control such functions as the creation of insulin, the level of blood pressure and many other human functions. Such genetic engineering enabled, for the first time, the creation of massive vats of isolated proteins by growing them in bacteria or in cells harvested from mammals—in quantities large enough for the commercial production of new drugs. (In fact, Boyer and Cohen’s early experiments involved inserting a gene from an African clawed toad into bacterial DNA for duplication.) In 1975 the first human gene was isolated, opening the door to gene therapy and creating the emphasis that led to the beginning of the massive, publicly funded Human Genome Project in 1990. In 1976, Bob Swanson, a venture capitalist at the now-famous Silicon Valley venture capital firm of Kleiner Perkins, formed a new business, Genentech, in conjunction with Herb Boyer (see above). Other early biotech firms followed quickly, generally funded by venture capital firms , angel investors and corporate venture partners (the same triumvirate of funding sources that fueled the recent Internet startup boom). These early biotech startups included many companies that grew into today’s super-successful biopharma corporations: Amgen, Cetus, Chiron, Biogen, Genetics Institute and Genzyme. The creation of these startups, focused on the development of new drugs, was particularly noteworthy because it was the first time in decades that new drug companies had been launched in significant numbers. In fact, most major drug companies in existence at the beginning of the 1970s could trace their histories back to the early 1900s or before. Internet Research Tip: For the latest biotech developments check out www.biospace.com and www.bio.org. Technological Frontiers in Therapies, Treatments and Procedures Stem cells and tissue engineering The potential of the relatively young science of tissue engineering appears to be unlimited. Transgenics (the use of organs and tissues grown in laboratory animals for transplantation to humans) is still considered by many to have great future




potential, and improvements in immune system suppression will eventually make it possib le for the human body to tolerate foreign tissue instead of rejecting it. There is also increasing theoretical evidence that one day malfunctioning or defective vital organs such as livers, bladders and kidneys could be replaced with perfectly functioning “neoorgans” (like spare parts) grown in the laboratory from the patient’s own stem cells, with minimal risk of rejection. The extremely versatile human stem cell has the ability to develop into virtually any type of cell or tissue in the body and is a potentially limitless source of cells. The ability of most human tissue to repair itself is due to the activity of these cells. The potential that cultured stem cells have for transplant medicine and basic developmental biology is enormous. Not only might an unlimited amount of human tissues for transplantation be available, but the whole transplant rejection problem could be solved if a tissue could be re-grown from the patient’s own cells, thus eliminating the need for powerful immunosuppressant drugs. The problem of the limited supply of donor organs might finally be solved. On any given day, tens of thousands of patients are waiting for an organ transplant, and many of these patients die as a result of the current shortage of transplantable organs. For example, the American Heart Association reported that in 1999, a mere 14% of the 16,000 Americans aged 55 or younger needing a new heart actually received one. There are 260 transplant centers in the United States, 196 of which perform heart transplants. In 2000, only 2,198 heart transplants were performed in the U.S., fewer than one per center per month. Furthermore, only 20% of the 25,000 healthy Americans who die unexpectedly each year under circumstances conducive to organ use actually donate organs. Neo-organs have the potential to save thousands of lives yearly. For example, expensive dialysis machines would be rendered obsolete if people with damaged kidneys could be given new ones grown from their own stem cells. Each year, approximately 250,000 individuals are admitted to hospitals in the U.S. for diseases associated with liver failure, costing patients and health plans an estimated $10 billion annually. Hospital programs, such as patient monitoring, education and mental health services, requiring several thousand hospital-based professionals, could be reduced significantly. The life of the patient

would also be improved since the fatigue and depression that often accompany dialysis would be avoided. Diabetics who are forced to cope with daily insulin injection treatments could also benefit from engineered tissues. If they could receive a fully functioning replacement pancreas, diabetics might throw away their hypodermic needles once and for all. This could also save the health care system immense sums, since diabetics tend to suffer from many ailments that require hospitalization and intensive treatment, including blindness, organ failure, diabetic coma and circulatory diseases. There are a multitude of additional potential applications for tissue engineering. Tissue engineering could mean less complex and less invasive methods to treat urological disorders, such as bladder reflux and incontinence. Breast cancer patients may eventually have soft tissue alternatives to breast prostheses or implants. Severe bone fractures may no longer require grafts of bone from other parts of the body. Instead, recombinant human bone growth promoters, or stem cells, might be injected into a porous material cut to a specific shape, such as a jaw or limb. While a completely rebuilt heart is many years away, scientists have already been able to grow new blood vessels. Tissue engineering concepts are currently being applied in the area of replacement skin. This is neoskin, actually grown in large quantities by starting in the lab with a small amount of human skin cells. The FDA has approved several replacement skin products, including AlloDerm, Transcyte and Apligraf. Many others are in various stages of development. Over a million people per year suffer from a variety of serious skin disorders, ranging from diabetic ulcers to skin cancer to severe burns. Apligraf, developed by Organogenesis, Inc., closely resembles true skin and consists of both epidermal and dermal skin layers grown from bovine cells and cells from human foreskin. Apligraf is approved to treat certain skin ulcers, such as diabetic ulcers, and is being tested in treatment of other skin conditions, including burns and dermatological surgery. Vitrix, another Organogenesis product, is a replacement connective tissue product that shows promise in healing deep wounds without scarring. Scientists at the LifeCell Corporation have succeeded in regenerating skin tissue from human donors. Purified human tissue from LifeCell is ready for use in the treatment of burn victims, periodontal surgery and plastic and reconstructive surgery.




Incredibly, once in place this tissue is readily accepted by the body and not only restores the tissue that was missing but also restores patients' power to regrow their own tissue. The patients’ own cells slowly replace the acellular tissue as new dermis is formed. LifeCell’s AlloDerm is available in a variety of sheet sizes to fit procedures ranging from repair of large burns to inner ear surgery. The firm also distributes a similar product, called Repliform, for urology and gynecology applications, such as urinary incontinence surgery or pelvic floor replacement, through a partnership with Boston Scientific. Most recently, the company brought to market an injectable form of AlloDerm, called Cymetra, for use in plastic and reconstructive surgical procedures. LifeCell is exploring the use of its cell preservation and regeneration technology in many other areas. For example, it is developing acellular vascular grafts as a potential alternative to autografted (from the patient) blood vessels in coronary bypass procedures. Elsewhere, the harvesting of replacement cartilage, which does not require the growth of new blood vessels, is being used to repair damaged joints and treat urological disorders. Genzyme Corp. recently won FDA approval for its replacement cartilage product Carticel. The Genzyme process involves harvesting the patient’s own cartilageforming cells and, from those cells, re-growing new cartilage in the laboratory. Finally, the physician injects the new cartilage into the damaged area. Full regeneration of the replacement cartilage is expected to take up to 18 months. The Genzyme process can cost up to $30,000, compared to $10,000 for typical cartilage surgery, and many patients who want this new therapy can’t get their health plans to pay for it. Other companies are exploring alternative methods that may be less expensive and therefore more attractive to health plans. LifeCell and Organogenesis are just a few of the many small biotech companies tapping into the potential $80 billion market for engineered tissues. The ultimate success or failure of these companies is directly proportional to the success or failure of their experiments and the ability of their products to make it all the way through clinical trails and the FDA approval process. Advances in human stem cell research may eventually lead to new treatments for brain disorders such as Parkinson’s, Alzheimer’s and disabilities associated with stroke and trauma. Until recently, it was thought that the brain lacked the stem cells

necessary for neuronal regeneration, but we now know that this activity does take place in certain parts of the brain. While these potential applications are several years away, human stem cell research may be more immediately applied to drug development. Pure populations of specific differentiated cells could be tested against hundreds of thousands of chemicals to see if the response to a new drug is effective or not. Researchers are also trying to develop tissues that act as drug delivery vessels. Other potential stem cell applications include injecting heart muscle cells directly into failing heart tissue to shore it up. Human stem cells could be a valuable research tool for studying birth defects, pregnancy loss and cancer biology. Currently, stem cells are being used in a promising treatment for various types of cancer. Autologous stem cell rescue may eventually replace traditional, painful and costly bone marrow transplants. Because chemotherapy will destroy a patient’s bone marrow, doctors use “growth factor” drugs to stimulate stem cell production in the patient’s own blood. Stem cells will regenerate bone marrow function in the patient after high-dose chemotherapy. Also, a vaccine is administered before stem cell collection to stimulate the immune system since the immune system may be suppressed following a stem cell transplant.

Companies to Watch: StemCells, Inc., Palo Alto, CA (www.stemcellsinc.com), is creating a bank of stem cells for transplant. ViaCell, Inc., Boston, MA (www.viacellinc.com), develops therapies using umbilical cord stems.

Genetic Research Begun in 1990, The Human Genome Project is a well-funded, 15-year international effort coordinated by the U.S. Department of Energy and the National Institutes of Health (NIH) to unravel the thousands of genes and determine the sequences of the 3 billion chemical bases that make up human DNA. Genes serve as the blueprint for proteins, which direct cellular activity. Rapid technological advances have put the project ahead of schedule. The Human Genome Project public consortium announced on June 26, 2000 that it had assembled a working draft




of the sequence of the human genome – the genetic blueprint for a human being. At the same time Celera Genomics announced that it had completed what it called “the first assembly of the human genome,” which revealed a total of 3.12 billion base pairs in the human genome. Celera Genomics, a for-profit corporation, has been using advanced computer technology in a race to beat the non-profit NIH in mapping the genome. Actually, the two organizations have been using widely different methods. Celera uses two independent approaches to assemble the human genome. First, Celera's Whole Genome Shotgun Assembly (see “Complementary approaches” below) utilizes all of the Celera-generated sequence data from the DNA of five individuals. The results of this assembly process are sequence segments, known as "scaffolds," reconstituting the 24 human chromosomes. Most of the genome is covered by sequence scaffolds of 1 million base pairs or larger. In the case of the NIH’s Human Genome Project consortium, the government-led organization considers its project to have involved two tasks: placing large fragments of DNA in the proper order to cover all of the human chromosomes and determining the DNA sequence of these fragments. The assembly consists of overlapping fragments covering 97% of the human genome, of which the sequence has already been assembled for approximately 85% of the genome. The sequence has been threaded together into a string of A’s, T’s, C’s and G’s arrayed along the length of the human chromosomes. The sequence information from the public project has been continuously, immediately and freely released to the world, with no restrictions on its use or redistribution. The information is scanned daily by scientists in academia and industry, as well as by commercial database companies providing information services to biotechnologists. Already, many tens of thousands of genes have been identified from the genome sequence. Analysis of the current sequence shows 38,000 predicted genes confirmed by experimental evidence. There are many thousands of additional gene predictions to be tested experimentally. (A research group at the University of Ohio recently did an analysis of genomic project results and estimated that we may eventually find that there are 65,000 to 75,000 total human genes. It will be a long time before the actual count is identified.) Large numbers of disease genes have been pinpointed by access to the working draft.

Consortium centers produced far more sequence data than expected (over 22.1 billion bases of raw sequence data, comprising overlapping fragments totaling 3.9 billion bases and providing sevenfold sequence coverage of the human genome). The consortium now expects to complete the finished draft by 2003, under budget and nearly two years ahead of the original projection. The consortium is currently setting new goals for understanding the human genome’s structure, function and roles in health and disease. Meanwhile, Celera is leveraging its technical base to validate drug targets and diagnostic marker candidates. Its research includes small molecule drug development and work on drugs that target asthma and anti-coagulation. It will produce about $80 million in revenues during 2003 from subscriptions and royalties on its genetics databases. Internet Research Tip: For the latest Human Genome Project developments and other government-backed biotech initiatives, check out: the National Human Genome Research Institute at www.genome.gov. Human DNA variation The greater-than-expected sequence production has also yielded a bumper crop of human genetic variations called single nucleotide polymorphisms or SNPs. The Human Genome Project had set a goal of discovering 100,000 SNPs by 2003. Already, with today's assembled sequences and other data accumulated by The SNP Consortium, scientists have now found more than 4 million. These SNPs provide a powerful tool for studies of human disease and human history. Background Sequencing, or determining the exact order of DNA's four chemical bases (commonly abbreviated A, T, C and G), has been expedited in the Human Genome Project by technological advances in deciphering DNA as well as the collaborative nature of the effort, which includes about 1,000 scientists worldwide working together effectively. The Human Genome Sequencing Project aims to determine the sequence of the euchromatic portion of the human genome. The euchromatic portion excludes certain regions consisting of long stretches of highly repetitive DNA that encode little genetic information and that are not recovered in the vector systems used by the genome project. Such regions




account for about 10% of the genome and are said to be heterochromatic. (For example, the center of chromosomes, called centromeres, consists of heterochromatic DNA.) The cost of sequencing the human genome is sometimes reported as $3 billion. However, this figure refers to the original estimate of total funding for the Human Genome Project over a 15-year period (1990-2005) for a wide range of scientific activities related to genomics. These include studies of human diseases, experimental organisms (such as bacteria, yeast, worms, flies and mice), development of new technologies for biological and medical research, computational methods to analyze genomes and ethical, legal and social issues related to genetics. Results from the genome mapping efforts Knowledge gained from the NIH and Celera projects assist the biotech industry in its move forward to completely revolutionize medicine, as commercial applications are developed to treat, diagnose and possibly prevent the many thousands of diseases that afflict mankind. Researchers all over the world are already benefiting from the projects. Electronic databases disseminate information from the projects rapidly, thus changing the way biomedical research is conducted. Scientists now believe that almost all diseases have some genetic component. For example, some people have a genetic predisposition to breast cancer or heart disease. In the early years of the 21st Century, newfound understanding of the human genetic system will likely lead to a huge breakthrough in gene therapy for many ailments. Eventually, we will be able to avoid the suffering of hundreds of types of genetic diseases through the genetic manipulation of future generations. Cleveland-based Athersys has developed a technology called RAGE (random activation gene expression) that is a simple, quick way to induce genes to produce proteins. This technology could cut years off biotech drug development timelines, enabling drug discovery companies to rapidly determine the function of genes about which little is currently known. The biggest payoffs from genomic research will come in diagnostics and therapies. Technology currently under development will translate gene information into in vivo and ex vivo therapies. New genetic understanding will enable us to determine who is at the greatest risk of suffering from certain diseases.

Meanwhile, in today’s recombinant DNA therapies, the implantation of selected strands of DNA into bacteria allows large-scale production of hormones, antibodies and other exciting new drugs. (For an example of a company acting in this area, see Genentech.) Recent additions to the medical arsenal developed from this technique include interferons, growth factor hormone, anticoagulants, human insulin (as opposed to the cow and pig insulin that diabetics have used for 60 years) and more effective immunosuppressive drugs. An anticoagulant proven highly effective for some heart attack patients, TPA (see the following section on new drugs) may dramatically reduce heart damage during an attack and cut hospital stays. These new drugs are often expensive, but they may greatly reduce the duration of hospital confinement and the need for any hospitalization at all in some cases. Nevertheless, the high costs associated with recombinant DNA research and production makes it necessary for physicians and hospitals to consider less expensive medicines and treatments and to weigh the costs and benefits involved. Extensive research related to the genetic defects responsible for congenital diseases such as sickle cell anemia is also being conducted. Researchers are experimenting with inserting healthy genetic material directly into cells to replace or repair defective or missing genes. Animal research is beginning to give way to clinical trials. In a recent rodent model, gene therapy was also used to alter a donor liver prior to surgery so that the immune system of the recipient became permanently tolerant of the new organ without the aid of immunosuppressive drugs. A onetime gene therapy treatment could be a source of cost control for the health care industry because immunosuppressive drugs are costly and make the patient vulnerable to infections, cancer and other complications. In addition, gene therapy in animal models is giving researchers a clear understanding of rheumatoid arthritis, which currently afflicts about 2.1 million Americans. Specific applications of gene therapy are already in use for treatment on a limited basis. For example, gene therapy is being used to treat rare immune system disorders. In addition, the Food and Drug Administration has approved gene therapy for use in cancer treatment. As a result, melanoma (a malignant skin cancer for which there is currently no effective cure once the disease has spread to other organs) and cystic fibrosis may be treatable by gene




therapy within a few years, which would greatly extend the life span of victims and significantly reduce their rates of hospitalization. Extensive research is underway to identify myriad other possible applications. Polymerase chain reaction (PCR) is a method of replicating genetic material. It creates sufficient amounts of DNA to allow detailed analysis. This may lead to better diagnosis and treatment of diseases such as AIDS, Lyme disease, tuberculosis, viral meningitis, cystic fibrosis, Huntington’s chorea, sickle cell anemia and many others. PCR shows promise of providing cancer susceptibility warnings. Genetic research is rapidly leading to breakthroughs in dozens of other vital areas of medicine. A recent gene discovered by scientists appears to play a major role in widespread forms of the more than 30 different types of congenital heart defects, the most common of all human birth defects. Genes that are used by bacteria to trigger the infection process have also been identified, which could lead to powerful vaccines and antibiotics against life-threatening bacteria such as salmonella. In the area of heart disease, about 300,000 patients yearly undergo heart bypass surgery in an effort to deliver an increased blood flow to and from the heart. Clogged arteries are bypassed with arteries moved from the leg or elsewhere in the patient’s body. Genetic experts have now developed the biobypass. That is, they have determined which genes and human proteins create a condition known as angiogenesis, which is the growth of new blood vessels that can increase blood flow without traumatic bypass surgery. This technique may become widespread in the near future. New Drug Delivery Systems Controlling how drugs are delivered is a huge business. Sales of drugs using new drug delivery systems is expected to balloon to $30 billion by 2007, up from $9.8 billion in 1998. Biotech drugs that can be administered without needles are a major part of

the drug industry’s strategy. Up until the biotech age, drugs were small chemical molecules capable of being absorbed by the stomach and passed into the blood stream. However, many new biotech drugs require injection directly into the bloodstream because they are based on larger molecules that cannot be absorbed by the stomach. Many new drug delivery techniques are already in development. In the near future, there may be an implantable microchip, controlled by a miniature computer, capable of releasing variable doses of multiple potent medications over an extended period, potentially up to one year. The miniscule silicon chips will bear a series of tiny wells, sealed with membranes that dissolve and release the contents when a command is received by the computer. Chips that can receive commands beamed through the skin are also conceptually possible. This technology would help treatment of conditions such as Parkinson’s disease or cancer, where doctors need to vary medications and dosages. This technology must first be tested in animals and then in humans to ensure that the chips are biocompatible. The chips will more likely be used first in external applications such as the staggering of compounds, which may facilitate laboratory testing and drug development. Other potential needle -free drug delivery systems include synthetic molecules attached to a drug, making it tougher for the stomach to render the medicine useless before it reaches the blood. A liquid form of the anticlotting agent Heparin is entering final testing, and an oral osteoporosis drug is under development. High-tech inhalers, which force medicine through the lungs, and biotech drugs that can be imbibed are also in the works. For the patient, this means less pain and the promise of better outcomes. Needle -free systems may also make toxic drugs safer and give older drugs new life. For example, the painkiller Fetanyl was recently converted into a lozenge.




Chapter 2 BIOTECH & GENETICS INDUSTRY STATISTICS Tables and Charts: Biotechnology Industry Profile, 2001: U.S., Europe and Canada Total R&D Investments by Research-Based Pharmaceutical Companies: 1970-2001 Domestic R&D as a Percentage of Sales, U.S. Research-Based Pharmaceutical Companies: 1970-2001 Annual Percent Change in U.S. Research & Development by Research-Based Pharmaceutical Companies: 1980-2001 U.S. Biotech Industry Financing, 2001 U.S. Biotech Industry Fundraising, 1996-Third Quarter 2002 Top 20 Global Biotech and Pharmaceutical Companies, 2001 Major Biotechnology Company Consolidations, 1st through 3rd Quarter 2002 The U.S. Drug Discovery, Development and Approval Process Total U.S. Biotechnology Patents Granted Per Year, 1985-2000 New U.S. Biotech Drug and Vaccine and Indication Approvals, 1982-2001 U.S. Drug Development Times U.S. FDA Approval Times for New Drugs, 1987-2001 Average Salaries in the U.S. Pharmaceutical and Biotechnology Industries: 2002 Global Agricultural Biotech At A Glance, 2001


p. 26 p. 27 p. 28 p. 29 p. 30 p. 31 p. 32 p. 33 p. 34 p. 35 p. 36 p. 37 p. 38 p. 39 p. 40



Biotechnology Industry Profile, 2001: U.S., Europe and Canada Based on Private and Public Companies US$ Billions

Characteristic

U.S.

Europe

Canada

Sales/Revenue

$39.0

$3.9

$1.5

Annual R&D Spending

$12.3

$2.5

$0.68

Number of Companies

2,000

1,570

339

Number of Employees

157,000

61,104

7,000

356

105

83

Number of Public Companies

Source: Burrill and Company.




Total R&D Investments by Research-Based Pharmaceutical Companies: 1970-2001 Based on Total Expenditures in the U.S. and Abroad US$ Millions Year 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 * Estimate.

Total R&D $618.5 683.8 726.1 825.0 940.8 1,061.5 1,163.7 1,276.1 1,404.0 1,626.8 1,976.7 2,339.5 2,773.7 3,217.6 3,578.8 4,077.6

Year 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001*

Total R&D 4,740.1 5,502.2 6,537.5 7,330.0 8,420.3 9,705.4 11,467.9 12,740.0 13,449.4 15,207.4 16,905.6 18,958.1 20,966.9 22,690.7 26,030.8 30,342.7

PhRMA Annual Membership Survey, 2002.

Total R&D Investments by Research-Based Pharmaceutical Companies: 1970-2001

R&D Expenditures (US$ Millions)

$35,000 $30,000 $25,000 $20,000 $15,000 $10,000 $5,000 $0 1970 1972 1974 1976 1978 1980 1982 1984 1986 1988 1990 1993 1995 1997 1999 2001




Domestic R&D as a Percentage of Sales, U.S. Research-Based Pharmaceutical Companies: 1970-2001* US$ Millions

Year

Domestic R&D

Domestic Sales

U.S. Exports to Affiliated Firms

R&D as a Percentage of Worldwide Sales

1970

$558.6

$4,552.5

$344.1

11.4%

1975

$894.5

$7,135.7

$753.7

11.3%

1980

$1,554.1

$11,788.6

$1,219.3

11.9%

1985

$3,370.7

$20,742.5

$1,556.9

15.1%

1990

$6,800.1

$38,486.7

$3,420.6

16.2%

1995

$11,833.9

$57,145.5

$3,993.3

19.4%

2000

$21,363.7

$115,881.8

$3,638.3

17.9%

2001*

$23,887.8

$130,673.9

$4,005.8

17.7%

* Preliminary. Source: PhRMA Annual Membership Survey, 2002.

Domestic R&D as a Percentage of Sales, U.S. ResearchBased Pharmaceutical Companies: 1970-2001*

R&D as a Percentage of Sales

25.0%

19.4%

20.0%

17.9%

17.7%

2000

2001*

16.2% 15.1% 15.0% 11.4%

11.3%

1970

1975

11.9%

10.0%

5.0%

0.0% 1980

1985

1990

1995




Annual Percent Change in U.S. Research & Development by ResearchBased Pharmaceutical Companies, 1980-2001 Year

Percent Change

1980

16.7%

1981 1982

20.7% 21.3%

1983 1984

17.7% 11.6%

1985 1986

13.3% 14.7%

1987 1988

16.2% 16.2%

1989 1990

15.0% 13.0%

1991 1992 1993

16.5% 17.4% 12.5%

1994 1995

6.0% 7.0%

1996 1997

14.8% 13.9%

1998 1999

11.0% 7.4%

2000 2001

8.0% 18.2% Source: PhRMA.

Annual Percent Change in U.S. R&D by Research-Based Companies, 1980-2001 25.0 20.7

21.3 17.7

16.7

16.2 14.7

15.0

16.5

16.2 15.0

13.3

18.2

17.4 14.8 13.9

13.0

12.5

11.6

11.0

10.0 6.0

7.4 8.0

7.0

5.0


2001

2000

1999

1998

1997

1996

1995

1994

1993

1992

1991

1990

1989

1988

1987

1986

1985

1984

1983

1982

1981

0.0 1980

Percent Change (%)

20.0



U.S. Biotech Industry Financing, 2001

Total Amount (US$ Mil.)

Percent Share

$292.2

2%

Follow-ons 1

$3,510.8

23%

Public/Other

$7,227.0

48%

Venture Funding

$3,763.3

25%

$300.7

2%

$15,094.0

100%

Type of Financing

IPOs

Milestones and Equity2 Total

1 Follow-ons refer to the offering of new shares as a form of additional financing; typically occur after a company has had an initial public offering (IPO). 2 Milestones refer to additional capital invested in a firm when it meets pre-agreed benchmarks in drug development or sales.

Source: BioWorld.




Milestones and Equity2 2%

IPOs 2%

Follow-ons 23%

Venture Funding 25%

1

Public/Other 48%

U.S. Biotech Industry Fundraising, 1996-Third Quarter 2002 US$ Millions

Type

IPO Follow-On1 PIPEs2 Debt Venture Capital Other Total

1996

1997

$1,465 2,414 537 352

$688 1,601 1,283 1,288

$449 103

$569 184

$5,320

$5,613

1998

1999

Public $369 $670 521 5,805 977 1,433 1,262 1,520 Private $800 $1,084 84 184 $4,013

$10,696

2000

2001

2002 Nine Months*

$6,490 12,651 4,061 5,728

$440 2,539 1,741 4,848

$445 779 830 4,734

$2,872 203

$2,397 9

$2,160 128

$32,005

$11,974

$9,096

* Figures through third quarter 2002. 1 Refers to the offering of additional new shares as a form of financing; typically occurs after a company has had an initial public offering (IPO). 2 Private Investment, Public Equity; Occurs when a private investor or mutual fund buys common stock for a company at a discount to the current market value per share. Source: Burrill and Company.




Top 20 Global Biotech and Pharmaceutical Companies, 2001 Based on 2001 Sales US$ Thousands

Rank

Company Name

2001 Sales (US$ 000)

1

Merck & Co., Inc.

$47,716,000

2

Johnson & Johnson

$33,004,000

3

Pfizer, Inc.

$32,259,000

4

Bristol Myers Squibb

$19,423,000

5

Novartis AG

$19,070,000

6

Astrazeneca plc

$16,480,000

7

Abbott Laboratories

$16,285,000

8

Wyeth

$14,128,000

9

Akzo Nobel NV

$12,576,000

10

Eli Lilly & Co.

$11,542,000

11

Schering-Plough Corp.

$9,802,000

12

Baxter International, Inc.

$7,663,000

13

Syngenta AG

$6,323,000

14

Monsanto Co.

$5,462,000

15

Amgen, Inc.

$3,763,000

16

Novo-Nordisk AG

$2,839,000

17

Amersham plc

$2,206,400

18

Genentech, Inc.

$2,081,700

19

Teva Pharmaceutical Industries

$2,077,400

20

Allergan, Inc.

$1,745,500 Source: Plunkett Research, Ltd.




Major Biotechnology and Pharmaceutical Company Consolidations, 1st through 3rd Quarter 2002* Value in US$ Million Rank

Acquirer

Acquired

Value (US$ Mil.)

1

Pfizer

Pharmacia

$49,900

2

Guidant

Cook

3

Alkermes, Inc.

Reliant Pharmaceuticals

$847

4

Cytyc

Digene

$554

5

Johnson & Johnson

Tibotec-Viro NV

$320

6

Berna Biotech

Rhein Biotech

$257

7

Versicor, Inc.

Biosearch Italia S.p.A.

$236

8

Schering AG

Collateral Therapeutics

$140

9

Serono S.A.

Genset S.A.

$104

10

Bio-Technology General Corp.

Rosemont Pharmaceuticals

$100

11

Martek Biosciences

Omega Tech

$90

12

Inwest Investments

Drug Royalty Corp.

$84

13

Bayer AG

Visible Genetics

$61

14

Chiron

Matrix Pharmaceutical

$61

15

Martek Biosciences

Omega Tech

$53

16

deCode

MediChem Life Sciences

$49

17

Endo Pharmaceuticals Holdings

BML Pharmaceuticals

$46

18

Genencor International

Enzyme Bio-Systems

$30

19

Qiagen

GenoVision

$28

20

Harvard Bioscience

Genomic Solutions

$27

21

Deltagen

22

Charles River Laboratories

Biological Laboratories

$23

23

Amersham plc

CodeLink (Motorola)

$20

24

Proteome Sciences

Xzillion Proteomics

$18

25

Lion

NetGenics

$16

26

Argonaut

Jones Chromatography

$16

27

Qiagen

Xeragon

$3,000

Bristol-Myers Squibb Pharma Research Lab

$24

$9

* Mergers and acquisitions reflect available data through third quarter 2002. Plunkett Research, Ltd.; Burrill and Company.




The U.S. Drug Discovery, Development and Approval Process

Discovery/Preclinical Testing: 6.5 Years ~ Laboratory and animal studies to assess safety, biological activity and formulations 5,000 compounds evaluated

Phase I: 1.5 Years 20-100 Healthy Volunteers ~ Scientists study how the drug works and whether it is safe 5 compounds enter clinical trials

Phase II: 2 Years 100-500 Patient Volunteers ~ Drug is tested to evaluate effectiveness and look for side effects

Phase III: 3.5 Years 1,000-5,000 Patient Volunteers ~ Drug is tested to confirm effectiveness and monitor adverse reactions from long-term use

U.S. FDA Review: 1.5 Years ~ Drug review process and approval ~ NDAs typically run 100,000+ pages 1 compound is approved

Phase IV: Ongoing ~ Additional postmarketing testing required by FDA

Source: Dimasi, Joseph, Risks, Regulation and Rewards in New Drug Development in the United States, Regulatory Toxicology and Pharmacology, Vol. 19, 1994; Boston Consulting Group, January 1996; Tufts Center for the Study of Drug Development; New Medicines in Development Series, PhRMA, 2001.




Total U.S. Biotechnology Patents Granted Per Year, 1985-2000

Source: U.S. Patent and Trademark Office.




New U.S. Biotech Drug 1 and Vaccine and Indication 2 Approvals, 1982-2001

1

Drugs developed through biotechnology methods. Note the significant number of drugs approved after 1994. 2

Indication refers to a specific disease, illness or condition for which a drug is approved as a treatment. Typically, a new drug is first approved for one indication. Then, application to the FDA is later made for approval of additional indications. Source: Biotechnology Industry Organization.




U.S. Drug Development Times in Years

Decade

Pre-Clinical

Clinical

Approval

Total Time

1960's

3.2

2.5

2.4

8.1

1970's

5.1

4.4

2.1

11.6

1980's

5.9

5.5

2.8

14.2

1990's

5.6

6.7

1.8

14.1

Source: Burrill and Company.

Drug Development Times, U.S. (in years)

2.8

4.4

5.5

6.7

3.2

5.1

5.9

5.6

1960's

1970's

1980's

1990's

2.4 Years in Development

1.8

2.1

2.5

Pre-Clinical

Clinical

Approval




U.S. FDA* Approval Times for New Drugs, 1987-2001 Year

Approval Time (in Months)

1987

32.4

1988

31.3

1989

32.5

1990

27.7

1991

30.3

1992

29.9

1993

26.5

1994

19.7

1995

19.2

1996

17.8

1997

16.2

1998

11.7

1999

12.6

2000

17.6

2001

16.4

* U.S. Food and Drug Administration. Source: FDA.

U.S. FDA* Approval Times for New Drugs, 1987-2001 35

Approval Time in Months

30

32.4

31.3

32.5

30.3 27.7

29.9 26.5

25 19.7 20 15

19.2 17.8

17.6

16.2 11.7

16.4

12.6

10 5 0 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001




Average Salaries in the U.S. Pharmaceutical and Biotechnology Industries: 2002

Biostatistics MS Entry-Level

$48,000-$60,500

PhD Entry-Level:

$86,000-$96,500 Clinical Research

Junior Laboratory Technician:

$26,500

Senior Laboratory Technician:

$34,000

Associate:

$42,000-$49,000

Senior Associate:

$59,000–$72,000

Manager:

$73,000-$101,000

Clinical Research Physician:

$90,000-$200,000

Product Management Marketing Analyst/Associate Product Manager: Product Manager:

$38,000-$75,000 $60,000-$100,000

Quality Assurance: Specialist:

$36,000-$75,500

Engineer:

$42,000-$86,000 Regulatory Affairs

Associate:

$38,000-$48,000

Senior Associate:

$71,000-$84,000

Source: Salary.com, Wetfeet.com, Stax Research (2002).




Global Agricultural Biotech At A Glance, 2001 Top Transgenic* Crop Producing Countries, 2001 Rank

Country Name

Amount Grown (in millions of hectares)

Percentage of Global GM Total

1

United States of America

35.7

68%

2

Argentina

11.8

22%

3

Canada

3.2

6%

4

China

1.5

3%

52.2

99%

Total

Note: The U.S.A., Argentina, Canada and China grew 99% of the world's genetically modified crops in 2001. * Also referred to as genetically modified (GM) crops. Source: ISAAA; James, Clive. "Global Review of Commercialized Transgenic Crops: 2001," ISAAA Briefs No. 24: Preview.

Top Genetically Modified (GM) Crops, 2001 Based on Amount of Area Dedicated for Crop Rank

GM Crop Name

Amount of Land used for GM Crop Growth

Percentage of Global GM Area

(in millions of hectares) 1

GM Soybean

33.3

63%

2

GM Corn

9.8

19%

3

GM Cotton

6.8

13%

4

GM Canola

2.7

5%

52.6

100%

Total

Source: ISAAA; James, Clive. "Global Review of Commercialized Transgenic Crops: 2001," ISAAA Briefs No. 24: Preview.

Percent Distribution of Crops that are Genetically Modified (GM), 2001 Based on GM and non-GM crops

GM Crop

Total Area of Crop Grown Amount of Land used for (Based on GM and non-GM GM Crop Growth crops)

Percent of Total Crops that are Genetically Modified

(in millions of hectares) Soybean

72

33.3

46%

Corn

140

9.8

7%

Cotton

34

6.8

20%

Canola

25

2.7

11%

Total

271

52.6

19%

Source: ISAAA; James, Clive. "Global Review of Commercialized Transgenic Crops: 2001," ISAAA Briefs No. 24: Preview.




Chapter 3 IMPORTANT BIOTECH & GENETICS INDUSTRY CONTACTS Addresses, Telephone Numbers and World Wide Web Sites Contents: I. Biotech Associations II. Biotech Careers III. Biotech Investing IV. Biotech Publications V. Biotech Resources VI. Corporate Information VII. Engineering Associations VIII. Health Care Business and Professional Associations IX. Health Care Careers X. Health Care Resources XI. Industry Research/Market Research XII. Laboratories/Research XIII. Libraries XIV. Online Health Data XV. U.S. Government Agencies


p. 42 p. 42 p. 43 p. 44 p. 44 p. 46 p. 47 p. 48 p. 49 p. 49 p. 49 p. 50 p. 51 p. 51 p. 51


I.


Biotech Associations

BIOCOM/san diego 4510 Executive Dr., Plaza 1 San Diego, CA 92121 Phone: 858-455-0300 Fax: 858-455-0022 Web Address: www.biocom.org BIOCOM/san diego is a trade association for the life science industry.

Fax: 763-765-2329 Web Address: www.biomaterials.org The Society for Biomaterials is a professional society that promotes advances in all phases of materials research and development by encouragement of cooperative educational programs, clinical applications and professional standards in the biomaterials field.

II.

Biotech Careers

BioIndustry Association (The) 14/15 Belgrave Sq. London, England SW1X 8PS Phone: 44-207-565-7190 Fax: 44-207-565-7191 E-mail: [email protected] Web Address: www.bioindustry.org Promotes bioscience development in the U.K. economy.

Bio Online Career Center 2855 Telegraph Ave. Berkele y, CA 94705 E-mail: [email protected] Web Address: http://career.bio.com/careercenter/index.jhtml Provided by Bio Online, this site lets the user search an extensive database of jobs in the life sciences field.

Biotechnology Industry Organization 1625 K St. NW, Ste. 1100 Washington, DC 20006 Phone: 202-962-9200 Web Address: www.bio.org The BIO is involved in the research and development of health care, agricultural, industrial and environmental biotechnology products.

Biotechemployment.com 395 South End Ave., Ste. 15-D New York, NY 10280 Phone: 212-912-0175 E-mail: [email protected] Web Address: www.biotechemployment.com Online resource for job seekers in biotechnology. The site includes resume posting, job search agents and employer profiles.

Environmental Mutagen Society 11250 Roger Bacon Dr., Ste. 8 Reston, VA 20190 Phone: 703-437-4377 Fax: 703-435-4390 E-mail: [email protected] Web Address: www.ems-us.org Focuses on research on the basics of mutagenesis. Laboratory Robotics Interest Group 1730 W. Circle Dr. Martinsville, NJ 08836-2147 Phone: 732-302-1038 Fax: 508-464-7685 E-mail: [email protected] Web Address: www.lab-robotics.org Focuses on the application of robotics in the laboratory. Society for Biomate rials 13355 10th Ave. N, Ste. 108 Minneapolis, MN 55441-5510 Phone: 763-543-0908

Chemist Jobs Phone: 44-151-647-0008 Fax: 44-151-647-0047 E-mail: [email protected] Web Address: www.chemjobs.net Leading Internet site for job seekers in chemistry and related fields. The site is aimed at chemists, biochemists, pharmaceutical scientists and chemical engineers looking for work. Clinical Research Job-Site E-mail: [email protected] Web Address: www.job-sites.com/cr/crjobs.htm Job listings for jobseekers in the clinical research field. Searchable by geographic location. Direct Links to Jobs at Bio Tech Biopharmaceutical Companies Web Address: www.sackskolken.com/links/USA/jobs/BioPlace.htm l




List of biotech employer links. This site links you to the company's employment page as well as the home page or site map.

Monthly newsletter that provides analysis, commentary, news and company developments for biotechnology investors.

Employment Links for the Biomedical Scientist Web Address: www.his.com/~graeme/employ.html Compiled by a fellow scientist, this site offers a list of links for jobseekers using the Internet to locate work in the biomedical field.

BioVenture Consultants Web Address: www.bioventureconsultants.com Provides consulting services, from business plan development to strategic planning, for bioscience companies. Also offers an extensive biotech tutorial.

PlanetJobs Web Address: www.bioplanet.com/planetforums/forumdisplay.php? fid=1 Posts jobs in the bioinformatics field by date.

Burrill & Company One Embarcadero Center, Ste. 2700 San Francisco, CA 94111 Phone: 415-591-5400 Fax: 415-591-5401 E-mail: [email protected] Web Address: www.burrillandco.com A private merchant bank concentrated on companies in the life sciences industries: biotechnology, pharmaceuticals, medical technologies, agricultural technologies, animal health and nutraceuticals.

Science Jobs Web Address: www.science-jobs.org/index.htm Online site for jobseekers in science. Contains many useful categories of links including employment newsgroups, scientific journals and placement agencies. Sciencejobs.com 275 Washington St. Newton, MA 02458 Phone: 617-558-4904 Fax: 617-558-4933 Web Address: www.sciencejobs.com/bio Produced by the publishers of Cell, BioMednet and New Scientist, this site helps jobseekers and employers in the bioscience fields find each other. Includes a job search engine and a free-of-charge email job alert service. SciWeb Biotechnology Career Center (The) 2934 Beverly Glen Circle PMB 403 Bel Air, CA 90077 E-mail: [email protected] Web Address: www.biocareer.com Database of biotechnology jobs. Provides access to a job search engine, resume posting, a discussion forum, career articles and career publications.

III.

Biotech Investing

BioTech Sage Report P.O. Box 7274 Beaverton, OR 97007-7274 Phone: 503-649-1355 Fax: 503-649-4490 Web Address: www.biotechnav.com

Medical Technology Stock Letter P.O. Box 40460 Berkeley, CA 94704 Phone: 510-843-1857 Fax: 510-843-0901 E-mail: [email protected] Web Address: www.bioinvest.com The eight-page newsletter provides financial advice about investing in biotechnology. Distributed by mail and electronically. SmallCaps Online Group LLC 1285 Avenue of the Americas, 35th Fl. New York, NY 10019 E-mail: [email protected] Web Address: www.smallcapsonline.com Online investment research information on small cap companies in the biotechnology and Internet industries. Techvest LLC 521 5th Ave., 26th Fl. New York, NY 10175 Phone: 212-262-4646 Fax: 212-262-4360 E-mail: [email protected] Web Address: www.techvestllc.com An investment banking, investment research and consulting firm that specializes in the biotech and health care sectors.



IV.


Biotech Publications

BioWorld Online 3525 Piedmont Rd. Bldg. 6, Ste. 400 Atlanta, GA 30305 Phone: 404-262-5476 Toll Free: 800-688-2421 E-mail: [email protected] Web Address: www.bioworld.com Provides daily newspapers for the biotech industry, attainable via fax and online. Genetic Engineering News 2 Madison Ave. Larchmont, NY 10538 Phone: 914-834-3100 Fax: 914-834-3729 E-mail: [email protected] Web Address: www.genengnews.com The most widely read publication in the field of biotechnology. Offers news on biotechnology, bioregulation, bioprocess, bioresearch and technology transfer. The web site also provides daily biotech news. PJB Publications, Ltd. 18/20 Hill Rise Richmond, Surrey TW10 6UA UK Phone: 44-0-20-8948-3262 Fax: 44-0-20-8332-8993 E-mail: [email protected] Web Address: www.pjbpubs.com/cms.asp Produces several publications and books for the pharmaceutical industry. Signals Phone: 415-433-1720 E-mail: [email protected] Web Address: www.signalsmag.com Online magazine of analysis for the biotechnology industry. Provides trends dealing with biotechnology, medical device and pharmaceutical companies involved in the development of medical products. Windhover Information 10 Hoyt St. Norwalk, CT 06851 Phone: 203-838-4401 Fax: 203-838-3214 E-mail: [email protected] Web Address: www.windhoverinfo.com

Provides analysis and commentary on health care and biotech business strategy.

V.

Biotech Resources

Bio Online 2855 Telegraph Ave., Ste. 210 Berkeley, CA 94705 Phone: 510-548-1171 Fax: 510-548-1173 E-mail: [email protected] Web Address: www.bio.com This site is an online community of scientists, professionals, businesses and organizations supporting life science for the purpose of an exchange of information. BioAbility P.O. Box 14569 Research Triangle Park, NC 27709-4569 Phone: 919-544-5111 Fax: 919-544-5401 E-mail: [email protected] Web Address: www.bioability.com Provides strategic business information to the biotechnology, pharmaceutical and life science industries. Bioengineering Industry Links Web Address: www.seas.upenn.edu/be/misc/bmelink/cell.html Provided by the University of Pennsylvania's Department of Bioengineering, this site features links to companies involved in cell and tissue engineering. Biofind Web Address: www.biofind.com This biotechnology portal offers a biotech job search, a biotech chat room, biotech event announcements as well as a place to post biotech innovations for companies to invest in. Biospace.com 245 11th St. San Francisco, CA 94103 Phone: 415-355-6500 Fax: 415-503-1070 Toll Free: 888-246-7722 Web Address: www.biospace.com Biospace.com offers information, breaking news and profiles on biotech companies.




Bio-Tech Info What's New Web Address: www.biotech-info.net/new.html Site discussing news in the biotechnology industry. BioTech Web Address: http://biotech.icmb.utexas.edu This site offers a comprehensive dictionary of biotech terms, plus extensive research data regarding biotechnology. Biotech Law Web Server Links Web Address: www2.ari.net/foley/page2.html Directory of links of biotech and pharmaceutical databases, publications and companies. Biotech Professional Resources Web Address: http://biotech.icmb.utexas.edu/pages/prores.html Contains a brief list of biotechnology links, including links to employment, funding, university programs, research facilities, organizations and biotechnology regulations. Biotech Rumor Mill E-mail: [email protected] Web Address: www.biofind.com/rumor An open discussion forum that attracts participants from the many biotech disciplines. Biotech Science Resources Web Address: http://biotech.icmb.utexas.edu/pages/scitools.html Links in several areas of biotech including molecular biology, genetics, biochemistry, microbiology and medicine. Biotech Web Links Web Address: www.biotech.ufl.org/BiotechWebLinks.html Broad list of biotech links, including links related to approved biotech drugs, databases, educational resources and biotech legislative information. Biotechnology Hot Links Web Address: http://strategis.ic.gc.ca/SSG/tc00057e.html Canadian site that offers links related to gene therapy, genetic testing and xenotransplantation. Biotechnology Information Directory Section Phone: 919-361-2286 Fax: 919-361-2290 E-mail: [email protected]

Web Address: www.cato.com/biotech Contains over 1,500 links of companies, research institutes, universities, sources of information and other directories related to biotechnology, pharmaceutical development and similar fields. Focuses on product development. Biotechnology Knowledge Center Web Address: www.biotechknowledge.com Supported by Monsanto, an online resource containing news, technical documents, a discussion board and a glossary. Biotechnology Links and Resource Guide Page Web Address: www.ukabc.org Provides links to life sciences and seeds companies, databases and information resources, publicly funded research bodies and industry associations. Biotechnology Program List of Links E-mail: [email protected] Web Address: www.biotech.ucdavis.edu Offers an index of links that concerns biotech funding, biotech companies and other assorted biotech topics. Biotechnology Resources on the Internet Web Address: www.sosei.com Assorted biotechnology links including biotech companies, biotech news, biotech vendors, jobs, government resources and pharmaceutical resources. Biotechterms.org Glossary of Biotech Terms Web Address: http://biotechterms.org Online version of Kimball R. Nill's book Glossary of Biotechnology Terms. The user can search the glossary by term for a definition. Business, Regulatory and Biotech Links Web Address: www.intrex.net/agbiotech/busbiot.htm Biotechnology and agriculture-based biotechnology links. Genetic Education Center: Human Genome Project Resources E-mail: [email protected] Web Address: www.kumc.edu/gec/prof/hgc.html List of links related to the human genome including human genome centers, information sites and news articles. Genetic Engineering for Non-Scientists Web Address: www.dnapatent.com/science




A brief primer on genetic engineering in layman's terms. Genetics of Cancer E-mail: [email protected] Web Address: www.intouchlive.com/cancergenetics An information resource on the genetic basis of cancer. Site contains a bulletin board, a list of case histories on various inherited forms of cancer and a collection of links on the latest concepts and terminology in genetics and cancer. Genomics, Biotech, Drug Discovery and IPR Links Web Address: www.sussex.ac.uk/Users/prpc9/links.htm Links to biotechnology companies, genome centers and pharmaceutical companies. GrantsNet Web Address: www.grantsnet.org Free online service to locate funding for training in the biomedical science industry and undergraduate science education. International Communication Forum in Human Genetics E-mail: [email protected] Web Address: www.hum-molgen.de One of the leading sources on the Web for the latest information in human molecular genetics. Contains artwork, news articles, a bulletin board and a variety of other services. Kruglick's Forensic DNA Links Web Address: www.kruglaw.com/f_dna.htm Contains a useful list of forensic links. MedWeb: Biomedical Internet Resources Web Address: www.medweb.emory.edu/MedWeb MedWeb lists resources by medical field and allows searches for articles by topic or date. Microbiology Network (The) Web Address: www.microbiol.org A communication starting point for microbiologists. The site incoudes a discussion forum, user's groups and extensive file libraries. Miscellaneous Resources Web Address: www.arabidopsis.com/main/msc/misc.html Diversified biotech links.

Patent Law for Non-Lawyers Web Address: www.dnapatent.com/law/index.html Informative site on how to patent in the industry of biotech and genetic engineering. Assumes a working knowledge of the industry. Also contains a discussion forum. PharmaPortal.com Web Address: www.pharmaportal.com Pharmaceutical portal containing news articles, searchable product database, career services, classified advertisements and various other links. Recombinant Capital 2033 N Main St., Ste. 1050 Walnut Creek, CA 94596-3722 Phone: 925-952-3870 Fax: 925-952-3871 E-mail: [email protected] Web Address: www.recap.com Contains databases of public information, including press releases, clinical trial references and a library of analyzed collaborations. Tufts Center for the Study of Drug Development 192 South St., Ste. 550 Boston, MA 02111 Phone: 617-636-2187 Web Address: http://csdd.tufts.edu Affiliated with Tufts University, the center provides analyses and commentary on pharmaceutical issues. Its mission is to improve the quality and efficiency of pharmaceutical development, research and utilization. WWW Virtual Library: Microbiology & Virology E-mail: [email protected] Web Address: www.microbiol.org/vlmicro/vl_assoc.htm Contains lists of organizations and associations in the fields of microbiology, biology and general science. User can also submit new links.

VI.

Corporate Information

Business Wire Web Address: www.businesswire.com Business Wire strives to deliver news in an appropriate and innovative manner. Smart News releases, industry-specific and company-specific news, today's headlines, conference calls, IPOs on the Internet, media services, Tradeshownews.com and




BW Connect On-line are all accessible through this informative and continuously updated site. CNNfn Home Page Web Address: http://money.cnn.com Provides the same in-depth financial information online that CNN's cable television financial news unit provides to television viewers. Disclosure Web Address: www.disclosure-investor.com An integrated site offering financial information from Disclosure, Inc., Datastream International, Vestek Systems and I/B/E/S, each Primark subsidiaries and leaders in the financial information field. Edgar Online Web Address: www.edgar-online.com A gateway and search tool for viewing corporate documents, such as annual reports on form 10K, filed with the U.S. Securities Exchange Commission. Hoover’s Online 5800 Airport Blvd. Austin, TX 78752 Phone: 512-374-4500 Fax: 512-374-4505 Toll Free: 800-486-8666 Web Address: www.hoovers.com Hoover's provides thousands of corporate profiles online. This comprehensive site also features links to news, lists, stock quotes and other corporate and business data. PRNewswire 810 7th Ave., 35th Fl. New York, NY 10019 Phone: 212-596-1500 Toll Free: 800-832-5522 E-mail: [email protected] Web Address: www.prnewswire.com PR Newswire provides comprehensive communications services for public relations and investor relations professionals ranging from information distribution and market intelligence to the creation of online multimedia content and investor relations web sites. Users can also view recent corporate press releases. Silicon Investor InfoSpace, Inc. 601 108th Ave. NE, Ste. 1200 Bellevue, WA 98004

Phone: 425-201-6100 Fax: 425-201-6150 Web Address: www.siliconinvestor.com Silicon Investor is focused on technology companies. The site serves as a financial discussion forum and offers quotes, profiles and charts.

VII.

Engineering Associations

American Society of Agricultural Engineers 2950 Niles Rd. St. Joseph, MI 49085 Phone: 269-429-0300 Fax: 269-429-3852 E-mail: [email protected] Web Address: www.asae.org Nonprofit professional and technical organization of members interested in engineering knowledge and technology for food and agriculture, associated industries and related resources. Institute of Biological Engineering 3938 West Rd., Ste. 277 Cortland, NY 13045 Phone: 607-753-9227 Fax: 607-753-9227 Toll Free: 877-423-2255 E-mail: [email protected] Web Address: www.ibeweb.org Professional organization encouraging inquiry and interest in biological engineering. International Society of Pharmaceutical Engineers 3816 W. Linebaugh Ave., Ste. 412 Tampa, FL 33624 Phone: 813-960-2105 Fax: 813-264-2816 Web Address: www.ispe.org Worldwide, nonprofit society of technical professionals who apply their practical knowledge in the regulated health care manufacturing industries. SRI International 333 Ravenswood Ave. Menlo Park, CA 94025-3493 Phone: 650-859-2000 Fax: 650-326-5512 Toll Free: 866-451-5998 E-mail: [email protected] Web Address: www.sri.com A nonprofit organization offering a wide range of services, including engineering services, information technology, pure and applied physical sciences,




product development, pharmaceutical discovery, biopharmaceutical discovery and policy issues.

VIII. Health Care Business and Professional Associations Advanced Medical Technology Association 1200 G St. NW, Ste. 400 Washington, DC 20005-3814 Phone: 202-783-8700 Fax: 202-783-8750 E-mail: [email protected] Web Address: www.himanet.com AdvaMed strives to be the advocate for a legal, regulatory and economic climate that advances global health care by assuring worldwide patient access to the benefits of medical technology. American Association of Blood Banks 8101 Glenbrook Rd. Bethesda, MD 20814-2749 Phone: 301-907-6977 Fax: 301-907-6895 E-mail: [email protected] Web Address: www.aabb.org The AABB promotes high standards of care for blood banking and transfusion medicine. American Medical Technologists 710 Higgins Rd. Park Ridge, IL 60068 Phone: 847-823-5169 Fax: 847-823-0458 E-mail: [email protected] Web Address: www.amt1.com AMT is a nonprofit certification agency and professional membership association representing individuals in allied health care.

E-mail: [email protected] Web Address: www.ashe.org The ASHE is the advocate and resource for continuous improvement in the health care engineering and facilities management professions. Health Industry Distributors Association 310 Montgomery St. Alexandria , VA 22314 Phone: 703-549-4432 Fax: 703-549-6495 E-mail: [email protected] Web Address: www.hida.org The HIDA is the international trade association representing medical products distributors. Health Sciences Communication Association 39 Wedgewood Dr., Ste. A Jewett City, CT 06351 Phone: 860-376-5915 Fax: 860-376-6621 E-mail: [email protected] Web Address: www.hesca.org The HSCA is an association of communications professionals committed to sharing knowledge and resources in the health sciences arena. Independent Medical Distributors Association 5800 Foxridge Dr., Ste. 115 Mission, KS 66202-2740 Phone: 913-262-4513 Fax: 913-262-0174 Toll Free: 800-398-5632 E-mail: [email protected] Web Address: www.imda.org

American Pharmaceutical Association 2215 Constitution Ave. NW Washington, DC 20037 Phone: 202-628-4410 Fax: 202-783-2351 Web Address: www.aphanet.org APhA is the national professional society of pharmacists.

International Association of Medical Equipment Remarketers & Servicers 9896 E Roadrunner Dr. Scottsdale , AZ 85262 Fax: 480-575-0891 Toll Free: 877-304-2637 E-mail: [email protected] Web Address: www.iamers.org IAMERS works to improve the quality of pre-owned medical equipment, both domestically and internationally.

American Society for Healthcare Engineering One N Franklin, 27th Fl. Chicago, IL 60606 Phone: 312-422-3800 Fax: 312-422-4571

Medical Device Manufacturers Association 1900 K St. NW, Ste. 300 Washington, DC 20006 Phone: 202-496-7150 Web Address: www.medicaldevices.org




The MDMA is a national trade association that represents independent manufacturers of medical devices, diagnostic products and health care information systems. Michigan Medical Device Association P.O. Box 170 Howell, MI 48844 Fax: 517-546-3356 Toll Free: 800-930-5698 E-mail: [email protected] Web Address: www.mmda.org The MMDA sponsors educational seminars and informational programs, is active in the areas of government relations, networking and business development and acts as a source for the dissemination of matters of interest to its members. Pharmaceutical Research and Manufacturers of America 1100 15th St. NW Washington, DC 20005 Phone: 202-835-3400 Web Address: www.phrma.org Represents the nation's leading research-based pharmaceutical and biotechnology companies.

IX.

Health Care Careers

4Work.com Web Address: www.4work.com This site contains tens of thousands of job openings and offers full search capability. Users can also post resumes. America's Health Care Source -Careers Web Address: www.healthcaresource.com This site offers career-related information for health care professionals.

X.

Health Care Resources

Access Excellence Web Address: www.accessexcellence.org Provides information for high school biology and life science teachers. Produced by the National Health Museum. Bioethics.net 3401 Market St., Ste. 320 Philadelphia , PA 19104-3308 Phone: 215-898-7136

Fax: 215-573-3036 Web Address: www.med.upenn.edu/~bioethic/ The web's first and largest site on bioethics. Discusses ethics dealing with human cloning, genetic engineering and other related scientific advances. CellsAlive.com Web Address: www.cellsalive.com Contains color images of cells and bacteria. Also covers cell biology, microbiology, immunology and microscopy. Aimed at the classroom setting. Citeline.com Web Address: www.citeline.com Allows user to search for information on diseases and therapies. Medical Biochemistry Subject List (The) Web Address: http://web.indstate.edu/thcme/mwking/subjects.html Produced by Indiana State University. A text-based introduction to biochemistry.

XI.

Industry Research/Market Research

Debbie Flanagan’s Industry Information E-mail: [email protected] Web Address: http://home.sprintmail.com/~debflanagan/industry.ht ml This site provides a wealth of information about where and how to get industry-specific information. The links are useful for job seekers and researchers of all types. Marketresearch.com 11810 Parklawn Dr. Rockville , MD 20852 Phone: 301-468-3650 Fax: 301-468-3651 Web Address: www.marketresearch.com This firm is a leading broker for market research and industry analysis written by professionals. Users can search the company's database of market research publications. Mindbranch 160 Water St. Williamstown, MA 01267 Phone: 413-458-7600 Fax: 413-458-1706 Toll Free: 800-774-4410 Web Address: www.mindbranch.com




This firm is a broker for industry research prepared by market research professionals. Users can browse the research organized by different industries. Multex Investor Web Address: www.multexinvestor.com This site is a good source for industry and company reports written by professional stock and business analysts. It also offers news and advice on stocks, funds and personal finance. Plunkett Research, Ltd. P.O. Drawer 541737 Houston, TX 77254-1737 Phone: 713-932-0000 Fax: 713-932-7080 E-mail: [email protected] Web Address: www.plunkettresearch.com Plunkett Research, Ltd. is a leading provider of market research, industry trends analysis and business statistics. Since 1985, it has served clients worldwide, including corporations, universities, libraries, consultants and government agencies. At the firm's web site, visitors can view product information and pricing, and visitors can access a great deal of basic market information on industries such as financial services, infotech, e-commerce, health care and biotech.

XII.

Laboratories/Research

Alberta Research Council 250 Karl Clark Rd. Edmonton, Alberta T6N 1E4 Canada Phone: 780-450-5111 Fax: 780-450-5333 E-mail: [email protected] Web Address: www.arc.ab.ca Provides research and development services on a contract basis. Access to resources at facilities in western Canada and to 600 experienced scientists, researchers and business experts. Applied Research Laboratories P.O. Box 8029 Austin, TX 78713 Phone: 512-835-3200 Fax: 512-835-3259 Web Address: www.arlut.utexas.edu Applied Research Laboratories at the University of Texas provides organizational directories and electronic resources.

Battelle Memorial Institute 505 King Ave. Columbus, OH 43201 Phone: 614-424-6424 Toll Free: 800-201-2011 Web Address: www.battelle.org Serves industry and government in developing new technologies and products. Inserts technology into systems and processes for manufacturers; pharmaceutical and agrochemical industries; trade associations and government agencies supporting energy, the environment, health, national security and transportation. The company has annual revenues of approximately $1 billion. Canada's National Research Council National Research Council of Canada, Building M-58 1200 Montreal Rd. Ottawa, Ontario K1A 0R6 Canada Phone: 613-993-9084 Fax: 613-952-7656 Toll Free: 877-672-2672 E-mail: [email protected] Web Address: www.nrc.ca Sixteen research institutes carry out multidisciplinary research with partners in industries and sectors key to Canada's economic development. Commonwealth Scientific and Industrial Research Organization Bag 10 Clayton South, VIC 3169 Australia Phone: 61-3-9545-2176 Fax: 61-3-9545-2175 E-mail: [email protected] Web Address: www.csiro.au Performs research and development over a broad range of areas including agriculture, minerals and energy, manufacturing, communications, construction, health and the environment. Computational Neurobiology Laboratory 10010 N. Torrey Pines Rd. La Jolla , CA 92037 Phone: 858-453-4100 Web Address: www.cnl.salk.edu Aimed at understanding the computational resources of the brain from the biophysical to the systems levels Daresbury Laboratory Daresbury, Warrington Cheshire, UK WA4 4AD




Phone: 44-1925-603000 Fax: 44-1925-603100 E-mail: [email protected] Web Address: www.dl.ac.uk Operated by the Council of the Central Laboratory of Research Councils, a strong resource in computational science and engineering.

XIII. Libraries Library and Info Systems Web Address: www.cellbio.wustl.edu/library.htm This site provides information on libraries at various higher institutions of learning in the United States. Multimedia Medical Reference Library Web Address: http://med-library.com/medlibrary The MMRL provides a free resource of medical information for both health care consumers and medical professionals. Well Cornell Medical Library E-mail: [email protected] Web Address: http://lib2.med.cornell.edu WWW Virtual Library: Bioscience – Medicine Oregon Health Sciences University, School of Medecine, Office of the Dean 3181 SW Sam Jackson Park Rd., L102 Portland, OR 97201 Phone: 503-494-8220 Web Address: www.ohsu.edu/cliniweb/wwwvl

XIV.

Online Health Data

MEDMarket 311 Sherman Ave. Coeur d'Alene, ID 83843 Web Address: www.medmarket.com MEDMarket serves as an online guide to the Healthcare Manufacturers Industry, featuring employment listings, an industry index and more. Medscape WebMD Medscape Health Network 224 W 30th St. New York, NY 10001-5399 Web Address: www.medscape.com Medscape, an online resource for better patient care, provides links to several journal articles, health carerelated sites and health care information.

PubMed Web Address: http://www.ncbi.nlm.nih.gov/entrez/query PubMed provides access to over 11 million MEDLINE citations dating back to the mid-1960s and additional life science journals. WEBMD.com 669 River Dr., Ctr. 2 Elmwood Park, NJ 07407 Phone: 201-703-3400 Fax: 201-703-3401 Web Address: www.WEBMD.com WebMD features a broad selection of interrelated health topics, current medical news and its own search engine.

XV.

U.S. Government Agencies

Department of Energy 1000 Independence Ave. SW Washington, DC 20585 Fax: 202-586-4403 Toll Free: 800-342-5363 Web Address: www.energy.gov Food and Drug Administration 5600 Fishers Ln. Rockville , MD 20857 Phone: 301-443-6597 Fax: 301-443-8818 Toll Free: 888-463-6332 Web Address: www.fda.gov The FDA strives to promote and protect public health by helping safe and effective products reach the market in a timely way and monitoring products for continued safety after they are approved for use. National Cancer Institute 6116 Executive Blvd., MSC 8322, Ste. 3036A Bethesda, MD 20892 Phone: 301-435-3848 Toll Free: 800-422-6237 Web Address: www.cancer.gov The NCI is the federal government's principal agency for cancer research and training. National Center for Biotechnology Information National Library of Medicine Bldg. 38 A Bethesda, MD 20894 Phone: 301-496-2475 Web Address: www.ncbi.nlm.nih.gov




National Center for Infectious Diseases Office of Health Communication, National Center for Infectious Diseases, CDC Mailstop C-14, 1600 Clifton Rd. Atlanta, GA 30333 Toll Free: 800-311-3435 Web Address: www.cdc.gov/ncidod

Arlington, VA 22230 Phone: 703-292-5111 Toll Free: 800-877-8339 E-mail: [email protected] Web Address: www.nsf.gov Independent government agency responsible for promoting science and engineering.

National Center for Research Resources 6705 Rockledge Dr., Ste. 5140 Bethesda, MD 20892 Phone: 301-435-0888 Web Address: www.ncrr.nih.gov The NCRR supports primary research to create and develop critical resources, models and technologies.

Oak Ridge National Laboratory P.O. Box 2008 Oak Ridge, TN 37831 Web Address: www.ornl.gov Multiprogram science and technology laboratory managed for the U.S. Department of Energy by U.T.Battelle, LLC. Conducts basic and applied research and development to create scientific knowledge and technological solutions.

National Center for Toxicological Research 3900 NCTR Rd. Jefferson, AR 72079 Phone: 870-543-7130 E-mail: [email protected] Web Address: www.fda.gov/nctr National Heart, Lung, and Blood Institute (NHLBI) Phone: 301-496-4236 E-mail: [email protected] Web Address: www.nhlbi.nih.gov The NHLBI provides leadership for a national program in diseases of the heart, blood vessels, lung and blood; blood resources; and sleep disorders.

United States Patent and Trademark Office General Information Services Division, U.S. Patent and Trademark Office Crystal Plaza 3, Room 2C02 Washington, DC 20231 Phone: 703-308-4357 Toll Free: 800-786-9199 Web Address: www.uspto.gov

National Human Genome Research Institute (NHGRI) Communications and Public Liaison Branch, NHGRI Bldg. 31, Room 4B09 31 Center Dr., MSC 2152 9000 Rockville Pike Bethesda, MD 20892-2152 Phone: 301-402-0911 Fax: 301-402-2218 Web Address: www.genome.gov National Institutes of Health Bethesda, MD 20892 Phone: 301-496-4000 E-mail: [email protected] Web Address: www.nih.gov The NIH is the steward of medical and behavioral research for the nation. National Science Foundation 4201 Wilson Blvd. Copyright©2003 Plunkett Research, Ltd., All Rights Reserved



Chapter 4 THE BIOTECH & GENETICS 400: WHO THEY ARE AND HOW THEY WERE CHOSEN Includes Indexes by Company Name, Industry & Location, And a Complete Table of Sales, Profits and Ranks

The companies chosen to be listed in PLUNKETT’S BIOTECH & GENETICS INDUSTRY ALMANAC are not the same as the “Fortune 500” or any other list of corporations. THE BIOTECH & GENETICS 400 (the actual count is 395 companies) were chosen specifically for their dominance in the many facets of biotech and genetics in which they operate. Complete information about each firm can be found in the “Individual Profiles,” beginning later in this chapter. These profiles are in alphabetical order by company name. THE BIOTECH & GENETICS 400 includes companies from all parts of the United States, Canada, Europe and beyond, and from all biotech and related industry segments: manufacturers and distributors of supplies and products; pharmaceuticals manufacturers; drug delivery system manufacturers; labs and testing services; blood and organ banks; nutriceutical manufacturers; related computer software and hardware companies and diagnostics firms. In fact, many fields that have only existed a few years are included, such as micro array makers

and companies dedicated to research and development in genomics and proteomics. Simply stated, the list contains 395 of the largest, most successful, fastest growing firms in biotech and related industries in the world. To be included in our list, the firms had to meet the following criteria: 1) U.S. based, for-profit corporations. (We have also added 48 foreign-based companies in order to better list leading firms in certain industry sectors.) 2) Publicly-held companies where stocks or bonds issued by the firm have been sold to the public (except for a very small number of firms that are privately-held that we have added in order to roundout certain niche sets of companies). 3) Prominence, or a significant presence, in biotech and supporting fields. (See the following Industry Codes section for a complete list of types of businesses that are covered). 4) The companies in THE BIOTECH & GENETICS 400 do not have to be exclusively in the biotech field.




5) Financial data and vital statistics must have been available to the editors of this book, either directly from the company being written about or from outside sources deemed reliable and accurate by the editors. A small number of companies that we would like to have included are not listed because of a lack of sufficient, objective data. The companies were chosen in this manner for the following reasons: • 395 companies so there is a broad base among which to make comparisons, and from which you can study the major players in this industry. • Non-Government because information about government research agencies can be obtained elsewhere, and so that researchers using PLUNKETT’S BIOTECH & GENETICS INDUSTRY ALMANAC can best study firms in the profit-seeking private sector, where innovative research and development are creating dynamic changes. • Companies with publicly traded stocks because publicly-held firms can be compared fairly, since they are required by law to meet government standards in their methods of reporting, and accounting for, their vital statistics.

INDUSTRY LIST, WITH CODES This book refers to the following list of unique industry codes, based on the NAIC code system (NAIC is used by many analysts as a replacement for older SIC codes because NAIC is more specific to today’s industry sectors): Health Care 325412 325413 325414 339113 325411

621511 621991

Manufacturing 325000

INDEXES TO THE BIOTECH & GENETICS 400, AS FOUND IN THIS CHAPTER AND IN THE BACK OF THE BOOK: Industry List, With Codes Index of Rankings Within Industry Groups Alphabetical Index Geographic Indexes Index of Headquarters Location, by State Index of Headquarters Location, by Country Index by Regions Where THE BIOTECH & GENETICS 400 Have Locations Index by Firms with International Operations Index of Firms Noted as “Hot Spots for Advancement” for Women/Minorities Index by Subsidiaries, Brand Names and Selected Affiliations

p. 54 p. 55 p. 64 p. 67 p. 71

Health Products, Manufacturing Drugs, Manufacturing In Vitro Diagnostic Substance, Manufacturing Biological Products Medical/Dental/Surgical Equipment and Supplies, Manufacturing Medicinal and Botanicals, Manufacturing Health Care-Clinics, Labs and Organizations Laboratories and Diagnostics --Medical Blood and Organ Banks

Chemicals Chemicals, Manufacturing

InfoTech 334413 334515

p. 72

511200

p. 78

514210

Computers & Electronics Manufacturing Chips (Semiconductors)/Integrated Circuits/Components, Manufacturing Test Equipment/Instruments, Manufacturing Software Computer Software Information & Data Processing Services Data Processing Services

p. 498

Services

p. 500

115112

541613 541710

Agriculture Agriculture, Crop Production Support Activities Consulting & Professional Services Consulting--Marketing Research and Development--Physical, Engineering and Life Sciences




INDEX OF RANKINGS WITHIN INDUSTRY GROUPS

Company

Industry Code

2001 Sales (Thousands)

2001 Profits

Sales Rank

(Thousands)

Profits Rank

Agriculture, Crop Production Support Activities

EXELIXIS PLANT SCIENCES INC SYNGENTA AG

115112 115112

6,323,000

1

223,000

1

28,900 11,300 9,000 3,900 2,352 4,700 13,700 27,800

1 4 6 8 9 7 3 2

10,300 800

5 10

-28,400 -6,800 -10,300 -4,600 -16,105 -56,500 -16,600 -2,100 -10,174 -30,100 -3,400

9 4 6 3 7 11 8 1 5 10 2

1 2

17,100 -23,400

1 2

2 1 3

598,000 4,339,000 295,000

2 1 3

Biological Products

ADVANCED TISSUE SCIENCES ANIKA THERAPEUTICS INC BIOSPHERE MEDICAL INC DIACRIN INC DONLAR BIOSYNTREX EMISPHERE TECHNOLOGIES GTC BIOTHERAPEUTICS INC LIFECELL CORPORATION NORTHFIELD LABORATORIES ORGANOGENESIS INC STEMCELLS, INC

325414 325414 325414 325414 325414 325414 325414 325414 325414 325414 325414

Blood and Organ Banks

SEROLOGICALS CORP V I TECHNOLOGIES INC

621991 621991

109,800 26,900

Chemicals, Manufacturing

AKZO NOBEL NV E I DU PONT DE NEMOURS & CO MONSANTO CO

325000 325000 325000

12,576,000 24,726,000 5,462,000

Chips (Semiconductors)/Integrated Circuits/Components, Manufacturing

AFFYMETRIX INC CALIPER TECHNOLOGIES CORP CIPHERGEN BIOSYSTEMS INC NANOGEN INC

334413 334413 334413 334413

224,900 26,900 19,000 11,200

1 2 3 4

-33,100 3,800 -25,800 -32,500

4 1 2 3

25,200 10,000 49,100

2 3 1

-21,400 -12,356 5,900

3 2 1

1,332,900

1

185,400

1

28,000

1

-3,800

1

16,285,000 63,606 19,600 200 6,000 42,200 11,805

9 61 95 221 138 71 108

1,550,000 -60,856 -4,500 -6,000 800 -19,600 -57,043 -2,300

9 217 87 96 55 157 213 75

Computer Software

INFORMAX INC LION BIOSCIENCE AG TRIPOS INC

511200 511200 511200 Consulting--Marketing

IMS HEALTH INC

541613

Data Processing Services

ERESEARCH TECHNOLOGY

514210 Drugs, Manufacturing

ABBOTT LABORATORIES ABGENIX INC ABLE LABORATORIES ACCESS PHARMACEUTICALS ADVANCED MAGNETICS INC AKORN INC ALEXION PHARMACEUTICALS ALFACELL CORPORATION

325412 325412 325412 325412 325412 325412 325412 325412




Company ALIZYME PLC ALLERGAN INC ALLIANCE PHARMACEUTICAL ALLOS THERAPEUTICS INC ALPHARMA INC ALTEON INC ALZA CORP AMARILLO BIOSCIENCES INC AMARIN CORPORATION PLC AMGEN INC AMYLIN PHARMACEUTICALS ANDRX CORP ANGIOTECH PHARMACEUTICALS ANTEX BIOLOGICS INC ANTIGENICS INC APHTON CORP ARENA PHARMACEUTICALS ARIAD PHARMACEUTICALS ASCENT PEDIATRICS INC ASTRAZENECA PLC ATLANTIC TECHNOLOGY VENTURES AUTOIMMUNE INC AVANIR PHARMACEUTICALS AVANT IMMUNOTHERAPEUTICS AVAX TECHNOLOGIES INC AVENTIS SA AVI BIOPHARMA INC AVIGEN INC AXONYX INC BARR LABORATORIES INC BENTLEY PHARMACEUTICALS BIGMAR INC BIO TECHNOLOGY GENERAL BIOCRYST PHARMACEUTICALS BIOGEN INC BIOMARIN PHARMACEUTICAL BIOMIRA INC BIOPURE CORPORATION BIORA AB BIOSPECIF ICS TECHNOLOGIES BIOTECH HOLDINGS LTD BIOTIME INC BIOTRANSPLANT INC BIOVAIL CORPORATION BONE CARE INTERNATIONAL BOSTON LIFE SCIENCES INC BRADLEY PHARMACEUTICALS

Industry Code 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412


Sales Rank

1,745,500 1,900

17 177

975,000 452

26 213

700 53,800 3,763,000

207 64 13

749,000 700 900 4,600

31 208 198 151

18,100 1,000

97 194

16,480,000 2,700 1,300 12,700 3,300 500 20,447,000 700 1,000

8 169 187 107 164 212 5 209 195

509,700 26,400

34 87

102,000 7,700 1,043,400 11,700 4,600 3,500 10,500 5,500 1,163 200 700 583,300 5,997

52 128 24 109 152 162 116 144 191 222 210 33 139

25,700

89


2001 Profits -9,600 224,900 -60,700 -20,100 -37,900 -11,583

Profits Rank 116 17 216 159 199 128

-500 -4,700 1,119,700 -72,000 37,500 -5,300 -6,700 -73,500 -31,300 -6,900 -19,800

64 89 11 224 37 93 99 225 189 100 158

1,097,000 -1,700 800 200 -22,800 -15,100 1,455,000 -26,900 -11,300 -8,144 62,500 1,400

12 69 56 61 166 140 10 178 127 105 32 53

-30,300 -5,000 272,700 -67,600 -24,300 -49,400 -2,400 -1,468 -1,938 -3,700 -42,600 87,400 -9,014 -10,300 3,600

187 90 15 221 171 208 77 67 74 85 201 28 108 122 47

(Thousands)



Company BRISTOL MYERS SQUIBB CO BRITISH BIOTECH PLC CAMBREX CORP CARACO PHARMACEUTICAL LABORATORIES CARDIOME PHARMACEUTICAL CARRINGTON LABORATO RIES CELGENE CORP CELL GENESYS INC CELL PATHWAYS INC CELL THERAPEUTICS INC CELLEGY PHARMACEUTICALS CELLTECH GROUP PLC CEL-SCI CORPORATION CEPHALON INC CERUS CORPORATION CHATTEM INC CHIRON CORP CIMA LABS INC COLLAGENEX PHARMACEUTICAL COLLATERAL THERAPEUTICS COLUMBIA LABORATORIES CONNETICS CORPORATION CORIXA CORPORATION CORTECH INC CORTEX PHARMACEUTICALS CORVAS INTERNATIONAL INC CUBIST PHARMACEUTICALS CURIS INC CV THERAPEUTICS INC CYTOGEN CORPORATION CYTRX CORPORATION DEPOMED INC DISCOVERY LABORATORIES DOR BIOPHARMA INC DRAXIS HEALTH INC DSM PHARMACEUTICALS INC DURECT CORP DUSA PHARMACEUTICALS INC DYAX CORP ELAN CORP PLC ELI LILLY & CO ENDO PHARMACEUTICALS HOLDINGS INC ENTREMED INC ENZON INC EPIMMUNE INC

Industry Code 325412 325412 325412


Sales Rank

19,423,000 2,500 498,900

6 172 35

5,900 402 17,600 114,200 28,300 900 6,200 900 441,400 400 226,100 4,500 198,300 1,140,700 32,000 35,200 5,200 1,800 34,100 58,100

140 214 98 51 86 199 136 200 36 215 44 155 45 23 82 75 146 180 76 63

4,443 300 14,400 1,100 6,800 11,700 4,400 3,700 1,100

157 218 102 192 131 110 158 161 193

325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412

33,000

325412 325412 325412 325412

2001 Profits

Profits Rank 5,245,000 4 -36,253 192 26,600 39

(Thousands)

78

-5,800 -4,557 400 -1,900 -28,700 -31,400 -80,300 -19,500 -80,800 -10,700 -55,500 -49,400 15,300 180,100 15,000 -8,100 -14,600 -15,800 -16,700 148,000 -200 -2,398 -23,400 -69,900 -81,900 -79,700 -12,100 -900 -17,600 -11,100 -14,600 -1,600

94 88 58 72 185 190 231 156 232 124 211 207 42 20 43 104 139 144 149 24 63 76 168 222 233 229 129 66 152 126 137 68

6,500 5,400 33,000 1,512,900 11,542,000

134 145 79 18 11

-44,900 -7,400 -17,200 -887,200 2,780,000

204 102 150 244 6

252,000 1,900 31,587 8,200

40 178 83 127

-36,500 -43,300 11,525 -2,600

193 203 45 78




Company ESSENTIAL THERAPEUTICS EXEGENICS INC FOREST LABORATORIES INC GELTEX PHARMACEUTICALS GENAERA CORPORATION GENELABS TECHNOLOGIES GENENTECH INC GENEREX BIOTECHNOLOGY GENTA INC GENZYME CORP GENZYME MOLECULAR ONCOLOGY GILEAD SCIENCES INC GLAXOSMITHKLINE PLC GLYCOGENESYS INC GUILFORD PHARMACEUTICALS HEMISPHERX BIOPHARMA INC HESKA CORP HI TECH PHARMACAL CO INC HOLLIS-EDEN PHARMACEUTICALS HUMAN GENOME SCIENCES HYBRIDON INC HYSEQ INC ICN PHARMACEUTICALS INC ICOS CORPORATION ID BIOMEDICAL CORPORATION IDEC PHARMACEUTICALS ILEX ONCOLOGY INC IMCLONE SYSTEMS INC IMMTECH INTERNATIONAL IMMUCELL CORPORATION IMMUNE RESPONSE CORP IMMUNEX CORP IMMUNOGEN INC IMPAX LABORATORIES INC INCARA PHARMACEUTICALS INKINE PHARMACEUTICAL CO INSITE VISION INC INSMED INCORPORATED INSPIRE PHARMACEUTICALS INTERFERON SCIENCES INC INTERMUNE PHARMACEUTICALS INC INTERNATIONAL ISOTOPES INTRABIOTICS PHARMACEUTICALS INTROGEN THERAPEUTICS INC ISIS PHARMACEUTICALS INC IVAX CORPORATION JOHNSON & JOHNSON

Industry Code 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412

2001 Sales

2001 Sales Profits Profits (Thousands) Rank (Thousands) Rank 10,700 115 -27,900 183 1,300 188 -8,800 107 1,205,200 21 215,100 19 900 4,800 2,081,700 1,000 100 1,223,600 6,600 233,800 29,858,600

201 148 15 196 224 19 132 43 4

20,500 400 48,300 29,600

94 216 67 84

12,800 1,600 24,600 858,100 93,400 1,600 272,700 24,600 33,200 1,354 6,400 10,000 986,800 4,479 6,600 100 4,300

106 182 90 29 54 183 38 91 77 186 135 118 25 156 133 225 159

300 7,300 1,500 40,000 2,200

219 130 184 73 175

300 53,300 1,215,400 33,004,000

220 65 20 2


-12,900 -13,000 150,300 -27,100 -46,700 -112,100 -29,700 52,300 -158,800 -22,700 -60,300 -9,100 -18,700 2,400 -15,800 -117,200 -5,300 -36,500 64,100 -80,200 -9,200 101,700 -121,000 -102,200 -9,863 400 -16,300 170,000 -15,290 -25,100 -22,200 -15,300 -9,600 -37,200 -23,100 -7,200 -118,200 -2,800 -67,400 -12,300 -73,800 243,200 5,668,000

132 133 22 179 205 236 186 34 241 165 215 109 154 50 143 237 92 194 31 230 112 27 239 235 121 60 147 21 141 174 163 142 117 196 167 101 238 80 220 130 226 16 3



Industry Company Code K V PHARMACEUTICAL CO 325412 KING PHARMACEUTICALS INC 325412 KOS PHARMACEUTICALS INC 325412 KOSAN BIOSCIENCES INC 325412 LA JOLLA PHARMACEUTICAL 325412 LABORATORIO CHILE SA 325412 LIGAND PHARMACEUTICALS 325412 LORUS THERAPEUTICS INC 325412 MATRIX PHARMACEUTICAL 325412 MAXIM PHARMACEUTICALS 325412 MEDAREX INC 325412 MEDICIS PHARMACEUTICAL 325412 MEDIMMUNE INC 325412 MEDIMMUNE VACCINES 325412 MERCK & CO INC 325412 MGI PHARMA INC 325412 MICROLOGIX BIOTECH INC 325412 MILLENNIUM PHARMACEUTICALS INC 325412 MIRAVANT MEDICAL TECHNOLOGIES 325412 MOLECULAR BIOSYSTEMS INC 325412 MYLAN LABORATORIES INC 325412 NABI BIOPHARMACEUTICALS 325412 NAPRO BIOTHERAPEUTICS 325412 NASTECH PHARMACEUTICAL 325412 NEORX CORPORATION 325412 NEOSE TECHNOLOGIES INC 325412 NEUROBIOLOGICAL TECHNOLOGIES 325412 INC NEUROCRINE BIOSCIENCES 325412 NEUROGEN CORP 325412 NEXMED INC 325412 NOVARTIS AG 325412 NOVAVAX INC 325412 NOVEN PHARMACEUTICALS 325412 NOVO-NORDISK AS 325412 NPS PHARMACEUTICALS INC 325412 ONYX PHARMACEUTICALS INC 325412 ORAPHARMA INC 325412 ORPHAN MEDICAL INC 325412 OSI PHARMACEUTICALS INC 325412 OXIGENE INC 325412 OXIS INTERNATIONAL INC 325412 PALATIN TECHNOLOGIES INC 325412 PALIGENT INC 325412 PDK LABS INC 325412 PENWEST PHARMACEUTICALS 325412 PEREGRINE PHARMACEUTICALS INC 325412


182,900 872,300 91,400 5,200

2001 Sales Profits Profits Rank (Thousands) Rank 46 23,600 41 28 218,000 18 55 2,400 49 147 -21,900 162 -24,700 173

76,300

58

-43,000 -9,800

202 120

3,200 42,300 167,800 618,700 14,000 47,716,000 33,000 2,059 246,200 4,700

165 70 47 32 103 1 80 176 41 150

-37,300 -2,700 40,400 149,000 -127,300 7,282,000 -34,800 -7,456 -192,000 -16,400

198 79 35 23 240 2 191 103 242 148

846,700 234,800 15,700 2,600 2,900 1,300

30 42 101 170 168 189

37,100 104,700 -25,800 -9,200 -23,800 -13,300

38 26 177 111 170 134

4,781 41,200 11,500 100 19,070,000 24,100 45,900 2,839,000 10,400 15,800 7,700 11,300 26,000 9,000 3,000 1,788 100

149 72 111 226 7 92 69 14 117 100 129 114 88 121 167 181 227

1,588 -36,900 -25,400 -16,200 4,181,000 -9,700 12,100 461,000 -50,000 -27,600 -25,700 -6,000 -23,700 -4,100 -3,500 -10,599 -1,700

52 195 175 146 5 119 44 13 209 181 176 95 169 86 83 123 71

40,000 979

74 197

-16,000 -9,535

145 115




Company PFIZER INC PHARMACEUTICAL FORMULATIONS INC PHARMACEUTICAL RESOURCES PHARMACYCLICS INC PHARMOS CORPORATION PHOTOGEN TECHNOLOGIES POLYDEX PHARMACEUTICALS PRAECIS PHARMACEUTICALS PROGENICS PHARMACEUTICALS PROTEIN DESIGN LABS INC PROTEIN POLYMER TECHNOLOGIES QLT INC QUESTCOR PHARMACEUTICALS REGENERON PHARMACEUTICALS INC REPLIGEN CORPORATION RIBOZYME PHARMACEUTICALS SANGSTAT MEDICAL CORP SCHERING-PLOUGH CORP SCICLONE PHARMACEUTICALS SCIOS INC SENETEK PLC SEPRACOR INC SHEFFIELD PHARMACEUTICALS SHIRE PHARMACEUTICALS SHIRE-BIOCHEM INC SICOR INC SIGA TECHNOLOGIES INC SKYEPHARMA PLC SONUS PHARMACEUTICALS SPECTRUM PHARMACEUTICALS SUPERGEN INC SYNAPTIC PHARMACEUTICAL TANOX INC TARGETED GENETICS CORP TARO PHARMACEUTICAL INDUSTRIES TELIK INC TEVA PHARMACEUTICAL INDUSTRIES TEXAS BIOTECHNOLOGY TITAN PHARMACEUTICALS TRANSKARYOTIC THERAPIES TRIANGLE PHARMACEUTICALS TULARIK INC UNIGENE LABORATORIES UNITED THERAPEUTICS CORP UNITED-GUARDIAN INC VALENTIS INC

Industry Code 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412


2001 Profits

Sales Rank

Profits Rank 7,788,000 1

(Thousands)

32,259,000

3

49,200 271,000 3,121 4,300

66 39 166 160

13,828 9,900 8,900 79,500 800 81,300 5,700 22,000 2,346 8,300 94,500 9,802,000 13,800 47,300 8,900 152,100 900 877,600 369,800 1,200 67,900 8,700 100 11,500 1,400 400 18,900 150,100 1,900 2,077,400 8,900 4,600 6,200 5,800 32,600 900 5,700 9,600 4,600

104 119 122 57 205 56 142 93 173 126 53 12 105 68 123 49 202 27

-14,600 53,900 -30,925 5,000 -9,700 131 -54,600 -1,900 2,600 -3,100 76,700 -8,700 -76,200 -5,278 -59,800 -9,300 1,943,000 -6,200 -62,500 400 -224,000 -9,500 38,800

138 33 188 46 118 62 210 73 48 81 30 106 228 91 214 113 8 97 218 59 243 114 36

37 190 60 125 228 112 185 217 96 50 179 16 124 153 137 141 81 203 143 120 154

79,300 -3,700 -13,900 500 -27,800 -55,600 -21,800 -21,400 -27,200 26,000 -18,600 278,200 -19,100 -17,500 -70,200 -75,900 -48,600 -12,500 -37,300 1,900 -38,200

29 84 136 57 182 212 161 160 180 40 153 14 155 151 223 227 206 131 197 51 200




Company VAXGEN INC VERTEX PHARMACEUTICALS VICAL INC VION PHARMACEUTICALS INC VIRAGEN INC VIRBAC INC VIROPHARMA INC WARNER CHILCOTT PLC WATSON PHARMACEUTICALS WOMEN FIRST HEALTHCARE WYETH XECHEM INTERNATIONAL XENOVA GROUP PLC XOMA LTD ZILA INC ZONAGEN INCORPORATED

Industry Code 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412


900 167,500 11,400 700 717 60,600 3,400

2001 Sales Profits Profits Rank (Thousands) Rank 204 -24,400 172 48 -66,300 219 113 -9,200 110 211 -13,800 135 206 -11,010 125 62 1,300 54 163 -83,000 234

1,160,700 28,400 14,128,000 200 2,600 17,300 73,700 2,300

22 85 10 223 171 99 59 174

116,400 -3,400 2,285,000 -1,700 -22,400 -28,000 -6,300 -800

25 82 7 70 164 184 98 65

2,206,400 65,600 35,200 21,800 9,600 113,300 11,000 17,300 31,362 11,229 2,300 45,200 34,900 7,000 27,500 34,100 37,100 18,300

1 3 6 11 16 2 15 13 9 14 18 4 7 17 10 8 5 12

312,800 6,700 700 3,400 -19,200 3,300 -2,200

1 2 7 3 15 4 9

-43,253 -4,750 -8,700 -7,200 3,200 -3,400 400 -36,800 1,400 -26,200

18 12 14 13 5 11 8 17 6 16

500

19

-2,900

10

4 7 5 3 2 1 6 8

5,900 2,229 6,800 -8,400 11,000 37,600 2,500 200

4 6 3 8 2 1 5 7

In Vitro Diagnostic Substance, Manufacturing

AMERSHAM PLC BIOSITE INC BIOSOURCE INTERNATIONAL BOSTON BIOMEDICA INC EPIX MEDICAL INC E-Z-EM INC HEMAGEN DIAGNOSTICS INC HYCOR BIOMEDICAL INC IGEN INTERNATIONAL INC IMMUNOMEDICS INC MATRITECH INC MYRIAD GENETICS INC NEOGEN CORPORATION SPECTRAL DIAGNOSTICS INC SYNBIOTICS CORP THIRD WAVE TECHNOLOGIES TRINITY BIOTECH PLC VIROLOGIC INC VYSIS INC XTRANA INC

325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413

Laboratories and Diagnostics--Medical

BIORELIANCE CORP CELSIS INTERNATIONAL PLC ENZO BIOCHEM INC HUNTINGDON LIFE SCIENCES ICON PLC IDEXX LABORATORIES INC MEDTOX SCIENTIFIC INC PACIFIC BIOMETRICS INC

621511 621511 621511 621511 621511 621511 621511 621511

69,700 27,181 58,400 99,200 116,200 386,100 49,100 1,900




Industry Code

Company


2001 Profits

Sales Rank

(Thousands)

Profits Rank

Medical/Dental/Surgical Equipment and Supplies, Manufacturing

AASTROM BIOSCIENCES INC ABAXIS INC ACCUMED INTERNATIONAL ACLARA BIOSCIENCES INC ALKERMES INC APPLERA CORPORATION BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BIO RAD LABORATORIES INC BIOCOMPATIBLES INTERNATIONAL PLC BIONX IMPLANTS INC CARDIOTECH INTERNATIONAL CEPHEID CYPRESS BIOSCIENCE INC DIAGNOSTIC PRODUCTS CORP DIGENE CORPORATION EMBREX INC GENZYME BIOSURGERY GLIATECH INC INTEGRA LIFESCIENCES CORP INVITROGEN CORPORATION LIFECORE BIOMEDICAL INC LUMINEX CORPORATION MALLINCKRODT INC MDS INC MOLECULAR DEVICES CORP NEOPROBE CORPORATION NORTH AMERICAN SCIENTIFIC ORASURE TECHNOLOGIES INC QIAGEN NV SYNOVIS LIFE TECHNOLOGIES TECHNE CORP THERAGENICS CORP

339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113

899 29,501

31 20

-5,926 188

20 14

3,200 56,000 1,644,100 1,711,900 7,663,000 817,500

27 14 3 2 1 5

-29,000 -16,900 27,200 21,500 612,000 44,200

28 25 7 9 1 3

100,200 18,900 1,543 11,400 1,600 283,400 34,200 44,700 253,100 3,100 87,700 629,300 34,100 20,900

11 24 30 25 29 7 17 16 9 28 13 6 18 22

-28,600 -2,500 5,705 -15,500 -7,200 39,000 -6,500 8,000 -144,100 -23,700 26,200 -147,700 -3,700 -15,700

27 16 12 23 22 4 21 11 29 26 8 30 17 24

1,031,000 92,200 7,600 19,300 32,600 263,800 28,500 115,400 50,000

4 12 26 23 19 8 21 10 15

46,000 -5,200

2 19

-2,000 -3,700 34,400 1,800 34,000 15,100

15 18 5 13 6 10

4 7 5 1 6 8 3 2

-25,500 -1,067 -2,900 -33,300 -7,876 -12,300 -13,700 1,065

7 2 3 8 4 5 6 1

Medicinals and Botanicals, Manufacturing

ATRIX LABORATORIES INC CYANOTECH CORPORATION FLAMEL TECHNOLOGIES SA HAUSER INC IOMED INC MACROCHEM CORPORATION MARTEK BIOSCIENCES CORP NUTRITION 21 INC

325411 325411 325411 325411 325411 325411 325411 325411

15,800 8,043 13,100 66,700 11,395 800 18,800 23,252

Research and Development--Physical, Engineering and Life Sciences

AAIPHARMA INC ALBANY MOLECULAR RESEARCH

541710 541710

141,100 56,800

9 13


5,900 34,400

7 5



2001 2001 Industry Sales Sales Profits Profits Company (Thousands) Code Rank (Thousands) Rank APPLIED MOLECULAR EVOLUTION INC 541710 3,600 37 -13,200 16 ARQULE INC 541710 58,400 12 -41,000 29 BIOANALYTICAL SYSTEMS INC 541710 25,300 23 1,800 10 CAMBRIDGE ANTIBODY TECHNOLOGY 541710 10,500 32 -17,300 22 GROUP PLC CELERA GENOMICS GROUP 541710 89,400 11 -186,200 38 CELERIS CORPORATION 541710 9,800 33 -2,700 13 CHARLES RIVER LABORATORIES CORP 541710 465,600 3 35,500 4 CHESAPEAKE BIOLOGICAL LAB 541710 COMMONWEALTH BIOTECHNOLOGIES 541710 4,800 36 -1,700 12 COMPUGEN LTD 541710 11,400 31 -15,100 18 COVALENT GROUP INC 541710 18,400 28 2,000 9 COVANCE INC 541710 855,900 2 47,900 2 CURAGEN CORPORATION 541710 23,500 25 42,900 3 DECODE GENETICS INC 541710 31,600 18 -47,800 33 DIVERSA CORPORATION 541710 36,000 16 -15,700 19 EPOCH BIOSCIENCES 541710 7,500 34 -4,600 14 EXELIXIS INC 541710 41,000 15 -71,200 35 GENE LOGIC INC 541710 43,300 14 -33,200 25 GENENCOR INTERNATIONAL 541710 326,000 6 17,800 6 GENOME THERAPEUTICS 541710 35,700 17 -10,100 15 GENSET SA 541710 17,400 30 -42,000 30 GERON CORPORATION 541710 3,600 38 -42,100 31 INCYTE GENOMICS INC 541710 219,300 7 -183,200 37 KENDLE INTERNATIONAL INC 541710 154,300 8 4,200 8 LARGE SCALE BIOLOGY CORP 541710 17,700 29 -20,700 23 LEXICON GENETICS INC 541710 30,600 21 -35,200 27 LYNX THERAPEUTICS INC 541710 19,300 27 -16,700 21 MAXYGEN INC 541710 30,500 22 -45,000 32 ORCHID BIOSCIENCES INC 541710 31,200 19 -84,700 36 OXFORD GLYCOSCIENCES PLC 541710 19,500 26 -36,900 28 PANVERA LLC 541710 PARADIGM GENETICS INC 541710 24,500 24 -16,000 20 PAREXEL INTERNATIONAL 541710 387,560 5 -825 11 PHARMACEUTICAL PRODUCT DEVELOPMENT INC 541710 431,500 4 49,200 1 PHARMACOPEIA INC 541710 122,300 10 -14,300 17 QUINTILES TRANSNATIONAL 541710 1,619,900 1 -33,900 26 SANGAMO BIOSCIENCES INC 541710 4,900 35 -25,200 24 SEQUENOM INC 541710 30,700 20 -62,600 34 Soap and Cleaning Compound Manufacturing PROCYTE CORPORATION

325610

9,700

1

-900

1

2 1

-24,800 31,200

2 1

Test Equipment/Instruments, Manufacturing

ILLUMINA INC MILLIPORE CORP

334515 334515

2,500 656,900




ALPHABETICAL INDEX If you are seeking a company by name and you do not find it on this list, please turn to the back of the book to the Index by Subsidiaries, Brand Names and Selected Affiliations. You may find your target firm there. AAIPHARMA INC AASTROM BIOSCIENCES INC ABAXIS INC ABBOTT LABORATORIES ABGENIX INC ABLE LABORATORIES ACCESS PHARMACEUTICALS ACCUMED INTERNATIONAL ACLARA BIOSCIENCES INC ADVANCED MAGNETICS INC ADVANCED TISSUE SCIENCES AFFYMETRIX INC AKORN INC AKZO NOBEL NV ALBANY MOLECULAR RESEARCH ALEXION PHARMACEUTICALS ALFACELL CORPORATION ALIZYME PLC ALKERMES INC ALLERGAN INC ALLIANCE PHARMACEUTICAL CORP ALLOS THERAPEUTICS INC ALPHARMA INC ALTEON INC ALZA CORP AMARILLO BIOSCIENCES INC AMARIN CORPORATION PLC AMERSHAM PLC AMGEN INC AMYLIN PHARMACEUTICALS INC ANDRX CORP ANGIOTECH PHARMACEUTICALS ANIKA THERAPEUTICS INC ANTEX BIOLOGICS INC ANTIGENICS INC APHTON CORP APPLERA CORPORATION APPLIED MOLECULAR EVOLUTION INC ARENA PHARMACEUTICALS INC ARIAD PHARMACEUTICALS ARQULE INC ASCENT PEDIATRICS INC ASTRAZENECA PLC ATLANTIC TECHNOLOGY VENTURES ATRIX LABORATORIES INC AUTOIMMUNE INC AVANIR PHARMACEUTICALS AVANT IMMUNOTHERAPEUTICS AVAX TECHNOLOGIES INC

AVENTIS SA AVI BIOPHARMA INC AVIGEN INC AXONYX INC BARR LABORATORIES INC BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BENTLEY PHARMACEUTICALS INC BIGMAR INC BIO RAD LABORATORIES INC BIO TECHNOLOGY GENERAL CORP BIOANALYTICAL SYSTEMS INC BIOCOMPATIBLES INTERNATIONAL PLC BIOCRYST PHARMACEUTICALS BIOGEN INC BIOMARIN PHARMACEUTICAL BIOMIRA INC BIONX IMPLANTS INC BIOPURE CORPORATION BIORA AB BIORELIANCE CORP BIOSITE INC BIOSOURCE INTERNATIONAL INC BIOSPECIFICS TECHNOLOGIES CORP BIOSPHERE MEDICAL INC BIOTECH HOLDINGS LTD BIOTIME INC BIOTRANSPLANT INC BIOVAIL CORPORATION BONE CARE INTERNATIONAL BOSTON BIOMEDICA INC BOSTON LIFE SCIENCES INC BRADLEY PHARMACEUTICALS BRISTOL MYERS SQUIBB CO BRITISH BIOTECH PLC CALIPER TECHNOLOGIES CORP CAMBREX CORP CAMBRIDGE ANTIBODY TECHNOLOGY GROUP CARACO PHARMACEUTICAL LABORATORIES CARDIOME PHARMACEUTICAL CORP CARDIOTECH INTERNATIONAL CARRINGTON LABORATORIES INC CELERA GENOMICS GROUP CELERIS CORPORATION CELGENE CORP CELL GENESYS INC CELL PATHWAYS INC CELL THERAPEUTICS INC CELLEGY PHARMACEUTICALS CELLTECH GROUP PLC CEL-SCI CORPORATION CELSIS INTERNATIONAL PLC CEPHALON INC CEPHEID CERUS CORPORATION CHARLES RIVER LABORATORIES CORP CHATTEM INC CHESAPEAKE BIOLOGICAL LAB




CHIRON CORP CIMA LABS INC CIPHERGEN BIOSYSTEMS INC COLLAGENEX PHARMACEUTICAL COLLATERAL THERAPEUTICS COLUMBIA LABORATORIES COMMONWEALTH BIOTECHNOLOGIES INC COMPUGEN LTD CONNETICS CORPORATION CORIXA CORPORATION CORTECH INC CORTEX PHARMACEUTICALS CORVAS INTERNATIONAL INC COVALENT GROUP INC COVANCE INC CUBIST PHARMACEUTICALS CURAGEN CORPORATION CURIS INC CV THERAPEUTICS INC CYANOTECH CORPORATION CYPRESS BIOSCIENCE INC CYTOGEN CORPORATION CYTRX CORPORATION DECODE GENETICS INC DEPOMED INC DIACRIN INC DIAGNOSTIC PRODUCTS CORPORATION DIGENE CORPORATION DISCOVERY LABORATORIES DIVERSA CORPORATION DONLAR BIOSYNTREX DOR BIOPHARMA INC DRAXIS HEALTH INC DSM PHARMACEUTICA LS INC DURECT CORP DUSA PHARMACEUTICALS INC DYAX CORP E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO EMBREX INC EMISPHERE TECHNOLOGIES ENDO PHARMACEUTICALS HOLDINGS INC ENTREMED INC ENZO BIOCHEM INC ENZON INC EPIMMUNE INC EPIX MEDICAL INC EPOCH BIOSCIENCES ERESEARCH TECHNOLOGY INC ESSENTIAL THERAPEUTICS INC EXEGENICS INC EXELIXIS INC EXELIXIS PLANT SCIENCES INC E-Z-EM INC FLAMEL TECHNOLOGIES SA FOREST LABORATORIES INC GELTEX PHARMACEUTICALS

GENAERA CORPORATION GENE LOGIC INC GENELABS TECHNOLOGIES INC GENENCOR INTERNATIONAL INC GENENTECH INC GENEREX BIOTECHNOLOGY GENOME THERAPEUTICS CORP GENSET SA GENTA INC GENZYME BIOSURGERY GENZYME CORP GENZYME MOLECULAR ONCOLOGY GERON CORPORATION GILEAD SCIENCES INC GLAXOSMITHKLINE PLC GLIATECH INC GLYCOGENESYS INC GTC BIOTHERAPEUTICS INC GUILFORD PHARMACEUTICALS INC HAUSER INC HEMAGEN DIAGNOSTICS INC HEMISPHERX BIOPHARMA INC HESKA CORP HI TECH PHARMACAL CO INC HOLLIS-EDEN PHARMACEUTICALS HUMAN GENOME SCIENCES INC HUNTINGDON LIFE SCIENCES HYBRIDON INC HYCOR BIOMEDICAL INC HYSEQ INC ICN PHARMACEUTICALS INC ICON PLC ICOS CORPORATION ID BIOMEDICAL CORPORATION IDEC PHARMACEUTICALS CORP IDEXX LABORATORIES INC IGEN INTERNATIONAL INC ILEX ONCOLOGY INC ILLUMINA INC IMCLONE SYSTEMS INC IMMTECH INTERNATIONAL IMMUCELL CORPORATION IMMUNE RESPONSE CORP (THE) IMMUNEX CORP IMMUNOGEN INC IMMUNOMEDICS INC IMPAX LABORATORIES INC IMS HEALTH INC INCARA PHARMACEUTICALS INCYTE GENOMICS INC INFORMAX INC INKINE PHARMACEUTICAL CO INSITE VISION INC INSMED INCORPORATED INSPIRE PHARMACEUTICALS INC INTEGRA LIFESCIENCES CORP INTERFERON SCIENCES INC INTERMUNE PHARMACEUTICALS INC




INTERNATIONAL ISOTOPES INTRABIOTICS PHARMACEUTICALS INTROGEN THERAPEUTICS INC INVITROGEN CORPORATION IOMED INC ISIS PHARMACEUTICALS INC IVAX CORPORATION JOHNSON & JOHNSON K V PHARMACEUTICAL CO KENDLE INTERNATIONAL INC KING PHARMACEUTICALS INC KOS PHARMACEUTICALS INC KOSAN BIOSCIENCES INC LA JOLLA PHARMACEUTICAL LABORATORIO CHILE SA LARGE SCALE BIOLOGY CORP LEXICON GENETICS INC LIFECELL CORPORATION LIFECORE BIOMEDICAL INC LIGAND PHARMACEUTICALS INC LION BIOSCIENCE AG LORUS THERAPEUTICS INC LUMINEX CORPORATION LYNX THERAPEUTICS INC MACROCHEM CORPORATION MALLINCKRODT INC MARTEK BIOSCIENCES CORP MATRITECH INC MATRIX PHARMACEUTICAL MAXIM PHARMACEUTICALS MAXYGEN INC MDS INC MEDAREX INC MEDICIS PHARMACEUTICAL CORP MEDIMMUNE INC MEDIMMUNE VACCINES MEDTOX SCIENTIFIC INC MERCK & CO INC MGI PHARMA INC MICROLOGIX BIOTECH INC MILLENNIUM PHARMACEUTICALS INC MILLIPORE CORP MIRAVANT MEDICAL TECHNOLOGIES MOLECULAR BIOSYSTEMS INC MOLECULAR DEVICES CORP MONSANTO CO MYLAN LABORATORIES INC MYRIAD GENETICS INC NABI BIOPHARMACEUTICALS NANOGEN INC NAPRO BIOTHERAPEUTICS INC NASTECH PHARMACEUTICAL CO INC NEOGEN CORPORATION NEOPROBE CORPORATION NEORX CORPORATION NEOSE TECHNOLOGIES INC NEUROBIOLOGICAL TECHNOLOGIES INC NEUROCRINE BIOSCIENCES INC

NEUROGEN CORP NEXMED INC NORTH AMERICAN SCIENTIFIC NORTHFIELD LABORATORIES NOVARTIS AG NOVAVAX INC NOVEN PHARMACEUTICALS NOVO-NORDISK AS NPS PHARMACEUTICALS INC NUTRITION 21 INC ONYX PHARMACEUTICALS INC ORAPHARMA INC ORASURE TECHNOLOGIES INC ORCHID BIOSCIENCES INC ORGANOGENESIS INC ORPHAN MEDICAL INC OSI PHARMACEUTICALS INC OXFORD GLYCOSCIENCES PLC OXIGENE INC OXIS INTERNATIONAL INC PACIFIC BIOMETRICS INC PALATIN TECHNOLOGIES INC PALIGENT INC PANVERA LLC PARADIGM GENETICS INC PAREXEL INTERNATIONAL PDK LABS INC PENWEST PHARMACEUTICALS CO PEREGRINE PHARMACEUTICALS INC PFIZER INC PHARMACEUTICAL FORMULATIONS INC PHARMACEUTICAL PRODUCT DEVELOPMENT INC PHARMACEUTICAL RESOURCES INC PHARMACOPEIA INC PHARMACYCLICS INC PHARMOS CORPORATION PHOTOGEN TECHNOLOGIES INC POLYDEX PHARMACEUTICALS PRAECIS PHARMACEUTICALS PROCYTE CORPORATION PROGENICS PHARMACEUTICALS PROTEIN DESIGN LABS INC PROTEIN POLYMER TECHNOLOGIES QIAGEN NV QLT INC QUESTCOR PHARMACEUTICALS QUINTILES TRANSNATIONAL CORP REGENERON PHARMACEUTICALS INC REPLIGEN CORPORATION RIBOZYME PHARMACEUTICALS SANGAMO BIOSCIENCES INC SANGSTAT MEDICAL CORP SCHERING-PLOUGH CORP SCICLONE PHARMACEUTICALS SCIOS INC SENETEK PLC SEPRACOR INC SEQUENOM INC




SEROLOGICALS CORP SHEFFIELD PHARMACEUTICALS SHIRE PHARMACEUTICALS PLC SHIRE-BIOCHEM INC SICOR INC SIGA TECHNOLOGIES INC SKYEPHARMA PLC SONUS PHARMACEUTICALS SPECTRAL DIAGNOSTICS INC SPECTRUM PHARMACEUTICALS STEMCELLS, INC SUPERGEN INC SYNAPTIC PHARMACEUTICAL SYNBIOTICS CORP SYNGENTA AG SYNOVIS LIFE TECHNOLOGIES INC TANOX INC TARGETED GENETICS CORP TARO PHARMACEUTICAL INDUSTRIES TECHNE CORP TELIK INC TEVA PHARMACEUTICAL INDUSTRIES TEXAS BIOTECHNOLOGY CORP THERAGENICS CORP THIRD WAVE TECHNOLOGIES INC TITAN PHARMACEUTICALS TRANSKARYOTIC THERAPIES TRIANGLE PHARMACEUTICALS TRINITY BIOTECH PLC TRIPOS INC TULARIK INC UNIGENE LABORATORIES UNITED THERAPEUTICS CORP UNITED-GUARDIAN INC V I TECHNOLOGIES INC VALENTIS INC VAXGEN INC VERTEX PHARMACEUTICALS INC VICAL INC VION PHARMACEUTICALS INC VIRAGEN INC VIRBAC INC VIROLOGIC INC VIROPHARMA INC VYSIS INC WARNER CHILCOTT PLC WATSON PHARMACEUTICALS INC WOMEN FIRST HEALTHCARE WYETH XECHEM INTERNATIONAL XENOVA GROUP PLC XOMA LTD XTRANA INC ZILA INC ZONAGEN INCORPORATED

GEOGRAPHICAL INDEXES 1) Company headquarters locations by state 2) Foreign company headquarters locations by country 3) Offices and subsidiaries by regions of the U.S. 4) Firms with international operations The headquarters locations of each company are on the following indexes to help you locate members of THE BIOTECH & GENETICS 400 within the part of the country, or the world, of interest. However, companies are constantly opening and closing various locations. You should consider contacting companies that particularly interest you, to see whether they have locations in your area.

INDEX OF HEADQUARTERS LOCATION, BY STATE To help you locate members of THE BIOTECH & GENETICS 400 geographically, the city and state of the headquarters of each company are indexed. ALABAMA BIOCRYST PHARMACEUTICALS; Birmingham

ARIZONA MEDICIS PHARMACEUTICAL CORP; Scottsdale ZILA INC; Phoenix

CALIFORNIA ABAXIS INC; Union City ABGENIX INC; Fremont ACLARA BIOSCIENCES INC; Mountain View ADVANCED TISSUE SCIENCES; La Jolla AFFYMETRIX INC; Santa Clara ALLERGAN INC; Irvine ALLIANCE PHARMACEUTICAL CORP; San Diego ALZA CORP; Mountain View AMGEN INC; Thousand Oaks AMYLIN PHARMACEUTICALS INC; San Diego APPLIED MOLECULAR EVOLUTION INC; San Diego ARENA PHARMACEUTICALS INC; San Diego AUTOIMMUNE INC; Pasadena AVANIR PHARMACEUTICALS; San Diego AVIGEN INC; Alameda BIO RAD LABORATORIES INC; Hercules BIOMARIN PHARMACEUTICAL; Novato BIOSITE INC; San Diego BIOSOURCE INTERNATIONAL INC; Camarillo BIOTIME INC; Berkeley CALIPER TECHNOLOGIES CORP; Mountain View CELL GENESYS INC; Foster City




CELLEGY PHARMACEUTICALS; South San Francisco CEPHEID; Sunnyvale CERUS CORPORATION; Concord CHIRON CORP; Emeryville CIPHERGEN BIOSYSTEMS INC; Fremont COLLATERAL THERAPEUTICS; San Diego CONNETICS CORPORATION; Palo Alto CORTEX PHARMACEUTICALS; Irvine CORVAS INTERNATIONAL INC; San Diego CV THERAPEUTICS INC; Palo Alto CYPRESS BIOSCIENCE INC; San Diego DEPOMED INC; Menlo Park DIAGNOSTIC PRODUCTS CORPORATION; Los Angeles DIVERSA CORPORATION; San Diego DURECT CORP; Cupertino EPIMMUNE INC; San Diego EXELIXIS INC; South San Francisco GENELABS TECHNOLOGIES INC; Redwood City GENENCOR INTERNATIONAL INC; Palo Alto GENENTECH INC; South San Francisco GERON CORPORATION; Menlo Park GILEAD SCIENCES INC; Foster City HAUSER INC; Long Beach HOLLIS-EDEN PHARMACEUTICALS; San Diego HYCOR BIOMEDICAL INC; Garden Grove HYSEQ INC; Sunnyvale ICN PHARMACEUTICALS INC; Costa Mesa IDEC PHARMACEUTICALS CORP; San Diego ILLUMINA INC; San Diego IMMUNE RESPONSE CORP (THE); Carlsbad IMPAX LABORATORIES INC; Hayward INCYTE GENOMICS INC; Palo Alto INSITE VISION INC; Almeda INTERMUNE PHARMACEUTICALS INC; Brisbane INTRABIOTICS PHARMACEUTICALS; Mountain View INVITROGEN CORPORATION; Carlsbad ISIS PHARMACEUTICALS INC; Carlsbad KOSAN BIOSCIENCES INC; Hayward LA JOLLA PHARMACEUTICAL; San Diego LARGE SCALE BIOLOGY CORP; Vacaville LIGAND PHARMACEUTICALS INC; San Diego LYNX THERAPEUTICS INC; Hayward MATRIX PHARMACEUTICAL; Fremont MAXIM PHARMACEUTICALS; San Diego MAXYGEN INC; Redwood City MEDIMMUNE VACCINES; Mountain View MIRAVANT MEDICAL TECHNOLOGIES; Santa Barbara MOLECULAR BIOSYSTEMS INC; San Diego MOLECULAR DEVICES CORP; Sunnyvale NANOGEN INC; San Diego NEUROBIOLOGICAL TECHNOLOGIES INC; Richmond NEUROCRINE BIOSCIENCES INC; San Diego NORTH AMERICAN SCIENTIFIC; Chatsworth ONYX PHARMACEUTICALS INC; Richmond

PANVERA LLC; San Diego PEREGRINE PHARMACEUTICALS INC; Tustin PHARMACYCLICS INC; Sunnyvale PROTEIN DESIGN LABS INC; Fremont PROTEIN POLYMER TECHNOLOGIES; San Diego QUESTCOR PHARMACEUTICALS; Union City SANGAMO BIOSCIENCES INC; Richmond SANGSTAT MEDICAL CORP; Fremont SCICLO NE PHARMACEUTICALS; San Mateo SCIOS INC; Sunnyvale SENETEK PLC; Napa SEQUENOM INC; San Diego SICOR INC; Irvine SPECTRUM PHARMACEUTICALS; Irvine STEMCELLS, INC; Palo Alto SUPERGEN INC; Dublin SYNBIOTICS CORP; San Diego TELIK INC; South San Francisco TITAN PHARMACEUTICALS; South San Francisco TULARIK INC; South San Francisco VALENTIS INC; Burlingame VAXGEN INC; Brisbane VICAL INC; San Diego VIROLOGIC INC; South San Francisco WATSON PHARMACEUTICALS INC; Corona WOMEN FIRST HEALTHCARE; San Diego XOMA LTD; Berkeley

COLORADO ALLOS THERAPEUTICS INC; Denver ATRIX LABORATORIES INC; Fort Collins HESKA CORP; Fort Collins NAPRO BIOTHERAPEUTICS INC; Boulder RIBOZYME PHARMACEUTICALS; Boulder XTRANA INC; Broomfield

CONNECTICUT ALEXION PHARMACEUTICALS; Cheshire APPLERA CORPORATION; Norwalk CURAGEN CORPORATION; New Haven IMS HEALTH INC; Fairfield NEUROGEN CORP; Branford VION PHARMACEUTICALS INC; New Haven

DELAWARE E I DU PONT DE NEMOURS & CO; Wilmington

FLORIDA ANDRX CORP; Davie APHTON CORP; Miami IVAX CORPORATION; Miami KOS PHARMACEUTICALS INC; Miami NABI BIOPHARMACEUTICALS; Boca Raton NOVEN PHARMACEUTICALS; Miami VIRAGEN INC; Plantation




GEORGIA CYTRX CORPORATION; Norcross SEROLOGICALS CORP; Norcross THERAGENICS CORP; Buford

HAWAII CYANOTECH CORPORATION; Kailua-Kona

IDAHO INTERNATIONAL ISOTOPES; Idaho Falls

ILLINOIS ABBOTT LABORATORIES; Abbott Park ACCUMED INTERNATIONAL; Chicago AKORN INC; Buffalo Grove BAXTER INTERNATIONAL INC; Deerfield DONLAR BIOSYNTREX; Bedford Park DOR BIOPHARMA INC; Lake Forest IMMTECH INTERNATIONAL; Vernon Hills NORTHFIELD LABORATORIES; Evanston VYSIS INC; Downers Grove

INDIANA BIOANALYTICAL SYSTEMS INC; West Lafayette ELI LILLY & CO; Indianapolis

KANSAS AVAX TECHNOLOGIES INC; Overland Park

MAINE IDEXX LABORATORIES INC; Westbrook IMMUCELL CORPORATION; Portland

MARYLAND ANTEX BIOLOGICS INC; Gaithersburg BIORELIANCE CORP; Rockville CELERA GENOMICS GROUP; Rockville CHESAPEAKE BIOLOGICAL LAB; Baltimore DIGENE CORPORATION; Gaithersburg ENTREMED INC; Rockville GENE LOGIC INC; Gaithersburg GUILFORD PHARMACEUTICALS INC; Baltimore HEMAGEN DIAGNOSTICS INC; Columbia HUMAN GENOME SCIENCES INC; Rockville IGEN INTERNATIONAL INC; Gaithersburg INFORMAX INC; Bethesda MARTEK BIOSCIENCES CORP; Columbia MEDIMMUNE INC; Gaithersburg NOVAVAX INC; Columbia UNITED THERAPEUTICS CORP; Silver Spring

MASSACHUSETTS ADVANCED MAGNETICS INC; Cambridge ALKERMES INC; Cambridge ANIKA THERAPEUTICS INC; Woburn ARIAD PHARMACEUTICALS; Cambridge ARQULE INC; Woburn

ASCENT PEDIATRICS INC; Wilmington AVANT IMMUNOTHERAPEUTICS; Needham BIOGEN INC; Cambridge BIOPURE CORPORATION; Cambridge BIOSPHERE MEDICAL INC; Rockland BIOTRANSPLANT INC; Charlestown BOSTON BIOMEDICA INC; West Bridgewater BOSTON LIFE SCIENCES INC; Boston CARDIOTECH INTERNATIONAL; Woburn CHARLES RIVER LABORATORIES CORP; Wilmington CUBIST PHARMACEUTICALS; Lexington CURIS INC; Cambridge DIACRIN INC; Charlestown DUSA PHARMACEUTICALS INC; Wilmington DYAX CORP; Cambridge EPIX MEDICAL INC; Cambridge ESSENTIAL THERAPEUTICS INC; Waltham GELTEX PHARMACEUTICALS; Waltham GENOME THERAPEUTICS CORP; Waltham GENZYME BIOSURGERY; Cambridge GENZYME CORP; Cambridge GENZYME MOLECULAR ONCOLOGY; Framingham GLYCOGENESYS INC; Boston GTC BIOTHERAPEUTICS INC; Framingham HYBRIDON INC; Cambridge IMMUNOGEN INC; Cambridge MACROCHEM CORPORATION; Lexington MATRITECH INC; Newton MILLENNIUM PHARMACEUTICALS INC; Cambridge MILLIPORE CORP; Bedford ORGANOGENESIS INC; Canton OXIGENE INC; Watertown PAREXEL INTERNATIONAL; Waltham PRAECIS PHARMACEUTICALS; Waltham REPLIGEN CORPORATION; Waltham SEPRACOR INC; Marlborough TRANSKARYOTIC THERAPIES; Cambridge V I TECHNOLOGIES INC; Watertown VERTEX PHARMACEUTICALS INC; Cambridge

MICHIGAN AASTROM BIOSCIENCES INC; Ann Arbor CARACO PHARMACEUTICAL LABORATORIES; Detroit NEOGEN CORPORATION; Lansing

MINNESOTA CIMA LABS INC; Eden Prairie LIFECORE BIOMEDICAL INC; Chaska MEDTOX SCIENTIFIC INC; St. Paul MGI PHARMA INC; Bloomington ORPHAN MEDICAL INC; Minnetonka SYNOVIS LIFE TECHNOLOGIES INC; St. Paul TECHNE CORP; Minneapolis

MISSOURI K V PHARMACEUTICAL CO; St. Louis




MALLINCKRODT INC; Hazelwood MONSANTO CO; St. Louis SHEFFIELD PHARMACEUTICALS; St. Louis TRIPOS INC; St. Louis

NEW HAMPSHIRE BENTLEY PHARMACEUTICALS INC; North Hampton

NEW JERSEY ABLE LABORATORIES; South Plainfield ALFACELL CORPORATION; Bloomfield ALPHARMA INC; Fort Lee ALTEON INC; Ramsey BIO TECHNOLOGY GENERAL CORP; Iselin BRADLEY PHARMACEUTICALS; Fairfield CAMBREX CORP; East Rutherford CELGENE CORP; Warren COLUMBIA LABORATORIES; Livingston CORTECH INC; Bedminster COVANCE INC; Princeton CYTOGEN CORPORATION; Princeton ENZON INC; Bridgewater GENTA INC; Berkeley Heights HUNTINGDON LIFE SCIENCES; Hackensack IMMUNOMEDICS INC; Morris Plains INTEGRA LIFESCIENCES CORP; Plainsboro INTERFERON SCIENCES INC; New Brunswick JOHNSON & JOHNSON; New Brunswick LIFECELL CORPORATION; Branchburg MEDAREX INC; Princeton MERCK & CO INC; Whitehouse Station NEXMED INC; Robbinsville ORCHID BIOSCIENCES INC; Princeton PALATIN TECHNOLOGIES INC; Cranbury PHARMACEUTICAL FORMULATIONS INC; Edison PHARMACOPEIA INC; Princeton PHARMOS CORPORATION; Iselin SCHERING-PLOUGH CORP; Kenilworth SYNAPTIC PHARMACEUTICAL; Paramus UNIGENE LABORATORIES; Fairfield WYETH; Madison XECHEM INTERNATIONAL; New Brunswick

NEW YORK ALBANY MOLECULAR RESEARCH; Albany ANTIGENICS INC; New York ATLANTIC TECHNOLOGY VENTURES; New York AXONYX INC; New York BARR LABORATORIES INC; Pomona BAUSCH & LOMB INC; Rochester BIOSPECIFICS TECHNOLOGIES CORP; Lynbrook BRISTOL MYERS SQUIBB CO; New York EMISPHERE TECHNOLOGIES; Tarrytown ENZO BIOCHEM INC; Farmingdale E-Z-EM INC; Westbury FOREST LABORATORIES INC; New York HI TECH PHARMACAL CO INC; Amityville IMCLONE SYSTEMS INC; New York

NUTRITION 21 INC; Purchase OSI PHARMACEUTICALS INC; Melville PALIGENT INC; New York PDK LABS INC; Hauppauge PENWEST PHARMACEUTICALS CO; Patterson PFIZER INC; New York PHARMACEUTICAL RESOURCES INC; Spring Valley PROGENICS PHARMACEUTICALS; Tarrytown REGENERON PHARMACEUTICALS INC; Tarrytown SIGA TECHNOLOGIES INC; New York UNITED-GUARDIAN INC; Hauppauge

NORTH CAROLINA AAIPHARMA INC; Wilmington DSM PHARMACEUTICALS INC; Greenville EMBREX INC; Durham INCARA PHARMACEUTICALS; Research Triangle Park INSPIRE PHARMACEUTICALS INC; Durham PARADIGM GENETICS INC; Research Triangle Park PHARMACEUTICAL PRODUCT DEVELOPMENT INC; Wilmington QUINTILES TRANSNATIONAL CORP; Durham TRIANGLE PHARMACEUTICALS; Durham

OHIO BIGMAR INC; Johnstown GLIATECH INC; Cleveland KENDLE INTERNATIONAL INC; Cincinnati NEOPROBE CORPORATION; Dublin

OREGON AVI BIOPHARMA INC; Portland EXELIXIS PLANT SCIENCES INC; Portland OXIS INTERNATIONAL INC; Portland

PENNSYLVANIA BIONX IMPLANTS INC; Blue Bell CELL PATHWAYS INC; Horsham CEPHALON INC; West Chester COLLAGENEX PHARMACEUTICAL; Newton COVALENT GROUP INC; Wayne DISCOVERY LABORATORIES; Doylestown ENDO PHARMACEUTICALS HOLDINGS INC; Chadds Ford ERESEARCH TECHNOLOGY INC; Philadelphia GENAERA CORPORATION; Plymouth Meeting HEMISPHERX BIOPHARMA INC; Philadelphia INKINE PHARMACEUTICAL CO; Blue Bell MYLAN LABORATORIES INC; Pittsburgh NEOSE TECHNOLOGIES INC; Horsham ORAPHARMA INC; Warminster ORASURE TECHNOLOGIES INC; Bethlehem PHOTOGEN TECHNOLOGIES INC; New Hope VIROPHARMA INC; Exton




TENNESSEE CELERIS CORPORATION; Nashville CHATTEM INC; Chattanooga KING PHARMACEUTICALS INC; Bristol

TEXAS ACCESS PHARMACEUTICALS; Dallas AMARILLO BIOSCIENCES INC; Amarillo CARRINGTON LABORATORIES INC; Irving EXEGENICS INC; Dallas ILEX ONCOLOGY INC; San Antonio INTROGEN THERAPEUTICS INC; Austin LEXICON GENETICS INC; The Woodlands LUMINEX CORPORATION; Austin TANOX INC; Houston TEXAS BIOTECHNOLOGY CORP; Houston VIRBAC INC; Fort Worth ZONAGEN INCORPORATED; The Woodlands

UTAH IOMED INC; Salt Lake City MYRIAD GENETICS INC; Salt Lake City NPS PHARMACEUTICALS INC; Salt Lake City

VIRGINIA CEL-SCI CORPORATION; Vienna COMMONWEALTH BIOTECHNOLOGIES INC; Richmond INSMED INCORPORATED; Glen Allen

INDEX OF HEADQUARTERS LOCATION BY COUNTRY To help you locate members of THE BIOTECH & GENETICS 400 that have non-U.S. headquarters, the city and country of the headquarters of such companies are included in the following index. CANADA ANGIOTECH PHARMACEUTICALS; Vancouver BIOMIRA INC; Edmonton BIOTECH HOLDINGS LTD; Vancouver BIOVAIL CORPORATION; Mississauga CARDIOME PHARMACEUTICAL CORP; Vancouver DRAXIS HEALTH INC; Mississauga GENEREX BIOTECHNOLOGY; Toronto ID BIOMEDICAL CORPORATION; Vancouver LORUS THERAPEUTICS INC; Toronto MDS INC; Toronto MICROLOGIX BIOTECH INC; Vancouver POLYDEX PHARMACEUTICALS; Toronto QLT INC; Vancouver SHIRE-BIOCHEM INC; Laval SPECTRAL DIAGNOSTICS INC; Toronto

CHILE LABORATORIO CHILE SA; Santiago

DENMARK

WASHINGTON CELL THERAPEUTICS INC; Seattle CORIXA CORPORATION; Seattle EPOCH BIOSCIENCES; Bothell ICOS CORPORATION; Bothell IMMUNEX CORP; Seattle NASTECH PHARMACEUTICAL CO INC; Bothell NEORX CORPORATION; Seattle PACIFIC BIOMETRICS INC; Seattle PROCYTE CORPORATION; Redmond SONUS PHARMACEUTICALS; Bothell TARGETED GENETICS CORP; Seattle

NOVO-NORDISK AS; Basgvaerd

FRANCE AVENTIS SA; Schiltingheim FLAMEL TECHNOLOGIES SA; Venissieux Cedex GENSET SA; Paris

GERMANY LION BIOSCIENCE AG; Heidelberg

ICELAND DECODE GENETICS INC; Reykjavik

WISCONSIN BONE CARE INTERNATIONAL; Madison THIRD WAVE TECHNOLOGIES INC; Madison

IRELAND ELAN CORP PLC; Dublin ICON PLC; Dublin TRINITY BIOTECH PLC; Wicklow WARNER CHILCOTT PLC; Dublin

ISRAEL COMPUGEN LTD; Tel Aviv TARO PHARMACEUTICAL INDUSTRIES; Haifa Bay TEVA PHARMACEUTICAL INDUSTRIES; Petach Tikva




SWEDEN

INDEX BY U.S. REGIONS WHERE THE BIOTECH & GENETICS 400 FIRMS HAVE LOCATIONS

BIORA AB; Malmo

SWITZERLAND NOVARTIS AG; Basel SYNGENTA AG; Basel

WEST

THE NETHERLANDS AKZO NOBEL NV; Arnhem QIAGEN NV; Venlo

UNITED KINGDOM ALIZYME PLC; Cambridge AMARIN CORPORATION PLC; London AMERSHAM PLC; Little Chalfont ASTRAZENECA PLC; London BIOCOMPATIBLES INTERNATIONAL PLC; Farnham BRITISH BIOTECH PLC; Oxford CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC; Melbourne CELLTECH GROUP PLC; Slough CELSIS INTERNATIONAL PLC; Cambridge GLAXOSMITHKLINE PLC; Brentford OXFORD GLYCOSCIENCES PLC; Abingdon Oxon SHIRE PHARMACEUTICALS PLC; Basingstoke SKYEPHARMA PLC; London XENOVA GROUP PLC; Slough

AAIPHARMA INC ABAXIS INC ABBOTT LABORATORIES ABGENIX INC ACLARA BIOSCIENCES INC ADVANCED TISSUE SCIENCES AFFYMETRIX INC AKORN INC AKZO NOBEL NV ALEXION PHARMACEUTICALS ALLERGAN INC ALLIANCE PHARMACEUTICAL CORP ALLOS THERAPEUTICS INC ALPHARMA INC ALZA CORP AMGEN INC AMYLIN PHARMACEUTICALS INC APPLERA CORPORATION APPLIED MOLECULAR EVOLUTION INC ARENA PHARMACEUTICALS INC ATRIX LABORATORIES INC AUTOIMMUNE INC AVANIR PHARMACEUTICALS AVENTIS SA AVI BIOPHARMA INC AVIGEN INC BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BIO RAD LABORATORIES INC BIOMARIN PHARMACEUTICAL BIOSITE INC BIOSOURCE INTERNATIONAL INC BIOTIME INC BOSTON BIOMEDICA INC BRISTOL MYERS SQUIBB CO CALIPER TECHNOLOGIES CORP CELL GENESYS INC CELL THERAPEUTICS INC CELLEGY PHARMACEUTICALS CELSIS INTERNATIONAL PLC CEPHALON INC CEPHEID CERUS CORPORATION CHARLES RIVER LABORATORIES CORP CHATTEM INC CHIRON CORP CIPHERGEN BIOSYSTEMS INC COLLATERAL THERAPEUTICS COMPUGEN LTD CONNETICS CORPORATION CORIXA CORPORATION CORTEX PHARMACEUTICALS




CORVAS INTERNATIONAL INC COVANCE INC CV THERAPEUTICS INC CYANOTECH CORPORATION CYPRESS BIOSCIENCE INC DEPOMED INC DIAGNOSTIC PRODUCTS CORPORATION DIVERSA CORPORATION DURECT CORP E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO EPIMMUNE INC EPOCH BIOSCIENCES ESSENTIAL THERAPEUTICS INC EXELIXIS INC EXELIXIS PLANT SCIENCES INC FOREST LABORATORIES INC GENE LOGIC INC GENELABS TECHNOLOGIES INC GENENCOR INTERNATIONAL INC GENENTECH INC GENSET SA GENZYME CORP GERON CORPORATION GILEAD SCIENCES INC GLAXOSMITHKLINE PLC HAUSER INC HEMAGEN DIAGNOSTICS INC HESKA CORP HOLLIS-EDEN PHARMACEUTICALS HYCOR BIOMEDICAL INC HYSEQ INC ICN PHARMACEUTICALS INC ICON PLC ICOS CORPORATION ID BIOMEDICAL CORPORATION IDEC PHARMACEUTICALS CORP IDEXX LABORATORIES INC ILLUMINA INC IMMUNE RESPONSE CORP (THE) IMMUNEX CORP IMPAX LABORATORIES INC INCYTE GENOMICS INC INFORMAX INC INSITE VISION INC INTEGRA LIFESCIENCES CORP INTERMUNE PHARMACEUTICALS INC INTERNATIONAL ISOTOPES INTRABIOTICS PHARMACEUTICALS INVITROGEN CORPORATION IOMED INC ISIS PHARMACEUTICALS INC IVAX CORPORATION JOHNSON & JOHNSON KENDLE INTERNATIONAL INC KOSAN BIOSCIENCES INC LA JOLLA PHARMACEUTICAL

LARGE SCALE BIOLOGY CORP LIGAND PHARMACEUTICALS INC LION BIOSCIENCE AG LYNX THERAPEUTICS INC MALLINCKRODT INC MARTEK BIOSCIENCES CORP MATRIX PHARMACEUTICAL MAXIM PHARMACEUTICALS MAXYGEN INC MDS INC MEDAREX INC MEDIMMUNE VA CCINES MERCK & CO INC MILLENNIUM PHARMACEUTICALS INC MIRAVANT MEDICAL TECHNOLOGIES MOLECULAR BIOSYSTEMS INC MOLECULAR DEVICES CORP MONSANTO CO MYRIAD GENETICS INC NABI BIOPHARMACEUTICALS NANOGEN INC NAPRO BIOTHERAPEUTICS INC NASTECH PHARMACEUTICAL CO INC NEORX CORPORATION NEOSE TECHNOLOGIES INC NEUROBIOLOGICAL TECHNOLOGIES INC NEUROCRINE BIOSCIENCES INC NORTH AMERICAN SCIENTIFIC NOVO-NORDISK AS NPS PHARMACEUTICALS INC ONYX PHARMACEUTICALS INC ORASURE TECHNOLOGIES INC OSI PHARMACEUTICALS INC OXIS INTERNATIONAL INC PACIFIC BIOMETRICS INC PANVERA LLC PAREXEL INTERNATIONAL PEREGRINE PHARMACEUTICALS INC PFIZER INC PHARMACEUTICAL PRODUCT DEVELOPMENT INC PHARMACYCLICS INC PROCYTE CORPORATION PROTEIN DESIGN LABS INC PROTEIN POLYMER TECHNOLOGIES QIAGEN NV QUESTCOR PHARMACEUTICALS QUINTILES TRANSNATIONAL CORP RIBOZYME PHARMACEUTICALS SANGAMO BIOSCIENCES INC SANGSTAT MEDICAL CORP SCHERING-PLOUGH CORP SCICLONE PHARMACEUTICALS SCIOS INC SENETEK PLC SEQUENOM INC SEROLOGICALS CORP SHIRE PHARMACEUTICALS PLC SICOR INC




SIGA TECHNOLOGIES INC SKYEPHARMA PLC SONUS PHARMACEUTICALS SPECTRAL DIAGNOSTICS INC SPECTRUM PHARMACEUTICALS STEMCELLS, INC SUPERGEN INC SYNBIOTICS CORP SYNGENTA AG TARGETED GENETICS CORP TELIK INC TITAN PHARMACEUTICALS TRINITY BIOTECH PLC TRIPOS INC TULARIK INC VALENTIS INC VAXGEN INC VERTEX PHARMACEUTICALS INC VICAL INC VIROLOGIC INC WATSON PHARMACEUTICALS INC WOMEN FIRST HEALTHCARE WYETH XOMA LTD XTRANA INC ZILA INC

IMMUNEX CORP INTERNATIONAL ISOTOPES INTROGEN THERAPEUTICS INC IVAX CORPORATION JOHNSON & JOHNSON LEXICON GENETICS INC LUMINEX CORPORATION MALLINCKRODT INC MDS INC MEDICIS PHARMACEUTICAL CORP MERCK & CO INC MONSANTO CO NABI BIOPHARMACEUTICALS NEORX CORPORATION ORCHID BIOSCIENCES INC PAREXEL INTERNATIONA L PFIZER INC QUINTILES TRANSNATIONAL CORP SCHERING-PLOUGH CORP SEROLOGICALS CORP SHIRE PHARMACEUTICALS PLC TANOX INC TEXAS BIOTECHNOLOGY CORP VIRBAC INC WYETH ZILA INC ZONAGEN INCORPORATED

SOUTHWEST ABBOTT LABORATORIES ACCESS PHARMACEUTICALS ACLARA BIOSCIENCES INC AFFYMETRIX INC AKORN INC AKZO NOBEL NV ALLERGAN INC ALPHARMA INC AMYLIN PHARMACEUTICALS INC APHTON CORP APPLERA CORPORATION AVENTIS SA BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BIO RAD LABORATORIES INC BRISTOL MYERS SQUIBB CO CARRINGTON LABORATORIES INC CHIRON CORP CONNETICS CORPORATION E I DU PONT DE NEMOURS & CO ELI LILLY & CO EXEGENICS INC FOREST LABORATORIES INC GENELABS TECHNOLOGIES INC GENENTECH INC GENZYME CORP GLAXOSMITHKLINE PLC IDEXX LABORATORIES INC ILEX ONCOLOGY INC

MIDWEST AAIPHARMA INC AASTROM BIOSCIENCES INC ABBOTT LABORATORIES ACCUMED INTERNATIONAL AFFYMETRIX INC AKORN INC AKZO NOBEL NV ALBANY MOLECULAR RESEARCH ALKERMES INC ALLERGAN INC ALPHARMA INC ALZA CORP AMGEN INC AMYLIN PHARMACEUTICALS INC AVAX TECHNOLOGIES INC AVENTIS SA BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BIGMAR INC BIO RAD LABORATORIES INC BIOANALYTICAL SYSTEMS INC BONE CARE INTERNATIONAL BRISTOL MYERS SQUIBB CO CAMBREX CORP CARACO PHARMACEUTICAL LABORATORIES CELSIS INTERNATIONAL PLC CHIRON CORP CIMA LABS INC




COVANCE INC DONLAR BIOSYNTREX DOR BIOPHARMA INC DSM PHARMACEUTICALS INC E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO FOREST LABORATORIES INC GENENTECH INC GENZYME CORP GLAXOSMITHKLINE PLC GLIATECH INC HESKA CORP ICN PHARMACEUTICALS INC ICON PLC IDEXX LABORATORIES INC IMMTECH INTERNATIONAL IMMUNEX CORP INCYTE GENOMICS INC IVAX CORPORATION JOHNSON & JOHNSON K V PHARMACEUTICAL CO KENDLE INTERNATIONAL INC KING PHARMACEUTICALS INC LIFECORE BIOMEDICAL INC LION BIOSCIENCE AG MALLINCKRODT INC MDS INC MEDTOX SCIENTIFIC INC MERCK & CO INC MGI PHARMA INC MONSANTO CO MYLAN LABORATORIES INC NABI BIOPHARMACEUTICALS NEOGEN CORPORATION NEOPROBE CORPORATION NORTHFIELD LABORATORIES ORPHAN MEDICAL INC PAREXEL INTERNATIONAL PENWEST PHARMACEUTICALS CO PFIZER INC PHARMACEUTICAL PRODUCT DEVELOPMENT INC PROTEIN DESIGN LA BS INC QUINTILES TRANSNATIONAL CORP SCHERING-PLOUGH CORP SEROLOGICALS CORP SHEFFIELD PHARMACEUTICALS SHIRE PHARMACEUTICALS PLC SPECTRAL DIAGNOSTICS INC SYNBIOTICS CORP SYNGENTA AG SYNOVIS LIFE TECHNOLOGIES INC TECHNE CORP THIRD WAVE TECHNOLOGIES INC TRIPOS INC UNITED THERAPEUTICS CORP VYSIS INC WATSON PHARMACEUTICALS INC

WYETH ZILA INC

SOUTHEAST AAIPHARMA INC ABBOTT LABORATORIES AFFYMETRIX INC AKORN INC AKZO NOBEL NV ALLERGAN INC ALPHARMA INC AMARILLO BIOSCIENCES INC AMYLIN PHARMACEUTICALS INC ANDRX CORP APHTON CORP AVENTIS SA BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BIO RAD LABORATORIES INC BIOANALYTICAL SYSTEMS INC BIOCRYST PHARMACEUTICALS BRISTOL MYERS SQUIBB CO CELERIS CORPORATION CHATTEM INC CHIRON CORP CYTRX CORPORATION DIAGNOSTIC PRODUCTS CORPORATION E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO EMBREX INC E-Z-EM INC FOREST LABORATORIES INC GENENTECH INC GENZYME BIOSURGERY GENZYME CORP GLAXOSMITHKLINE PLC HAUSER INC ICON PLC IDEXX LABORATORIES INC IMMUNEX CORP INSPIRE PHARMACEUTICALS INC IVAX CORPORATION JOHNSON & JOHNSON KING PHARMACEUTICALS INC KOS PHARMACEUTICALS INC LARGE SCALE BIOLOGY CORP MARTEK BIOSCIENCES CORP MDS INC MERCK & CO INC MONSANTO CO MYLAN LABORATORIES INC NABI BIOPHARMACEUTICALS NEOGEN CORPORATION NOVEN PHARMACEUTICALS NOVO-NORDISK AS PARADIGM GENETICS INC




PAREXEL INTERNATIONAL PFIZER INC POLYDEX PHARMACEUTICALS QUINTILES TRANSNATIONAL CORP SCHERING-PLOUGH CORP SEROLOGICALS CORP SHIRE PHARMACEUTICALS PLC SYNGENTA AG THERAGENICS CORP VIRAGEN INC WATSON PHARMACEUTICALS INC WYETH

NORTHEAST AAIPHARMA INC ABBOTT LABORATORIES ABLE LABORATORIES ADVANCED MAGNETICS INC AFFYMETRIX INC AKORN INC AKZO NOBEL NV ALBANY MOLECULAR RESEARCH ALEXION PHARMACEUTICALS ALFACELL CORPORATION ALKERMES INC ALLERGAN INC ALLIANCE PHARMACEUTICAL CORP ALPHARMA INC ALTEON INC AMARIN CORPORATION PLC AMGEN INC AMYLIN PHARMACEUTICALS INC ANIKA THERAPEUTICS INC ANTEX BIOLOGICS INC ANTIGENICS INC APPLERA CORPORATION ARIAD PHARMACEUTICALS ARQULE INC ASCENT PEDIATRICS INC ASTRAZENECA PLC ATLANTIC TECHNOLOGY VENTURES AVANT IMMUNOTHERAPEUTICS AVENTIS SA AXONYX INC BARR LABORATORIES INC BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BENTLEY PHARMACEUTICALS INC BIO RAD LABORATORIES INC BIO TECHNOLOGY GENERAL CORP BIOANALYTICAL SYSTEMS INC BIOGEN INC BIOMIRA INC BIONX IMPLANTS INC BIOPURE CORPORATION BIORELIANCE CORP BIOSOURCE INTERNATIONAL INC

BIOSPECIFICS TECHNOLOGIES CORP BIOSPHERE MEDICAL INC BIOTRANSPLANT INC BIOVAIL CORPORATION BOSTON BIOMEDICA INC BOSTON LIFE SCIENCES INC BRADLEY PHARMACEUTICALS BRISTOL MYERS SQUIBB CO CAMBREX CORP CARDIOTECH INTERNATIONAL CELERA GENOMICS GROUP CELERIS CORPORATION CELGENE CORP CELL PATHWAYS INC CEL-SCI CORPORATION CELSIS INTERNATIONAL PLC CEPHALON INC CHARLES RIVER LABORATORIES CORP CHESAPEAKE BIOLOGICAL LAB CHIRON CORP COLLAGENEX PHARMACEUTICAL COLUMBIA LABORATORIES COMMONWEALTH BIOTECHNOLOGIES INC COMPUGEN LTD CORTECH INC COVALENT GROUP INC COVANCE INC CUBIST PHARMACEUTICALS CURAGEN CORPORATION CURIS INC CYTOGEN CORPORATION DIACRIN INC DIAGNOSTIC PRODUCTS CORPORATION DIGENE CORPORATION DISCOVERY LABORATORIES DSM PHARMACEUTICALS INC DUSA PHARMACEUTICALS INC DYAX CORP E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO EMBREX INC EMISPHERE TECHNOLOGIES ENDO PHARMACEUTICALS HOLDINGS INC ENTREMED INC ENZO BIOCHEM INC ENZON INC EPIX MEDICAL INC ERESEARCH TECHNOLOGY INC ESSENTIAL THERAPEUTICS INC E-Z-EM INC FOREST LABORATORIES INC GELTEX PHARMACEUTICALS GENAERA CORPORATION GENE LOGIC INC GENELABS TECHNOLOGIES INC GENENTECH INC GENOME THERAPEUTICS CORP




GENTA INC GENZYME BIOSURGERY GENZYME CORP GENZYME MOLECULAR ONCOLOGY GLAXOSMITHKLINE PLC GLYCOGENESYS INC GTC BIOTHERAPEUTICS INC GUILFORD PHARMACEUTICALS INC HAUSER INC HEMAGEN DIAGNOSTICS INC HEMISPHERX BIOPHARMA INC HESKA CORP HI TECH PHARMACAL CO INC HUMAN GENOME SCIENCES INC HUNTINGDON LIFE SCIENCES HYBRIDON INC ICN PHARMACEUTICALS INC ICON PLC IDEXX LABORATORIES INC IGEN INTERNATIONAL INC ILEX ONCOLOGY INC IMCLONE SYSTEMS INC IMMUCELL CORPORATION IMMUNE RESPONSE CORP (THE) IMMUNEX CORP IMMUNOGEN INC IMMUNOMEDICS INC IMPAX LABORATORIES INC IMS HEALTH INC INCARA PHARMACEUTICALS INCYTE GENOMICS INC INFORMAX INC INKINE PHARMACEUTICAL CO INSMED INCORPORATED INTEGRA LIFESCIENCES CORP INTERFERON SCIENCES INC IVAX CORPORATION JOHNSON & JOHNSON KENDLE INTERNATIONAL INC KOS PHARMACEUTICALS INC LARGE SCALE BIOLOGY CORP LEXICON GENETICS INC LIFECELL CORPORATION LION BIOSCIENCE AG MACROCHEM CORPORATION MARTEK BIOSCIENCES CORP MATRITECH INC MDS INC MEDAREX INC MEDIMMUNE INC MEDTOX SCIENTIFIC INC MERCK & CO INC MILLENNIUM PHARMACEUTICALS INC MILLIPORE CORP MONSANTO CO MYLAN LABORATORIES INC NABI BIOPHARMACEUTICALS NASTECH PHARMACEUTICAL CO INC

NEOGEN CORPORATION NEOSE TECHNOLOGIES INC NEUROGEN CORP NEXMED INC NORTH AMERICAN SCIENTIFIC NOVARTIS AG NOVAVAX INC NOVO-NORDISK AS NUTRITION 21 INC ORAPHA RMA INC ORASURE TECHNOLOGIES INC ORCHID BIOSCIENCES INC ORGANOGENESIS INC OSI PHARMACEUTICALS INC OXIGENE INC PALATIN TECHNOLOGIES INC PALIGENT INC PAREXEL INTERNATIONAL PDK LABS INC PENWEST PHARMACEUTICALS CO PFIZER INC PHARMACEUTICAL FORMULATIONS INC PHA RMACEUTICAL PRODUCT DEVELOPMENT INC PHARMACEUTICAL RESOURCES INC PHARMACOPEIA INC PHARMOS CORPORATION PHOTOGEN TECHNOLOGIES INC PRAECIS PHARMACEUTICALS PROGENICS PHARMACEUTICALS QIAGEN NV QUINTILES TRANSNATIONAL CORP REGENERON PHARMACEUTICALS INC REPLIGEN CORPORATION SANGSTAT MEDICAL CORP SCHERING-PLOUGH CORP SEPRACOR INC SEQUENOM INC SEROLOGICALS CORP SHIRE PHARMACEUTICALS PLC SHIRE-BIOCHEM INC SIGA TECHNOLOGIES INC SPECTRAL DIAGNOSTICS INC SYNAPTIC PHARMACEUTICAL SYNBIOTICS CORP SYNGENTA AG TARO PHARMACEU TICAL INDUSTRIES TEVA PHARMACEUTICAL INDUSTRIES TITAN PHARMACEUTICALS TRANSKARYOTIC THERAPIES TRIANGLE PHARMACEUTICALS TRINITY BIOTECH PLC TRIPOS INC TULARIK INC UNIGENE LABORATORIES UNITED THERAPEUTICS CORP UNITED-GUARDIAN INC V I TECHNOLOGIES INC VERTEX PHARMACEUTICALS INC




VICAL INC VION PHARMACEUTICALS INC VIROPHARMA INC WATSON PHARMACEUTICALS INC WYETH XECHEM INTERNATIONAL

INDEX BY FIRMS WITH INTERNATIONAL OPERATIONS AAIPHARMA INC ABBOTT LABORATORIES ACCESS PHARMACEUTICALS AFFYMETRIX INC AKZO NOBEL NV ALIZYME PLC ALKERMES INC ALLERGAN INC ALPHARMA INC AMARIN CORPORATION PLC AMERSHAM PLC AMGEN INC AMYLIN PHARMACEUTICALS INC ANGIOTECH PHARMACEUTICALS APHTON CORP APPLERA CORPORATION ASTRAZENECA PLC AVAX TECHNOLOGIES INC AVENTIS SA AXONYX INC BAUSCH & LOM B INC BAXTER INTERNATIONAL INC BENTLEY PHARMACEUTICALS INC BIGMAR INC BIO RAD LABORATORIES INC BIO TECHNOLOGY GENERAL CORP BIOANALYTICAL SYSTEMS INC BIOCOMPATIBLES INTERNATIONAL PLC BIOGEN INC BIOMIRA INC BIONX IMPLANTS INC BIOPURE CORPORATION BIORA AB BIORELIANCE CORP BIOSOURCE INTERNATIONAL INC BIOSPECIFICS TECHNOLOGIES CORP BIOSPHERE MEDICAL INC BIOTECH HOLDINGS LTD BIOVAIL CORPORATION BRISTOL MYERS SQUIBB CO BRITISH BIOTECH PLC CAMBREX CORP CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC CARACO PHARMACEUTICAL LABORATORIES CARDIOME PHARMACEUTICAL CORP CARDIOTECH INTERNATIONAL CARRINGTON LABORATORIES INC CELLEGY PHARMACEUTICALS CELLTECH GROUP PLC CELSIS INTERNATIONAL PLC CEPHALON INC CEPHEID CHARLES RIVER LABORATORIES CORP CHATTEM INC




CHIRON CORP CIPHERGEN BIOSYSTEMS INC COLUMBIA LABORATORIES COMPUGEN LTD CONNETICS CORPORATION COVALENT GROUP INC COVANCE INC CUBIST PHARMACEUTICALS CYANOTECH CORPORATION DECODE GENETICS INC DIAGNOSTIC PRODUCTS CORPORATION DIGENE CORPORATION DRAXIS HEALTH INC DSM PHARMACEUTICALS INC DUSA PHARMACEUTICALS INC DYAX CORP E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO EMBREX INC ERESEARCH TECHNOLOGY INC EXELIXIS INC E-Z-EM INC FLAMEL TECHNOLOGIES SA FOREST LABORATORIES INC GELTEX PHARMACEUTICALS GENELABS TECHNOLOGIES INC GENEREX BIOTECHNOLOGY GENSET SA GENTA INC GENZYME BIOSURGERY GENZYME CORP GERON CORPORATION GILEAD SCIENCES INC GLAXOSMITHKLINE PLC HAUSER INC HEMAGEN DIAGNOSTICS INC HESKA CORP HUNTINGDON LIFE SCIENCES HYCOR BIOMEDICAL INC ICN PHARMACEUTICALS INC ICON PLC ID BIOMEDICAL CORPORATION IDEXX LABORATORIES INC IGEN INTERNATIONAL INC ILEX ONCOLOGY INC IMMUNOMEDICS INC IMS HEALTH INC INCYTE GENOMICS INC INFORMAX INC INTEGRA LIFESCIENCES CORP INTROGEN THERAPEUTICS INC INVITROGEN CORPORATION ISIS PHARMACEUTICALS INC IVAX CORPORATION JOHNSON & JOHNSON KENDLE INTERNATIONAL INC LABORATORIO CHILE SA

LIFECORE BIOMEDICAL INC LION BIOSCIENCE AG LORUS THERAPEUTICS INC LYNX THERAPEUTICS INC MALLINCKRODT INC MATRITECH INC MAXYGEN INC MDS INC MEDAREX INC MEDIMMUNE INC MERCK & CO INC MICROLOGIX BIOTECH INC MILLENNIUM PHARMACEUTICALS INC MILLIPORE CORP MOLECULAR DEVICES CORP MONSANTO CO NABI BIOPHARMACEUTICALS NANOGEN INC NAPRO BIOTHERAPEUTICS INC NEOGEN CORPORATION NEUROBIOLOGICAL TECHNOLOGIES INC NEXMED INC NOVARTIS AG NOVO-NORDISK AS NPS PHARMACEUTICALS INC ORASURE TECHNOLOGIES INC ORCHID BIOSCIENCES INC OSI PHARMACEUTICALS INC OXFORD GLYCOSCIENCES PLC PAREXEL INTERNATIONAL PDK LABS INC PENWEST PHARMACEUTICALS CO PFIZER INC PHARMACEUTICAL PRODUCT DEVELOPMENT INC PHARMACEUTICAL RESOURCES INC PHARMACOPEIA INC PHARMOS CORPORATION POLYDEX PHARMACEUTICALS QIAGEN NV QLT INC QUINTILES TRANSNATIONAL CORP SANGAMO BIOSCIENCES INC SANGSTAT MEDICAL CORP SCHERING-PLOUGH CORP SCICLONE PHARMACEUTICALS SEPRACOR INC SEQUENOM INC SEROLOGICALS CORP SHIRE PHARMACEUTICALS PLC SHIRE-BIOCHEM INC SICOR INC SKYEPHARMA PLC SPECTRAL DIAGNOSTICS INC SYNBIOTICS CORP SYNGENTA AG TANOX INC TARO PHARMACEUTICAL INDUSTRIES TECHNE CORP




TEVA PHARMACEUTICAL INDUSTRIES TRANSKARYOTIC THERAPIES TRINITY BIOTECH PLC TRIPOS INC TULARIK INC VALENTIS INC VAXGEN INC VERTEX PHARMACEUTICALS INC VIRAGEN INC VIRBAC INC VIROPHARMA INC VYSIS INC WARNER CHILCOTT PLC WATSON PHARMACEUTICALS INC WYETH XECHEM INTERNATIONAL XENOVA GROUP PLC




Individual Data Profiles On Each Of THE BIOTECH & GENETICS 400




AAIPHARMA INC

www.aaiintl.com

Industry Group Code: 541710 Ranks within this company's industry group: Sales: 9 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y

Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:

Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:

Y

TYPES OF BUSINESS:

Profits: 7

Computers: Hardware: Software: Arrays: Database Management:

Specialty: Specialty Servic es: Consulting: Blood Collection:

Y

GROWTH PLANS/SPECIAL FEATURES:

Research and Development Services Analytical Testing Bioanalytical Testing Clinical Distribution Devices Formulations Development Regulatory Affairs Consulting Drugs Microbiology Testing Services

AaiPharma, Inc., formerly Applied Analytical Industries, Inc. is a specialty pharmaceutical and product development company with comprehensive drug development capabilities in the United States, Europe and Asia. The company partners with pharmaceutical companies on both a fee-for-service and royalty and milestone payment basis, providing the expertise and knowledge to create quality health care products. The firm has earned a reputation for solving complex pharmaceutical challenges utilizing analytical testing and formulations development techniques, as well as validation and regulatory affairs support services. AaiPharma operates in three divisions: NeoSan Pharmaceuticals, aaiResearch and AAI International. NeoSan Pharmaceuticals acquires and commercializes branded pharmaceutical products in targeted therapeutic classes. The firm recently acquired the drugs Aquasol, Brethine, Darvon and Darvocet. aaiResearch provides research and development expertise and maintains a portfolio of drug-delivery technologies and intellectual property rights which the company uses to develop better and cheaper drugs. AAI International offers a comprehensive range of pharmaceutical product development services to international customers.

BRANDS/DIVISIONS/AFFILIATES: NeoSan Pharmaceuticals aaiResearch AAI International Applied Analytical Industries, Inc. Aquasol Brethine Darvon Darvocet

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frederick D. Sancilio, CEO Philip S. Tabbiner, COO Philip S. Tabbiner, Pres. William L. Ginna, Jr., Exec. VP/CFO Stephen Cottrell, Exec. VP-Mktg. & Sales Bowin Lindgren, Dir.-Human Resources George E. Van Lear, VP-Research Dev. John Hogan, Controller Richard J. Parker, Pres.-Clinical Trials Div. Gregory S. Bentley , Exec. VP/General Counsel David Johnston, Exec. VP-Non-Clinical Oper. J. Spencer Goldsmith, VP-eCommerce Eugene T. Haley, Treas. Eugene T. Haley, Int'l Managing Dir. Joachim Rexhaus, Exec. VP-European Oper. Vijay Aggarwal, Pres., AAI International

Phone: 910-254-7000 Fax: 910-815-2379 Toll-Free: 800-575-4224 Address: 2320 Scientific Park Dr., Wilmington, NC 28405 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $168,200 ( 9 months) 2002 Profits: $10,000 ( 9 months) Stock Ticker: AAII 2001 Sales: $141,100 2001 Profits: $5,900 Employees: 1,200 2000 Sales: $104,245 2000 Profits: $- 402 Fiscal Year Ends: 12/31 1999 Sales: $102,175 1999 Profits: $-7,913 1998 Sales: $98,243 1998 Profits: $6,538

SALARIES/BENEFITS: Pension Plan: Savings Plan:

COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $285,000 Bonus: $ ADVANTAGE: Offers an extensive portfolio of high quality drug development and support services.

OTHER THOUGHTS:

LOCATIONS: ("Y" = Yes)

Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:

West: Y

Southwest:

Midwest: Y

Southeast: Y

Note: Financial information, benefits and other data can change quickly and may vary from those stated here.


Northeast: Y

International: Y



AASTROM BIOSCIENCES INC

www.aastrom.com



Y


Y

TYPES OF BUSINESS:

Profits: 21


Specialty: Specialty Services: Consulting: Blood Collection:


Systems for Cell Reproduction Cell Therapy Kits

Aastrom Biosciences, Inc. is a leader in developing human cell therapy products in automated clinical systems, designed to enable therapeutic procedures using living cells in the treatment of diseases (including cancer) and in the restoration of normal tissues. The company has three product areas in various stages of development: tissue repair cells; therapeutic cells for immunotherapy; and devices for cell production. The AastromReplicell Cell Production System, Aastrom's lead product, is currently in multi-site U.S. clinical trials for the production of either bone marrow or umbilical cord blood cells to mitigate the toxicity of aggressive chemotherapy used to treat cancer and other blood disorders. The AastromReplicell System is designed to place patient-specific cell production capability directly in patient treatment centers and to enable physicians to access cells for therapy just as they do with traditional pharmaceuticals. This system is created as a family of products keyed by a multi-use instrumentation platform that operates single-use, therapyspecific kits tailored for each patient application. In Europe, the firm has begun market launch of the AastromReplicell System, the SC-I Therapy Kit for the production of bone-marrow derived stem cells and the CBI Therapy Kit for the production of umbilical cord blood cells. The AastromReplicell is also available for sale in the U.S. for research and investigational use. Recently, Aastrom was awarded a grant by the Defense Advanced Research Projects Agency to provide research and development of a system to engineer human stem cells into an artificial immune system. In other news, the company entered into an agreement with an Italian cancer treatment center, AUSL Ravenna, for the purchase and use of Aastrom’s bone marrow stem cell therapy product for an experimental clinical approach in the treatment of breast cancer.

BRANDS/DIVISIONS/AFFILIATES: AastromReplicell Zellera SC-I Therapy Kit CB-I Therapy Kit

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. R. Douglas Armstrong, CEO R. Douglas Armstrong, Pres. Michael S. Durski, CFO/VP-Finance and Admin. Steven Wolff, VP-Medical Research Michael S. Durski, Corp. Sec. Alan M. Wright, Sr. VP-Admin. and Financial Services Michael S. Durski, Treas. Robert J. Bard, VP-Quality Systems and Regulatory Affairs Brian S. Hampson, VP-Product Dev. R. Douglas Armstrong, Chmn.

Phone: 734-930-5555 Fax: 734-665-0485 Toll-Free: Address: 24 Frank Lloyd Wright Dr., Ann Arbor, MI 48106 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $ 900 (12 months) 2002 Profits: $-7,900 (12 months) Stock Ticker: ASTM 2001 Sales: $ 899 2001 Profits: $-5,926 Employees: 40 2000 Sales: $1,200 2000 Profits: $-9,400 Fiscal Year Ends: 6/30 1999 Sales: $ 900 1999 Profits: $-11,000 1998 Sales: $ 200 1998 Profits: $-17,200

SALARIES/BENEFITS: Pension Plan: Savings Plan: Y

COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $250,000 Stock Purch. Plan: Y Second Exec. Salary: $140,933 ADVANTAGE: Focus on cell reproduction technology.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



ABAXIS INC

www.abaxis.com




Y

TYPES OF BUSINESS:

Profits: 14




Equipment- Point-of-Care Blood Analyzer Systems Veterinary Products

Abaxis, Inc. develops, manufactures and markets portable blood analysis systems for use in any patient-care setting to provide clinicians with rapid blood constituent measurements. The company’s primary product consists of a compact 6.9-kilogram analyzer and a series of singleuse plastic discs, called reagent discs, containing all the chemicals required to perform a panel of up to 12 tests. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma using either venous or fingerstick samples. The system provides test results in less than 15 minutes with precision and accuracy equivalent to a clinical laboratory analyzer. Abaxis also sells a system that provides a complete blood count including three-part white blood cell differential in less than two minutes, with results for eight selectable species, plus two user-configurable programs. The company currently markets these systems for veterinary use under the names VetScan and VetScan HMT (DXS System) and in the human medical market under the name Piccolo. Abaxis sells its products in the U.S., Europe, Latin America and Asia. The firm's point-ofcare blood chemistry analyzer system has a total of 22 test methods. Nineteen of these tests are marketed for both human and veterinary markets. Abaxis markets its reagent products by configuring these 22 test methods in panels that are designed to meet a variety of clinical diagnostic needs. In recent news, the company announced the release of the VetScan T4-Cholesterol rotor, which will provide screening sensitivity and therapeutic monitoring for canine hypothyroidism, the most common endocrine disease in dogs, and feline hyperthyroidism in cats. Abaxis offers its employees comprehensive medical benefits, as well as a range of mutual funds and a flexible spending account plan.

BRANDS/DIVISIONS/AFFILIATES: Piccolo VetScan

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Clinton H. Severson, CEO Robert B. Milder, COO Clinton H.Severson, Pres. Alberto R. Santa Ines, VP-Finance/CFO Michael Mercer, VP-Domestic Mktg. and Sales Kenneth Aron, VP-Research and Dev. Vladimir E. Ostioch, VP-Eng. Clinton H. Severson, Chmn.

Phone: 510-675-6500 Fax: 510-441-6150 Toll-Free: 800-822-2947 Address: 3240 Whipple Rd., Union City, CA 94587 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $30,600 (12 months) 2002 Profits: $1,300 (12 months) Stock Ticker: ABAX 2001 Sales: $29,501 2001 Profits: $ 188 Employees: 124 2000 Sales: $23,200 2000 Profits: $- 600 Fiscal Year Ends: 3/31 1999 Sales: $13,300 1999 Profits: $-4,200 1998 Sales: $12,200 1998 Profits: $-4,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $250,000 Stock Purch. Plan: Second Exec. Salary: $155,000 ADVANTAGE: Sophisticated portable systems that can perform up to 12 different blood tests.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $226,500 Bonus: $143,500

Northeast:

International:



ABBOTT LABORATORIES

www.abbott.com


Y Y Y



Y

TYPES OF BUSINESS:

Profits: 9




Drugs-Antibiotics and Synthetic Hormones Nutritional Products Diagnostic Systems Intravenous and Irrigation Fluid Equipment Electronic Drug Delivery Systems Diagnostic Imaging Products

Abbott Laboratories' principal business is the discovery, development, manufacture and sale of a diversified line of health care products and services. The company operates through five major business segments: pharmaceutical products, diagnostic products, hospital products, Ross products and international. Principal pharmaceutical products include Depakote, which treats epilepsy, migraine, and bipolar disorder; the anti-infective clarithromycin; various forms of erythromycin; and a broad line of cardiovascular products. The diagnostics segment markets systems for blood banks, hospitals, commercial laboratories, alternate-care testing sites and consumers. Hospital products include drugs and drug delivery systems, perioperative and intensive care products, cardiovascular, renal and oncology products. This segment also markets intravenous and irrigation solutions, related manual and electronic administration equipment and diagnostic imaging equipment. Ross products include a broad line of adult and pediatric nutritionals, specialty pharmaceuticals and consumer products. Ross brands include Similac and Isomil infant formulas, Ensure, Pedialyte, Selsun Blue and the Fact Plus line of pregnancy tests. The international segment markets a broad line of hospital, pharmaceutical and adult and pediatric nutritional products outside the United States. The firm also conducts its own research and development. Among Abbott’s developments is Norvir, an AIDS drug that, when taken with another protease inhibitor or other anti-viral drugs, can reduce HIV in the blood to undetectable levels. Through a joint venture with TAP Pharmaceutical Products, Abbott makes the best-selling prostate cancer drug Lupron. The company offers employees adoption assistance, legal assistance, flexible hours, telecommuting, an onsite childcare center, sports programs and wellness programs. It also offers 12-week summer internships to college students in such areas as engineering, research and marketing. Abbott has been recognized as one of the top 50 Best Companies for Minorities in FORTUNE Magazine.

BRANDS/DIVISIONS/AFFILIATES: Depakote Similac Koss Ensure Pedialyte Selsun Blue Norvir Lupron

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Miles D. White, CEO Thomas C. Freyman, Sr. VP-Finance/CFO Thomas M. Wascoe, Sr. VP-Human Resources Jeffrey M. Leiden, Exec. VP/Chief Scientific Officer Karen L. Miller, VP-IT Gary L. Flynn, VP/Controller John C. Landgraf, VP-Corp. Eng. Jose M. de Lasa, Corp. Sec. Jose M. de Lasa, General Counsel William G. Dempsey, Sr. VP-Int'l Oper. Steven J. Weger, Jr., VP-Corp. Planning & Dev. Catherine V. Babington, VP-Public Affairs Catherine V. Babington, VP-Investor Rel. Greg W. Linder, VP/Treas. Richard A. Gonzalez, Pres./CEO, Medical Products Group Joy A. Amundson, Sr. VP-Ross Products Christopher B. Begley, Sr. VP-Hospital Products Jeffrey M. Leiden, Pres./CEO, Pharmaceuticals Group

Phone: 847-937-6100 Fax: 847-937-1511 Toll-Free: Address: 100 Abbott Park Rd., Abbott Park, IL 60064-6400 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $12,845,414 ( 9 months) 2002 Profits: $2,166,596 ( 9 months) Stock Ticker: ABT 2001 Sales: $16,285,000 2001 Profits: $1,550,000 Employees: 71,426 2000 Sales: $13,745,900 2000 Profits: $2,786,000 Fiscal Year Ends: 12/31 1999 Sales: $13,177,600 1999 Profits: $2,445,800 1998 Sales: $12,512,700 1998 Profits: $2,334,400

SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y

COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $1,455,622 Stock Purch. Plan: Second Exec. Salary: $619,569 ADVANTAGE: Heavily involved in research/Worldwide recognition.

OTHER THOUGHTS:


Apparent Women Officers or Directors: 5 Hot Spot for Advancement for Women/Minorities: Y

West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $2,100,000 Bonus: $700,000

Northeast: Y

International: Y



ABGENIX INC

www.abgenix.com


Y


Y


Profits: 214


TYPES OF BUSINESS:



Drugs-Diversified Antibody Research

Abgenix, a leading biopharmaceutical company, develops and intends to commercialize several products for a variety of diseases. The company specializes in developing treatments for inflammatory and autoimmune disorders and cancer, as well as cardiovascular diseases, transplant-related and infectious diseases. Abgenix has developed a proprietary technology known as XenoMouse to help rapidly generate highly specific, fully human antibody product candidates. Under the XenoMouse model, the antibody gene of a genetically engineered mouse is suppressed and replaced with human antibody gene expression. The rest of the mouse’s immune system is left intact. The firm generates revenues by licensing XenoMouse technology to pharmaceutical and biotechnology companies interested in developing antibody-based products. The company has recently collaborated with such prestigious firms as Millennium Pharmaceuticals, Pfizer, Human Genome Sciences, Johnson and Johnson, Chiron and Amgen. Abgenix's newest collaboration is a drug discovery alliance with Lexicon Genetics, Inc. The firm's partnership with Abbott Laboratories is a recent one as well; the two companies are working jointly to generate fully-human antibodies. The company also owns SLAM technology, which enables the rapid identification of antibodies with desired function and characteristics. Abgenix recently deployed XenoMax, a technology in which SLAM is used to select and isolate antibodies with particular function and characteristics from antibody-producing cells generated by XenoMouse animals. The company provides a comprehensive program of employee compensation and benefits, including medical, dental, vision, EAP, a flexible spending program, a 401(k) plan and stock options.

BRANDS/DIVISIONS/AFFILIATES: XenoMouse Cell Genesys Lexicon Genetics, Inc. Chiron Pfizer Johnson and Johnson SLAM XenoMax

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. R.Scott Greer, CEO Raymond M. Withy, COO Raymond M. Withy, Pres. Kurt W. Leutzinger, CFO John C. Meyer, Dir.-Human Resources C. Geoffery Davis , Chief Scientific Officer H. David Miller, VP-IT Gisela M. Schwab, Chief Medical Officer Patrick M. Murphy, VP-Mfg. Susan L. Thorner, Corp. Sec. Susan L. Thorner, VP/General Counsel Catherine Maynard, VP-Oper. Gayle M. Mills, VP-Bus. Dev. Gregory M. Bell, VP-Clinical Dev., Inflammation Steve M. Chamow , VP-Process Sciences Bruce A. keyt, VP-Preclinical Dev. Gregory M. Landes, VP-Product Discovery

Phone: 510-608-6500 Fax: 510-608-6511 Toll-Free: Address: 6701 Kaiser Dr., Fremont, CA 94555 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $31,595 ( 9 months) 2002 Profits: $-170,015 ( 9 months) Stock Ticker: ABGX 2001 Sales: $63,606 2001 Profits: $-60,856 Employees: 324 2000 Sales: $59,449 2000 Profits: $-8,793 Fiscal Year Ends: 12/31 1999 Sales: $15,330 1999 Profits: $-19,499 1998 Sales: $4,803 1998 Profits: $-16,827


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Collaboration with major firms/Proprietary XenoMouse technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International:



ABLE LABORATORIES

www.ablelabs.com


Y



Profits: 85


TYPES OF BUSINESS:



Drugs-Generic

Able Laboratories, Inc., which recently merged with DynaGen, Inc., develops, manufactures and sells prescription generic medications. These generic drugs are the chemical and therapeutic equivalents of brandname drugs. Its manufacturing facility produces the medications in tablet, capsule and suppository dosage form. Some of these generic drugs deal with the treatment of health issues involving tension headaches, attention disorder, anxiety disorder, obesity and rheumatoid arthritis. The company has received 16 abbreviated new drug application (ANDA) approvals and one new drug application approval from the FDA. There are several drug applications pending. Recently, Able Labs announced that it entered into an ANDA transfer and marketing agreement with IVAX Pharmaceuticals, Inc., a subsidiary of IVAX Corporation, for Able Labs ' Tramadol Hydrochloride Tablets. Able Labs will manufacture and supply Tramadol exclusively to IVAX under their label, and IVAX will exclusively sell Able Labs' manufactured product. In other news, Able Labs received FDA approval for its ANDAs for hydrocodone bitartrate and acetaminophen tablets and its acetaminophen and codeine phosphate tablets.

BRANDS/DIVISIONS/AFFILIATES: Superior Pharmaceutical Co. Able Labs DynaGen, Inc. Tramadol

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dhananjay G. Wadekar, CEO Dhananjay G. Wadekar, Pres. Dhananjay G. Wadekar, CFO Loken Patel, V P-Mktg. and Sales George H. Sager, Jr., Controller Dhananjay G. Wadekar, Corp. Sec. Kamlesh Haribhakti, Dir.-Product Dev. Dhananjay G. Wadekar, Treas. Shailesh Daftari, Exec. VP Shashikant Shah, VP-Quality/Regulatory Dwight Nix, VP-Nat'l Accounts Iva Klemick, Dir.-Regulatory Affairs Dhananjay G. Wadekar, Chmn.

Phone: 781-449-4926 Fax: 781-890-0118 Toll-Free: Address: 200 Highland Ave., Ste. 301, Needham , MA 02494 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $36,828 ( 9 months) 2002 Profits: $7,057 ( 9 months) Stock Ticker: ABLA 2001 Sales: $19,600 2001 Profits: $-4,500 Employees: 180 2000 Sales: $31,500 2000 Profits: $-8,500 Fiscal Year Ends: 12/31 1999 Sales: $29,100 1999 Profits: $-8,200 1998 Sales: $25,000 1998 Profits: $-12,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Merger with DynaGen.

OTHER THOUGHTS:

Top Exec. Salary: $145,000 Second Exec. Salary: $



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



ACCESS PHARMACEUTICALS

www.accesspharma.com


Y



Profits: 95


TYPES OF BUSINESS:



Drugs-Drug Delivery Systems Polymer Technology Cancer Treatment Oral Disease Treatment Dermatology Disorder Treatment

Access Pharmaceutical is an emerging pharmaceutical company that develops novel low-development risk product candidates and technologies with long-term product opportunities. The firm is currently focused on developing drug delivery systems and advanced polymer technology for application in cancer treatment, dermatology and oral diseases. The company has seven proprietary technology platforms, including synthetic polymers, vitamin mediated targeted delivery, nanoparticles and nanoparticle networks, bio-erodible hydrogels, Residerm, carbohydrate targeting technology and agents for the prevention and treatment of viral diseases, including HIV. Additionally, the company and one of its partners, GlaxoSmithKline, jointly developed a product for the treatment of canker sores. GlaxoSmithKline is marketing this product under the trade name Aphthasol within the U.S. Another partner, Strakan Limited, received authorization to market this product in the United Kingdom under the trade name Aptheal. Strakan has also used the patented Residerm technology to develop zinc clindamycin for the treatment of acne, which it began marketing in the U.K. under the trade name Zindaclin in 2002. Recently, the newly created subsidiary Access Pharmaceuticals Australia acquired the targeted therapeutic technology business of Biotech Australia. Under the terms of the acquisition agreement, Access Pharmaceuticals Australia acquired the patents to three targeted therapeutics technologies and retained the scientific group that has developed this technology. Several products in development include Amlexanox Cream and Gel, OraRinse and Mucoadhesive Liquid Technology, OraDisc, DACH Platinum and Polymer Platinate. Access provides medical, life and long-term disability insurance to its employees. Additionally, employees are allowed three to four weeks of vacation and holiday time per year.

BRANDS/DIVISIONS/AFFILIATES: Block Drug Company Aphthasol Residerm OraRinse Amlexanox OraDisc Biotech Australia Access Pharmaceuticals Australia

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kerry P. Gray, CEO Kerry P. Gray, Pres. Stephen B. Thompson, CFO/VP David P. Nowotnik, VP-Research and Dev. Stephen B. Thompson, Treas. Herbert H. McDade, Jr., Chmn.

Phone: 214-905-5100 Fax: 214-905-5101 Toll-Free: Address: 2600 Stemmons Fwy., Ste. 176, Dallas , TX 752077 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 500 ( 9 months) 2002 Profits: $-7,100 ( 9 months) Stock Ticker: AKC 2001 Sales: $ 200 2001 Profits: $-6,000 Employees: 28 2000 Sales: $ 107 2000 Profits: $-5,428 Fiscal Year Ends: 12/31 1999 Sales: $ 15 1999 Profits: $-3,300 1998 Sales: $ 100 1998 Profits: $-3,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Novel drug delivery technology.

OTHER THOUGHTS:

Top Exec. Salary: $307,449 Second Exec. Salary: $196,254



West:

Southwest: Y

Midwest:

Southeast:



Bonus: $105,000 Bonus: $19,960

Northeast:

International: Y



ACCUMED INTERNATIONAL

www.accumed.com

Industry Group Code: 339113 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:



Y Y

TYPES OF BUSINESS:

Profits: Computers: Hardware: Software: Arrays: Database Management:



Equipment-Diagnosis Screening Instruments Clinical Diagnostic Products

AccuMed International, Inc., recently acquired by Ampersand Medical Corporation, is engaged in the marketing and development of screening instruments and systems for clinical diagnostic laboratories, hospitals and other applications. The company’s integrated systems use technology that improves efficiency and achieves significant improvements in disease detection. The firm is currently developing computer-aided image cytometry instruments and systems that support early detection and diagnosis programs for screening high-risk individuals for cellular disease. AccuMed designs, builds and supplies two product lines. The first product line consists of AcCells computer-aided microscopes, which help medical experts to examine and diagnose specimens of human cells. These products include robotic slide-feeding systems, bar-code readers, electro-mechanical scanning stages, automatic physical dotters and data management system software. The second product line consists of AcCell-Savant, which includes all the AcCell components along with electronic imaging system and image analysis software.

BRANDS/DIVISIONS/AFFILIATES: BCAM International Ventana Medical Systems CellMetrix Ampersand Medical Corporation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul F. Lavallee, CEO Norman J. Pressman, Pres. Joseph Plandowski, Sr. VP-Sales & Mktg. Darlene Czaja, Human Resources Admin. Norman J. Pressman, Chief Scientific Officer

Phone: 312-642-9200 Fax: 312-642-8684 Toll-Free: Address: 920 N. Franklin St., Ste. 402, Chicago, IL 60610 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $ 477 2000 Profits: $-3,098 Fiscal Year Ends: 12/31 1999 Sales: $ 136 1999 Profits: $1,400 1998 Sales: $ 300 1998 Profits: $-8,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVAN TAGE: Innovative technology for disease detection.

OTHER THOUGHTS:


Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:

West:

Southwest:

Midwest: Y

Bonus: $ Bonus: $

Southeast:



Northeast:

International:



ACLARA BIOSCIENCES INC

www.aclara.com




Profits: 29


TYPES OF BUSINESS:

Y Y Y



Drug Discovery Microchips Biochemical Analysis and Synthesis Products

Aclara BioSciences, Inc., formerly Soane BioSciences, Inc., provides miniaturized microfluidic tools for biochemical analysis and synthesis. It develops multiple products to address the genomic, proteomic and pharmaceutical drug screening markets. Its proprietary microfluidics technology allows researchers to rapidly perform large numbers of chemical and biological measurements in a multiplexed, automated format. The Aretas HTS assay miniaturization device enables biochemical assays to be performed at nanoliter volumes. The eTag chemistry platform was developed specifically to bring genomics and functional proteomics assays to the drug development process. The eTag assay system enables gene expression, protein expression and protein function analysis concurrently from the same sample. Focusing on pharmaceutical development, Aclara provides high-throughput, multiplexed gene expression and protein expression assays for screening of pharmaceutical drug candidates. Another microfluidic product, the Plurex Multiplexing Card, integrates proprietary chemistry into a microfluidic card that enables a novel approach to multiplexing the polymerase chain reactions (PCR). LabCard, another multiplexing system device, contains 96 channels that support multiple PCR reactions. The advantages of LabCard include high throughput, minimal reagent and sample use, reliability, compatibility, multiple detection platforms and user-defined primers. The company is developing a LabCard-based eTag analysis system that will enable much greater throughput at higher sensitivity through the integration of chemistry and microfluidic components. Recently, Aclara entered into license and supply agreements with Third Wave Technologies Inc., a manufacturer and marketer of genetic analysis products. Under this agreement, Aclara will incorporate Third Wave’s Invader technology and Cleavase enzyme with its own eTag technology to offer the eTag Assay System for multiplexed gene expression applications in the research market.

BRANDS/DIVISIONS/AFFILIATES: Soane BioSciences, Inc. Plurex Multiplexing Card eTag GeneMate System Microsequencer System DNA Sample Preparation System Aretas HTS LabCard

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph M. Limber, CEO Joseph M. Limber, Pres. Alfred G. Merriweather, VP-Finance/CFO Dan G. Morrow , VP-Oper. Dennis W. Harris, Sr. VP-Systems Integration and Bus. Dev. Sharat Singh, Sr. VP-eTag Assay Tech. Stephen C. Macevicz, VP-Intellectual Property Thomas R. Baruch, Chmn.

Phone: 650-210-1200 Fax: 650-210-1210 Toll-Free: Address: 1288 Pear Ave., Mountain View, CA 94043 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,768 ( 9 months) 2002 Profits: $-30,138 ( 9 months) Stock Ticker: ACLA 2001 Sales: $3,200 2001 Profits: $-29,000 Employees: 170 2000 Sales: $3,500 2000 Profits: $-59,200 Fiscal Year Ends: 12/31 1999 Sales: $2,900 1999 Profits: $-8,200 1998 Sales: $1,400 1998 Profits: $-5,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $320,000 Stock Purch. Plan: Y Second Exec. Salary: $220,000 ADVANTAGE: Miniaturized, proprietary technology referred to as microfluidics.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest:

Southeast:



Bonus: $112,000 Bonus: $51,150

Northeast:

International:



ADVANCED MAGNETICS INC

www.advancedmagnetics.com


Y



Profits: 53


TYPES OF BUSINESS:



Drugs-Diagnostic Contrast Agents Organ-Specific Contrast Agents

Advanced Magnetics, Inc. (AMI) develops and markets therapeutic iron compounds for treating anemia as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Code 7228 is the firm's lead product in development for use as an iron replacement for patients suffering from chronic anemia and for use in magnetic resonance angiography. It is also being evaluated for magnetic resonance imaging applications in oncology. The company’s liver contrast agent, Feridex I.V., has been approved by the FDA and is being marketed in the United States, Europe, Japan, Argentina, South Korea, China and Israel. The firm’s oral contrast agent, GastroMARK, is manufactured for delineating the bowel in MRI procedures and is approved and marketed for sale in the United States and Europe. In addition, AMI received a letter of intent from the FDA for the approval of Combidex, a contrast agent for the diagnosis of lymph node and liver disease. Recently, AMI announced it entered into two clinical trial agreements with the Biomedical Imaging Program and the National Cancer Institute to study the use of Combidex and Code 7228 MRI contrast agents in the detection of metastatic disease in lymph nodes. In other news, the firm announced a recent study showing that Combidex may also be useful for the imaging of brain tumors and may assist in viral vector delivery of therapeutic agents.

BRANDS/DIVISIONS/AFFILIATES: Feridex I.V. GastroMARK Combidex Code 7228

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jerome Goldstein, CEO Leonard M. Baum, COO Leonard M. Baum, Pres. James A. Matheson, VP-Finance Jerome M. Lewis, VP-Scientific Oper. Marlene Kaplan Goldstein, Sec. Paula M. Jacobs, VP-Dev. Jerome Goldstein, Treas. Mark C. Roessel, VP-Regulatory Affairs Dennis R. Lawler, VP-Quality Control Jerome Goldstein, Chmn.

Phone: 617-497-2070 Fax: 617-547-2445 Toll-Free: Address: 61 Mooney St., Cambridge, MA 02138 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $4,686 ( 9 months) 2002 Profits: $ 671 ( 9 months) Stock Ticker: AVM 2001 Sales: $6,000 2001 Profits: $ 800 Employees: 24 2000 Sales: $4,074 2000 Profits: $-11,263 Fiscal Year Ends: 9/30 1999 Sales: $7,430 1999 Profits: $-4,400 1998 Sales: $6,404 1998 Profits: $-6,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $272,886 Stock Purch. Plan: Y Second Exec. Salary: $149,769 ADVANTAGE: Expertise in diagnostic contrast agents drug development.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



ADVANCED TISSUE SCIENCES

www.advancedtissue.com



Y


Profits: 8


TYPES OF BUSINESS:



Skin Replacement Products Tissue Replacement Technology

Advanced Tissue Sciences, a leader in tissue engineering technology, develops products for the repair or replacement of damaged and destroyed tissues. The firm’s efforts are concentrated in four areas: wound care, aesthetic and reconstructive, cardiovascular and orthopedic. The company’s three main products are Transcycle, a temporary wound covering for the treatment of burns; Dermagraft, a treatment for skin ulcers; and NouriCel, a product for skin care and other aesthetic applications. Advanced Tissue holds more than 100 patents, including patents covering the growth of vascularized human tissues or organs on threedimensional scaffolds inside the body, three-dimensional tissue constructs made with genetically modified cells and the growth of three-dimensional tissue-engineered tubular structures. The company is currently developing heart tissue. It joined a 10-year, $10 million collaborative effort led by the University of Washington to develop a fully functional human heart using stem, cardiac and skeletal muscle cells. The firm has also presented data showing Dermagraft’s ability to stimulate blood vessel formation in the heart, a capability critical to the regeneration of damaged cardiac tissue. Advanced Tissue's threedimensional stromal tissue culture is a technology critical to the company’s research on stem cells that could lead to the eventual growth of organs in labs. The company recently announced a major restructuring effort. Separate business units will be established to focus on new commercial opportunities for core technologies. New subsidiary BioNuvia is the first of these units. BioNuvia will develop and market bioengineered products primarily designed for appearance enhancement and body rejuvenation. Current products NouriCel, NouriCel-MD and human-based collagen for aesthetic applications are now part of the BioNuvia line. BioNuvia will explore the option to develop subsidiaries of its own, while Advanced Tissue will continue establishing other business units.

BRANDS/DIVISIONS/AFFILIATES: ATS Orthopedics, Inc. ATS Dermagraft, Inc. Segenix, Inc. DermEquip, LLC Dermagraft LaserDerm TransCyte BioNuvia

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Arthur J. Benvenuto, CEO Joseph R. Kletzel, COO Arthur J. Benvenuto, Pres. Mark J. Gergen, Sr. VP/CFO Robert O. Gaskin, Jr., VP-Human Resources David L. Horwitz, Sr. VP-Tech. Terry E. Gibson, VP-Oper. Mark J. Gergen, Sr. VP/Chief Dev. Officer Mark J. Gergen, VP-Investor Rel. Charles E. Anderson, VP-Quality Kenneth R. Heilbrunn, VP-Clinical Research Anthony Ratcliffe, VP-Research

Phone: 858-713-7300 Fax: 858-713-7400 Toll-Free: Address: 10933 N. Torrey Pines Rd., La Jolla, CA 92037-1005 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $16,000 ( 9 months) 2002 Profits: $-26,100 ( 9 months) Stock Ticker: ATISQ.OB 2001 Sales: $28,900 2001 Profits: $-28,400 Employees: 226 2000 Sales: $25,271 2000 Profits: $-24,571 Fiscal Year Ends: 12/31 1999 Sales: $42,803 1999 Profits: $-21,306 1998 Sales: $20,481 1998 Profits: $-43,285


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $441,000 Stock Purch. Plan: Second Exec. Salary: $330,750 ADVANTAGE: Owns significant patents/A leader in skin replacement technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $500,000 Bonus: $200,000

Northeast:

International:



AFFYMETRIX INC

www.affymetrix.com



Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Sv cs.: Assays/Diagnostics:

Y

TYPES OF BUSINESS:

Profits: 4


Y



Chips-Genetics Genetic Testing Instruments

Affymetrix develops technology for examining and managing complex genetic information for use in biomedical research, genomics and clinical diagnostics. The cornerstone of the company is its GeneChip technology, used for sequence analysis, genotyping and gene expression monitoring. The firm maintains three primary focuses as part of its business strategy: gene expression monitoring, which identifies gene functions; polymorphism analysis, which examines mutations of gene sequences and disease management, which is aimed at using genetic analysis to develop better health care solutions for various diseases. The company recently launched the NetAffx web site, its first Internet source aimed at giving users a new web-based tool that will streamline public and private information (from various databases) with the data that is produced by Affymetrix's GeneChip arrays. The firm has also extended its product line by introducing the GeneChip CustomExpress array program. The improved technology will offer customers a single system for any gene expression study. Notably, Affymetrix has entered an important agreement with deCODE to develop DNA-based tests for patients that would predict responsiveness to treatments. Such responses would play a key role in the production of more effective medicines. The company has recently expanded into agriculture by entering into a custom supply agreement with Monsanto Co., which will allow Monsanto to use the GeneChip technology to study plant development and disease.

BRANDS/DIVISIONS/AFFILIATES: Genetic MicroSystems, Inc. GeneChip Spotted Array Systems GeneChip CustomExpress GenFlex Tag Array Perlegen Sciences, Inc. Neomorphic NetAffx

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen P. A. Fodor, CEO Susan E. Siegel, Pres. Gregory T. Schiffman, VP/CFO Thane Kreiner, VP-Sales/Mktg. Karen H. Haynes, VP-Human Resources/Admin. Richard P. Rava, Sr. VP/Chief Tech. Officer Barbara A. Caulfield, General Counsel Ronald D. Verdoorn, Exec. VP-Global Oper. Edward Hurwitz, Sr. VP-Corp. Strategy and New Ventures Robert H. Ellis, Exec. VP-Product Dev. and Quality

Phone: 408-731-5000 Fax: 408-481-0422 Toll-Free: Address: 3380 Central Expy., Santa Clara, CA 95051 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $211,575 ( 9 months) 2002 Profits: $554,000 ( 9 months) Stock Ticker: AFFX 2001 Sales: $224,900 2001 Profits: $-33,100 Employees: 905 2000 Sales: $200,830 2000 Profits: $-53,990 Fiscal Year Ends: 12/31 1999 Sales: $109,074 1999 Profits: $-25,504 1998 Sales: $52,413 1998 Profits: $-26,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $420,433 Stock Purch. Plan: Second Exec. Salary: $372,933 ADVANTAGE: Owns leading gene analysis technology/Growth through acquisitions.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $175,000 Bonus: $150,000

Northeast: Y

International: Y



AKORN INC

www.akorn.com


Y



Y

TYPES OF BUSINESS:

Profits: 155




Drugs-Ophthalmic and Injectable Surgical Pharmaceutical Products Over-the-Counter Ophthalmic Products Injectable Pharmaceutical Products Sterile Contract Manufacturing Services Surgical Instruments

Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes. Through its ophthalmics division, the company markets an extensive line of diagnostic and therapeutic ophthalmic pharmaceutical products as well as surgical instruments and related supplies. Diagnostic products, primarily used in the office setting, include mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions and angiography dyes. Therapeutic products, sold primarily to wholesalers and other national account customers, include antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines and anti-edema medications. Surgical products include surgical knives and other surgical instruments, balanced salt solution, post-operative kits, surgical tapes, eye shields, anti-ultraviolet goggles, facial drape supports and other supplies. Non-pharmaceutical products include various artificial tear solutions, preservative-free lubricating ointments, lid cleansers, vitamin supplements and contact lens accessories. Akorn also markets a line of specialty injectable pharmaceutical products, including anesthesia products used in the treatm ent of rheumatoid arthritis and pain management. The company provides its employees with tuition reimbursement and a comprehensive health benefits plan.

BRANDS/DIVISIONS/AFFILIATES: Taylor Pharmaceuticals, Inc. Opthalmic Division Pasadena Research Laboratories, Inc. Sufenta Alfenta Paremyd

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John N. Kapoor, CEO Antonio Pera, COO Antonio Pera, Pres. Ben J. Pothast, VP/CFO Neil Shanahan, Human Resources Abu Alam, VP-Research and Dev. Rita McConville, Corp. Controller Kevin M. Harris, Corp. Sec. Kevin M. Harris, Treas. Shahid Ahmed, VP-Quality Assurance

Phone: 847-279-6100 Fax: 847-943-3694 Toll-Free: 800-535-7155 Address: 2500 Millbrook Dr., Buffalo Grove, IL 60089-4694 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $41,259 ( 9 months) 2002 Profits: $-1,153 ( 9 months) Stock Ticker: AKRN.PK 2001 Sales: $42,200 2001 Profits: $-19,600 Employees: 310 2000 Sales: $66,927 2000 Profits: $2,187 Fiscal Year Ends: 12/31 1999 Sales: $64,632 1999 Profits: $6,670 1998 Sales: $56,667 1998 Pr ofits: $4,647


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Merger with Pasadena Research Laboratories, Inc.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Bonus: $ Bonus: $

Southeast: Y



Northeast: Y

International:



AKZO NOBEL NV

www.akzonobel.com


Y



Profits: 1


TYPES OF BUSINESS:



Manufacturing-Paint Pharmaceuticals Chemicals

Based in The Netherlands, Akzo Nobel N.V. is leading producer of health care products, coatings and chemicals. The pharmaceuticals division provides products for both the human and animal health care markets, including contraceptives, fertility drugs, antipsychotics, over-thecounter drugs, antidepressants and veterinary medicines. Akzo Nobel manufactures the Sikkens, International, Crown and Interpon coating brands. These coating products were used on London’s Millennium Wheel, La Scala Opera House in Milan, the Oresund Bridge between Denmark and Sweden and Stadium Australia in Sydney. The company is also one of the world’s leading chemicals producers, primarily specializing in chemicals found in cosmetics, plastics, glass and baked goods. Subsidiaries include Advanced BioScience Laboratories, Inc., Colbond Geosynthetics, Akzo Nobel, Inc., DioSynth, Inc., Intervet, Inc., Organon Teknika Corporation and Rosemont Pharmaceutical Corporation. Akzo Nobel has operations in 80 countries. The firm has experienced rapid growth and was labeled Europe’s fastest growing pharmaceutical company. Recently, Akzo Nobel’s polymer chemicals high purity metalorganics unit acquired Mochem GmbH, an active member in the field of metalorganics for semiconductors in opto-electronics. The company is also investing in a non-stick coatings facility in Southern China to be built adjacent to its existing wood coatings plant. This facility will provide coatings for the cookware industry and for specialized industrial applications. In other news, Akzo Nobel's coatings unit announced the purchase of a 50% stake in Industrial de Acabados, a Mexican powder coatings producer. The new joint venture, Akzo Nobel INDA, will manufacture and market powder coatings products under the Interpon brand.

BRANDS/DIVISIONS/AFFILIATES: Advanced BioScience Laboratories, Inc. Colbond Geosynthetics Akzo Nobel, Inc. DioSynth, Inc. Intervet, Inc. Organon Teknika Corporation Rosemont Pharmaceutical Corporation Akzo Nobel INDA

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Cees J.A. van Lede, CEO Fritz W. Frohlich, CFO Olle Werner, VP-Human Resources Bart C.M.I. Beusmans, Corp. Sec. A. Jan A.J. Eijsbouts, General Counsel Dag Strömqvist, Pres.-Chemicals Paul K. Brons, Pres.-Pharma Rudy M.J. van der Meer, Pres.-Coatings Fritz Hensel, Sr. VP-Finance Cees J.A. van Lede, Chmn.

Phone: +31-26-366-4433 Fax: +31-26-366-3250 Toll-Free: Address: Velperweg 76, Arnhem, 6800 SB The Netherlands

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $6,649,000 ( 6 months) 2002 Profits: $452,000 ( 6 months) Stock Ticker: AKZOY 2001 Sales: $12,576,000 2001 Profits: $598,000 Employees: 66,300 2000 Sales: $12,215,800 2000 Profits: $842,700 Fiscal Year Ends: 12/31 1999 Sales: $12,590,100 1999 Profits: $-547,000 1998 Sales: $23,996,300 1998 Profits: $1,171,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: An international giant in chemicals, coatings and health care products.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $ Bonus: $

Northeast: Y

International: Y



ALBANY MOLECULAR RESEARCH

www.albmolecular.com




Y

TYPES OF BUSINESS:

Profits: 5




Research and Development Services

Albany Molecular Research, Inc. (Albany) is a leading, fully integrated provider of drug discovery and development, chemistry research and manufacturing services to companies in the pharmaceutical, genomic and biotechnology industries. Albany also provides contract chemistry services to customers across the entire product development cycle, from lead discovery to commercial manufacturing. These services include drug discovery, medicinal chemistry, chemical development, analytical chemistry services and small-scale and pilot-plant manufacturing. The company has also expanded its service offerings to include commercial manufacturing through its strategic relationship with Organichem Corporation. Albany’s services permit its customers to reduce overall drug development time and cost and to simultaneously pursue a greater number of drug discovery and development opportunities. Albany’s proprietary research and development activities led to the development, patenting and manufacturing of a substantially pure form of the active ingredient in the nonsedating antihistamine marketed by Aventis as Allegra. The company’s key research facilities include Albany Research Center, Bothell Research Center, Bruno Biotechnology Development Center and Syracuse Research Center. Recently, Albany added drug metabolism assay and metabolite production capabilities to its drug discovery and development technologies, which will provide information concerning the metabolic properties and enzyme interactions of compounds. In other news, the company signed a three-year drug discovery research agreement with Merck & Co., Inc. Under this agreement, Albany will perform chemistry research and lead optimization using computer-assisted chemical design and synthesis technologies. Albany also announced a drug discovery collaboration with Genzyme Corp., in which it will provide libraries of natural product extracts for biological screening.

BRANDS/DIVISIONS/AFFILIATES: Allegra Organichem Corp. Flourous Technologies, Inc. EnzyMed Bothell Research Center Syracuse Research Center Bruno Biotechnology Development Center Albany Research Center

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas E. D'Ambra, CEO Donald E. Kuhla, COO Donald E. Kuhla, Pres. David P. Waldek, CFO Harold Meckler, VP-Science and Tech. David P. Waldek, Corp. Sec. James J. Grates, VP-Oper. Lawrence D. Jones, Sr. VP-Bus. Dev. David P. Waldek, Treas. Barry A. Berkowitz, Corp. VP Michael P. Trova, Sr. VP-Medicinal Chemistry Thomas E. D'Ambra, Chmn.

Phone: 518-464-0279 Fax: 518-464-0289 Toll-Free: Address: 21 Corporate Circle, Albany, NY 12203 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $91,312 ( 9 months) 2002 Profits: $29,538 ( 9 months) Stock Ticker: AMRI 2001 Sales: $56,800 2001 Profits: $34,400 Employees: 532 2000 Sales: $66,603 2000 Profits: $23,593 Fiscal Year Ends: 12/31 1999 Sales: $43,471 1999 Profits: $13,800 1998 Sales: $33,294 1998 Profits: $10,497


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $279,231 Stock Purch. Plan: Second Exec. Salary: $250,000 ADVANTAGE: Highly diversified research and development.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $108,750 Bonus: $

Northeast: Y

International:



ALEXION PHARMACEUTICALS www.alexionpharmaceuticals.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 104 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y


Y


Profits: 210


TYPES OF BUSINESS:



Drugs-Neurological Disease Xenotransplantation Technology

Alexion Pharmaceuticals, Inc. is engaged in drug discovery, research and product and clinical development. The company develops products for the treatment of cardiovascular, autoimmune and hematologic disorders, inflammation and cancer stemming from unwanted effects of the immune system. The firm focuses on technologies that shut down particular components of the human immune system to reduce inflammation while allowing beneficial aspects of the immune system to remain functional. Alexion is currently collaborating with Procter & Gamble to develop Pexelizumab, a treatment for cardiovascular diseases associated with coronary angioplasty. The company is also working to develop 5G1.1, a treatment for rheumatoid arthritis, nephritis, psoriasis, dermatomyositis and lupus. Alexion’s Apogen program targets the autoimmune disease multiple sclerosis. Furthermore, the firm is a major pioneer in the field of xenotransplantation, which is the transplant of organs from animals to humans; the company is currently developing various treatments to prevent human immune systems from rejecting animal organs. Recently, entered into a drug target discovery and validation agreement with CuraGen Corporation, a genomics -based pharmaceutical company. Under this agreement, CuraGen will apply its genomic technologies to identify potential drug targets derived from Alexion's research materials.

BRANDS/DIVISIONS/AFFILIATES: Apogen Program Pexelizumab 5G1.1

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Leonard Bell, CEO David W. Keiser, COO David W. Keiser, Pres. Barry P. Luke, VP-Finance Russell P. Rother, VP-Discovery Research Daniel N. Caron, Sr. Dir.-Eng. and Oper. Samuel S. Chu, VP-Mfg. and Process Sciences Thomas I.H. Dubin, VP/General Counsel Paul W. Finnegan, VP-Oper. Paul W. Finnegan, VP-Dev. Leonard Bell, Treas. Stephen P. Squinto, Exec. VP-Research Nancy Motola, VP-Regulatory Affairs and Quality Assurance Scott A. Rollins, VP-Drug Dev. and Project Mgmt. Katherine S. Bowdish, Sr. VP-Antibody Discovery John H. Fried, Chmn.

Phone: 203-272-2596 Fax: 203-271-8190 Toll-Free: Address: 325 Knotter Dr., Cheshire, CT 06410 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $6,500 (12 months) 2002 Profits: $-56,500 (12 months) Stock Ticker: ALXN 2001 Sales: $11,805 2001 Profits: $-57,043 Employees: 140 2000 Sales: $21,400 2000 Profits: $-20,200 Fiscal Year Ends: 7/31 1999 Sales: $18,800 1999 Profits: $-6,400 1998 Sales: $5,000 1998 Profits: $-8,765


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Focus on immune system diseases.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:



Bonus: $100,000 Bonus: $50,000

Northeast: Y

International:



ALFACELL CORPORATION

www.alfacell.com


Y



Profits: 73 Computers: Hardware: Software: Arrays: Database Management:

TYPES OF BUSINESS:



Drugs-Cancer and AIDS

Alfacell Corporation is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of cancer and other pathological conditions. The company is dedicated to finding a new class of anti-cancer and anti-viral drugs from amphibian ribonucleases (RNases). Researchers have learned that eggs and early embryos of leopard frogs contain certain proteins that are a potential aid in cancer research and therapy. The RNases degrade ribonucleic acids, causing an interruption in protein synthesis and resulting in inhibition of cell growth and induction of programmed cell death. The company’s proprietary product is Onconase, which targets solid tumors that have become resistant to other chemotherapeutic drugs. Alfacell is currently engaged in phase III clinical studies of Onconase and its effects on tumor cell death in leukemia and prostate cells and its anti-viral activity at two stages in the HIV-1 lifecycle. The company has partners in Canada, Europe, Japan and Latin America. It also has strategic research collaborations with The National Institute of Health, Harvard University, New York Medical College, Institute of Medicinal Virology at Johann Wolfgang University of Frankfurt, Germany and University Degli Studi G.D. Annunzio in Chieti, Italy. Recently, Alfacell expanded its research partnership with The National Cancer Institute (NCI). NCI will evaluate Alfacell’s Onconase as a radiation enhancer.

BRANDS/DIVISIONS/AFFILIATES: Onconase ONC+ Mab P-32

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kuslima Shogen, CEO Kuslima Shogen, CFO Stanislaw M. Mikulski, Exec. VP/Medical Dir. Kuslima Shogen, Chmn.

Phone: 973-748-8082 Fax: 973-748-1355 Toll-Free: Address: 225 Belleville Ave., Bloomfield, NJ 07003 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 282 ( 9 months) 2002 Profits: $-19,000 ( 9 months) Stock Ticker: ACEL.OB 2001 Sales: $ 2001 Profits: $-2,300 Employees: 14 2000 Sales: $ 51 2000 Profits: $-1,722 Fiscal Year Ends: 7/31 1999 Sales: $ 168 1999 Profits: $-3,156 1998 Sales: $ 300 1998 Profits: $-6,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Unique anti-cancer therapies.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



ALIZYME PLC

www.alizyme.com


Y Y




TYPES OF BUSINESS:



Drugs-Gastrointestinal Colonic Drug Delivery System

Alizyme Therapeutics develops prescription drugs for the treatment of obesity and related diseases as well as gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel diseases and mucositis. Alizyme generally takes products from an early stage into clinical development through the proof of efficacy in humans stage, in phase II clinical trials, with the intention of licensing out products for late-stage clinical trials and eventual marketing. The company applies novel COLAL technology, which delivers drugs directly to the colon. Products in phase II trials include Renzapride for treatment of IBS; ATL-962 for treatment of obesity; and ATL-104 for treatment of mucositis. COLAL-PRED used for treatment of inflammatory bowel disease is currently in phase III development. This product incorporates an antiinflammatory steroid with the colonic drug delivery system COLAL and is under development for the management of ulcerative colitis. Recently, Alizyme announced it had been granted permission from the U.K. Medicines Control Agency to undertake a phase IIb clinical trial to evaluate ATL-962 for the treatment of obesity.

BRANDS/DIVISIONS/AFFILIATES: Renzapride ATL-1251 ATL-2502 ATL-962 COLAL COLAL-PRED

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard M.J. Palmer, CEO Timothy P. McCarthy, Dir.-Finance Roger Hickling, Head-Dev. Oper. Brian Richards, Chmn.

Phone: +44-1223-896-000 Fax: +44-1223-896-001 Toll-Free: Address: Granta Park, Great Abington, Cambridge, CB1 6CX UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $17,854 ( 6 months) 2002 Profits: $-7,110 ( 6 months) Stock Ticker: Private 2001 Sales: $ 2001 Profits: $-9,600 Employees: 15 2000 Sales: $ 2000 Profits: $-8,400 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-6,700 1998 Sales: $ 1998 Profits: $-7,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: COLAL drug delivery system.

OTHER THOUGHTS:

Top Exec. Salary: $ Second Exec. Salary: $



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



ALKERMES INC

www.alkermes.com

Industry Group Code: 339113 Ranks within this company's indus try group: Sales: 14 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Profits: 26


TYPES OF BUSINESS:



Drugs-Sustained-Release Injection Systems

Alkermes specializes in the development of sophisticated drug delivery technologies. Two of the company's main areas of focus, ProLease and Medisorb technologies, release injectable drugs in controlled amounts over a specified short period of time. Significant concentration is also placed on Alkermes’ Advanced Inhalation Research (AIR) technology, a major innovation among pulmonary delivery systems, which maximizes drug delivery to the lungs. Aside from patenting new products, the company’s expansion is concentrated toward forming partnerships to license its products. Alkermes first product, Nutropin Depot, developed in collaboration with Genetech, Inc., is based on ProLease technology. Risperdal Consta, an anti-psychotic drug developed in collaboration with Janssen Pharmaceutica, is based on Medisorb technology and is expected to be the firm’s second product to reach the U.S. market. Recently, the company announced its partner, Johnson & Johnson Pharmaceutical Research and Development, received approval to market Risperdal Consta in Germany. Alkermes also entered an alliance with Eli Lilly and Company to develop an inhaled form of insulin for the treatment of diabetes based on the Alkermes AIR pulmonary drug delivery system. The company has proprietary projects in development stages including Albuterol for the treatment of asthma and Vivitrex for the treatment of alcohol abuse. Employee benefits at Alkermes include tuition reimbursement, a comprehensive health plan and transportation subsidies. Notably, every employee starts with an allowance of three weeks of vacation time per year.

BRANDS/DIVISIONS/AFFILIATES: ProLease Medisorb Nutropin Depot Albuterol Vivitrex Albulast Risperdal Consta AIR

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard F. Pops, CEO David Broecker, COO David Broecker, Pres. James M. Frates, VP/CFO J. Duncan Higgons, Sr. VP-Mktg. Raymond T. Bartus, Sr. VP-Life Sciences Research and Dev. Elliot W. Ehrich, VP-Medical Affairs Gordon Pugh, VP-Oper. J. Duncan Higgons, Sr. VP-Bus. Dev. James M. Frates, Treas. Michael J. Landine, VP-Corp. Dev. Paul F. Hebert, VP- Process Dev. Stephen E. Zale, VP-Formulations

Phone: 617-494-0171 Fax: 617-494-9263 Toll-Free: Address: 88 Sidney St., Cambridge, MA 02139-4234 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $54,100 (12 months) 2002 Profits: $-61,400 (12 months) Stock Ticker: ALKS 2001 Sales: $56,000 2001 Profits: $-16,900 Employees: 415 2000 Sales: $22,900 2000 Profits: $-68,000 Fiscal Year Ends: 3/31 1999 Sales: $33,900 1999 Profits: $-41,100 1998 Sales: $25,500 1998 Profits: $-12,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $406,462 Stock Purch. Plan: Y Second Exec. Salary: $294,685 ADVANTAGE: Focus on new drug delivery technologies.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $175,000 Bonus: $100,000

Northeast: Y

International: Y



ALLERGAN INC

www.allergan.com


Y



Y

TYPES OF BUSINESS:

Profits: 16




Supplies-Eye Care Niche Pharmaceuticals Skin Care Products Medical Devices

Allergan is a technology-driven, global health care company that develops and commercializes specialty pharmaceutical products for the ophthalmic, neurological, dermatological and other specialty markets, as well as ophthalmic surgical devices and contact lens care solutions. The company focuses on products for the treatment of a wide range of disease areas, including glaucoma and retinal disease, cataracts, dry eye, psoriasis, acne photodamage, movement disorders, metabolic disease and various cancers. The cornerstone of the company’s product line is its Alphagan ophthalmic solution, which is used for the treatment of open-angle glaucoma and ocular hypertension. Other products introduced by Allergan include Array multifocal lens for cataract patients, BOTOX for neuromuscular disorder sufferers, Refresh Tears for dry eyes and M.D. Forte for ultraviolet sunscreen protection. The company’s expansion has been predicated on the release of new products and the revision of its existing product line. The FDA recently granted approval for the use of BOTOX in smoothing wrinkles. This innovative application of the muscle relaxant has become one of the fastest growing cosmetic treatments performed by surgeons in the United States. In other news, the company’s board of directors recently approved a spin-off of its pharmaceutical and optical medical device businesses into two independent companies. Following the completion of the divestiture, Allergan will change its name to Advanced Medical Optics, Inc. and will become a specialty pharmaceutical company with businesses in ophthalmic, dermatological and neuromuscular/neurotoxin pharmaceuticals.

BRANDS/DIVISIONS/AFFILIATES: CrownPharma, Ltd. Pacific Pharma, Inc. Herbert Laboratories AMO Holdings, Inc. BOTOX Alphagan Betagan Advanced Medical Optics, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David E.I. Pyott, CEO David E.I. Pyott, Pres. Eric Brandt, CFO Lester J. Kaplan, VP-Research James M. Hindman, Controller Francis R. Tunney, Jr., Corp. Sec. Francis R. Tunney, Jr., General Counsel Jacqueline J. Schiavo, VP-Oper. George M. Lasezkay , VP-Corp. Dev. Jeffrey L. Edwards , VP-Investor Rel. Jeffrey L. Edwards , Treas. David A. Fellows, VP/Pres.-Asia/Pacific Region Nelson R. A. Marques, VP/Pres-Latin America Region

Phone: 714-246-4500 Fax: 714-246-6987 Toll-Free: 800-347-4500 Address: 2525 Dupont Dr., Irvine, CA 92612-9534 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,006,800 ( 9 months) 2002 Profits: $10,800 ( 9 months) Stock Ticker: AGN 2001 Sales: $1,745,500 2001 Profits: $224,900 Employees: 6,436 2000 Sales: $1,625,500 2000 Profits: $215,100 Fiscal Year Ends: 12/31 1999 Sales: $1,452,400 1999 Profits: $188,200 1998 Sales: $1,296,100 1998 Profits: $-90,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Technology-based growth strategy.

OTHER THOUGHTS:




West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $875,000 Bonus: $223,000

Northeast: Y

International: Y



ALLIANCE PHARMACEUTICAL CORP Industry Group Code: 325412 Ranks within this company's industry group: Sales: 172 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Y

TYPES OF BUSINESS:

www.allp.com Profits: 213




Drugs-Cardiovascular and Respiratory Reusable Magnetic Resonance Imaging Accessories

Alliance Pharmaceutical Corp. is a pharmaceutical research and development company that focuses on developing scientific discoveries into medical products. Subsequently, these advances are licensed to multinational pharmaceutical companies in exchange for fixed payments and royalty or profit sharing payments. Two of the company's products in late stage development are Oxygent, an intravascular oxygen carrier that reduces the need for donor blood in patients at risk of acute tissue hypoxia (oxygen deficiency); and Imavist (formerly nam ed Imagent), an intravenous contrast agent for enhancement of ultrasound images to assess cardiac structure and function and to detect organ lesions and blood flow abnormalities. Alliance and Baxter Healthcare Corporation have formed a joint venture to further develop and market Oxygent in the U.S., Canada and Europe, and Imavist is licensed on a worldwide basis to Schering AG, Germany. The company's strategy is to identify potential new medical products through its own efforts and scientific collaborations with researchers and clinicians in universities and medical centers, where many of the basic causes of disease and potential targets for new therapies are discovered. The company seeks collaborative relationships for the final stages of product development, including completing late-phase human testing, obtaining worldwide regulatory approvals, building large-scale manufacturing capacities and marketing.

BRANDS/DIVISIONS/AFFILIATES: Oxygent LiquiVent Imavist Astral, Inc. MDV Technologies, Inc. Baxter Healthcare Pulmospheres Schering AG

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Duane J. Roth, CEO Theodore D. Roth, COO Theodore D. Roth, Pres. Tim Hart, CFO Carole McWilson, Dir.-Human Resources David H. Klein, Sr. VP-Pharmaceutical R&D Keith W. Chapman, VP-Oper. Harold W. DeLong, Exec. VP-Bus. Dev. Gwen Roseberg, VP-Corp. Comm. Tim Hart, Treas. Howard C. Dittrich, VP-Regulatory Affairs

Phone: 858-410-5200 Fax: 858-410-5343 Toll-Free: Address: 3040 Science Park Rd., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $10,300 (12 months) 2002 Profits: $-34,200 (12 months) Stock Ticker: ALLP.OB 2001 Sales: $1,900 2001 Pr ofits: $-60,700 Employees: 178 2000 Sales: $16,000 2000 Profits: $-46,467 Fiscal Year Ends: 6/30 1999 Sales: $8,251 1999 Profits: $-62,473 1998 Sales: $21,209 1998 Profits: $-33,003


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $454,250 Bonus: $200,000 Stock Purch. Plan: Second Exec. Salary: $337,462 Bonus: $110,000 ADVANTAGE: Has several collaborative relationships with multinational pharmaceutical companies.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



ALLOS THERAPEUTICS INC

www.allos.com


Y




TYPES OF BUSINESS:

Specialty: Specialty Services: Cons ulting: Blood Collection:


Drugs-Diversified Small-Molecule Therapies

Allos Therapeutics focuses its efforts on developing and commercializing innovative small molecule drugs for improving cancer treatments. Small-molecule pharmaceuticals developed by Allos increase the level of oxygen released by red blood cells, therefore alleviating tumor resistance that occurs due to poor oxygenation. The company’s lead compound, RSR13, is a product designed to make solid tumors more receptive to radiation therapy. Allos demonstrated in Phase II clinical trials that RSR13 significantly improves the efficacy of radiation therapy for treating brain metastases, tumors that have spread to the brain, glioblastoma multiforme, a highly aggressive form of primary brain cancer, and non-small cell lung cancer. The firm has recently announced initiation of a Phase I/II clinical trial of RSR13 for patients with locally advanced cancer of the cervix receiving chemoradiation. Beyond its uses for cancer treatment, RSR13 is being tested for applications relating to cardiovascular disease and stroke. Other products for the treatment of acute hypoxia, RSR46 and JP7, are in preclinical stages of the development process. Allos is currently researching pyruvarte kinsase inhibitors for the treatment of chronic hypoxia. Allos offers a wide range of employee benefits with comprehensive protection, individual choice and flexibility.

BRANDS/DIVISIONS/AFFILIATES: RSR13 RSR46 JP7

CONTACTS: Note: Officers with more than one job titl e may be intentionally listed here more than once. Michael E. Hart, CEO Michael E. Hart, Pres. Daniel R. Hudspeth, CFO/VP Barbara E. Baring, VP-Human Resources Jean-Francois Liard, Sr. VP-Clinical Dev. Douglas G. Johnson, Sr. Dir.-Mfg. Michael E. Hart, Corp. Sec. Eric Malek, Dir.-Corp. Dev. Monique Greer, Dir.-Corp. Comm. Markus F. Herzig, Sr. VP-Regulatory Affairs John O. Hackman, Sr. Dir.-Biometrics and Statistics Stephen J. Hoffman, Chmn.

Phone: 303-426-6262 Fax: 303-412-9160 Toll-Free: Address: 7000 N. Broadway, Ste. 400, Denver, CO 80221 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-18,700 ( months) Stock Ticker: ALTH 2001 Sales: $ 2001 Profits: $-20,100 Employees: 61 2000 Sales: $ 100 2000 Profits: $-23,361 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-11,288 1998 Sales: $ 1998 Profits: $-8,574


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $275,000 Stock Purch. Plan: Y Second Exec. Salary: $239,979 ADVANTAGE: Focus on novel pharmaceuticals to treat certain types of cancer.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $32,681 Bonus: $27,191

Northeast:

International:



ALPHARMA INC

www.alpharma.com


Y



Profits: 196


TYPES OF BUSINESS:



Drugs-Animal Health Proprietary Human Pharmaceutical Products Animal Health Products

Alpharma, Inc. is a multinational pharmaceutical company that develops, manufactures and markets specialty generic and proprietary human pharmaceutical and animal health products. The company is the largest manufacturer of generic liquid and topical pharmaceuticals in the United States and has an established and growing market position in finished pharmaceuticals in Europe and the Far East. Alpharma offers a comprehensive range of over 800 tablet, capsule, liquid and topical generic human phrmaceutical products and over 100 animal health products. It is one of the world's leading producers of important specialty antibiotics. The company is also known as a leading provider of animal feed additives for poultry and livestock and vaccines for farmed fish. Alpharma is continuing to strengthen its international market presence and is accelerating research and development for new products. Alpharma announced that its international pharmaceutical division purchased a 20% ownership of indiemed.com, a new European pharmaceutical e-commerce business. Indiemed.com is the first e-commerce company to market its services toward the whole pharmaceutical supply chain. Alpharma also recently acquired the medicated feed additive business of Roche, which manufactures products for preventing and treating diseases in livestock. The company also recently acquired the oral solid dose pharmaceutical business of F.H. Faulding and Co., Ltd.

BRANDS/DIVISIONS/AFFILIATES: indiemed.com Roche F.H. Faulding and Co., Ltd.

CONTACTS: Note: Officers with more than one job ti tle may be intentionally listed here more than once. Ingrid Wiik, CEO Ingrid Wiik, Pres. Jeffrey E. Smith, CFO/VP-Finance Nancy V. Ryan, VP-Human Resources John S. Towler, VP/Controller Robert F. Wrobel, VP/Chief Legal Officer David R. Jackson, VP/Corp. Comm. David R. Jackson, VP-Investor Rel. Albert N. Marchio II, Treas. Liang Chao, General Mgr.-China Market Stig Jarle Pettersen, VP-Finance, Int'l Pharmaceutical Div. Thomas L. Anderson, VP/Pres., U.S. Pharmaceuticals Div. Bruce I. Andrews, VP/Pres., Animal Health Div.

Phone: 201-947-7774 Fax: 201-947-4879 Toll-Free: 800-645-4216 Address: One Executive Dr., Fort Lee, NJ 07024 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $895,811 ( 9 months) 2002 Profits: $-27,271 ( 9 months) Stock Ticker: ALO 2001 Sales: $975,000 2001 Profits: $-37,900 Employees: 4,900 2000 Sales: $919,523 2000 Profits: $61,143 Fiscal Year Ends: 12/31 1999 Sales: $732,443 1999 Profits: $36,972 1998 Sales: $604,584 1998 Profits: $24,211

SALARIES/BENEFITS: Pension Plan: Y Savings Plan:

COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: The largest manufacturer of generic liquid and topical pharmaceuticals in the U.S.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $ Bonus: $

Northeast: Y

International: Y



ALTEON INC

www.alteonpharma.com


Y



Profits: 127


TYPES OF BUSINESS:



Drugs-Diabetes Cardiovascular Drugs Glucose Lowering Agents

Alteon, Inc. is a product-based biopharmaceutical company primarily engaged in the discovery and development of oral drugs to reverse or inhibit cardiovascular aging and diabetic complications. Its product candidates represent novel approaches to some of the largest pharmaceutical markets. Two of the firm's compounds are in clinical development, and several others are in early development. These candidates were developed as a result of research on the advanced glycosylation end-product (AGE) pathway, a fundamental process and consequence of aging and diabetes that causes or contributes to many medical disorders. Alteon's current research and drug development activities targeting this pathway take three directions: the breaking of AGE crosslinks between proteins; the prevention or inhibition of AGE formation; and the reduction of the AGE burden through a novel class of anti-hyperglycemic agents, or glucose lowering agents (GLAs). Since its inception, Alteon has created an extensive library of compounds targeting the AGE pathway and has actively pursued patent protection for these discoveries. The company's lead product candidate is ALT-711, an AGE crosslink barrier that offers the first therapeutic approach to breaking these crosslinks, which may reverse tissue damage caused by aging and diabetes , thereby restoring flexibility and function to blood vessels and organs of the body. Results suggest that ALT-711 is a novel potential therapy for systolic hypertension, which occurs as a result of vascular stiffening due to age or diabetes. Other products in development include ALT-744 for skin aging and Pimagedine for diabetic kidney disease. Alteon maintains a number of licensing and collaboration agreements relating to the development and distribution of its AGE technology. In recent news, the company completed several rounds of trials in the development of ALT-711 and expects to release this data during 2003.

BRANDS/DIVISIONS/AFFILIATES: Pimagedine ALT-711 ALT-744

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kenneth I. Moch, CEO Kenneth I. Moch, Pres. Elizabeth A. O'Dell, VP-Finance Robert C. deGroof, Sr. VP-Scientific Affairs Elizabeth A. O'Dell, Corp. Sec. Elizabeth A. O'Dell, VP-Admin. Judith S. Hedstrom, Sr. VP-Corp. Dev. Susan M. Pietropaolo, Dir.-Corp. Comm. Susan M. Pietropaolo, Dir.-Investor Rel. Elizabeth A. O'Dell, Treas. Henry W. Founds, Exec. Dir.-Non-Clinical Oper.

Phone: 201-934-5000 Fax: 201-934-8880 Toll-Free: Address: 170 Williams Dr., Ramsey, NJ 07446 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 346 ( 9 months) 2002 Profits: $-13,798 ( 9 months) Stock Ticker: ALT 2001 Sales: $ 452 2001 Profits: $-11,583 Employees: 33 2000 Sales: $ 570 2000 Profits: $-9,570 Fiscal Year Ends: 12/31 1999 Sales: $1,435 1999 Profits: $-10,932 1998 Sales: $1,321 1998 Profits: $-26,346


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Significant partnerships.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $100,000 Bonus: $50,000

Northeast: Y

International:



ALZA CORP

www.alza.com


Y Y




TYPES OF BUSINESS:



Drugs-Drug Delivery Technologies Drug Therapies and Systems

ALZA Corporation develops and markets innovative pharmaceutical products using advanced drug delivery technologies to add medical and economic value to drug therapies. The company focuses on several therapeutic areas, including oncology, AIDS, pain management, endocrinology and urology. ALZA's Therapeutic Discovery Corporation selects and develops new human pharmaceutical products, combining the company's proprietary drug delivery systems with various drug compounds, and commercializes such products, usually through licensing arrangements with ALZA. Some of the company’s more commonly known drugs are Ditropan XL for the treatment of urge urinary incontinence, DUROS for the palliative treatment of advanced prostate cancer, OROS for the treatment of attention deficit/hyperactivity disorder, E-TRANS (fentanyl) for chronic pain, E-TRANS (LHRH) for infertility and E-TRANS Macroflux for Type II diabetes. Another drug, Caelyx, treats advanced ovarian cancer. ALZA operates as a wholly owned subsidiary of Johnson and Johnson. ALZA offers employees an extensive benefits package including 85% paid dental coverage, stock options, bonuses, maternity leave, telecommuting and transit. In addition, the company also matches gifts to charities and has a holiday shutdown period and a sabbatical program.

BRANDS/DIVISIONS/AFFILIATES: Caelyx Ditropan XL E-TRANS Therapeutic Discovery Corp. NeuTrexin Crescendo Pharmaceuticals Johnson and Johnson DUROS

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Samuel R. Saks, Company Group Chairman Robert Clark, CFO/VP-Finance Joseph Michalcewicz, VP-Human Resources B. Michael Silber, VP-Research Suzanne C. Martin, VP-Program Mgmt. and IT Janne L. Wissel, Sr. VP-Oper. Erik D. Wilberg, VP-Bus. Dev. Detlef Albrecht, VP-Clinical Dev. Suneel Gupta, VP-Research and Pharmacology Howard B. Rosen, VP-Strategic and New Product Planning

Phone: 650-564-5000 Fax: 650-564-7070 Toll-Free: 800-233-5222 Address: 1900 Charleston Rd., Mountain View, CA 94039 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2,442 2000 Sales: $988,500 2000 Profits: $223,300 Fiscal Year Ends: 12/31 1999 Sales: $795,900 1999 Profits: $91,000 1998 Sales: $646,900 1998 Profits: $108,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Advanced drug delivery technologies.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Bonus: $ Bonus: $

Southeast:



Northeast:

International:



AMARILLO BIOSCIENCES INC

www.amarbio.com


Y Y



Profits: 62


TYPES OF BUSINESS:



Drugs-Diversified Nutritionals Orally Delivered Drugs

Amarillo Biosciences, Inc., a development-stage company, focuses its development efforts on biologics for the treatment of human and animal diseases. The company is currently channeling its research into human health indications for the use of low-dose orally administered natural interferon alpha, or IFN[alpha], particularly for the treatment of Sjogren's syndrome, fibromyalgia, idiopathic pulmonary fibrosis and asthma. Amarillo Biosciences owns or licenses 20 United States patents relating to lowdose oral natural IFN[alpha]. The company is developing a topical formulation of the drug. It has also obtained licenses for natural human interferon gama (IFNg) and tumor necrosis factor alpha from its Japanese partner, Hayashibara Biochemical Laboratories, Inc. Recently, Amarillo Biosciences executed a license agreement with Atrix Laboratories, Inc. of Fort Collins, Colorado, providing the rights to oral low-dose interferon alpha for the treatment of Behcet's disease and oral papillomavirus warts in HIV-positive patients. In other news, the company signed another license agreement with African Health Solution, LLC, providing the rights to low-dose oral interferon alpha for the treatment of hepatitis B patients in 40 African countries. Amarillo Biosciences also announced the expansion of its existing relationship with Global Damon of Seoul, Korea. Global Damon will distribute Amarillo Biosciences' dietary supplement for dry mouth in Korea. In addition, the company agreed to supply nutraceuticals in territories of China, Taiwan and Pakistan through agreements with STC International and Majsons Corporation.

BRANDS/DIVISIONS/AFFILIATES: Hayashibara Biochemical Laboratories, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph M. Cummins, CEO Kathleen L. Kelleher, COO Joseph M. Cummins, Pres. Joseph M. Cummins, CFO Kathleen L. Kelleher, VP-Bus. Dev. Joseph M. Cummins, Chmn.

Phone: 806-376-1741 Fax: 806-376-9301 Toll-Free: Address: 800 W. 9th Ave., Amarillo, TX 79101 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 100 ( 9 months) 2002 Profits: $- 700 ( 9 months) Stock Ticker: AMAR 2001 Sales: $ 700 2001 Profits: $- 500 Employees: 4 2000 Sales: $ 100 2000 Profits: $-3,400 Fiscal Year Ends: 12/31 1999 Sales: $ 108 1999 Profits: $-6,119 1998 Sales: $ 222 1998 Profits: $-2,333


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Expertise in low dose oral interferons/Owns a large number of patents.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Bonus: $ Bonus: $

Northeast:

International:



AMARIN CORPORATION PLC

www.amarincorp.com


Y



Profits: 87


TYPES OF BUSINESS:



Drugs-Generic Prescription Drugs Over-the-Counter Drugs

Amarin Corporation is an emerging specialty pharmaceutical company engaged in the development and sale of pharmaceutical products worldwide. The company’s strategy is to obtain and acquire licenses for pharmaceutical products that larger companies do not actively market. Its U.S. subsidiary, Amarin Pharmaceuticals, Inc., increases the sales of these products through aggressive promotion activities, including the use of the Internet. The European subsidiary, Amarin Development AB, is responsible for researching and developing drug solutions to enhance new and existing drugs. LAX-101, currently in phase III studies, is being developed to treat Huntington’s disease. The company also has the rights for Moraxen, a drug used to treat severe pain in end-stage cancer. Amarin Development AB has entered into a research collaboration with CellGate, Inc., whereby CellGate’s technology will be used to develop drug transporter conjugates that will aid Amarin’s controlled-release technology. Recently, Amarin acquired the U.S. rights to Permax, a dopamine receptor agonist indicated as adjunctive therapy in the management of Parkinson's disease.

BRANDS/DIVISIONS/AFFILIATES: Amarin Pharmaceuticals, Inc. Amarin Development AB LAX-101 Moraxen Permax

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard A.B. Stewart, CEO Michael Coffee, COO Michael Coffee, Pres. Nigel Bell, CFO Jonathan Lamb, Corp. Sec. Jonathan Lamb, General Counsel Donald R. Joseph, VP-Commercial Dev. Stephan Ohlsson, Managing Dir.-Amarin Development Michael M. Wess, VP-Medical Affairs, Amarin Pharmaceuticals Margie Nemcik-Cruz, VP-Regulatory Affairs, Amarin Pharmaceuticals Thomas G. Lynch, Chmn.

Phone: +44-20-7499-9009 Fax: +44-20-7499-9004 Toll-Free: Address: 7 Curzon St., London, W1J 5HG UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $51,500 ( 9 months) 2002 Profits: $5,600 ( 9 months) Stock Ticker: AMRN 2001 Sales: $53,800 2001 Profits: $-4,700 Employees: 84 2000 Sales: $26,200 2000 Profits: $2,400 Fiscal Year Ends: 12/31 1999 Sales: $11,200 1999 Profits: $4,400 1998 Sales: $ 1998 Profits: $


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Aggressive promotion activities/Product line growth through acquisition.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



AMERSHAM PLC

www.nycomed-amersham.com


Y



Y

TYPES OF BUSINESS:

Profits: 1




Contrasting and Radiotherapy Agents Treatment for Prostate Cancer Radiopharmaceuticals Industrial Separations Technology

Amersham is a leading producer of contrasting agents that enhance the quality of images in procedures such as xrays, magnetic resonance imaging and ultrasounds. It also produces radiopharmaceuticals used in nuclear medicine imaging. The company’s life sciences business division, Amersham Biosciences, offers drug discovery and systems for gene and protein analysis and drug screening. Amersham Biosciences is a market leader in industrial separators, where it provides systems for the purification and production of biopharmaceuticals. This division also provides research products for use in different laboratories. Amersham Health, another division, produces imaging and radiotherapy agents, which help in the diagnosis and treatment of diseases. Its products focus on areas of cardiology, neurology and oncology. Recently, Amersham Health signed an agreement with Link Pharmaceuticals, a U.K. hospital specialty sales and marketing company to promote the therapy product Metastron for the treatment of pain from metastatic prostate cancer. In other news, Amersham Health’s radiopharmaceutical imaging agent, MYOVIEW, was approved for use in breast cancer screening in 12 European countries, including France, Germany, the U.K. and Spain. MYOVIEW was originally used to diagnose heart disease by visualising blood flow to the heart muscle. In addition, Amersham Biosciences recently opened its first Malaysian branch office.

BRANDS/DIVISIONS/AFFILIATES: Amersham Biosciences Amersham Health MYOVIEW Theragenics Corporation TheraSeed OncoSeed Pharmacia

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William M. Castell, CEO Andrew Carr, Pres. Giles F. B. Kerr, Dir.-Finance George Battersby, Dir.-Group Human Resources Robert Allnutt, Sec./Group Legal Advisor Lynne Gailey, Dir.-Corp. Affairs Alexandra Morris, Mgr.-Investor Rel. John M. Padfield, CEO-Amersham Health

Phone: +44-1494-544000 Fax: +44-1494-542266 Toll-Free: Address: Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $1,140,500 ( 6 months) 2002 Profits: $147,600 ( 6 months) Stock Ticker: AHM 2001 Sales: $2,206,400 2001 Profits: $312,800 Employees: 9,500 2000 Sales: $1,834,000 2000 Profits: $104,000 Fiscal Year Ends: 12/31 1999 Sales: $1,848,000 1999 Profits: $21,000 1998 Sales: $1,893,000 1998 Profits: $-3,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: A leading producer of imaging agents, the company has diversified into many additional areas.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast:

International: Y



AMGEN INC

www.amgen.com


Y



Profits: 10


TYPES OF BUSINESS:



Drugs-Diversified Advanced Cellular Biology Advanced Molecular Biology

Amgen, Inc. is a global biotechnology company that develops, manufactures and markets human therapeutics based on advanced cellular and molecular biology. Its products are used for the treatment of nephrology, cancer, inflammatory disorders and metabolic and neurodegenerative diseases. Amgen manufactures and markets four human therapeutic products: Neupogen, Epogen, Infergen and Stemgen. Neupogen selectively stimulates the growth of infection-fighting white blood cells (known as neutrophils). Epogen stimulates the production of red blood cells. Infergen stimulates the immune system to fight viral infections and is being marketed for the treatment of Hepatitis C. Stemgen is approved for stem cell therapy in Australia, Canada and New Zealand. Amgen also has promising drugs that are currently in various stages of development. These drugs under development include Aranesp, a version of Epogen that is longer lasting and can be marketed worldwide, and Abarelix, a drug used for prostate cancer. It has research and marketing alliances with companies such as Hoffmann-La Roche, Johnson & Johnson and Kirin. The firm recently announced that it intends to acquire Immunex in a deal valued at $16 billion.

BRANDS/DIVISIONS/AFFILIATES: Neupogen Epogen Infergen Stemgen Immunex Aranesp Abarelix

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kevin W. Sharer, CEO Kevin W. Sharer, Pres. Richard D. Nanula, CFO George Morrow , Sr. VP-Sales & Mktg. Brian McNamee, VP-Human Resources Roger Perlmutter, Exec. VP-Research & Dev. Hassan Dayem, Sr. VP/CIO Marc M.P. de Garidel, VP/Controller Sarah M. Jensen, VP-Eng. & Oper. Services Edward E. Bjurstrom, VP-Mfg. Steven M. Orde, Sr. VP-Sec. Steven M. Orde, General Counsel Dennis M. Fenton, Exec. VP-Oper. Richard D. Nanula, Exec. VP-Strategy Peter B. Teeley, Sr. VP-Gov't. Affairs & Public John J. Elginer, Treas. Beth C. Seidenberg, Sr. VP-Dev. George Morstyn, Sr. VP-Dev./Chief Medical Officer

Phone: 805-447-1000 Fax: 805-447-1010 Toll-Free: 800-772-6436 Address: 1 Amgen Center Dr., Thousand Oaks , CA 91320-1799 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $3,756,900 ( 9 months) 2002 Profits: $-1,848,300 ( 9 months) Stock Ticker: AMGN 2001 Sales: $3,763,000 2001 Profits: $1,119,700 Employees: 7,700 2000 Sales: $3,629,400 2000 Profits: $1,138,500 Fiscal Year Ends: 12/31 1999 Sales: $3,340,100 1999 Profits: $1,096,400 1998 Sales: $2,718,200 1998 Profits: $863,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $ Bonus: $ ADVANTAGE: A global biotechnology company with a specific market niche/One of the best known and fastest growing biotech firms.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Southeast:



Northeast: Y

International: Y



AMYLIN PHARMACEUTICALS INC

www.amylin.com


Y




TYPES OF BUSINESS:



Drugs-Diabetes Drugs for Metabolic Disorders

Amylin Pharmaceuticals, Inc. develops novel medicines for treating diabetes and related metabolic disorders. The company was founded after the discovery of amylin, a hormone that is missing in persons with type 1 diabetes and deficient in those with type 2 diabetes. Amylin Pharmaceuticals, Inc. is currently developing and testing four products. SYMLIN, a drug intended to treat diabetics who use insulin, is in phase III clinical studies. This drug is a synthetic version of the human hormone (amylin) that demonstrates activity in blood glucose regulation. Marketing authorization applications for SYMLIN have been accepted for filing by the EMEA and Swiss Regulatory Authorities. AC2993 is currently in phase III evaluation for the treatment of type 2 diabetes. It is an amino acid peptide that exhibits several anti-diabetic, or glucose lowering, actions. AC2993 LAR, an injectable long-acting formulation of AC2993, is currently in phase II evaluation also. AC3056, an in-licensed drug from Aventis Pharma, is being evaluated as a treatment to prevent restenosis after vascular repair procedures and for diseases resulting from atherosclerosis. AC3056 is currently in phase I studies. Recently, Amylin signed a global agreement with Eli Lilly to collaborate on the development and commercialization of its AC2993, receiving $325 million from Lilly, which greatly improved Amylin's financial condition..

BRANDS/DIVISIONS/AFFILIATES: Amylin Europe, Ltd. Pramlintide SYMLIN AC2993 LAR AC2993 AC3056

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph C. Cook, Jr., CEO Mark G. Foletta, CFO/VP-Finance Cathy Jackson, Human Resources Admin. Andrew A. Young, VP/Sr. Research Fellow Nancy K. Dahl, VP/Corp. Sec. Nancy K. Dahl, General Counsel Martin R. Brown, Sr. VP-Oper. Michael Step, Sr. VP-Corp. Dev. Alain D. Baron, Sr. VP-Clinical Research Daniel M. Bradbury, Exec. VP Julia R. Brown, Exec. VP Joann L. Data, Sr. VP-Regulatory Affairs and Quality Assurance Joseph C. Cook, Jr., Chmn.

Phone: 858-552-2200 Fax: 858-552-2212 Toll-Free: Address: 9373 Towne Centre Dr., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,600 ( 9 months) 2002 Profits: $80,600 ( 9 months) Stock Ticker: AMLN 2001 Sales: $ 2001 Profits: $-72,000 Employees: 215 2000 Sales: $ 100 2000 Profits: $-44,000 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-30,600 1998 Sales: $16,200 1998 Profits: $-51,098


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $475,000 Stock Purch. Plan: Second Exec. Salary: $300,000 ADVANTAGE: Has developed a synthetic hormone with excellent potential to treat diabetes.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y




Northeast: Y

International: Y



ANDRX CORP

www.andrx.com


Y Y



Profits: 35


TYPES OF BUSINESS:



Drugs-Controlled Release Drug Delivery Technologies

Andrx Corporation formulates and commercializes controlled-release oral pharmaceuticals using proprietary drug delivery technologies. To date, the company has developed 10 different drug delivery technologies that have been patented or for which patent applications have been filed. Andrx believes that its technologies are flexible and can be modified to apply to a variety of pharmaceutical products. Through Andrx Pharmaceuticals and Andrx Laboratories, the company is applying proprietary drug delivery technologies and formulation skills, either directly or through collaborative arrangements, to the development of generic versions of select brand name pharmaceuticals. Andrx also markets and distributes generic drugs manufactured by third parties. Andrx is a 50% partner in ANCIRC Pharmaceuticals, a joint venture with Watson, for the development of up to eight generic controlled-release pharmaceuticals. Andrx Labs develops controlled-release products using the technologies created by Andrx Laboratories. The company also manufactures and sells internally developed products, including Cartia XT, Diltia XT, Ketroprofen Extended Release and Metformin IR, along with the bioequivalent versions of Cardizem CD, Dilacor XR, Oruvail and Glucophage. Anda, a unit of the company, purchases products directly from manufactures and wholesalers and markets them through its telemarketing staff and sales representatives. Andrx uses POL Physicians Online to gain access to physicians through the Internet. In recent news, Andrx received tentative FDA approval for generic Novaldex, generic Clariditin-D24 and generic GlucophageXR. The drug Alcor has been approved by the FDA and generic K-Dur received FDA marketing approval.

BRANDS/DIVISIONS/AFFILIATES: ANCIRC Pharmaceuticals Cartia XT Andrx Laboratories Andrx Pharmaceuticals Diltia XT Metformin IR Anda, Inc. Ketroprofen

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard J. Lane, CEO Elliot F. Hahn, Pres. Angelo C. Malahias, VP/CFO Scott Lodin, Exec. VP/Corp. Sec. Scott Lodin, General Counsel Elliot F. Hahn, Chmn.

Phone: 954-584-0300 Fax: 954-217-4327 Toll-Free: Address: 4955 Orange Dr., Davie, FL 33314 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $553,604 ( 9 months) 2002 Profits: $-59,436 ( 9 months) Stock Ticker: ADRX 2001 Sales: $749,000 2001 Profits: $37,500 Employees: 1,837 2000 Sales: $520,000 2000 Profits: $58,500 Fiscal Year Ends: 12/31 1999 Sales: $476,000 1999 Profits: $94,100 1998 Sales: $247,100 1998 Profits: $8,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $348,400 Bonus: $175,000 Stock Purch. Plan: Second Exec. Salary: $323,600 Bonus: $150,000 ADVANTAGE: Applies proprietary drug delivery technologies and formulation skills to the development of generic versions of brand name drugs.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Northeast:

International:



ANGIOTECH PHARMACEUTICALS

www.angiotech.com


Y



Profits: 91


TYPES OF BUSINESS:



Drugs-Inflammatory Disease Medical Device Coatings

Angiotech Pharmaceuticals, Inc. is a Canadian pharmaceutical company dedicated to the development of medical device coatings and treatments for chronic inflammatory diseases. These treatments are bas ed upon the company’s discovery that paclitaxel, one of the most commercially successful and clinically effective anticancer drugs ever produced, also blocks an important cellular pathway involved in inflammation. The firm is currently developing polymeric formulations to deliver paclitaxel as a stent coating for restenosis, an intravenous treatment for secondary progressive multiple sclerosis and rheumatoid arthritis and a topical gel for psoriasis. Other medical device programs include paclitaxel-loaded surgical implants for the treatment of restenosis associated with peripheral vascular surgery. The company has alliances with device manufactures to provide support in these developments. Boston Scientific Corp. and Cook, Inc. develop paclitaxel-coated stents, and C.R. Bard develops vascular wraps. Angiotech also has research collaborations with worldwide institutions to aid in its internal product research efforts. Recently, Angiotech signed a definitive agreement to acquire Cohesion Technologies, Inc., a biomaterials and biosurgical company. Under this agreement, Angiotech will gain Cohesion's product development and research, clinical experience, delivery systems and specialized sales force. Angiotech offers a comprehensive benefits package, along with training and professinal development programs, an employee fitness center and parking and transit passes.

BRANDS/DIVISIONS/AFFILIATES: Cohesion Technologies, Inc. Boston Scientific Alcon C.R. Bard Cook, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William L. Hunter, CEO William L. Hunter, Pres. David M. Hall, CFO David D. McMasters, General Counsel/VP-Intellectual David Hartnett, Sr. VP-Oper. Jeanne M. Bertonis, VP-Corp. Dev. Rui Avelar, VP-Corp. Comm. Rui Avelar, VP-Investor Rel. David T. Howard, Chmn.

Phone: 604-221-7676 Fax: 604-221-2330 Toll-Free: Address: 6660 NW Marine Dr., Vancouver, BC V6T 1Z4 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $4,700 ( 9 months) 2002 Profits: $-11,700 ( 9 months) Stock Ticker: ANPI 2001 Sales: $ 700 2001 Profits: $-5,300 Employees: 56 2000 Sales: $2,900 2000 Profits: $-1,200 Fiscal Year Ends: 9/30 1999 Sales: $2,100 1999 Profits: $-6,474 1998 Sales: $ 500 1998 Profits: $-4,407


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Expertise in medical device coatings.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



ANIKA THERAPEUTICS INC

www.anikatherapeutics.com


Y


Y


Profits: 4


TYPES OF BUSINESS:



Drugs-Bone, Cartilage and Soft Tissue Tissue Repair Technology

Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices intended to promote the protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions, such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues and the transport of molecules to and within cells. The company's currently marketed products consist of ORTHOVISC, an HA product used in the treatment of some forms of osteoarthritis in humans, and HYVISC, an HA product used in the treatment of equine osteoarthritis. ORTHOVISC is approved for sale and marketed in Canada, Europe, Turkey, Israel and Iceland. The company also manufactures AMVISC and AMVISC Plus, used as viscoelastic supplements in ophthalmic surgery, for Bausch & Lomb Surgical, a subsidiary of Bausch & Lomb. STAARVISC II, an injectable ophthalmic viscoelastic, is produced for STAAR Surgical Company, and ShellGel, also an injectable ophthalmic viscoelastic, is produced for Cytosol Ophthalmics, Inc. Anika is currently developing INCERT, an HA-based product designed for use in the prevention of post-surgical adhesions. Anika holds exclusive rights to manufacture OSSIGEL for Orquest, Inc. Recently, Anika announced a three-year supply agreement with a unit of Allergan, Inc. Allergan will market Anika's CoEase, a product used during opthalamic surgery, including cataract and intraocular lens implantation. In other news, the company signed an exclusive distribution agreement for ORTHOVISC in Canada with Rivex Pharma, Inc. and in the U.K. with Surgicraft, Ltd., a manufacturer and distributor of medical devices.

BRANDS/DIVISIONS/AFFILIATES: ORTHOVISC HYVISC INCERT AMVISC STAARVISC II ShellGel CoEase

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Charles H. Sherwood, CEO Charles H. Sherwood, Pres. William J. Knight, VP-Finance/CFO Bob Tellis, Sr. VP-Sales and Mktg. Scott P. Bruder, VP-Research and Dev. Frank Luppino, Exec. Dir.-Oper. Ed Gaj, Jr., Exec. Dir.-New Bus. Dev. William J. Knight, Treas. Ed Gaj, Jr., Exec. Dir.-Mktg.

Phone: 781-932-6616 Fax: 781-935-4120 Toll-Free: Address: 236 W. Cummings Park, Woburn, MA 01801 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $9,000 ( 9 months) 2002 Profits: $-3,700 ( 9 months) Stock Ticker: ANIK 2001 Sales: $11,300 2001 Profits: $-6,800 Employees: 67 2000 Sales: $16,335 2000 Profits: $ 174 Fiscal Year Ends: 12/31 1999 Sales: $13,500 1999 Profits: $-2,500 1998 Sales: $13,273 1998 Profits: $3,752


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $205,750 Stock Purch. Plan: Second Exec. Salary: $203,696 ADVANTAGE: Focus on unique technologies based on hyaluronic acid.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $54,500 Bonus: $54,500

Northeast: Y

International:



ANTEX BIOLOGICS INC

www.antexbiologics.com


Y


Clinical: Trials: Labs: Equipment/Supplies: Research & Dev . Svcs.: Assays/Diagnostics:

Profits: 98


TYPES OF BUSINESS:



Drugs-Bacterial Infection Vaccines and Antibiotics

Antex Biologics, Inc. is a biopharmaceutical company committed to developing and marketing products to prevent and treat infections and related diseases. Its AntexPharma subsidiary focuses on developing new antibiotics with broad-spectrum activity as organismspecific antibacterial agents. Antex has developed three platform technologies. Antigen Receptor Technology (ART) and Nutriment Signal Transduction (NST) enhance the company’s ability to discover disease-specific proteins. The company has also developed a Virulence Expression Profiling (VEP) platform, which uses functional genomics to profile and identify disease-specific proteins. The firm’s Antex Proteomics subsidiary identifies vaccine and smallmolecule drug candidates for internal development and commercialization, in addition to establishing collaborations with other biotechnology companies for access to its database. Over the years, Antex has formed strategic alliances with major pharmaceutical companies. The company licensed Hin47 to Aventis Pasteur. It also established a strategic alliance with GlaxoSmithKline to develop and commercialize human bacterial vaccines. In addition, Antex entered into a cooperative research and development agreement with the U.S. Navy whereby the Navy will support and conduct clinical trials of CAMPYVAX, a vaccine to prevent diarrhea. AntexPharma also has a development and license agreement with the University of Maryland, Baltimore, for new peptides intended to treat serious symptoms related to lung disorders. Recently, Antex announced that two Phase II trials for its HELIVAX vaccine against Helicobacter pylori, a bacterial pathogen responsible for peptic ulcers and stomach cancers, are scheduled to begin. In other news, the company was issued three new patents: one from South America for a protein from the Neisseria family, the second from Singapore for a protein from the Moraxella catarrhalis bacteria family and the third from Mexico for the method of producing enhanced antigenic Helicobacter pylori bacteria. These new patents increase the company’s totals to 101 issued patents and 339 pending applications.

BRANDS/DIVISIONS/AFFILIATES: AntexPharma Antex Proteomics HELIVAX Hin47 CAMPYVAX Maryland Industrial Partnerships

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. V.M. Esposito, CEO Stephen N. Keith, COO Stephen N. Keith, Pres. Jeffrey V. Pirone, CFO/Exec. VP James Jackson, VP-Research Alan Liss, VP-Product Dev. Kyle W. Keese, VP-Bus. Dev.

Phone: 301-590-0129 Fax: 301-590-1251 Toll-Free: Address: 300 Professional Dr., Gaithersburg, MD 20879 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 300 ( 9 months) 2002 Profits: $-6,700 ( 9 months) Stock Ticker: ANX 2001 Sales: $ 900 2001 Profits: $-6,700 Employees: 36 2000 Sales: $ 349 2000 Profits: $-6,296 Fiscal Year Ends: 12/31 1999 Sales: $2,600 1999 Profits: $-3,500 1998 Sales: $4,500 1998 Profits: $-2,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,015 Stock Purch. Plan: Second Exec. Salary: $143,339 ADVANTAGE: Research and development agreement with the U.S. Navy.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



ANTIGENICS INC

www.antigenics.com


Y



Profits: 222


TYPES OF BUSINESS:



Drugs-Cancer, Infectious Disease and Autoimmune Disease

Antigenics is focused on therapeutic vaccines and treatments for cancer, infectious diseases and autoimmune disorders. The company’s lead development programs include immunotherapeutics based on a specific class of proteins, known as heat shock proteins, and an immune system adjuvant called QS-21. Oncophage, its lead product, uses proprietary heat shock protein technology to stimulate a powerful T cell-based immune response capable of targeting and killing cancer cells. It is currently in Phase III trials for treatment of renal cell carcinoma and melanoma. In addition, Antigenics is developing Aroplatin and ATRA-IV, unique liposomal formulations of anticancer drugs that are designed to offer improvements over existing cancer drugs. Antigenics is also developing immunotherapeutics to treat infectious diseases such as genital herpes, AIDS and tuberculosis and autoimmune disorders such as diabetes and multiple sclerosis. AG-702 is its heat shock protein-based therapy for genital herpes. The company has seven corporate partners that have licensed the QS-21 adjuvant for a variety of human diseases: GlaxoSmithKline, WyethLederle Vaccines, Aventis Pasteur, Progenics Pharmaceuticals, VaxGen, Elan Corporation and Korea Green Cross. These pharmaceutical and biotechnology companies are using QS-21 in their products developed for the treatment of several chronic and debilitating diseases, including malaria, hepatitis B, melanoma and HIV. Recently, Antigenics announced that the first patient has been enrolled in a Phase II study evaluating Aroplatin as a treatment for metastatic colorectal cancer. The trial will evaluate the effects of Aroplatin monotherapy in patients whose disease is not responsive to standard treatments. Additionally, the company acquired Aronex Pharmaceuticals, Inc., which adds two advanced-stage cancer products to its portfolio of trial programs.

BRANDS/DIVISIONS/AFFILIATES: Oncophage Aroplatin ATRA -IV QS-21 AG-702 Aronex Pharmaceuticals, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Garo Armen, CEO Russell Herndon, COO Russell Herndon, Pres. Jeff Rona, CFO Pramod K. Srivastava, Chief Scientific Officer Jonathan J. Lewis , Chief Medical Officer Neal F. Gordon, Sr. VP-Mfg. Oper. Deanna Petersen, VP-Bus. Dev. Garo Armen, Chmn.

Phone: 212-994-8200 Fax: 212-332-4778 Toll-Free: Address: 630 5th Ave., Ste. 2100, New York, NY 10111 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,700 ( 9 months) 2002 Profits: $-39,600 ( 9 months) Stock Ticker: AGEN 2001 Sales: $4,600 2001 Profits: $-73,500 Employees: 208 2000 Sales: $ 443 2000 Profits: $-46,729 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-18,100 1998 Sales: $ 1998 Profits: $-8,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Focus on immune system therapies.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $93,750 Bonus: $30,000

Northeast: Y

International:



APHTON CORP

www.aphton.com


Y




TYPES OF BUSINESS:



Drugs-Gastrointestinal and Reproductive-System Disease Anti-Hormone Therapy

Aphton Corporation is a biopharmaceutical company that is developing products using its innovative vaccine-like technology for neutralizing and eliminating hormones that participate in gastrointestinal system and reproductive system diseases. The firm is also developing products for neutralizing hormones in order to prevent pregnancy. The company’s lead products include G-17, GnRH Pharmaccine and immuno-contraception. G-17 is being used to treat advanced pancreatic, stomach, esophagus and colorectal cancers. It is also being tested for the treatment of gastro-intestinal ulcerations and gastroesophageal reflux disease. Aphton has a strategic alliance with Aventis Pasteur for all cancer applications of G-17 immunogen in North America, Mexico and Europe. GnRH Pharmaccine is being developed to treat reproductive system cancers including prostate cancer. The company has a strategic alliance with GlaxoSmithKline for all human applications of GnRH Pharmaccine. Aphton's immuno-contraceptive product, which prevents pregnancy, is in phase II trials, funded by the World Health Organization. Immuno-contraception neutralizes the female hormone known as hCG. Aphton also belongs to an alliance with Schering-Plough, a worldwide pharmaceutical company, for all animal applications of its anti-gastrin immunogen. Recently, Aphton received approval to initiate a clinical trial in Europe for patients suffering from gastroesophageal reflux disease.

BRANDS/DIVISIONS/AFFILIATES: GnRH Pharmaccine G17

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Philip C. Gevas, Co-CEO Philip C. Gevas, Pres. Douglas A. Eayers, CFO Sue A. Russell, Dir.-Human Resources Richard Ascione, VP/Dir.-Laboratory Molecular Medicine Frederick W. Jacobs , Chief Accounting Officer Dov Michaeli, Chief Medical Officer/Dir.-Medical Science Peter Blackburn, VP-Mfg. Theo de Roij, VP-Bus. and Product Dev. Jeannette L. Whitmore, VP-Corp. Comm. Jeannette L. Whitmore, VP-Investor Rel. Frederick W. Jacobs , VP/Treas. William A. Hasler, Co-CEO Paul Broome, VP-Clinical Trials and Regulatory Affairs, Europe Peter Blackburn, VP-Program Dev. Donald Henderson, VP/Managing Dir.-Finance and Admin., Europe Philip C. Gevas, Chmn.

Phone: 305-374-7338 Fax: 305-374-7615 Toll-Free: 877-274-8660 Address: 80 SW 8th St., Ste. 2160, Miami, FL 33130 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-30,845 ( months) Stock Ticker: APHT 2001 Sales: $ 2001 Profits: $-31,300 Employees: 50 2000 Sales: $ 2000 Profits: $-11,200 Fiscal Year Ends: 1/31 1999 Sales: $ 1999 Profits: $-9,800 1998 Sales: $ 1998 Profits: $-6,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $183,333 Stock Purch. Plan: Second Exec. Salary: $165,000 ADVANTAGE: Innovative vaccine-like technology/Significant alliances.

OTHER THOUGHTS:



West:

Southwest: Y

Midwest:

Southeast: Y




Northeast:

International: Y



APPLERA CORPORATION

www.applera.com



Y Y


Y

TYPES OF BUSINESS:

Profits: 7


Y Y



Equipment-Life Sciences and Genomics Genetic Database Management Proteomics Medical Software Microbial Populations DNA Sequencing Organic Synthesis High Throughput Screening

Applera Corporation, formerly known as PE Corporation, provides leading technology and information solutions that help life scientists understand and use the power of biology. Two divisions of the company, Applied Biosystems and Celera Genomics integrated to form a separate joint venture, Celera Diagnostics. Applied Biosystems is principally engaged in the development, manufacture, sale and service of instrument systems and associated consumable products for life science research and related applications. Its products are used in applications including the synthesis, amplification, purification, isolation, analysis and sequencing of nucleic acids, proteins and other biological molecules. Celera Genomics is principally engaged in integrating high throughput technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera Genomics' lines of business are online information and therapeutic discovery. Pharmaceutical, biotechnology and academic customers use this information, along with the firm’s customized information technology solutions, to enhance their capabilities in the fields of life science research and pharmaceutical and diagnostic discovery and development. Celera Genomics intends to leverage its capabilities in genomics, proteomics and bioinformatics, both in internal programs and through collaborations, to identify drug targets and diagnostic markers and to discover and develop novel therapeutic candidates. Celera Diagnostics focuses on the discovery, development and commercialization of novel diagnostic tests in order to pursue new methods for diagnosing and treating disease. The Applera groups recently announced a collaboration with Myriad Proteomics and the Institute for Systems Biology to develop more effective measures of medical research and solutions. Applera offers its employees an educational assistance plan, travel accident insurance, basic and supplemental life insurance and an adoption assistance program.

BRANDS/DIVISIONS/AFFILIATES: PE Corporation Applied Biosystems Celera Genomics Millipore Corporation Diversa Corporation Celera Diagnostics

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Tony L. White, CEO Tony L. White, Pres. Dennis L. Winger, CFO/Sr. VP Barbara J. Kerr, VP-Human Resources Ronald D. Edelstein, CIO Vikram Jog, Corp. Controller William B. Sawch, General Counsel/Sr. VP Kenneth D. Noonan, VP-Corp. Dev. John S. Ostaszewski, Treas. Michael W. Hunkapiller, Pres., Applied Biosystems Group/Sr. VP J. Craig Venter, Pres./Chief Scientific Officer, Celera Genomics Kathy P. Ordonez, Sr. VP/Pres.-Celera Genomics and Celera Diagnostic Elaine J. Heron, VP-PE Biosystems

Phone: 203-840-2000 Fax: 203-762-6000 Toll-Free: 800-761-5381 Address: 301 Merritt 7, Norwalk, CT 06856-5435 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,701,218 (12 months) 2002 Profits: $-40,581 (12 months) Stock Ticker: Private 2001 Sales: $1,644,100 2001 Profits: $27,200 Employees: 5,544 2000 Sales: $1,371,000 2000 Profits: $95,500 Fiscal Year Ends: 6/30 1999 Sales: $1,216,900 1999 Profits: $175,900 1998 Sales: $1,531,200 1998 Profits: $56,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Cutting edge genomics technology.

OTHER THOUGHTS:




West: Y

Southwest: Y

Midwest:

Southeast:



Bonus: $1,150,000 Bonus: $462,977

Northeast: Y

International: Y



APPLIED MOLECULAR EVOLUTION INCwww.amevolution.com Industry Group Code: 541710 Ranks within this company's industry group: Sales: 36 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y


Y Y


Y

TYPES OF BUSINESS:

Profits: 16




Research and Development-Directed Evolution Biopharmaceuticals Human Biotherapeutics Drugs-Small Molecule

Applied Molecular Evolution, Inc. (AME) is a leader in the application of directed evolution to the development of biotherapeutics. The company uses its proprietary system technology to develop improved versions of currently marketed, FDA-approved biopharmaceuticals as well as novel human biotherapeutics. It does so by adjusting amino acids in individual proteins to create positive characteristics. There are three components to the AMEsystem technology. DirectAME is a gene synthesis process that enables the rapid production of a library of variant genes based on an initial gene. ExpressAME consists of gene expression systems that efficiently produce proteins from the genes generated using DirectAME. SelectAME is a series of tests or screens which facilitate the selection and identification of proteins with the optimal, desired commercial properties from the protein libraries produced using ExpressAME. AME has collaborations with leading developers of biotherapeutics including Centocor, Lilly, Chiron, MedImmune, BristolMyers Squibb, Seattle Genetics, Cell Matrix and Bios ynexus. The company also has academic collaborations with University of Nebraska Medical Center, The Mayo Clinic, Scripps Research Institute and MD Anderson Cancer Center. Recently, AME granted NascaCell GmbH a non-exclusive, worldwide license to its Kauffman patents for directed molecular evolution. NascaCell will use the licensed technology to generate aptamers, antibody-like nucleic acids that specifically bind to and inactivate target molecules. The company also entered into an agreement to engineer an antibody therapeutic for Centocor, Inc. AME will apply its technology to optimize the function of the antibody Centocor provides. AME also recently agreed to optimize another therapeutic antibody candidate for Eli Lilly. Among its flexible, comprehensive benefits, AME offers educational assistance and a private corporate fitness center.

BRANDS/DIVISIONS/AFFILIATES: AME System DirectAME ExpressAME SelectAME

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William D. Huse, CEO William D. Huse, Pres. Lawrence E. Bloch, CFO Jeffry D. Watkins, Chief Scientific Officer James B. Breitmeyer, Chief Medical Officer Lawrence E. Bloch, Corp. Sec. William L. Respess, VP/General Counsel Keith S. Manchester, VP-Bus. Dev. Chris Erdman, Dir.-Corp. Comm. William D. Huse, Chmn.

Phone: 858-597-4990 Fax: 858-597-4950 Toll-Free: Address: 3520 Dunhill St., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $5,652 ( 9 months) 2002 Profits: $-13,463 ( 9 months) Stock Ticker: AMEV 2001 Sales: $3,600 2001 Profits: $-13,200 Employees: 83 2000 Sales: $2,693 2000 Profits: $-13,559 Fiscal Year Ends: 12/31 1999 Sales: $2,600 1999 Profits: $-3,376 1998 Sales: $2,600 1998 Profits: $-1,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $285,000 Stock Purch. Plan: Y Second Exec. Salary: $175,000 ADVANTAGE: Leader in directed cell evolution/AME system technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $109,725 Bonus: $57,750

Northeast:

International:



ARENA PHARMACEUTICALS INC

www.arenapharm.com


Y


Y


Y

TYPES OF BUSINESS:

Profits: 99


Y



Drugs-Drug Discovery Database Management Drugs-Receptor Based

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused principally on discovering and developing drugs that target G protein-coupled receptors, called GPCRs. The company applies its proprietary CART technology in order to discover these receptor-based drugs. Moreover, the company has developed a webbased database that can be used to access relevant information and data generated from its research and development programs. The database allows individual users to obtain information on specific G protein-coupled receptor (GPCR) targets, including gene sequence information, the results of drug screening and the results of animal studies. Arena has entered into drug discovery and development collaborative arrangements with many leading pharmaceutical and biotechnology companies, including Eli Lilly, Taisho Pharmaceutical Co., Ltd., Fujisawa Pharmaceutical Co., Ltd., and TaiGen Biotechnology Co., Ltd. BRL Screening, Inc., a subsidiary of the company, acquired Bunsen Rush Laboratories, Inc., a research-based company that provided screening for the pharmaceutical and biotechnology industries using proprietary and patented Melanophore Technology. Arena has an ongoing program directed towards the development of novel anti-obesity drugs. It has also identified several orphan GPCRs, which are believed to represent therapeutic targets for the treatment of a variety of cancers, including ovarian, colorectal, gastrointestinal and uterine cancer. Other identified orphan GPCRs target cardiovascular disease, diabetes, inflammation and Alzheimer’s disease. Recently, Arena entered into a multiyear research and licensing agreement with Merck & Co., Inc. The company will utilize Arena's CART and Melanophore technologies along with its chemistry group to discover and commercialize compounds with therapeutic capability. Arena offers its employees medical, life and disability insurance and flexible spending accounts.

BRANDS/DIVISIONS/AFFILIATES: CART Technology Melanophore Technology BRL Screening, Inc. Bunsen Rush Laboratories, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jack Lief, CEO Jack Lief, Pres. Joseph F. Mooney, CFO Dominic P. Behan, VP-Research Steven W. Spector, Corp. Sec./VP Steven W. Spector, General Counsel Louis J. Scotti, VP-Bus. Dev. Joyce H. Williams , VP-Drug Dev. Robert Hoffman, VP-Finance Nigel Beeley, Chief Chemical Officer Derek T. Chalmers, VP-Research

Phone: 858-453-7200 Fax: 858-453-7210 Toll-Free: Address: 6166 Nancy Ridge Dr., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $13,057 ( 9 months) 2002 Profits: $-24,051 ( 9 months) Stock Ticker: ARNA 2001 Sales: $18,100 2001 Profits: $-6,900 Employees: 209 2000 Sales: $7,683 2000 Profits: $-6,362 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-10,200 1998 Sales: $ 1998 Profits: $-3,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $502,083 Stock Purch. Plan: Second Exec. Salary: $262,083 ADVANTAGE: Proprietary CART technology for drug discovery.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $55,000

Northeast:

International:



ARIAD PHARMACEUTICALS

www.ariad.com


Y



Profits: 156


TYPES OF BUSINESS:



Drugs-Diversified Small-Molecule Drugs Oncology and Hematology Products Osteoporosis Products

ARIAD Pharmaceuticals, Inc. is engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. The company has seven lead product candidates, including a drug candidate, AP23573, that controls cell proliferation and nutrient uptake to tumors to treat cancer; a bone-targeted drug candidate, AP23451, to treat the complications of cancer that has spread to bone; a regulated protein therapy product to treat anemia, AP22594; a T cell immunotherapy product in which a nonimmunosuppresant drug, AP1903, may be used to treat graft-vs-host disease; and a dual-action drug candidate, AP23485, that blocks bone resorption and stimulates bone formation to treat osteoporosis. ARIAD's strategy includes developing its current lead products at least through phase 2 clinical trials; establishing the commercial infrastructure to market its portfolio of hematology and oncology products in the U.S.; and pursuing a worldwide partner for its os teoporosis candidate and partners for hematology and oncology products outside the U.S. The firm's RegTech cell-signaling regulation technologies are already being used in over 500 academic investigations and are the subject of more than 120 published papers in the scientific literature. In recent news, the firm announced the discovery of a novel anti-cancer product candidate designed to treat the progression and spread of solid tumors, such as colon cancer. ARIAD also recently announced findings that make possible the use of stem cell therapy to potentially cure genetic blood diseases, such as sickle cell disease, as well as chronic diseases including congestive heart failure and diabetes. Ariad offers its employees benefits including tuition reimbursem ent, stock options and medical, dental and life insurance, as well as free parking or subway passes.

BRANDS/DIVISIONS/AFFILIATES: Ariad Gene Therapeutics RegTech ARGENT Signaling ARGENT Transcription RPD Secretion Technologies AP23573 AP23451 AP22594

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Harvey J. Berger, CEO Harvey J. Berger, Pres. Edward M. Fitzgerald, Sr. VP/CFO Kathy Lawton, Mgr.-Human Resources Timothy P. Clackson, Sr. VP-Science and Tech. Joseph Bratica, Controller Camille Bedrosian, VP/Chief Medical Officer Laurie A. Allen, Sr. VP/Corp. Sec. Laurie A. Allen, Chief Legal Officer Thomas A. Pearson, Sr. VP-Corp. Strategy Thomas A. Pearson, Sr. VP-Corp. Comm. Edward M. Fitzgerald, Treas. John D. Iuliucci, Sr. VP-Drug Dev. Tomi K. Sawyer, VP-Drug Discovery David L. Bernstein, Sr. VP/Chief Patent Officer Fritz Casselman, Sr. VP/Chief Bus. Officer Harvey J. Berger, Chmn.

Phone: 617-494-0400 Fax: 617-494-8144 Toll-Free: Address: 26 Landsdowne St., Cambridge, MA 02139-4234 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 25 ( 9 months) 2002 Profits: $-21,029 ( 9 months) Stock Ticker: ARIA 2001 Sales: $1,000 2001 Profits: $-19,800 Employees: 69 2000 Sales: $2,178 2000 Profits: $-13,832 Fiscal Year Ends: 12/31 1999 Sales: $12,913 1999 Profits: $24,200 1998 Sales: $13,100 1998 Profits: $-26,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $395,000 Stock Purch. Plan: Y Second Exec. Salary: $221,000 ADVANTAGE: Extensive list of products in development.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:




Northeast: Y

International:



ARQULE INC

www.arqule.com



Y


Y

TYPES OF BUSINESS:

Profits: 28




Research-Drug Discovery High-Throughput Chemical Compound Research

ArQule seeks to bridge the gap between genomics and clinical development by applying its proprietary technology platform and world-class chemistry capabilities to drug discovery. Discovering new compounds to test is a major obstacle to drug companies. Due in part to the lack of early information about lead compounds and the lack of alternative chemotypes, very few lead compounds meet the minimum criteria to become clinical candidates. Additionally, too many approved lead compounds are only marginally acceptable clinical candidates and are therefore more likely to fail during clinical development. In order to solve these problems, ArQule has developed the AMAP Chemistry Operating System, which allows it to perform high-throughput, automated production of new chemical compounds. The AMAP system forms the foundation of the company’s parallel synthesis approach to combinatorial chemistry. AMAP consists of an integrated series of automated workstations that perform tasks such as weighing and dissolution, chemical synthesis, thermally controlled agitation and reaction process development. The AMAP system also incorporates purification, quality control, the ability to reformat libraries and the ability to replicate libraries for multiple customers. ArQule’s proprietary Array Information Management and Process Control Management System (AIMS/PCMS) software controls and monitors the overall production process within the system. The software allows the firm to capture information about every compound in the library, as well as to process this information and to audit test data. The company's clients include Bayer, Johnson & Johnson, Pfizer and Pharmacia Corporation. As part of its strategic growth plan, the firm completed a merger with Camitro Corporation, a predictive modeling company.

BRANDS/DIVISIONS/AFFILIATES: AMAP Chemistry Operating System AIMS/PCMS Camitro Corporation Sankyo Company, Ltd. Compass and Mapping Array Libraries Directed Array

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen A. Hill, CEO Stephen A. Hill, Pres. David C. Hastings, CFO Anthony S. Messina, VP-Human Dev. Philippe Bey, Chief Scientific Officer Alan L. Hillyard, CIO J. David Jacobs, VP-Legal/General Counsel Michael Rivard, VP-Strategic Dev. Jean M. Devine, Director-Investor Rel. David C. Hastings, Treas. Carmen M. Baldino, V P-Chemistry Sheila H. DeWitt, VP- Drug Discovery Philippe Bey, Sr. VP-Research and Dev.

Phone: 781-994-0300 Fax: 781-376-6019 Toll-Free: Address: 19 Presidential Way, Woburn, MA 01801-5140 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $46,658 ( 9 months) 2002 Profits: $-18,700 ( 9 months) Stock Ticker: ARQL 2001 Sales: $58,400 2001 Profits: $-41,000 Employees: 385 2000 Sales: $50,300 2000 Profits: $3,900 Fiscal Year Ends: 12/31 1999 Sales: $18,600 1999 Profits: $-17,400 1998 Sales: $22,200 1998 Profits: $-6,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $328,462 Stock Purch. Plan: Y Second Exec. Salary: $245,686 ADVANTAGE: Superior, proprietary technology/Strong client base.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $140,000 Bonus: $84,000

Northeast: Y

International:



ASCENT PEDIATRICS INC

www.ascentpediatrics.com


Y




TYPES OF BUSINESS:



Drugs-Reformulated Pediatric Drugs

Ascent Pedriatics is engaged in the development and marketing of pharmaceuticals for use in the treatment of common pediatric illnesses. Ascent seeks to develop a broad line of products that are based on commonlyprescribed off-patent pharmaceuticals, attempting to improve the products by reducing their dosing frequency, improving their taste, making them easier to administer or developing them as substitutes for products with considerable side effects. Ascent also specializes in taste masking, which involves the removal or masking of an objectionable or unpleasant taste of various common ingredients used in pediatric pharmaceuticals. The company believes that a drug's taste is a critical factor in pediatric patient compliance, particularly when frequent dosing is required. In late 1999, the firm devoted its resources to obtaining regulatory approval of Primsol and Orapred and currently is preparing for the commercial launch of these products. Ascent also entered into a strategic alliance with Alpharma, Inc. in which Ascent will borrow $40 million to finance its growing operations.

BRANDS/DIVISIONS/AFFILIATES: Feverall Alpharma Primsol Orapred

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Alan R. Fox, CEO Alan R. Fox, Pres. Eliot Lurier, VP/CFO Gregory A. Vannatter, VP-Mktg. And Business Diane Worrick, VP-Human Resources Mumtaz Ahmed, VP-Medical Affairs Bobby R. Owen, VP-Oper. William E. Brochu, VP-Regulatory and Quality Affairs Steve Evans, National Sales Dir.

Phone: 978-658-2500 Fax: 978-658-3939 Toll-Free: Address: 187 Ballardvale St., Ste. B125, Wilmington, MA 01887 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $4,464 2000 Profits: $-14,339 Fiscal Year Ends: 12/31 1999 Sales: $7,048 1999 Profits: $-15,653 1998 Sales: $4,476 1998 Profits: $-18,231


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Unique strategy to improve existing drugs for use by children.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International:



ASTRAZENECA PLC

www.astrazeneca.com


Y



Profits: 11


TYPES OF BUSINESS:



Drugs-Diversified Pharmaceutical Manufacturing Therapeutic Drugs

AstraZeneca is a leading pharmaceutical company that provides innovative, effective products to fight disease in areas of medical necessity. Formed in 1999, the company is the result of the merger of the Zeneca Group with Astra. The company focuses on therapeutic interventions in cardiovascular, central nervous system, gastrointestinal, infection, oncology, pain control and anesthesia and respiratory areas. The firm’s product lines include Accolate, Atacand, Casodex, Diprivan, EMLA, Nolvadex, Prilosec, Rhinocort and Zomig, to name a few. The United Kingdom -based company conducts business in Sweden, the U.K. and the United States. AstraZeneca’s research facilities are the Bioinformatics Centre, the AstraZeneca Transgenic Centre and the AstraZeneca Biotech Laboratory. The company recently announced it received the U.S. patent rights for Nolvadex, a drug developed for the treatment of breas t cancer. Additionally, the company received FDA approval for Faslodex, another treatment for breast cancer, and Atacand HCT, a therapeutic drug for hypertension. The FDA also approved Symbicort Turbuhaler for the treatment of asthma and Pulmicort Respules, a breakthrough in the treatment of asthma in children and infants.

BRANDS/DIVISIONS/AFFILIATES: Bioinformatics Centre Novartis Agribusiness Pulmicort Respules Accolate Faslodex Diprivan Prilosec Zeneca Group

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Tom McKillop, CEO Johnathan Symonds, CFO Michael O'Brien, Exec. VP-Int'l Sales & Mktg. Tony Thorpe, Human Resources Claes Wilhelmsson, Exec. Dir.-Research & Dev. Barrie Thorpe, Exec. VP-Oper. Ake Stavling, Exec. Dir.-Bus. Dev. & Integration David Brennan, VP-North America Bruno Angelici, VP-Europe and Row John Patterson, Exec. VP

Phone: +44-20-77304-500 Fax: +44-20-77304-515 Toll-Free: Address: 15 Stanhope Gate, London, W1 Y6LN UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $13,153,000 ( 9 months) 2002 Profits: $2,408,000 ( 9 months) Stock Ticker: AZN 2001 Sales: $16,480,000 2001 Profits: $1,097,000 Employees: 54,600 2000 Sales: $18,103,000 2000 Pr ofits: $865,000 Fiscal Year Ends: 12/31 1999 Sales: $18,445,000 1999 Profits: $-3,539,000 1998 Sales: $15,402,000 1998 Profits: $1,036,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Produces Prilosec for treating ulcers.

OTHER THOUGHTS:

Top Exec. Salary: $1,191,000 Second Exec. Salary: $732,000



West:

Southwest:

Midwest:

Southeast:



Bonus: $588,000 Bonus: $347,000

Northeast: Y

International: Y



ATLANTIC TECHNOLOGY VENTURES Industry Group Code: 325412 Ranks within this company's industry group: Sales: 164 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



www.atlan.com Profits: 67


TYPES OF BUSINESS:


Y


Investments in Biotech Firms Pharmaceutical Development

Atlantic Technology Ventures is a diversified pharmaceutical development company with a variety of goals. The firm seeks to identify early development-stage biomedical, pharmaceutical or medical devices or other technologies and to acquire proprietary rights, fund research and development efforts and bring the resulting products to market. Atlantic focuses its efforts on drugs used for the treatment of cancer, infectious disease, ophthalmic disorders, pain and inflammation. Its scope of operations has recently expanded to include the commercialization of a broad portfolio of patented technologies. The firm’s name, previously Atlantic Pharmaceuticals, changed in accordance with these efforts. Recently, the firm’s majority-owned subsidiary, Optex, sold to Bausch & Lomb substantially all of its assets including those related to the Catarex technology. Aside from ophthalmic efforts, Atlantic Technology Ventures’ pain and inflammation developments are substantial. The firm is currently developing its proprietary compound CT-3 as an alternative to nonsteroidal antiinflammatory drugs such as asprin or ibuprofen. Atlantic is conducting additional preclinical tests to study the analgesic activity of CT-3, particularly with reference to neuropathic pain. The company is also preparing to conduct Phase II clinical trials to evaluate the efficacy of CT-3 in multiple-sclerosis -associated tremors and spasticity. Recently, Atlantic Technology Ventures licensed from its inventors the worldwide rights to ATV-02, an antimicrobial agent for the local treatment of topical infections. The company also recently licensed the exclusive worldwide rights for CT-3 to Indevus Pharmaceuticals. Indevus is now responsible for the clinical development, regulatory activities and commercialization of this compound.

BRANDS/DIVISIONS/AFFILIATES: ATV-02 Optex Atlantic Pharmaceuticals CT-3

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frederic P. Zotos, CEO Fredrick P. Zotos, Pres. Nicholas J. Rossettos, CFO A. Joseph Rudick, Chief Scientific Officer A. Joseph Rudick, Chief Medical Officer Nicholas J. Rossettos, Corp. Sec. Michael L. Ferrari, VP-Bus. Dev. Nicholas J. Rossettos, Treas.

Phone: 212-267-2503 Fax: 212-267-2159 Toll-Free: Address: 350 5th Ave., Ste. 5507, New York, NY 10118 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 500 ( 9 months) 2002 Profits: $-1,176 ( 9 months) Stock Ticker: ATLC.OB 2001 Sales: $2,700 2001 Profits: $-1,700 Employees: 5 2000 Sales: $5,359 2000 Profits: $-5,802 Fiscal Year Ends: 12/31 1999 Sales: $1,200 1999 Profits: $-2,400 1998 Sales: $3,000 1998 Profits: $-2,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $208,750 Stock Purch. Plan: Second Exec. Salary: $125,000 ADVANTAGE: Increased commercialization of its patented technologies.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $50,000 Bonus: $25,000

Northeast: Y

International:



ATRIX LABORATORIES INC

www.atrixlabs.com


Y Y



Profits: 12


TYPES OF BUSINESS:



Equipment-Dental/Periodontol Drug Delivery Systems Oncology Products Pain Management Products Veterinary Products

Atrix Laboratories is engaged in the research, development and commercialization of a broad range of medical, dental and veterinary products based on its proprietary drug delivery systems. Its five patented drug delivery technologies involve proprietary oncology, pain management, growth hormone releasing peptide-1, oral interferon and dermatology products. Atrigel is a release implant for local or systemic delivery of drugs, proteins and peptides from minutes to months. Bema is used in the delivery of drugs from minutes to hours. SMP is a topical gel providing two-stage dermal delivery of water insoluble drugs. MCA is a water-resistant topical gel providing sustained drug delivery. BCP is a non-cytotoxic gel/liquid for topical delivery. Atrix has significant strategic alliances with companies including Pfizer, Inc., SanofiSynthelabo, Inc., MediGene AG, Fujisawa Healthcare, Inc., Elan International Services, Ltd., Geneva Pharmaceuticals, Inc. and CollaGenex Pharmaceuticals, Inc. Atrix executed a non-exclusive comprehensive research and worldwide licensing agreement with Pfizer to provide broad-based access to its proprietary drug delivery systems in the development of new products. Recently, Pfizer submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for a novel bone growth product which uses Atrix's proprietary Atrigel drug delivery technology. Atrix also formed a joint venture with Elan Corporation to develop and commercialize oncology and pain management products. The joint venture will utilize Atrix’s Bema and Atrigel systems to control side effects caused by chemotherapy, radiation therapy, breakthrough cancer pain and tumor-directed cytotoxic agents. In other news, Atrix entered into an exclusive North American marketing agreement with EmerGen, Inc. for a leuprolide product for the treatment of endometriosis . The company also launched Eligard 22.5mg, a new product for the treatment of advanced prostate cancer. Atrix Laboratories provide its employees with health and dental benefits and tuition assistance.

BRANDS/DIVISIONS/AFFILIATES: Atridox Atrisorb Gtr Atrigel Elan Corp. Eligard Bema ViroTex SMP

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David R. Bethune, CEO Brian G. Richmond, CFO Stephen L. Warren, VP-Research and Dev. Michael R. Duncan, VP-Technical Oper. Michael R. Duncan, VP-Mfg. Brian G. Richmond, Corp. Sec. Charles P. Cox, Sr. VP-Corp. Dev. Brian G. Richmond, Treas. Richard L. Dunn, Principle Research Scientist Mark D. Sweeney , VP-Quality Assurance David W. Osborne, VP-Dermatology Div. J. Steven Garrett, VP-Dental Div. David R. Bethune, Chmn.

Phone: 970-482-5868 Fax: 970-482-9735 Toll-Free: Address: 2579 Midpoint Dr., Fort Collins , CO 80525 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $19,135 ( 9 months) 2002 Profits: $-12,807 ( 9 months) Stock Ticker: ATRX 2001 Sales: $15,800 2001 Profits: $-25,500 Employees: 148 2000 Sales: $10,043 2000 Profits: $-47,411 Fiscal Year Ends: 12/31 1999 Sales: $5,600 1999 Profits: $-13,200 1998 Sales: $21,100 1998 Profits: $1,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $271,667 Stock Purch. Plan: Y Second Exec. Salary: $260,000 ADVANTAGE: Holds several patents relating to drug delivery technology..

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



AUTOIMMUNE INC

www.autoimmuneinc.com


Y



Profits: 54


TYPES OF BUSINESS:



Drugs -Immune System and Inflammatory Dis ease

AutoImmune, Inc., a biopharmaceutical company, focuses on the development of a new class of therapeutics for the treatment of autoimmune and other cell -mediated inflammatory diseases and conditions. The firm’s preclinical and clinical data indicates that its proprietary approach to therapy can induce tissue-specific immunosuppression without toxicity or significant side effects. Additional clinical and commercial advantages of the firm's approach include the possibility of administering products orally (the preferred method for treating chronic diseases) and the potential for application to a variety of inflammatory diseases and conditions. The company’s products are based upon the principles of mucosal tolerance. When proteins are administered by a mucosal route (e.g., oral, nasal or by aerosol to the lungs) the body's natural immune system mechanisms suppress the response that would otherwise arise against a foreign substance. This immune suppression can be directed toward a specific tissue through appropriate selection and dosing of the protein in a mucosally delivered product. To date, AutoImmune has completed 10 human clinical trials of Colloral (its principal product) involving over 1,900 patients to investigate its use in treating rheumatoid arthritis. AutoImmune also completed a market analysis for Colloral as a nutraceutical product. The company recently announced the formation of Colloral, LLC, a joint venture with Deseret Laboratories International, for the manufacture, marketing and sale of Colloral. AutoImmune has license agreements with Teva Pharmaceutical Industries, Ltd. and BioMS Medical Corporation. Teva is working on an oral formulation of Copaxone and BioMS Medical Corporation is analyzing results from the phase II trial of AutoImmune's MBP8298 product for the treatment of chronic progressive multiple sclerosis.

BRANDS/DIVISIONS/AFFILIATES: Colloral Colloral, LLC Deseret Laboratories International Copaxone MBP8298

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert C. Bishop, CEO Robert C. Bishop, Pres. Heather A. Ellerkamp , Dir.-Finance Heather A. Ellerkamp , Treas. Robert C. Bishop, Chmn.

Phone: 626-792-1235 Fax: 626-792-1236 Toll- Free: Address: 1199 Madia St., Pasadena , CA 91103 US

FINANCIALS:

Sales and profits are in thousands of dollars —add 000 to get the full amount . Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 300 ( 9 months) 2002 Profits: $- 638 ( 9 months) Stock Ticker: AIMM 2001 Sales: $1,300 2001 Profits: $ 800 Employees: 2000 Sales: $4,010 2000 Profits: $3,148 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-10,700 1998 Sales: $ 1998 Profits: $-13,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $113,245 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $45,683 Bonus: $ ADVANTAGE: Innovative therapeutics for the treatment of autoimmune and other cell-mediated diseases.

OTHER THOUGHTS:


Apparent Women Officers or Directors : 1 Hot Spot for Advancement for Women/Minorities :

West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



AVANIR PHARMACEUTICALS

www.avanir.com


Y



Y

TYPES OF BUSINESS:

Profits: 59




Drugs-Oral Herpes Human Antibody Technology Research Central Nervous System Research Allergy and Asthma Drugs

Avanir Pharmaceuticals is engaged in research, development, commercialization, licensing and sales of innovative drug products and antibody generation services. Avanir’s subsidiary, Xenerex Biosciences, is engaged in research collaborations with partner companies for developing and commercializing completely human antibody products to target antigens. The company’s lead product, Abreva cream, is a topical treatment for oral-facial herpes (more commonly known as cold sores or fever blisters). Abreva’s performance claims were approved by the FDA, making the drug the first overthe-counter product for cold sore treatment with such approval. GlaxoSmithKline is the marketing partner for the Abreva product in the U.S. and Canada. Beyond cold sore medications, Avanir develops asthma and allergy pharmaceuticals. Using a combination of tissue culture, in vitro assays and in vivo models, the firm has screened and identified several active candidate compounds that appear to be significantly selective and specific in their inhibition of human responses to allergens. Avanir has filed several patent applications for its candidate compounds. Avanir also conducts central nervous system research and human antibody technology development. Neurodex, a medication for the treatment of emotional lability in neurodegenerative diseases, neuropathic pain and chronic cough is currently under trial. Cholesterol-lowering and inflammation drugs and work on genital herpes medications are in development as well. Avanir has agreements with several companies for the promotion of Docosanol 10% cream and Neurodex, including Biopharm Group, CTS Chemical Industries, Ltd., Medison Pharma, Ltd. and Shanghai New Asiatic Pharmaceutical Co., Ltd. In recent news, Xenerex Biosciences was awarded funding from the Center for Commercialization of Advanced Technology (CCAT) to develop a treatment that will reduce the damaging effects of exposure to anthrax toxins. Avanir offers a competitive benefits package, including medical, dental and vision insurance.

BRANDS/DIVISIONS/AFFILIATES: Xenerex Biosciences Abreva Dososanal Neurodex

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gerald J. Yakatan, CEO Gerald J. Yakatan, Pres. Gregory P. Hansen, VP/CFO James E. Berg, VP-Clinical and Regulatory Affairs Gregory P. Hansen, Corp. Sec. J. David Hansen, Pres./COO, Xenerex Biosciences J. David Hansen, VP-Commercial Dev.

Phone: 858-622-5200 Fax: 858-658-7447 Toll-Free: Address: 11388 Sorrento Valley Rd., Ste. 200, San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $7,600 ( 9 months) 2002 Profits: $-5,800 ( 9 months) Stock Ticker: AVN 2001 Sales: $12,700 2001 Profits: $ 200 Employees: 44 2000 Sales: $10,687 2000 Profits: $- 582 Fiscal Year Ends: 9/30 1999 Sales: $ 100 1999 Profits: $-8,600 1998 Sales: $ 600 1998 Profits: $-8,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $388,462 Stock Purch. Plan: Second Exec. Salary: $213,462 ADVANTAGE: Novel therapeutic products to treat chronic illness.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:




Northeast:

International:



AVANT IMMUNOTHERAPEUTICS

www.avantimmune.com

Industry Group Code: 325412 Ranks w ithin this company's industry group: Sales: 159 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Profits: 163


TYPES OF BUSINESS:



Drugs-Cardiovascular, Pulmonary and Autoimmune Disorder

AVANT Immunotherapeutics, Inc., is a biopharmaceutical company that uses novel applications of immunology to prevent and treat illnesses caused by autoimmune diseases, cardiovascular diseases, cancer, inflammation, infectious diseases and organ transplant rejection. AVANT was created from the merger of T Cell Sciences and Virus Research Institute. Using its expertise in immunology, AVANT is building business franchises in three major disease areas: travelers' vaccines, cholesterol management and anti-viral vaccines. Each of AVANT's products addresses large market opportunities for which current therapies are inadequate or non-existent. The company’s products derive from a broad set of technologies with the ability to inhibit the complement system, regulate T and B cell activity and enable the creation and delivery of preventative and therapeutic vaccines. AVANT is using these technologies to develop vaccines and immunotherapeutics that prevent or treat disease caused by infectious organisms, as well as drugs and treatment vaccines that modify undesirable activity by the body's own proteins or cells. All of the firm’s products are in various stages of research and development. Recently, AVANT agreed to acquire the technology and intellectual property portfolio of Universal Preservation Technologies, Inc. (UPT). Through this acquisition, AVANT will gain exclusive rights to UPT's VitriLife process for use in its oral vaccines and certain other non-injectable applications. In other news, DynPort Vaccine Company, a partner of AVANT, initiated a phase I clinical trial of an injectable recombinant anthrax vaccine.

BRANDS/DIVISIONS/AFFILIATES: T Cell Sciences Virus Research Institute Universal Preservation Technologies, Inc. VitriLife

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Una S. Ryan, CEO Una S. Ryan, Pres. Avery W. Catlin, Sr. VP/CFO Henry C. Marsh, VP-Research Alistair W.E. Wheeler, VP-Medical Affairs J. Barrie Ward, Chmn.

Phone: 781-433-0771 Fax: 781-433-0262 Toll-Free: Address: 119 4th Ave., Needham , MA 02494 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $5,900 ( 9 months) 2002 Profits: $-10,400 ( 9 months) Stock Ticker: AVAN 2001 Sales: $3,300 2001 Profits: $-22,800 Employees: 71 2000 Sales: $ 763 2000 Profits: $-21,975 Fiscal Year Ends: 12/31 1999 Sales: $1,500 1999 Profits: $-11,300 1998 Sales: $2,200 1998 Profits: $-51,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $315,000 Stock Purch. Plan: Second Exec. Salary: $208,586 ADVANTAGE: Several significant therapies under development.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $37,800 Bonus: $17,285

Northeast: Y

International:



AVAX TECHNOLOGIES INC

www.avax-tech.com


Y



Profits: 138


TYPES OF BUSINESS:



Drugs-Cancer Melanoma Treatment

AVAX Technologies, Inc. is a development-stage biopharmaceutical company engaged in the development and commercialization of products and technologies for the treatment of cancer and other life-threatening diseases. AVAX recently initiated its own research to supplement that being done through research agreements with several universities. The company is primarily focusing its efforts on the development of immunotherapies for the treatment of cancer. The firm places the majority of its focus on its autologous cell vaccines, called AC Vaccines, which have been developed with the help of Thomas Jefferson University. The vaccines use a patient’s own cancer cells and are designed to stimulate the patient's immune system to recognize, contain and eliminate malignant cells. The company's leading AC Vaccine is M-Vax, which is designed as an immunotherapy for the post-surgical treatment of stage-three melanoma. AVAX believes that M-Vax is the first immunotherapy to show a substantial increase in the survival rate for patients with this type of melanoma. In Phase II clinical trials, over 400 melanoma patients were treated post-surgically on an outpatient basis with M-Vax. Another vaccine, O-Vax, is currently in clinical trials for the treatment of individuals with ovarian cancer. AVAX plans to utilize the technology used to develop M-Vax and O-Vax for the treatment of other cancers, including breast, kidney and lung cancer. In recent news, AVAX signed a distribution agreement with Ferrer Internacional, S.A. for the sales and distribution of the AC Vaccine technology in European, Latin American and Asian territories. AVAX also reached a production agreement with MediGene AG for the processing of clinical samples of MediGene’s vaccine for the treatment of malignant melanoma.

BRANDS/DIVISIONS/AFFILIATES: AC Vaccine M-Vax O-Vax

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard P. Rainey, Acting Pres. Richard P. Rainey, VP-Finance Lorne F. Erdile, Dir.-Research Richard P. Rainey, VP-Admin.

Phone: 913-693-8491 Fax: 913-693-8497 Toll-Free: Address: 9200 Indian Creek Pkwy., Ste. 200, Overland Park, KS 66210 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 500 ( 9 months) 2002 Profits: $-6,700 ( 9 months) Stock Ticker: AVXT 2001 Sales: $ 500 2001 Profits: $-15,100 Employees: 43 2000 Sales: $ 112 2000 Profits: $-16,277 Fiscal Year Ends: 12/31 1999 Sales: $1,500 1999 Profits: $-7,868 1998 Sales: $ 100 1998 Profits: $-5,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $253,750 Stock Purch. Plan: Second Exec. Salary: $216,666 ADVANTAGE: Innovative immunotherapy for the post-surgical treatment of melanoma.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $91,000 Bonus: $60,000

Northeast:

International: Y



AVENTIS SA

www.aventis.com


Y



Y

TYPES OF BUSINESS:

Profits: 10




Drugs-Diversified Pharmaceutical Manufacturing Drug Research and Development Animal Health Vaccines and Proteins Skin Care Treatment

Aventis is a global leader in the pharmaceutical industry. The company offers a wide assortment of patented prescription drugs to treat patients with serious diseases through its many subsidiaries, including Aventis Pharma, which accounts for about 85% of revenues. Aventis has leading positions in several therapeutic areas, such as cardiology, oncology, diabetes and respiratory. The firm is also involved in animal health and nutrition through Merial, its joint venture with Merck & Co., Inc.; human vaccines developm ent and research through Aventis Pasteur; and therapeutic proteins through Aventis Behring. Other subsidiaries of the firm include Aventis Pharmaceuticals, Inc., the U.S. branch of Aventis; and Dermick Laboratories, Inc., which makes treatments for skin problems, such as dermatitis, acne and rosacea. Aventis concentrates its marketing efforts on its strategic prescription drug brands, such as Allegra/Telfast, a drug that treats seasonal allergies; Lovenox/Clexane, which treats deep vein thrombosis (DVT) and heart attacks; and Taxotere, a leading drug for the treatment of breast cancer. The firm focuses on advertising to the word’s largest markets, such as the U.S., France, Germany and Japan, through its sales force of over 19,000 people. The U.S. accounts for the majority of sales of Aventis’ strategic brands. In addition, Aventis is continually developing therapeutic innovations, including compounds for the treatment of diabetes, cancer, cardiovascular diseases and respiratory problems. Other research and development efforts include progress in AIDS vaccines, Alzheimer’s treatments and Parkinson’s care. In recent news, Aventis is shifting its focus to purely pharmaceutical businesses, with the divesture of the Aventis CropScience and Aventis Animal Nutrition subsidiaries.

BRANDS/DIVISIONS/AFFILIATES: Aventis Pharma Allegra/Telfast Lovenox/Clexane Merial Aventis Pasteur Aventis Behring Taxotere Dermick Laboratories, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Igor Landau, Chair-Managing Board Patrick Langlois, Exec. VP/CFO Rene Penisson, Group Exec. VP.-Human Resources Dirk Oldenburg, General Counsel/Exec. VP Thierry Soursac , Exec. VP-Commercial Oper. Frank L. Douglas, Exec. VP-Drug Innovation and Approval Arvind K. Sood, Head-Investor Rel. Richard J. Markman, CEO, Aventis Pharma David J. Williams , Pres./CEO, Aventis Pasteur Heinz-Werner Meier, Exec. VP-Human Resources Robert J. Bitterman, Pres., Dermick Laboratories, Inc.

Phone: +33-3-88-99-1100 Fax: +33-3-88-99-1101 Toll-Free: Address: 1, Avenue de l'Europe, Schiltingheim , F-67300 France

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $13,629,000 ( 9 months) 2002 Profits: $2,057,000 ( 9 months) Stock Ticker: AVE 2001 Sales: $20,447,000 2001 Profits: $1,455,000 Employees: 91,729 2000 Sales: $21,006,000 2000 Profits: $-27,000 Fiscal Year Ends: 12/31 1999 Sales: $12,714,000 1999 Profits: $-859,000 1998 Sales: $15,501,900 1998 Profits: $921,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: One of the world's largest pharmaceutical firms.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Bonus: $ Bonus: $

Southeast: Y



Northeast: Y

International: Y



AVI BIOPHARMA INC

www.antivirals.com


Y Y



Profits: 175


TYPES OF BUSINESS:



Drugs-Cancer and Cardiovascular Disease Cancer Immunotherapy Gene Targeted Drugs Drug Delivery Systems

AVI BioPharma, Inc. (formerly Antivirals, Inc.) is a biopharmaceutical company that develops therapeutic products using two distinct platform technologies: cancer immunotherapy and gene-targeted drugs (NeuGene). The company’s focus is on the treatment of life-threatening diseases, with applications in cardiovascular disease, colorectal cancer, pancreatic cancer, polycystic kidney disease, and drug metabolism. The cancer immunology sector is currently developing Avicine and Xactin for the treatment of cancer. Avicine has completed three Phase II trials for colorectal and pancreatic cancer. The NeuGene antisense products include Resten-NG for the treatment of cardiovascular restenosis, Oncomyc-NG for the treatment of cancer and NeuBiotics for the treatment of infectious disease. AVI Biopharma has many collaborative research programs with universities around the world. The company is currently involved in a strategic alliance with SuperGen, Inc. for the shared development and marketing of Avicine. AVI BioPharma and Abgenix, Inc. have an alliance for the development of human monoclonal antibodies for cancer. The company also has a research alliance with XTL Pharmaceuticals for pre-clinical development of hepatitis B and C antisense drugs. Recently, AVI BioPharma announced the initiation of two human clinical trials that will evaluate its AVI-4557 drug in modifying the function of a liver enzyme critical to the metabolism of many drugs.

BRANDS/DIVISIONS/AFFILIATES: Avicine Xactin Resten-NG Oncomyc-NG AVI-4557 XTL Pharmaceuticals Abgenix, Inc. Antivirals, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Denis R. Burger, CEO Alan P. Timmins, COO Alan P. Timmins, Pres. Mark M. Webber, CFO Patrick L. Iversen, Sr. VP-Research and Dev. Mark M. Webber, CIO Dwight D. Weller, Sr. VP-Mfg. and Chemistry David Mason, VP-Regulatory Affairs and Clinical Dev. Denis R. Burger, Chmn.

Phone: 503-227-0554 Fax: 503-227-0751 Toll-Free: Address: One SW Columbia, Ste. 1105, Portland, OR 97258 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 600 ( 9 months) 2002 Profits: $-25,400 ( 9 months) Stock Ticker: AVII 2001 Sales: $ 700 2001 Profits: $-26,900 Employees: 85 2000 Sales: $1,297 2000 Profits: $-9,240 Fiscal Year Ends: 12/31 1999 Sales: $ 17 1999 Profits: $-8,278 1998 Sales: $ 120 1998 Profits: $-26,734


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $280,000 Stock Purch. Plan: Second Exec. Salary: $230,400 ADVANTAGE: Strategic partnerships/Significant research successes.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $100,000 Bonus: $75,000

Northeast:

International:



AVIGEN INC

www.avigen.com


Y



Profits: 126


TYPES OF BUSINESS:



Drugs-Hemophilia Gene Therapy Products Gene Delivery Technology

Avigen is focused on the development of gene therapy products for the treatment of disease. The firm has developed a proprietary technology based on adenoassociated virus vectors, known as AAV Vectors. This technology is designed to deliver DNA into the cells of patients in order to produce therapeutic results as an alternative to existing pharmaceutical and surgical treatments. Rather than treating the symptoms of a disease, the company's gene-based products target the root cause at the fundamental cellular level, holding great promise for treating a variety of disease that are not adequately addressed by current medical science. AAV vectors can be used to deliver genes that promote therapeutic responses in patients suffering from illnesses including hemophilia, metabolic diseases and non-genetic diseases such as Parkinson's disease, congestive heart failure, anemia and cancer. All of Avigen's products in development are based on this technology, which is designed to take advantage of the natural efficiency with which viruses deliver genes to cells, without the safety concerns that arise from disease-related viruses. The therapies are safe, efficient, stable and effective. Avigen owns, co-owns or holds licenses to 25 issued U.S. patents and 34 pending patent applications. In recent news, the firm announced a collaboration with Sangamo Biosciences to evaluate potential therapies for chronic pain, based on Sangamo's zinc finger DNA binding protein transcription factors and Avigen's gene delivery system. Avigen employees receive health care, eye care and disability benefits, as well as generous stock options. More than a third of its workers hold advanced degrees.

BRANDS/DIVISIONS/AFFILIATES: AAV Vectors

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John Monohan, CEO Kenneth G. Chahine, COO John Monohan, Pres. Thomas J. Paulson, VP-Finance/CFO Alan McClelland, VP- Research and Dev. Frederick Johnson, VP-Oper. Kenneth G. Chahine, VP-Bus. Dev. Kenneth G. Chahine, VP-Intellectual Property Elliot G. Grossbard, VP-Clinical Affairs Janice Castillo, VP-Regulatory Affairs

Phone: 510-748-7150 Fax: 510-748-7155 Toll-Free: Address: 1301 Harbor Bay Pkwy., Alameda, CA 94502 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 29 ( 9 months) 2002 Profits: $-21,221 ( 9 months) Stock Ticker: AVGN 2001 Sales: $1,000 2001 Profits: $-11,300 Employees: 143 2000 Sales: $ 58 2000 Profits: $-15,000 Fiscal Year Ends: 6/30 1999 Sales: $ 185 1999 Profits: $-9,600 1998 Sales: $ 1998 Profits: $-8,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $315,000 Stock Purch. Plan: Second Exec. Salary: $220,080 ADVANTAGE: Unique biotech strategy/Proprietary gene delivery technology/25 patents.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $200,000 Bonus: $100,000

Northeast:

International:



AXONYX INC

www.axonyx.com


Y




TYPES OF BUSINESS:



Drugs-Central Nervous System Degeneration

Axonyx, Inc. is a biopharmaceutical company engaged in the discovery, acquisition and development of proprietary pharmaceutical compounds and new technologies useful for the diagnosis and treatment of Alzheimer’s Disease and other memory disorders. The company has a comprehensive portfolio of five technologies focused solely on the central nervous system. The firm is preparing a Phase III clinical trial for Phenserine, its lead drug candidate for the treatment of Alzheimer’s Disease. Tolserine and Phenethylnorcymserine are also being developed to treat Alzheimer’s Disease. Axonyx has signed a license agreement with Applied Research Systems, a subsidiary of Serono International, under which it granted exclusive sublicense to its patent rights regarding the Amyloid Inhibitory Peptide and the Prion Inhibitory Peptide technology. The company also has a research agreement with Thomas Jefferson University, under which Axonyx agreed to fund a gilatide research program. Gilatide, a potential pharmaceutical peptide, is designed to enhance memory and cognition. Recently, Axonyx extended its agreement with the U.S. Army Medical Research Institute of Chemical Defense. The U.S. Army will continue to study Axonyx’s AchE and BchE compounds for testing against chemical warfare agents. Axonyx also entered into a three-year consulting and research agreement with the Laboratory of Molecular Neurobiology at the University of Melbourne.

BRANDS/DIVISIONS/AFFILIATES: Phenserine Tolserine Phenethylnorcymserine Prion Inhibitory Peptide Amyloid Inhibitory Peptide

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Marvin S. Hausman, CEO Gosse B. Bruinsma, COO Marvin S. Hausman, Pres. Michael R. Espey, Corp. Sec. Michael R. Espey, General Counsel Gosse B. Bruinsma, Treas. Robert G. Burford, VP-Product Dev. Gosse B. Bruinsma, Pres.-Axonyx Europe Albert D. Angel, Chmn.

Phone: 212-688-4770 Fax: 212-688-4843 Toll-Free: Address: 825 Third Ave., 40th Fl., New York, NY 10022 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-5,000 ( months) Stock Ticker: AXYX 2001 Sales: $ 2001 Profits: $-8,144 Employees: 7 2000 Sales: $1,605 2000 Profits: $-4,870 Fiscal Year Ends: 12/31 1999 Sales: $ 146 1999 Profits: $-5,000 1998 Sales: $ 1998 Profits: $- 700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $225,000 Stock Purch. Plan: Y Second Exec. Salary: $175,000 ADVANTAGE: Focus on neurological disorders such as Alzheimer's.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



BARR LABORATORIES INC

www.barrlabs.com


Y



Profits: 30


TYPES OF BUSINESS:



Drugs-Breast Cancer Pharmaceuticals

Barr Laboratories, Inc. is an established pharmaceutical company engaged in the development, manufacture and marketing of generic and proprietary prescription pharmaceuticals. The company currently markets more than 80 generic and five proprietary products, representing various dosage strengths and product forms of 32 chemical entities. The firm’s product line is concentrated primarily on six core therapeutic categories: oncology, female healthcare, cardiovascular, anti-infectives, pain management and psychotherapeutics. Barr’s business strategy has three core components, including the development and marketing of generic pharmaceuticals that have one or more barriers to entry, developing the generic version and then challenging patents protecting select brand pharmaceuticals where the company believes that such patents are either invalid, unenforceable or not infringed by the company's product. The third business focus is centered on the development and introduction of proprietary pharmaceuticals. The company's largest selling product, Tamoxifen Citrate (Tamoxifen), the generic equivalent of Nolvadex, is used to treat advanced breast cancer, as well as impede the recurrence of tumors following surgery. Recently, Barr completed a merger with Duramed Pharmaceuticals, Inc. which will operate under the Barr Laboratories name. In addition, the company has received F.D.A. approval for many of its generic medicines which include: Flutamide capsules, a generic form of Eulexin that treats metastatic carcinoma of the prostrate; Fluoxetine Hydrochloride, a generic form of Eli Lilly's Prozac, an anti-depressant; Norethindrone Acetate, the generic equivalent to Aygestin which is utilized in women's healthcare; Nortel which substitutes Ortho-McNeil's Modicon and Ortho-Novum tablets; and Trexal, an antimetabolite used to treat certain neoplastic diseases. Barr has also challenged Aventis' Allegra patent in the hopes that it may market its generic Fexofenadine HCL version.

BRANDS/DIVISIONS/AFFILIATES: Tamoxifen Meperidine Fexofenadine HCL Trexal Nortel Norethindrone Acetate Fluoxetine Hydrochloride Flutamide

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bruce L. Downey , CEO Paul M. Bisaro, COO Paul M. Bisaro, Pres. William T. McKee, VP/CFO Timothy P. Catlett, VP-Sales and Mktg. Catherine F. Higgins, VP-Human Resources Salah Ahmed, VP-Research and Dev. Suzanne Donaghy, VP/CIO Ann S. Boyle, VP/Controller Michael J. Bogda, VP- Engineering Michael J. Bogda, VP-Mfg. William T. McKee, Corp. Sec. Martin Zeiger, General Counsel Mary E. Petit, Sr. VP-Operations Martin Zeiger, Sr. VP- Strategic Bus. Dev. Jake Hansen, VP-Govt. Affairs William T. McKee, Treas. Carole S. Ben-Maimon, Pres./COO-Barr Research, Inc. Christine Mundkur, VP-Quality and Regulatory Counsel Robert G. Bell, VP- Proprietary Product Dev.

Phone: 845-362-1100 Fax: 845-362-2774 Toll-Free: 800-227-7522 Address: 2 Quaker Rd., Pomona, NY 10970-0519 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,189,000 (12 months) 2002 Profits: $212,200 (12 months) Stock Ticker: BRL 2001 Sales: $509,700 2001 Profits: $62,500 Employees: 685 2000 Sales: $482,278 2000 Profits: $42,342 Fiscal Year Ends: 6/30 1999 Sales: $444,033 1999 Profits: $49,250 1998 Sales: $377,304 1998 Profits: $32,720


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Aggressive generic drug strategy.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $400,000 Bonus: $200,000

Northeast: Y

International:



BAUSCH & LOMB INC

www.bausch.com


Y



Y

TYPES OF BUSINESS:

Profits: 9




Supplies-Eye Care Generic and Prescription Pharmaceuticals Vision Care Surgical Products

Bausch and Lomb Inc. is a world leader in the development, manufacture and marketing of health care products for the eye. Bausch and Lomb operates in three segments: vision care, pharmaceuticals and surgical products. The company’s vision care division includes contact lenses, lens care products and the vision accessories business. Vision care products are marketed to licensed eye care professionals, health products retailers, independent pharmacies, drug stores, food stores and mass merchandisers by the company's sales force and distributors. The pharmaceutical division manufactures and sells generic and proprietary prescription pharmaceuticals with a strategic emphasis in the ophthalmic field and over-the-counter ophthalmic medications. Finally, the surgical sector manufactures and sells products and equipment for cataract, refractive and retinal surgery. Some of Bausch and Lomb’s significant consumer and eye care professional recognition products include ReNu, ReNu MultiPlus, Sensitive Eyes, Medalist, Boston, Optima FW, SofLens, PureVision and Opcon. Bausch and Lomb sold its Charles River Laboratories, its sunglass division (including the Ray Ban brand) and the Miracle-Ear hearing aid business. In an effort to increase its international business, the company acquired Woehlk Contact Lens GmbH, a seller of soft and rigid gas permeable contact lenses and distributor of contact lens solutions. Bausch and Lomb recently bought French eye medicine company Groupe Chauvin in a bid to become a top European eye care company. The firm also announced plans to develop the Envision TD drug delivery system, a tiny implant that will continually release therapeutic levels of medicine directly inside the eye for up to three years. The system is currently undergoing clinical trials for the treatment of posterior uveitis and diabetic macular edema in the U.S., Europe and Japan. Bausch and Lomb offers employment around the world, with positions ranging from customer service to research and development. It offers comprehensive benefits.

BRANDS/DIVISIONS/AFFILIATES: Arnette Optic Illusions, Inc. Orbtek Woehlk Contact Lens GmbH ReNu Polymer Technology Corp. Bausch & Lomb Vision Care Groupe Chauvin Envision TD

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ronald L. Zarrella, CEO C. E. Sassano, COO C. E. Sassano, Pres. Stephen C. McCluski, CFO Ian J. Watkins, VP-Human Resources Gary M. Aron, Sr. VP-Research and Dev. Marie L. Smith, CIO Jurij Z. Kushner, Controller Gary M. Aron, Sr. VP-Eng. Jean F. Geisel, Sec. Robert B. Stiles, General Counsel Angela J. Panzarella, VP-Strategy Barbara M. Kelley, VP-Corp. Comm. Barbara M. Kelley, VP-Investor Rel. Alan H. Resnick, VP-Treas. Alan H. Farnsworth, Sr. VP/Pres., Europe, Middle East and Africa Geoffrey F. Idle, VP/Pres., Bausch and Lomb, Japan

Phone: 585-338-6000 Fax: 585-338-6007 Toll-Free: 800-344-8815 Address: 1 Bausch & Lomb Pl., Rochester, NY 14604-2701 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,339,300 ( 9 months) 2002 Profits: $40,000 ( 9 months) Stock Ticker: BOL 2001 Sales: $1,711,900 2001 Profits: $21,500 Employees: 11,600 2000 Sales: $1,772,400 2000 Profits: $83,400 Fiscal Year Ends: 12/31 1999 Sales: $1,764,300 1999 Profits: $444,800 1998 Sales: $1,604,500 1998 Profits: $25,200


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $790,865 Stock Purch. Plan: Second Exec. Salary: $376,800 ADVANTAGE: Strategic positioning in eye care products/Increasing international market share.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $ Bonus: $

Northeast: Y

International: Y



BAXTER INTERNATIONAL INC

www.baxter.com



Y


Y

TYPES OF BUSINESS:

Profits: 1




Supplies-Intravenous and Renal Dialysis Systems Tissue Heart Valves Valve-Repair Products Cardiac-Monitoring Products Kidney Failure Products Intravenous Products Biotech Investments and Products

Baxter International, Inc. develops, manufactures and distributes its products in 28 countries and sells them in over 100 countries. The company operates in three segments: medication delivery, which provides a range of intravenous solutions and specialty products that are used in combination for fluid replenishment, nutrition therapy, pain management, antibiotic therapy and chemotherapy; BioScience, which develops biopharmaceuticals, biosurgery products, vaccines and blood collection, processing and storage products and technologies; and renal, which develops products and provides services to treat end-stage kidney disease. The medication delivery segment recently grew with the acquisition of ASTA Medica Oncology, a German-based manufacturer of chemotherapy drugs. The BioScience division is known as a leading producer of both plasma-based and recombinant clotting factors for hemophilia, as well as biopharmaceuticals used to treat immune deficiencies, cancer and other disorders. It recently received European licensure for Ceprotin, a new protein C concentrate used to treat congenital protein C deficiency. Baxter has been growing its presence in renal care by addressing the needs of kidney-disease patients from initial diagnosis through dialysis and organ replacement. It recently acquired the assets and exclusive rights to a proprietary recombinant drug for the treatment of anemia. In addition, Baxter purchased Fusion Medical Technologies, Inc., a company that develops and commercializes proprietary products used to control bleeding during surgery. Of the company's officials and managers, 13.6% are minorities, and 24.2% of the employees in the entire work force are minorities. In recent years, 30% of the participants in the company's financial development program have been minorities. The company offers employees a relaxed work environment with business casual dress.

BRANDS/DIVISIONS/AFFILIATES: Immuno International AG Research Medical, Inc. Baxter World Trade Corporation Baxter Healthcare Corporation Cook Pharmaceutical Solutions ASTA Medica Oncology Ceprotin Fusion Medical Technologies, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Harry M. Jansen Kraemer, Jr., CEO Brian P. Anderson, CFO Karen J. May, Corp. VP-Human Resources Norbert G. Riedel, Chief Scientific Officer J. Michael Gatling, Corp. VP-Global Mfg. Oper. Jan Stern Reed, Corp. Sec. Thomas J. Sabatino, Jr., General Counsel Timothy B. Anderson, Sr. VP-Corp. Strategy & Dev. Neville J. Jeharajah, Corp. VP-Investor Rel. Steven J. Meyer, Treas. Eric A. Beard, Pres., Europe Carlos del Salto, Sr. VP-Intercontinental/Pres., Latin America David F. Drohan, Pres., Medication Delivery Thomas H. Glanzmann, Pres., BioScience

Phone: 847-948-2000 Fax: 847-948-3948 Toll-Free: 800-422-9837 Address: 1 Baxter Pkwy., Deerfield, IL 60015-4633 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $6,074,000 ( 9 months) 2002 Profits: $769,000 ( 9 months) Stock Ticker: BAX 2001 Sales: $7,663,000 2001 Profits: $612,000 Employees: 48,000 2000 Sales: $6,896,000 2000 Profits: $740,000 Fiscal Year Ends: 12/31 1999 Sales: $6,380,000 1999 Profits: $797,000 1998 Sales: $5,706,000 1998 Profits: $315,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $880,000 Stock Purch. Plan: Y Second Exec. Salary: $600,000 ADVANTAGE: A leader in manufacturing heart valves/Worldwide marketing.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $528,000 Bonus: $252,000

Northeast: Y

International: Y



BENTLEY PHARMACEUTICALS INC www.bentleypharm.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 84 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y Y



Profits: 51


TYPES OF BUSINESS:



Drugs-Diversified Drug Delivery Technologies

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. The company has U.S. and international patent and other proprietary rights to technologies that enhance or facilitate the absorption of drugs across membranes of the skin, mouth, nose, vagina and eye. Bentley is developing products incorporating these technologies and seeks to form alliances with major biotechnology companies to facilitate the development and commercialization of its products. Currently, the company has strategic alliances with Pfizer, Inc., Auxilium A2, Inc. and Teva Pharmaceutical Industries. The firm has a significant commercial presence in Spain, where it manufactures and markets more than 100 pharmaceutical products. The company's product line consists of generic and branded products within four primary areas: cardiovascular, gastrointestinal, infectious and neurological diseases. Bentley's CPE-215 technology enhances the absorption of drugs across skin membranes and can be incorporated into a variety of formats and products, including creams, ointments, gels, solutions, lotions, sprays or patches. The technology has a record of safety in humans as a food additive and fragrance. Bentley has a number of products in various stages of development, including a topical testosterone gel for the treatment of hypogonadism; an improved acetaminophen for pain relief; an antifungal nail lacquer; an androgenic steroid therapy for chronic fatigue syndrome; and intranasal insulin for diabetes. The company's branded products include Belmazol, sold by others as Prilosec; Senioral, sold by others as Denoral; and Enalapril Belmac, sold by others as Vasotec. In recent news, the firm received approval to market Paroxetine, the generic equivalent of Paxil, in Spain. Bentley also recently extended its research and development relationship with Pfizer, giving Pfizer access to the company's drug delivery platform.

BRANDS/DIVISIONS/AFFILIATES: Belmac Corp. Laboratorios Belmac Laboratorios Davur Belmazol Mio Relax Enalapril Belmac Senioral Codeisan

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James R. Murphy, CEO James R. Murphy, Pres. Michael D. Price, VP/CFO Robert M. Stote, Sr. VP/Chief Science Officer Robert J. Gyurik, VP-Pharmaceutical Dev. Michael D. Price, Corp. Sec. Jordan A. Hovrath, VP/General Counsel Michael D. Price, Treas. James R. Murphy, Chmn.

Phone: 603-964-8006 Fax: 603-964-6889 Toll-Free: Address: 65 Lafayette Rd., 3rd Fl., North Hampton, NH 038622403 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $28,200 ( 9 months) 2002 Profits: $ 945 ( 9 months) Stock Ticker: BNT 2001 Sales: $26,400 2001 Profits: $1,400 Employees: 265 2000 Sales: $18,617 2000 Profits: $- 745 Fiscal Year Ends: 12/31 1999 Sales: $20,200 1999 Profits: $-1,100 1998 Sales: $15,200 1998 Profits: $-2,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Has a large international market.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:




Northeast: Y

International: Y



BIGMAR INC

www.bgmr.com


Y




TYPES OF BUSINESS:



Drugs-Infusion Solutions Generic Drugs

Bigmar, Inc. manufactures generic pharmaceutical oncology products and intravenous infusion solutions through its Swiss subsidiaries and markets these products in Europe, the United States and other countries, primarily through pharmaceutical distributors. Currently, the company has distribution rights for more than 20 generic oncology products. Bioren, one of Bigmar’s three subsidiaries, is engaged in manufacturing and marketing various pharmaceutical products in Switzerland. Its products include 22 types of intravenous infusion solutions (IV Solutions) and other related products. Bioren's strategy is to expand its IV Solutions product line and its market penetration. Bigmar Pharmaceuticals, another subsidiary, manufactures and markets oncology products, such as calcium leucovorin, methotrexate and cisplatin. These products are marketed in the United States, Italy, Germany, Switzerland, Brazil, Greece and Spain. Recently, Bioren and PLM Langeskov entered into an agreement that grants Bioren the exclusive rights to distribute its IV Solutions throughout Switzerland and Liechtenstein in PLM's collapsible containers.

BRANDS/DIVISIONS/AFFILIATES: Bioren Bigmar Therapeutics Bigmar Pharmaceuticals IV Solutions

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John G. Tramontana, CEO Bernard Kramer, COO Cynthia R. May, Pres. Phillippe J.H. Rohrer, CFO Massimo Pedrani, Exec. VP-Research and Dev. Cynthia R. May, Corp. Sec. Phillippe J.H. Rohrer, Treas. John G. Tramontana, Chmn.

Phone: 740-966-5800 Fax: 740-966-5801 Toll-Free: Address: 9711 Sportsman Club Rd., Johnstown, OH 43031-9141 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: BGMR.PK 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $7,651 2000 Profits: $-4,900 Fiscal Year Ends: 12/31 1999 Sales: $7,700 1999 Profits: $-6,300 1998 Sales: $6,400 1998 Profits: $-7,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Focus on generic products/International marketing.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



BIO RAD LABORATORIES INC

www.bio-rad.com




Y Y Y

TYPES OF BUSINESS:

Profits: 3




Equipment-Life Sciences Research Clinical Diagnostics Analytical Instruments Proprietary Equipment Sales and Service Laboratory Services

Bio-Rad Laboratories manufactures and supplies the life science research, health care, analytical chemistry and other markets with a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates in two industry segments: life science and clinical diagnostics. The life science segment focuses on specific segments of the life science market, including laboratory devices, biomaterials, imaging products and microscopy systems. Bio-Rad primarily uses electrophoresis, image analysis and microplate readers, chromatography, gene transfer and sample preparation and amplification as its primary technological applications . Bio-Rad supplies its services to universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers and biotechnology researchers. Its clinical diagnostics industry encompasses a broad array of technologies incorporated into a variety of tests used to detect, identify and quantify substances in blood or other bodily fluids and tissues. The test results are used as aids for medical diagnosis, detection, evaluation, monitoring and treatment of diseases and other medical conditions. Bio-Rad recently acquired Quantase, Ltd. of Perth, Scotland, a company specializing in newborn screening diagnostic products. It also announced a distribution agreement with Immucor which will transfer all of Immucor’s commercial activities in France to Bio-Rad. Bio-Rad stresses the overall organization of its employees into small entrepreneurial teams in order to spur innovation. The firm offers its employees tuition reimbursement and dental and vision insurance.

BRANDS/DIVISIONS/AFFILIATES: Chiron Diagnostics Corp. Pasteur Sanofi Diagnostics Bio-Metrics Properties, Ltd. Blood Virus Diagnostics, Inc. Polaron Instruments Quantase, Ltd.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David Schwartz , CEO James J. Bennett, COO David Schwartz , Pres. Richard Anderson, VP-Human Resources James R. Stark, Controller Sanford S. Wadler, Sec. Sanford S. Wadler, General Counsel Ronald Hutton, Treas. Norman Schwartz, VP/Group Mgr. John Goetz, VP/Group Mgr.

Phone: 510-724-7000 Fax: 510-741-5817 Toll-Free: 800-224-6723 Address: 1000 Alfred Nobel Dr., Hercules , CA 94547 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $424,842 ( 6 months) 2002 Profits: $35,005 ( 6 months) Stock Ticker: BIO 2001 Sales: $817,500 2001 Profits: $44,200 Employees: 4,300 2000 Sales: $725,884 2000 Profits: $31,100 Fiscal Year Ends: 12/31 1999 Sales: $555,399 1999 Profits: $11,721 1998 Sales: $447,863 1998 Profits: $24,302


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: Y ADVANTAGE: Diverse group of customers.

OTHER THOUGHTS:




West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $271,882 Bonus: $266,482

Northeast: Y

International: Y



BIO TECHNOLOGY GENERAL CORP

www.btgc.com


Y



Profits: 184


TYPES OF BUSINESS:



Drugs-Weight Loss Endocrine and Metabolic Disorders Products Cardio/Pulmonary Diseases Products Ophthalmic and Skin Disorders Products

Bio Technology General (BTG) is engaged in the research, development, manufacture and marketing of biopharmaceutical products. Through a com bination of internal research and development, acquisitions, collaborative relationships and licensing arrangements, BTG has developed a portfolio of therapeutic products, including nine products that have received regulatory approval for sale. Additionally, the firm has four products in registration or clinical trials and several products in preclinical development. BTG's approved products include Oxandrin for the treatment of weight loss, used primarily for AIDS patients; Bio-Tropin, which treats growth hormone deficiency in children; BIOLON, used as protection of the corneal endothelium during ophthalmic implant surgery; Delatestryl, a treatment for hypogonadism and delayed puberty; Bio-Hep-B, the first recombinant hepatitis B vaccine; and Silkis, a vitamin D derivative utilized in the treatment of psoriasis and many other drugs. BTG recently acquired Myelos Corp., a privately held biopharmaceutical company focused on the development of novel therapeutics to treat diseases of the nervous system. The acquisition has added the drug Prosaptide, a new compound for the treatment of neuropathic pain associated with diabetic peripheral neuropathy, to the company’s lineup.

BRANDS/DIVISIONS/AFFILIATES: Oxadrin Bio-Tropin Delatestryl BIOLON Arthease BioLon Bio-Hep-B Myelos Corp.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Sim Fass, CEO Yehuda Sternlicht, CFO Donald A. Fishbein, VP-Mktg. Norman Barton, Chief Medical Officer Ronald J. Simko, VP-Mfg. Robert M. Shaw, Corp. Sec. Robert M. Shaw, General Counsel Leah Berkovits, VP-Admin. Lawrence B. Brown, VP-Bus. Dev. Leah Berkovits, VP-Corp. Comm. John Bond, Treas. Sim Fass, Pres., BTG, Ltd. Dov Kanner, Gen. Mgr, BTG, Ltd. Ernest L. Kelly, Sr. VP-Quality Assurance Thomas Eckhardt, VP-Regulatory Affairs

Phone: 732-632-8800 Fax: 732-632-8844 Toll-Free: Address: 70 Wood Ave. S., Iselin, NJ 08830 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $71,900 ( 9 months) 2002 Profits: $8,900 ( 9 months) Stock Ticker: BTGC 2001 Sales: $102,000 2001 Profits: $-30,300 Employees: 378 2000 Sales: $84,900 2000 Profits: $7,700 Fiscal Year Ends: 12/31 1999 Sales: $85,300 1999 Profits: $13,900 1998 Sales: $76,900 1998 Profits: $17,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $419,583 Stock Purch. Plan: Y Second Exec. Salary: $243,750 ADVANTAGE: Innovative products for niche diseases.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $160,000 Bonus: $75,000

Northeast: Y

International: Y



BIOANALYTICAL SYSTEMS INC

www.bioanalytical.com




Y Y Y

TYPES OF BUSINESS:

Profits: 10



Y


Contract Research Services Instruments-Liquid Chromotography Bioanalytical Separation Instrumentation Chemical Analyzers Diagnostic Kits In Vivo Sampling Devices Support Screening Drug Evaluation

Bioanalytical Systems, Inc. is a contract research organization (CRO) providing research and development resources to many of the leading pharmaceutical, medical device and biotechnology companies in the world. The company concentrates on services and tools to improve the speed and efficiency of preclinical development. It has played a significant role in understanding the underlying causes of central nervous system disorders, diabetes, osteoporosis and other diseases. The company offers an efficient, variable-cost alternative to its clients' internal product development, compliance and quality control programs. Bioanalytical Systems’ services and products combine basic research with diagnostic and therapeutic experience. The firm is capable of supporting the analytical needs of researchers and clinicians, from small molecule drugs and hormones through large biomolecules such as proteins. The analytical services provided include support screening and pharmacological testing, toxicology and safety testing, formulation development, laboratory testing, regulatory and compliance consulting and quality control testing. In addition to these services, Bioanalytical Systems designs, manufactures and markets a broad range of products that collect, separate, detect and quantify chemicals in biological samples. These tools and the Vetronics line of veterinary physiological monitors are used to track complex chemical, physiological and behavioral effects in laboratory animal models. The company’s principal clients include scientists engaged in drug metabolism studies, pharmacokinetics and basic neuroscience research at pharmaceutical research organizations. Recently, Bioanalytical Systems and RenaSci Consultancy, Ltd. of Nottingham, U.K. announced the formation of a strategic alliance for drug discovery and development. In other news, the company signed a definitive agreement to acquire PharmaKinetics Laboratories, Inc. in Baltimore, Maryland. The compay also has plans to acquire LC Resources, Inc., a private company based in Walnut Creek, California.

BRANDS/DIVISIONS/AFFILIATES: BAS Analytics, Ltd. BAS Technicol, Ltd. Bioanalytical Systems, Ltd. LC Resources, Inc. Vetronics PharmaKinetics Laboratories

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Peter T. Kissinger, CEO Peter T. Kissinger, Pres. Douglas P. Wieten, VP-Finance/CFO Candice B. Kissinger, Sr. VP-Mktg. Lina L. Reeves-Kerner, VP-Human Resources Michelle L. Carson, Controller Donnie A. Evans, VP-Eng. Candice B. Kissinger, Corp. Sec. Michael P. Silvon, VP-Bus. Dev. Douglas P. Wieten, Treas. Craig S. Bruntlett, Sr. VP-Int'l Sales Stephen Geary, VP-U.S. Sales and Mktg. Ronald E. Shoup, Pres., BAS Analytics Peter T. Kissinger, Chmn.

Phone: 765-463-4527 Fax: 765-497-1102 Toll-Free: Address: 2701 Kent Ave., West Lafayette, IN 47906 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $26,500 (12 months) 2002 Profits: $1,100 (12 months) Stock Ticker: BASI 2001 Sales: $25,300 2001 Profits: $1,800 Employees: 260 2000 Sales: $19,200 2000 Profits: $-1,400 Fiscal Year Ends: 9/30 1999 Sales: $19,900 1999 Profits: $ 600 1998 Sales: $18,200 1998 Profits: $ 400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $108,000 Stock Purch. Plan: Second Exec. Salary: $88,800 ADVANTAGE: State-of-the-art research services/Innovative research products.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast: Y



Bonus: $18,000 Bonus: $16,000

Northeast: Y

International: Y



BIOCOMPATIBLES INTERNATIONAL PLC www.biocompatibles.com Industry Group Code: 339113 Ranks within this company's industry group: Sales: 11 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:



Y

TYPES OF BUSINESS:

Profits: 28




Supplies-Phosphorycholine Coatings Site and Lesion-Specific Stents Ureteric Stents and Catheters

Biocompatibles is an international biomaterials firm that focuses on the development and commercial marketing of its phosphorylcholine (PC) technology, a chemical group found in membranes of living cells. When devices are coated with the firm's PC materials, they can significantly reduce the incidence of adverse interactions with blood, tears, urine and other body fluids. Biocompatibles’ two divisions, eye care and cardiovascular, are commercializing contact lenses and coronary stents, among other products. The company’s eye care division focuses on the application of Biocompatibles’ PC technology to contact lenses and eye care products, refractive surgical devices, ophthalmic surgical devices and the management of ocular diseases. Among the division’s products are Proclear Compatibles and Proclear Tailor-Made Toric. Biocompatibles’ contact lenses are the only ones approved by the FDA for easing discomfort for symptoms related to dryness. Recently, Cooper Companies, Inc. purchased the eye care division of Biocompatibles. The cardiovascular stent business and associated drug delivery programs were sold to its marketing partner, Abbott Laboratories. The cardiovascular division of Biocompatibles’ business produces and markets the BiodivYs io Stent. Biocompatibles licences PC technology to the Italian medical device company Sorin-Dideco for use on its cardiopulmonary bypass systems. Recently, the company began new product developments of PC gel systems for the treatment of tumors, the filling of aneurysms and the bulking of tissue to compensate for loss of shape or elasticity.

BRANDS/DIVISIONS/AFFILIATES: BiodivYsio Stents Proclear Biocompatibles Cardiovascular Ireland Biocompatibles Eyecare, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Crispin Simon, CEO Geoffrey Pierson, Dir.-Group Human Resources Fiona Evans, Sec. Mike Driver, Dir.-Group Dev. Richard Needham, Chmn.

Phone: +44-1252-732-732 Fax: +44-1252-732-777 Toll-Free: Address: Frensham House, Farnham Business Park, Weydon Ln., Farnham , Surrey GU9 8QL UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $32,423 ( 9 months) 2002 Profits: $17,882 ( 9 months) Stock Ticker: BCTBF.PK 2001 Sales: $100,200 2001 Profits: $-28,600 Employees: 1,173 2000 Sales: $82,200 2000 Profits: $-29,900 Fiscal Year Ends: 12/31 1999 Sales: $36,400 1999 Profits: $-31,000 1998 Sales: $26,900 1998 Profits: $-72,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Innovative technology relating to fluids in the human body.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



BIOCRYST PHARMACEUTICALS

www.biocryst.com


Y



Profits: 88


TYPES OF BUSINESS:



Drugs-Immunological, Infectious and Inflammatory Disease

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on the development of pharmaceuticals for the treatment of infectious, inflammatory and cardiovascular diseases and disorders. The company has several products under development. Its PNP inhibitor, known as BCX-1777, is in Phase I/II trials. BCX1777 is in development at M.D. Anderson Cancer Center for patients with T-cell leukemia and T-cell lymphomas. The company is developing tissue factor/factor VIIa inhibitors and cardiovascular inhibitors for the treatment of cardiovascular and acute coronary events. Hepatitis C inhibitors and viral inhibitors are also in developmental stages. The company uses strategic alliances early in the drug identification process, through the aggressive inlicensing of drug targets, and in late-stage clinical development with large pharmaceutical or biotechnology companies that have expertise in its therapeutic areas of focus. BioCryst currently has collaborations with leading academic organizations including the University of Alabama at Birmingham, Emory University and St. Jude's Children Research Hospital, as well as commercial collaborations with 3-Dimensional Pharmaceuticals, Inc. and Sunol Molecular Corporation. In recent news, BioCryst announced that patient enrollment is complete in the first Phase III trial of once-a-day orally administered peramivir (RWJ-270201), its influenza neuraminidase inhibitor.

BRANDS/DIVISIONS/AFFILIATES: BCX-1777 RWJ-270201

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Charles E. Bugg, CEO J. Claude Bennett, COO J. Claude Bennett, Pres. Michael A. Darwin, CFO Michael A. Darwin, Corp. Sec. John R. Uhrin, VP- Corp. Dev. Michael A. Darwin, Treas. Yarlagadda S. Babu, VP-Drug Discovery Tami Warren, Dir.-Clinical Dev. Charles E. Bugg, Chmn.

Phone: 205-444-4600 Fax: 205-444-4640 Toll-Free: Address: 2190 Parkway Lake Dr., Birmingham , AL 35244 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-14,200 ( months) Stock Ticker: BCRX 2001 Sales: $7,700 2001 Profits: $-5,000 Employees: 77 2000 Sales: $7,700 2000 Profits: $-11,600 Fiscal Year Ends: 12/31 1999 Sales: $5,300 1999 Profits: $-5,300 1998 Sales: $7,600 1998 Profits: $-4,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $381,576 Stock Purch. Plan: Y Second Exec. Salary: $291,707 ADVANTAGE: Proprietary drug for the prevention of influenza.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y




Northeast:

International:



BIOGEN INC

www.biogen.com


Y


Y


Profits: 14


TYPES OF BUSINESS:



Drugs-Multiple Sclerosis Genetic Engineering

Biogen, Inc. is a biopharmaceutical company that develops, manufactures and markets drugs for human health care. The company currently derives its revenues from worldwide sales of AVONEX, for the treatment of relapsing forms of multiple sclerosis, and from sales by Biogen’s licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. In addition, Biogen has a significant number of ongoing research programs and a pipeline of development stage products, the furthest along of which, AMEVIVE, is currently being considered for approval by the FDA and regulatory authorities in the European Union and Canada for the treatment of moderate to severe psoriasis. Biogen focuses its research on biological systems and processes where its scientific expertise in molecular biology, cell biology, immunology and protein chemistry can lead to a greater understanding of disease processes and, as a result, to the creation of new pharmaceuticals. The company recently launched PsoriasisSupport.com, a website that will provide content and community support for people with psoriasis. Biogen’s partners include Schering-Plough, SmithKline Beecham, Merck and Abbott Laboratories. Employee benefits at Biogen include maternity leave and tuition reimbursement.

BRANDS/DIVISIONS/AFFILIATES: AVONEX AMEVIVE PsoriasisSupport.com Biogen Japan, Ltd.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James C. Mullen, CEO James C. Mullen, Pres. Peter N. Kellogg, CFO Frank A. Burke, Jr., VP-Human Resources Burt Adelman, Exec. VP-Research and Dev. Patrick J. Purcell, CIO Thomas J. Bucknum, General Counsel Kees Been, Sr. VP-Bus. Dev. Sylvie L. Gregoire, Exec. VP-Tech. Oper. Hans Peter Hasler, Exec. VP-Commercial Oper. Nadine Cohen, Sr. VP-Regulatory Affairs Toshio Nakata, Pres., Biogen Japan, Ltd.

Phone: 617-679-2000 Fax: 617-679-2617 Toll-Free: Address: 14 Cambridge Center, Cambridge, MA 02142-1481 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $845,934 ( 9 months) 2002 Profits: $157,724 ( 9 months) Stock Ticker: BGEN 2001 Sales: $1,043,400 2001 Profits: $272,700 Employees: 1,992 2000 Sales: $926,452 2000 Profits: $333,577 Fiscal Year Ends: 12/31 1999 Sales: $794,435 1999 Profits: $220,450 1998 Sales: $557,587 1998 Profits: $138,697


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,024,324 Bonus: $993,000 Stock Purch. Plan: Y Second Exec. Salary: $914,513 Bonus: $218,800 ADVANTAGE: Marketer of AVONEX, a treatment for relapsing forms of multiple sclerosis/Expertise in molecular biology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International: Y



BIOMARIN PHARMACEUTICAL

www.biomarinpharm.com


Y



Profits: 218


TYPES OF BUSINESS:



Drugs-Mucopolysaccharidosis -I Carbohydrate Enzyme Therapies

BioMarin Pharmaceutical, Inc. is a developer of carbohydrate enzyme therapies for debilitating, lifethreatening, chronic genetic disorders and other diseases and conditions. Its lead drug product, Aldurazyme, is being developed for the treatment of mucopolysaccharidosis -I, or MPS-I. MPS-I is a lifethreatening genetic disorder caused by the lack of a sufficient quantity of the enzyme (alpha)-L-iduronidase. Patients with MPS-I have multiple debilitating symptoms resulting from the buildup of carbohydrate residues in all tissues in the body. These symptoms include delayed physical and mental growth, enlarged liver and spleen, skeletal and joint deformities, airway obstruction, heart disease, reduced endurance and pulmonary function and impaired hearing and vision. BioMarin has a joint venture with Genzyme for the worldwide development and commercialization of Aldurazyme. The company recently completed regulatory filings seeking approval to market Aldurazyme in the U.S. and Europe. Neutralase is also being developed for reversal of anticoagulation by heparin in patients undergoing coronary artery bypass graft (CABG), surgery and angioplasty. Other products that BioMarin is developing include Aryplase for the treatment of MPS VI and Vibrilase for the treatment of acute burn injuries. In recent news, BioMarin completed the acquisition of Glyko Biomedical, Ltd., a Canadian company.

BRANDS/DIVISIONS/AFFILIATES: Aldurazyme Glyko Biomedical Genzyme Neutralase Aryplase Vibrilase

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Fredric D. Price, CEO John C. Klock, Pres. Louis Drapeau, CFO/VP-Finance Christopher M. Starr, Sr. VP-Scientific Oper. Kim R. Tsuchimoto, VP/Controller John L. Jost, VP-Mfg. and Process Dev. Louis Drapeau, Corp. Sec. Jeffrey I. Landau, VP-Admin. Emil D. Kakkis, Sr. VP-Bus. Oper. Robert A. Baffi, VP-Quality Assurance and Control Brian K. Brandley, VP-Pharmacology and Toxicology Robert A. Heft, VP-Product Dev. and Program Mgmt. Stuart J. Swiedler, VP-Clinical Affairs Fredric D. Price, Chmn.

Phone: 415-884-6700 Fax: 415-382-7427 Toll-Free: Address: 371 Bel Marin Keys Blvd., Ste. 210, Novato, CA 94949 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $8,621 ( 9 months) 2002 Profits: $-32,684 ( 9 months) Stock Ticker: BMRN 2001 Sales: $11,700 2001 Profits: $-67,600 Employees: 216 2000 Sales: $12,326 2000 Profits: $-37,364 Fiscal Year Ends: 12/31 1999 Sales: $7,000 1999 Profits: $-28,100 1998 Sales: $1,200 1998 Profits: $-12,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Joint venture with Genzyme.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:




Northeast:

International:



BIOMIRA INC

www.biomira.com


Y



Y

TYPES OF BUSINESS:

Profits: 168




Drugs-Cancer Diagnostics

Biomira, Inc. focuses its biotechnology expertise on the development of cancer therapeutics. The firm’s proprietary immunotherapy and organic chemistry knowledge has resulted in the development of the Theratope vaccine, a drug currently in Phase III trials for metastatic breast cancer involving 1,030 breast cancer patients in 10 countries across the globe. The drug’s trial is the largest of its kind. Theratope is also being tested in a Phase II trial for the treatment in colorectal cancer. BLP25 Liposomal vaccine is being designed to generate a cellular immune response to the tumor-associated antigen mucin MUC1. It is being developed for metastatic cell lung cancer and potential prostate cancer treatment. Biomira has formed a strategic alliance with Merck KgaA, a German chemical-pharmaceutical company. Biomira and EMD Pharmaceuticals, Inc., Merck’s U.S. affiliate, will jointly market Theratope and BLP25 vaccines in the U.S., while Merck will have sole development and marketing rights for Biomira’s vaccines in the rest of the world. In recent news, Biomira completed enrollment of patients in its Phase IIb clinical trial for BLP25. There are now 168 patients from Canada and the United Kingdom enrolled in the trial.

BRANDS/DIVISIONS/AFFILIATES: Theratope BLP25 Merck KgaA

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. T. Alexander McPherson, CEO Mark D. Young, COO T. Alexander McPherson, Pres. Edward A. Taylor, CFO/VP-Finance Robert D. Aubrey , VP-Mktg. Paul Bokenfohr, Human Resources B. Michael Longnecker, Sr. VP-Research and Dev. Guy Ely, VP-Clinical and Regulatory Affairs Edward A. Taylor, Corp. Sec. Edward A. Taylor, VP-Admin. Robert D. Aubrey , VP-Bus. Dev. Thomas J. Facklam, VP-Tech. Oper. and Quality Mircea Popescu, VP/Mgr.-Biomira U.S.A. Eric E. Baker, Chmn.

Phone: 780-450-3761 Fax: 780-463-0871 Toll-Free: 877-234-0444 Address: 2011 94th St., Edmonton, Alberta T6N 1H1 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $4,028 ( 9 months) 2002 Profits: $-22,809 ( 9 months) Stock Ticker: BIOM 2001 Sales: $4,600 2001 Profits: $-24,300 Employees: 162 2000 Sales: $3,000 2000 Profits: $-29,300 Fiscal Year Ends: 12/31 1999 Sales: $3,100 1999 Profits: $-20,200 1998 Sales: $3,900 1998 Profits: $-14,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Novel vaccines that trigger the immune system to identify and fight cancer cells.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



BIONX IMPLANTS INC

www.bionximplants.com




Y

TYPES OF BUSINESS:

Profits: 17




Equipment- Polymer Implants

Bionx Implants is a leading manufacturer of self-enforced, resorbable polymer implants, including screws, pins and stents. The company’s polymer implants are used in orthopedic trauma, sports medicine, dentistry, maxillofacial surgery and urology. Bionx’s resorbable pins can be used in open surgical procedures and percutaneous and endoscopic techniques. Bionx’s Meniscus Arrow was the first resorbable, arthroscopically implanted fixation device designed for use in the repair of longitudinal, vertical tears of the medial and lateral meniscus. The firm recently announced the release of BioCuff, a bioresorbable screw and spiked washer implant used to fixate torn rotator cuff tissue back to bone. In addition to the release of BioCuff, the company introduced the Wedge, a bioresorbable interference fit implant used to attach a graft using cruciate ligament reconstruction, including bone-patella, tendonbone or soft tissue grafts. Bionx, having signed a collaboration agreement with Toray Medical Co., Ltd., has introduced its products to the Japanese market. Toray has exclusive distribution rights to the Bionx resorbable stent products for urology applications in Japan. In exchange for exclusive Japanese distribution rights, Toray makes investments to achieve market clearance for the Bionx stent products in Japan, and is required to meet market penetration and minimum purchase requirements.

BRANDS/DIVISIONS/AFFILIATES: Meniscus Arrow BioSorb Smart Pin Smart Tack Smart Screw Bankart Tack Wedge, The BioCuff

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gerard S. Carlozzi, CEO Gerard S. Carlozzi, Pres. Drew Karazin, VP-Finance/CFO Ira Benson, VP-Mktg. & Sales Pertti Tormala, Exec. VP-Research and Dev. Pertti Viitanen, VP-Mfg. Drew Karazin, VP-Admin. James Hogan, Pres.-Stenting Div. Michael Matz, VP-Sales, Craniofacial Div.

Phone: 215-643-6177 Fax: 215-653-0984 Toll-Free: 800-349-3801 Address: 1777 Sentry Parkway W., Gwynedd Hall, Ste. 400, Blue Bell, PA 19422 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $13,628 ( 9 months) 2002 Profits: $-2,668 ( 9 months) Stock Ticker: BINX 2001 Sales: $18,900 2001 Profits: $-2,500 Employees: 108 2000 Sales: $18,232 2000 Profits: $-4,609 Fiscal Year Ends: 12/31 1999 Sales: $21,068 1999 Profits: $-12,463 1998 Sales: $21,100 1998 Profits: $1,261


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Expansion into Japanese market.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



BIOPURE CORPORATION

www.biopure.com


Y



Profits: 205


TYPES OF BUSINESS:



Drugs-Oxygen Therapeutics Veterinary Drugs

Biopure develops, manufactures and markets oxygen therapeutics, including Hemopure, for human use, and Oxyglobin, for veterinary use. The company is developing Hemopure as an alternative to red blood cell transfusions, as well as for use in the treatment of other critical care conditions. During 2001, Biopure received approval to sell Hemopure for human use in South Africa and launched animal-based Oxyglobin in Europe. The firm also began construction for a new $110-million manufacturing plant for the production of Hemopure. The average Hemopure molecule is less than 1/1000th the size of a red blood cell. Once infused into a patient, these molecules disperse throughout the plasma space and are in continuous contact with the blood vessel wall, turning plasma into an oxygen-delivering substance. Plasma containing Hemopure flows everywhere blood flows and can also bypass partial blockages or pass through constricted vessels that impede the normal passage of red blood cells. As an alternative to red blood cell transfusion, Hemopure's advantages include immediate onset of action, more efficient oxygen release, long shelf life, universal compatibility, low viscosity and room temperature storage. Studies show that the product could also be used for applications including trauma treatment, ischemic conditions including heart attack and stroke and malignant hypoxic tumors. Oxyglobin, the firm's other product, is used for the treatment of anemia in dogs and is marketed and sold to veterinary hospitals and small animal veterinary practices in the U.S. and Europe. In recent news, Biopure's marketing application for Hemopure as a treatment for anemia in patients undergoing orthopedic surgery was accepted by the FDA for review. The company also received a grant from the U.S. Army to develop the drug for military trauma applications. Biopure employees receive benefits including medical, dental and life insurance, tuition reimbursement, transportation assistance and access to a credit union.

BRANDS/DIVISIONS/AFFILIATES: Hemopure Oxyglobin Oxygen Bridge

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas A. Moore, CEO Thomas A. Moore, Pres. Francis H. Murphy, CFO William A. Eudailey, VP-Mktg. and Sales Carolyn R. Fuchs, VP-Human Resources Carl W. Rausch, Chief Tech. Officer Virginia T. Rentko, VP-Veterinary Medicine Jane Kober, Sr. VP/Corp. Sec. Jane Kober, General Counsel Barry L. Scott, VP-Int'l Bus. Dev. Geoffrey J. Filbey, VP-Eng. Howard P. Richman, VP-Regulatory Affairs and Compliance Maria S. Gawryl, Sr. VP-Research and Dev. Alain C. Massot, VP-Int'l Mktg. and Sales

Phone: 617-234-6500 Fax: 617-234-6505 Toll-Free: 877-879-2787 Address: 11 Hurley St., Cambridge, MA 02141 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,916 ( 9 months) 2002 Profits: $-35,012 ( 9 months) Stock Ticker: BPUR 2001 Sales: $3,500 2001 Profits: $-49,400 Employees: 211 2000 Sales: $3,100 2000 Profits: $-29,282 Fiscal Year Ends: 10/31 1999 Sales: $2,900 1999 Profits: $-35,500 1998 Sales: $1,100 1998 Profits: $-30,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $324,170 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $309,332 Bonus: $ ADVANTAGE: Unique therapies for anemia and shock/Product may be used as an alternative to red blood cell transfusions.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International: Y



BIORA AB

www.biora.se


Y



Profits: 75


TYPES OF BUSINESS:



Drugs-Oral Disease Wound Treatments Bone Treatments

Biora AB focuses its efforts on developing new, proprietary products for the dental market and on expanding the indications for its Emdogain product. Biora AB has treated over 200,000 patients with Em dogain, which is marketed in 25 countries throughout Europe, North and South America, Asia and Africa. Emdogain is a topically applied adjunt to periodontal surgery that leaves a protein matrix on the roots of teeth in order to facilitate a foundation for periodontal tissues. The company’s dedication to continued product development has produced Emdogain Gel, a version of the product that is prepackaged in a syringe. The pre-packaged nature of this product provides greater ease of use than others of its kind and reduces inchair time for the dental patient. Further research and development efforts concerning Emdogain are ongoing, including studies of the drug’s mechanism of action, recession defects, treatment of avulsed teeth, endodonics, impacted wisdom teeth, wound healing, local bone formation and dry mouth. Studies have shown that Emdogain has the ability to lead to periodontal regeneration. Another product, PrefGel, is a root surface gel that promotes the cleaning of the tooth root surface during surgery without damaging the surrounding tissues. The company’s two largest subsidiaries are located in the United States and Germany. Subsidiary BioEx was formed to develop enamel matrix protein-based products for indications outside the oral cavity. BioEx is currently involved in a project for stimulating bone formation and a patent application for the inhibition of certain cancer cells. Biora has several research collaborations with universities in the U.S., Europe, Japan and Australia.

BRANDS/DIVISIONS/AFFILIATES: Emdogain BioEx Emdogain Gel PrefGel

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Donna Janson, CEO Donna Janson, Pres. Svante Lundell, CFO Christer Tingnell, Dir.-Mktg. Stina Gestrelius, Dir.-Research and Dev. Kerstin Palsson, Group Controller Lars Heijl, Dir.-Medical Tommie Johansson, Dir.-Corp. Comm. Tommie Johansson, Dir.-Investor Rel. Stina Gestrelius, Dir.-Regulatory Affairs Per Wahlstrom, Chmn.

Phone: +46-40-32-13-33 Fax: +46-40-32-13-55 Toll-Free: Address: Medeon Science Park, Malmo, SE-205, 12 Sweden

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 3 months. 2002 Sales: $3,900 ( 3 months) 2002 Profits: $- 100 ( 3 months) Stock Ticker: BIORY 2001 Sales: $10,500 2001 Pr ofits: $-2,400 Employees: 79 2000 Sales: $8,200 2000 Profits: $-6,100 Fiscal Year Ends: 12/31 1999 Sales: $6,800 1999 Profits: $-7,300 1998 Sales: $4,600 1998 Profits: $-5,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Focus on unique drugs for dental patients.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



BIORELIANCE CORP

www.bioreliance.com


Y



Y Y Y

TYPES OF BUSINESS:

Profits: 4




Research-Nonclinical Product Testing Contract Drug Manufacturing

BioReliance Corporation is a leading contract service organization that provides testing, development and manufacturing services for biologics and for other biomedical products. Its clients include biotechnology and pharmaceutical companies worldwide. BioReliance provides its services throughout the product cycle, starting from early preclinical development through licensed production. Through its testing and development business, the firm evaluates products to ensure that they are free of disease-causing agents and do not cause adverse effects; characterizes products' chemical structures; develops formulations for long-term stability; and validates purification processes under regulatory guidelines. In its manufacturing business, BioReliance develops unique production processes and manufactures biologics on behalf of clients both for use in clinical trials and for the worldwide commercial market. BioReliance's testing services include assessments of the cell banks used to manufacture biologics, validation of purification processes for clearance of adventitious agents such as viruses and testing of in-process and final products. Recently, BioReliance entered into a laboratory agreement with MedImmune, Inc., in which it will perform a range of tests for MedImmune’s developed products. In other news, the company entered into a multi-year manufacturing agreement with Celltech Group, one of Europe’s largest biotechnology companies. Under this agreement, BioReliance will manufacture and supply clinical-grade, antibody fragment-based drugs to Celltech. BioReliance provides its employees with health benefits, tuition reimbursement and bonuses.

BRANDS/DIVISIONS/AFFILIATES:

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Capers W. McDonald, CEO Capers W. McDonald, Pres. John L. Coker, VP-Finance/CFO Ronald R. Baker, VP-Mktg. and Sales John J. Gilly, VP-U.S. Mfg. John L. Coker, Corp. Sec. John L. Coker, VP-Admin. John L. Coker, Treas. Raymond F. Cosgrove, VP-European Testing and Dev. David Jacobson-Kram, VP-Toxicology and Laboratory Animal Health

Phone: 301-738-1000 Fax: 301-738-1036 Toll-Free: Address: 14920 Broschart Rd., Rockville, MD 20850 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $61,340 ( 9 months) 2002 Profits: $8,077 ( 9 months) Stock Ticker: BREL 2001 Sales: $69,700 2001 Profits: $5,900 Employees: 556 2000 Sales: $55,900 2000 Profits: $1,200 Fiscal Year Ends: 12/31 1999 Sales: $47,200 1999 Profits: $-1,000 1998 Sales: $49,800 1998 Profits: $3,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Experts in biology manufacturing.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $173,750 Bonus: $94,825

Northeast: Y

International: Y



BIOSITE INC

www.biosite.com



Y


Y Y

TYPES OF BUSINESS:

Profits: 2




Drugs-Diagnostics Protein Microarray s Drug Abuse Tests Food-Born Bacteria Tests Heart Disease Diagnostics

Biosite, Inc. is a research-based diagnostics company dedicated to the discovery and development of novel protein-based tests that improve physicians' ability to diagnose diseases. The firm combines separate yet integrated discovery and diagnostics businesses to access proteomics research, identify proteins with high diagnostics value, develop and commercialize products and educate the medical community on new approaches to diagnosis. Biosite is a leading provider of rapid immunoassays, or antibody-based diagnostic tests, sold primarily for use in hospitals worldwide. The company's products include the Triage Drugs of Abuse Panel, the Triage Cardiac Panel and the Triage BNP Test. The Triage Drugs of Abuse Panel is a small, self-contained, qualitative test capable of detecting a broad spectrum of commonly overdosed prescription and illicit drugs in urine within approximately 10 minutes. The product is used in nearly 50% of U.S. acute care hospitals. In 2002, the FDA approved the Triage TOX Drug Screen, a secondgeneration drug test capable of simultaneously screening up to eight classes of commonly abused drugs. The Triage Cardiac System aids in the detection of acute myocardial infarction, otherwise known as heart attack. The system is in the early stages of market penetration and produced nearly $18 million in net sales in 2001. The Triage BNP Test is the first and only blood test currently approved in the U.S. for the diagnosis of congestive heart failure. The firm's Biosite Discovery business is dedicated to the identification of new protein markers of acute diseases that lack effective diagnostic tests. In addition, Biosite maintains collaborative agreements with a number of partners, including Amgen, Inc., Medarex, Inc. and Corixa Corp. Recently, the company entered into a multiyear agreement with MedImmune, under which Biosite will use its Omniclonal phage display technology to generate antibodies to drug targets provided by MedImmune.

BRANDS/DIVISIONS/AFFILIATES: Triage Drugs of Abuse Panel Triage Meter Biosite Discovery Trans-Phage Technology Medarex, Inc. Triage BNP Test Triage TOX Drug Screen Omniclonal Phage Display Technology

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kim D. Blickenstaff, CEO Kim D. Blickenstaff, Pres. Christopher J. Twomey, VP-Finance/CFO James E. Douglas, VP-Mktg. and Sales Laura Weatherford, Human Resources Kenneth F. Buechler, VP-Research and Dev. Thomas M. Watlington, Sr. VP-Commercial Oper. Christopher R. Hibberd, VP-Strategic Planning and Bus. Dev. Nadine Padilla, VP-Corp. and Investor Rel. Peter Witerzens, VP-Oper. Gunars E. Valkirs, VP-Discovery Gary A. King, VP-Worldwide Mktg.

Phone: 858-455-4808 Fax: 858-455-4815 Toll-Free: Address: 11030 Roselle St., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $72,529 ( 9 months) 2002 Profits: $8,426 ( 9 months) Stock Ticker: BSTE 2001 Sales: $65,600 2001 Profits: $6,700 Employees: 351 2000 Sales: $55,000 2000 Profits: $6,163 Fiscal Year Ends: 12/31 1999 Sales: $43,700 1999 Profits: $1,100 1998 Sales: $37,100 1998 Profits: $-1,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $311,250 Bonus: $100,567 Stock Purch. Plan: Second Exec. Salary: $246,000 Bonus: $176,581 ADVANTAGE: Biosite's Triage brand rapid diagnostic tests are used in nearly 50% of U.S. hospitals and in approximately 40 international markets

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



BIOSOURCE INTERNATIONAL INC

www.biosource.com




Y Y

TYPES OF BUSINESS:

Profits: 7




Supplies-Enzyme-Linked Immunosorbent Assay Test Kits (ELISA) Clinical Diagnostics Immunology Molecular Biology

BioSource International, Inc. develops, manufactures and distributes products used worldwide in disease-related biomedical research and clinical diagnostics. Its products enable scientists and biom edical researchers to better understand the biochemistry, immunology and cell biology of the human body, as well as disease processes. It offers over 3,200 products that are grouped into the following product lines: assays, antibodies bioactive proteins and peptides, oligonucleotides, serum, buffers and media. BioSource intends to increase its organic growth rate through focused research and development and sales and marketing investments in cell biology markets with high growth potential. The firm recently launched the industry’s first p38 MAPK ELISA assay. The protein p38 MAPK is important in drug discovery research focused on mitogen activated protein kinases. Companies are studying p38 MAPK modifiers as drug candidates in a wide variety of diseases including several types of cancer, Parkinson’s Disease, diabetes and cardiovascular disease. BioSource’s new p38 MAPK ELISA kit is directly targeted at applications for these areas of research.

BRANDS/DIVISIONS/AFFILIATES: Keystone Laboratories BioSource Europe, S.A. Quality Controlled Biochemical Biofluids p38 MAPK ELISA

CONTACTS: Note: Officers with more than one job ti tle may be intentionally listed here more than once. Leonard Hendrickson, CEO Leonard Hendrickson, Pres. David S. Thrower, VP-Global Sales and Mktg. Cirilo Cabridilla, Jr., VP-Molecular Biology Kevin J. Reagan, VP-Immunology Jozef Vangenechten, Gen. Mgr., BioSource Europe, S.A.

Phone: 805-987-0086 Fax: 805-383-5386 Toll-Free: 800-242-0607 Address: 542 Flynn Rd., Camarillo, CA 93012 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $30,175 ( 9 months) 2002 Profits: $-1,097 ( 9 months) Stock Ticker: BIOI 2001 Sales: $35,200 2001 Profits: $ 700 Employees: 257 2000 Sales: $32,210 2000 Profits: $- 166 Fiscal Year Ends: 12/31 1999 Sales: $29,257 1999 Profits: $3,577 1998 Sales: $21,859 1998 Profits: $-5,136


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Focus on molecular biology.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



BIOSPECIFICS TECHNOLOGIES CORP www.biospecifics.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 140 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Profits: 65


TYPES OF BUSINESS:



Drugs-Skin Wound Therapies Tissue Remodeling Therapies

BioSpecifics Technologies Corporation is a pharmaceutical company focused on health-related disorders, including wound healing and tissue remodeling. The company produces and licenses a fermentationderived enzyme named Collagenase ABC that has been approved by the FDA for debriding chronic dermal ulcers and severely burned areas. Additionally, the firm researches and develops products derived from the enzyme for potential pharmaceutical use. The company acquires the majority of its revenue through a license agreement with Abbott Laboratories for the sale of powdered Collagenase and Collagenase Santyl Ointment. BioSpecifics Technologies is currently developing injectable Collagenase ABC. Clinical trials are underway for the treatment of Dupuytren’s disease, Peyronie’s disease, frozen shoulder and lipolysis using the injectable form of collagenase. The company also has a joint research project with Bausch & Lomb for the treatment of glaucoma. The company extended marketing rights to Smith & Nephew, Inc. to market Collagenase Santyl Ointment in the United States. BioSpecifics is also in collaboration with University Hospital and Medical Center at Stony Brook for a clinical study using the injectable form of Collagenase.

BRANDS/DIVISIONS/AFFILIATES: Collagenase ABC Biospecifics Pharma GmbH Collagenase Santyl Ointment

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Edwin H. Wegman, Pres. Albert Horcher, Principal Financial Officer Albert Horcher, Chief Acc. Officer Albert Horcher, Corp. Sec. Albert Horcher, Treas. Thomas L. Wegman, Exec. VP Rainer Friedel, Managing Dir., Biospecifics Pharma GmbH Edwin H. Wegman, Chmn.

Phone: 516-593-7000 Fax: 516-593-7039 Toll-Free: Address: 35 Wilbur St., Lynbrook, NY 11563 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $8,200 (12 months) 2002 Profits: $- 300 (12 months) Stock Ticker: BSTC 2001 Sales: $5,500 2001 Profits: $-1,468 Employees: 44 2000 Sales: $6,600 2000 Profits: $ 200 Fiscal Year Ends: 1/31 1999 Sales: $7,100 1999 Profits: $1,200 1998 Sales: $5,800 1998 Profits: $ 800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $412,961 Stock Purch. Plan: Second Exec. Salary: $205,895 ADVANTAGE: License agreement with Abbott Laboratories.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



BIOSPHERE MEDICAL INC

www.biospheremed.com


Y



Profits: 6


TYPES OF BUSINESS:



Drugs-Bioengineered Microspheres Tissue Engineering Technology

Biosphere Medical pioneers the use of its proprietary bioengineered acrylic beads, known as microspheres, for medical applications using embolotherapy techniques, as well as to develop potential applications in several nonembolotherapy applications. The firm believes its microsphere platform enables the rapid development of a new micro-interventional market, which will expand the capability of catheter-based interventional technologies and permit clinicians to treat medical conditions in a more effective and minimally invasive manner. Embolotherapy is a minimally invasive procedure in which embolic materials, such as microspheres, are delivered through a catheter into the blood vessels to inhibit blood flow to tumors or vascular defects or to control blood loss presurgically. The company's initial product, Embosphere microspheres, is targeted for the treatment of hypervascularized tumors and arteriovenous malformations. Microspheres have a number of advantages over currently available embolic materials, including ease of use and more controlled delivery. Nonembolotherapy applications of Biosphere's products include tissue bulking, repair and regeneration. The company, through subsidiary BSMD Ventures, Inc., is exploring and developing its products for these uses and for the treatment of such conditions as stress urinary incontinence and gastroesophageal reflux disease. In 2000, Biosphere established Biosphere Medical Japan, Inc., to develop and commercialize its Embosphere and HepaSphere SAP products in the Far East.

BRANDS/DIVISIONS/AFFILIATES: Biosphere Medical Japan, Inc. Embosphere HepaSphere SAP BSMD Ventures, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul A. Looney, CEO Paul A. Looney, Pres. Robert M. Palladino, VP/CFO Tom M. Keenan, VP- Int'l Sales and Mktg. Jonathan R. McGrath, VP-Worldwide Research and Dev. Peter Sutcliffe, VP-Mfg. Robert T. Phelps, VP-Sales, Mktg. and Bus. Dev.

Phone: 781-681-7900 Fax: 781-792-2745 Toll-Free: 800-394-0295 Address: 1050 Hingham St., Rockland, MA 02370 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $9,106 ( 9 months) 2002 Profits: $-5,624 ( 9 months) Stock Ticker: BSMD 2001 Sales: $9,000 2001 Profits: $-10,300 Employees: 87 2000 Sales: $3,961 2000 Profits: $-8,447 Fiscal Year Ends: 12/31 1999 Sales: $2,300 1999 Profits: $-4,500 1998 Sales: $ 202 1998 Profits: $-1,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $220,577 Stock Purch. Plan: Second Exec. Salary: $210,000 ADVANTAGE: Expertise in embolotherapy/Ability to create therapies that restrict blood flow.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:




Northeast: Y

International: Y



BIOTECH HOLDINGS LTD

www.biotechltd.com


Y



Profits: 72


TYPES OF BUSINESS:



Drugs-Diabetes Health Care Products Personal Care Products

Biotech Holdings, Ltd. is engaged in the research, development, manufacture and marketing of various pharmaceutical, personal care and health care products, including topical creams, lotions, sunscreen, skin care products, Vitamin E and bath products. The company’s proprietary product is Diab II, a treatment for type II diabetes designed to increase insulin utilization by the body. As part of a new class of drugs labeled insulin sensitizers, Diab II is designed to control high blood sugar levels in individuals with diabetes. Diab II is currently marketed in China and is licensed for sale in Argentina, Chile, Peru and Venezuela, among other international areas. Biotech announced its plan to introduce the product into Brazil to increase its presence in the Latin market. The company has opened a new facility in Canada, where it manufactures and markets its Diab II product. Recently, Biotech Holdings announced the introduction of two new lines of products, Larisse skin care brand and Feelgood progesterone cream, for sales direct to consumers through the Internet across North America.

BRANDS/DIVISIONS/AFFILIATES: Diab II Larisse Feelgood

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert B. Rieveley, CEO Robert B. Rieveley, Pres. Lorne D. Brown, CFO Ping Sun, VP- Research and Dev. Gale V. Belding, Exec. VP Robert B. Rieveley, Chmn.

Phone: 604-736-3351 Fax: 604-736-3806 Toll-Free: 888-216-1111 Address: W. Broadway Ave., Ste. 400-1501, Vancouver, BC V6J 4Z6 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,006 (12 months) 2002 Profits: $-2,140 (12 months) Stock Ticker: BIOHF.OB 2001 Sales: $1,163 2001 Profits: $-1,938 Employees: 2000 Sales: $ 834 2000 Profits: $-2,400 Fiscal Year Ends: 3/31 1999 Sales: $1,733 1999 Profits: $-2,258 1998 Sales: $ 889 1998 Profits: $-2,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Novel treatment for type II diabetes.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



BIOTIME INC

www.biotimeinc.com


Y



Profits: 83

Computer s: Hardware: Software: Arrays: Database Management:

TYPES OF BUSINESS:



Drugs-Blood Replacement Solutions Organ Preservation Solutions

BioTime, Inc. is a development-stage company engaged in the research and development of synthetic solutions that can be used as blood plasma expanders, blood replacement solutions during hypothermic surgery and organ preservation solutions. The firm is also developing a specially formulated hypothermic blood substitute solution to be used for the replacement of very large volumes of patients' blood during cardiac surgery, neurosurgery and other surgeries that involve lowering body temperature to hypothermic levels. Hextend, the company's first product, is a physiologically balanced blood plasma volume expander for the treatment of hypovolemia, a condition associated with blood loss during surgery. Hextend maintains circulatory system fluid volume and keeps vital organs perfused during surgery. The product is sold in the U.S. and Canada through Abbot Laboratories. BioTime is developing two other blood volume replacement products, PentaLyte and HetaCool. The company has completed Phase I clinical trials of PentaLyte and plans to test the product for the treatment of hypovolemia. HetaCool is a modified formulation of Hextend. Other potential uses of BioTime's products include use during anti-cancer therapies.

BRANDS/DIVISIONS/AFFILIATES: Hextend HetaCool PentaLyte

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul Segall, CEO Ronald S. Barkin, COO Stephen A. Seinberg, CFO Hal Sternberg, VP-Research Judith Segall, VP-Tech. Harold Waitz, VP-Eng. Judith Segall, Corp. Sec. Stephen A. Seinberg, Treas. Harold Waitz, VP-Regulatory Affairs

Phone: 510-845-9353 Fax: 510-845-7914 Toll-Free: Address: 935 Pardee St., Berkeley, CA 94710 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 203 ( 9 months) 2002 Profits: $-2,068 ( 9 months) Stock Ticker: BTX 2001 Sales: $ 200 2001 Profits: $-3,700 Employees: 12 2000 Sales: $ 100 2000 Profits: $-4,900 Fiscal Year Ends: 12/31 1999 Sales: $1,000 1999 Profits: $-5,500 1998 Sales: $ 300 1998 Profits: $-2,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $163,000 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $125,083 Bonus: $ ADVANTAGE: Received FDA approval for Hextend/Unique solutions for the treatment of blood loss and for use in blood replacement during surgeries.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



BIOTRANSPLANT INC

www.biotransplant.com


Y



Profits: 198


TYPES OF BUSINESS:



Drugs-Organ Transplant Rejection

BioTransplant, Inc. is developing pharmaceutical products and systems that enable the body's immune system to better tolerate the transplantation of foreign cells, tissues and organs. Its technology will reduce or eliminate the need for lifelong immunosuppressive therapy, which refers to the long-term administration of potentially debilitating drugs after a transplantation procedure in an effort to reduce the likelihood that the patient's body will reject the transplanted cells, tissue or organ. The technology will also minimize infections and health complications, which may result from transplantation, improve the treatment of certain cancers, reduce the cost of treating end-stage organ disease and increase the supply of organs or cells available for transplantation procedures. BioTransplant has acquired Eligix, Inc., a biomedical device company, through which it gained the late-stage products of Eligix HDM Cell Separation System technology. These systems use antibodies to remove unwanted cells from bone marrow, peripheral blood stem cell and donor leukocyte grafts used in transplantation procedures. The company signed an exclusive distribution agreement with Gambro BCT for the marketing of these products. The company is also in collaboration with MedImmune, Inc. to develop MEDI-507, also known as Siplizumab, an antibody designed to treat and prevent organ and tissue transplant rejection and autoimmune disorders. The company’s AlloMune Systems are being tested to a f cilitate in the treatment of lymphoma, renal cell cancer, melanoma and kidney transplantation malignancies. BioTransplant and Novartis have formed a joint venture, Immerge BioTherapeutics, Inc., to further develop technology bases in xenotransplantation, which is the transplantation of cells, tissues or organs from one species to another. Immerge BioTherapeutics is currently conducting animal studies to test the use of miniature swine organs in swineto-primate transplantation. Recently, the company received authorization to affix the CE Mark to Eligix CD8SC, signifying regulatory approval to market the device in Europe.

BRANDS/DIVISIONS/AFFILIATES: AlloMune System XenoMune System Eligix HDM Cell Separation System MEDI-507 Eligix, Inc. Siplizumab Eligix CD8-SC Immerge BioTherapeutics

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Donald Hawthorne, CEO Donald Hawthorne, Pres. Donald Hawthorne, CFO Tara Clark, VP-Mktg. Barbara Wallner, Chief Scientific Officer/VP-Research Constance Garrison, VP-Regulatory Affairs and Quality Assurance Elliot Lebowitz , Chmn.

Phone: 617-241-5200 Fax: 617-241-8780 Toll-Free: Address: Charlestown Navy Yard Bldg. 75, 3rd Ave., Charlestown, MA 02129 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 345 ( 9 months) 2002 Profits: $-5,170 ( 9 months) Stock Ticker: BTRN 2001 Sales: $ 700 2001 Profits: $-42,600 Employees: 105 2000 Sales: $4,600 2000 Profits: $-11,700 Fiscal Year Ends: 12/31 1999 Sales: $8,700 1999 Profits: $-8,700 1998 Sales: $6,700 1998 Profits: $-9,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $282,000 Bonus: $70,200 Stock Purch. Plan: Second Exec. Salary: $211,000 Bonus: $26,000 ADVANTAGE: Technology for use in transplant of organs from swine to humans/Technologies that may eliminate the need for use of immunosuppressive drugs by organ transplant patients.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



BIOVAIL CORPORATION

www.biovail.com


Y Y



Profits: 26


TYPES OF BUSINESS:



Drugs-Hypertension Generic Drugs Drug Delivery Technologies Nutraceuticals

Biovail Corp. is a full-service pharmaceutical company involved in the development, testing, registration, manufacturing, sale and marketing of pharmaceutical products that make use of its oral controlled-release and FlashDose technologies. The firm's proprietary controlledrelease drug delivery technology platforms include Consurf, CEFORM and Shearform, all highly flexible and able to be tailored to the physical, chemical and clinical properties of any given drug compound. Biovail markets its own and other select licensed products directly to health care professionals through its North American sales operations at Biovail Pharmaceuticals, Inc. and Biovail Pharmaceuticals Canada. The company develops and markets products in the areas of cardiovascular, pain management and central nervous system therapy, with an emphasis on chronic care medications. In addition, Biovail Ventures invests in strategic technology partnerships, early-stage development companies and acquisitions that will strengthen its core competencies. The company also owns Nutravail Technologies, Inc., which specializes in the development of innovative nutraceuticals, nutritional products and functional foods, with over 80 patents, including the SportSafe line of products. Biovail's products include Cedax for respiratory infections, Rondec for allergies, Teventen for hypertension, Cardizem CD for angina and hypertension and Zovirax for herpes virus. In recent news, the firm received FDA approval for an orally disintegrating version of zolpidem, a sleep aid sold under the name Ambien. Biovail also recently entered into an agreement with Reliant Pharmaceuticals to co-promote a number of Biovail products, including Teventen and Cedax.

BRANDS/DIVISIONS/AFFILIATES: Cedax FlashDose Cardizem CD SportSafe Consurf Nutravail Technologies, Inc. Biovail Technologies, Ltd. Biovail Pharmaceuticals, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Eugene N. Melnyk, CEO Brian H. Crombie, Sr. VP/CFO Debbie Yip, Dir.-Human Resources John R. Miszuk, VP/Controller Patrick Dwyer, VP-Mfg. Kenneth C. Cancellara, Sr. VP/Corp. Sec. Kenneth C. Cancellara, General Counsel Rolf K. Reininghaus, Sr. VP-Corp. and Strategic Dev. William S. Poole, Pres.-North American Pharmaceuticals Kenneth G. Howling, VP-Finance Eugene N. Melnyk, Chmn.

Phone: 905-286-3000 Fax: 905-286-3050 Toll-Free: Address: 7150 Mississauga Rd., Mississauga, Ontario L5N8M5 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $549,328 ( 9 months) 2002 Profits: $190,585 ( 9 months) Stock Ticker: BVF 2001 Sales: $583,300 2001 Profits: $87,400 Employees: 1,322 2000 Sales: $309,200 2000 Profits: $-148,000 Fiscal Year Ends: 12/31 1999 Sales: $176,500 1999 Profits: $-110,000 1998 Sales: $112,800 1998 Profits: $41,600


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $552,644 Stock Purch. Plan: Second Exec. Salary: $377,353 ADVANTAGE: Controlled-release technology/Growth through acquisitions.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



BONE CARE INTERNATIONAL

www.bonecare.com


Y



Profits: 107


TYPES OF BUSINESS:



Drugs-Hormone Production Vitamin D Hormone Therapies

Bone Care International, Inc. is a pharmaceutical company engaged in discovering, developing and commercializing improved vitamin D hormone therapies to treat secondary hyperparathyroidism in patients with kidney or renal disease, osteoporosis and many other diseases. The company’s lead products, Hectorol Injection and Hectorol Capsules, are FDA-approved for reducing elevated parathyroid hormone levels in patients undergoing chronic renal analysis. Bone Care International is currently researching Hectorol for the treatment of osteoporosis, psoriasis and cancers of the prostate, breast and colon. The company is also investigating the use of LR-103, BCI202 and other research compounds in pre-clinical studies as treatments for psoriasis and cancers. LR-103 inhibits growth of skin cells as well as breast and colon cancer cells. LR-103 currently is in the late stages of pre-clinical research, and the company plans to begin Phase I clinical studies with LR-103 in 2003. Recently, Bone Care International received FDA approval for treatment of secondary hyperparathyroidism in chronic kidney disease patients. In other news, the company announced it selected DRAXIS Pharma, Inc. as a secondary manufacturer of Hectoral Injection. Bone Care International, Inc. offers its employees health, dental, life and disability insurance, tuition assistance, stock option plans and a 401(k) savings plan.

BRANDS/DIVISIONS/AFFILIATES: Hectorol Injection Hectorol Capsules LR-103 BCI-202

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul L. Berns, CEO Paul L. Berns, Pres. Robert A. Beckman, VP-Finance Carmine Durham, VP- Mktg. Jennifer Nelson, Dir.-Human Resources Basil Mundy, VP-Corp. Dev. James Caruso, VP-Sales Andrew Morgan, VP-Regulatory, Quality and Compliance Richard B. Mazess, Chmn.

Phone: 608-662-7800 Fax: 608-662-0032 Toll-Free: 888-389-3300 Address: 1600 Aspen Commons , Madison, WI 53562 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $15,000 (12 months) 2002 Profits: $-69,000 (12 months) Stock Ticker: BCII 2001 Sales: $5,997 2001 Profits: $-9,014 Employees: 86 2000 Sales: $ 400 2000 Profits: $-9,800 Fiscal Year Ends: 6/30 1999 Sales: $ 100 1999 Profits: $-5,800 1998 Sales: $ 100 1998 Profits: $-4,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $176,730 Stock Purch. Plan: Y Second Exec. Salary: $167,069 ADVANTAGE: Expertise in vitamin D hormone therapies.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



BOSTON BIOMEDICA INC

www.bbii.com


Y



Y Y Y

TYPES OF BUSINESS:

Profits: 3




Drugs-Diagnostics Laboratory Services Medical Instruments Laboratory Instruments Pressure Cycling Technology Clinical Trials After-Sales Services

Boston Biomedica, Inc. and its subsidiaries provide products and services for the detection and treatment of infectious diseases such as AIDS and viral hepatitis. The firm's business units are BBI Diagnostics, a manufacturer of quality control and other diagnostic products used to increase the accuracy of in vitro diagnostic tests; BBI Biotech Research Laboratories, the research and development arm of the company; BBI Source Scientific (BBISS), a developer and manufacturer of laboratory and medical instruments; and the pressure cycling technology (PCT) research and development segment. The PCT segment develops solutions for health care problems including extraction of nucleic acids, inactivation of pathogens in human plasma, food safety and genomics. This division is currently manufacturing prototypes of the Barocycler instrument and disposable PULSE tubes utilizing PCT technology. Formerly, Boston Biomedica was also engaged in clinical laboratory activities, but the firm exited this segment of business in late 2000. BBI Diagnostics' products include quality control panels, diagnostic components and Accurun run controls, all used in connection with infectious disease testing. BBISS manufactures lab instruments including readers, washers and other small medical devices used in hospital and clinics and in research, environmental and food testing labs. Products include MicroChem and MicroChemII photometers, ChemStat automated photometers, EXECWASH washing systems and Verif-EYE reflectance readers. Boston Biomedica's other services include clinical trials, laboratory instrumentation services and after-sales services, including third-party maintenance. In recent news, the company announced that it has released for sale the first product based on its PCT technology, the PCT Sample Preparation System, which consists of the Barocycler instrument and single-use PULSE tubes. The product will be sold for use in the fields of genomics and proteomics.

BRANDS/DIVISIONS/AFFILIATES: BBI Source Scientific BBI Biotech Research Laboratories BBI Diagnostics PULSE Barocycler Accurun MicroChem ChemStat

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard T. Schumacher, CEO Kevin W. Quinlan, COO Kevin W. Quinlan, Pres. Kathleen W. Benjamin, VP-Human Resources Patricia E. Garrett, Sr. VP-Science and Tech. Richard J. D'Allesandro, VP-IT Patricia E. Garrett, Sr. VP-Strategic Programs Kevin W. Quinlan, Treas. Mark M. Manak, Sr. VP/Mgr., BBI Biotech Research Laboratories David F. Petersen, Sr. VP/Mgr., BBI Source Scientific Richard T. Schumacher, Chmn.

Phone: 508-580-1900 Fax: 508-580-1110 Toll-Free: 800-676-1881 Address: 375 West St., West Bridgewater, MA 02379 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $16,685 ( 9 months) 2002 Profits: $-1,522 ( 9 months) Stock Ticker: BBII 2001 Sales: $21,800 2001 Profits: $3,400 Employees: 202 2000 Sales: $19,470 2000 Profits: $-8,001 Fiscal Year Ends: 12/31 1999 Sales: $19,798 1999 Profits: $- 800 1998 Sales: $19,265 1998 Profits: $-4,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: New focus on drug development.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



BOSTON LIFE SCIENCES INC

www.bostonlifesciences.com


Y



Y Y

TYPES OF BUSINESS:




Drug Development and Marketing Therapeutic Drugs Diagnostic Products

Boston Life Sciences, Inc. is a biotechnology company engaged in the development and commercialization of novel diagnostics and therapeutic products to treat chronic debilitating diseases, such as cancer, central nervous system disorders and autoimmune diseases. Currently, the company has 10 products in development. These products include Altropane, a radio-imaging agent for the diagnosis of Parkinson’s disease and Attention Deficit Hyperactivity Disorder, and Troponin I, a naturally occurring anti-angiogenesis factor for the treatment of solid tumors. AF-1 and Inosine are nerve growth factors for the treatment of stroke, spinal cord and optic nerve injury. C-MAF is a transcription factor that controls molecules associated with autoimmune disease and allergies. Boston Life Sciences is involved in several research and development collaborations, primarily with Harvard University and its affiliates. The company has a manufacturing agreement with MDS Nordion, Inc. to supply the Aptropane imaging agent. Recently, the company received an allowance of claims pertaining to the patent for Inosine to treat stroke injury. In other news, Boston Life Sciences reported that it has completed the testing of Altropane for the diagnosis of Parkinsonian syndromes. The company also announced that its lead anti-cancer compound, Troponin I, when administered by constant infusion in extremely low doses to mice, dramatically suppressed growth of melanoma metastases in the lung.

BRANDS/DIVISIONS/AFFILIATES: Altropane Troponin I Inosine AF-1 C-MAF

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. S. David Hillson, CEO Robert J. Rosenthal, COO S. David Hillson, Pres. Joseph Hernon, Exec. VP/CFO Marc E. Lanser, Exec. VP/Chief Scientific Officer Samuel B. Martin, Controller Richard M. Thorn, Sr. VP-Mfg. Joseph Hernon, Corp. Sec. Richard M. Thorn, Sr. VP-Product Dev. Jeanne-Marie Varga, Sr. VP-Regulatory Affairs Jennifer Lambert, Clinical Research Coordinator Leslie M. Levine, Sr. VP-Intellectual Property S. David Hillson, Chmn.

Phone: 617-425-0200 Fax: 617-425-0996 Toll-Free: Address: 137 Newbury St., 8th Fl., Boston, MA 02116 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 100 ( 9 months) 2002 Profits: $-8,100 ( 9 months) Stock Ticker: BLSI 2001 Sales: $ 2001 Profits: $-10,300 Employees: 14 2000 Sales: $ 100 2000 Profits: $-10,654 Fiscal Year Ends: 12/31 1999 Sales: $ 200 1999 Profits: $-13,964 1998 Sales: $ 1998 Profits: $-6,897


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $300,000 Bonus: $95,000 Stock Purch. Plan: Y Second Exec. Salary: $245,000 Bonus: $70,000 ADVANTAGE: Exclusive license to a methodology that stimulates regeneration of the optic nerve.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



BRADLEY PHARMACEUTICALS

www.bradpharm.com


Y Y



Profits: 45


TYPES OF BUSINESS:



Drugs-Respiratory Drugs-Dermatology Nutritionals

Bradley Pharmaceuticals markets over-the-counter and prescription pharmaceutical and health related products. The firm’s product line currently includes dermatological brands marketed by its wholly owned subsidiary, Doak Dermatologics, and nutritional, respiratory, personal hygiene and internal medicine brands marketed by its Kenwood Therapeutics division. Bradley’s growth strategy is to make acquisitions, including through co-marketing and licensing agreements, of established products from major pharmaceutical organizations that the company believes require intensified marketing and promotional attention. Products include Trans -ver-sal, Deconamine, Pamine, Acidmantle, Carmol 40 tissue-softeners, ENTsol Spray and ENTsol Single Use and Glutofac-MX, a prescription-only nutritional multi-vitamin. Glutofac-MX helps maintain proper mineral levels and is especially useful for the elderly and patients with special nutritional needs, an inadequate diet, illness, infection, trauma or recent surgery.

BRANDS/DIVISIONS/AFFILIATES: Kenwood Laboratories Doak Dermatologics Carmol 40 ENTsol Deconamine Pamine Acidmantle

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Daniel Glassman, CEO Daniel Glassman, Pres. R. Brent Lenczycki, CFO Bradley Glassman, VP-Mktg. & Sales Dileep Bhagwat, VP/Chief Scientific Officer Bruce W. Simpson, Corp. Sec. Gene L. Goldberg, Sr. VP-Bus. Planning Iris S. Glassman, Treas. Robert Dubin, Sr. VP-Sales and Contract Admin. Robert Corbo, VP-Quality Assurance and Regulatory Affairs

Phone: 973-882-1505 Fax: 973-575-5366 Toll-Free: Address: 383 Rte. 46 W., Fairfield, NJ 07004 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $28,543 ( 9 months) 2002 Profits: $5,523 ( 9 months) Stock Ticker: BPRX 2001 Sales: $25,700 2001 Profits: $3,600 Employees: 124 2000 Sales: $18,557 2000 Profits: $-2,063 Fiscal Year Ends: 12/31 1999 Sales: $18,850 1999 Profits: $ 561 1998 Sales: $15,900 1998 Profits: $ 900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $237,900 Stock Purch. Plan: Second Exec. Salary: $152,400 ADVANTAGE: Successful growth strategy/Broad product line.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $209,000 Bonus: $79,900

Northeast: Y

International:



BRISTOL MYERS SQUIBB CO

www.bms.com


Y Y



Y

TYPES OF BUSINESS:

Profits: 4




Drugs-Cardiovascular Medical Devices Nutritional Products Beauty Aids Personal Care Products

The Bristol-Myers Squibb Company is one of the largest health and personal care companies in the world. Highly diversified, Bristol Myers produces and distributes pharmaceutical products, medical devices, nonprescription health products, nutritionals and beauty aids. BristolMyers is a producer of many important medicines and a leader in providing drugs for anti-cancer therapies and treatments for heart disease, high blood pressure, stroke, type-2 diabetes, HIV/AIDS, depression, anxiety and pain. Some leading and well-known products include Pravachol, a cholesterol-reduction drug; TAXOL, a cancer treatment drug; and Excedrin, a headache and migraine drug. Its Clairol group, the number one hair products company in the U.S., produces hair care products, skin care products and hair color, with such products as Nice n’ Easy, Infusium 23, Loving Care and Herbal Essences. Mead Johnson Nutritionals, a subsidiary of the company, offers nutritional products for infants and adults, including energy drinks, energy bars, beverages, infant formula and vitamins such as Boost, Enfamil and Poly-Vi-Sol. Another subsidiary, ConvaTec, offers ostomy care and modern wound care products such as Active Life, a one-piece ostomy system; DuiDERM, a hydroactive gel; and SAFClens, a chronic wound cleanser. In recent news, BristolMyers Squibb acquired DuPont Pharmaceuticals Company, which will strengthen its virology and cardiovascular franchises, as well as its research and development and discovery efforts. In addition, the company and ImClone Systems entered into an agreement to co-develop and co-promote Erbitux, a drug used for the treatment of certain types of cancer. Bristol-Myers’ employees enjoy high pay, above-average benefits and two weeks or more of vacation each year. Some facilities offer child-care services, and the firm sends baby formula to an employee's home for a newborn's first year. The company also gives bonuses to all of its employees at Christmas.

BRANDS/DIVISIONS/AFFILIATES: ConvaTec Clairol, Inc. Mead Johnson Nutritionals Excedrin Nice n' Easy Boost DuPont Pharmaceuticals Erbitux

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Peter R. Dolan, CEO Peter R. Dolan, Pres. Frederick S. Schiff, Sr. VP/CFO Wendy L. Dixon, Chief Mktg. Officer Stephen E. Bear, Sr. VP-Human Resources James B. D. Palmer, Chief Scientific Officer Curtis L. Tomlin, VP/Controller Andrew G. Bodnar, Sr. VP-Medical and External Affairs Sandra Leung, Corp. Sec. John L. McGoldrick, Exec. VP/General Counsel Tamar D. Howson, Sr. VP-Corp. Dev. John L. Skule, Sr. VP-Corp. Affairs Harrison M. Bains, Treas. Elliott Sigal, Sr. VP-Drug Discovery and Exploratory Dev. Graham Brazier, VP-Bus. Dev. Jack Geltosky, VP-External Science and Tech. James E. Foley, VP-Bus. Dev., Asia

Phone: 212-546-4000 Fax: 212-546-4020 Toll-Free: Address: 345 Park Ave., New York, NY 10154-0037 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $8,135,000 ( 6 months) 2002 Profits: $1,025,000 ( 6 months) Stock Ticker: BMY 2001 Sales: $19,423,000 2001 Profits: $5,245,000 Employees: 46,000 2000 Sales: $18,216,000 2000 Profits: $4,711,000 Fiscal Year Ends: 12/31 1999 Sales: $16,878,000 1999 Profits: $4,167,000 1998 Sales: $15,061,000 1998 Profits: $3,141,000


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Y Top Exec. Salary: $1,033,333 Bonus: $1,314,922 Stock Purch. Plan: Y Second Exec. Salary: $712,000 Bonus: $521,626 ADVANTAGE: Large research and development budget/Continues to launch new products rapidly.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Northeast: Y

International: Y



BRITISH BIOTECH PLC

www.britbio.co.uk


Y



Y

TYPES OF BUSINESS:

Profits: 189




Drugs-Cancer, Asthma, Arthritis and Multiple Sclerosis

British Biotech engages in the discovery research of new compounds and creates partnerships with pharmaceutical companies to complete the development and marketing of those compounds. The company is organized into five departments: information management, regulatory management, pharmacology and therapeutics, chemistry and biology. The firm's research is focused on metalloenzyme inhibition programs. Metalloenzymes can be found in human genomic databases and control a broad range of biological processes. New classes of antibiotics that inhibit bacterial metalloenzymes are being discovered. The four discovery project areas involve inhibitors of polypeptide deformylase (PDF), LpxC inhibitors, gram -positive and broad-spectrum indications. BB-10901, a tumour activated prodrug targeting small-cell lung cancer cells, is being in-licensed from ImmunoGen. British Biotech is developing BB-10153, an agent for the treatment of cardiovascular disease, and BB-83698, an inhibitor targeted at pneumonia patients. Recently, British Biotech signed an agreement with GeneSoft, Inc. to discover and develop anti-infective drugs based on its metalloenzyme inhibitors. In addition, the company and MethylGene, Inc., a Canadian biopharmaceuticals company, entered into a collaboration granting British Biotech the European development and commercialization rights for MG98, MethylGene’s leading experimental anticancer drug. In other recent news, the company announced that its research collaboration with Serono SA has been extended for another year. This collaboration was first created to discover new treatments for inflammatory diseases. British Biotech offers employees a competitive salary and benefits package as well as an active sports and socal club.

BRANDS/DIVISIONS/AFFILIATES: BB-10901 BB-10153 BB-83698 GeneSoft, Inc. MethylGene Inc. MG98 Serono SA Marimastat

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Tim Edwards , CEO Tony Weir, Dir.-Finance Giles Campion, Chief Medical Officer Sue Barrowcliffe, Dir.-Dev. Chris Hampson, Chmn.

Phone: +44-1865-748-747 Fax: +44-1865-781-047 Toll-Free: Address: Watlington Rd., Cowley, Oxford, OX4 6LY UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $2,100 (12 months) 2002 Profits: $-24,700 (12 months) Stock Ticker: BBIOY 2001 Sales: $2,500 2001 Profits: $-36,253 Employees: 180 2000 Sales: $4,100 2000 Profits: $-39,400 Fiscal Year Ends: 4/30 1999 Sales: $6,800 1999 Profits: $-64,100 1998 Sales: $ 800 1998 Profits: $-75,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Strategic alliances.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



CALIPER TECHNOLOGIES CORP

www.calipertech.com




Profits: 1


TYPES OF BUSINESS:

Y Y Y



Chips-Bioanalysis Chip Reading Software Chip Reading Instruments Chip Reading Reagents

Caliper Technologies Corp. designs, manufactures and commercializes LabChip devices and systems, which enable experiments to be conducted on a small chip. The company’s LabChip systems are designed to accelerate laboratory experimentation and have potential applicability in the pharmaceutical, agriculture, chemical and diagnostics industries. Caliper Technologies has developed three types of LabChip systems based on distinct chip formats: personal laboratory systems, high throughput systems and application development systems. The personal laboratory systems use chips with reservoirs for the various chemical reagents. The high throughput systems use sipper chip systems with a short tube that draws nanoliter volumes of reagents into the chip. The application development system is a microscope-based instrument that uses chips capable of performing many different analytical experiments, or assays, and analyses. The company’s first personal laboratory system is the Agilent 2100 Bioanalyzer, a desktop instrument designed to perform a wide range of everyday scientific applications using a menu of different LabChip kits. This LabChip system brings the benefits of miniaturized, integrated and automated experimentation to the researcher’s desktop. High throughput systems are being designed to perform tens of thousands of pharmaceutical experiments per day on each chip. The hardware platforms on which these systems run today include the Caliper AMS 90 SE, Caliper 42 and Caliper 250. Caliper Technologies has five ongoing collaborations, including relationships with Millennium, GlaxoSmithKline and the National Aeronautics and Space Administration (NASA). Recently, the company and Agilent Technologies, Inc. launched the RNA 6000 Pico LabChip kit for the automated quality control of both total and messenger RNA (mRNA) samples. The new kit makes it useful for cancer research. Caliper Technologies offers its employees on-site dry cleaning services, massage therapy and yoga classes, as well as a corporate discount plan with Celluar One and 24Hour Fitness.

BRANDS/DIVISIONS/AFFILIATES: Agilent Technologies Agilent 2100 Bioanalyzer RNA 6000 Pico LabChip Caliper AMS 90 SE Caliper 250 Caliper 42 Millennium

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael R. Knapp, CEO James L. Knighton, Pres. Anthony T. Hendrickson, VP-Finance Michael Merion, VP-Mktg. and Sales J. Wallace Parce, VP-Research Bruce E. MacMillan, VP/General Counsel William Wright, VP- Partnership Oper. William C. Kruka, VP-Bus. Dev. Robert E. Nagle, VP- Product Dev. Anne R. Kopf-Sill, VP-New Products Daniel L. Kisner, Chmn.

Phone: 650-623-0700 Fax: 650-623-0500 Toll-Free: Address: 605 Fairchild Dr., Mountain View, CA 94043-2234 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $20,900 ( 9 months) 2002 Profits: $-30,429 ( 9 months) Stock Ticker: CALP 2001 Sales: $26,900 2001 Pr ofits: $3,800 Employees: 2000 Sales: $18,564 2000 Profits: $-13,317 Fiscal Year Ends: 12/31 1999 Sales: $12,087 1999 Profits: $-14,373 1998 Sales: $8,155 1998 Profits: $-2,975


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $423,516 Stock Purch. Plan: Y Second Exec. Salary: $285,866 ADVANTAGE: Cutting-edge semi-conductor technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $180,000 Bonus: $110,000

Northeast:

International:



CAMBREX CORP

www.cambrex.com


Y Y



Y

TYPES OF BUSINESS:

Profits: 37




Drug Ingredients for Over the Counter and Prescription Drugs Chemical Processes Polymer Systems High Throughput Screening Animal Health Products Nutritional Supplements

Cambrex Corporation primarily provides products and services worldwide to the life sciences industry. Cambrex operates in four segments, Human Health, Biosciences, Animal Health/Agriculture and Specialty and Fine Chemicals. The Human Health, Biosciences and Animal Health/Agriculture segments facilitate all the ongoing analysis of the business in the area of life sciences. Currently, the company's overall strategy for these segments is to focus on niche markets that have global opportunities, build on strong customer relations to enhance its new products pipeline and support state-ofthe-art technology. The Human Health division manufactures active pharmaceutical ingredients that are used in prescription and over-the-counter drugs that treat gastro-intestinal, cardiovascular, endocrine, central nervous system, respiratory, anti-infective and various other problems. Moreover, this segment constitutes the largest portion of the company's revenue. Recently, Cambrex acquired Marathon Biopharmaceuticals through a share purchase of CoPharma, Inc. In addition, the firm purchased Bio Science Contract Production Corp., which deals with cGMP manufacture of purified bulk biologics and pharmaceutical ingredients. The company also recently sold its in vitro diagnostic product line to Diagnostic Hybrids, Inc. Employee benefits at Cambrex include employee awards, tuition reimbursement plans, scholarship programs, and a health plan, all of which begin on the first day of employment.

BRANDS/DIVISIONS/AFFILIATES: Biowhittaker, Inc. Cosan Chemical Corporation Heico Chemicals, Inc. LumiTech, Ltd. Nepera, Inc. CoPharma, Inc. Marathon Biopharmaceuticals Bio Science Contract Production Corp.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James A. Mack, CEO Claes Glassell, Pres. Claes Glassell, COO Salvatore J. Guccione, Sr. VP/CFO Steven M. Klosk, VP-Human Resources Ron D. Carroll, VP/Chief Tech. Officer Robert J. Congiusti, VP-Info. Services John P. Hopkins, VP/Controller Peter E. Thauer, Sr. VP/Corp. Sec. Peter E. Thauer, Sr. VP-Law/General Counsel Steven M. Klosk, Exec. VP-Admin. Thomas N. Bird, VP-Bus. Dev. John A. Antonelli, Jr., VP/Treas. Monika Lekander, Pres., Innovator Pharmaceuticals Aaron H. Heifetz, General Mgr., Cambrex Bio Science N. David Eansor, VP/General Mgr.-Biotherapeutics John Hopkins, VP-Finance

Phone: 201-804-3000 Fax: 201-804-9852 Toll-Free: Address: One Meadowlands Plaza, East Rutherford, NJ 07073 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $385,622 ( 9 months) 2002 Profits: $33,260 ( 9 months) Stock Ticker: CBM 2001 Sales: $498,900 2001 Profits: $26,600 Employees: 2,079 2000 Sales: $484,246 2000 Profits: $49,605 Fiscal Year Ends: 12/31 1999 Sales: $481,388 1999 Profits: $38,132 1998 Sales: $457,241 1998 Profits: $39,102


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $537,500 Stock Purch. Plan: Second Exec. Salary: $364,845 ADVANTAGE: Has technical expertise in a wide range of chemical processes.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $114,000 Bonus: $48,000

Northeast: Y

International: Y



CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC www.cambridgeantibody.com Industry Group Code: 541710 Ranks within this company's industry group: Sales: 30 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y


Y Y


Profits: 21


TYPES OF BUSINESS:



Drugs-Human Antibodies

Based in the United Kindgom, Cambridge Antibody Technology uses its proprietary technologies in human monoclonal antibodies to conduct drug discovery research. The firm’s technology aids in the validation of drug targets and is intended to generate short-term revenues through partnerships with pharmaceutical and biotechnology companies. Cambridge uses the phage display method (which illustrates bacterial viruses) to create libraries of antibodies. These antibodies then target chosen molecules. The formation of a large library of such antibodies combined with a proprietary polysome display technology gives Cambridge an edge over its competitors. Cambridge has introduced the use of robotics to automate the isolation and screening process of human monoclonal antibodies. The firm has formed several strategic relationships to help it achieve its ends, including collaborations with Abbot Laboratories, Amrad, Lonza Biologics, Merck, Immunex, Elan, Human Genome Sciences and Zyomyx. The firm has a strong patent portfolio in both the United States and Europe. Currently, six products are undergoing clinical trials. These include D2E7, a treatment for rheumatoid arthritis and Crohn’s disease; CAT-152, a compound for glaucoma surgery; J695, an autoimmunity/inflammation drug; CAT-192, for local and systemic fibrosis; CAT-213, for allergic rhinitis; and LymphoStat-B, for autoimmune disorders. Recently, the company announced a licensing agreement with Japan's Chugai Pharmaceutical Co., Ltd. For Cambridge's proprietary antibody phage display libraries. In other news, Cambridge and Xerion Pharmaceuticals announced the expansion of their existing business relationship into a research collaboration that will explore and evaluate the therapeutic potential of a cell surface protein known to play a role in allergic reactions. Cambridge Antibody Technology offers employees a competitive benefits package, including options and share schemes.

BRANDS/DIVISIONS/AFFILIATES: D2E7 CAT-152 J695 CAT-192 CAT-213 LymphoStat-B

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Peter Chambré, CEO John Aston, CFO Kevin Johnson, Chief Tech. Officer David Glover, Chief Medical Officer Diane Mellett, Sr. VP/Corp. Sec. Diane Mellett, General Counsel Nigel Burns, VP-Pre-Clinical Dev. Jason Avery, Sr. VP-Bus. Alliances Alex Duncan, VP-Drug Discovery Peter Garland, Chmn.

Phone: +44-1763-263-233 Fax: +44-1763-263-413 Toll-Free: Address: Science Park, Melbourne, Cambridgeshire SG8 6JJ UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $10,000 ( 9 months) 2002 Profits: $-31,900 ( 9 months) Stock Ticker: CATG 2001 Sales: $10,500 2001 Profits: $-17,300 Employees: 2000 Sales: $14,800 2000 Profits: $-7,600 Fiscal Year Ends: 12/31 1999 Sales: $3,000 1999 Profits: $-21,000 1998 Sales: $2,300 1998 Profits: $-11,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Develops and maintains a library of antibodies which are displayed using polysome technology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast:

International: Y



CARACO PHARMACEUTICAL LABORATORIES www.caraco.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 136 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Profits: 93


TYPES OF BUSINESS:



Drugs-Generic

Caraco Pharmaceutical Lab develops, manufactures and markets generic drugs for prescription and over-thecounter markets. The company’s product portfolio includes 12 products in 22 strengths and 36 package sizes. It currently markets all 12 products. These drugs relate to a variety of therapeutic segments, including the central nervous system, cardiology, pain management and diabetes. Caraco has submitted 10 new drug applications to the FDA for the approval of generic drug marketing. Six of these 10 applications have been approved. The company has collaborative agreements with several companies, including Hexal-Pharma GmbH&Co., Clonmel Chemicals Co., Ltd. and Sun Pharmaceutical Industries (Sun Pharma). Under these agreements, Caraco develops generic drugs for each company to market as its own brand. Caraco develops products for Germanybased Hexal-Pharma and Ireland-based Clonmel Chemical on a regular basis. Pharmaceutical products that the company produces include (with prescription name) guaifenesin LA (Humabid LA), metoprolol tartrate (Lopressor), miraphen PSE (Entex PSE) and carbamazephine (Tegretol). In recent news, Caraco received FDA approval to manufacture and market ticlopidine hydrochloride, a platelet inhibitor for cardiac patients.

BRANDS/DIVISIONS/AFFILIATES: Tegretol Entex PSE Humabid LA Lopressor

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Narendra N. Borkar, CEO Jitendra N. Doshi, COO Narendra N. Borkar, CFO Dilip S. Shanghvi, Chmn.

Phone: 313-871-8400 Fax: 313-871-8314 Toll-Free: Address: 1150 Elijah McCoy Dr., Detroit, MI 48202 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $14,828 ( 9 months) 2002 Profits: $ ( 9 months) Stock Ticker: CARA 2001 Sales: $5,900 2001 Profits: $-5,800 Employees: 76 2000 Sales: $2,400 2000 Profits: $-7,600 Fiscal Year Ends: 12/31 1999 Sales: $2,900 1999 Profits: $-9,700 1998 Sales: $2,700 1998 Profits: $-5,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Focus on generic drugs.

OTHER THOUGHTS:




West:

Southwest:

Midwest: Y

Southeast:



Bonus: $ Bonus: $

Northeast:

International: Y



CARDIOME PHARMACEUTICAL CORP Industry Group Code: 325412 Ranks within this company's industry group: Sales: 208 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



www.cardiome.com Profits: 86


TYPES OF BUSINESS:



Drugs-Arrhythmias Drugs-Intractable Cough Drugs-Male Sexual Dysfunction

Cardiome Pharma Corp., formerly know as Nortran Pharmaceuticals, Inc., is a drug discovery and development company focused on developing proprietary drugs to treat or prevent cardiac diseases. The company operates productively in the cardiovascular, pain and respiratory areas, focusing its efforts on three projects designed to prevent or treat atrial and/or ventricular arrhythmia. Project RSD1235 is currently in a Phase II clinical trial using intravenous administration to convert new onset atrial fibrillation patients to normal heart rhythm. Project RSD1122 is an orally active agent to treat ventricular or atrial arrhythmia. Kv1.5 project is a discovery-stage project focused on discovering an agent that treats atrial arrhythmia by selectively blocking a specific ion channel found only in atrial cardiac tissue. Cardiome also recently acquired a clinical-stage project designed to treat congestive heart failure from ILEX Oncology, Inc. Oxypurinol, the lead candidate in this project, is a xanthine oxidase inhibitor. Cardiome is involved in academic collaborations with the Montreal Heart Institute and the University of British Columbia (UBC). In recent news, Cardiome announced it has completed the acquisition of Paralex, Inc., a New Yorkbased company. In other news, the company entered into an agreement under which UBC will acquire all technology pertaining to its pre-clinical anti-tussive program. Cardiome Pharmaceuticals offers medical and dental benefits, an employee stock oprion program, professional development and support activities and social events.

BRANDS/DIVISIONS/AFFILIATES: RSD1235 RSD1122 Kv1.5 Oxypurinol Paralex, Inc. Nortran Pharmaceuticals, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert W. Rieder, CEO Robert W. Rieder, Pres. Christina Yip, Dir.-Finance Alan Ezrin, Chief Scientific Officer Christina Yip, Corp. Sec. Christina Yip, Dir.-Admin. Sheila M. Grant, Dir.-Bus. and Clinical Dev. Alan F. Moore, Exec. VP-Clinical Dev. and Regulatory Affairs Gregory N. Beatch, VP-External Scientific Affairs Mark C. Rogers, Chmn.

Phone: 604-222-5577 Fax: 604-222-6617 Toll-Free: 800-330-9928 Address: 3650 Westbrook Mall, Vancouver, BC V6S 2L2 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,143 ( 9 months) 2002 Profits: $-5,632 ( 9 months) Stock Ticker: COMRF.OB 2001 Sales: $ 402 2001 Profits: $-4,557 Employees: 32 2000 Sales: $ 192 2000 Profits: $-3,000 Fiscal Year Ends: 11/30 1999 Sales: $ 294 1999 Profits: $-2,909 1998 Sales: $ 239 1998 Profits: $-3,616


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $258,836 Stock Purch. Plan: Y Second Exec. Salary: $241,250 ADVANTAGE: Low -risk, low -cost strategy/Several therapies under development.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International: Y



CARDIOTECH INTERNATIONAL

www.cardiotech-inc.com



Y


Profits: 12


TYPES OF BUSINESS:



Synthetic Blood Vessels

CardioTech International makes synthetic blood vessels including vascular grafts, peripheral grafts and coronary artery bypass grafts. CT Biomaterials, a division of CardioTech, manufactures these products and sells them to device manufacturers. The products are made from polyurethane-based biomaterial and sold under the tradenames ChronoFlex, HydroThane, ChronoPrene, PolyBlend, HydroMed, HydroSlip and ChronoThane. CardioTech’s research efforts are focused on the development of CardioPass, a coronary artery bypass graft. This graft is used to replace, bypass or provide a new lining or arterial wall for occluded, damaged, dilated or severely diseased arteries. By replacing or bypassing diseased arteries, its vascular graft products provide access during dialysis treatment for patients undergoing hemodialysis. Recently, CardioTech entered into a definitive agreement to acquire Gish Biomedical, Inc., which specializes in the manufacture and sale of products used in open heart surgery, vascular access and orthopedic surgery. In other news, CardioTech received FDA approval to market SpyroDerm, its newly developed water-absorbent wound and burn dressing.

BRANDS/DIVISIONS/AFFILIATES: CardioTech International, Ltd. CT Biomaterials CardioPass Gish Biomedical, Inc. ChronoFlex HydroThane CardioPass SpyroDerm

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael Szycher, CEO Thomas Lovett, Controller Kenneth R. Nelson, Production Mgr. Michael Szycher, Treas. Michael Szycher, Chmn.

Phone: 781-933-4772 Fax: 781-933-3933 Toll-Free: Address: 78E Olympia Ave., Woburn, MA 01801-2057 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,200 (12 months) 2002 Profits: $-2,000 (12 months) Stock Ticker: CTE 2001 Sales: $1,543 2001 Profits: $5,705 Employees: 9 2000 Sales: $1,497 2000 Profits: $-3,814 Fiscal Year Ends: 3/31 1999 Sales: $1,083 1999 Profits: $-2,625 1998 Sales: $ 900 1998 Profits: $-1,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $225,481 Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Novel synthetic blood vessel technology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



CARRINGTON LABORATORIES INC www.carringtonlabs.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 95 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Y

TYPES OF BUSINESS:

Profits: 56




Drugs-Carbohydrate-Based Alginates Anti-Fungal Ointments Cleansers Injectable Human Anti-Cancer Vaccines Poultry Vaccines Topical Dressings Veterinary Anti-Cancer Vaccines

Carrington Laboratories, Inc. is a world-class research, development and manufacturing operation. The company formulates aloe vera into a variety of FDA or USDA regulated devices, biologics, drugs in development and various cosmetic and food grade products. The firm grows its aloe vera on a plantation in Costa Rica, ensuring an organic environment of sunshine, warm temperatures and volcanic soil. The aloe vera is harvested and freeze-dried using a patented process, before being shipped to the company’s manufacturing facility in Irving, Texas. Carloe, Inc., a subsidiary of the Carrington Laboratories, markets raw materials and finished products from aloe vera utilizing patented complex carbohydrate technology. In addition, the company’s Mom’s Aloe Store subsidiary is the exclusive online retailer of Carrington and AloeCeuticals products. Mom’s Aloe Store also features health care articles and product specials. Carrington recently received clearance from the FDA to market its SaliCept Oral Patch. The product is intended for use in tooth extraction sites and to help manage alveolar osteitis and will be dispensed by licensed oral surgeons and dental professionals. The oral patch will continue to be marketed for general oral pain applications in nonprescription form. In a related move, Carrington granted exclusive Japanese distribution rights for the Oral Patch to Sunstar, Inc., a leading manufacturer of oral care products in Japan. The company also recently formed a subsidiary, DelSite Biotechnologies, Inc., to oversee a new product development initiative. In other news, the firm entered into a marketing alliance with Medline Industries . Under the agreement, the two companies merged their sales forces in order to increase marketing and distribution synergies.

BRANDS/DIVISIONS/AFFILIATES: WoundCare.com SaliCept Oral Patch Mom's Aloe Store Medline Industries Carloe, Inc. Sabila Industrial, S.A. DelSite Biotechnologies, Inc. RadiaCare Gel

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Carlton E. Turner, CEO Carlton E. Turner, Pres. Robert W. Schnitzius, CFO Carol Kitchell, Dir.-Human Resources Kenneth M. Yates, VP-Research & Dev. Robert W. Schnitzius, Corp. Sec. Robert W. Schnitzius, Treas. Robert A. Fildes, Interim Exec. VP-Research & Dev.

Phone: 972-518-1300 Fax: 972-518-1020 Toll-Free: 800-527-5216 Address: 2001 Walnut Hill Ln., Irving, TX 75038 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $11,326 ( 9 months) 2002 Profits: $-2,442 ( 9 months) Stock Ticker: CARN 2001 Sales: $17,600 2001 Profits: $ 400 Employees: 181 2000 Sales: $23,103 2000 Profits: $-3,476 Fiscal Year Ends: 12/31 1999 Sales: $28,100 1999 Profits: $-2,000 1998 Sales: $23,600 1998 Profits: $-1,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Product portfolio based primarily on complex carbohydrate technology derived from the aloe vera plant.

OTHER THOUGHTS:



West:

Southwest: Y

Midwest:

Southeast:



Northeast:

International: Y



CELERA GENOMICS GROUP

www.celera.com



Y


Y

TYPES OF BUSINESS:

Profits: 36


Y Y



Research-Human Genome Mapping Genetic Database Management Software

Celera Genomics Group, a division of Applera Corporation, is engaged principally in the generation, compilation, sale and support of genomic information as well as related information management and analysis software. The company also provides discovery, validation and licensing of proprietary gene products, genetic markers and information concerning genetic variability and related consulting, contract research and development services. Specifically, it assists pharmaceutical, biotechnology and life science research entities in areas of research, including new drugs and improved drug development processes; novel genes and factors that regulate and control gene expression; and interrelationships between genetic variability, disease and drug response. Notably, Celera completed mapping the human genome well ahead of the government-sponsored Human Genome Project and faster than its own expectations. The underlying human genetic sequence is the basis for Celera’s development of a value-added, integrated information and discovery system. The system includes increasing layers of functional information such as gene expression data, comparative data from other model organisms (such as the Drosophila fruit fly and mouse), genetic variation and ultimately gene function. Users of the information and discovery system will have the ability to browse, view and analyze the data in an integrated way that should assist scientists and commercial enterprises in accelerating their understanding of the human genetic code. In recent news, Celera announced its intentions to acquire Axys Pharmaceuticals, Inc., with the expectation that the biopharmaceutical company will elevate its drug discovery capabilities to new levels. It also purchased a small stake in HuBit Genomix, Inc., a Japan-based biotechnology firm, in order to expand its research and development in analyzing genetic variation. In other news, Celera sold its animal genomics and genotyping business to MetaMorphix, Inc., in order to focus on its human therapeutics business.

BRANDS/DIVISIONS/AFFILIATES: PE Corporation Applera Corporation Hospital for Sick Children (The) Celera Diagnostics Applied Biosystems Paracel Axys Pharmaceuticals, Inc. HuBit Genomix, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kathy Ordonez , Pres. Peter Chambre, COO/VP-Applera Ugo DeBlasi, VP-Finance Barbara J. Kerr, VP-Human Resources Robert Booth, Sr. VP-Research and Dev. John Reynders, VP-IS Samuel Broder, Chief Medical Officer James P. Yee, Head of Dev. Werten Bellamy , Group Counsel Lothar Krinke, VP-Bus. Dev. and Strategic Planning Jason Molle, Sr. VP-Online Bus. David Block, Exec. VP/COO- Therapeutics Mark Adams , VP-Genome Programs Shi-Ping Hsu, General Mgr., Paracel Scott Patterson, VP-Proteomics

Phone: 240-453-3000 Fax: 240-453-4000 Toll-Free: 877-235-3721 Address: 45 W. Gude Dr., Rockville, MD 20850 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $120,900 (12 months) 2002 Profits: $-211,800 (12 months) Stock Ticker: CRA 2001 Sales: $89,400 2001 Profits: $-186,200 Employees: 866 2000 Sales: $42,700 2000 Profits: $-92,700 Fiscal Year Ends: 6/30 1999 Sales: $12,500 1999 Profits: $-44,900 1998 Sales: $4,200 1998 Profits: $-8,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $889,227 Stock Purch. Plan: Second Exec. Salary: $484,069 ADVANTAGE: Aggressive strategy/Rapid development of gene-mapping data.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $646,834 Bonus: $258,851

Northeast: Y

International:



CELERIS CORPORATION

www.celeriscorp.com




Y

TYPES OF BUSINESS:

Profits: 13



Y


Services-Regulatory Consulting, Clinical Research and Clinical Trial Management Services

Celeris Corp. is a provider of specialty clinical research and information technology services that expedite and streamline the clinical trial and regulatory submission process for pharmaceutical, medical device and biotechnology companies. The firm's strategy is to offer select services for new drugs, devices and other regulated health care products on a stand-alone basis or as part of a clinical study management program. These services include clinical monitoring services, data management services and regulatory consulting. The firm provides clinical monitors with experience in multiple therapeutic areas on a contract basis In addition, Celeris has developed KnowledgePort, a secure web portal that allows clients unprecedented and continuous access to study data, enabling them to evaluate projects and make betterinformed decisions during the course of clinical research. Regulatory consulting is provided through subsidiary CL McIntosh. Recently, Celeris was acquired by STATPROBE, Inc., a privately held, full-service contract research organization.

BRANDS/DIVISIONS/AFFILIATES: Celeris Data Management and Information Systems CL McIntosh Regulatory Consulting KnowledgePort STATPROBE

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Barbara A. Cannon, CEO Barbara A. Cannon, Pres. Paul R. Johnson, VP/CFO Gary Bynum, Dir.-Human Resources Donald F. Fortin, VP/Chief Scientific Officer Paul R. Johnson, Corp. Sec. John Nehra, Chmn.

Phone: 615-341-0223 Fax: 615-341-0258 Toll-Free: 888-399-2266 Address: 1801 West End Ave., Ste. 750, Nashville, TN 37203 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-2,439 ( months) Stock Ticker: CRSC 2001 Sales: $9,800 2001 Profits: $-2,700 Employees: 95 2000 Sales: $11,200 2000 Profits: $-4,600 Fiscal Year Ends: 12/31 1999 Sales: $10,100 1999 Profits: $-2,100 1998 Sales: $6,400 1998 Profits: $-12,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $225,000 Stock Purch. Plan: Second Exec. Salary: $180,263 ADVANTAGE: Large customer base/Integrated service for drug manufacturers.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Bonus: $ Bonus: $

Northeast: Y

International:



CELGENE CORP

www.celgene.com


Y


Y


Profits: 70


TYPES OF BUSINESS:



Drugs-Immunotherapy Agricultural Products Small-Molecule Drugs

Celgene Corp. is a commercial-stage biopharmaceutical company primarily engaged in the discovery, development and commercialization of small molecule drugs designed to treat cancer and immunological diseases through gene and protein regulation. Celgene's drugs are designed to modulate multiple disease-related genes, including cytokines, growth factor genes and apoptosis genes. Because these drugs can be administered orally, they have the potential to advance the standard of care beyond current injectible protein drugs. The FDA approved the firm's first commercialized product, THALOMID, for sale in the U.S. in 1998. THALOMID is used for the treatment of acute cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL), a complication of leprosy, and as a maintenance therapy to prevent and suppress cutaneous manifestation recurrences. The FDA has also approved Focalin, Celgene's chirally pure version of Ritalin, a treatment for attention deficit disorder. Currently, the company has two immunomodulatory drugs, or IMIDs, in development: REVIMID and ACTIMID. REVIMID is being evaluated for multiple myeloma and metastatic malignant melanoma therapy. ACTIMID is also being evaluated for the treatment of multiple myeloma. In addition, the company has developed the S.T.E.P.S. program, an educational program to instruct in the safe and appropriate use of THALOMID. Other products in development include SelCIDs, small molecule drugs that modulate disease-causing cytokines, and SERMs, which overcome many of the risks associated with hormone replacement therapy. In recent news, Celgene advanced its leading JNK inhibitor into clinical tes ting. In addition, a study in Blood, the journal of the American Society of Hematology, showed that REVIMID has anti-tumor activity in patients with relapsed and refractory multiple myeloma.

BRANDS/DIVISIONS/AFFILIATES: Celgro, Inc. THALOMID S.T.E.P.S. Focalin REVIMID ACTIMID SelCIDs SERM

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John W. Jackson, CEO Sol J. Barer, COO Sol J. Barer, Pres. Robert J. Hugin, Sr. VP/CFO George W.J. Matcham, Sr. VP-Research and Dev. David I. Stirling, Exec. VP-Pharmaceutical Research and Dev. Joseph J. Day, Sr. VP-Planning and Bus. Dev. David I. Stirling, Chief Scientific Officer Steven D. Thomas, VP-Regulatory Affairs and Project Mgmt. Jerome B. Zeldis, Chief Medical Officer/VP-Medical Affairs John W. Jackson, Chmn.

Phone: 732-271-1001 Fax: 732-271-4184 Toll-Free: Address: 7 Powder Horn Dr., Warren, NJ 07059 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $98,573 ( 9 months) 2002 Profits: $-3,574 ( 9 months) Stock Ticker: CELG 2001 Sales: $114,200 2001 Profits: $-1,900 Employees: 383 2000 Sales: $84,200 2000 Profits: $-16,300 Fiscal Year Ends: 12/31 1999 Sales: $38,000 1999 Profits: $-29,600 1998 Sales: $19,200 1998 Pr ofits: $-29,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Growth in rev enues/Acquisitions.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $230,344 Bonus: $131,625

Northeast: Y

International:



CELL GENESYS INC

www.cellgenesys.com


Y



Y

TYPES OF BUSINESS:

Profits: 182




Drugs-Viral Infections and Cancer Human Disease Therapy Gene Delivery Technologies

Cell Genesys, Inc. is a biotechnology company that focuses its research and product development efforts on human disease therapies that are based on innovative gene modification technologies. The company’s strategic objective is to develop and commercialize ex vivo and in vivo gene therapies to treat major, life-threatening diseases and disorders. Cell Genesys' clinical programs include GVAX cancer vaccines in Phase II studies for prostate cancer and Phase I/II studies for lung cancer. GVAX vaccines are being developed through a worldwide collaboration with the pharmaceutical division of Japan Tobacco. In addition, Cell Genesys has preclinical programs that are evaluating potential gene therapies for hemophilia, cancer, HIV, cardiovascular disorders and Parkinson's disease. The company also has assets outside of its core business, which help maintain financial strength while product candidates are under development. These assets include Cell Genesys' equity ownership of Abgenix, Inc., which is focused on the development and commercialization of antibody therapies and a licensing program in gene activation technology. The company recently acquired Calydon, Inc., a private biotechnology company focused on developing therapeutic products for cancer. With this addition, Cell Genesys now has three diverse cancer therapy product platforms. The firm owns newly launched Ceregene, Inc., a biotechnology company whose core focus is on gene therapies for neurologic disorders, including Alzheimer's and Parkinson's disease. This subsidiary was launched as a result of the acquisition of Neurologic Gene Therapeutics, a private start-up company. In other news, the company has obtained the use of a larger manufacturing facility located in the major shipping hub of Memphis, Tennessee. The firm is planning to manufacture its GVAX lung cancer vaccines from this new location.

BRANDS/DIVISIONS/AFFILIATES: GVAX Cancer Vaccine Abgenix, Inc. Somatix Therapy Corporation Japan Tobacco Calydon, Inc. Ceregene, Inc. Neurologic Gene Therapeutics

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen A. Sherwin, CEO Joseph J. Vallner, COO Joseph J. Vallner, Pres. Matthew J. Pfeffer, CFO Christine McKinley, VP-Human Resources Dale G. Ando, VP-Clinical Research and Reg. Affairs Michael W. Ramsay, VP-Mfg. Robert H. Tidwell, VP-Corp. Dev. James G. McArthur, Dir.-Preclinical Biology and Immunology Dale G. Ando, VP-Clinical Research Malcolm J. McKay, VP-Quality and Regulatory Affairs Peter K. Working, VP-Research and Dev.

Phone: 650-425-4400 Fax: 650-425-4457 Toll-Free: Address: 342 Lakeside Dr., Foster City, CA 94404 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $37,173 ( 9 months) 2002 Profits: $-15,049 ( 9 months) Stock Ticker: CEGE 2001 Sales: $28,300 2001 Profits: $-28,700 Employees: 262 2000 Sales: $24,209 2000 Profits: $168,920 Fiscal Year Ends: 12/31 1999 Sales: $33,600 1999 Profits: $-12,000 1998 Sales: $24,100 1998 Profits: $-12,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $445,000 Stock Purch. Plan: Second Exec. Salary: $315,000 ADVANTAGE: Strong acquisitions and licensing agreements.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $200,000 Bonus: $100,000

Northeast:

International:



CELL PATHWAYS INC

www.cellpathways.com


Y



Profits: 187


TYPES OF BUSINESS:



Drugs-Cancer

Cell Pathways, Inc. (CPI) is a pharmaceutical company focused on the research, development and commercialization of products to prevent and treat cancer. CPI is in the development stage until it receives approval and generates significant revenues from the marketing of one of its pharmaceutical drug candidates. The company's technology is based on its discovery of a novel mechanism, which, based on its research, can be targeted to induce selective apoptosis, or programmed cell death, in precancerous and cancerous cells without affecting normal cells. CPI has created a new class of selective apoptotic anti-neoplastic drugs (SAANDS) and has synthesized over 500 new chemical compounds in this new class. In screening assays, over 200 of these new compounds display significantly greater apoptotic potency than CPI's lead drug candidate, Aptosyn. Aptosyn is designed for the treatment of adenomatous polposis coli, lung cancer and the prevention of prostate, colon and breast cancer recurrence. CP-461 is in clinical development for the treatment of chronic lymphocytic leukemia, Crohn’s disease, renal cell carcinoma, prostate caner and solid tumors. CPI has entered into an agreement with Sinclair Pharmaceuticals, Ltd. of the United Kingdom to be the exclusive distributor in North America of their Gelclair product, an oral gel approved for treating oral mucositis, which affects many cancer patients receiving chemotherapy and radiation therapy. Recently, CPI announced the signing of a three-year agreement with Celgene Corporation aimed at broadening physician awareness and sales of Gelclair.

BRANDS/DIVISIONS/AFFILIATES: Aptosyn CP-461 SAANDS Gelclair

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert J. Towarnicki, CEO Robert J. Towarnicki, Pres. Brian J. Hayden, VP/CFO Lloyd G. Glenn, VP-Sales and Mktg. Susan Little, Dir.-Human Resources Rifat Pamukcu, Exec. VP-Research and Dev. Martha E. Manning, Controller Robert E. Bellet, Sr. VP-Clinical and Regulatory Affairs Martha E. Manning, Sr. VP/Corp. Sec. Brian J. Hayden, Treas. Rifat Pamukcu, Chief Scientific Officer Robert W. Stevenson, VP-Intellectual Property W. Joseph Thompson, VP-Research Robert J. Towarnicki, Chmn.

Phone: 215-706-3800 Fax: 215-706-3801 Toll-Free: Address: 702 Electronic Dr., Horsham , PA 19044 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 699 ( 9 months) 2002 Profits: $-12,142 ( 9 months) Stock Ticker: CLPA 2001 Sales: $ 900 2001 Profits: $-31,400 Employees: 77 2000 Sales: $ 329 2000 Profits: $-26,916 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-19,634 1998 Sales: $ 1998 Profits: $-19,345


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $274,200 Stock Purch. Plan: Second Exec. Salary: $205,950 ADVANTAGE: Unique anti-cancer therapies/Patented SAANDS technology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $100,000 Bonus: $75,000

Northeast: Y

International:



CELL THERAPEUTICS INC

www.cticseattle.com


Y



Profits: 228


TYPES OF BUSINESS:



Drugs-Cancer, Inflammatory Disease and Immune Disease

Cell Therapeutics focuses on developing, acquiring and commercializing treatments for cancer. The company’s goal is to build a leading, vertically integrated biopharmaceutical company with a diversified portfolio of oncology drugs and drug candidates. Cell Therapeutics’ research and in-licensing activities are concentrated on identifying new, less toxic and more effective ways to treat cancer. The company has one marketed product, TRISENOX, an arsenic trioxide injection. This lead product is designed to treat leukemia, lymphomas and other cancers. Products that the company is researching include XYOTAX, CT-2106 and CT-2584. XYOTAX is linked to paclitaxel, the active ingredient in Taxol, the world’s best-selling cancer drug. It is currently in Phase II trials in the U.S. and Europe. CT-2106 appears to be capable of delivering more chemotherapy directly to tumors and is in development for the treatment of advanced colon, lung and ovarian cancer. Recently, Cell Therapeutics announced it would partner with Hope Heart Institute to collaborate on the research of new cancer targets. PanGenex, Inc., a majority-owned subsidiary of Cell Therapeutics, will be involved in this two-year agreement through the use of its double gene technology. Cell Therapeutics offers its workforce medical benefits, annual incentives, stock options and an employee assistance program.

BRANDS/DIVISIONS/AFFILIATES: TRISENOX XYOTAX CT-2106 CT-2584 PanGenex, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James A. Bianco, CEO Edward F. Kenney, COO/Exec. VP James A. Bianco, Pres. Louis A. Bianco, Exec. VP-Finance Carolyn M. Paradise, Chief Medical Officer Louis A. Bianco, Exec. VP-Admin. Susan O. Moore, Exec. VP-Corp. Resource Dev. Jack W. Singer, Exec. VP Michael B. Mumford, Exec. VP-Dev. and Tech. Oper. James Canfield, Exec. VP/Chief Admin. Officer

Phone: 206-282-7100 Fax: 206-284-6206 Toll-Free: 800-215-2355 Address: 201 Elliott Ave. W, Ste. 400, Seattle, WA 98119-4230 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $8,940 ( 9 months) 2002 Profits: $-80,440 ( 9 months) Stock Ticker: CTIC 2001 Sales: $6,200 2001 Profits: $-80,300 Employees: 283 2000 Sales: $ 502 2000 Profits: $-51,929 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-36,280 1998 Sales: $13,200 1998 Profits: $-24,972


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Focus on drugs for cancer patients.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:



Bonus: $222,013 Bonus: $48,874

Northeast:

International:



CELLEGY PHARMACEUTICALS

www.cellegy.com


Y



Profits: 154


TYPES OF BUSINESS:



Drugs-Diversified Topical Drugs Skin Care Products

Cellegy Pharmaceuticals, Inc. is a specialty biopharmaceutical company engaged in the development of prescription drugs and skin care products. Prescription products are directed towards the treatment of gastrointestinal disorders, sexual dysfunction of both men and women and selected conditions affecting women's health. The company's lead product candidate, Cellegesic (formerly known as Anogesic), is under review by the FDA for the treatment of chronic anal fissures, a painful condition which often requires surgery in the absence of drug therapy. Rectogesic, a similar product, is in review for sale in the United Kingdom. Another lead product candidate is Tostrex, a testosterone gel for the treatment of male hypogonadism. The company is also developing Tostrelle, a gel for the treatment of female sexual dysfunction in postmenopausal women. In late 2001, Cellegy acquired Vaxis Technologies, expanding its pipeline of products for the treatment of sexual dysfunction. Vaxis's products include nitroglycerine and other nitric oxide products for disorders including prostate cancer and Reynaud's Disease. Cellegy's research and development programs also focus on inflammation and second generation products for anorectal diseases. The firm's scientists have discovered a family of compounds useful in reducing inflammation associated with skin, mucous membrane and gastrointestinal disorders. These compounds are known as CELLEDIRM. In addition, the company produces non-prescription skin care and cosmeceutical products, including moisturizers and skin protectants. Cellegy's C79 Intensive Moisturizer is marketed through a major retailer. The company selfmarkets to specialty physicians in the United States and maintains a marketing and sales agreement with Ventiv Health, Inc. Cellegy also has a long-term manufacturing agreement with PanGeo Pharma, Inc. In recent news, the firm formed a female sexual health advisory board to be in place during the development of its products for female sexual dysfunction. Cellegy offers stock options to all of its employees.

BRANDS/DIVISIONS/AFFILIATES: Cellegesic Tostrex Tostrelle CELLEDIRM C79 Intensive Moisturizer Vaxis Technologies Cellegy Canada, Inc. Quay Pharmaceuticals

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. K. Michael Forrest, CEO K. Michael Forrest, Pres. A. Richard Juelis, CFO/VP-Finance Vivien Mak, VP-Research Daniel L. Azarnoff, Sr. VP-Medical and Regulatory Affairs Michael P. Miller, VP-Commercial Oper. John J. Chandler, VP-Corp. Dev. Mark Leonard, Public and Media Rel. Jung-Chung Lee, VP-Dev. William Schary, VP-Regulatory Affairs and Quality David A. Karlin, VP-Clinical Research

Phone: 650-616-2200 Fax: 650-616-2222 Toll-Free: Address: 349 Oyster Point Blvd., Ste. 200, South San Francisco, CA 94080 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 562 ( 9 months) 2002 Profits: $-11,633 ( 9 months) Stock Ticker: CLGY 2001 Sales: $ 900 2001 Profits: $-19,500 Employees: 36 2000 Sales: $1,600 2000 Profits: $-11,400 Fiscal Year Ends: 12/31 1999 Sales: $1,000 1999 Profits: $-9,300 1998 Sales: $ 800 1998 Profits: $-7,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $302,820 Stock Purch. Plan: Second Exec. Salary: $189,000 ADVANTAGE: Expertise in gastrointestinal medications.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International: Y



CELLTECH GROUP PLC

www.celltechgroup.com


Y



Profits: 229


TYPES OF BUSINESS:



Drugs-Diversified Pain Therapies Cancer Therapies Autoimmune Drugs Vaccines

Celltech Group is a leading European biotechnology company involved in the discovery, development, marketing, distribution and manufacturing of innovative drugs. The company consists of two operating companies: Celltech R&D and Celltech Pharmaceuticals. Celltech R&D, the discovery and development business, focuses on the areas of autoimmune and inflammatory disorders and cancer. Key products in development stages include CDP 870 for the treatment of rheumatoid arthritis and Crohn’s disease and PDE 4 for asthma. The company has formed strategic partnerships with Pharmacia, Merck & Co, Bristol-Myers Squibb, Schering Plough, American Home Products, AstraZeneca, Johnson & Johnson, Biogen, Abgenix, Neogenesis and Targeted Genetics. Celltech Pharmaceuticals is the firm's international pharmaceutical business, with operations in the U.S. and Europe. The company’s current product portfolio is focused in the areas of central nervous system, inflammatory, dermatology, gastrointestinal, rheumatology and cardiovascular therapy. Recently, Celltech entered into a long-term agreement with Biochemie, an affiliate of Novartis. Under this agreement Biochemie will manufacture PEGylated antibody fragment-based drugs for supply to Celltech. The company also purchased Thiemann S.A., a pharmaceutical sales and marketing organization based in Germany. In other news, Celltech announced an agreement with Amgen for the research, development and global marketing of novel treatments for osteoporosis.

BRANDS/DIVISIONS/AFFILIATES: Celltech Medeva Celltech Pharmaceuticals Celltech R&D Thiemann PDE 4 CDP 870

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Peter J. Fellner, Group Chief Executive Peter V. Allen, Dir.-Finance Peter Nicholls, Human Resources Melanie G. Lee, Dir.- Research and Discovery J.A.D. Slater, Corp. Sec. Ursula Ney, Dir.- Dev. Garry Watts , Exec. Dir. John Ferguson, Exec. Dir./European Dir., Celltech Medeva John B.H. Jackson, Chmn.

Phone: +44-1753-534-655 Fax: +44-1753-536-632 Toll-Free: Address: 208 Bath Rd., Slough, Berkshire SL1 3WE UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $246,109 ( 6 months) 2002 Profits: $168,861 ( 6 months) Stock Ticker: CLL 2001 Sales: $441,400 2001 Profits: $-80,800 Employees: 2,029 2000 Sales: $329,800 2000 Profits: $-601,500 Fiscal Year Ends: 6/30 1999 Sales: $77,600 1999 Profits: $51,300 1998 Sales: $51,100 1998 Profits: $-27,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: The first biotech drug company established in the U.K./Merger with Medeva.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International: Y



CEL-SCI CORPORATION

www.cel-sci.com


Y



Profits: 123


TYPES OF BUSINESS:



Drugs-Cancer and AIDS, Infectious Diseases

Cel-Sci Corp. is a development-stage company involved in the research and development of drugs designed to treat cancers and infectious diseases. MultiKine, one of its product candidates, is being tested for the treatment of cancer of the head/neck and prostate, as well as for cervical dysplasia induced by human papilloma virus (HPV) in HIV-infected women. MultiKine has been tested in over 160 patients in clinical trials conducted in the U.S., Canada, Europe and Israel. The company is also working on a drug technology called LEAPS, which provides vaccines for diseases including AIDS, chronic genital and oral herpes, malaria, colon cancer, breast cancer and autoimmune myocarditis. LEAPS is currently being evaluated through eight research collaborations, with organizations including the Max-Delbruck Center for Molecular Medicine, the National Institute of Allergy and Infectious Diseases, Johns Hopkins University and the Naval Medical Research Center. Recently, Cel-Sci formed an agreement with the Cincinnati Children's Hospital Medical Center to evaluate Cel-Sci's new compound CEL-1000 for protection against herpes. CEL1000 has shown high levels of efficacy against herpes simplex, malaria and cancer in animal testing. The company also signed a cooperative research and development agreement with the Naval Medical Research Center of the U.S. Navy to jointly evaluate a newly discovered compound called derG. DerG is a small peptide that has induced protective responses in animals against malaria, herpes simplex and cancer. Cel-Sci offers its employees a comprehensive benefits package, which includes health, dental, vision and longterm disability insurance. It also offers flexible spending accounts, tuition reimbursement and an employee referral program.

BRANDS/DIVISIONS/AFFILIATES: MultiKine LEAPS CEL-1000 DerG

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Geert R. Kersten, CEO Maximilian de Clara, Pres. Geert R. Kersten, CFO Eyal Talor, Sr. VP-Research Eyal Talor, Sr. VP-Mfg. Patricia B. Prichep, Corp. Sec. Patricia B. Prichep, Sr. VP-Oper. Geert R. Kersten, Treas. Daniel H. Zimmerman, Sr. VP-Cellular Immunology Research M. Douglas Winship, Sr. VP-Regulatory Affairs and Quality Assurance

Phone: 703-506-9460 Fax: 703-506-9471 Toll-Free: Address: 8229 Boone Blvd., Ste. 802, Vienna, VA 22182 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 376 ( 9 months) 2002 Profits: $-6,970 ( 9 months) Stock Ticker: CVM 2001 Sales: $ 400 2001 Profits: $-10,700 Employees: 30 2000 Sales: $ 400 2000 Profits: $-8,500 Fiscal Year Ends: 9/30 1999 Sales: $ 500 1999 Profits: $-7,500 1998 Sales: $ 800 1998 Profits: $-6,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $357,167 Stock Purch. Plan: Second Exec. Salary: $265,175 ADVANTAGE: Developing drugs that target large markets.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



CELSIS INTERNATIONAL PLC

www.celsis.com




Y Y

TYPES OF BUSINESS:

Profits: 6




Instruments-Microbial Contamination Detection and Measurement Microbial Risk Management Products Laboratory Services Outsourcing

Celsis International is a leading provider of rapid diagnostic and monitoring systems to detect contamination in finished products through the utilization of its ATP bioluminescence-based systems. It offers these services across many industries, including dairy, beverage, food, pharmaceutical and personal care products. The company anticipates that the increasing demand for sensitive and reliable microbial testing coupled with the desire of manufacturers to speed up product delivery will further increase the demand for its rapid testing methods. The firm’s Celsis Laboratory Group is a leading analytical laboratory services provider and has become an outsourcing partner with manufacturers, formulators, repackagers and their suppliers in a broad range of industries. Celsis’s products reduce microbiological testing time from five to seven days to between 24 and 48 hours. With the products, the company offers validation support, training, instrument support and assistance to meet its customer needs. Recently, Celsis announced the introduction of its exclusive Advance.im software, which allows for complete control over tests and results produced with the Celsis Advance and Celsis Advance Coupe luminometers. Advance.im software saves documentation time in the laboratory by providing an instrument-PC interface for electronic data handling that also deploys a complete array of tools for trend analysis and report generation. In other news, Celsis acquired Concell B.V., a European company active in dairy, food and cosmetics testing markets.

BRANDS/DIVISIONS/AFFILIATES: ATP Bioluminescence Celsis Laboratory Group RapiScreen Advance.im Celsis Advance Advance Coupe Concell B.V. AKuScreen

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jay Lecoque, CEO Jay Lecoque, Pres. Christian Madrolle, Dir.-Finance Vicky Benesch, Dir.-Mktg. Peter Grant, Technical Dir. Jenny Parsons, Dir.-Corp. Comm. Jack Rowell, Chmn.

Phone: +44-0122-3426008 Fax: +44-0122-3426003 Toll-Free: Address: Cambridge Science Park, Milton Rd., Cambridge, CB4 0FX UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $13,700 ( 6 months) 2002 Profits: $-2,838 ( 6 months) Stock Ticker: CEITF.PK 2001 Sales: $27,181 2001 Profits: $2,229 Employees: 2000 Sales: $28,405 2000 Profits: $4,006 Fiscal Year Ends: 3/31 1999 Sales: $26,070 1999 Profits: $ 521 1998 Sales: $23,930 1998 Profits: $-1,382


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Unique products for the detection of microbial contamination.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



CEPHALON INC

www.cephalon.com


Y



Profits: 208


TYPES OF BUSINESS:



Drugs-Sleep-Related Disorders Drugs-Neurological Disorders Drugs-Cancer Drugs-Pain Medications

Cephalon is engaged in creating treatments for diseases such as Lou Gehrig’s disease, narcolepsy, Alzheimer’s disease, cancer and multiple sclerosis. Currently, the company markets Provigil tablets, which are sold in the U.S., the United Kingdom, Austria, Ireland, Italy, Switzerland, Latin America, Japan, South Korea and Taiwan. Once the property of Abbott Laboratories, Gabitril, a drug used for the treatment of epilepsy, is now also sold by Cephalon. In addition, the firm also markets its lead product, Actiq, which is a treatment breakthrough for cancer pain. Apart from the above mentioned products, the company also sells nine additional treatments in Europe. A report recently showed that Provigil significantly increases wakefulness in patients that suffer from abnormal daytime sleepiness due to obstructive sleep apnea. The drug is designed as a wake-promoting agent for sleep disorders related to narcolepsy. Two other studies proved that the treatment is safe and effective with respect to long term dosages. In other news, Actiq received marketing approval in 16 European countries, and Modafinil, which is homologous to Provigil, has received acceptance in Mexico and Taiwan. Additionally, Cephalon completed the acquisition of French pharmaceutical company Group Lafon. Employees at Cephalon receive a full benefits package that includes flexible spending accounts.

BRANDS/DIVISIONS/AFFILIATES: Myotrophin Provigil Anesta Actiq Group Lafon Gabitril Modafinil Apokinin

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frank Baldino, Jr., CEO J. Kevin Buchi, Sr. VP/CFO Carl A. Savini, Sr. VP-Human Resources Jeffry L. Vaught, Sr. VP-Research and Dev. John E. Osborn, Corp. Sec. John E. Osborn, Sr. VP/General Counsel Robert P. Roche, Jr., Sr. VP-Pharmaceutical Oper. Peter E. Grebow , Sr. VP-Worldwide Bus. Dev. Paul Blake, Sr. VP-Clinical Research & Regulatory Affairs Franck P. Kiser, VP-Worldwide Drug Delivery Tech.

Phone: 610-344-0200 Fax: 610-344-0065 Toll-Free: Address: 145 Brandywine Pkwy., West Chester, PA 19380 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $362,591 ( 9 months) 2002 Profits: $48,691 ( 9 months) Stock Ticker: CEPH 2001 Sales: $226,100 2001 Profits: $-55,500 Employees: 1,127 2000 Sales: $111,790 2000 Profits: $-101,200 Fiscal Year Ends: 12/31 1999 Sales: $51,434 1999 Profits: $-79,400 1998 Sales: $16,330 1998 Profits: $-71,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $649,500 Stock Purch. Plan: Second Exec. Salary: $309,446 ADVANTAGE: Multidisciplinary technology approach.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $1,800,900 Bonus: $245,237

Northeast: Y

International: Y



CEPHEID

www.cepheid.com




Y Y

TYPES OF BUSINESS:

Profits: 24




Equipment-Biological Testing Genetic Profiling DNA Purification DNA Amplication and Detection Systems

Cepheid provides proprietary microfluidic and microelectronic technologies for the development of fast, versatile, miniaturized systems that can perform all the steps required to analyze complex biological samples with a single platform. The company is primarily focused on the detection of DNA in such application areas as life sciences research, clinical diagnostics, environment, biodefense and pharmacogenomics. Cepheid’s technologies, I-CORE module and Fluidic systems, simplify and reduce the DNA analysis process. These technologies are incorporated into the company’s Smart Cycler II System, a highly versatile and efficient rapid thermal cycler. This system incorporates real-time optical detection for DNA amplification and analysis. The Smart Cycler II TD System is the transportable version of the Smart Cycler II, tailored to the evolving needs of today’s molecular biology laboratories. Cepheid’s GeneXpert family of products combines sample preparation with the amplification and detection functions performed by its ICORE module into an integrated, automated DNA analysis instrument. These products are designed to purify, concentrate, detect and identify targeted DNA sequences, sample to result, in less than 30 minutes. Cepheid has distribution agreements with Fisher Scientific in the United States and Canada; with Eurogentec in Belgium, France, Germany, the Netherlands, Switzerland and the United Kingdom; with Takara Biomedical in Japan, Taiwan and South Korea; and with BioSynTech in Malaysia and Singapore. Recently, Cepheid announced a collaboration with Applied Biosystems Group to develop and sell reagents designed to detect biothreat agents for use with its GeneXpert system. In other news, the company was selected to participate in a research program with the Children’s Medical Center of Dallas to develop rapid diagnostic methods for improving the diagnosis of infectious diseases in children.

BRANDS/DIVISIONS/AFFILIATES: Smart Cycler I-CORE Smart Cycler II Fluidic GeneXpert

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John Bishop, CEO Kurt Petersen, COO Kurt Petersen, Pres. John Sluis, CFO/VP-Finance Cris McReynolds, VP-Mktg. Lee Christel, VP-Eng. Cris McReynolds, VP-Bus. Dev. Thomas L. Gutshall, Chmn.

Phone: 408-541-4191 Fax: 408-541-4192 Toll-Free: Address: 904 Caribbean Dr., Sunnyvale, CA 94089 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $10,001 ( 9 months) 2002 Profits: $-16,266 ( 9 months) Stock Ticker: CPHD 2001 Sales: $11,400 2001 Profits: $-15,500 Employees: 143 2000 Sales: $7,062 2000 Profits: $-14,819 Fiscal Year Ends: 12/31 1999 Sales: $3,600 1999 Profits: $-7,900 1998 Sales: $3,600 1998 Profits: $-3,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $259,898 Stock Purch. Plan: Y Second Exec. Salary: $225,466 ADVANTAGE: Valuable partnerships with government agencies/International distribution.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International: Y



CERUS CORPORATION

www.cerus.com


Y



Profits: 204


TYPES OF BUSINESS:



Drugs-Blood Transfusion

Cerus Corp. develops medical systems and therapeutics based on its proprietary Helinx technology for controlling biological replication. The company's advanced systems are focused on enhancing the safety of blood products used for transfusion. The INTERCEPT Blood System is designed to inactivate viruses, bacteria, other pathogens and white blood cells. Cerus is also pursuing therapeutic applications of Helinx to treat and prevent serious diseases. With its development and commercialization partner, Baxter Healthcare Corp., Cerus is also developing the INTERCEPT Platelet System, Plasma System and Red Blood Cell System. The firm's Helinx technology prevents the replication of DNA or RNA. When its inactivation compounds are combined with blood components for treatment, they cross bacterial cell walls or viral membranes and move into the interior of the nucleic acid structure and bind to the nucleic acid, preventing replication and consequent infection. Cerus is also focusing research and development efforts on other potential health care applications for its platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation procedures and treatments for proliferative disorders, such as restenosis. Recently, Cerus announced final European regulatory clearance for the INTERCEPT Blood System. In addition, the company received an addition $6.5 million award o t expand its collaboration with the U.S. Armed Forces and the Department of Defense, for continued development of technologies for military applications. Cerus offers its employees benefits including health, dental, vision and life insurance, flexible spending accounts, athletic club membership and stock options.

BRANDS/DIVISIONS/AFFILIATES: Helinx INTERCEPT Blood System Baxter Healthcare Corp.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen T. Isaacs, CEO Stephen T. Isaacs, Pres. Gregory W. Schafer, VP-Finance/CFO James R. Vaughn, VP-Mktg. David N. Cook, VP-Biotherapeutic Research and Dev. Laurence M. Corash, Chief Medical Officer/VP-Medical Affairs Lori L. Roll, Corp. Sec. Howard G. Ervin, VP-Legal Affairs Lori L. Roll, VP-Admin. George D. Cimino, VP-Dev. Thomas W. Dubensky, VP-Vaccine Research William M. Greenman, VP-Bus. Dev. John E. Hearst, VP-New Science Opportunities Lily Lin, VP-Global Scientific Affairs

Phone: 925-288-6000 Fax: 925-288-6001 Toll-Free: Address: 2525 Stanwell Dr., Concord, CA 94520 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $6,882 ( 9 months) 2002 Profits: $-41,442 ( 9 months) Stock Ticker: CERS 2001 Sales: $4,500 2001 Profits: $-49,400 Employees: 169 2000 Sales: $1,851 2000 Profits: $-36,033 Fiscal Year Ends: 12/31 1999 Sales: $2,400 1999 Profits: $-22,600 1998 Sales: $2,900 1998 Profits: $-29,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $380,000 Bonus: $162,308 Stock Purch. Plan: Y Second Exec. Salary: $304,000 Bonus: $114,570 ADVANTAGE: Unique technology that prevents the replication of DNA and RNA/Military applications for its products.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



CHARLES RIVER LABORATORIES CORP Industry Group Code: 541710 Ranks within this company's industry group: Sales: 3 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:



Y Y

TYPES OF BUSINESS:

www.criver.com

Profits: 4


Y


Y


Research and Development-Animal Research Models Analytical Testing Bioactivity Software Biosafety Testing Contract Staffing Laboratory Diagnostics

Charles River Laboratories, Inc. is a provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. The company is a global leader in providing the animal research models required for the research and development of new drugs, devices and therapies. The firm operates 76 production facilities and laboratories in 15 countries. Charles River Laboratories is divided into two segments, research models and biomedical products and services. The research models segment consists of the commercial production and sale of animal research models, principally purpose-bred rats, mice and other rodents for use by researchers. The biomedical products and services unit includes discovery services, development services, in vitro detection systems and vaccine support products. Charles River Laboratories provides over 55 different types of surgical alterations on rodents, including splenectomies, bile duct catheterizations, ovariectomies and castrations. EndoScan-V software provides easy-to-use template set-up with customized reports for the collection and reporting of endotoxin values. Endo-Scan-V users can download endotoxin-specific data into BioTrend, the company’s stand-alone software for trending assay data and monitoring lab proficiency. Charles River Laboratories entered into an agreement with the Tufts University School of Veterinary Medicine to further develop and commercialize a novel cloning technology that is applied to immunodeficient mice. Effective cloning of this highvalue research model through Tufts’ proprietary cloning techniques is expected to increase the utility of the model for researchers, as well as improve the efficiency with which it is produced at the company. The firm recently acquired Springborn Laboratories, Inc., a leading provider of nonclinical toxicology services.

BRANDS/DIVISIONS/AFFILIATES: Sierra Biomedical Endo-Scan-V BioTrend Springborn Laboratories, Inc. Primedica Genetic Models, Inc. Pathology Associated International

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James C. Foster, CEO James C. Foster, Pres. Thomas F. Ackerman, CFO/Sr. VP David P. Johst, Sr. VP-Human Resources Kathleen A. Murray , Dir.-Tech. Oper. Dennis R. Shaughnessy, General Counsel David P. Johst, Sr. VP-Admin. Dennis R. Shaughnessy, Sr. VP-Corp. Dev. Yifan Luo, Supervisor-Surgical Services Real H. Renaud, Sr. VP-Europe and North American Animal Oper. Julia D. Palm, Sr. VP-Biomedical Products and Services William J. White, Sr. Dir.-Professional Services

Phone: 978-658-6000 Fax: 978-658-7132 Toll-Free: 800-522-7287 Address: 251 Ballardvale St., Wilmington, MA 01887-1000 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $411,685 ( 9 months) 2002 Profits: $32,627 ( 9 months) Stock Ticker: CRL 2001 Sales: $465,600 2001 Profits: $35,500 Employees: 4,000 2000 Sales: $306,600 2000 Profits: $-11,200 Fiscal Year Ends: 12/31 1999 Sales: $231,400 1999 Profits: $17,100 1998 Sales: $205,100 1998 Profits: $23,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $447,910 Stock Purch. Plan: Second Exec. Salary: $249,730 ADVANTAGE: Ability to provide customized lab rodent services/Proprietary assay software.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $720,375 Bonus: $252,425

Northeast: Y

International: Y



CHATTEM INC

www.chattem.com


Y



Profits: 40


TYPES OF BUSINESS:



Drugs-Over the Counter

Chattem, Inc. is a leading marketer and manufacturer of a variety of branded consumer products, including over-thecounter drugs, toiletries and skin care products. The company's branded products target niche market segments and are among the market leaders in their respective categories. Through creative and cost effective marketing techniques, Chattem supports these brands on a national level across all major distribution channels, including food, drug and mass merchandisers. Some of the firm’s more notable products are the Gold Bond line of medicated powders and creams; topical analgesics Flexall, Sportscreme, Aspercreme and Icy-Hot; Dexatrim, an appetite suppressant; Pamprin; Ban deodorant and antiperspirant; Phisoderm cleanser; and dietary supplements Garlique, Harmonex and Rejuvex. The company also operates an international division that controls several distributors in Mexico and Peru, as well as subsidiaries in Canada and the United Kingdom. The company recently announced the completion of its acquisition of Selsun Blue from Abbott Laboratories for $75 million. Chattem sponsors many community events, including the American Heart Walk, which brings together thousands of people in communities all over the country to raise money for the American Heart Association.

BRANDS/DIVISIONS/AFFILIATES: pHisoderm Icy-Hot Rejuvex Bull Frog Sunblock Gold Bond Ban Deodorant Selsun Blue Dexatrim

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Zan Guerry, CEO A. Alexander Taylor, II, COO A. Alexander Taylor, II, Pres. Chris Keller, CFO/Dir.-Finance Robert S. Marshall, VP-Mktg. Bruce Long, Dir.-Human Resources Donald K. Riker, Chief Scientific Officer/VP-Research & Dev. B. Derrill Pitts, VP-Mfg. Oper. Charles M. Stafford, VP-Sales Luke J. Lenahan, VP-Int'l

Phone: 423-821-4571 Fax: 423-821-0395 Toll-Free: 800-366-6077 Address: 1715 W. 38th St., Chattanooga, TN 37409 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $171,490 ( 9 months) 2002 Profits: $5,547 ( 9 months) Stock Ticker: CHTT 2001 Sales: $198,300 2001 Profits: $15,300 Employees: 408 2000 Sales: $252,699 2000 Profits: $-1,700 Fiscal Year Ends: 11/30 1999 Sales: $298,142 1999 Profits: $20,200 1998 Sales: $220,064 1998 Profits: $15,300


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Stock Purch. Plan: ADVANTAGE: Well-known brand names.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast: Y



Bonus: $368,607 Bonus: $313,600

Northeast:

International: Y



CHESAPEAKE BIOLOGICAL LAB

www.cblinc.com


Y



Y Y

TYPES OF BUSINESS:




Research and Development and Commercial Drug Production

Chesapeake Biological Laboratories, Inc. is an established contract service provider of pharmaceutical and biopharmaceutical product development and production services for parenteral (injectable) and other sterile products. The company is a subsidiary of Canadian plasma manufacturer Cangene. It serves a broad range of customers, from major international pharmaceutical firms to emerging biotechnology companies. Chesapeake has provided services on a contract basis to more than 150 pharmaceutical and biotechnology companies and has contributed to the development and production of more than 175 therapeutic products. Customers contract with Chesapeake to produce development-stage products for use in FDA-required toxicology studies and clinical trials and to provide manufacturing services for FDA-approved products for commercial sale. The specialized development services provided by the company include research and development on sterile product formulations; test method development and validation; process design and manufacturing validations; regulatory and compliance consulting; preparation of clinical trial and toxicology materials; container-closure system design; and accelerated and ongoing stability studies. Recently, Chesapeake and its partners were awarded a federal contract for the production of a smallpox vaccine.

BRANDS/DIVISIONS/AFFILIATES: Cangene

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas P. Rice, CEO John T. Botek, COO John T. Botek, Pres. John T. Jannsen, CFO Charles Proby, VP-Mktg. and Sales Narlin Beaty, Chief Tech. Officer Joseph G. Wendel, Controller Joseph G. Wendel, Treas. Vicki Wolff-Long, VP-Project Mgmt. and Laboratory Services Elizabeth Troll, Dir.-Quality Assurance and Regulatory Affairs

Phone: 410-843-5000 Fax: 410-843-4414 Toll-Free: Address: 1111 S. Paca St., Baltimore, MD 21230-2591 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Private 2001 Sales: $ 2001 Profits: $ Employees: 130 2000 Sales: $10,800 2000 Profits: $2,400 Fiscal Year Ends: 3/31 1999 Sales: $6,700 1999 Profits: $-5,400 1998 Sales: $7,000 1998 Profits: $- 400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Client base of over 150 firms.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International:



CHIRON CORP

www.chiron.com


Y



Y

TYPES OF BUSINESS:

Profits: 19




Drugs-Cancer Quantitative Probe Tests Adult and Pediatric Vaccines Oncology Ophthalmic Surgical Products Blood Testing

Chiron is a biotechnology company that participates in three global health care businesses: biopharmaceuticals, vaccines and blood testing. The company applies a broad and integrated scientific approach to the development of innovative products for preventing and treating cancer, infectious diseases and cardiovascular disease. Chiron’s products include Proleukin, which is marketed as a treatment for metastatic renal cell carcinoma and metastatic melanoma. The firm also manufactures recombinant human platelet-derived growth factor, the active ingredient in Regranex Gel, which is marketed by Ortho-McNeil Pharmaceutical, Inc. as a treatment for diabetic foot ulcers. Chiron also produces Betaseron for Berlex Laboratories, Inc. and its parent company, Schering AG. Betaseron is marketed as a treatment for multiple sclerosis. In addition, the company sells a line of traditional pediatric and adult vaccines. Chiron is currently in the process of establishing product franchises in the fields of inhaled antibiotics, meningococcal vaccines and blood screening. These franchises are aimed at providing physicians and patients with products and services that will offer increased efficiency, safety and convenience of use. Manon Acquisition Corp., a subsidiary of Chiron, recently acquired Matrix Pharmaceutical, Inc. Matrix develops local and systemic cancer treatments and is developing a next-generation nucleoside analogue for the treatment of solid tumors and hematological malignancies. The company offers its employees educational assitance, credit union membership and acess to prepaid legal services, as well as discounted auto and home insurance. The firm also has a LifeCare service that povides information and support on topics such as adoption, prenatal planning and child care.

BRANDS/DIVISIONS/AFFILIATES: Regranex Gel Proleukin Betaseron Ortho-McNeil Pharmaceutical, Inc. Berlex Laboratories, Inc. Manon Acquisition Corp. Matrix Pharmaceutical, Inc. Biocine S.A.R.L.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Sean P. Lance, CEO Sean P. Lance, Pres. James R. Sulat, CFO Lewis T. Williams , Chief Scientific Officer David V. Smith, Controller William G. Green, Corp. Sec. William G. Green, General Counsel Peder K. Jensen, VP-Bus. Dev. Joyce A. Lonergan, VP-Investor Rel. John A. Lambert, Pres.-Chiron Vaccines Linda W. Short, VP-Corp. Resources David V. Smith, Principal Acc. Officer Craig A. Wheeler, Pres.-Chiron Biopharmaceuticals

Phone: 510-655-8730 Fax: 510-655-9910 Toll-Free: Address: 4560 Horton St., Emeryville, CA 94608-2916 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $876,700 ( 9 months) 2002 Profits: $113,700 ( 9 months) Stock Ticker: CHIR 2001 Sales: $1,140,700 2001 Profits: $180,100 Employees: 3,736 2000 Sales: $972,119 2000 Profits: $8,500 Fiscal Year Ends: 12/31 1999 Sales: $762,646 1999 Profits: $160,600 1998 Sales: $736,673 1998 Profits: $524,100


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $742,308 Stock Purch. Plan: Y Second Exec. Salary: $433,077 ADVANTAGE: Facilities on four continents/Very rapid growth record.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $1,250,000 Bonus: $345,000

Northeast: Y

International: Y



CIMA LABS INC

www.cimalabs.com


Y Y



Profits: 41


TYPES OF BUSINESS:



Drugs-Reformulated Drug Delivery Systems

Cima Labs develops and manufactures fast-dissolve and enhanced-absorption oral drug delivery systems. OraSolv and DuraSolv, the firm's proprietary fast-dissolve technologies, are oral dosage forms that dissolve quickly in the mouth without chewing or the need for water. The company manufactures five pharmaceutical brands utilizing these technologies, including Triaminic Softchews for Novartis, Tempra FirsTabs for Bristol-Myers Squibb and Zomig-ZMT for AstraZeneca. Cima's technologies enable consumers in certain age groups or with limited ability to swallow conventional tablets to receive medication in an oral dosage form that is more convenient than traditional tablet-based dosage forms. Both OraSolv and DuraSolv are capable of incorporating taste-masked active drug ingredients into tablets with the benefits of ease of administrations, improved dosing compliance and increased accuracy compared to liquid formulations. The company is also developing several new drug delivery technologies, including sustained release technology and new OraVescent technologies, such as OraVescent SL, for delivery under the tongue, and OraVescent BL, for delivery between the gum and cheek. Cima is also developing OraVescent SS, designed for site-specific administration, which would allow an active drug to be transported to a specific part of the gastrointestinal tract to be released for absorption. PakSolv is the firm's proprietary packaging system for soft, brittle tablets and is used for all of its OraSolv products. In addition, Cima is evaluating applications for its microem ulsions technology, designed to improve the bioavailability of a range of active drug ingredients. In recent news, Cima formed a collaborative agreement with Aventis to develop a fastdissolve version of Allegra, a leading antihistamine. In addition, the company commenced clinical trials of its OraVescent fentanyl product for treating cancer pain.

BRANDS/DIVISIONS/AFFILIATES: DuraSolv OraSolv OraVescent PakSolv Triaminic Softchews Tempra FirsTabs Zomig-ZMT

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John M. Siebert, CEO John Hontz, COO John M. Siebert, Pres. David A. Feste, VP-Finance/CFO Ronald Gay, Dir.-Human Resources David A. Feste, Corp. Sec.

Phone: 952-947-8700 Fax: 952-947-8770 Toll-Free: Address: 10000 Valley View Rd., Eden Prairie, MN 55344-9631 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $31,124 ( 9 months) 2002 Profits: $11,955 ( 9 months) Stock Ticker: CIMA 2001 Sales: $32,000 2001 Profits: $15,000 Employees: 171 2000 Sales: $23,900 2000 Profits: $4,000 Fiscal Year Ends: 12/31 1999 Sales: $13,400 1999 Profits: $-1,300 1998 Sales: $7,600 1998 Profits: $-3,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $292,398 Stock Purch. Plan: Second Exec. Salary: $209,877 ADVANTAGE: Successful introduction of new drug delivery techniques.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



CIPHERGEN BIOSYSTEMS INC

www.ciphergen.com



Y


Y

TYPES OF BUSINESS:

Profits: 2


Y



Chips-Proteomics

Ciphergen Biosystems, Inc. is a leader in the emerging proteomics field of protein-based biology research. The company develops, manufactures, sells and services ProteinChip Systems and related products that discover, characterize and assay proteins from native biological samples. The novel ProteinChip System captures, separates and quantitatively analyzes proteins directly from crude biological materials with minimal sample preparation, allowing researchers to compare proteins in the disease versus normal state and quantitatively analyze protein interactions. With the acquisition of BioSepra S.A., the company is able to combine BioSepra’s process chromatography developments with ProteinChip technology to simplify protein purification. Biomarker Discovery Center facilities in California, Pennsylvania and Denmark were established by Ciphergen to partner with its pharmaceutical clients in order to offer services in solving complex biological research problems. These facilities are equipped with the latest technology and are staffed with leading research scientists to aid in research and development. The Biomarker Discover Centers are actively collaborating with Aaron Diamond AIDS Research Center, the National Institute of Allergy and Infectious Diseases, the Johns Hopkins University School of Medicine, Pfizer and Eastern Virginia Medical School. Recently, Ciphergen announced that Novartis has expanded its use of ProteinChip technology and has entered into an agreement to cover compound projects with the Biomarker Discovery Centers.

BRANDS/DIVISIONS/AFFILIATES: BioSepra S.A. ProteinChip Systems Biomarker Discovery Center

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William E. Rich, CEO William E. Rich, Pres. Matthew J. Hogan, CFO/VP Martin L. Verhoef , VP-Mktg. and Sales Egisto Boschetti, VP-Research and Dev. Daniel M. Caserza, Corp. Controller David A. DeNola, VP-Oper. Robert M. Maurer, VP-Bus. Dev. John R. Storella, VP- Intellectual Property Affairs

Phone: 510-505-2100 Fax: 510-505-2101 Toll-Free: 888-864-3770 Address: 6611 Dumbarton Circle, Fremont, CA 94555 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $25,708 ( 9 months) 2002 Profits: $-22,367 ( 9 months) Stock Ticker: CIPH 2001 Sales: $19,000 2001 Profits: $-25,800 Employees: 229 2000 Sales: $8,900 2000 Profits: $-20,300 Fiscal Year Ends: 12/31 1999 Sales: $5,000 1999 Profits: $-7,700 1998 Sales: $2,900 1998 Profits: $-8,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $233,000 Bonus: $220,000 Stock Purch. Plan: Y Second Exec. Salary: $199,091 Bonus: $43,250 ADVANTAGE: Has established facilities and partnerships that capitalize on its chip technology to identify proteins.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International: Y



COLLAGENEX PHARMACEUTICAL

www.collagenex.com


Y



Profits: 103


TYPES OF BUSINESS:



Drugs-Dental Disease Dermatology Products

CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on providing innovative medical therapies to the dental and dermatology markets. Dental products that CollaGenex markets include Periostat, its own development; Atridox, Atrisorb-Freeflow and Atrisorb-D Freeflow, products of Atrix Laboratories; and Vioxx, developed by Merck. Periostat is the first and only pharmaceutical to treat adult periodontitis by inhibiting the enzymes that destroy periodontal support tissues. Adult periodontitis, a chronic disease characterized by the progressive loss of attachment between the tooth root and the surrounding periodontal structures, may result in tooth loss if untreated. Vioxx is a prescription non-steroidal antiinflammatory drug. Products for the dermatology market include Pandel, used for the treatment of dermatitis and psoriasis, and PR-Q, developed for the treatment of dry skin. CollaGenex’s development products are based on its core technologies, IMPACS and Restoraderm. IMPACS compounds have the potential to treat diseases that cause inflammation and destruction of the connective tissues. Restoraderm delivers ingredients to the dermal layers underlying the skin. Recently, CollaGenex and Medtronic, Inc. entered into a license agreement involving IMPACS; Medtronic will use IMPACS to treat aortic aneurysms and other forms of vascular disease with medical devices. In other news, the company and Discovery Laboratories, Inc. announced a research collaboration to develop a treatment for respiratory diseases .

BRANDS/DIVISIONS/AFFILIATES: Periostat Atridox Vioxx Atrisorb-Freeflow PR-Q Pandel IMPACS Restoraderm

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Brian M. Gallagher, CEO Brian M. Gallagher, Pres. Nancy C. Broadbent, CFO David P. Pfeiffer, VP-Mktg. and Sales Nancy C. Broadbent, Sec. Nancy C. Broadbent, Treas. Robert A. Ashley, Sr. VP-Commercial Dev. Jeffrey S. Day, VP-Dermatology Douglas C. Gehrig, VP-Sales Michael Romanowicz, VP-Professional Affairs and Managed Care Brian M. Gallagher, Chmn.

Phone: 215-579-7388 Fax: 215-579-8577 Toll-Free: Address: 41 University Dr., Ste. 200, Newton, PA 18940 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $32,957 ( 9 months) 2002 Profits: $- 186 ( 9 months) Stock Ticker: CGPI 2001 Sales: $35,200 2001 Profits: $-8,100 Employees: 155 2000 Sales: $24,300 2000 Profits: $-8,830 Fiscal Year Ends: 12/31 1999 Sales: $16,100 1999 Profits: $-14,600 1998 Sales: $3,500 1998 Profits: $-11,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $315,000 Stock Purch. Plan: Second Exec. Salary: $225,000 ADVANTAGE: Focus on drugs for dental care/Unique therapy for periodontitis.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $131,615 Bonus: $93,908

Northeast: Y

International:



COLLATERAL THERAPEUTICS

www.collateralthx.com


Y




TYPES OF BUSINESS:



Drugs-Cardiovascular Disease

Collateral Therapeutics is focused on the discovery and development of non-surgical gene therapy products for the treatment of cardiovascular diseases, including coronary artery disease, peripheral vascular disease, congestive heart failure and heart attack. The firm believes that its products under development hold the potential to revolutionize the treatment of cardiovascular diseases. These products could provide a new standard of care by offering patients simpler, more cost-effective and lowerrisk alternatives to currently available treatments such as coronary artery bypass surgery and angioplasty. Collateral’s initial gene therapy products are designed to promote and enhance angiogenesis, a natural biological process that results in the growth of additional blood vessels to increase levels of blood flow to oxygendeprived tissues. The company’s lead product, GENERX, is being developed as a treatment for chest pain due to coronary artery disease. GENERX is undergoing two Phase 2b/3 trials, one in the U.S and one in Europe. GENVASCOR, a second product designed for the treatment of patients with peripheral vascular disease, is beginning Phase 1/2 trials in Europe. Preclinical research is underway for GENEVX, for ischemic heart disease, and CORGENIC, for congestive heart failure. Collateral has several research and license agreements with academic institutions, including the Regents of the University of California, New York University, University of Texas Southwestern Medical Center and the Veterans Medical Research Foundation in San Diego. Recently, Collateral Therapeutics was acquired by Schering AG.

BRANDS/DIVISIONS/AFFILIATES: CORGENIC GENERX GENVASCOR GENEVX Schering AG

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jack W. Reich, CEO Christopher J. Reinhard, COO Christopher J. Reinhard, Pres. Christopher J. Reinhard, CFO John F. Warner, VP-Research and Tech. Tyler M. Dylan, Corp. Sec. Tyler M. Dylan, General Counsel Jeffrey Friedman, VP-Dev. Patricia L. Novak, Sr. Dir.-Program Mgmt. Juliet Singh, VP- Regulatory Affairs and Quality Assurance

Phone: 858-794-3400 Fax: 858-794-3440 Toll-Free: Address: 11622 El Camino Real, San Diego, CA 92130 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 3 months. 2002 Sales: $12,000 ( 3 months) 2002 Profits: $5,600 ( 3 months) Stock Ticker: Private 2001 Sales: $5,200 2001 Profits: $-14,600 Employees: 70 2000 Sales: $2,000 2000 Profits: $-14,600 Fiscal Year Ends: 12/31 1999 Sales: $6,400 1999 Profits: $-7,700 1998 Sales: $5,400 1998 Profits: $-4,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Successful trials of new products for non-invasive treatment of cardiovascular diseases.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



COLUMBIA LABORATORIES

www.columbialabs.com


Y



Profits: 141


TYPES OF BUSINESS:



Pharmaceutical Products for Women's' Health Pediatric Drugs Cold Remedies Endocrinology Products

Columbia Laboratories, Inc. is dedicated to research and development of women's health care and endocrinology products, including those intended to treat infertility, endometriosis and hormonal deficiencies. The company is also developing hormonal products for men and a buccal delivery system for peptides. Columbia's products primarily utilize its patented Bioadhesive Delivery System (BDS) technology. The firm's products include Crinone, Advantage-S and Replens. Crinone, a prescription drug, is a sustained-release, vaginally delivered natural progesterone product. It is the first product to deliver progesterone directly to the uterus, thereby maximizing therapeutic benefit and avoiding side effects seen with orally delivered synthetic therapies. Crinone has been approved for marketing for one or more medical indications in over 28 countries. Advantage-S, an overthe-counter product, is a female contraceptive gel that uses the firm's BDS technology with the active ingredient nonoxynol-9. Replens replenishes vaginal moisture on a sustained basis and relieves discomfort associated with vaginal dryness. Additional products produced by the company include Advanced Formula Legatrin PM, for pain and sleeplessness associated with muscle aches and leg cramps; Vaporizer, a portable cough suppressant; and Diasorb, a pediatric antidiarrheal product. These therapies, which do not use the BDS, have been licensed to other companies. In recent news, the FDA accepted for review Columbia's new drug application for its Striant buccal bioadhesive product. In addition, the company formed a European license and supply partnership with Ardana Bioscience. Ardana will market, distribute and sell Striant in 18 European countries.

BRANDS/DIVISIONS/AFFILIAT ES: Crinone Striant Replens Advantage-S Bioadhesive Delivery System Columbia Research Laboratories, Inc. Vaporizer Diasorb

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. G. Fredrick Wilkinson, CEO G. Fredrick Wilkinson, Pres. David L. Weinberg, VP-Finance/CFO Howard L. Levine, VP-Research and Dev. Michael McGrane, VP/Corp. Sec. Michael McGrane, General Counsel David L. Weinberg, VP-Admin. David L. Weinberg, Treas. Dominique de Ziegler, VP-Pharmaceutical Dev. Annick Blondeau, VP-Regulatory Affairs Robert Mills, Sr. VP-Oper. William J. Bologna, Chmn.

Phone: 973-994-3999 Fax: 973-994-3001 Toll-Free: Address: 220 S. Orange Ave., Livingston, NJ 07039 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $6,700 ( 9 months) 2002 Profits: $-10,200 ( 9 months) Stock Ticker: COB 2001 Sales: $1,800 2001 Profits: $-15,800 Employees: 19 2000 Sales: $13,173 2000 Profits: $-2,603 Fiscal Year Ends: 12/31 1999 Sales: $18,921 1999 Profits: $-2,210 1998 Sales: $10,018 1998 Profits: $-13,860


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Stock Purch. Plan: Second Exec. Salary: $318,750 ADVANTAGE: Crinone is the first drug to deliver progesterone directly to the uterus.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



COMMONWEALTH BIOTECHNOLOGIES INC biotech.com Industry Group Code: 541710 Ranks within this company's industry group: Sales: 34 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:


Y


Y Y

TYPES OF BUSINESS:

www.cbi-

Profits: 12




Genetic Research and Development Services DNA Sequencing Genetic Testing Services Molecular Biologies Biophysical Analysis Paternity Testing

Commonwealth Biotechnologies, Inc. provides research and development services to entities including private companies, academic institutions and government agencies. It delivers cutting-edge expertise in analytical and synthetic chemistries and biophysical technologies from a variety of sources. Commonwealth serves two types of customers, those who need information for shortterm projects and those who need it for long-term services. The company specializes in DNA sequencing, nucleic acid synthesis, peptide and protein technologies, molecular biologies, genetic testing services and biophysical analysis. It also conducts genome services, which focuse on expression studies and target gene detection. Recently, Commonwealth signed a license and sales agreement with MediRox AB, based in Linköping, Sweden. MediRox will use CBI's HepArrest for use as an in vitro reagent for reversal of heparin-induced anticoagulation in blood samples collected at the point of care from patients. The company has also licensed its DNA sequencing reagent, Accutrac, to Applied Biosystems, Inc.

BRANDS/DIVISIONS/AFFILIATES: AccuTrac HepArrest

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert B. Harris, Pres. James H. Brennan, CFO James H. Brennan, Human Resources James H. Brennan, Controller Thomas R. Reynolds, Sr. VP/Sec. Richard J. Freer, Chmn.

Phone: 804-648-3820 Fax: 804-648-2641 Toll-Free: 800-735-9224 Address: 601 Biotech Dr., Richmond, VA 23235 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $3,444 ( 9 months) 2002 Profits: $- 232 ( 9 months) Stock Ticker: CBTE 2001 Sales: $4,800 2001 Profits: $-1,700 Employees: 33 2000 Sales: $4,400 2000 Profits: $- 900 Fiscal Year Ends: 12/31 1999 Sales: $2,600 1999 Profits: $-2,100 1998 Sales: $1,600 1998 Profits: $-2,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $170,047 Stock Purch. Plan: Second Exec. Salary: $167,380 ADVANTAGE: Patented automated DNA sequencing.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



COMPUGEN LTD

www.cgen.com



Y Y


Profits: 5


TYPES OF BUSINESS:

Y Y



Biotechnology Databases and Solutions DNA Chips Genomics Proteomics

Compugen is a pioneer in the fields of computational genomics and proteomics. Headquartered in Israel with offices in California and New Jersey, the company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in the drug discovery, therapeutic and diagnostic arenas. Core products include LEADS, a bioinformatics platform for the analysis of genomic and protein data; DNA chip design and analysis; Z3, a two-dimensional gel electrophoresis image analysis software system; a portfolio of novel genes and gene variants; and Gencarta, an advanced gene and transcript database. Compugen provides its products and services to pharmaceutical, biotechnology and other life science organizations through corporate solutions and to individual life scientists through the LabOnWeb.com web site. Recently, the firm launched its Gencarta genome and proteome database over the web, at www.gencarta.com. In other news, Compugen expanded its collaboration with Novartis to identify, prioritize and validate new drug targets.

BRANDS/DIVISIONS/AFFILIATES: LEADS Technology Z3 LabOnWeb.com Z4000 Evogene OligoLibraries Gencarta

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mor Amitai, CEO Mor Amitai, Pres. Nurit Benjamini, CFO Erez Chimovits, Exec. VP-Mktg. and Sales Michael Preminger, VP-New Research Lior D. Ma'ayan, Exec. VP-Corp. Dev. Salomon Z. Langer, Sr. VP-Drug Discovery Martin Gerstel, Chmn.

Phone: +972-3-7658-585 Fax: +972-3-7658-555 Toll-Free: Address: 72 Pinchas Rosen St., Tel Aviv, 69512 Israel

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $8,434 ( 9 months) 2002 Profits: $-8,988 ( 9 months) Stock Ticker: CGEN 2001 Sales: $11,400 2001 Profits: $-15,100 Employees: 176 2000 Sales: $6,900 2000 Profits: $-13,400 Fiscal Year Ends: 12/31 1999 Sales: $3,200 1999 Profits: $-8,100 1998 Sales: $4,500 1998 Profits: $-3,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Pioneer in the fields of computational genomics and proteomics.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



CONNETICS CORPORATION

www.connetics.com


Y



Profits: 147


TYPES OF BUSINESS:



Drugs-Dermatology Topical Steroids

Connetics Corp. is a specialty pharmaceutical company focusing exclusively on the treatment of dermatological conditions. The firm currently markets two products, Luxiq Foam and OLUX Foam, which compete in the topical steroids market and have clinically proven therapeutic advantages for the treatment of scalp dermatoses in a novel formulation. Luxiq is a foam preparation of a mildpotency topical steroid for mild to moderate conditions such as psoriasis, eczema and dermatitis. OLUX is one of the most widely prescribed super high-potency topical steroids. Recently, OLUX received FDA approval for nonscalp indications. The company's Connetics Center for Skin Biology brings together dermatologists and pharmacologists from across the country to explore how topical drugs interact with and penetrate the skin. The Center's goal is to learn how to optimize drug penetration, distribution and efficiency at the targeted treatment site on the skin and to evaluate new chemical entities for the development of innovative dermatological products. In 2001, the company acquired the Soltec Research division of Australia-based F. H. Faulding, establishing Connetics as the only independent company serving the dermatology segment that has integrated product innovation, development and commercialization abilities. The acquisition also enabled Connetics to control its delivery technologies worldwide. In recent news, the firm and DPT Laboratories completed a state-of-the-art aerosol manufacturing facility in San Antonio, Texas. Connetics offers its employees health insurance and disability coverage, pre-tax spending accounts and education assistance.

BRANDS/DIVISIONS/AFFILIATES: Luqix OLUX Soltec Research Connetics Center for Skin Biology

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas G. Wiggans, CEO C. Gregory Vontz , Exec. VP/COO Thomas G. Wiggans, Pres. John L. Higgins, CFO/Exec. VP-Finance Joseph Finster, Sr. VP-Mktg. Rebecca Gardiner, Sr. VP-Human Resources Katrina J. Church, Corp. Sec. Katrina J. Church, Exec. VP-Legal Affairs/General Counsel John L. Higgins, Exec. VP-Admin. John L. Higgins, Exec. VP-Corp. Dev. Rebecca Gardiner, Sr. VP-Organizational Dynamics Robert G. Lederer, Sr. VP-Commercial Oper. Charles J. Democko, VP-Regulatory Affairs Linda J. Fenney, Sr. VP-Product Dev. G. Kirk Raab, Chmn.

Phone: 650-843-2800 Fax: 650-843-2899 Toll-Free: Address: 3400 W. Bayshore Rd., Palo Alto, CA 94303 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $37,798 ( 9 months) 2002 Profits: $-10,979 ( 9 months) Stock Ticker: CNCT 2001 Sales: $34,100 2001 Profits: $-16,700 Employees: 162 2000 Sales: $40,800 2000 Profits: $27,000 Fiscal Year Ends: 12/31 1999 Sales: $26,900 1999 Profits: $-27,300 1998 Sales: $9,100 1998 Profits: $-26,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $420,000 Bonus: $210,000 Stock Purch. Plan: Y Second Exec. Salary: $277,880 Bonus: $110,000 ADVANTAGE: Successful clinical trials/Drugs in development with indications for multiple disease therapies.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest:

Southeast:



Northeast:

International: Y



CORIXA CORPORATION

www.corixa.com


Y



Profits: 23


TYPES OF BUSINESS:



Drugs-Cancer and Infectious Disease Drugs-Autoimmune Diseases

Corixa Corporation is a research and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. The company is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of separate proprietary vaccine components. Specifically, its product development revolves around five platforms: antigens, antibody therapeutics, adjuvants, targeted oncologics and autoimmune disease therapeutics. Consequently, the firm uses its expertise in immunology and its proprietary technology platforms to discover and develop vaccines, antigen-based products (including monoclonal antibody-based products) and novel adjuvants. Currently, the company has 16 compounds undergoing clinical trials and 22 preclinical programs, as well as 32 collaborated studies. The company’s partners include GlaxoSmithKline, Medicis, Organon, ScheringPlough and Zambon Group. Corixa’s main product, Melacine, entered the market and is designed to treat Stage IV melanoma, an aggressive malignancy that has a very high rate of mortality. The company also has several drugs in clinical trials that are being tested to treat rheumatoid arthritis, multiple sclerosis and infectious diseases such as hepatitis B, herpes virus, human papilloma virus and malaria. Recently, Corixa announced a collaboration with Genesis Research and Development Corporation, Ltd. for the development of PVAC, a treatment for psoriasis.

BRANDS/DIVISIONS/AFFILIATES: Melacine PVAC Detox Coulter Pharmaceutical

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steven Gillis, CEO David Fanning, COO/Sr. VP Michelle Burris, Sr. VP/CFO Bernie Paul, VP- Human Resources Steven Reed, Exec. VP/Chief Scientific Officer William Derrick, VP/CIO Kathleen McKereghan, Sr. VP/Corp. Sec. Kathleen McKereghan, General Counsel Cindy Jacobs, Sr. VP-Clinical Research Gary Christianson, VP-Tech. Oper. Kenneth Grabstein, Exec. VP/Dir.-Immunology Monica Krieger, VP-Regulatory Affairs Steven Gillis, Chmn.

Phone: 206-754-5711 Fax: 206-754-5715 Toll-Free: Address: 1124 Columbia St., Ste. 200, Seattle, WA 98104 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $39,328 ( 9 months) 2002 Profits: $-187,940 ( 9 months) Stock Ticker: CRXA 2001 Sales: $58,100 2001 Profits: $148,000 Employees: 496 2000 Sales: $37,000 2000 Profits: $-667,100 Fiscal Year Ends: 12/31 1999 Sales: $26,500 1999 Profits: $-54,800 1998 Sales: $18,300 1998 Profits: $-21,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $435,600 Bonus: $72,600 Stock Purch. Plan: Second Exec. Salary: $290,000 Bonus: $ ADVANTAGE: Rapidly growing product line/Drugs in development that are targeted to treat a wide variety of diseases.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



CORTECH INC Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y




TYPES OF BUSINESS:



Drugs-Inflammatory Disorders Protease Inhibitors Bradykinin Antagonists

Cortech, Inc. is a biopharmaceutical company focused primarily on protease inhibitors and bradykinin antagonists. Past research and development efforts have produced a technology portfolio with potential therapeutic applications across a wide range of medical conditions. The company ceased research and development activities in 2000 and now seeks to use collaborative partners to conduct and fund ongoing development of the components of its portfolio that have not yet been licensed. Cortech licenses the worldwide rights to an oral elastase inhibitor program to Ono Pharmaceutical Co., based in Japan. Elastase is a protein-degrading enzyme considered to play a major role in tissue damage and organ failure in severe inflammatory conditions. Bradycor, or Deltibant, is Cortech's lead first-generation bradykinin antagonist, which may have therapeutic applications in the management of traumatic brain injury. Currently, the firm is seeking to redeploy its assets into an operating business through acquisitions and/or a merger partner.

BRANDS/DIVISIONS/AFFILIATES: Ono Pharmaceutical Bradycor Deltibant

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul O. Koether, CEO John W. Galuchie, Jr., Pres. Sue Ann Itzel, Principal Acc. and Financial Officer Sue Ann Itzel, Treas. Paul O. Koether, Chmn.

Phone: 908-234-1881 Fax: 908-766-5840 Toll-Free: Address: 376 Main St., Bedminster, NJ 07921 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-1,067 ( months) Stock Ticker: CRTQ 2001 Sales: $ 2001 Profits: $- 200 Employees: 2000 Sales: $ 877 2000 Profits: $ 400 Fiscal Year Ends: 12/31 1999 Sales: $3,225 1999 Profits: $2,600 1998 Sales: $1,300 1998 Profits: $-4,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Partnership with Ono Pharmaceutical.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International:



CORTEX PHARMACEUTICALS

www.cortexpharm.com


Y



Profits: 74


TYPES OF BUSINESS:



Pharmaceuticals for Treatment of Mental Illnesses

Cortex Pharmaceuticals is engaged in the discovery, development and commercialization of innovative pharmaceuticals for the treatment of neurodegenerative diseases and other neurological and psychiatric disorders. Cortex is developing a family of chemical compounds, known as AMPAKINE compounds, that enhance the activity of AMPA-type glutamate receptor, a complex of proteins that is involved in communication between nerve cells in the human brain. These drugs have the potential for treatment of mental illnesses such as Alzheimer’s disease, schizophrenia, depression and other diseases. The company is involved in a number of strategic partnerships with pharmaceutical leaders including Les Laboratories Servier and NV Organon. Servier is licensed to develop and commercialize Cortex’s AMPAKINE technology in Europe Asia, the Middle East and South America. Cortex's exclusive worldwide license agreement with NV Organon enables Organon to develop and commercialize the AMPAKINE compounds for the treatment of schizophrenia and depression. Recently, Cortex announced that it is collaborating with several research organizations to carry out a Phase II clinical study to evaluate one of the company’s AMPAKINE compounds as a potential treatment for fragile X syndrome and autism. The FRAXA Foundation will provide funding for the trial at Rush-Presbyterian-St. Luke’s Medical Center, and Cortex will provide study medication. In other news, Cortex was granted five new international patents for its AMPAKINE technology. Cortex provides its employees with medical, dental, vision and life insurance. It also offers stock options.

BRANDS/DIVISIONS/AFFILIATES: AMPAKINE

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Roger G. Stoll, CEO Roger G. Stoll, Pres. Maria S. Messinger, CFO/VP Gary Rogers, VP-Pharmaceutical Research Maria S. Messinger, Corp. Sec. James H. Coleman, Sr. VP-Bus. Dev. Joann L. Data, Sr. VP-Clinical Dev. and Regulatory Affairs Ursula V. Staubli, VP-Biological Research Roger G. Stoll, Chmn.

Phone: 949-727-3157 Fax: 949-727-3657 Toll-Free: Address: 15241 Barranca Pkwy., Irvine, CA 92618 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $6,400 (12 months) 2002 Profits: $-1,000 (12 months) Stock Ticker: COR 2001 Sales: $4,443 2001 Profits: $-2,398 Employees: 28 2000 Sales: $5,509 2000 Profits: $- 200 Fiscal Year Ends: 6/30 1999 Sales: $3,200 1999 Pr ofits: $-1,600 1998 Sales: $ 100 1998 Profits: $-5,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $261,385 Stock Purch. Plan: Second Exec. Salary: $180,000 ADVANTAGE: Innovative drugs for the treatment of mental illnesses.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $82,875 Bonus: $40,000

Northeast:

International:



CORVAS INTERNATIONAL INC

www.corvas.com


Y



Profits: 165


TYPES OF BUSINESS:



Drugs-Blood Clot Formation and White Blood Cell Activation

Corvas International is a clinical-stage biopharmaceutical firm engaged in the design and development of a new generation of therapeutic agents for cardiovascular, cancer, stroke and other major diseases. Corvas’s drug candidates target major cardiovascular diseases such as heart attack, unstable angina, deep vein thrombosis and pulmonary embolism, as well as cancer and acute inflammation associated with reperfusion injury in ischemic stroke. The firm has developed its portfolio of drug candidates by integrating its in-depth knowledge of the biology of blood clot formation (thrombosis), inflammation and, more generally, tumor vascular biology with advanced and proprietary drug discovery and design technology. The drug design programs focus on the inhibition and modulation of protease enzymes involved in disease. Its research is aimed at developing drugs that will prevent the spread of tumor cells and will be able to treat selective organs and tissues in the body without affecting other organs. The company is currently developing its lead product candidate, a novel proprietary injectable anticoagulant known as rNAPc2, for the treatment of acute coronary syndromes, which include unstable angina. Corvas recently announced an exclusive collaboration with Abgenix, Inc. to discover and develop antibodies.

BRANDS/DIVISIONS/AF FILIATES: rNAPc2

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Randall E. Woods, CEO Randall E. Woods, Pres. George P. Vlasuk, Chief Scientific Officer/Exec. VP-Research and Dev Carolyn M. Felzer, VP/Controller Kevin S. Helmbacher, Corp. Sec. Kevin S. Helmbacher, General Counsel Stephen F. Keane, VP-Corp. Dev. William E. Rote, Exec. Dir.-Dev. Edwin L. Madison, VP-Biological Research J. Edward Semple, Exec. Dir-Medicinal Chemistry M. Blake Ingle, Chmn.

Phone: 858-455-9800 Fax: 858-455-7895 Toll-Free: Address: 3030 Science Park Rd., San Diego, CA 92121-1102 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 116 ( 9 months) 2002 Profits: $-17,194 ( 9 months) Stock Ticker: CVAS 2001 Sales: $ 300 2001 Profits: $-23,400 Employees: 95 2000 Sales: $6,100 2000 Profits: $-10,700 Fiscal Year Ends: 12/31 1999 Sales: $6,300 1999 Profits: $-13,000 1998 Sales: $10,000 1998 Profits: $-8,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $395,000 Stock Purch. Plan: Second Exec. Salary: $310,589 ADVANTAGE: Strategic partnerships/Excellent technology relative to thrombosis.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $191,194 Bonus: $265,000

Northeast:

International:



COVALENT GROUP INC

www.covalentgroup.com




Y Y

TYPES OF BUSINESS:

Profits: 9


Y



Management- Drug and Medical Device Clinical Trials Trial Management Software Disease Assessment Software Biostatistical Analysis

Covalent Group, Inc. is a total research management organization that designs and manages clinical trials in the drug and medical device development process. It also designs and manages associated cost containment and quality-of-care components. The company specializes in Phase I through IV clinical trials, cost effectiveness studies and outcomes studies for major customer groups such as pharmaceutical companies, managed care organizations, insurers and employers. It offers a full array of integrated services, including study design, clinical trial monitoring and management, data management, biostatistical analysis and regulatory affairs services. Covalent is structured to deliver customized high-quality solutions to its Fortune 500 and other clients. To aid its pharmaceutical and managed care customers in clinical trials and outcomes research projects, Covalent has also developed several proprietary products utilizing interactive speech recognition technology. They include TeleTrial, a clinical trial management system, and Virtual HouseCall, a disease assessment system. Covalent recently signed several clinical consulting contracts with top pharmaceutical companies. The contracts cover a wide range of therapeutic areas including oncology, neurology, gastroenterology, cardiovascular diseases, vaccines and infectious diseases. These agreements reflect Covalent's ongoing strategy of leveraging its consultative services to further research management and development programs. By partnering early in the development process with pharmaceutical companies, the company is able to proactively optimize the design and conduct of clinical trials. Covalent's consultative approach to clinical development benefits its clients by focusing on innovative results -oriented solutions and integrating these solutions with operational expertise and experience.

BRANDS/DIVISIONS/AFFILIATES: TeleTrial Virtual HouseCall

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kenneth M. Borrow , CEO Brian Dickson, COO Jorge A. Leon, CFO Mary Ann Flafinski, VP-Human Resources David Weitz, VP/CIO Brian Dickson, Chief Medical Officer David Weitz, Corp. Sec. David Weitz, Treas.

Phone: 610-975-9533 Fax: 610-975-9556 Toll-Free: Address: 1275 Drummers Ln., Ste. 100, Wayne, PA 19087 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $20,824 ( 9 months) 2002 Profits: $1,784 ( 9 months) Stock Ticker: CVGR 2001 Sales: $18,400 2001 Profits: $2,000 Employees: 108 2000 Sales: $12,027 2000 Profits: $1,000 Fiscal Year Ends: 12/31 1999 Sales: $14,700 1999 Profits: $1,400 1998 Sales: $9,400 1998 Profits: $- 900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $261,458 Stock Purch. Plan: Second Exec. Salary: $199,000 ADVANTAGE: Significant new contracts for research services.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $55,000 Bonus: $15,000

Northeast: Y

International: Y



COVANCE INC

www.covance.com




Y Y

TYPES OF BUSINESS:




Research and Development-Drug Preclinical/Clinical Trials Laboratory Testing Analysis Drug Approval Assistance Health Economics

Covance, Inc. is a leading contract research organization providing a wide range of product development services to pharmaceutical, biotechnology and medical device industries. The company also provides health economics and outcomes services for managed care organizations, hospitals and other health care providers; and laboratory testing services to the chemical, agrochemical and food industries. Covance provides early development services, which include preclinical and Phase I clinical service capabilities, and late-stage development services, which include clinical development, clinical support and commercialization services. Covance Biotechnology Services provides drug manufacturing for biotech firms too small for their own operations. Covance canceled its proposed merger with PAREXEL International due to investor criticism. The firm plans to focus attention on customers who are biased towards development approaches that are flexible and innovative. The firm believes that these customers would be more likely to use more than one of its services. In order to repay its debt, the company has sold Covance Biotechnology Services to Akzo Nobel’s pharma business unit Diosynth, along with its sale of its pharmaceutical packaging operation to Fisher Scientific International earlier in the year. Covance recently opened a new formulations facility at its nonclinical laboratory in Vienna, Virginia. Covance offers its employees medical, dental, vision, 401(k) savings, a stock purchase plan, tuition reimbursement and alternative work schedules. The dress code is business casual.

BRANDS/DIVISIONS/AFFILIATES: Covance Central Diagnostics, Inc Covance Research Products, Inc. Covance Laboratories, Inc. Covance Clinical and Periapproval Services, Inc. Covance Pharmaceutical Packaging Services, Inc. Covance Health Economics and Outcomes Services Covance Clinical Research Unit, Inc.

CONTACTS: Note: Officers with more than one job

Profits: 2

title may be

intentionally listed here more than once. Christopher A. Kuebler, CEO Christopher A. Kuebler, Pres. William Klitgaard, Sr. VP/CFO Raul Valentine, Dir.-Human Resources Jeffrey S. Hurwitz, Corp. Sec. Jeffrey S. Hurwitz, General Counsel Beth Leahy, VP-Comm. Beth Leahy, VP-Investor Rel. Joseph L. Herring, Pres., Early Dev. Services F. John Mills, Pres., Clinical Support Services Alan Horgan, Pres., Clinical Development Services

Phone: 609-452-4440 Fax: 609-452-9375 Toll-Free: 800-773-0011 Address: 210 Carnegie Center, Princeton, NJ 08540-6233 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $648,800 ( 9 months) 2002 Profits: $40,300 ( 9 months) Stock Ticker: CVD 2001 Sales: $855,900 2001 Profits: $47,900 Employees: 7,200 2000 Sales: $868,087 2000 Profits: $15,236 Fiscal Year Ends: 12/31 1999 Sales: $829,980 1999 Profits: $45,818 1998 Sales: $731,574 1998 Profits: $48,608


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $ Bonus: $ ADVANTAGE: Provides turnkey services that assist drug companies in bringing new drugs to market/Offices in 17 countries.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Southeast:



Northeast: Y

International: Y



CUBIST PHARMACEUTICALS

www.cubist.com


Y

Other : AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:


Profits: 219


TYPES OF BUSINESS:



Drugs-Infectious Disease

Cubist Pharmaceuticals, Inc. is focused on the research, development and commercialization of novel antimicrobial drugs to combat serious and life-threatening bacterial and fungal infections. The firm is currently conducting multiple Phase III trials for Cidecin, its lead product candidate and the first in a new class of antimicrobial drugs called lipopeptides. Because Cidecin attacks bacteria through a novel mechanism and has demonstrated the unique ability in vitro to rapidly kill virtually all clinically significant gram positive bacteria, it may be particularly effective in treating infections caused by drug-resistant bacteria that cannot be eradicated by existing antibiotics. In addition, its oncedaily dosing regimen is optimally safe and effective, as well as more convenient and cost-effective than multiple daily doses. The firm expects to file a new drug application for Cidecin by the end of 2002. Cubist is also developing an oral formulation of the antibiotic ceftriaxone, which has only been available in intravenous form, marketed under the brand name Rocephin. The company is also developing, through a research agreement with Emisphere Technologies, an oral formulation of daptomycin, a member of the lipopeptide class. Cubist also generates revenues through the licensing of its VITA functional genomics technology. Other patented assets and technologies include the NatChem family of compound extracts from a collection of rare fungi; NatGen technologies, a set of advanced genetic tools that enable the cloning of large fragments of DNA; and Directed Biosynthesis, a tool for the genetic modification of metabolic pathways. In recent news, the company announced that it received a patent for once-daily Cidecin. In addition, Cubist and Gilead Sciences announced the termination of their European marketing agreement for Cidecin. Cubist reacquired all rights to the product. Cubist offers its employees benefits including medical plans, tuition reimbursement, flexible spending accounts, on-site massage therapy and subsidized parking and public transportation.

BRANDS/DIVISIONS/AFFILIATES: Cidecin Rocephin TerraGen Discovery, Inc. VITA Technology NatGen NatChem Directed Biosynthesis

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Scott M. Rocklage, CEO Michael W. Bonney, COO Michael W. Bonney, Pres. Thomas A. Shea, VP-Finance/CFO Francis P. Tally, Exec. VP-Scientific Affairs Robert J. McCormack, Sr. VP-Drug Dev. Robert J. Janosky, VP-Mfg. Christopher D.T. Guiffre, Corp. Sec. Christopher D.T. Guiffre, General Counsel Thomas A. Shea, VP-Admin. Oliver S. Fetzer, Sr. VP-Bus. Dev. David W.J. McGirr, Treas. Thomas J. Slater, VP-Commercial Dev. Dennis D. Keith, VP- Chemistry Dev. Frederick B. Oleson, Jr., VP-Pre-Clinical Dev. Julian E. Davies, Exec. V P-Tech. Dev.

Phone: 781-860-8660 Fax: 781-861-0566 Toll-Free: Address: 65 Hayden Ave., Lexington, MA 02421 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $10,399 ( 9 months) 2002 Profits: $-57,659 ( 9 months) Stock Ticker: CBST 2001 Sales: $14,400 2001 Profits: $-69,900 Employees: 180 2000 Sales: $5,200 2000 Profits: $-44,300 Fiscal Year Ends: 12/31 1999 Sales: $6,800 1999 Profits: $-24,100 1998 Sales: $1,700 1998 Profits: $-14,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Focus on lipopeptides.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $245,313 Bonus: $40,502

Northeast: Y

International: Y



CURAGEN CORPORATION

www.curagen.com



Y


Profits: 3


TYPES OF BUSINESS:


Y


Bio-Pharmaceuticals Genomics Technology Research Alliances Genetic Databases Genetic Coding and Expressions Bioinformatics

CuraGen is a genomics -based drug discovery and development company that researches, develops and uses technologies based on the discovery of genes and an understanding of their functions and relationships. The company works independently to accelerate the discovery and development of products to improve human and animal health and the vitality of agriculture. It has established internal programs to develop products to treat metabolic diseases, cancer, inflammatory diseases and central nervous system (CNS) disorders. Specifically, its genomics technology and information systems platform, known as GeneScape, has four primary systems: SeqCalling, for gene sequencing and discovery of variations in gene sequences; GeneCalling, a patented technology for gene discovery; PathCalling, for analyzing the function and relationship among genes; and SNPCalling, to identify and characterize human genetic variations. CuraGen markets such genomic technologies and information to pharmaceutical, biotechnology, agricultural and animal health companies through research collaborations. The firm currently has strategic alliances with Abgenix, Inc., Biogen, Inc., COR Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Inc., Sequenom, Inc., Roche Vitamins, Inc. and Pioneer HiBred International, Inc. In recent news, CuraGen’s product CG53135 has been clinically shown to stimulate cell growth, reduce tissue inflammation and degeneration and minimize the severity of damage associated with intestinal inflammation. Benefit plans for qualified employees consist of extensive insurance (including pet insurance) plans and perks designed to lure well-educated high-tech employees. Employees also enjoy wireless cell phone, day care and Avis corporate discounts.

BRANDS/DIVISIONS/AFFILIATES: GeneScape GeneCalling PathCalling SeqCalling SNPCalling CG53135 HSB Group, Inc. Women's Health U.S.A., Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Johnathan M. Rothberg, CEO Johnathan M. Rothberg, Pres. David M. Wurzer, Exec. VP/CFO Donna Starzecki, Dir.-Human Resources Timothy Shannon, Sr. VP-Research and Dev./Chief Medical Officer John E. Murphy, CIO/VP Bruce E. Taillon, Group Leader-Eng. Elizabeth A. Whayland, Corp. Sec. Thomas F. McCaffery, III, General Counsel/VP Steven Henck, Dir.-Oper. Hovan Asdourian, Sr. VP-Bus. Dev. Mark R. Vincent, Dir.-Corp. Comm. Mark R. Vincent, Dir.-Investor Rel. David M. Wurzer, Treas. Richard H. Booth, CEO, HSB Group, Inc. Robert E. Patricelli, CEO/Pres., Women's Health U.S.A., Inc. Michael P. McKenna, VP-Collaborative Research Elizabeth A. Whayland, Dir.-Financial Mgmt. Johnathan M. Rothberg, Chmn.

Phone: 203-401-3330 Fax: 203-401-3333 Toll-Free: Address: 555 Long Wharf Dr., 11th Fl., New Haven, CT 06511 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $14,490 ( 9 months) 2002 Profits: $-61,534 ( 9 months) Stock Ticker: CRGN 2001 Sales: $23,500 2001 Profits: $42,900 Employees: 506 2000 Sales: $20,838 2000 Profits: $-26,978 Fiscal Year Ends: 12/31 1999 Sales: $15,104 1999 Profits: $-25,763 1998 Sales: $9,257 1998 Profits: $-18,937


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $334,387 Stock Purch. Plan: Second Exec. Salary: $235,594 ADVANTAGE: Excellent genomics technology/Strong research alliances.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $112,500 Bonus: $75,000

Northeast: Y

International:



CURIS INC

www.curisinc.com


Y



Profits: 230


TYPES OF BUSINESS:



Drugs-Regenerative Medicine Signaling Pathway and Stem Cell Technologies

Curis, Inc. is engaged in the discovery of drug targets and the development of therapeutics based upon the systems used by the body to control tissue formation, maintenance and repair. The firm has identified key regulators responsible for turning on the mechanisms for tissue repair in response to trauma, injury or disease. Independently and through strategic alliances, the company is focusing its research efforts on regulators of tissue repair with applications including kidney disease, cancer and neurological disorders. As part of its realignment towards these products, the company has suspended clinical development efforts for Vascugel and Chondrogel. Curis's proprietary signaling pathways and stem cell technologies include the Bone Morphogenic Protein (BMP) and the Hedgehog family of product candidates. The BMP family of regulators orchestrates the development and repair of bone and kidneys. OP-1, marketed by Stryker Corp., is approved in four major markets for the repair of long bone fractures. Curis is currently developing BMP-7 for the repair of damaged kidney tissue. The Hedgehog family of proteins are key to the formation, maintenance and repair of tissues in the nervous system and cartilage, as well as in the control of blood vessel formation. In recent news, the company completed a $14-million royalty buyout, whereby Stryker will eliminate its future royalty obligations for BMP-7. Curis offers its employees a PPO medical plan, prescription drug benefits, vision, health and dental insurance, an employee assistance program, education assistance, stock option grants, company-paid parking and public transportation and membership in company sports teams.

BRANDS/DIVISIONS/AFFILIATES: Bone Morphogenic Protein Hedgehog BMP-7 OP-1 Chondrogel Vascugel

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Daniel R. Passeri, CEO Daniel R. Passeri, Pres. Christopher U. Missling, Sr. VP-Finance/CFO Bruce J. Hudson, VP-Human Resources Lee L. Rubin, Sr. VP-Research/Chief Scientific Officer James S. Sigler, VP-Mfg. Elizabeth Potthoff, VP/General Counsel Bruce J. Hudson, VP-Admin. Henry McCusker, VP-Strategic Planning Henry McCusker, VP-Comm. Mark Noel, VP-Tech. Mgmt. and Bus. Dev. Lynne G. Baird, VP-Regulatory Affairs and Preclinical Dev. James R. McNab, Jr., Chmn.

Phone: 617-503-6500 Fax: 617-503-6501 Toll-Free: Address: 61 Moulton St., Cambridge, MA 02138 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 570 ( 9 months) 2002 Profits: $-94,566 ( 9 months) Stock Ticker: CRIS 2001 Sales: $1,100 2001 Profits: $-81,900 Employees: 105 2000 Sales: $1,000 2000 Profits: $-350,400 Fiscal Year Ends: 12/31 1999 Sales: $5,100 1999 Profits: $-12,100 1998 Sales: $12,600 1998 Profits: $-21,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $364,942 Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $288,846 Bonus: $ ADVANTAGE: Strategic consolidation and integration of technology/Expertise in cell and tissue growth promotion.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



CV THERAPEUTICS INC

www.cvt.com


Y



Profits: 226


TYPES OF BUSINESS:



Drugs-Chronic Cardiovascular Diseases Small Molecule Therapies

CV Therapeutics is a biopharmaceutical company engaged in the discovery and development of new small molecule drugs to treat cardiovascular disease. CV has several research and preclinical development programs designed to bring drug candidates into human clinical testing. The company is currently conducting clinical trials for three of its products. Ranolazine, a potential treatment for angina, the heart pain that results from a shortage of oxygen-rich blood available to the heart, is currently in its second Phase III trial. Another product candidate in clinical trials, CVT-510, is a potential treatment to reduce heart rate during atrial arrhythmias. CVT-3146 is being developed to use as an agent in cardiac perfusion imaging studies. CV is jointly developing CVT-3146 with Fujisawa Healthcare, Inc. For the treatment of acute and chronic congestive heart failure, CV’s partner, Biogen, Inc, is developing Adentri. Recently, CV announced that results in Phase III trials for CVT-510 show patients with PSVT were able to convert back to a normal heart rate. CV Therapeutics offers its employees a flexible spending plan, an employee assistance program and tuition reimbursement.

BRANDS/DIVISIONS/AFFILIATES: Ranolazine CVT-510 CVT-3146 Adentri Fujisawa Healthcare, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Louis G. Lange, CEO Daniel K. Spiegelman, Sr. VP/CFO David C. McCaleb, VP- Mktg. Diane Laguri, VP-Human Resources Richard M. Lawn, VP-Discovery Research Patricia Borga Suvari, General Counsel Peter M. Strumph, VP-Oper. Brent K. Blackburn, Sr. VP-Drug Discovery and Preclinical Dev. Andrew A. Wolff, Sr. VP-Clinical Research and Dev. Luiz Belardinelli, VP-Drug Research and Pharmacological Sciences Sandra L. Skettino, VP-Clinical Research and Oper. Louis G. Lange, Chmn.

Phone: 650-384-8500 Fax: 650-858-0390 Toll-Free: Address: 3172 Porter Dr., Palo Alto, CA 94304 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $5,694 ( 9 months) 2002 Profits: $-53,295 ( 9 months) Stock Ticker: CVTX 2001 Sales: $6,800 2001 Profits: $-79,700 Employees: 222 2000 Sales: $3,300 2000 Profits: $-38,400 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-23,100 1998 Sales: $4,500 1998 Profits: $-12,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $375,000 Bonus: $400,000 Stock Purch. Plan: Y Second Exec. Salary: $260,000 Bonus: $175,000 ADVANTAGE: Continuing development efforts/ Discovery of a specific gene related to the removal of cholesterol from cells.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



CYANOTECH CORPORATION

www.cyanotech.com


Y


Y


Profits: 3


TYPES OF BUSINESS:



Microalgae Products Nutritional Supplements Aquaculture Feed Animal Nutrition Immunological Diagnostics

Cyanotech Corp. is a worldwide leader in the development and commercialization of high-value natural products derived from microalgae, a diverse group of over 30,000 species of microscopic plants with a wide range of physiological and biochemical characteristics and naturally high levels of proteins, amino acids, vitamins, pigments and enzymes. The firm has designed, developed and implemented proprietary production and harvesting technologies, systems and processes that eliminate the stability and contamination problems frequently encountered in the production of microalgae. The company's natural products include nutritional supplements, aquaculture feed, animal nutrition and immunological diagnostics products. The Spirulina line of vitamins and supplements includes Spirulina Pacifica, the firm's principal source of revenue, made from a unique strain of microalgae that provides a vegetable-based, highly absorbable source of beta-carotene, mixed carotenoids, B vitamins, gamma linolenic acid, amino acids and other phytonutrients. Spirulina products are marketed in approximately 20 countries around the world. NatuRose is Cyanotech's natural astaxanthin product for the animal nutrition market, used in aquaculture to impart a pink to red color to pen-raised fish and shrimp. BioAstin, an astaxanthin product for the human nutrition market, has antioxidant properties surpassing those of vitamins C and E and beta carotene. The company's proprietary technologies include Integrated Culture Biology Management, Ocean-Chill Drying and PhytoDome Closed Culture System, or PhytoDome CCS. Cyanotech's subsidiaries include Nutrex Hawaii and Cyanotech Japan YK. Recently, the firm received patent allowance for the use of astaxanthin to retard and prevent sunburn, marking the third patent Cyanotech has received for the product's protective properties.

BRANDS/DIVISIONS/AFFILIATES: NatuRose BioAstin Spirulina Pacifica Nutrex Hawaii, Inc. Cyanotech Japan YK PhytoDome CCS Ocean-Chill Drying Integrated Culture Biology Management

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gerald R. Cysewski, CEO Gerald R. Cysewski, Pres. Ronald P. Scott, Exec. VP-Finance Kelly J. Moorhead, VP-Mktg. and Sales R. Shane Rohan, VP- Production Ronald P. Scott, Corp. Sec. Glenn D. Jensen, VP-Oper. Ronald P. Scott, Treas. Ronald P. Scott, Exec. VP-Admin. Gerald R. Cysewski, Chmn.

Phone: 808-326-1353 Fax: 808-329-4533 Toll-Free: 800-395-1353 Address: 73-4460 Queen Kaahumanu Hwy., Ste. 102, KailuaKona, HI 96740 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $8,200 (12 months) 2002 Profits: $-2,600 (12 months) Stock Ticker: CYAN 2001 Sales: $8,043 2001 Profits: $-1,067 Employees: 53 2000 Sales: $7,400 2000 Profits: $-4,500 Fiscal Year Ends: 3/31 1999 Sales: $6,700 1999 Profits: $-2,600 1998 Sales: $7,600 1998 Profits: $- 300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: ADVANTAGE: Microalgae expertise.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International: Y



CYPRESS BIOSCIENCE INC

www.cypressbio.com


Y



Y

TYPES OF BUSINESS:

Profits: 23

Computers: Hardware: Softw are: Arrays: Database Management:



Equipment- Immune System Disease Pharmaceutical Treatments

Cypress Bioscience, Inc. develops, manufactures and markets products that improve the diagnosis and treatment of patients with functional somatic syndromes (FSSs), such as fibromyalgia syndrome (FMS) and other pain and central nervous system disorders. Recently, the company launched a genomic research program to better understand the genetic factors associated with FMS. Cypress has signed a license agreement with Pierre Fabre Medicament to develop and market products with the compound milnacipran for the treatment of FMS in the U.S. and Canada. Phase II clinical trials are underway to determine the link between milnacipran and FMS. Recently, Cypress announced that it entered into an agreement with Collrgium Pharmaceutical, Inc., to develop new analogs of milnacipran. In other news, results from clinical trials of milnacipran showed its potential effectiveness in an animal model of visceral pain. The company gained FDA approval for its leading product, Prosorba, which treats symptoms of moderate to severe rheumatiod arthritis. The product will help adult patients with long standing diseases, whose recoveries have failed with the use of disease-modifying anti-rheumatic drugs. Fresenius Medical Care North America recently agreed to acquired Cypress's Prosorba assets.

BRANDS/DIVISIONS/AFFILIATES: Prosorba Cyplex Infusible Platelet Membranes Fresenius Medical Care North America

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jay D. Kranzler, CEO John N. Bonfiglio, Exec. VP/COO Jay D. Kranzler, Pres. Sabrina Martucci Johnson, CFO R. Michael Gendreau, VP-Clinical Dev. R. Michael Gendreau, Chief Medical Officer Jay D. Kranzler, Corp. Sec. Srinivas G. Rao, Chief Scientific Officer Jay D. Kranzler, Chmn.

Phone: 858-452-2323 Fax: 858-452-1222 Toll-Free: Address: 4350 Executive Dr., Ste. 325, San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $6,400 ( 9 months) 2002 Profits: $ 699 ( 9 months) Stock Ticker: CYPB 2001 Sales: $1,600 2001 Profits: $-7,200 Employees: 9 2000 Sales: $3,000 2000 Profits: $-8,500 Fiscal Year Ends: 12/31 1999 Sales: $1,900 1999 Profits: $-7,800 1998 Sales: $2,700 1998 Profits: $-9,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $438,000 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $230,000 Bonus: $ ADVANTAGE: Agreement with Fresenius Medical Care North America/Technology with potential in multiple markets.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



CYTOGEN CORPORATION

www.cytogen.com


Y


Y


Profits: 128


TYPES OF BUSINESS:

Y



Drugs-Cancer Protein Pathway Database Proteomics Diagnostic Imaging Agents

Cytogen Corp. is a biopharmaceutical company with a mission to set new standards in cancer care. Its principal lines of business focus on prostate cancer and oncology. Both are built upon the company's expertise in antibodies and molecular recognition, which are directed to the development of novel products for the diagnosis, imaging, staging and treatment of cancer. The firm has established a pipeline of product candidates based on its proprietary antibody and prostate specific membrane antigen (PSMA) technologies. FDA-approved products include ProstaScint, a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer; BrachySeed, a uniquely designed, next-generation radioactive seed implant for the treatment of localized prostate cancer; Quadramet, a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer; and OncoScint CR/OV, a diagnostic imaging agent for colorectal and ovarian cancer. Cytogen is involved in strategic alliances with Progenics Pharmaceuticals, Inc., The Dow Company, Memorial Sloan-Kettering Cancer Center, Molecular Staging, Inc., Elan Corp. and Draxis Health, Inc. Recently, Cytogen and Advanced Magnetics, Inc. announced studies in the use of Combidex in detecting lymph node disease in breast cancer patients. In other news, the company announced it has entered into a five-year agreement with Matritech, Inc. Under this agreement, Cytogen will be the sole U.S. distributor for Matritech’s NMP2 BladderCheck test. Cytogen offers its employees tuition assistance, flexible spending accounts and stock options.

BRANDS/DIVISIONS/AFFILIATES: ProstaScint BrachySeed Quadramet OncoScint PSMA Technology

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. H. Joseph Reiser, CEO H. Joseph Reiser, Pres. Lawrence R. Hoffman, CFO/VP Deborah A. Kaminsky, VP-Sales and Mktg. William F. Goeckeler, VP-Research and Dev. Michael D. Becker, VP-Investor Rel. James A. Grigsby , Chmn.

Phone: 609-750-8200 Fax: 609-750-8124 Toll-Free: Address: 600 College Rd. E, Princeton, NJ 08540 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $9,564 ( 9 months) 2002 Profits: $-12,176 ( 9 months) Stock Ticker: CYTOD 2001 Sales: $11,700 2001 Profits: $-12,100 Employees: 115 2000 Sales: $10,500 2000 Profits: $-27,300 Fiscal Year Ends: 12/31 1999 Sales: $11,200 1999 Profits: $ 700 1998 Sales: $19,900 1998 Profits: $-13,200


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $314,423 Stock Purch. Plan: Second Exec. Salary: $219,423 ADVANTAGE: Expertise in antibodies and molecular recognition.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $100,000 Bonus: $45,311

Northeast: Y

International:



CYTRX CORPORATION

www.cytrx.com


Y



Profits: 64


TYPES OF BUSINESS:



Drugs-Sickle Cell Anemia Human Therapeutic Products Animal Therapeutic Products

CytRx Corporation develops and markets human therapeutic products. Its current research and development activities include FLOCOR, an intravenous agent for treatment of sickle cell disease and other acute vaso-occlusive disorders, and TranzFect, a delivery technology for DNA-based vaccines. The company also has a research pipeline with opportunities in the areas of muscular dystrophy, cancer, spinal cord injury, vaccine delivery and gene therapy. FLOCOR is designed to allow blood cells to float over one another, and research has found this process to improve blood flow and restore oxygen delivery. The company’s focus is to find a treatment for sickle cell anemia and to use FLOCOR in this process. FLOCOR is in testing stages for the treatment of acute stroke, heart attack, shock, cancer and acute respiratory distress syndrome related to sickle cell anemia. CytRx has licensed its gene delivery technology, TranzFect, to Merck & Co., Inc. in an exclusive agreement to evaluate the company’s gene delivery technology in a gene-based vaccine for HIV. In other news, CytRx announced the completion of its merger with Global Genomics Capital, Inc., a genomics holding company.

BRANDS/DIVISIONS/AFFILIATES: Vaxcel, Inc. VetLife FLOCOR TRANZFECT Global Genomics Capital, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steven A. Kriegsman, CEO Steven A. Kriegsman, Pres. Mark W. Reynolds, VP-Finance/CFO William B. Fleck, VP-Human Resources Kathy Hernandez , Corp. Sec. R. Martin Emanuele, VP- Research and Bus. Dev. J. Michael Grindel, VP-Drug Dev. Max Link, Chmn.

Phone: 770-368-9500 Fax: 770-368-0622 Toll-Free: Address: 154 Technology Pkwy., Norcross, GA 30092 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,255 ( 9 months) 2002 Profits: $-3,589 ( 9 months) Stock Ticker: CYTR 2001 Sales: $4,400 2001 Profits: $- 900 Employees: 5 2000 Sales: $3,300 2000 Profits: $- 300 Fiscal Year Ends: 12/31 1999 Sales: $1,400 1999 Profits: $-15,000 1998 Sales: $2,100 1998 Profits: $-5,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $360,150 Stock Purch. Plan: Second Exec. Salary: $208,300 ADVANTAGE: Focus on treatment of acute vaso-occlusive disorders.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Bonus: $55,250 Bonus: $17,750

Northeast:

International:



DECODE GENETICS INC

www.decode.com



Y


Profits: 7


TYPES OF BUSINESS:

Y

Specialty: Specialty Services: Consulting: Blood Collec tion:


Bioinformatics and Medical Records Databases Bioinformatic Software Products Genetic Disease Research

deCODE Genetics, an Icelandic firm, performs genetic and medical research in order to identify disease genes, drug targets and diagnostic targets. The firm also uses informatics technology in order to compile health information, which it then uses to develop and sell services for the health care industry internationally. It is a population-based genomics corporation and uses one of the most advanced genotyping labs in the world. Iceland’s unique, genetically homogenous population and extensive genealogical records make it an ideal site for the type of research that deCODE conducts. By conducting experiments on the genetic information on such a population, the company is able to gain insights into the pathogenesis of certain illnesses in a way that would not be possible under other less optimal circumstances. The firm’s research model links the family trees of Icelanders suffering from particular illnesses, then clusters patients into large extended families containing hundreds of persons. The comparison of DNA samples from closely and distantly related individuals with the same disease helps expedite the process of identifying specific genes that cause the illness. deCODE is involved in strategic collaborations with Affymetrix, Applied Biosystems, Genmab, Merck, Pharmacia, Roche and Wyeth. Recently, deCODE announced it has generated a 3-D image of how the cancer drug topotecan works together to prevent cell division. Many employees at deCODE enjoy swimming in Iceland's geothermically heated outdoor pools, and company groups have been organized for basketball and soccer games. Cos tume parties, white-river rafting, holiday events and Friday happy-hours are also part of the culture at deCODE. The firm offers relocation assistance for international recruits.

BRANDS/DIVISIONS/AFFILIATES: Icelandic Health Sector Database Encode Genmab DecodeGT

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kari Stefansson, CEO Kari Stefansson, Pres. Lance Thibault, CFO Asta Bjarnadottir, Dir.-Human Resources Jeffrey Gulcher, VP-Research and Dev. Hakon Guethbjartsson, VP-Informatics Michael Young, Sr. VP-Bus. Dev. Pall Magnusson, VP-Info. and Comm. Lance Thibault, Treas. Hannes Smarason, Exec. VP/Sr. Bus. Officer Mark Gurney, VP-Pharmaceutical Discovery C. Augustine Kong, VP-Statistics Kari Stefansson, Chmn.

Phone: +354-570-1900 Fax: +354-570-1903 Toll-Free: Address: Sturlugata 8, Reykjavik, IS-101 Iceland

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $31,900 ( 9 months) 2002 Profits: $-113,700 ( 9 months) Stock Ticker: DCGN 2001 Sales: $31,600 2001 Profits: $-47,800 Employees: 592 2000 Sales: $21,546 2000 Profits: $-31,119 Fiscal Year Ends: 12/31 1999 Sales: $16,600 1999 Profits: $-23,800 1998 Sales: $12,700 1998 Profits: $-10,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $372,597 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $204,696 Bonus: $ ADVANTAGE: Partnership with AstraZeneca/Ability to conduct research on Iceland's unique controlled population groups.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast:

International: Y



DEPOMED INC

www.depomedinc.com


Y



Profits: 150

Computers: Hardw are: Software: Arrays: Database Management:

TYPES OF BUSINESS:



Drugs-Drug Delivery Oral Drug Delivery Systems

DepoMed, Inc. is a development-stage company engaged in the development of new and proprietary oral drug delivery technologies. The company's primary system is the patented Gastric Retention (GR) System, designed to be retained the stomach for an extended period of time while it delivers the incorporated drug on a controlledrelease basis. The technology allows a drug that normally must be taken several times per day to be administered only once per day. Several drug compounds involving this system are in advanced clinical development. DepoMed has also developed the Reduced Irritation (RI) System, designed to provide for significant reduction in local upper gastrointestinal irritation from the effects of certain drugs. The firm develops proprietary products utilizing these technologies both internally and in collaboration with other pharmaceutical and biotechnology companies. DepoMed's Metformin GR, a once-daily metformin product for Type II diabetes, is currently in Phase III human clinical trials. In addition, the company completed Phase I trials for a once-daily formulation of the antibiotic CIPRO, Ciprofloxacin GR. DepoMed has also initiated Phase I trials of a GR drug for cardiovascular conditions. The company formed a joint venture with Elan Corp., DepoMed Development, Ltd., to develop and commercialize undisclosed products. DepoMed has also entered into an agreement with AVI BioPharma to investigate controlled oral-delivery versions of AVI's NEUGENE antisense agents. In recent news, the company announced the Phase I results of its oral-release dosage form of Lasix, Furosemide GR, for the treatment of hypertension. In addition, DepoMed formed an agreement with ActivBiotics to develop a controlled-release product for the treatment of gastrointestinal diseases.

BRANDS/DIVISIONS/AFFILIATES: Gastric Retention System Reduced Irritation System Metformin GR Ciprofloxacin GR DepoMed Development, Ltd.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John W. Fara, CEO John W. Fara, Pres. John. F. Hamilton, VP/CFO John N. Shell, V P-Oper. Bret Berner, VP-Product Dev. John W. Fara, Chmn.

Phone: 650-462-5900 Fax: 650-513-0999 Toll-Free: Address: 1360 O'Brien Dr., Menlo Park, CA 94025 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,372 ( 9 months) 2002 Profits: $-21,397 ( 9 months) Stock Ticker: DMI 2001 Sales: $3,700 2001 Profits: $-17,600 Employees: 41 2000 Sales: $1,776 2000 Profits: $-9,703 Fiscal Year Ends: 12/31 1999 Sales: $ 115 1999 Profits: $-17,209 1998 Sales: $ 763 1998 Profits: $-2,778


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $356,032 Stock Purch. Plan: Second Exec. Salary: $211,032 ADVANTAGE: Unique drug delivery technology/Partnership with AVI BioPharma.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $72,500 Bonus: $40,000

Northeast:

International:



DIACRIN INC

www.diacrin.com



Y


Profits: 3


TYPES OF BUSINESS:



Cell Transplantation Therapy

Diacrin, Inc. is developing cell transplantation technology for treating human diseases that are characterized by cell dysfunction or cell death. Many of its products are developed in cells from pigs. Products in development include porcine spinal cord cells for spinal cord injury; porcine neural cells for stroke, focal epilepsy and chronic intractable pain; NeuroCell-PD for Parkinson's disease; human liver cells for cirrhosis; porcine liver cells for acute liver failure; and human muscle cells for cardiac disease. Diacrin pioneered the use of porcine, or pig, cells for clinical transplantation to address the inadequate supply of human donor cells. These cells are functionally similar to human cells and are capable of integrating into the surrounding tissue. The company has completed Phase I and II trials of NeuroCell-PD. The firm's remaining products are in Phase I trials. Diacrin is also developing a proprietary technology designed to modulate the human immune system in order to prevent rejection of transplanted cells without the use of immunosuppressive drugs. This immunomodulation technology involves the selective treatment of cell populations prior to transplantation. In recent news, Diacrin licensed its muscle cell transplantation technology for cardiac disease to Terumo Corp., an international pharmaceutical and medical device company based in Japan. The firm also released the results of Phase I clinical trials of this technology.

BRANDS/DIVISIONS/AFFILIATES: NeuroCell- PD

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas H. Fraser, CEO E. Michael Egan, COO Thomas H. Fraser, Pres. Douglas B. Jacoby, Dir.-Research Kevin Kerrigan, Controller Abdellah Sentissi, Sr. Dir.-Quality Control Jonathan H. Dinsmore, Dir.-Cell Transplantation Roger J. Gay, Sr. Dir.-Process Dev.

Phone: 617-242-9100 Fax: 617-242-0070 Toll-Free: Address: 13th St., Bldg. 96, Charlestown, MA 02129 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 700 ( 9 months) 2002 Profits: $-4,800 ( 9 months) Stock Ticker: DCRN 2001 Sales: $3,900 2001 Profits: $-4,600 Employees: 30 2000 Sales: $5,200 2000 Profits: $-3,537 Fiscal Year Ends: 12/31 1999 Sales: $4,300 1999 Profits: $-4,800 1998 Sales: $5,200 1998 Profits: $-4,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $275,000 Bonus: $137,500 Stock Purch. Plan: Second Exec. Salary: $220,000 Bonus: $110,000 ADVANTAGE: Joint venture with Genzyme/Technologies that enable unique cell transplants and that may stop graft rejection.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



DIAGNOSTIC PRODUCTS CORPORATION www.dpcweb.com Industry Group Code: 339113 Ranks within this company's industry group: Sales: 7 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:



Y Y

TYPES OF BUSINESS:

Profits: 4




Supplies-Immunodiagnostic Kits Nonisotopic Diagnostic Tests Immunoassay Analyzers

Diagnostic Products Corp. manufactures and distributes medical immunodiagnostic test kits and related instrumentation that utilize technology derived from immunology and molecular biology. The tests are used to diagnose and manage a wide variety of medical conditions such as allergies, anemia, cancer, diabetes, infectious disease, substance abuse and veterinary applications. The company’s instrument systems include the IMMULITE family of chemiluminescent immunoassay analyzers, AlaSTAT for non-invasive allergy testing and the MARK 5 HSS for automating immunohistochemical testing. The firm’s newest system, IMMULITE 2000, with its advanced software features and expanding menu, is becoming widely accepted by laboratories worldwide that are seeking improved automation. Additionally, Diagnostic Products’ IMMULITE Turbo assays provide test results in about 15 minutes. The impact of the company’s patented technology on the future of patient care will reduce costs and improve patient outcomes. Diagnostic Products recently signed an agreement with Medical Electronic Systems, Ltd. (MES) that allows the company to distribute MES’s SQA-V sperm analyzer in the U.S., Puerto Rico, Canada and Brazil. It also entered into an agreement with Matritech in which the firm will develop and market an automated version of Matritech’s NMP22 test kit for bladder cancer. Diagnostic Products offers its employees medical, disability and life insurance, education assistance, flexible spending accounts and credit union membership.

BRANDS/DIVISIONS/AFFILIATES: IMMULITE AlaSTAT MARK 5 HSS IMMULITE 2000 IMMULITE Turbo Minerva Pharmaceuticals Dade Behring, Inc. Novation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael Ziering, CEO Sidney A. Aroesty, COO James L. Brill, VP-Finance Nicholaas Arnold, VP-Mktg. & Sales Said El Shami, Chief Scientific Officer Marilyn Ziering, Corp. Sec. Kathy J. Maugh, VP-Oper. Robert DiTullio, VP-Reg. Affairs and Quality Systems Said El Shami, Sr. VP-Research & Dev. Kathy J. Maugh, VP-Tech. Oper. Ira Ziering, VP-Int'l

Phone: 310-645-8200 Fax: 310-645-9999 Toll-Free: 800-678-6699 Address: 5700 W. 96th St., Los Angeles , CA 90045-5597 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $238,775 ( 9 months) 2002 Profits: $34,763 ( 9 months) Stock Ticker: DP 2001 Sales: $283,400 2001 Profits: $39,000 Employees: 1,955 2000 Sales: $247,867 2000 Profits: $28,250 Fiscal Year Ends: 12/31 1999 Sales: $216,200 1999 Profits: $20,500 1998 Sales: $196,600 1998 Profits: $20,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $475,000 Stock Purch. Plan: Second Exec. Salary: $320,000 ADVANTAGE: Advanced testing systems that provide prompt results.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast: Y



Bonus: $80,000 Bonus: $60,000

Northeast: Y

International: Y



DIGENE CORPORATION

www.digene.com




Y Y

TYPES OF BUSINESS:

Profits: 22




Supplies-DNA/RNA Tests Human Papillomavirus

Digene Corp. develops, manufactures and markets its proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases. The company uses its patented Hybrid Capture Gene Analysis System to focus on women’s cancer and infectious diseases. The firm’s lead product is the only FDA-approved test for human papillomavirus (HPV), the cause of more than 99% of cervical cancer cases. Digene is currently working to establish its HPV test as the standard for cervical cancer screening instead of the current Pap smear. An FDA panel recently recommended approval of the DNA Pap testing for primary cervical cancer screening, although the FDA still wishes to see more information. Digene also developed its Hybrid Capture technology to include DNA tests for the detection of chlamydia, gonorrhea and other sexually transmitted infections. In addition, the firm operates in genomics research with the goal of applying its technology platform to develop gene expression DNA microarray products and services, expand its clinical testing services for use in the pharmaceutical market and correlate proprietary genebased information with clinical diseases. The company markets its product through a direct sales force in the U.S. and through distributors in other countries. Abott Laboratories markets and distributes all of the company’s women’s cancer and infectious diseases products and certain blood virus products in Europe, Africa and the Middle East. Digene offers its employees a health care plan; dental, vision and prescription drug coverage; life insurance; short and long term disability insurance and tuition reimbursement.

BRANDS/DIVISIONS/AFFILIATES: Hybrid Capture Gene Analysis System Diagene Europe

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Evan Jones, CEO Charles M. Fleischman, COO Evan Jones, Pres. Charles M. Fleischman, CFO Greg Brown, VP-Global Sales and Mktg. Larry Welman, VP-Human Resources Attila T. Lorincz, Chief Scientific Officer Joseph P. Slattery, Controller Jeanmarie Curley, VP-Mfg. Donna M. Seyfried, VP-Bus. Dev. Belinda Patrick, Sr. VP-Mfg. Oper. Jay Payne, VP-Research and Dev. Joseph P. Slattery, VP-Finance Susan M. Keese, VP-Product Oper. and Mktg.

Phone: 301-944-7000 Fax: 301-944-7121 Toll-Free: 800-344-3631 Address: 1201 Clopper Rd., Gaithersburg, MD 20878 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $48,800 (12 months) 2002 Profits: $-9,400 (12 months) Stock Ticker: DIGE 2001 Sales: $34,200 2001 Profits: $-6,500 Employees: 193 2000 Sales: $23,000 2000 Profits: $-6,800 Fiscal Year Ends: 6/30 1999 Sales: $17,500 1999 Profits: $-9,300 1998 Sales: $12,000 1998 Profits: $-14,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $273,910 Stock Purch. Plan: Second Exec. Salary: $271,410 ADVANTAGE: Manufactures the only FDA approved test for human papillomavirus.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $150,000 Bonus: $60,000

Northeast: Y

International: Y



DISCOVERY LABORATORIES

www.discoverylabs.com


Y



Profits: 125


TYPES OF BUSINESS:



Pharmaceutical Treatments for Respiratory Diseases Drugs-Osteoporosis Drugs-Cystic Fibrosis Drugs-Chronic Bronchitis

Discovery Laboratories, Inc., formerly known as Ansan Pharmaceuticals, Inc., is a biopharmaceutical company that develops and commercializes medically novel respiratory therapies and pulmonary drug delivery products. The company is currently focusing on lung diseases, with an emphasis on neonatal conditions. It hopes to develop treatments for newborn meconium aspiration syndrome, infant respiratory distress syndrome, acute lung injury and cystic fibrosis. Its lead product, Surfaxin, is an engineered humanized surfactant and is currently in Phase III clinical trials for respiratory distress syndrome in premature infants, a Phase III clinical trial for meconium aspiration syndrome in full-term infants and a Phase II clinical trial for acute lung injury and acute respiratory distress syndrome in adults. The company is conducting research and development of aerosolized formulations of its humanized surfactant to treat respiratory conditions such as asthma. Recently, Discovery Laboratories announced a research collaboration with CollaGenex Pharmaceuticals, Inc. to develop treatments for chronic obstructive pulmonary disease, cystic fibrosis and chronic interstitial lung disease.

BRANDS/DIVISIONS/AFFILIATES: Ansan Pharmaceuticals, Inc. Esteve Group Surfaxin SuperVent

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert J. Capetola, CEO Christopher J. Schaber, COO/Exec. VP Robert J. Capetola, Pres. John G. Cooper, CFO/Sr. VP Cynthia Davis, Mgr.-Human Resources Robert Segal, VP-Clinical Research Cynthia Davis, Controller David Lopez, Sr. VP/General Counsel Cynthia Davis, VP-Admin. Deni M. Zodda, Sr. VP-Bus. Dev. Robert Segal, Sr. VP-Clinical Research and New Drug Evaluation Huei Tsai, VP-Biometrics Vincent J. Benn, VP-Worldwide Clinical Oper.

Phone: 215-340-4699 Fax: 215-340-3940 Toll-Free: Address: 350 S. Main St., Ste. 307, Doylestown, PA 18901 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,388 ( 9 months) 2002 Profits: $-12,186 ( 9 months) Stock Ticker: DSCO 2001 Sales: $1,100 2001 Profits: $-11,100 Employees: 50 2000 Sales: $1,783 2000 Profits: $-10,861 Fiscal Year Ends: 12/31 1999 Sales: $ 334 1999 Profits: $-5,000 1998 Sales: $ 400 1998 Profits: $-15,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Novel therapeutics for critical care.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $120,000 Bonus: $60,000

Northeast: Y

International:



DIVERSA CORPORATION

www.diversa.com


Y


Y Y


Profits: 18


TYPES OF BUSINESS:



Research-Enzyme and Biological Compound Discovery Gene Expression Libraries Proprietary Gene Screening Technologies Enzymes for Oil Well Fracturing

Diversa Corp. is a leader in applying proprietary genomic technologies for the rapid discovery and optimization of novel products from genes and gene pathways. The firm is directing its integrated portfolio of technologies to the discovery, evolution and production of commercially valuable molecules with pharmaceutical applications, such as monoclonal antibodies and orally active drugs, as well as enzymes and small molecules with agricultural, chemical and industrial applications. The company has formed joint ventures with The Down Chemical Company (Innovase) and Syngenta Seeds (Zymetrics, Inc.). Innovase and Zymetrics are focused on the near-term commercialization of products for industrial and agricultural markets, respectively. Diversa's Gene Site Saturation Mutagenesis (GSSM) technology is a powerful mutagenesis system designed to optimize enzyme stability and binding affinity while minimizing immunogenicity. The company's complementary technology, Tunable GeneReassembly, synthesizes DNA fragments to create novel genes. Diversa uses the large collection of genetic material captured in its PathwayLibrary to accelerate the discovery of small-molecule pharmaceuticals. The firm's protein therapeutics and antibody program focuses on the application of its DirectEvolution technologies, as well as the GigaMatrix screening platform, to improve protein therapeutics and to generate novel antibodies. The company's products include Pyrolase 160 and Pyrolase 200 enzymes for oil and gas well fracturing operations and ThermalAce, a thermostable DNA polymerase. Recently launched products include feed and food additives, enzymes for baking and malting, flavor and fragrance ingredients and enzymes for peptide synthesis. In other news, Diversa licensed a product for improved enzymatic synthesis of key pharmaceutical intermediates to the pharmaceutical division of Dow. Diversa offers its employees health, dental and vision insurance, stock options, health club reimbursement and flexible spending accounts.

BRANDS/DIVISIONS/AFFILIATES: Innovase ThermalAce Zymetrics, Inc Pyrolase 160 Enzyme Pyrolase 200 Enzyme Replicase Gene Site Saturation Mutagenesis Tunable GeneReassembly

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jay M. Short, CEO Jay M. Short, Pres. Karin Eastham, CFO/Sr. VP-Finance Janice Delperdang, Dir.-Human Resources Jay M. Short, Chief Tech. Officer R. Patrick Simms , Sr. VP-Oper. William H. Baum, Exec. VP-Bus. Dev. Carolyn A. Erickson, VP-Intellectual Property

Phone: 858-526-5000 Fax: 858-526-5551 Toll-Free: Address: 4955 Directors Pl., San Diego, CA 92121-1609 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $22,600 ( 9 months) 2002 Profits: $-21,800 ( 9 months) Stock Ticker: DVSA 2001 Sales: $36,000 2001 Profits: $-15,700 Employees: 276 2000 Sales: $24,301 2000 Profits: $-8,064 Fiscal Year Ends: 12/31 1999 Sales: $10,300 1999 Profits: $-9,000 1998 Sales: $1,300 1998 Profits: $-13,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $320,000 Stock Purch. Plan: Second Exec. Salary: $260,000 ADVANTAGE: Innovative enzyme and gene evolution/Royalty-based research agreements.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $256,000 Bonus: $130,000

Northeast:

International:



DONLAR BIOSYNTREX

www.donlar.com


Y


Y


Profits: 7


TYPES OF BUSINESS:



Polymers Water Treatment Pharmaceutical Development Oil Field Equipment Treatment Detergents Crop Nutrition Management

Donlar BioSyntrex Corporation, formerly Biomune Systems, Inc., engages in the research, development, distribution and sale of biodegradable polymers that are environmentally friendly. These non-toxic, non-hazardous polymers are designed for use in industrial, agricultural and consumer markets. The company is commercializing its technologies within oil production, water treatment, laundry and dishwasher detergent, crop nutrition management, crop protection and seed coatings divisions. The firm's biopolymer application in the oil industry prevents scale and corrosion of platform pillars. Its products also inhibit mineral corrosion in heating, cooling and pumping operations. The company's low molecular weight, high molecular weight and low color biopolymers are known as A-2C, A-3C, B-3D, A-5D, C-10D, C-20C, ALC-70 and ALC-130. Donlar BioSyntrex’s proteins increase fertilizer efficiency and reduce the amount of herbicides and insecticides needed. These AgriSciences’ products include the AmiSorb, Lynx, Volt and AmiGro brands. In recent news, Donlar BioSyntrex announced that it signed an agreement to merge with its parent company, Donlar Corporation.

BRANDS/DIVISIONS/AFFILIATES: AmiSorb Lynx Volt AmiGro Donlar A-2C Donlar ALC-130 Biomune Systems, Inc Donlar Corporation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Larry Koskan, CEO Robert Pietrangelo, Sr. VP/COO Larry Koskan, Pres. Grace Fan, Dir.-Research Gerald Gleich, Chief Tech. Officer-Donlar Pharmaceutical Corp. Donald Anderson, Dir-Mfg. Joel Lurquin, Corp. Sec. Christine Fenlon, Dir.-Comm. Joel Lurquin, Treas. Larry Koskan, Chmn.

Phone: 708-563-9200 Fax: 708-563-9220 Toll-Free: 888-563-9200 Address: 6502 S. Archer Rd., Bedford Park, IL 60501 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $1,892 ( 6 months) 2002 Profits: $-5,261 ( 6 months) Stock Ticker: BIME 2001 Sales: $2,352 2001 Profits: $-16,105 Employees: 13 2000 Sales: $1,382 2000 Profits: $-13,714 Fiscal Year Ends: 9/30 1999 Sales: $ 794 1999 Profits: $-12,149 1998 Sales: $2,800 1998 Profits: $-1,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $161,367 Stock Purch. Plan: Second Exec. Salary: $159,623 ADVANTAGE: Expertise in biodegradable polymers with applications in multiple industries.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



DOR BIOPHARMA INC

www.dorbiopharma.com


Y




TYPES OF BUSINESS:



Drugs-Drug Delivery Unique Oral Formulations

DOR BioPharma, Inc., formerly Endorex Corporation, is a drug delivery firm focused on developing oral formulations of small molecule drugs that are traditionally delivered in non-oral formats. DOR BioPharma is developing drug delivery platforms based on the combination of lipids and polymers. The development of orBec focuses on a novel oral formulation to treat a series of gastrointestinal disorders, the first of which is graft vs. host disease. Oraphine is being developed for the treatment of rheumatoid arthritis. The company’s oral drug delivery systems include LPM systems, LPE systems and PLP systems. The company is developing LPM as an oral dosage formulation drug used to treat endometriosis and prostate cancer. It is also utilizing both LPE and PLP systems to develop an oral dosage form of paclitaxel. Recently, DOR BioPharma announced that it has initiated a program to produce orally administered vaccines to protect against exposure to biological agents that can potentially be used in bioterrorist attacks. In other news, the company entered into an agreement with the University of Texas Medical Branch at Galveston to license patent applications such as orBec for the treatment of irritable bowel syndrome.

BRANDS/DIVISIONS/AFFILIATES: orBec Oraphine LPM System LPE System PLP System Endorex Corporation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steve Kanzer, CEO Steve Kanzer, Pres. David Franckowiak, VP-Finance Panayiotis P. Constantinides, VP-Research and Dev. Steve Koulogeorge, Controller Steve Koulogeorge, Corp. Sec. John R. McCracken, VP-Bus. Dev. Steve Koulogeorge, Treas. Steve Kanzer, Chmn.

Phone: 847-573-8990 Fax: 847-573-9285 Toll-Free: Address: 28101 Ballard Dr., Unit F, Lake Forest, IL 60045 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-4,101 ( months) Stock Ticker: DOR 2001 Sales: $ 2001 Profits: $-14,600 Employees: 22 2000 Sales: $ 100 2000 Profits: $-4,796 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-7,501 1998 Sales: $ 1998 Profits: $-47,554


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $254,600 Stock Purch. Plan: Second Exec. Salary: $163,000 ADVANTAGE: Expertise in the oral delivery of protein and peptide-based drugs and vaccines.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



DRAXIS HEALTH INC

www.draxis.com


Y



Profits: 66


TYPES OF BUSINESS:



Drugs-Dog Cognitive Dysfunction and Cushing's Disease Niche Pharmaceuticals Veterinary Pharmaceuticals Radiopharmaceuticals

DRAXIS Health, Inc. is a pharmaceutical company focused on niche and specialty pharmaceuticals. It operates in diverse business segments through its subsidiaries. The veterinary pharmaceutical unit, Deprenyl Animal Health, Inc., develops a number of pharmaceuticals for animal health. Its leading product, Anipryl, is licensed to Pfizer Animal Health and is used to treat ailments suffered by aging dogs. DRAXIS Pharmaceutica markets pharmaceuticals in Canada. DRAXIMAGE, Inc. researches, develops, manufactures and markets radiopharmaceuticals and diagnostic imaging agents. DRAXIS Pharma, Inc. manufactures its own products, specializing in liquid and freeze-dried injectables and other sterile products. Recently, DRAXIS Pharma, Inc. received a letter of acceptance from the FDA to manufacture solid dosage form products, such as capsules and tablets, for the U.S. market. In other news, DRAXIS Health announced that DRAXIMAGE expanded the production of BrachySeed to treat prostate cancer and other localized tumors. Cytogen Corporation markets the company’s BrachySeed implants in the U.S.

BRANDS/DIVISIONS/AFFILIATES: Deprenyl Animal Health, Inc. Anipryl DRAXIS Pharmaceutica DRAXIMAGE, Inc. DRAXIS Pharma, Inc. BrachySeed

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Martin Barkin, CEO Martin Barkin, COO Martin Barkin, Pres. Jim A.H. Garner, Sr. VP-Finance/CFO Jack A. Carter, VP-Human Resources Roger Mailhot, VP-Scientific and Regulatory Affairs Douglas M. Parker, Corp. Sec. Douglas M. Parker, General Counsel Jerry Ormiston, VP-Investor Rel. Dan Brazier, Pres., DRAXIS Pharmaceutical Raymond Dore, Pres., DRAXIMAGE, Inc. Dwight Gorham, Pres., DRAXIS Pharma, Inc. Brian M. King, Chmn.

Phone: 905-677-5500 Fax: 905-677-5502 Toll-Free: Address: 6870 Goreway Dr., Mississauga, Ontario L4V 1P1 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $28,804 ( 9 months) 2002 Profits: $1,477 ( 9 months) Stock Ticker: DRAX 2001 Sales: $33,000 2001 Profits: $-1,600 Employees: 313 2000 Sales: $52,700 2000 Profits: $-29,400 Fiscal Year Ends: 12/31 1999 Sales: $48,400 1999 Profits: $-8,100 1998 Sales: $35,600 1998 Profits: $5,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $297,000 Stock Purch. Plan: Y Second Exec. Salary: $180,000 AD VANTAGE: Focus on niche and specialty pharmaceuticals.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $109,500 Bonus: $45,000

Northeast:

International: Y



DSM PHARMACEUTICALS INC www.dsm.com/pharma/pharmaceuticals Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Profits: Computers: Hardware: Software: Arrays: Database Managem ent:

TYPES OF BUSINESS:



Drugs-Diversified Active Pharmaceutical Ingredients (API) Chemical Intermediates

DSM Pharmaceuticals, Inc., a subsidiary of DSM and formerly known as Catalytica, Inc. is an outsourcing partner for both large and small pharmaceutical companies. It has support capabilities combined with operational expertise in chemical manufacturing pperations, pharmaceutical product operations and sterile product operations. The firm can produce a wide range of products, from penultimate intermediates to active pharmaceutical ingredients, at its chemical manufacturing facilities. DSM has an extended history of production of products under FDA guidelines (cGMP). The pharmaceutical product operations turn active pharmaceutical ingredients and excipients processed by chemical manufacturing operations or other chemical suppliers into finished dosage forms. These operations encompass solid-dose, ointments, creams and liquids, cytotoxics and small scale production. The cytotoxics and small scale operation includes both manufacturing and packaging facilities. These activities are backed up by key expertise in chirality and biocatalysis and technological strength and cGMP manufacturing capabilities. In sterile production operations, the firm can produce liquid injectables, freeze-dried formulations, biologicals, drop dose, ophthalmics and otic preparations. The sterile production operations have passed CDER, CBER and European inspections. DSM Pharmaceuticals, Inc. offers its employees medical, prescription drug, dental, vision, life and disability insurance, educational assistance, a legal plan and home and auto insurance plans.

BRANDS/DIVISIONS/AFFILIATES: DSM DSM Pharmaceutical Products DSM Fine Chemicals DSM Biologics Catalytica, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Wesley P. Wheeler, CEO Wesley P. Wheeler, Pres. Terence S. Novak, VP-Mktg. & Sales/New Bus. Dev. Peter Elverding, Chmn., DSM

Phone: 252-707-2307 Fax: 252-707-2046 Toll-Free: Address: 5900 NW Greenville Blvd.,, Greenville, NC 27834 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: World leader in pharmaceutical development and manufacturing services.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



DURECT CORP

www.durect.com


Y



Y

TYPES OF BUSINESS:

Profits: 201




Drugs-Drug Delivery Fluid Control Catheters Pain Therapy Systems

DURECT Corporation pioneers the treatment of chronic diseases through the development and commercialization of pharmaceutical delivery systems. By combining innovative engineering techniques and delivery technology with proprietary pharmaceutical and biotechnology drug formations, the firm is able to control the duration and rate of drug delivery. Beyond targeting pharmaceutical administration time, DURECT’s products focus on delivering drugs to specific areas of the body in order to meet the needs of patients with highly site-specific illnesses. Both small molecule pharmaceuticals and biotechnology molecules like proteins, peptides and genes can be delivered through DURECT’s systems. The company utilizes DUROS technology, a drug delivery platform that is licensed from ALZA Corporation. DUROS, a pump, operates much like a small syringe. The DUROS system operates through osmosis, using a salted compartment to draw water from the body into the pump that then dispenses the correct amount of a given pharmaceutical into the patient. The system, which can store and release drugs in the body for up to a year, can deliver highly viscous and concentrated formations with precision to less than 1/100th of a drop per day continually. The company also uses pills, patches, injections and controlled-release products to treat patients with a number of diseases, especially those of the ear. A wholly-owned subsidiary of DURECT, Southern BioSystems, Inc., is currently researching and developing pharmaceutical systems in a variety of therapeutic areas, including chronic pain, local post-operative pain, central nervous system disorders, cardiovascular disease and cancer, based on its proprietary SABER, DURIN and MICRODUR drug delivery platform technologies. Recently, the company announced the expansion of its agreement with Thorn BioScience for the development and commercialization of veterinary products using the SABER delivery system. In other news, DURECT and Endo Pharmaceuticals Holdings, Inc. announced an agreement to collaborate on the development of the Chronogesic pain therapy system.

BRANDS/DIVISIONS/AFFILIATES: IntraEAR DUROS Technology ALZA Corporation CHRONOGESIC SABER DURIN MICRODUR Southern BioSystems, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James E. Brown, CEO James E. Brown, Pres. Thomas A. Schreck, IV , CFO Felix Theeuwes, Chief Scientific Officer Dennis M. Fisher, VP-Medical Affairs Scott M. Wheelright, VP-Mfg. Jean I. Liu, VP-Legal/General Counsel Timothy S. Nelson, VP-Bus. and Comm. Dev. Randolph M. Johnson, VP-Preclinical Research/Dir.-CNS Edward M. Gillis, VP-Eng. Judy A. Magruder, Sr. VP-Regulatory and Dev. Tai Wah Chan, VP- Pharmaceutical Research and Dev. Felix Theeuwes, Chmn.

Phone: 408-777-1417 Fax: 408-777-3577 Toll-Free: Address: 10261 Bubb Rd., Cupertino, CA 95014 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $5,179 ( 9 months) 2002 Profits: $-28,714 ( 9 months) Stock Ticker: DRRX 2001 Sales: $6,500 2001 Profits: $-44,900 Employees: 150 2000 Sales: $3,200 2000 Profits: $-19,900 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-8,700 1998 Sales: $ 1998 Profits: $-1,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $350,000 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $320,000 Bonus: $ ADVANTAGE: Unique, targeted drug delivery technologies/License agreement with ALZA Corporation.

OTHER THOUGHTS:



West: Y

Southwest:

Midw est:

Southeast:



Northeast:

International:



DUSA PHARMACEUTICALS INC

www.dusapharma.com


Y



Profits: 101


TYPES OF BUSINESS:



Drugs-Cancer and Skin Disease Photodynamic Therapy Photodetection

DUSA Pharmaceuticals, Inc. is primarily engaged in the development of Levulan Photodynamic Therapy (PDT) and Photo Detection (PD) for multiple medical indications. PDT and PD utilize light-activated compounds such as Levulan to induce a therapeutic or detection effect. DUSA’s researchers developed Levulan PDT/PD to detect and/or treat a variety of superficial conditions, such as early cancers, pre-cancers and other skin conditions. The firm has completed two Phase III studies on Levulan PDT for Actinic Keratosis (AK) and intends to complete a Phase IV long-term AK tracking study soon. In addition, DUSA has completed a study in acne, testing its proprietary nonlaser red light source (PDT illuminator) with Levulan, to help identify effective doses. In a new study to begin shortly, DUSA will be testing a non-laser blue light source and its Kerastick brand drug applicator to determine its use for acne. DUSA has also been conducting a Phase I/II study in the treatment of high-grade dysplasia associated with Barrett's esophagus. The company recently reacquired Levulan PDT dermatology rights from Schering AG and received Notice of Termination from the German firm related to the marketing, development and supply agreement between the parties. DUSA has authorized Schering AG to withdraw the application for regulatory approval of Levulan PDT in Australia, and intends the same in Austria and South Africa. DUSA is focusing on the U.S. market, since the American AK market is the largest in the world. The company has FDA approval for its BLU-U Blue Light Photodynamic Therapy Illuminator. BLU-U is us ed with Levulan Photodynamic Therapy to treat non-hyperkeratotic actinic keratoses of particular areas of the skin and is offering an improved BLU-U placement program for physicians. In addition, the company is engaged in clinical trials of Bladder Cancer PD, Hair Removal PDT, Acne PDT and Endometrial Ablation PDT.

BRANDS/DIVISIONS/AFFILIATES: Levulan BLU-U Actinic Keratoses (AK) PDT Bladder Cancer PD Hair Removal PDT Acne PDT Kerastick Endometrial Ablation PDT

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. D. Geoffrey Shulman, CEO Ronald Carroll, Exec. VP/COO D. Geoffrey Shulman, Pres. D. Geoffrey Shulman, CFO Paul Sowyrda, VP Prod. Dev./Mktg. Stuart L. Marcus , Sr. VP-Scientific Affairs/Chief Sci. Officer Nanette W. Mantell, Sec. Mark C. Carota, VP-Oper. Ronald L. Carroll, Chief Bus. Officer/ VP Strategy. & Bus. Dev. Scott Lundahl, VP-Tech.

Phone: 978-657-7500 Fax: 978-657-9193 Toll-Free: Address: 25 Upton Dr., Wilmington, MA 01887 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $25,321 ( 9 months) 2002 Profits: $9,455 ( 9 months) Stock Ticker: DUSA 2001 Sales: $5,400 2001 Profits: $-7,400 Employees: 55 2000 Sales: $2,100 2000 Profits: $-6,500 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-5,500 1998 Sales: $ 500 1998 Profits: $-5,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Collaboration with Schering AG for the development of Levulan PDT.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



DYAX CORP

www.dyax.com


Y


Y


Y Y

TYPES OF BUSINESS:

Profits: 148




Drugs-Phage Display-Based Protein, Peptide and Antibody Identification Chromatography Systems

Dyax Corp. is a biopharmaceutical company principally focused on the discovery, development and commercialization of therapeutic products. Two of its products are in early-stage clinical trials, and the firm is beginning clinical trials for a second indication of one of these candidates. DX-890 is in development as a treatment for lung disease and inflammatory diseases including cystic fibrosis and ulcerative colitis. DX-88 is in development for applications in hereditary angiodema and complications of cardiopulmonary bypass. The company also has a number of other research and development programs. Dyax focuses on protein-, peptide- and antibody-based drugs. With its proprietary phage display methodology, the firm identifies a brand range of compounds with potential for the treatment of diseases. The phage display process involves generating one or more phage display libraries; screening new and existing libraries to select binding compounds with high affinity and high specificity; and producing and evaluating the selected binding compounds. The company seeks collaborations to co-develop its product candidates but expects to fund a substantial portion of development itself. Other operations include funded research in separations and diagnostic imaging and the licensing of its phage display patents. Through its Biotage subsidiary, Dyax develops, manufactures and sells chromatography separations systems and products, which are used in laboratories and pharmaceutical manufacturing to separate molecules in liquid mixtures. In recent news, the firm announced a collaboration with Thios Pharmaceuticals to develop therapeutic antibodies using phage display technology. Employee benefits at Dyax include medical and dental coverage, flexible spending accounts, education reimbursement, an employee assistance program, concierge service and health club reimbursement.

BRANDS/DIVISIONS/AFFILIATES: BioFLASH Phage Display Technology Kiloprep Parallex Flex Biotage, Inc. DX-890 DX-88

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Henry E. Blair, CEO Henry E. Blair, Pres. Stephen S. Galliker, CFO/Exec. VP-Finance Robert C. Ladner, Chief Scientific Officer Anthony Williams , Sr. VP-Medical Affairs and Clinical Oper. Stephen S. Galliker, Exec. VP-Admin. Jack H. Morgan, Sr. VP-Corp. Dev. and Bus. Oper. David Patteson, Pres., Biotage, Inc. Scott C. Chappel, Exec. VP-Research and Tech. Lynn G. Baird, Sr. VP-Preclinical and Regulatory Affairs

Phone: 617-225-2500 Fax: 617-225-2501 Toll-Free: Address: 300 Technology Sq., Cambridge, MA 02139 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $30,044 ( 9 months) 2002 Profits: $-20,441 ( 9 months) Stock Ticker: DYAX 2001 Sales: $33,000 2001 Profits: $-17,200 Employees: 2000 Sales: $25,200 2000 Profits: $-15,200 Fiscal Year Ends: 12/31 1999 Sales: $16,800 1999 Profits: $-13,200 1998 Sales: $14,100 1998 Profits: $-7,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: Y ADVANTAGE: Important strategic partnerships.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $124,740 Bonus: $96,300

Northeast: Y

International: Y



E I DU PONT DE NEMOURS & CO

www.dupont.com


Y


Y


Profits: 1


TYPES OF BUSINESS:



Chemical Manufacturing Textiles Polymers Performance Coatings Nutrition and Health Products Electronics

E. I. du Pont de Nemours and Company (DuPont) is the second largest chemical manufacturer in the United States, with operations in approximately 75 countries. Dupont produces chemicals and treatments for an extensive number of industries including aerospace, agriculture, electronics, polymers, textiles, nutrition and transportation, with products such as Teflon, Lycra, Stainmaster, Antron, Dacron, Kevlar, Corian and Mylar. The company is segmented into five business platforms: Agriculture and Nutrition; Electronic and Communication Technologies; Performance Materials; Coatings and Color Technologies; and Safety and Protection. In recent news, the company announced plans to form a new subsidiary, DuPont Textiles and Interiors. More recently, the firm expanded its agriculture and nutrition businesses through an alliance with Bunge Limited. The resulting joint venture, called Solae LLC, will focus on the global production and distribution of food ingredients such as soy proteins and lecithins. DuPont offers its employees family leave options, counseling on topics including parenting, continuing education and career planning, dependent care spending accounts and flexible work schedules.

BRANDS/DIVISIONS/AFFILIATES: Teflon Lycra Stainmaster Antron Dacron Kevlar Corian Mylar

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Charles Holliday, CEO Richard R. Goodmanson, Exec. VP/COO Gary M. Pfeiffer, Sr. VP/CFO Dennis Zeleny, Sr. VP-Global Human Resources Thomas M. Connelly, Sr. VP-Science and Tech. Stacey J. Mobley, Sr. VP/General Counsel W. Donald Johnson, Group VP-Oper. and Svcs. John W. Himes, Sr. VP-Corp. Strat. Edward J. Donnelly, Group VP-DuPont Coatings Diane H. Gulyas, Group VP-DuPont Electronic and Comm. Tech. John C. Hodgson, Exec. VP Ellen J. Kullman, Group VP-DuPont Safety & Protection Charles Holliday, Chmn.

Phone: 302-774-1000 Fax: 302-774-7321 Toll-Free: Address: 1007 Market St., Wilmington, DE 19898 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $18,324,000 ( 9 months) 2002 Profits: $1,491,000 ( 9 months) Stock Ticker: DD 2001 Sales: $24,726,000 2001 Profits: $4,339,000 Employees: 2000 Sales: $28,268,000 2000 Profits: $2,314,000 Fiscal Year Ends: 12/31 1999 Sales: $26,918,000 1999 Profits: $7,690,000 1998 Sales: $24,767,000 1998 Profits: $4,480,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: The second largest chemical manufacturer in the U.S.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Bonus: $ Bonus: $

Southeast: Y



Northeast: Y

International: Y



ELAN CORP PLC

www.elan.com


Y



Profits: 239


TYPES OF BUSINESS:


GROWT H PLANS/SPECIAL FEATURES:

Drugs-Neurology Drugs-Acute Care Drugs-Pain Management Drugs-Autoimmune Diseases Drugs-Delivery

Elan Corporation, a leading global specialty pharmaceutical company, focuses on the discovery, development and marketing of therapeutic products and services in neurology, acute care and pain management. The firm also deals with the development and commercialization of products through the use of its extensive range of proprietary drug delivery technologies. The Irish company conducts its worldwide business through wholly owned subsidiaries incorporated in Ireland, the United States, the United Kingdom and other countries. Elan is focusing its research and development in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, pain management and autoimmune diseases. The company uses its proprietary technologies and multidisciplinary expertise to develop, market and license drug delivery products to its pharmaceutical clients. Elan scientists discovered of the use of the compound AN1792, also known as AIP-001, an immunotherapeutic agent that is under development in collaboration with Wyeth for the treatment of Alzheimer's disease. The firm also collaborates with Pharmacia to develop beta secratese inhibitors for the treatment of Alzheimer's disease. In addition, the firm, in collaboration with Biogen, Inc., has under development certain neurologic, autoimmune and pain products including a humanized monoclonal antibody, Antegren (natalizumab), for use in multiple sclerosis and Crohn’s disease. Its core pipeline is comprised of four products: Antegren (for acute and chronic multiple sclerosis and Crohn’s disease) in Phase III, Prialt (for severe chronic pain) in Phase III, Zonegran (for migraine and mania) in Phase II and ELN-154088 (for pain) to begin Phase II trials soon. In August 2002, the company was under scrutiny for its accounting practices and debt load. In response, it announced plans to cut its workforce by 20% and take other steps to cut costs and improve its outlook. As part of this effort, it recently completed the sale of its United States, Canadian and any Japanese rights to Abelcet (injectible amphotericin B lipid formulation), and certain related assets to Enzon, Inc.

BRANDS/DIVISIONS/AFFILIATES: AN-1792 AIP-001 Antegren Biogen, Inc. Prialt Wyeth Pharmacia Zonegran

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Donal J. Geaney, CEO Shane Cooke, CFO/Exec. VP. Campbell Fitch, VP-Human Resources Ivan Leiberburg, Chief Scientific and Medical Officer William Daniel, Controller Lisabeth F. Murphy, Exec. VP-Legal Affairs, Intellectual Property Paul Breen, VP-Oper. Seamus C. Mulligan, Exec. VP-Bus. and Corp. Dev. Arthur Falk, VP-Corp. Compliance Lars Ekman, Pres. Research & Dev. Mary Pendergast, Executive VP, Govt. Affairs Garo Armen, Chmn.

Phone: +353-1-709-4000 Fax: +353-1-662-4949 Toll-Free: +866-347-3185 Address: Lincoln House, Lincoln Place, Dublin, 2 Ireland

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,374,900 ( 9 months) 2002 Profits: $339,200 ( 9 months) Stock Ticker: ELN 2001 Sales: $1,512,900 2001 Profits: $-887,200 Employees: 4,500 2000 Sales: $1,302,000 2000 Profits: $-294,500 Fiscal Year Ends: 12/31 1999 Sales: $1,007,800 1999 Profits: $303,400 1998 Sales: $676,700 1998 Profits: $-1,190,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Extensive list of important partnerships and marketing or research agreements.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Southeast: Y



Bonus: $ Bonus: $

Northeast: Y

International: Y



ELI LILLY & CO

www.lilly.com


Y Y



Profits: 6


TYPES OF BUSINESS:


Y


Drugs-Depression Computer-Based Prescription Drug Claims Processing Pharmacy Benefit Design Administration and Management Services Disease-Management Services Animal Health Products Vitamins Medical Communication Networks

Eli Lilly and Company develops, manufactures and sells pharmaceutical products. Through PCS Health Systems, the company provides prescription benefit management services in the U.S., employing more than 35,000 people worldwide. The company markets its medicines in 159 countries, and additionally has major research and development facilities in nine countries. Eli Lilly also conducts clinical trials in more than 30 countries. The firm owns Integrated Medical Systems, Inc., which develops and operates physician-focused medical communication networks. Eli Lily's Prozac is the most widely prescribed branded antidepressant worldwide. Eli Lilly's products include central-nervous system agents, anti-infectives, endocrine products, an anti-ulcer agent, oncolytic agents, cardiovascular therapy products, sedatives and vitamins. Eli Lilly recently launched a separate e-business venture, InnoCentive LLC. This is a wholly owned enterprise that will use the power of the Internet to create and enhance open-source scientific research and development. In other news, the company and the Singapore Economic Development Board entered into an agreement for Lilly to establish a groundbreaking R&D center in Singapore that will focus on systems biology. Eli Lilly has also announced plans for a $100 million research facility to be built at its corporate headquarters in Indianapolis. The building, scheduled for completion in 2003, will provide laboratories for approximately 370 scientists and support personnel engaged in drug discovery. Over the next decade, the company plans to invest $1 billion in its Indianapolis operations, while creating over 7,500 new jobs. Eli Lilly was recently named one of the 100 most ethical companies in the U.S. The number of minority employees at Eli Lilly has increased rapidly. The company offers employees one week of vacation when they get married, as well as 54 hours of paid vacation yearly for taking care of a sick child. The firm also has as an on-site fitness center, flexible hours or telecommuting, parenting and dependant care leaves, adoption assistance and tuition reimbursement.

BRANDS/DIVISIONS/AFFILIATES: Axid Ceclor Prozac Integrated Medical Systems, Inc. Tazidime Singapore Economic Development Board InnoCentive LLC. PCS Health Systems

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Sidney Taurel, CEO Sidney Taurel, Pres. Charles E. Golden, Exec. VP/CFO Richard D. Pilnik, VP-Global Mktg. & Sales Pedro P. Granadillo, VP- Human Resources August M. Watanabe, Exec. VP-Science & Tech. Mitchell E. Daniels, Jr., VP/CIO Michael L. Eagle, VP- Mfg. Rebecca O. Goss, General Counsel Mitchell E. Daniels, Jr., Sr. VP-Corp. Strategy and Policy Richard D. DiMarchi, VP-Research Tech. and Product Dev. Albertus J. van den Bergh, Pres.-European Oper. Lorenzo Tallarigo, Pres.-Intercontinental Regional Oper. Gino Santini, Pres.-U.S. Oper.

Phone: 317-276-2000 Fax: 317-277-6579 Toll-Free: 800-545-5979 Address: Lilly Corporate Center, Indianapolis , IN 46285-0001 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $8,121,900 ( 9 months) 2002 Profits: $1,971,600 ( 9 months) Stock Ticker: LLY 2001 Sales: $11,542,000 2001 Profits: $2,780,000 Employees: 41,100 2000 Sales: $10,862,200 2000 Profits: $3,057,800 Fiscal Year Ends: 12/31 1999 Sales: $10,002,900 1999 Profits: $2,720,900 1998 Sales: $9,236,800 1998 Profits: $2,097,900


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Well-known worldwide for its pharmaceutical products.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Bonus: $ Bonus: $

Southeast: Y



Northeast: Y

International: Y



EMBREX INC

www.embrex.com




Y

TYPES OF BUSINESS:

Profits: 11




Equipment- In Ovo Automated Injection Systems Animal Health Products

Embrex, Inc. is an international agricultural biotechnology company specializing in the poultry industry. The firm is focused on developing patented biological and mechanical products that improve bird health, help reduce pollution costs and provide other economic benefits to the industry. Embrex's proprietary Inovoject system is an automated, in-the-egg injection system that can inoculate 20,000 to 50,000 eggs per hour, eliminating the need for manual, post-hatch injection of certain vaccines. Vaccines and other compounds are injected in precisely calibrated volumes into targeted compartments within the egg. The company markets the system to commercial poultry producers, charging a fee for each egg injected. Embrex also introduced the Vaccine Saver and Egg Remover modules to provide additional automation benefits in poultry hatcheries. The firm also markets the Viral Neutralizing Factor (VNF) technology, used in the development of certain avian vaccines, as well as Bursaplex, a VNF-based vaccine for protection against infectious bursal disease. Embrex is currently developing various other proprietary mechanical and biological products for the poultry industry. These include in ovo products for the control of coccidiosis, caused by a protozoan parasite, and Newcastle disease. Newplex, one of these candidates, is currently being manufactured for field trials. Embrex is also developing an avian gender sorting device. In recent news, the company announced plans to build a biological manufacturing facility in North Carolina, which will be designed to product the firm's Inovocox vaccine for coccidiosis. The firm offers its employees medical, dental and vision care insurance and a daycare reimbursement account.

BRANDS/DIVISIONS/AFFILIATES: Inovoject Bursamune Bursaplex Inovocox Embrex Europe, Ltd. Newplex Egg Remover Vaccine Saver

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Randall L. Marcuson, CEO Randall L. Marcuson, Pres. Don T. Seaquist, VP-Finance Brian V. Cosgriff, VP-North American Sales Catherine A. Ricks, VP-Research and Dev. Don T. Seaquist, VP-Admin. Ellen T. Corliss, VP-Corp. Comm. Ellen T. Corliss, VP-Investor Rel. Brian C. Hrudka, VP-Global Mktg. and Latin American Sales David M. Baines, VP-Global Sales Joseph P. O'Dowd, VP-Global Product Dev. and Supply Robin Shyr, VP-Embrex Asia

Phone: 919-941-5185 Fax: 919-941-5186 Toll-Free: 800-849-3629 Address: 1040 Swabia Ct., Durham , NC 27703 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $33,862 ( 9 months) 2002 Profits: $5,765 ( 9 months) Stock Ticker: EMBX 2001 Sales: $44,700 2001 Profits: $8,000 Employees: 2000 Sales: $38,800 2000 Profits: $6,600 Fiscal Year Ends: 12/31 1999 Sales: $33,800 1999 Profits: $5,700 1998 Sales: $28,600 1998 Profits: $2,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $290,000 Stock Purch. Plan: Y Second Exec. Salary: $205,000 ADVANTAGE: Unique products focused on the poultry industry.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Bonus: $170,800 Bonus: $65,000

Northeast: Y

International: Y



EMISPHERE TECHNOLOGIES

www.emisphere.com


Y



Profits: 10


TYPES OF BUSINESS:



Drug Delivery Systems

Emisphere Technologies creates oral drug delivery systems for macromolecules and compounds that are not currently available in oral form. The firm specializes in the design, production and distribution of drug-delivery systems for diabetes, clotting disorders and asthma medications. Emisphere enables these medications to be absorbed orally, nasally, ocularly or through gastrointestinal membranes. Currently, the firm is directing its attention towards developing an oral delivery compound for heparin, an anticoagulant drug. The company and Novartis AG are collaborating on the development for a treatment of osteoporosis. Emisphere and Eli Lilly are working on a follow-up to their previously announced research and option agreement to develop formulations of teraparatide, a human parathyroid hormone, and somatotropin, a human growth hormone that will be administered orally. The company’s preclinical programs involve Regeneron Pharmaceuticals, Inc. and Cubist Pharmacueticals, Inc. Emisphere currently has eight products using its oral drug delivery technology in human testing trials. Emisphere Technologies offers its employees tuition reimbursement, financial advisors, a childcare and eldercare referral program and corporate discounts for entertainment.


CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael M. Goldberg, CEO Alan W. Dunton, COO Alan W. Dunton, Pres. Fredrick D. Cobb, Asst. VP-Finance Barbara Mohl, Asst. VP-Human Resources Friedrich K. Pfetsch, Controller/Chief Acc. Officer Shepard M. Goldberg, Sr. VP-Mfg. Shepard M. Goldberg, Sr. VP-Oper. Lewis H. Bender, Sr. VP-Bus. Dev. Steven M. Dinh, VP- Product Candidate Dev. Fredrick D. Cobb, Asst. VP-Acc. Michael M. Goldberg, Chmn.

Phone: 914-347-2220 Fax: 914-347-2498 Toll-Free: Address: 765 Old Saw Mill River Rd., Tarrytown, NY 10591 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,553 ( 9 months) 2002 Profits: $-59,346 ( 9 months) Stock Ticker: EMIS 2001 Sales: $4,700 2001 Pr ofits: $-56,500 Employees: 241 2000 Sales: $5,889 2000 Profits: $-26,897 Fiscal Year Ends: 12/31 1999 Sales: $10,200 1999 Profits: $-30,700 1998 Sales: $15,900 1998 Profits: $-7,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $427,842 Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $258,151 Bonus: $ ADVANTAGE: Specialized drug delivery systems that enable patients with drug ingestion problems to receive needed oral medications.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



ENDO PHARMACEUTICALS HOLDINGS INC Industry Group Code: 325412 Ranks within this company's industry group: Sales: 38 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



www.endo.com

Profits: 190


TYPES OF BUSINESS:



Drugs-Pain Management

Endo Pharmaceuticals Holdings, Inc. is a fully integrated specialty pharmaceutical company with market leadership in pain management. The company researches, develops, produces and markets branded and generic pharm aceutical products, which are primarily used for the treatment of pain. The firm’s branded products include Percocet, used to treat moderate-to-severe pain; Lidoderm, used to treat post-herpetic neuralgia; and Percodan, used to treat severe pain. The com pany’s primary generic product is a morphine sulfate extendedrelease tablet, which account for 17% of total sales. Endo has increased its sales and marketing efforts in recent years in order to strengthen its visibility in the brand and generic areas. Marketing efforts focus on Percocet and Percodan, which Endo believes to be the gold standards of pain management. The company currently has several products in development, including MorhpiDex, a patented opioid analgesic; Oxymorphone ER, an oral extendedrelease version of oxymorphone; and various other analgesic products. In other news, Endo has acquired BML Pharmaceuticals, Inc., a research and development firm focusing on proprietary prescriptive pharmaceutical products in the treatment of cancer and infectious diseases. Included in the acquisition is Immunol, BML’s lead product in the development stage. Immunol is a prescription oral rinse for the treatment of oral mucositis, painful mouth sores that often occur in cancer patients.

BRANDS/DIVISIONS/AFFILIATES: Algos Pharmaceutical Corporation Lidoderm Percocet Percodan MorhpiDex BML Pharmaceuticals, Inc. Endo Pharmaceuticals, Inc. Immunol

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Carol Ammon, CEO Carol Ammon, Pres. Jeffrey R. Black, CFO/Sr. VP David Bass, VP-Human Resources David A. Lee, Sr. VP-Research and Dev. Caroline B. Manogue, Sr. VP/Sec. Caroline B. Manogue, General Counsel Mariann T. MacDonald, Exec. VP-Oper. Jeffrey R. Black, Treas. Peter A. Lankau, Sr. VP-U.S. Bus.

Phone: 610-558-9800 Fax: 610-558-8979 Toll-Free: Address: 100 Painters Dr., Chadds Ford, PA 19317 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $285,482 ( 9 months) 2002 Profits: $9,069 ( 9 months) Stock Ticker: ENDP 2001 Sales: $252,000 2001 Profits: $-36,500 Employees: 2000 Sales: $197,429 2000 Profits: $-156,840 Fiscal Year Ends: 12/31 1999 Sales: $138,500 1999 Profits: $3,260 1998 Sales: $108,370 1998 Profits: $ 201


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Expertise in pain management drugs.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $303,750 Bonus: $218,700

Northeast: Y

International:



ENTREMED INC

www.entremed.com

Industry Group Code: 325412 Ranks within this company's industry group: Sales: 171 Drugs: Drugs: Contract Manufacturing: Drug Delivery Sy stems: Nutriceuticals:

Y



Profits: 200


TYPES OF BUSINESS:



Drugs-Cancer and Rheumatoid Arthritis Pharmaceutical Development

EntreMed is a leader in the development of drugs that inhibit the abnormal growth of new blood vessels. Its medications assist those with cancer, rheumatoid arthritis, blindness, psoriasis and other diseases. Currently, EntreMed has four product candidates: Endostatin, Angiostatin, Panzem and ENMD 0995, in clinical trials, as well as a pipeline of new proteins, small molecules, vaccines and gene-based medicines in development. Endostatin and Angiostatin target blood vessel growth while Panzem attacks tumor cells and their blood cells. The company's most recent product candidate, ENMD 0995, is being developed for the treatment of myeloma. The firm is currently developing antiangiogenic product candidates that may enable new strategies in cancer therapy. Current standard-of-care treatments involve surgery, radiation therapy and chemotherapy, all of which are invasive, toxic or traumatic. Trials are underway for the orally administered thalidomide pill, a cancer treatment. EntreMed currently has strategic partnerships with several prestigious firms and universities, including the Bristol-Myers Squibb Company, Cleveland Retinal Associates, Columbia University, Harvard Medical School, the National Cancer Institute, Notre Dame University, the University of Cincinnati and the World Health Organization. Recently, EntreMed received an FDA research grant to support its Phase II Endostatin trial at Dana-Farber/Partners CancerCare in Boston and the University of California at San Francisco. The company provides a comprehensive benefits package for employees.

BRANDS/DIVISIONS/AFFILIATES: Angiostatin Endostatin Panzem ENMD 0995

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John W. Holaday, CEO Neil Campbell, COO Neil Campbell, Pres. Steven A. Goldfarb, VP-Finance David Jackson, VP-Mfg. James D. Johnson, Sr. VP/General Counsel David Jackson, VP-Oper. Amy Finan, Dir.-Corp. Comm. Joanna C. Horobin, Exec. VP-Commercial Dev. Victor S. Pribluda, VP-Discovery Research Carolyn Sidor, VP-Clinical and Regulatory Affairs B. Kim Lee Sim, VP-Clinical and Regulatory Affairs John W. Holaday, Chmn.

Phone: 301-217-9858 Fax: 301-217-9594 Toll-Free: Address: 9640 Medical Center Dr., Ste. 200, Rockville, MD 20850 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 714 ( 9 months) 2002 Profits: $-37,517 ( 9 months) Stock Ticker: ENMD 2001 Sales: $1,900 2001 Profits: $-43,300 Employees: 112 2000 Sales: $3,700 2000 Profits: $-48,800 Fiscal Year Ends: 12/31 1999 Sales: $5,000 1999 Profits: $-36,900 1998 Sales: $5,200 1998 Profits: $-13,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $395,000 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $295,000 Bonus: $ ADVANTAGE: Alternative cancer treatments/Unique technology that inhibits the growth of abnormal blood vessels.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



ENZO BIOCHEM INC

www.enzo.com




Y Y Y

TYPES OF BUSINESS:

Profits: 3



Y


Services-Clinical Reference Labs and Diagnostic Testing Medical Diagnostic Products Therapeutic Products Clinical Reference Laboratory

Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques. It also provides diagnostic services to the medical community. The company concentrates on developing enabling technologies for detecting and identifying genes and modifying gene expression, a technology used o f r the diagnosis of infectious and other diseases. Enzo also uses these technologies as a platform for its planned entry into the clinical diagnostics market. The company operates three subsidiaries: Enzo Diagnostics, Inc., Enzo Therapeutics, Inc. and Enzo Clinical Labs, Inc. Enzo Diagnostics' primary market focus is infectious disease diagnostics and genetic abnormality detection. Enzo Therapeutics develops a broad range of proprietary methodologies and products to combat cancer, viruses and other diseases. Enzo Clinical Labs is a full-service clinical reference laboratory that serves the medical community through a network of patient service centers.

BRANDS/DIVISIONS/AFFILIATES: Enzo Therapeutics, Inc. Enzo Diagnostics, Inc. Enzo Clinical Labs, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Elazar Rabbani, CEO Shahram K. Rabbani, COO Barry W. Weiner, Pres. Herbert B. Bass, VP-Finance Shahram K. Rabbani, Corp. Sec. Barbara E. Thalenfeld, VP-Corp. Dev. Shahram K. Rabbani, Treas. Dean Engelhardt, Exec. VP Norman E. Kelker, Sr. VP David C. Goldberg, VP-Bus. Dev.

Phone: 516-755-5500 Fax: 516-755-5561 Toll-Free: 800-221-7705 Address: 60 Executive Blvd., Farmingdale, NY 11735 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $54,000 (12 months) 2002 Profits: $6,900 (12 months) Stock Ticker: ENZ 2001 Sales: $58,400 2001 Profits: $6,800 Employees: 255 2000 Sales: $50,000 2000 Profits: $6,600 Fiscal Year Ends: 7/31 1999 Sales: $44,300 1999 Profits: $6,500 1998 Sales: $40,400 1998 Profits: $3,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $344,307 Bonus: $245,000 Stock Purch. Plan: Second Exec. Salary: $310,191 Bonus: $230,000 ADVANTAGE: Has proprietary technologies and expertise in manipulating and modifying genetic material and other biological molecules.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



ENZON INC

www.enzon.com


Y



Profits: 43


TYPES OF BUSINESS:



Drugs-Polyethylene Glycol Technology Single-Chain Antibody Technology

Enzon, Inc. is a biopharmaceutical company that develops and commercializes products for life-threatening diseases. The firm is focused on the advancement of its product pipeline through continued research and development of its proprietary PEG and SCA technologies. Enzon's PEG (polyethylene glycol) technology is used to improve the delivery, safety and efficacy of proteins and small molecules with known therapeutic efficacy. SCA (singlechain antibody) technology is used to discover and produce antibody-like molecules that can offer the therapeutic benefits of monoclonal antibodies while addressing some of their limitations. The company has developed four products that use PEG technology, with several more in development. PEG-INTRON, is a PEGenhanced version of Schering-Plough's INTRON product. The PEG version allows for more frequent dosing and yields greater efficacy. The drug has approval for use as a monotherapy and in combination with REBETOL. In addition, it may have further applications for treating HIV, hepatitis B and multiple sclerosis. PROTHECAN is a PEG-enhanced version of camptothecin, a compound shown to be potent against certain types of tumors. ADAGEN is a PEG treatment for severe combined immunodeficiency disease, or SCID. ONCASPAR is used for the treatment of acute lymphoblastic leukemia. The firm has also initiated Phase I trials of a PEG version of paclitaxel. Enzon has licensed its SCA technology to several firms that are developing pharmaceuticals based on the genetically engineered proteins. Recently, the company acquired the North American and Japanese rights to Abelcet, Elan Corp.'s injectible amphotericin B lipid formulation.

BRANDS/DIVISIONS/AFFILIATES: ONCASPAR ADAGEN PEG-INTRON PROTHECAN SCA Ventures Abelcet

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Arthur J. Higgins, CEO Arthur J. Higgins, Pres. Kenneth J. Zuerblis, VP-Finance/CFO Ulrich M. Grau, Chief Scientific Officer Kenneth J. Zuerblis, Corp. Sec.

Phone: 908-541-8600 Fax: 908-575-9457 Toll-Free: Address: 685 Rte. 202/206, Bridgewater, NJ 08807 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $75,800 (12 months) 2002 Profits: $45,800 (12 months) Stock Ticker: ENZN 2001 Sales: $31,587 2001 Profits: $11,525 Employees: 106 2000 Sales: $17,000 2000 Profits: $-6,300 Fiscal Year Ends: 6/30 1999 Sales: $13,200 1999 Profits: $-4,900 1998 Sales: $14,600 1998 Profits: $-3,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $500,000 Stock Purch. Plan: Second Exec. Salary: $280,615 ADVANTAGE: PEG (polyethylene glycol) technology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $750,000 Bonus: $136,000

Northeast: Y

International:



EPIMMUNE INC

www.epimmune.com


Y



Profits: 76


TYPES OF BUSINESS:



Drugs-Vaccines

Epimmune, Inc. focuses on the development of novel vaccines for the treatment of infectious diseases and cancer, particularly in the field of T-cell recognition and activation. The company has four technology platforms: Epitope Identification System (EIS), PADRE, ImmunoSense and ImmunoStealth. EIS enables the rapid identification of novel epitopes that can stimulate specific cytotoxic T-cells' and helper T-cells' immune responses. This technology also enables rapid immunological evaluation of the vast quantities of genomic data generated, making feasible the development of new vaccine candidates for such complex diseases as tuberculosis, malaria, herpes simplex virus and chlamydia. PADRE technology consists of a family of small molecules that stimulate the immune response. When combined with disease-specific antigens, PADRE induces important signals that enhance the antigen-specific immune response, enabling the production of more effective antibody responses. Using its ImmunoSense technology, Epimmune can rapidly analyze gene sequence data for antigens recognized by the immune system to identify new vaccine and drug targets for diseases caused or controlled by the immune system. ImmunoStealth technology identifies and eliminates undesirable antibody responses to proteins used as therapeutic drugs. The company is involved in many corporate, scientific and academic collaborations, including Rhein Biotech, Bavarian Nordic, Anosys, Emory University School of Medicine, University of Rome, University of Alberta and University of Naples. Recently, Epimmune entered into a license agreement with Valentis, Inc., to use its DNA vaccine delivery technology for the treatment of cancer.

BRANDS/DIVISIONS/AFFILIATES: Epitope Identification System PADRE ImmunoSense ImmunoStealth EpiGene Vaccines

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Emile Loria, CEO Emile Loria, Pres. Robert J. De Vaere, VP-Finance/CFO Robert W. Chesnut, Exec. VP-Research and Dev. John D. Fikes, Dir.-Cancer Program Robert W. Chesnut, Corp. Sec. Robert J. De Vaere, VP-Admin. Michael R. McClurg, VP-Bus. Dev. Mark J. Newman, VP-Infectious Disease Program Alessandro Sette, VP/Chief Scientific Officer

Phone: 858-860-2500 Fax: 858-860-2600 Toll-Free: Address: 5820 Nancy Ridge Dr., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $5,493 ( 9 months) 2002 Profits: $-4,754 ( 9 months) Stock Ticker: EPMN 2001 Sales: $8,200 2001 Profits: $-2,600 Employees: 52 2000 Sales: $1,600 2000 Profits: $-4,700 Fiscal Year Ends: 12/31 1999 Sales: $4,200 1999 Profits: $-8,300 1998 Sales: $3,700 1998 Profits: $-21,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $231,008 Stock Purch. Plan: Second Exec. Salary: $178,500 ADVANTAGE: Expertise in the field of T-cell recognition and activation.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $120,000 Bonus: $50,000

Northeast:

International:



EPIX MEDICAL INC

www.epixmed.com


Y



Y Y

TYPES OF BUSINESS:

Profits: 15




Drugs-Vascular Disease Diagnosis Products MRI Contrast Agents

EPIX Medical, Inc. is a specialty pharmaceutical company engaged in the development of targeted contrast agents to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The firm's lead product, MS-325, is an injectable intravascular contrast agent designed for multiple cardiovascular imaging applications, including peripheral vascular disease and coronary artery disease. EPIX believes that MS-325 will significantly enhance the quality of MRI images and provide physicians with a non-invasive and cost-effective diagnostic method. MS-325 has the potential to replace highly invasive and costly conventional x-ray angiography, over which it has a number of advantages. MS-325 is safer, involving only low-energy radio waves rather than ionizing radiation; allows arterial and venous imaging in a single exam; and enables wholebody and three-dimensional data. Additional applications for the product include breast cancer, myocardial perfusion and arthritis imaging. The product is currently in Phase III clinical trials. EPIX's business strategy includes maximizing the value of its strategic relationships, which include collaborations with Schering AG, General Electric Medical Systems, Siemens Medical Systems and Pfizer. Recently, EPIX completed patient enrollment in a second Phase III study of MS-325. The firm offers a competitive compensation package that includes stock options; health, dental, life and disability insurance; tuition reimbursement; health club reimbursement; and transportation.

BRANDS/DIVISIONS/AFFILIATES: MS-325

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael D. Webb, CEO Stephen C. Knight, COO Stephen C. Knight, Pres. Pamela E. Carey, VP-Finance/CFO Gregg Mayer, VP-Strategic Mktg. Alan P. Carpenter, Exec. VP-Research and Dev. Gregory Sorensen, Dir.-Medical/VP-Clinical Dev. Pamela E. Carey, VP-Admin. Robert Weisskoff, VP-Bus. Dev. and Imaging Gregg Mayer, VP-Corp. Comm. Randall B. Lauffer, Chief Scientific Officer Susan M. Flint, VP- Regulatory Affairs and Clinical Oper. Christopher F. Gabrieli, Chmn.

Phone: 617-250-6000 Fax: 617-250-6031 Toll-Free: Address: 71 Rogers St., Cambridge, MA 02142-1118 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $8,559 ( 9 months) 2002 Profits: $-16,809 ( 9 months) Stock Ticker: EPIX 2001 Sales: $9,600 2001 Profits: $-19,200 Employees: 88 2000 Sales: $6,900 2000 Profits: $-27,300 Fiscal Year Ends: 12/31 1999 Sales: $1,100 1999 Profits: $-17,000 1998 Sales: $1,800 1998 Profits: $-14,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $282,832 Stock Purch. Plan: Y Second Exec. Salary: $265,887 ADVANTAGE: Producer of drugs to enhance MRI testing.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $106,062 Bonus: $83,090

Northeast: Y

International:



EPOCH BIOSCIENCES

www.epochbio.com



Y


Y Y Y

TYPES OF BUSINESS:

Profits: 14




Genetic Analysis Technology Contract Research Services Diagnostics Technologies

Epoch Biosciences, Inc. is a biotechnology company developing technologies and products to help scientists around the world perform genetic research and analysis, pervasive in academic, pharmaceutical, clinical, agricultural, veterinary and forensic laboratories. These technologies facilitate rapid, accurate and cost-effective analysis on a large scale. The firm has developed patented technologies to improve the output of automated genetic analysis systems. Epoch earns revenues through licensing its technology to other companies and selling its products to end-users. The firm is also involved in contract research activities, whereby third-party companies pay for specific research and development carried out by Epoch's scientists. Epoch's technologies include Minor Grove Binders (MGB), useful for DNA detection using real-time assays; modified nucleotide bases; fluorescent dyes and quenchers to enable detection of DNA probes; attachment chemistry; and design software to aid customers in the use of its products. These products include the Eclipse Probe System, which consists of a gene expression system, viral load detection, an allelic discrimination system and a custom system. This system incorporates the performance advantages of MGB and the Eclipse Dark Quencher. DNAnchor microarray systems incorporate the firm's attachment chemistry and modified bases to provide enhanced hybridization. Dyes and quenchers also include Redmond Red, Yakima Yellow and Bothell Blue. Modified bases include Super G, Super A and Super T. Recently, Epoch licensed its MGB Eclipse Probe Systems to QIAGEN in a worldwide sales and marketing agreement.

BRANDS/DIVISIONS/AFFILIATES: Epoch Pharmaceuticals Minor Grove Binders MGB Eclipse Eclipse Dark Quencher Eclipse Probe System DNAnchor Redmond Red Bothell Blue

CONTACTS: Note: Officers with more than one job title may be intenti onally listed here more than once. William G. Gerber, CEO William G. Gerber, Pres. Bert W. Hogue, VP/CFO Walt Mahoney, Sr. VP-Research and Dev. Cy Cabradilla, VP-Oper. Merl F. Hoekstra, VP-Corp. Dev.

Phone: 425-482-5555 Fax: 425-482-5550 Toll-Free: 800-562-5544 Address: 21720 23rd Dr. SE, Ste. 150, Bothell, WA 98021 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $7,428 ( 9 months) 2002 Profits: $-3,642 ( 9 months) Stock Ticker: EBIO 2001 Sales: $7,500 2001 Profits: $-4,600 Employees: 53 2000 Sales: $1,400 2000 Profits: $-4,900 Fiscal Year Ends: 12/31 1999 Sales: $ 200 1999 Profits: $-4,700 1998 Sales: $ 200 1998 Profits: $-5,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $285,585 Bonus: $100,000 Stock Purch. Plan: Second Exec. Salary: $163,744 Bonus: $40,000 ADVANTAGE: Epoch's technology has application potential in the developing field of molecular diagnostics genomics.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



ERESEARCH TECHNOLOGY INC

www.ert.com




Y

TYPES OF BUSINESS:

Profits: 3


Y


Y Y


Software-Clinical Trials Integrated Software Applications Technology Consulting Services Electrocardiogram Testing-Centralized Distance Learning Centralized Electrocardiographic Services

eResearch Technology, Inc. (ERT) is a provider of technology and services that enable the pharmaceutical, biotechnology and medical device industries to collect, interpret and distribute cardiac safety and clinical data more efficiently. The company is a market leader in providing centralized electrocardiographic (diagnostic) services. ERT is also a leading provider of technology and services that streamline the clinical trials process by enabling its customers to evolve from traditional paperbased methods to electronic processing, leveraging the power of the Internet. The firm provides its products and services through two divisions, diagnostics technology and services and clinical research technology and services. (ERT has discontinued providing clinical research services.) Until recently, the company’s operations were conducted through its subsidiary, eRT Operating Company, but this subsidiary has merged with the company. ERT’s products and services include EXPeRT diagnostics tests, eResearch Network technology, eData Entry technology and the eResCom central command and control web portal, as well as the recently introduced Accelerator series of products. The firm also recently launched eHealth Education, an interactive web-based training service for clinical research professionals. In other news, ERT has joined forces with IBM to provide enhanced and extended hosting solutions, adding IBM’s ebusiness hosting services to its Accelerator series.

BRANDS/DIVISIONS/AFFILIATES: EXPeRT eResearch Network eData Entry eResCom Accelerator eRT Operating Company eHealth Education

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph A. Esposito, CEO Joseph A. Esposito, Pres. Bruce Johnson, Sr. VP/CFO Scott Grisanti, Chief Mktg. Officer Marian Wissman, Dir.-Human Resources Joel Morganroth, Chief Scientist Jeffrey S. Litw in, Sr. VP/Chief Medical Officer Bruce Johnson, Corp. Sec. Scott Grisanti, Sr. VP-Bus. Dev. Robert S. Brown, Sr. VP-Diagnostics Tech. and Services Vincent Renz , Sr. VP-Tech. and Consulting John R. Bauer, VP

Phone: 215-972-0420 Fax: 215-972-0414 Toll-Free: Address: 30 S. 17th St., Philadelphia, PA 19103-4001 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $29,389 ( 9 months) 2002 Profits: $3,241 ( 9 months) Stock Ticker: ERES 2001 Sales: $28,000 2001 Profits: $-3,800 Employees: 196 2000 Sales: $28,100 2000 Profits: $ 100 Fiscal Year Ends: 12/31 1999 Sales: $42,800 1999 Profits: $5,300 1998 Sales: $31,800 1998 Profits: $ 700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $270,000 Stock Purch. Plan: Second Exec. Salary: $175,000 ADVANTAGE: Focus on streamlining the data collection process.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $90,000 Bonus: $30,000

Northeast: Y

International: Y



ESSENTIAL THERAPEUTICS INC www.essentialtherapeutics.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 111 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Profits: 180


TYPES OF BUSINESS:



Drugs-Infectious Disease Hematology and Oncology Drugs

Essential Therapeutics, Inc. (ETI), formerly Microcide Pharmaceuticals, is a biopharmaceutical company committed to the discovery, development and commercialization of critical products for life-threatening diseases in hematology, oncology and infectious disease. The company was formed in late 2001 when Microcide merged with The Althexis Company, Inc. ETI has broadbased antibiotic and antifungal discovery and development programs with a significant product pipeline. With its March 2002 acquisition of Maret Corporation, ETI also has pre-clinical and clinical programs in hematology, oncology and infectious diseases. Accordingly, ETI is developing a family of peptide drugs that stimulate progenitor cell growth, with initial clinical focus on blood cell growth. The firm's lead product, ETRX 101, is a small-molecule angiotensin derivative for treatment and prophylaxis of the suppression of blood cells. The company's novel cephalosporin platform targets serious gram -positive multidrug resistant infections. ETI has partnered with Johnson & Johnson to develop this program. The company's efflux pump inhibitor program targets gram -negative infections and serious fungal infections. This program is in development under partnerships with Daiichi and Schering-Plough. The structure-based drug design platform focuses on novel cell wall biosynthesis inhibitors with intrinsic activity against a range of resistant organisms. ETI has partnered with PLIVA Pharmaceuticals to develop this platform. Other areas of research include its microbial genomics program, which seeks to identify new classes of antimicrobial agents. In recent news, the company formed a collaborative agreement with Fujisawa Pharmaceutical Co. to develop assay systems for the discovery of novel antibiotics, as well as to perform high-throughput screening of the compounds in Fujisawa's library.

BRANDS/DIVISIONS/AFFILIATES: Microcide Pharmaceuticals ETRX-101 Althexis Company, Inc. (The) Maret Corporation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mark Skaletsky, CEO Timothy Noyes, COO Paul Mellett, Sr. VP/CFO Robert D. Testorff, VP-Human Resources George H. Miller, Exec. VP-Research and Dev. Robert B. Kammer, VP-Clinical Research/Sr. Medical Advisor Robert D. Testorff, VP-Admin. Nancy E. Wetherbee, VP-Bus. Dev. Florrie Eubanks, Investor Rel. Manuel Navia, Sr. VP/Sr. Scientific Advisor Martha J. Carter, Sr. VP-Regulatory Affairs Jerry Buysse, VP-Discovery Biology and Assay Dev. Michael Dudley, VP-Pharmacology and Microbiology Mark Skaletsky, Chmn.

Phone: 781-647-5554 Fax: 781-647-5552 Toll-Free: Address: 1365 Main St., Waltham, MA 02451 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $7,217 ( 9 months) 2002 Profits: $-34,273 ( 9 months) Stock Ticker: ETRX 2001 Sales: $10,700 2001 Profits: $-27,900 Employees: 139 2000 Sales: $5,900 2000 Profits: $13,900 Fiscal Year Ends: 12/31 1999 Sales: $9,400 1999 Profits: $-10,700 1998 Sales: $11,200 1998 Profits: $-9,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Significant partnerships.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:



Bonus: $84,000 Bonus: $49,220

Northeast: Y

International:



EXEGENICS INC

www.cytoclonal.com


Y



Profits: 106


TYPES OF BUSINESS:



Drugs-Therapeutic and Diagnostic Products for Cancer Drugs-Kidney Disease Drugs-Infectious Diseases

eXegenics Inc., formerly Cytoclonal Pharmaceutics, Inc., specializes in developing therapeutic and diagnostic products to treat and prevent cancer and infectious diseases. Its lead proprietary pharmaceutical platform programs, Quantum Core Technology (QCT) and Optimized Anti-Sense Inhibitory Sequence (OASIS), are focused on the creation of new pharmaceutical products. QCT is a computer-assisted drug design technology platform, primarily targeted to the inhibition of proteins involved in disease processes. OASIS is a patented technology platform that uses computers to design antisense sequences, which are molecules capable of blocking the expression of specific genes. In addition, eXegenics is engaged in a program with Bristol-Myers Squibb, Inc., to optimize the production of paclitaxel, the active ingredient in Taxol. The company is also seeking to outlicense its other proprietary technologies, including a production system for manufacturing a recombinant form of glucocerebrosidase that is intended for use as an enzyme replacement therapy for Type 1 Gaucher's Disease. Current company developments include an antiMRSA program, an anti-tuberculosis program and an inhibitor enzyme program. Recently, the company obtained rights from the University of California and the University of British Columbia to use enzyme targets to develop drugs for the treatment of tuberculosis.

BRANDS/DIVISIONS/AFFILIATES: Cytoclonal Pharmaceutics, Inc. Quantum Core Technology Optimized Anti-Sense Inhibitory Sequence OASIS

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ronald L. Goode, CEO Ronald L. Goode, Pres. Joan H. Gillett, Principal Acc. Officer Joan H. Gillett, VP/Controller Joan H. Gillett, Corp. Sec. Arthur P. Bollon, Exec. VP Robert J. Rousseau, VP-Licensing Gary E. Frashier, Chmn.

Phone: 214-358-2000 Fax: 214-350-9514 Toll-Free: Address: 2110 Research Row, Ste. 621, Dallas , TX 75235 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 556 ( 9 months) 2002 Profits: $-6,336 ( 9 months) Stock Ticker: EXEG 2001 Sales: $1,300 2001 Profits: $-8,800 Employees: 29 2000 Sales: $ 900 2000 Profits: $-7,200 Fiscal Year Ends: 12/31 1999 Sales: $1,400 1999 Profits: $-4,400 1998 Sales: $1,200 1998 Profits: $-2,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Proprietary technologies.

OTHER THOUGHTS:




West:

Southwest: Y

Midwest:

Southeast:



Bonus: $25,000 Bonus: $105,000

Northeast:

International:



EXELIXIS INC

www.exelixis.com



Y Y


Profits: 33


TYPES OF BUSINESS:



Research-Genetic Data Model System Genetics Genomics Drugs-Cancer Drugs-Agriculture

Exelixis, Inc. is a leading biotechnology company focused on the life sciences industries through its expertise in comparative genomics and model system genetics. These technologies provide a rapid, efficient and costeffective way to move from DNA sequence data to knowledge about the function of genes and the proteins that they encode. The firm’s technology is broadly applicable to all life science industries including pharmaceutical, diagnostic, agricultural biotechnology and animal health. Exelixis believes that the proprietary technology created through Genoptera will provide unique insecticide targets that would be difficult to generate using alternative technology. The firm, in collaboration with IMCB, has identified a gene that mediates the immune response. Recently, Exelixis and Bristol-Myers Squibb got into a licensing agreement to create a new generation of potential cancer drugs and received an exclusive worldwide license to develop and commercialize the Bristol-Myers Squibb anticancer compound, Rebeccamycin. Phase I and early Phase II clinical trials are underway at the National Cancer Institute. The firm also announced its broad alliance with GlaxoSmithKline plc to discover, develop and commercialize novel therapeutics in the areas of vascular biology, inflammatory disease and oncology. Exelixis has two subsidiaries, Artemis Pharmaceuticals GmbH headquartered in Cologne, Germany and Exelixis Plant Sciences in Portland, Oregon. The firm has a portfolio of 41 issued U.S. patents and 169 pending U.S. patent applications. In addition to these, 13 U.S. and corresponding international patent applications were filed with Aventis Cropsciences as part of its Agrinomics joint venture. Another 11 U.S. or international patent applications were filed with Bayer Corporation as part of the Genoptera joint venture.

BRANDS/DIVISIONS/AFFILIATES: Artemis Pharmaceuticals GmbH IMCB Bayer AG Bristol-Myers Squibb Company GlaxoSmithKline plc Aventis Cropsciences Exelixis Plant Sciences, Inc. Rebeccamycin

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. George A. Scangos , CEO George A. Scangos , Pres. Glen Y. Sato, CFO Geoffrey Duyk, Exec. VP/Chief Scientific Officer Pamela A. Simonton, VP-Corp. Tech. Dev. Gregory D. Plowman, VP-Pharmaceutical Research Kimberly J. Manhard, VP-Regulatory Affairs Lloyd M. Kunimoto, Sr. VP-Bus. Dev. Jane Green, VP-Corp. Comm. Michael Morrissey , VP-Discovery Research Glen Y. Sato, VP-Legal Affairs Robert M. Myers, Exec. VP-Pharmaceuticals Jeffrey R. Latts, Sr. VP/Chief Medical Officer

Phone: 650-837-7000 Fax: 650-837-8300 Toll-Free: Address: 170 Harbor Way, South San Francisco, CA 94083 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $31,869 ( 9 months) 2002 Profits: $-65,267 ( 9 months) Stock Ticker: EXEL 2001 Sales: $41,000 2001 Profits: $-71,200 Employees: 571 2000 Sales: $24,800 2000 Profits: $-75,300 Fiscal Year Ends: 12/31 1999 Sales: $10,500 1999 Profits: $-18,700 1998 Sales: $2,300 1998 Profits: $-15,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Innovative biotech research/Genoptera joint venture.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



EXELIXIS PLANT SCIENCES INC www.exelixis.com/discovery/subsidiaries#eps Industry Group Code: 115112 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:


Y



TYPES OF BUSINESS:



Agriculture-Produce Spoilage Reduction Products Biotech Products For Agriculture Plant Genomics

Exelisis Plant Sciences, Inc. (EPS), formerly Agritope, Inc., is a wholly owned subsidiary of Exelisis, Inc. EPS is an agricultural biotechnology company that develops improved plant products and provides technology to the agricultural industry. The firm conducts plant research activities in Portland, Oregon and plant genomics in South San Francisco, California. EPS investigates plant biotechnology ranging from disease resistance and environmental stress to human nutrition. The company is working to produce biochemical compounds from plants which have value in human and animal nutrition and that are known to reduce the risk of disease and or certain types of cancer. EPS has developed assays by which it can determine the genetic mechanisms of plants and how these compound productions are controlled in them. EPS and Aventis CropScience formed a joint venture company called Agrinomics LLC. This venture focuses on finding and determ ining the function of plant genes. Recently, Aventis CropScience was acquired by Bayer, and the collaboration was transferred to Bayer CropScience.

BRANDS/DIVISIONS/AFFILIATES: Aventis CropScience Agrinomics LLC Exelixis, Inc. Bayer CropScience Agritope, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bruce C. Galton, CEO Bruce C. Galton, Pres. D. Ry Wagner, VP-Research Gilbert N. Miller, Exec. VP/Sec. Matthew G. Kramer, VP-Product Dev. Matthew G. Kramer, GM and VP-Agricultural Trait Development

Phone: 503-670-7702 Fax: 503-403-5790 Toll-Free: Address: 16160 SE Upper Boones Ferry Rd., Portland, OR 97224-7744 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 9/30 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Pr ofits: $


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Partnerships with Aventis/Unique agricultural focus.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International:



E-Z-EM INC

www.ezem.com


Y



Y Y

TYPES OF BUSINESS:

Profits: 4




Equipment-Diagnostic Imaging Therapeutics Devices Powdered and Liquid Barium Sulfate Diagnostic Radiology Devices Custom Contract Pharmaceuticals Gastrointestinal Cleansing Laxatives Varicose Vein Treatment

E-Z-EM, Inc. is primarily engaged in developing, manufacturing and marketing diagnostic products used by radiologists and other physicians during image-assisted procedures to detect anatomic abnormalities and diseases. The company also manufactures and markets a variety of therapeutic and diagnostic products for use principally in the diagnosis and treatment of vascular disease through its AngioDynamics, Inc. subsidiary. E-ZEM contrast systems consist of specially developed powdered and liquid barium sulfate formulations and consumable medical devices, which function together as a system for examination of the various parts of the gastrointestinal tract. The company also produces noncontrast systems that include diagnostic radiology devices, custom contract pharmaceuticals, gastrointestinal cleansing laxatives, X-ray protection equipment and immunoassay tests. Recently, E-Z-EM introduced Varibar, the first family of formulations specifically designed for fluoroscopic examination of the swallowing process. It also released the first meal kit designed to replace a clear liquid diet which is utilized prior to the examination of the colon. In other news, the company has taken a small equity stake in PointDX, a company focused on the development of virtual colonoscopy software. Additionally, subsidiary AngioDynamics unveiled a new minimally invasive system for varicose vein treatment, the ELVS. The company offers its employees a comprehensive health plan, along with discounts at optical retail stores, employee training, development programs and tuition reimbursement. In addition, the company encourages business casual attire and sponsors various recreational events.

BRANDS/DIVISIONS/AFFILIATES: AngioDynamics, Inc. Enteric Products, Inc. Toho Kagaku Kenkyusho Co., Ltd. E-Z-CAT Dry HDC Corporation Varibar PointDX ELVS System

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Anthony A. Lombardo, CEO Anthony A. Lombardo, Pres. Dennis J. Curtin, CFO Joseph J. Palma, VP-Sales and Mktg. Sandra D. Baron, VP-Human Resources Michael A. Davis, Dir.-Medical Joseph A. Cacchioli, Controller Jeffrey Peacock, VP-Scientific and Tech. Oper. Frank H. Kerringon, Dir.-Corp. Comm. Judith K. Meritz, VP-Regulatory Affairs

Phone: 516-333-8230 Fax: 516-997-9534 Toll-Free: Address: 717 Main St., Westbury, NY 11590-5021 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $122,100 (12 months) 2002 Profits: $ 600 (12 months) Stock Ticker: EZM 2001 Sales: $113,300 2001 Profits: $3,300 Employees: 896 2000 Sales: $112,100 2000 Profits: $6,000 Fiscal Year Ends: 5/31 1999 Sales: $107,200 1999 Profits: $4,800 1998 Sales: $102,900 1998 Profits: $-6,000


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Y Top Exec. Salary: $262,500 Bonus: $11,813 Stock Purch. Plan: Second Exec. Salary: $261,667 Bonus: $38,125 ADVANTAGE: E Z EM, Inc. is a world leader in developing and manufacturing contrast agents for gastrointestinal radiology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Northeast: Y

International: Y



FLAMEL TECHNOLOGIES SA

www.flamel-technologies.fr


Y Y Y



Y

TYPES OF BUSINESS:

Profits: 5




Drugs-Drug Delivery Collagen-Based Biomaterials Contract Manufacturing Analytical Services

Flamel Technologies is a drug delivery company engaged in the development of innovative products based on its two delivery platform technologies in the agricultural and ophthalmic fields. Its drug delivery products are Medusa, a controlled delivery system for therapeutic proteins and peptides, and Micropump, a controlled delivery system for small-molecule oral drugs. The Medusa product is used in the treatment of diabetes. The company has developed two drug products that utilize the Micropump technology: Asacard, an aspirin in two dosage forms, and Genvir, a treatment for genital herpes. The Micropump product is designed to help reduce side effects of many oral drugs and to decrease dosing frequencies. Colcys, a biomaterial product line designed by the company, is a family of proprietary collagen-based implantable biomaterials, which are used for post-surgical adhesion prevention. Aside from these technologies, Flamel also provides services including clinical batch manufacturing, pharmaceutical manufacturing and analytical services. Flamel’s strategy is to partner with pharmaceutical companies to develop, market and sell its pharmaceutical products and to partner with firms to receive funding in the fields of agrochemicals and ophthalmology. The company’s strategic partners include G.D. Searle, Corning, Inc., Monsanto Company and Novo-Nordisk AS. Flamel recently announced an update in connection with its licensing agreement with Servier Monde, marking another important step in placing Micropump technology into products available on the market. In other news, the firm entered into an agreement to license Micropump technology to GlaxoSmithKline in connection with the sachet formulation of its drug Augmentin.

BRANDS/DIVISIONS/AFFILIATES: Medusa Micropump Asacard Genvir Colcys

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gerard Soula, CEO Gerard Soula, Pres. Stephen Willard, CFO Patrick Perrin, Dir.-Human Resources Remi Meyrueix, Dir.-Science Patrick Perrin, Controller Philippe Vivet, Dir.-Medicine Rafael Jorda, VP-Mfg. and Dev. Steve Willard, General Counsel Patrick Perrin, Dir.-Admin. Roger Kravtzoff, Dir.-Pharmaceutical Dev. Emmanuelle Bardet, Chief Pharmacist

Phone: +33-4-7278-3434 Fax: +33-4-7278-3435 Toll-Free: Address: 33 Ave. du Docteur Georges Levy, Venissieux Cedex, 69693 France

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $15,962 ( 9 months) 2002 Profits: $3,332 ( 9 months) Stock Ticker: FLML 2001 Sales: $13,100 2001 Profits: $-2,900 Employees: 138 2000 Sales: $10,900 2000 Profits: $-9,500 Fiscal Year Ends: 12/31 1999 Sales: $11,000 1999 Profits: $-6,700 1998 Sales: $9,500 1998 Profits: $-7,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Unique technologies and diversified services.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



FOREST LABORATORIES INC

www.frx.com


Y



Profits: 18


TYPES OF BUSINESS:



Drugs-Asthma Over-the-Counter Pharmaceuticals Name-Brand Proprietary Drugs Generic Drugs

Forest Laboratories, Inc. develops, manufactures and sells branded and generic prescription and over-the-counter pharmaceuticals that are used to treat a wide range of illnesses. In order to broaden the company's product base and support its strong growth rate, Forest Laboratories acquired the products Climara (treatment for hypertension and angina) and Tiazac (treatment of high blood pressure). These products represent markets with current sales totaling $7 billion and as much as $500 million in potential sales for Forest. The company is in a strategic alliance with H. Lundbeck A/S, which covers the U.S. marketing rights to central nervous system products developed by Lundbeck. Three new products already licensed to Forest are Celexa, also known as Citalopram (treatment for depression), Lu25-109 (treatment for Alzheimer’s disease) and Lu28-179 (anxiolytic compound). The generic industry has greatly dissipated for Forest recently, due to the expanding presence of the major branded drug companies. The company has several generic products pending with the FDA, in an attempt to broaden its product line. In recent news, the firm has continued to pursue licensing agreements and strategic alliances with various companies and their products. Forest entered into a license agreement for the development and marketing in the U.S. of Neramexane, a patented novel NMDA receptor antagonist developed by Merz + Co. of Germany. Forest also has a distribution, marketing, trademark license and supply agreement for the U.S. rights to acamprosate (Campral). This agreement was reached with Lipha S.A., a subsidiary of Merck KgaA, and is for the treatment of alcohol addiction. In other news, the FDA has approved the firm’s new drug application for Flunisolide HFA, which is used to treat asthma. The drug uses a new non-CFC propellant and a built-in spacer. The FDA also granted Forest marketing approval for Benicar for the treatment of hypertension. Forest Labs offers its employees competitive salaries, benefits and incentives.

BRANDS/DIVISIONS/AFFILIATES: H. Lundbeck A/S UAD Laboratories Inwood Laboratories, Inc. Pharmax Limited Tosara Group Celexa Aerobid Tiazac

CONTACTS: Note: Officers with more than one job ti tle may be intentionally listed here more than once. Howard Solomon, CEO Kenneth E. Goodman, COO Kenneth E. Goodman, Pres. John E. Eggers, CFO Elaine Hochberg, Sr. VP-Mktg. Bernard J. McGovern, VP-Human Resources Lawrence S. Olanoff, Exec. VP-Scientific Affairs John A. DiBella, Controller Ivan Gergel, VP-Medical Terrill J. Howell, VP-Mfg. William J. Candee III, Sec. Richard Overton, VP-Oper. Mary E. Prehn, VP-Licensing & Corp. Dev. Shankar Hariharan, VP-Pharmaceutical Research and Dev. William B. Sparks, Exec. VP-Forest Pharmaceuticals Raymond Stafford, CEO, Forest Europe

Phone: 212-421-7850 Fax: 212-750-9152 Toll-Free: 800-947-5227 Address: 909 Third Ave., New York, NY 10022 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,566,600 (12 months) 2002 Profits: $338,000 (12 months) Stock Ticker: FRX 2001 Sales: $1,205,200 2001 Profits: $215,100 Employees: 2,826 2000 Sales: $899,300 2000 Profits: $112,688 Fiscal Year Ends: 3/31 1999 Sales: $624,000 1999 Profits: $77,173 1998 Sales: $474,700 1998 Profits: $36,697


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $823,765 Stock Purch. Plan: Second Exec. Salary: $549,887 ADVANTAGE: Large product base/Excellent distribution channels.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $400,000 Bonus: $250,000

Northeast: Y

International: Y



GELTEX PHARMACEUTICALS

www.geltex.com


Y




TYPES OF BUSINESS:



Drugs-Kidney Failure Polymer-based Pharmaceuticals Drugs-Anti-Obesity

GelTex Pharmaceuticals, Inc., a wholly owned subsidiary of Genzyme Corporation, is focused on the development of non-absorbed, polymer-based pharmaceuticals that selectively bind to and eliminate target substances from the intestinal tract. The company acquired SunPharm Corporation, and as a result, it gained additional expertise in two chemically related classes of molecules, polyamines and iron chelators. GelTex's first product, Renagel, treats end-stage renal disease and has FDA approval for marketing in the U.S. The firm is in agreement with Chugai Pharmaceutical Co., Ltd. to market and sell Renagel in Japan where the product is in Phase III clinical trials. GelTex is also involved in a collaborative agreement with Sankyo Pharma, Inc. regarding Welchol, an FDA approved lipid-lowering agent. Other products in the company's pipeline include: C. difficile (for infectious diseases) in Phase II trials; Polyamines (for cancer) in Phase II trials; Iron Chelators (for iron overload) in the research and development stage; Anti-obesity (for weight management) in the research and development stage; and Oral Mucositis (for ulcers of the mouth) in the research and development stage.

BRANDS/DIVISIONS/AFFILIATES: SunPharm Corporation Renagel Tablets Welchol Genzyme Corporation Chugai Pharmaceutical Co. Sankyo Pharma, Inc. Polyamines Iron Chelators

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Timothy Noyes, Pres. Edmund J. Sybertz, Sr. VP-Research & Dev. Mukund Chorghade, VP-Chemical Dev. Sciences Steven K. Burke, VP-Clinical Research Cynthia Arbeeny , VP-Metabolic Diseases Research Judith Marquis, VP-Preclinical Development Joann Nestor, VP-Administration/Sr. Corp. Counsel Thomas Neenan, VP-New Ventures Scott De'Aeth, VP-Quality Affairs Jeffrey Klinger, VP-Infectious Diseases W. Harry Mandeville, VP-Chemical Tech. Randy Holmes-Farley, VP-Chemical Research

Phone: 781-290-5888 Fax: 781-290-5890 Toll-Free: 800-510-5059 Address: 153 2nd Ave., Waltham, MA 02451 US

FINANCIALS:



COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Award winning staff/Expansion into Japanese market.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



GENAERA CORPORATION

www.genaera.com


Y



Profits: 131


TYPES OF BUSINESS:



Drugs-Infection, Cancer and Asthma

Biopharmaceutical company Genaera Corporation, formerly Magainin Pharmaceuticals, focuses its research and development efforts in anti-angiogenesis, respiratory genomics, obesity and infectious disease. The firm’s lead product candidate, Squalamine, is currently being evaluated in clinical studies for the treatment of solid tumors. Clinical studies are ongoing in non-small cell lung cancer, ovarian cancer and certain other solid tumors as well. Additional studies are expected to commence soon for Squalamine in pediatric neuroblastoma and prostate cancer. The firm also maintains a research program evaluating Squalamine in eye disease. Another product, Trodulamine, is being tested for use in appetite suppression and weight loss. Genaera has an active respiratory research and development program. The two areas of concentration in this program involve the development of a blocking antibody to interleukin-9 (IL9) to treat the root cause of asthma and the development of mucoregulators, which reduce mucin gene production in patients with chronic obstructive lung diseases. LOMUCIN is currently in clinical trials for the treatment of asthma and cystic fibrosis. Recently, the company entered into a three-year option agreement with E.I. du Pont de Nemours for the use of its peptide technology. In other news, Genaera announced that the United States Department of Defense, Army Medical Research and Material Command awarded a grant to the University of Chicago School of Medicine for a clinical trial of Squalamine for the treatment of prostate cancer. Genaera Corporation offers its employees an educational assistance program and flexible spending accounts.

BRANDS/DIVISIONS/AFFILIATES: Squalamine Trodulamine LOMUCIN Magainin Pharmaceuticals

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Roy C. Levitt, CEO Kenneth J. Holroyd, Exec. VP/COO Roy C. Levitt, Pres. Christopher P. Schnittker, Sr. VP/CFO Michael E. Petrone, VP-Clinical Research Sean Johnston, Sr. VP-Mfg. Angeline K. Shashlo, Sr. VP-Regulatory Affairs and Project Mgmt. Michael R. Dougherty, Chmn.

Phone: 610-941-4020 Fax: 610-941-5399 Toll-Free: Address: 5110 Campus Dr., Plymouth Meeting, PA 19462 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,202 ( 9 months) 2002 Profits: $-10,335 ( 9 months) Stock Ticker: GENR 2001 Sales: $ 900 2001 Profits: $-12,900 Employees: 57 2000 Sales: $ 200 2000 Profits: $-12,400 Fiscal Year Ends: 12/31 1999 Sales: $ 200 1999 Profits: $-12,200 1998 Sales: $ 200 1998 Profits: $-23,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $334,355 Stock Purch. Plan: Second Exec. Salary: $275,237 ADVANTAGE: Expertise in immune response systems.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $85,000 Bonus: $75,000

Northeast: Y

International:



GENE LOGIC INC

www.genelogic.com



Y


Profits: 24


TYPES OF BUSINESS:

Y



Research-Gene Ex pression Data (Drug Discovery) Bioinformatics Genomic Databases Custom Discovery Databases

Gene Logic is a leading provider of integrated genomics based information products, services and bioinformatics related to gene activity in human disease and toxicity, which enable global pharmaceutical and biotechnology companies. The company is building and commercializing a comprehensive survey of gene expression in human and animal tissues. The firm markets gene expression database products to global pharmaceutical, health care and life science industries. Its GeneExpress reference database includes BioExpress, ToxExpress and Genesis: The GeneExpress Enterprise System. BioExpress is a broad and in-depth survey of gene expression in a wide range of normal and diseased human tissues, tissues from experimental animals and human and animal cell lines. DataSuites are disease/indication-specific subsets derived from BioExpress, which provides comprehensive gene expression, genetic and clinical information from a focused range of normal and diseased tissue samples. CustomSuites, which combine proprietary information from BioExpress and customers’ proprietary information generated either in-house or by Gene Logic, are customized DataSuites tailored to the specific research interests of its customers. ToxExpress is a collection of predictive models based on gene expression profiles and predictive modeling capabilities. Genesis Enterprise System is a proprietary bioinformatics system that allows customers to combine and analyze detailed clinical histories and full genomic information. In addition, the company provides custom database services to clients who wish to discover drug targets using previously gathered information. Recently, Gene Logic introduced ToxSuites and ToxScreen Reports, expanding the information products within its ToxExpress database. ToxSuites will be comprised of liver and kidney organ data sets, and ToxScreen Reports will provide summaries of liver toxicity of individual compounds. Gene Logic provides dental insurance, flexible spending accounts and life insurance to its employees, pays 100% of qualified college tuition and provides an annual bonus.

BRANDS/DIVISIONS/AFFILIATES: GeneExpress BioExpress ToxExpress Genesis: The GeneExpress Enterprise System DataSuites CustomSuites ToxSuites ToxScreen Reports

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mark D. Gessler, CEO Mark D. Gessler, Pres. Philip L. Rohrer, Jr., CFO David S. Murray, Sr. VP-Mktg. and Sales Victor M. Markowitz, Sr. VP/Chief Info. Officer F. Dudley Staples, Jr., Sr. VP/Corp. Sec. F. Dudley Staples, Jr., General Counsel Douglas Dolginow , Sr. VP-Pharmacogenomics Mark D. Gessler, Chmn.

Phone: 301-987-1700 Fax: 301-987-1701 Toll-Free: 800-436-3564 Address: 708 Quince Orchard Rd., Gaithersburg, MD 20878 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $40,093 ( 9 months) 2002 Profits: $-18,870 ( 9 months) Stock Ticker: GLGC 2001 Sales: $43,300 2001 Profits: $-33,200 Employees: 272 2000 Sales: $26,883 2000 Profits: $-24,017 Fiscal Year Ends: 12/31 1999 Sales: $19,200 1999 Profits: $-20,600 1998 Sales: $13,200 1998 Profits: $-44,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Bonus: $249,986 Stock Purch. Plan: Y Second Exec. Salary: $292,320 Bonus: $129,255 ADVANTAGE: Strong alliances with other biotech companies/Excellent bioinformatics technologies.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



GENELABS TECHNOLOGIES INC

www.genelabs.com


Y



Profits: 132


TYPES OF BUSINESS:

Speci alty: Specialty Services: Consulting: Blood Collection:


Drugs-Small Molecule Drugs-Viruses Drugs-Lupus

Genelabs Technologies, Inc. is engaged in the discovery and development of a new class of pharmaceutical products. Its focus is on developing a product for the treatment of lupus, discovering compounds that target DNA and determining compounds that restrain the hepatitis E virus (HEV). The firm is currently engaged in using its proprietary DNA-binding technology for the discovery and development of novel small-molecule compounds. The company focuses on therapeutic intervention through drugs that prevent protein-binding in disease-invoking genes. Prestara is Genelabs' proprietary hormone treatment for systemic lupus in women. The company has completed several clinical trials of the product and recently received approval from the FDA for a New Drug Application. A third Phase III trial in men with lupus is also underway. GlaxoSmithKline Biologicals was granted an exclusive worldwide license to Genelabs' HEV technology for the development of a vaccine. Recently, GlaxoSmithKline began a Phase II clinical trial for a new treatment product. Genelabs is involved in research and development collaborations with Watson Pharmaceuticals, Inc., Genovate Biotechnology Co., Ltd., Teva Pharmaceuticals Industries, Ltd., DuPont Pharmaceuticals, Abbott Laboratories, Inc., University of Iowa Research Foundation and the University of California, San Francisco. Recently, Genelabs submitted a proposal to the FDA for a Phase III trial of Prestara; the results may provide evidence in support of marketing approval in the U.S. Genelabs Technologies offers employees medical, life, vision and dental insurance, tuition reimbursement, bonus incentives and cash awards for employees who accomplish special achievements. The company also provides stock options and purchase plans. Other benefits include vacation time, personal and work-related counseling and a fitness and recreation center.

BRANDS/DIVISIONS/AFFILIATES: Prestara DNA-Binding Technology HEV Technology

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Irene A. Chow , CEO James A.D. Smith, Pres. Matthew M. Loar, CFO Lynn M. Hughes, VP-Human Resources and Corp. Services Ronald C. Griffith, VP-Research Kenneth E. Schwartz, VP-Medical Affairs Heather C. Keller, VP/Corp. Sec. Heather C. Keller, General Counsel Roy J. Wu, VP-Bus. Dev. Matthew M. Loar, VP-Finance Irene A. Chow , Chmn.

Phone: 650-369-9500 Fax: 650-368-0709 Toll-Free: Address: 505 Penobscot Dr., Redwood City, CA 94063-4738 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,796 ( 9 months) 2002 Profits: $-12,090 ( 9 months) Stock Ticker: GNLB 2001 Sales: $4,800 2001 Profits: $-13,000 Employees: 90 2000 Sales: $6,965 2000 Profits: $-12,300 Fiscal Year Ends: 12/31 1999 Sales: $8,017 1999 Profits: $-12,800 1998 Sales: $7,800 1998 Profits: $-6,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $450,000 Stock Purch. Plan: Y Second Exec. Salary: $285,000 ADVANTAGE: Developed revolutionary drug discovery technology.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest:

Southeast:



Bonus: $157,500 Bonus: $53,438

Northeast: Y

International: Y



GENENCOR INTERNATIONAL INC

www.genencor.com



Y


Profits: 6


TYPES OF BUSINESS:



Research and Development-Genetically Modified Enzymes Vitamin C Production Vaccine Discovery Solutions Modified Proteins Proteomics

Genencor International develops novel enzyme and protein-based products for the health care, agricultural and industrial chemical markets through its i-biotech solution. The firm’s solution has led to the development of several technologies, including those enabling the synthesis of new molecules and the improvement of naturally occurring enzymes. In fact, the company has over 250 biotechnology products in commerce and owns over 3,000 patents and applications. The firm's health care segment focuses on the treatment of viral infections and cancer via drug development platforms in protein therapeutics and immunotherapeutics. Hepatitis B virus (HBV), human papillomavirus (HPV), and hepatitis C virus (HCV) are the main focus of its development products. In addition to medically based applications for the firm’s genetically modified enzymes, the company’s modified proteins are used in laundry detergent, artificial sweetening products, baking processes and brewing facilities. Genencor and Eastman Chemical Company are partnering to develop a production method for vitamin C that is more cost-effective than current methods. Recently, the company and DuPont announced the development of a compound in a new corn-based polymer for DuPont. In other news, the company and the University of Leicester will participate in a collaboration between the European Union (EU) and the People's Republic of China to discover metabolic and genetic products.

BRANDS/DIVISIONS/AFFILIATES: i-biotech Solution Genentech Corning Glass Works

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jean-Jacques Bienaime, CEO Jean-Jacques Bienaime, Pres. Raymond J. Land, Sr. VP/CFO Richard J. Ranieri, Sr. VP-Human Resources Michael V. Arbige, Sr. VP-Tech. Stuart L. Melton, Sr. VP/Corp. Sec. Stuart L. Melton, General Counsel Debby Jo Blank, Chief Bus. Officer Carole Beth Cobb, Sr. VP-Global Supply Thomas J. Pekich, Group VP-Bioproducts W. Thomas Mitchell, Chmn.

Phone: 650-846-7500 Fax: 650-845-6503 Toll-Free: Address: 925 Page Mill Rd., Palo Alto, CA 94304 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $261,939 ( 9 months) 2002 Profits: $6,676 ( 9 months) Stock Ticker: GCOR 2001 Sales: $326,000 2001 Profits: $17,800 Employees: 2000 Sales: $316,230 2000 Profits: $31,410 Fiscal Year Ends: 12/31 1999 Sales: $316,600 1999 Profits: $16,625 1998 Sales: $289,100 1998 Profits: $13,739

SAL ARIES/BENEFITS: Pension Plan: Savings Plan: Y

COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $511,539 Bonus: $306,923 Stock Purch. Plan: Second Exec. Salary: $308,462 Bonus: $132,968 ADVANTAGE: Mutation technology tools/Highly successful R&D has led to 3000 patents or patent applications.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



GENENTECH INC

www.gene.com


Y



Profits: 21


TYPES OF BUSINESS:



Drugs-Biotechnology Genetically Engineered Drugs Cardiovascular and Oncology Research

Genentech, Inc. is a biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Genentech is responsible for producing technology that has spawned 14 approved biotechnology products, including the nine manufactured by the firm. The company’s products consist of a variety of cardio-centric medications, as well as cancer, GHD and cystic fibrosis treatments. Biotechnology products offered by Genentech include Herceptin, which is used in treatments of certain metastatic breast cancers; Nutropin, a sustained release formulation of growth hormone for the treatment of growth hormone deficiency (GHD) in children; and Pulmozyme Inhalation Solution for the treatment of cystic fibrosis. Through its long-standing Patient Assistance Program, Genentech assures that everyone who needs these important medicines can get them. The firm also supports the continuing improvement of patient care through its post-marketing studies, which collect data on the health progress of patients who use Genentech medicines nationwide. Scientists of the company publish around 250 scientific papers per year and are highly regarded as among the most prolific in the scientific industry. The firm’s scientists focus mainly in the areas of cardiovascular disease and cancer, the number one and number two fatal diseases in the U.S. To continue its innovative scientific research, the company is currently investing in expanding its research facilities. Genentech recently broke ground on the expansion site of its Founders Research Center. Upon completion in late 2003, Founders Research Center will be the single largest biotechnology research facility in the world. In other news, the FDA recently approved Nutropin AQ PEN for the delivery of Nutropin recombinant growth hormone. Over 30% of employees are minorities. Genentech was recently name one of the Top 100 Companies to Work for in America by Fortune magazine for the third consecutive year. Company perks include on-campus bicycles, an onsite hair salon and free espresso.

BRANDS/DIVISIONS/AFFILIATES: Activase TNKase Herceptin Rityxan Activase Pulmozyme Nutropin Depot Nutropin AQ

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Arthur D. Levinson, CEO Myrtle S. Potter, COO Louis J. Lavigne, Jr., CFO Kimberly J. Popovits, Sr. VP-Mktg. & Sales David Nagler, VP-Human Resources Richard H. Scheller, Sr. VP-Research Guy Kraines, VP-Corp. IT John M. Whiting, Controller Susan Desmond-Hellmann, Chief Medical Officer W. Robert Arathoon, VP-Global Mfg. Oper. Stephen G. Juelsgaard, Corp. Sec. Stephen G. Juelsgaard, General Counsel Myrtle S. Potter, Exec. VP-Commercial Oper. Susan Desmond-Hellmann, Exec. VP-Dev. Susan Bentley, Sr. Dir.-Investor Rel. Joseph S. McCracken, VP-Bus. & Commercial Dev. David A. Ebersman, Sr. VP-Product Oper. Stephen G. Dilly, VP-Medical Affairs Sean A. Johnston, VP-Intellectual Property

Phone: 650-225-1000 Fax: 650-225-6000 Toll-Free: 800-488-6519 Address: One DNA Way, South San Francisco, CA 94080-4990 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,940,932 ( 9 months) 2002 Profits: $-29,041 ( 9 months) Stock Ticker: DNA 2001 Sales: $2,081,700 2001 Profits: $150,300 Employees: 4,950 2000 Sales: $1,736,400 2000 Profits: $-74,200 Fiscal Year Ends: 12/31 1999 Sales: $1,401,000 1999 Profits: $-1,157,500 1998 Sales: $1,150,900 1998 Profits: $181,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $ Bonus: $ ADVANTAGE: Strong strategic alliance strategy/High new product potential/Excellent record of successful development.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Northeast: Y

International:



GENEREX BIOTECHNOLOGY

www.generex.com


Y



Profits: 176


TYPES OF BUSINESS:



Large Molecule Drug Delivery Systems

Generex Biotechnology Corporation is engaged in the research and development of proprietary drug delivery technologies. The company is focused on formulations to administer large molecule drugs orally using a hand-held aerosol applicator, with a particular interest in diabetes therapy. The company has partnered with Eli Lilly regarding the development and testing of a liquid insulin formulation, known as Oralin, that can be administered by an oral spray. This treatment provides diabetics with an alternative to insulin injections. Generex also designed the RapidMist Device, a hand-held aerosol mechanism, to administer the product into the mouth, where the insulin is absorbed through the skin of the cheeks into the bloodstream. The product is more convenient than insulin shots in that it does not have to be refrigerated, is painless and is easy for diabetic patients to use. Generex is involved in a joint venture with Elan Corporation to develop the product buccal morphine for the treatment of acute pain. Recently, the company announced the approval of an investigational new drug application from Health Canada for the pain treatment product buccal fentanyl. Fentanyl is similar to morphine and is used for the management of pain in cancer patients.

BRANDS/DIVISIONS/AFFILIATES: RapidMist Device Oralin

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Anna Gluskin, CEO Rose C. Perri, COO Anna Gluskin, Pres. Pankaj Modi, VP-Research and Dev. Slava Jarnitskii, Controller Gerald Bernstein, VP-Medical Affairs Rose C. Perri, Corp. Sec. Steven Peltzman, VP-Bus. Dev. Rose C. Perri, Treas.

Phone: 416-364-2551 Fax: 416-364-9363 Toll-Free: 800-391-6755 Address: 33 Harbour Sq., Ste. 202, Toronto, Ontario M5J 2G2 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $ (12 months) 2002 Profits: $-13,700 (12 months) Stock Ticker: GNBT 2001 Sales: $1,000 2001 Profits: $-27,100 Employees: 25 2000 Sales: $ 100 2000 Profits: $-8,841 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-6,240 1998 Sales: $ 1998 Profits: $-4,664


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Agreement with Eli Lilly.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $300,000 Bonus: $250,000

Northeast:

International: Y



GENOME THERAPEUTICS CORP

www.genomecorp.com



Y


Profits: 15


TYPES OF BUSINESS:

Y



Drug Target Discovery Genomics Database

Genome Therapeutics Corporation is a leader in the field of genomics -based drug target discovery, defined as the identification and functional characterization of genes associated with infectious and human diseases. The company’s two business segments are the biopharmaceutical division and GenomeVision Services. The company has over 10 years of experience in the field of genomic research and has been sponsored by the United States government. Genome Therapeutics has developed numerous technologies and tools that are widely used in the genomic field. The company’s lead product, Ramoplanin, is in Phase III clinical trials for the prevention of bloodstream infections. Six other products are being developed in collaboration with companies including Schering-Plough, Wyeth, AstraZeneca and bioMerieux for the treatment of asthma, osteoporosis and ulcers. The firm developed the PathoGenome Database, a commercial source of microbial genomic information that provides customers with genomic information about microbial organisms and fungi. The databas e was introduced on the Internet for worldwide access through a partnership with Compugen via that company's LabOnWeb.com. Its GenomeVision Services includes library construction and customized sequencing services to pharmaceutical companies, biotechnology companies and research institutions on a contract basis. Recently, the company, the University of Southampton and ScheringPlough Corporation introduced the discovery of a gene linked to asthma, known as ADAM33. This finding will aid in the development of prevention and treatment of asthma. Genome Therapeutics offers a wide range of benefits to its employees, including health and dental insurance, life insurance and disability benefits. In addition, the firm reimburses qualified tuition expenses. Genome Therapeutics also offers flexible work schedules, confidential counseling services, fitness center access, a bonus for employee referral and stock options.

BRANDS/DIVISIONS/AFFILIATES: Ramoplanin GenomeVision Services LabOnWeb.com PathoGenome Database Compugen ICAgen

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steven M. Rauscher, CEO Steven M. Rauscher, Pres. Stephen Cohen, Sr. VP/CFO Martin Williams , Sr. VP-Mktg. Joseph A. Pane, VP-Human Resources Richard Labaudiniere, Sr. VP-Research and Dev. Timothy S. Leach, VP-Clinical and Medical Affairs Martin Williams , Sr. VP-Corp. Dev. Christopher Taylor, Investor Rel. and Corp. Mktg. Robert J. Hennessey, Chmn.

Phone: 781-398-2300 Fax: 781-893-9535 Toll-Free: Address: 100 Beaver St., Waltham, MA 02453 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $17,149 ( 9 months) 2002 Profits: $-25,175 ( 9 months) Stock Ticker: GENE 2001 Sales: $35,700 2001 Profits: $-10,100 Employees: 204 2000 Sales: $26,400 2000 Profits: $-2,800 Fiscal Year Ends: 8/31 1999 Sales: $24,000 1999 Profits: $-6,300 1998 Sales: $19,200 1998 Profits: $-15,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: A leader in genomics technology.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $121,500 Bonus: $75,134

Northeast: Y

International:



GENSET SA

www.genxy.com



Y


Y

TYPES OF BUSINESS:

Profits: 29




Genomics Research Drug Discovery Biotechnology

Genset SA is a genomics company focused on generating a pipeline of drug targets and candidates in the areas of CNS and metabolic disorders. The firm has successfully used its integrated technology platform and association studies approach to identify and characterize drug targets and drug response markers in the fields of CNS, metabolic and other diseases. Building upon its expertise accumulated in various alliances with pharmaceutical partners and its portfolio of genomic patients, the company intends to pursue and validate novel drug targets and candidates for its own account, starting with a lead protein candidate in its obesity program. The company’s recently adopted business strategy is aimed at capturing a greater portion of the value to be derived from its discoveries, such as Famoxin, Genset’s first potential product in the field of obesity. Under the new strategy, the firm will no longer enter into limited gene discovery, pharmacogenomics or service agreements for the benefit of others. Genset recently agreed to sell its oligonucleotides division to a specialty chemical company in Germany for approximately $25 million. The firm believes this transaction will help it move forward with its research and development activities.

BRANDS/DIVISIONS/AFFILIATES: Sanofi-Synthelabo Abbott Laboratories Ceres Corixa Genset Pacific Pty., Ltd. Genset Oligos Famoxin Janssen

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Andre Pernet, CEO Andre Pernet, Pres. John Varian, CFO Agnes Le Saux -Narjoz, VP-Mktg. Jean Elias, VP-Human Resources Daniel Cohen, Dir.-Scientific Strategy Robert Abarbanel, CIO/Chief Tech. Officer John Ford, VP-Biopharmaceuticals Jonathan Burnham, General Counsel Cecile Tharaud, VP-Oper. Jeffery S. Vick, VP-Worldwide Bus. Dev. Philippe Rousseau, VP-Finance Bernard Bihain, VP-Functional Genomics Paul Moser, VP-CNS Dev. David Bradfute, VP-Intellectual Property

Phone: +33-1-55-04-5900 Fax: +33-1-55-04-5929 Toll-Free: Address: 24 Rue Royale, Paris , 75008 France

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $17,400 2001 Profits: $-42,000 Employees: 529 2000 Sales: $25,200 2000 Profits: $-29,100 Fiscal Year Ends: 12/31 1999 Sales: $23,400 1999 Profits: $-18,700 1998 Sales: $149,400 1998 Profits: $-81,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Multiple strategic partnerships for biotech research.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



GENTA INC

www.genta.com


Y Y



Profits: 202


TYPES OF BUSINESS:



Drugs-Cancer Antisense Drugs DNA Medicines

Genta, Inc. is a biopharmaceutical company dedicated to the development of innovative drugs to treat cancer. In the past, the firm's research efforts have focused primarily on the development of antisense drugs, which are designed to selectively prevent the production of proteins that contribute to the cause or progression of disease. Recently, the company has broadened its portfolio into other DNA medicines, which consist of decoy aptamers and small molecules, including gallium products and androgenics compounds. Genta's lead antisense drug is Genasense, a molecule designed to block the production of a protein that contributes to the inherent resistance of cancer cells to anticancer treatment, including chemotherapy, radiation and monoclonal antibodies. Current efforts focus on using the drug as a pre-treatment to amplify the effectiveness of other treatments. The drug is in the last stage of clinical testing. In addition, Genta is developing two small molecule drugs containing gallium: Ganite, an intravenous drug, and an oral formulation of a gallium -containing compound. Ganite previously received marketing approval for the treatment of cancer-related hypercalcemia. The firm now believes that the drug may be active as a treatment for certain types of cancer, particularly non-Hodgkin's lymphoma. Genta has filed an investigational new drug exemption with the FDA toward this end. The firm is also developing androgenics compounds for the treatment of the hormone-sensitive stage of prostate cancer, as well as decoy aptamer technology, designed to bind proteins called transcription factors that can selectively turn genes on or off. Genta has partnered with Molecular Biosystems, Inc. for the licensing of a portfolio of antisense applications. With SkyePharma, the company formed Genta Jago Technologies, a joint venture. The two firms currently seek to terminate this involvement. Recently, Genta initiated new clinical trials to test Genasense as a treatment for colorectal cancer and solid tumors. Genta offers employees a benefits package that includes stock options and medical, dental and life insurance.

BRANDS/DIVISIONS/AFFILIATES: Genasense Ganite Androgenics Technologies, Inc. Genta Pharmaceuticals Europe Genta Jago Technologies

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Raymond P. Warrell, Jr., CEO William P. Keane, VP/CFO Bruce A. Williams, Sr. VP-Sales and Mktg. Loretta M. Itri, Exec. VP-Clinical Research and Dev. Bharat Mehta, VP-Mfg. Oper. Thomas C. Burger, VP-Corp. Dev. Tara Spiess, Dir.-Corp. Comm. Tara Spiess, Dir.-Investor Rel. Robert E. Klem, VP/Chief Tech. Officer Paul F. Manley, VP-Regulatory Affairs Jean O'Connor, VP-Quality Assurance Raymond P. Warrell, Jr., Chmn.

Phone: 908-286-9800 Fax: 908-464-1701 Toll-Free: Address: 2 Connell Dr., Berkeley Heights , NJ 07922 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,240 ( 9 months) 2002 Profits: $-44,808 ( 9 months) Stock Ticker: GNTA 2001 Sales: $ 100 2001 Profits: $-46,700 Employees: 60 2000 Sales: $ 22 2000 Profits: $-12,451 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-7,444 1998 Sales: $ 105 1998 Profits: $-7,586


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Expertise in anti-cancer products.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $100,000 Bonus: $24,700

Northeast: Y

International: Y



GENZYME BIOSURGERY

www.genzymebiosurgery.com




Y

TYPES OF BUSINESS:

Profits: 30




Equipment-Surgery Cardiac Sutures Biomaterials Biotherapeutics

A division of Genzyme Corp., Genzyme Biosurgery develops and markets a portfolio of devices, biomaterials and biotherapeutics primarily for the cardiovascular and general surgery markets. Genzyme Biosurgery is organized into two segments: orthopaedics and cardiothoracic. Specifically, Genzyme Surgical Products is a leading provider of specialty cardiovascular closures used in coronary artery bypass graft procedures and valve implantation procedures. Genzyme Biosurgery is also developing a gene therapy approach to inadequate circulation caused by blood vessel constriction or blockage, including both coronary artery disease (CAD) and peripheral arterial disease (PAD). The company is currently researching Sepragel, an ortho prevention product for joint repair. Synvisc II is used to treat the pain and immobility associated with osteoarthritis of the knee, and Carticel II is used to treat damaged articular cartilage in the knee. Genzyme Biosurgery markets products directly to physicians and hospital administrators throughout the United States and Europe. It also uses a network of distributors to sell certain products in the United States, Europe, Asia and Latin America. Recently, Genzyme Biosurgery and Exactech, Inc., formed an agreement to collaborate for the purpose of developing orthopedic products.

BRANDS/DIVISIONS/AFFILIATES: Synvisc II Carticel II Genzyme Corp. Genzyme Surgical Products Sepragel

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Earl M. Collier, Jr., CEO Earl M. Collier, Jr., Pres. David B. Johnston, VP-Finance Anthony G. Chambers, VP-Sales and Mktg. Russell J. Campanello, Sr. VP-Human Resources John M. McPherson, Sr. VP-Research and Dev. Richard A. Moscicki, Sr. VP-Clinical and Regulatory Affairs Joel W. Cummings, VP-Oper. Peter Wirth, Exec. VP-Corp. Dev. John Connolly, Exec. VP-Genzyme Surgical Products C. Van Heek, Exec. VP-Therapeutics and Genetics Alan E. Smith, Sr. VP-Research Henri A. Termeer, Chmn.

Phone: 617-252-7500 Fax: 617-252-7600 Toll-Free: Address: One Kendall Sq., Cambridge, MA 02139 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $181,400 ( 9 months) 2002 Profits: $-160,700 ( 9 months) Stock Ticker: GZBX 2001 Sales: $253,100 2001 Profits: $-144,100 Employees: 2000 Sales: $145,200 2000 Profits: $-162,200 Fiscal Year Ends: 12/31 1999 Sales: $132,400 1999 Profits: $-78,100 1998 Sales: $121,100 1998 Profits: $-90,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: A leading provider of specialty cardiovascular sutures and other closure devices.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Bonus: $ Bonus: $

Northeast: Y

International: Y



GENZYME CORP

www.genzyme.com


Y



Y Y

TYPES OF BUSINESS:

Profits: 233




Drugs Surgical Products Biopharmaceuticals Diagnostic Products Genetic Testing Services Oncology Drugs

Genzyme Corporation develops, manufactures and markets innovative products and services for major unmet medical needs. The company operates worldwide in 26 countries, primarily in North America and Europe. The firm conducts operations through three divisions: Genzyme Biosurgery, Genzyme General and Genzyme Molecular Oncology. Genzyme Biosurgery develops and markets a portfolio of devices, advanced biomaterials and biotherapeutics, primarily for the cardiothoracic, orthopaedic and general surgery markets. Genzyme General primarily develops and markets drugs and services for the treatment of genetic disorders and their chronic debilitating diseases. This division’s major products include Cerezyme and Ceredase (for the treatment of Gaucher’s disease), Renagel, Thyrogen and Seprafilm. Moreover, Genzyme General has a strong pipeline of therapeutic products under development. The division also manufactures and markets diagnostic products, genetic testing services and pharmaceutical intermediates. Genzyme Molecular Oncology is developing a new generation of cancer products, focusing primarily on cancer vaccines and angiogenesis inhibitors. This division draws from a broad array of medical expertise in the gene discovery, gene therapy, small molecule drug discovery, protein therapeutic and genetic diagnostic fields. The company recently completed the acquisition of Novazyme Pharmaceuticals, a developer of enzyme replacement therapies for lysosomal storage disorders, for approximately $137.5 million. In other news, Genzyme licensed the exclusive rights to use a gene believed to be implicated in metastatic colon cancer. Genzyme offers its employees several family-oriented employee benefits such as day care, elder care and adoption resource and referral services.

BRANDS/DIVISIONS/AFFILIATES: Renagel Thyrogen Cerezyme Seprafilm Novazyme Pharmaceuticals Genzyme General Genzyme Molecular Oncology Genzyme Biosurgery

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Henri A. Termeer, CEO Henri A. Termeer, Pres. Michael S. Wyzga, Sr. VP-Finance/CFO Zoltan Csimma, Sr. VP-Human Resources Alan E. Smith, Sr. VP-Research/Chief Scientific Officer Michael S. Wyzga, Corp. Controller Richard A. Moscicki, Sr. VP/Chief Medical Officer Thomas J. DesRosier, General Counsel Mark Bamforth, Sr. VP-Corp. Oper. Richard H. Douglas, Sr. VP-Corp. Dev. Elliott D. Hillback, Jr., Sr. VP-Corp. Affairs Evan M. Lebson, Treas. Earl M. Collier, Exec. VP/Pres.-Biosurgery Roger W. Louis, Chief Compliance Officer Mara Aspinall, VP/Pres.-Genetics and Pharmaceuticals Alison Lawton, Sr. VP-Regulatory Affairs

Phone: 617-252-7500 Fax: 617-252-7600 Toll-Free: Address: One Kendall Sq., Cambridge, MA 02139-1562 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $587,461 ( 6 months) 2002 Profits: $71,086 ( 6 months) Stock Ticker: GENZ 2001 Sales: $1,223,600 2001 Profits: $-112,100 Employees: 5,200 2000 Sales: $752,483 2000 Profits: $85,956 Fiscal Year Ends: 12/31 1999 Sales: $635,366 1999 Profits: $142,077 1998 Sales: $569,319 1998 Profits: $133,052


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $ Bonus: $ ADVANTAGE: Genzyme Corp. owns the largest recombinant protein manufacturing operation in the world.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Northeast: Y

International: Y



GENZYME MOLECULAR ONCOLOGY www.genzyme.com/molecularoncology Industry Group Code: 325412 Ranks within this company's industry group: Sales: 129 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Profits: 183


TYPES OF BUSINESS:



Drugs-Gene-based Cancer Cancer Vaccines Angiogenesis Inhibitors Cancer Pathway Regulators

Genzyme Molecular Oncology, a division of Genzyme Corp., is dedicated to creating the next generation of cancer treatments. The company attempts to create therapies that build on a genetic understanding of cancer to enhance the immune system’s cancer-fighting abilities, starve tumors by cutting off their blood supply, correct cancer cell defects and selectively attack tumors. The firm’s new generation of cancer products focuses on cancer vaccines, angiogenesis inhibitors and cancer pathway regulators. Currently, the company is conducting five clinical trials in partnership with leading researchers and institutions. Genzyme Molecular Oncology has plans to launch three new clinical trials once these five are completed. The firm’s database, SAGE, is an important part of Genzyme Molecular Oncology’s discovery efforts with emphasis on identification of tumor antigens and antiangiogenic factors, analyzing the effects of drugs on human tissue and gaining insight into disease pathways. SAGE (Serial Analysis of Gene Expression) genomics technology has been used by researchers at Johns Hopkins University to identify 79 genes, including 14 novel genes, implicated in tumor blood vessel growth, or angiogenesis. Under a sponsored research agreement with Johns Hopkins, Genzyme has rights to all intellectual property developed by the University related to the genes found in this groundbreaking study. The database consists of more than 6 million tags believed to represent in excess of 125,000 unique transcripts from major cancers and normal tissues. Genzyme Molecular Oncology offers SAGE to pharmaceutical, biotechnology and genomics companies through license and service agreements. In recent news, two scientists from the firm found a gene expression method that moves closer to conclusive identification of all the genes in the human genome. This new method, Long SAGE, is an expansion of the SAGE approach. Genzyme Molecular Oncology offers comprehensive health and medical benefits and adoption/parental leave.

BRANDS/DIVISIONS/AFFILIATES: SAGE Database Myriad Genetics, Inc. Long SAGE NeuralStem Biopharmaceuticals

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gail J. Maderis, CEO Gail J. Maderis, Pres. Michael S. Wyzga, CFO/Sr. VP Susan Lankton-Rivas , Dir.-Human Resources Katherine W. Klinger, Sr. VP-Research and Dev.

Phone: 508-872-8400 Fax: 508-271-2604 Toll-Free: Address: 15 Pleasant St. Connector, Framingham , MA 017019322 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $7,000 ( 9 months) 2002 Profits: $-18,500 ( 9 months) Stock Ticker: GZMO 2001 Sales: $6,600 2001 Profits: $-29,700 Employees: 5,200 2000 Sales: $5,700 2000 Profits: $-23,100 Fiscal Year Ends: 12/31 1999 Sales: $4,600 1999 Profits: $-28,800 1998 Sales: $19,400 1998 Profits: $-19,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Innovative cancer research/Relationship with Genzyme.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International:



GERON CORPORATION

www.geron.com


Y



Profits: 30


TYPES OF BUSINESS:



Drugs Therapeutic and Diagnostic Pr oducts Telomerase Technologies Human Stem Cell Technologies Nuclear Transfer Technologies

Geron Corp. is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, as well as research tools for drug discovery. Its product development programs are based on three patented core technologies: telomerase, human embryonic stem cells and nuclear transfer. Telomeres are the ends of chromosomes, which protect them from degradation and act as molecular clocks for cellular aging. Telomerase is an enzyme that restores telomere length, which extends the cell's ability to multiply or replicate. The firm seeks to activate the enzyme to increase the lifespan of prematurely aged cells to treat chronic degenerative diseases. In addition, the therapy is hoped to inhibit the enzyme in cancer cells, and also to diagnose cancer by measuring telomerase activity. Geron seeks to use embryonic stem cells as a potential source for the manufacture of replacement cells and tissues for organ repair applications. The company is also involved in nuclear transfer, a method for generating whole animals from genetic material derived solely from the nucleus of a single cell. Geron is actively licensing this technology to others for applications in agriculture and production of biological therapies. Regenerative medicine applications of these technologies include the treatment of Parkinson's Disease, heart disease, diabetes, osteoporosis and hematologic diseases. The firm owns or has licenses to more than 80 U.S. patents, with more than 335 pending applications worldwide. In mid-2002, Geron announced that it would cut approximately 30% of its workforce and slow its stem cell research in the areas of blood, bone and cartilage. The firm will focus on cancer therapies with a goal of using stem cells to treat diseases of cardiac, neural and pancreatic tissues. In recent news, the company received its first U.S. patent for human hepatocytes derived from embryonic stem cells. Geron offers its employees medical, dental and vision coverage, flexible spending accounts, continuing education, transportation reimbursement, health club membership and a credit union.

BRANDS/DIVISIONS/AFFILIATES: Infinity Roslin Biotechnology Centre

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas B. Okarma, CEO Thomas B. Okarma, Pres. David L. Greenwood, CFO Jeannine Niacaris, VP-Human Resources Calvin B. Harley, Chief Scientific Officer William D. Stempel, Corp. Sec. William D. Stempel, General Counsel Jeannine Niacaris, VP-Admin. Services David L. Greenwood, Sr. VP-Corp. Dev. David L. Greenwood, Treas. Jane S. Lebkowski, VP-Regenerative Medicine Melissa A. Kelly, VP-Corp. Dev/Mgr.-Research and Dev. Tech. David J. Earp, VP-Intellectual Property Richard L. Tolman, VP- Drug Discovery

Phone: 650-473-7700 Fax: 650-473-7701 Toll-Free: 800-782-3279 Address: 230 Constitution Dr., Menlo Park, CA 94025 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 955 ( 9 months) 2002 Profits: $-26,679 ( 9 months) Stock Ticker: GERN 2001 Sales: $3,600 2001 Profits: $-42,100 Employees: 142 2000 Sales: $6,600 2000 Profits: $-45,800 Fiscal Year Ends: 12/31 1999 Sales: $5,400 1999 Profits: $-46,400 1998 Sales: $6,800 1998 Profits: $-10,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $342,500 Stock Purch. Plan: Y Second Exec. Salary: $275,000 ADVANTAGE: Multiple strategic alliances for biomedical research and development.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $150,000 Bonus: $75,350

Northeast:

International: Y



GILEAD SCIENCES INC

www.gilead.com


Y



Profits: 32


TYPES OF BUSINESS:



Drugs-Infectious Disease and Cancer Biopharmaceutical Products AIDS and Influenza Medication Cancer Treatment Products

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. The company discovers, develops, manufactures and commercializes proprietary therapeutics for challenging infectious diseases, such as viral and bacterial infections and cancer. Gilead maintains research, development, manufacturing or sales and marketing facilities in the United States, Europe and Australia. In order to solidify its commitment to become a global leader in advancing treatments for the most challenging human diseases, the firm merged with NeXstar Pharmaceuticals, Inc. As a result of the merger, Gilead has a broad-based leadership position in infectious disease, including antifungals and antibiotics, as well as a specialized focus in oncology. The firm currently has five products undergoing active research and development, with two of these in late-stage clinical trials. Four products are available on the market: AmBisome for the prevention of fungal infections, Tamiflu for the treatment of influenza and Vistide and DaunoXome, both of which are used in the treatment of AIDS. In a major development, the firm recently received approval from the U.S. Food and Drug Administration for its antiretroviral agent Viread. This product is to be used for the treatment of human immunodeficiency virus (HIV) infection when taken in combination with other antiretroviral agents, and is currently available in pharmacies. Viread is the first nucleotide analogue reverse inhibitor approved for the treatment of HIV, and remains in cells for longer periods of time than many other antiretroviral drugs, allowing for once-daily dosing. Gilead also recently initiated a trial to evaluate Tenofovir topical gel as a preventive for vaginal HIV transmission. The company has an assistance program for its employees and offers tuition reimbursement for job-related courses. The firm also offers a subsidized café, free health club membership, on-site massages, vacation discounts and a variety of sports teams and family events. The company's dress code is casual.

BRANDS/DIVISIONS/AFFILIATES: Roche Pharmaceuticals AmBisome Fujisawa Healthcare, Inc. Tamiflu EyeTech Pharmaceuticals, Inc. MiKasome Tenofovir DF NeXstar Pharmaceuticals, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John C. Martin, CEO John C. Martin, Pres. Sharon A. Surrey-Barbari, VP-CFO Michael K. Inouye, Sr. VP-Sales & Mktg. Marsha Roberts, VP-Human Resources Norbert W. Bischofberger, Exec. VP-Research and Dev. Nicole Onetto, Sr. VP-Medical Affairs Anthony D. Caracciolo, VP-Mfg. Mark L. Perry, Exec. VP-Oper. John F. Milligan, VP-Corp. Dev. Crispin G.S. Eley, Sr. VP-Pharmaceutical Oper. Choung U. Kim, V P-Medicinal Chemistry Max D. Hensley, VP-Intellectual Property

Phone: 650-574-3000 Fax: 650-578-9264 Toll-Free: 800-445-3235 Address: 333 Lakeside Dr., Foster City, CA 94404 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $321,763 ( 9 months) 2002 Profits: $36,618 ( 9 months) Stock Ticker: GILD 2001 Sales: $233,800 2001 Profits: $52,300 Employees: 1,000 2000 Sales: $195,600 2000 Profits: $-56,800 Fiscal Year Ends: 12/31 1999 Sales: $169,000 1999 Profits: $-66,500 1998 Sales: $151,100 1998 Profits: $-44,800


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $ Bonus: $ ADVANTAGE: Strong research, development and commercialization capabilities in antiviral and cancer therapies.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International: Y



GLAXOSMITHKLINE PLC

www.gsk.com


Y



Profits: 241


TYPES OF BUSINESS:



Drugs-Prescription Asthma Drugs Respiratory Drugs Antibiotics Antivirals Dermatalogicals Neurologicals Consumer Health Products

GlaxoSmithKline plc (GSK), formed from the merger of Glaxo Wellcome and SmithKline Beecham, and its subsidiaries constitute a major global drug and health products engaged in the creation, discovery, development, manufacture and marketing of pharmaceutical and consumer health-related products. GSK’s headquarters are located in Middlesex, England, with operation headquarters in Philadelphia, Pennsylvania and Triangle Park, North Carolina, in addition to operating companies in approximately 70 countries. The firm’s major markets are the U.S., Japan, the U.K., France, Germany and Italy. GSK operates in two industry segments: pharmaceuticals (prescription drugs and vaccines) and consumer health care (over-the-counter medicines, oral care and nutritional health care). Pharmaceutical product offerings include treatments for central nervous system disorders, such as Paxil for depression and anxiety and Lamictal for epilepsy; respiratory treatments, such as Flovent for asthma and Ventolin for bronchitis; anti-bacterials such as Augmentin and Amoxil; anti-virals such as Valtrex for genital herpes and Zeffix for hepatitis B; gastro-intestinal treatments such as Zantac for ulcer, reflux and dyspepsia; cardiovascular treatments such as Lanoxin for congestive heart failure; and arthritis treatments such as Relafen for osteoarthritis. Consumer health care products include over-the-counter medicines such as Tums, Citrucel and Nicorette; oral care products such as Aquafresh and Polident; and nutritional health care products. In recent news, GSK acquired a Hungarian manufacturing facility, giving the firm increased capacity in key vaccine antigens, such as those for diphtheria and whooping cough. The company also recently announced the development and commercialization of a new treatment for the management of post-operative bowel paralysis, Alvimopan.

BRANDS/DIVISIONS/AFFILIATES: Glaxo Wellcome SmithKline Beecham Paxil Augmentin Zantac Relafen Tums Nicorette

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. J.P. Garnier, CEO Robert Ingram, COO John Coombe, CFO Daniel Phelan, Sr. VP-Human Resources Tachi Yamada, Research and Dev. Ford Calhoun, Sr. VP-IT John Ziegler, Pres.-Consumer Healthcare Timothy Tyson, Global Mfg. and Supply Rupert Bondy, Sr. VP/General Counsel Robert Ingram, Pres.-Pharmaceutical Oper. Jennie Younger, Sr. VP-Corp. Comm. and Partnerships James Palmer, Sr. VP-New Product Dev. Howard Pien, Pres., Pharmaceuticals Int'l David Stout, Pres., U.S. Pharmaceuticals Chris Viehbacher, Pres., Pharmaceutical Europe

Phone: +44-20-8047-5000 Fax: +44-20-8047-7807 Toll-Free: 888-825-5249 Address: 980 Great West Rd., Brentford, Middlesex TW8 9GS UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $23,005,000 ( 9 months) 2002 Profits: $4,771,000 ( 9 months) Stock Ticker: GSK 2001 Sales: $29,858,600 2001 Profits: $-158,800 Employees: 100,000 2000 Sales: $26,346,500 2000 Profits: $-7,537,200 Fiscal Year Ends: 12/31 1999 Sales: $24,476,800 1999 Profits: $1,401,900 1998 Sales: $23,319,700 1998 Profits: $1,544,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: One of the world's leading healthcare companies/The largest healthcare company in the U.K.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Northeast: Y

International: Y



GLIATECH INC

www.gliatech.com


Y



Y

TYPES OF BUSINESS:

Profits: 27




Supplies-Surgical Scarring Reduction Devices Absorbable Medical Devices Monoclonal Antibody Technology

Gliatech, Inc. is engaged in the discovery and development of biosurgical and pharmaceutical products to improve surgical outcomes and to treat neurological disorders. These products are based on glial cells, which perform key roles in the formation and function of the central nervous system. The firm’s biosurgical products include the ADCON family of products, which consists of proprietary, resorbable carbohydrate polymer medical devices designed to inhibit scarring and adhesions following surgery. The proprietary monoclonal antibody is designed to block the inappropriate activation of the complement pathway and inhibit inflammation associated with a variety of indications, such as coronary bypass surgery, heart attack and stroke. Gliatech is expanding its line of ADCON products to address surgeries including pelvic and gynecological, abdominal, implant and prosthetic and cardiac procedures. In addition to biosurgical products, the company is pursuing the development of small-molecule drug candidates for the treatment of several neurological disorders, including attention deficit hyperactive disorder (ADHD), sleep disorders, anxiety, schizophrenia and Alzheimer's disease (AD). Abgenix, Inc. has exclusive rights to Gliatech’s antibody therapies for cardiovascular and inflammatory diseases. Recently, Gliatech filed for protection under Chapter 11 of the U.S. Bankruptcy code.

BRANDS/DIVISIONS/AFFILIATES: ADCON

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert P. Pinkas, CEO Rodney E. Dausch, COO Steven L. Basta, Pres. Thomas F. Barnish, CFO/VP-Finance Clark E. Tedford, Exec. VP-Research and Dev. Thomas F. Barnish, Corp. Sec. Thomas F. Barnish, Treas. Robert J. Bard, VP-Regulatory Affairs Robert P. Pinkas, Chmn.

Phone: 216-831-3200 Fax: 216-831-4220 Toll-Free: Address: 23420 Commerce Park Rd., Cleveland, OH 44122 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,800 ( 9 months) 2002 Profits: $-16,800 ( 9 months) Stock Ticker: GLIA 2001 Sales: $3,100 2001 Profits: $-23,700 Employees: 58 2000 Sales: $23,655 2000 Profits: $-12,919 Fiscal Year Ends: 12/31 1999 Sales: $28,000 1999 Profits: $- 400 1998 Sales: $17,300 1998 Profits: $-3,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Glial cell technology.

OTHER THOUGHTS:




West:

Southwest:

Midwest: Y

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



GLYCOGENESYS INC

www.glycogenesys.com


Y




TYPES OF BUSINESS:



Drugs Cleaning Products Home and Garden Care Products Automotive Care Products Agricultural Products Fungicides Chemicals

GlycoGenesys, Inc., formerly SafeScience, Inc., conducts its business through two wholly-owned subsidiaries, International Gene Group, Inc. and SafeScience Products, Inc. International Gene Group (IGG) develops human therapeutics. IGG has been focused on developing GCS100, a complex carbohydrate intended to fight cancerous tumors and metastasis, which it licenses exclusively from Wayne State University and Karmanos Cancer Institute. GCS-100 has the potential for therapeutic effect on multiple cancer types, such as pancreatic, colorectal, prostate, breast and liver cancer. GCS-100 has the potential to induce cell death and interfere with cellular adhesion and angiogenesis. It is being developed through a joint venture in the area of oncology with Elan Corporation. A Phase II clinical trial for patients with pancreatic cancer was recently completed. In the agricultural area, SafeScience Products has developed and/or licensed products that include an EPA-approved plant defense booster, Elexa, for application in crops and other plants against certain fungal diseases.

BRANDS/DIVISIONS/AFFILIATES: GCS-100 International Gene Group, Inc. SafeScience Products, Inc. Elexa SafeScience, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bradley J. Carver, CEO Bradley J. Carver, Pres. John Burns, Sr. VP/CFO Jean Nichols, Interim Chief Scientific Officer Mark Staples, VP-Dev. and Mfg. John Burns, Corp. Sec. William Fabbri, General Counsel Frederick Pierce, VP-Bus. Dev. Ram Sasisekharan, Chmn.

Phone: 617-422-0674 Fax: 617-422-0675 Toll-Free: 800-260-0675 Address: Park Square Bldg., 31 St. James Ave., Ste. 810, Boston, MA 02116 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-7,900 ( months) Stock Ticker: GLGS 2001 Sales: $ 2001 Profits: $-22,700 Employees: 13 2000 Sales: $ 100 2000 Profits: $-17,300 Fiscal Year Ends: 12/31 1999 Sales: $1,400 1999 Profits: $-12,300 1998 Sales: $ 100 1998 Profits: $-6,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Joint venture strategy.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $35,000 Bonus: $25,000

Northeast: Y

International:



GTC BIOTHERAPEUTICS INC

www.transgenics.com


Y



Y

TYPES OF BUSINESS:

Profits: 7




Drugs-Anticoagulants Genetically Engineered Therapeutic Products Specialized Contract Research Services Transgenic Drug Programs

GTC Biotherapeutics, Inc., formerly Genzyme Transgenics Corp. (GTC), is the leader in the application of transgenic technology to the development of recombinant proteins for therapeutic uses. Currently, GTC is using its technology platform to work toward commercialization in 15 therapeutic protein drug programs. Twelve of the programs focus on proteins that are proprietary to its partners and three focus on proteins that the firm began developing internally. In general, GTC uses collaboration agreements in developing its programs to provide the opportunity to participate in more potential therapeutics than would be practical independently. These agreements also provide current revenues and augment the company’s capabilities in areas such as clinical development and product marketing. GTC’s technology platform includes the ability to generate transgenic animals that express specific recombinant proteins in their milk and provide for animal husbandry, breeding and milking, as well as the ability to purify the milk to a clarified intermediate bulk material that may undergo manufacturing to obtain a clinical grade product. The firm generates transgenic animals through microinjection and nuclear transfer, and it expects to rely primarily on nuclear transfer techniques in new program development work. GTC uses goats in most of its commercial development programs due to relatively short generation times and relatively high milk production volume. Products include Remicade, a monoclonal antibody marketed for rheumatoid arthritis, and Antegren, still in development and intended as a treatment for neurological disorders. Genzyme Transgenics offers employees benefits including health, dental and life insurance, company options, tuition reimbursement and fitness membership rebates.

BRANDS/DIVISIONS/AFFILIATES: Antegren Genzyme Transgenics Corp Genzyme Corp. Remicade D2E7 Antithrombin III Progenics Pharmaceuticals, Inc. Centocor, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Geoffrey F. Cox, CEO Geoffrey F. Cox, Pres. John B. Green, Sr. VP-Finance/CFO Jack Heffernan, Human Resources Harry M. Meade, VP-Research and Dev. Daniel S. Woloshen, Sr. VP/General Counsel Gregory Liposky, Sr. VP-Oper. Paul Horan, Sr. VP-Corp. Dev. Thomas E. Newberry, VP-Corp. Comm. Thomas E. Newberry, VP-Investor Rel. John B. Green, Treas. Carol A. Ziomek, VP-Dev. Suzanne Groet, VP-Therapeutic Protein Dev. Mark Adams , Sr. Dir.-Commercial Dev. Scott P. Fulton, VP- Program Mgmt.

Phone: 508-620-9700 Fax: 508-370-3797 Toll-Free: Address: 175 Crossing Blvd., Ste. 410, Framingham , MA 017019322 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $8,839 ( 9 months) 2002 Profits: $-18,029 ( 9 months) Stock Ticker: GZTC 2001 Sales: $13,700 2001 Profits: $-16,600 Employees: 168 2000 Sales: $16,200 2000 Profits: $-14,100 Fiscal Year Ends: 12/31 1999 Sales: $13,800 1999 Profits: $-18,800 1998 Sales: $11,600 1998 Profits: $-19,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $239,114 Bonus: $53,254 Stock Purch. Plan: Y Second Exec. Salary: $212,698 Bonus: $47,068 ADVANTAGE: A leader in the application of transgenic technology to the development of genetically engineered proteins.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



GUILFORD PHARMACEUTICALS INC www.guilfordpharm.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 91 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Profits: 212


TYPES OF BUSINESS:



Drugs-Neurological Diagnostic Products

Guilford Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the research, development and marketing of products that target the neurological, surgical and critical care markets. Its proprietary drug, GLIADEL Wafer, is used to treat a type of brain cancer. Guilford is marketing the product in the U.S. and parts of Europe. Its neurological products program is engaged in the research and development of small molecules that regenerate damaged nerves or protect nerves from damage for potential treatment of a range of neurodegenerative diseases and conditions, such as Parkinson’s disease, Alzheimer’s disease, stroke, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury and peripheral neuropathies. AQUAVAN Injection is a water-soluble prodrug of propofol, which is the most widely used general anesthetic in the world. Guilford’s scientists are developing novel compounds to protect brain cells from ischemia. These compounds, known as NAALADase inhibitor compounds, target neuropathic pain and disease modification of diabetic neuropathy. In animal models, it has been demonstrated that treatment with NAALADase inhibitors can normalize pain sens itivity, improve nerve conduction velocity and promote re-myelination of peripheral nerves. Neuro-immunophilin ligands are a novel class of drugs developed by Guilford that may have the ability to cause nerve growth as well as repair. Its neuro-immunophilin ligand drug GPI 1485 recently began Phase II clinical trials. In other news, Guilford began a Phase II trial of AQUAVAN Injection in Europe. Guilford offers its employees discretionary bonuses, dental and vision plans, education reimbursement, a fitness center and on-site chair masssages. The company has a policy of business casual attire and offers residency sponsorship for employees who are foreign nationals.

BRANDS/DIVISIONS/AFFILIATES: GLIADEL Wafer AQUAVAN Injection NAALADase Inhibitors GPI 1485

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Craig R. Smith, CEO David P. Wright, Pres./Chief Bus. Officer Andrew R. Jordan, CFO Michael Kelly, VP-Mktg. and Sales Margaret M. Contessa, Sr. VP-Human Resources Barbara S. Slusher, Sr. VP-Research Valerie Riddle, VP-Medical Affairs Nancy J. Linck, Sr. VP/Corp. Sec. Nancy J. Linck, General Counsel John P. Brennan, Sr. VP-Oper. Thomas C. Seoh, Sr. VP-Corp. Dev. Gregory M. Hockel, VP-Regulatory Affairs Andrew R. Jordan, Treas. Denise Battles, VP-Corp. Quality Jean-Marie Vallet, VP-Bus. Dev. William C. Vincek, VP-Pharmaceutical Dev. Craig R. Smith, Chmn.

Phone: 410-631-6300 Fax: 410-631-6338 Toll-Free: Address: 6611 Tributary St., Baltimore, MD 21224 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $12,932 ( 9 months) 2002 Profits: $-44,932 ( 9 months) Stock Ticker: GLFD 2001 Sales: $20,500 2001 Profits: $-60,300 Employees: 289 2000 Sales: $18,100 2000 Profits: $-47,100 Fiscal Year Ends: 12/31 1999 Sales: $21,600 1999 Profits: $-26,900 1998 Sales: $12,500 1998 Profits: $-29,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $483,333 Stock Purch. Plan: Second Exec. Salary: $320,000 ADVANTAGE: Alliance with Amgen/Novel treatments for brain cancer.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $210,000 Bonus: $90,000

Northeast: Y

International:



HAUSER INC

www.hauser.com


Y



Y Y

TYPES OF BUSINESS:

Profits: 11




Vitamins/Nutrition Manufacturing Color Enhancers Plant-Based Products Testing Services Chemical Engineering Services Contract Research and Development Bulk Fine Chemicals

Hauser, Inc. is a leading supplier of natural product extracts, botanical raw materials and related products to the dietary supplement market in the United States. Hauser manufactures extracts from raw botanical materials using its proprietary technologies in extraction and purification. The firm and its subsidiaries source, process and distribute products for sale to customers including branded product sellers. The company, through its subsidiary Hauser Technical Services, Inc., also provides interdisciplinary laboratory testing services, chemical engineering services and contract research and development. These services are principally marketed to the pharmaceutical, dietary supplement and food ingredient industries. Recent acquisitions include Wilcox Drug Company, Inc., a distributor of raw botanical materials, and ZetaPharm, Inc., a distributor of bulk fine chemicals, excipients and generic active ingredients. Hauser’s natural products include RoseOx and RoseEssential Plus antioxidants and TT550, a gingerbased anti-nausea product. The company relies on its patents, trade secrets and confidentiality agreements to develop and maintain its competitive position. Proprietary technologies include the firm’s dynamic liquid/solid extraction isolation process. In recent news, Hauser announced an agreement to license certain intellectual property and provide consulting services to Tisorex, a New Jersey company formed to produce bulk paclitaxel using raw material harvested from taxus bacata trees. Hauser offers employees flexible spending accounts, a prescription drug plan and life, accidental death and longterm disability insurance plans.

BRANDS/DIVISIONS/AFFILIATES: Hauser Chemical Research, Inc. Hauser Northwest, Inc. Shuster Laboratories Wilcox Drug Company Hauser Laboratories Hauser Technical Services, Inc. ZetaPharm, Inc. Botanicals International Extracts

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kenneth C. Cleveland, CEO Kenneth C. Cleveland, Pres. Tom Hanlon, CFO Peter Hafermann, VP-Mktg. & Sales Peg Bundegaard, Human Resources Brian Hufford, VP-Mfg. Suzanne Brink, Mgr.-Investor Rel. Diter W. Luelsdorf , Pres./CEO, ZetaPharm, Inc.

Phone: 310-669-2100 Fax: 310-637-3644 Toll-Free: Address: 2550 El Presidio St., Long Beach, CA 90810 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $58,800 ( 9 months) 2002 Profits: $27,700 ( 9 months) Stock Ticker: HAUS 2001 Sales: $66,700 2001 Profits: $-33,300 Employees: 310 2000 Sales: $81,200 2000 Profits: $-28,400 Fiscal Year Ends: 3/31 1999 Sales: $36,300 1999 Profits: $-29,700 1998 Sales: $32,000 1998 Profits: $-3,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $280,000 Stock Purch. Plan: Y Second Exec. Salary: $200,000 ADVANTAGE: Products come from natural sources such as tree extracts.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast: Y



Bonus: $ Bonus: $

Northeast: Y

International: Y



HEMAGEN DIAGNOSTICS INC

www.hemagen.com




Y Y

TYPES OF BUSINESS:

Profits: 9

Computers: Hardware: Software: Array s: Database Management:



Supplies-Diagnostic Kits

Hemagen Diagnostics, Inc. develops, manufactures and markets proprietary medical diagnostic test kits, or assays, used to aid in the diagnosis of autoimmune and infectious diseases, in general health assessment and for research purposes. The firm also develops, manufactures and markets materials for the manufacture of diagnostic test kits. In addition to internal development of products, Hemagen Diagnostics has sought to enter growth markets via the acquisition of synergistic companies, products and assets. The firm offers approximately 148 test kits that have been cleared by the FDA for sale in the United States. Brand-name products are sold worldwide through the company's sales force and through national and international distributors. Hemagen markets products in South America through its majority-owned Brazilian subsidiary, Hemagen Diagnosticos Comercio, Importacao e Exportacao, Ltd. In addition, the company sells certain of its products on a private-label basis to multinational distributors of medical diagnostic products. In recent news, the firm agreed to distribute two new electrolyte analyzers. The human analyzer, EasyLyte, and the veterinary analyzer, EasyVet, are manufactured by Medica Corporation. The analyzers test for sodium, potassium and chloride in whole blood, serum or urine and were evaluated and recognized by Hemagen to be the most effective instruments for its purposes. The firm is now able to offer a broader base of blood chemistry test package for the in-house laboratory.

BRANDS/DIVISIONS/AFFILIATES: Hemagen Diagnosticos Comercio EasyLyte EasyVet Analyst Bench-top Chemistry System ELISA Acute Phase Reactant Assays

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jerry L. Ruyan, CEO William P. Hayles, Pres. Deborah F. Ricci, CFO Ricardo M. de Oliveira, Sr. VP-Research and Dev. Ira Marks, Gen. Mgr., RAICHEM

Phone: 443-367-5500 Fax: 410-997-7812 Toll-Free: 800-495-2180 Address: 9033 Red Branch Rd., Columbia, MD 02451 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $7,177 ( 9 months) 2002 Profits: $-1,113 ( 9 months) Stock Ticker: HMGN 2001 Sales: $11,000 2001 Profits: $-2,200 Employees: 68 2000 Sales: $11,000 2000 Profits: $-5,100 Fiscal Year Ends: 12/31 1999 Sales: $14,600 1999 Profits: $-5,200 1998 Sales: $12,300 1998 Profits: $


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: FDA approval for 148 of its products.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:




Northeast: Y

International: Y



HEMISPHERX BIOPHARMA INC

www.hemispherx.net


Y



Y Y

TYPES OF BUSINESS:

Profits: 108




Drugs-RNA-Related Viral Detection Kits

In the course of almost three decades, Hemispherx Biopharma, Inc. has established a strong platform of laboratory, preclinical and clinical data for the purpose of successfully commercializing its portfolio of nucleic acid drugs for the treatment of viral diseases, immune system dysfunction and certain cancers. The company's proprietary drug technology utilizes specifically configured ribonucleic acid (RNA). Ampligen, the firm’s main product, is administered intravenously. The drug is presently undergoing Phase III clinical trials in the United States and Europe for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome. Hemispherx is heavily focused on seeking the required regulatory approvals that will allow the progressive introduction of Ampligen and other compounds. Currently, the firm holds more than 300 patents worldwide, with over 80 additional patent applications pending to provide further proprietary protection in various international markets. Hemispherx is also ramping up its focus on HIV and the complications of AIDS. A potential use of Ampligen may lie in treating HIV patients, especially those with a multi-drug resistant virus. Hemispherx is in preclinical stages of developing OragenT, a nucleic acid technology related to Ampligen. These drugs have the potential for becoming oral, broadspectrum treatments for various viral diseases such as HIV infection and chronic HBV infection. The company is involved in strategic alliances with Bioclones Limited, Biovail, the California Institute of Molecular Medicine, Chronix Biomedical and Laboratorios Del Dr. Esteve S.A. Recently, Hemispherx entered into an agreement with Sigma-Aldrich Fine Chemicals to manufacture an active ingredient for Ampligen. Hemis pherx offers employees a comprehensive range of benefits and competitive salaries.

BRANDS/DIVISIONS/AFFILIATES: OragenT Ampligen

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William A. Carter, CEO William A. Carter, Pres. Robert A. Peterson, CFO William A. Carter, Chief Scientific Officer David R. Strayer, Medical Dir. Carol A. Smith, Dir.-Mfg. and Process Dev. Josephine M. Dolhancryck, Treas. William A. Carter, Chmn.

Phone: 215-988-0080 Fax: 215-988-1739 Toll-Free: Address: One Penn Center, 1617 JFK Blvd., Philadelphia, PA 19103 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 800 ( 9 months) 2002 Profits: $-6,000 ( 9 months) Stock Ticker: HEB 2001 Sales: $ 400 2001 Profits: $-9,100 Employees: 48 2000 Sales: $ 800 2000 Profits: $8,600 Fiscal Year Ends: 12/31 1999 Sales: $ 700 1999 Profits: $12,300 1998 Sales: $ 400 1998 Profits: $7,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $456,608 Stock Purch. Plan: Second Exec. Salary: $174,591 ADVANTAGE: Holds many patents/Alliances with Anderson Clinical Research.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



HESKA CORP

www.heska.com


Y



Y

TYPES OF BUSINESS:

Profits: 152




Drugs-Animal Health & Pet Care Animal Health Products Veterinary Diagnostics Products and Services Monitoring Instruments

Heska Corp. focuses on the discovery, development and marketing of animal health care products. The company makes a concerted effort to use biotechnology to create a broad range of diagnostic, therapeutic and vaccine products to animals, primarily dogs, cats and horses. Heska also sells veterinary diagnostic and patient monitoring instruments and offer diagnostic services to veterinarians in the United States and Europe principally for companion animals. Its Diamond Animal Health subsidiary manufactures food animal vaccines as well as other food animal products that are marketed and distributed by other animal health companies. In addition, Diamond manufactures certain companion animal health products for marketing and sale by Heska. The firm recently shifted its product distribution strategy and expects to rely on independent distributors for a greater portion of domestic sales. In addition, Heska introduced a new test for early detection of canine kidney damage, the E.R.D.-Screen Urine Test, a rapid in-clinic immunoassay that detects trace amounts of albumin in urine, a condition believed to be associated with the early stages of renal disease.

BRANDS/DIVISIONS/AFFILIATES: Diamond Animal Health Solo Step CH Batch Test Strips E.R.D.-Screen Urine Test

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert B. Grieve, CEO James H. Fuller, COO James H. Fuller, Pres. Ronald L. Hendrick, CFO Mark Cicotello, VP-Human Resources Dan T. Stinchcomb, Exec. VP-Research and Dev. Carol T. Verser, Exec. VP-Bus. Dev. Carol T. Verser, Exec. VP-Intellectual Property

Phone: 970-493-7272 Fax: 970-437-5215 Toll-Free: 800-464-3752 Address: 1613 Prospect Pkwy., Fort Collins , CO 80525 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $33,619 ( 9 months) 2002 Profits: $-13,130 ( 9 months) Stock Ticker: HSKA 2001 Sales: $48,300 2001 Profits: $-18,700 Employees: 336 2000 Sales: $52,700 2000 Profits: $-21,900 Fiscal Year Ends: 12/31 1999 Sales: $51,200 1999 Profits: $-35,800 1998 Sales: $39,800 1998 Profits: $-44,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $297,499 Stock Purch. Plan: Y Second Exec. Salary: $255,149 ADVANTAGE: Successful product development/Veterinary focus.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Southeast:



Bonus: $23,174 Bonus: $18,540

Northeast: Y

International: Y



HI TECH PHARMACAL CO INC

www.hitechpharm.com


Y Y Y



Profits: 48


TYPES OF BUSINESS:



Drugs-Generic Nutritional Products Over-the-Counter Products Ophthalmic Products Manufacturing Contract Services Inhalation Products Diabetes Products

Hi-Tech Pharmacal Co., Inc. is a manufacturer and marketer of prescription, over-the-counter and nutritional products that are sold in liquid and semi-solid forms. The company is also a leading manufacturer of ophthalmic, optic and inhalation products and provides sterile manufacturing contract services. Hi-Tech currently markets in excess of 70 generic products to approximately 100 customers consisting of generic distributors, drug wholesalers, chain drug stores, mass merchandise chains and mail order companies. The company also markets a line of branded products primarily for people with diabetes, including Diabetic Tussin, DiabetiDerm, DiabetiSweet, DiabetiGest and DiabetiRinse. In addition, Hi-Tech markets other niche over-the-counter brands to the general health care marketplace under such brands as Kosher Care, Nasal Ease and Soothing Comfort. The firm and one of its directors each has a 21.25% interest in Marco HiTech JV Ltd., which markets raw materials for nutraceutical products and has licensed the patent rights to Huperzine and analogues from the Mayo Clinic. HiTech recently acquired SweetThoughts.com, an Internet site dedicated to providing health education, support and products for people with diabetes. In addition, the firm signed its first international distribution agreement for its branded products for diabetes. Dr. Po Pharmaceuticals, in alliance with the Diabetes Association, will market and distribute Hi-Tech’s DiabetiTussin line to doctors, drug stores and hospitals in Taiwan.

BRANDS/DIVISIONS/AFFILIATES: Steri-Med Bactrim Pediatric Suspension Rx Choice DiabetiTussin Huperzine A Albuterol Sulfate Inhalation Solution Marco HiTech JV, Ltd. SweetThoughts.com

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David S. Seltzer, CEO David S. Seltzer, Pres. Arthur S. Goldberg, CFO David S. Seltzer, Corp. Sec. Elan Bar-Giora, Exec. VP-Oper. David S. Seltzer, Treas.

Phone: 631-789-8228 Fax: 631-789-8429 Toll-Free: Address: 369 Bayview Ave., Amityville, NY 11701-2802 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $33,300 (12 months) 2002 Profits: $3,500 (12 months) Stock Ticker: HITK 2001 Sales: $29,600 2001 Profits: $2,400 Employees: 148 2000 Sales: $26,400 2000 Profits: $1,700 Fiscal Year Ends: 4/30 1999 Sales: $23,300 1999 Profits: $1,900 1998 Sales: $22,400 1998 Profits: $1,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $325,000 Bonus: $119,000 Stock Purch. Plan: Second Exec. Salary: $230,000 Bonus: $30,000 ADVANTAGE: With a long list of prescription and over-the-counter generic and branded products, Hi-Tech Pharmacal Co., Inc. continues to grow as one of the few niche generic manufacturers.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



HOLLIS-EDEN PHARMACEUTICALS

www.holliseden.com


Y




TYPES OF BUSINESS:



Drugs-Infectious Disease Drugs-Immune System Disorders Drugs-Hormonal Imbalances

Hollis -Eden Pharmaceuticals, Inc., a development-stage company, is engaged in the discovery, development and commercialization of products for the treatment of infectious diseases and other conditions resulting from immune system disorders and hormonal imbalances. Its initial technology efforts are focused on a series of potent hormones and hormone analogs that it believes are key components of the body's natural regulatory system. The firm seeks to use these compounds as a hormone replacement therapy to reestablish balance to the immune system in situations of dysregulation. Pre-clinical and early clinical studies have indicated that these compounds have the ability to significantly reduce a number of wellknown inflammatory mediators while increasing innate and adaptive immunity and reversing bone marrow suppression. The compounds are safe, cost-effective to manufacture and unlikely to produce resistance. The lead compound in this series is HE2000, currently in Phas e II trials for HIV, malaria and hepatitis B. HE2200 is entering Phase II trials to test response to vaccination in the elderly. HE2500 is in Phase II clinical trials for the treatment of cardiovascular disease. This product is under development in partnership with Aeson Therapeutics. In addition, the National Cancer Institute is exploring use of the drug as a treatment for cancer and HE2200 and HE2500 also have autoimmune indications. Moreover, Hollis -Eden has entered into a collaboration with the U.S. military to develop HE2100 for use as a radioprotectant. Hollis -Eden owns or has obtained more than 80 U.S. and foreign patents, with more than 130 applications pending. Recently, the company announced an update on its relationship with Aeson, of which it owns 25%. Hollis Eden has the option to purchase the remaining shares of the firm, but it has decided not to exercise this option.

BRANDS/DIVISIONS/AFFILIATES: Aeson Therapeutics, Inc. HE2000 HE2100 HE2200 HE2500 Aeson

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard B. Hollis, CEO Daniel D. Burgess, COO Richard B. Hollis, Pres. Daniel D. Burgess, CFO Robert L. Marsella, VP-Mktg. James M. Frincke, Chief Scientific Officer Robert W. Weber, Controller/Chief Acc. Officer Dwight R. Stickney, Medical Dir.-Oncology Eric J. Loumeau, VP/Corp. General Counsel Robert L. Marsella, VP-Bus. Dev. Christopher L. Reading, Exec. VP-Scientific Dev. Richard B. Hollis, Chmn.

Phone: 858-587-9333 Fax: 858-558-6470 Toll-Free: Address: 4435 Eastgate Mall, Ste. 400, San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-14,300 ( months) Stock Ticker: HEPH 2001 Sales: $ 2001 Profits: $-15,800 Employees: 44 2000 Sales: $ 100 2000 Profits: $19,500 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-15,300 1998 Sales: $ 1998 Profits: $-5,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Stock Purch. Plan: Y Second Exec. Salary: $264,000 ADVANTAGE: Expertise in the treatment of infectious diseases and immune system disorders.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $280,000 Bonus: $26,400

Northeast:

International:



HUMAN GENOME SCIENCES INC

www.hgsi.com


Y


Y


Profits: 234

Computers: Hardware: Softw are: Arrays: Database Management:

TYPES OF BUSINESS:


GROWTH PLAN S/SPECIAL FEATURES:

Drugs-Gene-Based Pharmaceutical and Biopharmaceutical Products Protein Drug Manufacturing

Human Genome Sciences, Inc. is engaged in the research and development of proprietary pharmaceutical and diagnostic products based on the discovery and understanding of the medical utility of genes. The firm, a leader in genetic research, possesses one of the largest databases of human genes and microbes in the world. It has developed the industry's first genomics -derived drugs to reach a stage of testing on humans. Human Genome Sciences has seven products in human clinical trials and two awaiting FDA approval to enter human clinical trials. Myeloid Progenitor Inhibitory Factor-1, known as MPIF-1, is a protein designed to protect blood cells from the toxic effects of several chemotherapy drugs. Keratinocyte Growth Factor-2, known as KGF-2 or Repifermin, is a protein designed to speed the repair of damage to the cells lining the mouth, throat, gastrointestinal tract and related tissues and to heal serious chronic wounds to the skin. Vascular Endothelial Growth Factor-2 is a genetherapy drug designed to regenerate the blood vessels of the heart and limbs. B Lymphocyte Stimulator is an immune stimulant that could lead to the improved treatment of immune deficiency disorders and certain types of leukemia and lymphoma. The company has developed one product, Lp-PLA2, with cooperation from GlaxoSmithKline, and has licensed another to Vascular Genetics, Inc. The firm is working toward becoming an independent, global and fully integrated biopharmaceutical company. The firm encourages employees to enhance their professional development by providing tuition reimbursement programs, encouraging attendance at professional conferences and sponsoring skill-building seminars.

BRANDS/DIVISIONS/AFFILIATES: Takeda Chemical Industries, Ltd. Medarex, Inc. Schering Corporation Synthelabo S.A. Merck KGaA Cambridge Antibody Technology, plc

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William A. Haseltine, CEO Steven C. Mayer, Sr. VP/CFO Jeanne M. Riley, VP-Strategic Mktg. Susan Bateson McKay, Sr. VP-Human Resources Craig A. Rosen, Exec. VP-Research and Dev. Michael R. Fannon, VP/CIO Alain D. Cappeluti, Controller Arthur C. Louie, VP-Medical Affairs James H. Davis, Corp. Sec. James H. Davis, General Counsel Fazal R. Kahn, VP-Oper. Ellen S. Baron, Sr. VP-Bus. Dev. David C. Stump, Sr. VP-Drug Dev. Reiner L. Gentz, Sr. VP-Protein Dev. Sally D. Bolmer, VP-Regulatory Affairs Steven M. Ruben, VP-Research

Phone: 301-309-8504 Fax: 301-309-8512 Toll-Free: Address: 9410 Key West Ave., Rockville, MD 20850 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,926 ( 9 months) 2002 Profits: $-159,871 ( 9 months) Stock Ticker: HGSI 2001 Sales: $12,800 2001 Profits: $-117,200 Employees: 1,010 2000 Sales: $22,100 2000 Profits: $-243,800 Fiscal Year Ends: 12/31 1999 Sales: $24,500 1999 Profits: $-42,200 1998 Sales: $29,600 1998 Profits: $-23,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $483,654 Bonus: $210,000 Stock Purch. Plan: Y Second Exec. Salary: $364,038 Bonus: $200,000 ADVANTAGE: Possesses one of the largest databases of human genes and microbes in the world/Partnerships with major drug firms.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



HUNTINGDON LIFE SCIENCES

www.huntingdon.com




Y Y Y

TYPES OF BUSINESS:

Profits: 8




Services-Labs/Testing Agricultural Chemical Development Programs Veterinary Medicines and Food Regulatory Assessment Programs Retrospective Testing of Existing Chemicals

Huntingdon Life Sciences Group is one of the world’s leading contract research organizations, providing product development services to the pharmaceutical, agrochemical, veterinary and biotechnology industries. The company provides leading technology and support to its clients in non-clinical safety testing of new compounds in early stage development and assessment. In addition, Huntingdon tests the effects of these compounds on the environment. The company's services are designed to meet the regulatory requirements of governments around the world. Huntingdon offers drug development services for many therapeutic areas including anti-cancer, antiinflammatory, cardiovascular, central nervous system, hormones and fertility. Recently, the firm became a wholly owned subsidiary of Life Sciences Research, Inc.

BRANDS/DIVISIONS/AFFILIATES: Life Sciences Research, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Andrew H. Baker, CEO Brian Cass, COO Richard Michaelson, CFO Richard Michaelson, Corp. Sec. Andrew H. Baker, Chmn.

Phone: 732-873-2550 Fax: 732-873-3992 Toll-Free: Address: 401 Hackensack Ave., Hackensack, NJ 07601 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $84,700 ( 9 months) 2002 Profits: $1,100 ( 9 months) Stock Ticker: HTDLY.PK 2001 Sales: $99,200 2001 Profits: $-8,400 Employees: 1,387 2000 Sales: $88,600 2000 Profits: $-9,800 Fiscal Year Ends: 12/31 1999 Sales: $81,500 1999 Profits: $-5,700 1998 Sales: $73,700 1998 Profits: $-34,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: One of the world's leading contract research organizations.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



HYBRIDON INC

www.hybridon.com


Y



Profits: 90


TYPES OF BUSINESS:



Drugs-AIDS, Cancer and Hepatitis Antisense Technology Synthetic DNA

Hybridon, Inc. is a leading company engaged in the discovery and development of novel therapeutics and diagnostics using synthetic DNA. Its activities are based on four technologies: proprietary immunomodulatory oligonucleotide (IMO) technology, which uses synthetic DNA to modulate responses of the immune system; antisense technology, which uses synthetic DNA to inhibit the production of disease-associated proteins at the cellular level; cancer therapy potentiation, which uses synthetic DNA to enhance the anti-tumor activity of certain marketed anticancer drugs; and Cyclicon technology, which uses novel synthetic DNA structures in drug target validation and drug discovery. The firm's advanced antisense chemistries have several advantages over earlier antisense drug candidates, including fewer side effects, greater stability in the body, greater potency and greater potential for multiple routes of administration, including oral delivery. Hybridon's IMO compounds can be used as monotherapies in the treatment of conditions such as cancer, asthma, allergies and infectious diseases, as well as in combination therapies with antibodies, vaccines and chemotherapies. Currently, the firm is developing GEM 231, a second-generation antisense drug used to potentiate the anti-tumor activity of irinotecan. The company is also bringing its lead IMO preclinical candidate, HYB 2055, into trials. In mid-2001, Hybridon formed a licensing agreement with Isis Pharmaceuticals, allowing Isis to use the patents for its antisense chemistry and delivery applications. The company has also collaborated with EpiGenesis Pharmaceuticals to develop up to five antisense drugs for the treatment of respiratory diseases. Notably, the firm was recently ranked among the Top 50 Most Innovative Small Companies by Inc. Magazine.

BRANDS/DIVISIONS/AFFILIATES: Cyclicons GEM 231 IMO Technology Camptosar HYB 2055

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen R. Seiler, CEO Sudhir Agrawal, Pres. Robert G. Andersen, CFO Sudir Agrawal, Chief Scientific Officer Robert G. Andersen, VP-Oper. Felice A. de Jong, Dir.-Bus. Dev. Jin-yan Tang, VP-Chemistry Timothy M. Sullivan, VP-Preclinical Drug Dev. R. Russell Martin, Sr. VP-Drug Dev.

Phone: 617-679-5500 Fax: 617-679-5592 Toll-Free: Address: 345 Vassar St., Cambridge, MA 02139 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $27,873 ( 9 months) 2002 Profits: $20,221 ( 9 months) Stock Ticker: HYBN 2001 Sales: $1,600 2001 Profits: $-5,300 Employees: 22 2000 Sales: $ 573 2000 Profits: $-2,923 Fiscal Year Ends: 12/31 1999 Sales: $1,180 1999 Profits: $-10,500 1998 Sales: $1,623 1998 Profits: $-19,793


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $345,000 Stock Purch. Plan: Y Second Exec. Salary: $251,000 ADVANTAGE: Holds many U.S. and European patents relating to antisense technology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $300,000 Bonus: $172,500

Northeast: Y

International:



HYCOR BIOMEDICAL INC

www.hycorbiomedical.com

Industry Group Code: 325413 Ranks within this company's industry group: Sales: 12 Drugs: Drugs: Contract Manufacturing: Drug Deliv ery Systems: Nutriceuticals:



Y Y

TYPES OF BUSINESS:

Profits:




Diagnostics Autoimmune Diagnostics Allergy Diagnostics

Hycor Biomedical researches, develops and manufactures medical diagnostic products for clinical laboratories and specialty physicians, with a particular focus on allergy and autoimmune testing and urinalysis products. It operates two wholly-owned subsidiaries, Hycor Biomedical GmbH and Hycor Biomedical, Ltd. The company’s main product is its leading KOVA Microscopic Urinalysis product, which examines human urine for specific signs of disease. Hycor’s allergy diagnostic product line, which includes HYTEC 480 and 288, features radioimmunoassays and enzymatic immunoassays that test for reactions to more than 900 allergens. Furthermore, the company’s smallest division, which is devoted to autoimmune diagnostics, manufactures devices that test for systemic lupus erythematosus and rheumatoid arthritis. HY-TEC 288, the world’s first blood-based automated allergy and autoimmune disease testing system, permits eight autoimmune factors and hundreds of allergies in a single run. The firm also received FDA marketing approval for its rheumatoid factor IgA ELISA autoimmune test, which will help diagnose rheumatoid arthritis. In recent news, Hycor Biomedical announced the renewal of a three-year supply agreement with Laboratory Corporation of America Holdings. Under this agreement, Hycor will continue to serve as the primary supplier of in vitro allergy testing reagents to Laboratory Corp.

BRANDS/DIVISIONS/AFFILIATES: Cogent Diagnostics, Ltd. KOVA HY-TEC 288 HY-TEC 480 ELISA Hycor Biomedical, Ltd. Hycor Biomedical GmbH

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. J. David Tholen, Pres. J. David Tholen, CEO Reginald P. Jones, Sr. VP/CFO Mary Jo Deal, Sr. VP-Mktg. and Sales Thomas M. Li, VP-Research and Dev. Nelson F. Thune, Sr. VP-Oper. and Planning Reginald P. Jones, Treas.

Phone: 714-933-3000 Fax: 714-933-3222 Toll-Free: 800-382-2527 Address: 7272 Chapman Ave., Garden Grove, CA 92841 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $13,774 ( 9 months) 2002 Profits: $ 992 ( 9 months) Stock Ticker: HYBD 2001 Sales: $17,300 2001 Profits: $ Employees: 149 2000 Sales: $17,072 2000 Profits: $ 981 Fiscal Year Ends: 12/31 1999 Sales: $18,400 1999 Profits: $ 200 1998 Sales: $18,400 1998 Profits: $-6,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $235,955 Bonus: $27,612 Stock Purch. Plan: Y Second Exec. Salary: $219,253 Bonus: $25,657 ADVANTAGE: Maker of the world's first blood-based automated allergy and autoimmune disease testing system.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International: Y



HYSEQ INC

www.hyseq.com


Y



Profits: 191


TYPES OF BUSINESS:

Y



Drugs-Acute and Chronic Disease Proprietary Chip Technology Biopharmaceuticals DNA Sequencing

Hyseq Pharmaceuticals, Inc., formerly Hyseq, Inc., is engaged in the research and development of novel biopharmaceutical protein-based products for the treatment of human disease from its collection of proprietary genes discovered using its high-throughput signature-by-hybridization platform. The company is researching several product candidates to treat a variety of serious diseases and medical conditions. These product candidates target markets including cardiovascular disease, cancer, infectious disease and oncology. Hyseq intends to develop and commercialize these types of product candidates on its own and in collaboration with other biotechnology or pharmaceutical companies. The company has focused primarily on fulllength gene sequencing, patenting, bioinformatics, cloning and early-stage research activities to prioritize potential therapeutic protein candidates. It has filed patent applications on approximately 10,000 full-length human gene sequences. Hyseq is involved in collaborations with Aurora Biosciences Corporation, Kirin Brewery Co., Ltd. and Deltagen, Inc. Hyseq has also entered into a collaboration with Amgen, Inc., with the goal of developing and commercializing alfimeprase, a thrombolytic enzyme, for the treatment of peripheral arterial occlusion (PAO) and other cardiovascular indications. Preclinical studies suggest that alfimeprase is a promising agent for dissolving blood clots and may be well-suited for the PAO indication. Recently, the company entered into a definitive merger agreement with VARIAGENICS, Inc.

BRANDS/DIVISIONS/AFFILIATES: GeneSolutions, Inc. IL-1Hy1 CD39L4 HyChip Hyseq, Inc. VARIAGENICS, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ted W. Love, CEO Ted W. Love, Pres. Peter S. Garcia, Sr. VP/CFO Linda A. Fitzpatrick, Sr. VP-Human Resources Walter Funk, VP-Research Lily Rin-Laures, Sr. VP/General Counsel Nina V. Giles, VP-Bus. Dev. Luis Peña, VP-Product Dev. George B. Rathmann, Chmn.

Phone: 408-524-8100 Fax: 408-524-8141 Toll-Free: Address: 670 Almanor Ave., Sunnyvale, CA 94085 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $22,915 ( 9 months) 2002 Profits: $-28,580 ( 9 months) Stock Ticker: HYSQ 2001 Sales: $24,600 2001 Profits: $-36,500 Employees: 224 2000 Sales: $15,604 2000 Profits: $-22,253 Fiscal Year Ends: 12/31 1999 Sales: $6,400 1999 Profits: $-18,500 1998 Sales: $9,600 1998 Profits: $-16,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $491,221 Stock Purch. Plan: Y Second Exec. Salary: $265,000 ADVANTAGE: Heavy research and development relating to DNA sequencing.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



ICN PHARMACEUTICALS INC

www.icnpharm.com


Y Y



Profits: 29


TYPES OF BUSINESS:



Drugs-Viral Disease Oncology Drugs Dermatology Drugs Central Nervous System Compounds Pain Management Drugs Over-The-Counter Drugs Nutritional Products HIV Treatment Drugs

ICN Pharmaceuticals is a global, research-based pharmaceutical company that primarily develops, manufactures and markets a broad spectrum of pharmaceutical, over-the-counter and nutritional products under the ICN brand name. The firm operates in over 90 countries, primarily in North and Latin America, Europe and the Pacific Rim. The company’s pharmaceutical products treat viral and bacterial infections, diseases of the skin, neuromuscular disorders, cancer, cardiovascular disease, diabetes and psychiatric disorders. The firm’s cornerstone product is Ribavirin, a drug for the treatment of chronic hepatitis C. Other products offered by ICN include Insta-Glucose for the treatment of hypoglycemia, Limbitrol for depression and Dalmane for sleeping disorders. Currently, the firm’s research and development efforts are focused on antiviral and anticancer drugs. These program areas include hepatitis C, hepatitis B, HIV and cancer. ICN also has research and development efforts emphasizing dermatology, central nervous system compounds and pain management. Through the course of its history, the firm has developed a longstanding expertise in nucleic acid chemistry. ICN owns one of the largest libraries of nucleosides (components of DNA) in the pharmaceutical industry. The firm recently acquired a promising, liver-targeting compound from Metabasis Therapeutics that could be utilized for the treatment of hepatitis B. ICN also recently announced plans to divide the company into three separate entities: Ribapharm, ICN International and ICN Americas. The spin-off of Ribapharm has been completed, but the divestiture has sparked a controversial proxy contest among shareholders.

BRANDS/DIVISIONS/AFFILIATES: ICN Biomedicals Ribavirin Levovirin Insta-Glucose Limbitrol Dalmane Efudex Ribapharm

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert W. O'Leary, CEO Timothy C. Tyson, COO Timothy C. Tyson, Pres. Barry G. Bailey, CFO James McCoy, Exec. VP-Human Rel. Johnson Yiu-Nam Lau, Sr. VP-Research and Dev. Gregory Keever, Corp. Sec. Gregory Keever, General Counsel Bill A. MacDonald, Exec. VP-Strategic Planning Alan F. Charles, Exec. VP-Public Rel. Joseph T. Schepers, VP-Investor Rel. David Watt, Exec. VP, Biomedicals Group

Phone: 714-545-0100 Fax: 714-641-7223 Toll-Free: 800-548-5100 Address: 3300 Hyland Ave., Costa Mesa, CA 92626 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to ge t the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $686,411 ( 9 months) 2002 Profits: $-34,172 ( 9 months) Stock Ticker: ICN 2001 Sales: $858,100 2001 Profits: $64,100 Employees: 11,970 2000 Sales: $800,300 2000 Profits: $90,200 Fiscal Year Ends: 12/31 1999 Sales: $747,400 1999 Profits: $118,600 1998 Sales: $838,100 1998 Profits: $-352,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $901,446 Bonus: $1,009,612 Stock Purch. Plan: Second Exec. Salary: $587,586 Bonus: $287,200 ADVANTAGE: Continues to grow internationally through acquisitions including an expanding market share in Europe.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Southeast:



Northeast: Y

International: Y



ICON PLC

www.iconclinical.com




Y Y Y

TYPES OF BUSINESS:

Profits: 2



Y


Services-Clinical Trial Research Data Management and Analysis Laboratory Services Regulatory Affairs Consulting

ICON provides clinical research services to the pharmaceutical and biotechnology industries throughout Europe, North America and the Pacific Rim. ICON’s global presence allows it to conduct clinical research trials on several scales, from local tests to worldwide programs. The firm deals largely with oncological and neurological testing and manages several aspects of the clinical trial process. Study design, data management and analysis and laboratory services are all provided by ICON, as is regulatory affairs consulting. The company has developed a broad range of Phase I to IV support services and was the first firm of its kind awarded ISO 9002 quality certification. The firm’s approach to project management emphasizes the apportionment of an exclusively dedicated multidisciplinary team for each individual project undertaken by ICON. As a result, the company has been able to maintain several strong client-provider relationships. Beyond focusing on client relations, ICON is actively acquiring firms in an attempt to continue to expand its multinational presence. Recently, ICON announced the intention to acquire Barton & Polansky Associates, Inc. (BPA) and its sister company, Managed Clinical Solutions, Inc. (MCS). BPA specializes in clinical research services for immuno-suppressant drugs. MCS will operate as a new and separate division of ICON providing contract staffing solutions to the pharmaceutical research industry. Due to the multinational nature of ICON, its employees are encouraged to speak a number of languages. Training at the firm is comprehensive and intense and covers introductory issues, study-specific issues, procedure, quality control and computing. Personnel are evaluated twice yearly.

BRANDS/DIVISIONS/AFFILIATES: Pacific Research Associates, Inc. YRCR, Ltd. S.A.R.L. UCT, Inc. Protocole Barton & Polansky Associates, Inc. Managed Clinical Solutions, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John Climax, CEO William Taaffe, Pres. Peter Gray, CFO Eimear Kenny, Human Resources Dir. Allan Morgan, Chief Medical Dir. William Taaffe, COO-U.S. Oper. Ronan Lambe, Chmn. Markus H. Weissbach, Pres.-European Oper.

Phone: +353-1-2161-100 Fax: +353-1-2161-200 Toll-Free: Address: S. County Business Park Leopardstown, Dublin, Ireland

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $156,600 (12 months) 2002 Profits: $14,200 (12 months) Stock Ticker: ICLR 2001 Sales: $116,200 2001 Profits: $11,000 Employees: 1,300 2000 Sales: $80,800 2000 Profits: $6,100 Fiscal Year Ends: 5/31 1999 Sales: $59,900 1999 Profits: $8,100 1998 Sales: $45,200 1998 Profits: $4,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Global presence in clinical trial services.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Bonus: $ Bonus: $

Southeast: Y



Northeast: Y

International: Y



ICOS CORPORATION

www.icos.com


Y



Profits: 227


TYPES OF BUSINESS:



Drugs-Blood Flow Biopharmaceutical Products

ICOS Corporation researches and develops new pharmaceuticals, determining points of intervention within various diseases so as to create specific and efficacious drugs. The company combines its capabilities in molecular, cellular and structural biology, high-throughput drug screening, medicinal chemistry and gene expression profiling to develop innovative products with significant commercial potential. This integrated approach has been applied to erectile dysfunction and other urologic dis orders, sepsis, pulmonary arterial hypertension and other cardiovascular diseases and inflammatory diseases. Products being developed by the company include Cialis for male erectile dysfunction, LeukArrest for ischemic stroke, Pafase and IC14 for sepsis, IC747 for psoriasis and other chronic inflammatory diseases and Sitaxsentan for pulmonary arterial hypertension. ICOS’s expansion plans are concentrated mostly toward the development of its products and receiving marketing approval for them. Significant collaboration partners include Eli Lilly and Company, Suntory Ltd., Texas Biotechnology Corp. and Biogen, Inc. ICOS and Biogen are working to develop and commercialize the orally active, small molecule LFA-1 antagonists as oral therapeutics for the treatm ent of inflammatory conditions. The companies will cross-license LFA-1 antagonist technology and patents, including IC747. Employees are offered tuition reimbursement, an on-site child care facility and credit union membership. Additionally, the firm offers organized team sports, company picnics, an annual golf tournament and company mixers.

BRANDS/DIVISIONS/AFFILIATES: Cialis Pafase Sitaxsentan LeukArrest Afferon Corp. Array BioPharma, In c. Texas Biotechnology Corporation Biogen, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul N. Clark, CEO Paul N. Clark, Pres. Michael A. Stein, CFO Leonard M. Blum, VP- Mktg. & Sales Michelle Yetman, Dir.-Human Resources Patrick W. Gray, VP-Science Gary L. Wilcox , Corp. Sec. Gary L. Wilcox , Exec. VP-Oper. Clifford J. Stocks, VP-Bus. Dev. Thomas P. St. John, VP-Therapeutic Dev. W. Michael Gallatin, VP-Scientific Dir.

Phone: 425-485-1900 Fax: 425-489-0356 Toll-Free: Address: 22021 20th Ave. SE, Bothell, WA 98021 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $66,721 ( 9 months) 2002 Profits: $-114,156 ( 9 months) Stock Ticker: ICOS 2001 Sales: $93,400 2001 Profits: $-80,200 Employees: 469 2000 Sales: $90,700 2000 Profits: $-97,900 Fiscal Year Ends: 12/31 1999 Sales: $79,600 1999 Profits: $-33,200 1998 Sales: $110,800 1998 Profits: $31,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $600,000 Stock Purch. Plan: Y Second Exec. Salary: $440,000 ADVANTAGE: Expansion through the development of strategic alliances.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



ID BIOMEDICAL CORPORATION

www.idbiomed.com


Y



Y

TYPES OF BUSINESS:

Profits: 111




Drugs-Vaccines Pharmaceutical Development Diagnostics Gene-Based Testing Platform

ID Biomedical Corporation specializes in the development of pharmaceuticals geared towards gene-based diagnostic testing and subunit vaccines. Drug-resistant bacteria, tuberculosis, HIV/AIDS, group A streptococcal disease and e.coli are among the areas in which ID Biomedical focuses. The firm’s proprietary Cycling Probe Technology has led to the development of Velogene, a gene-based testing platform intended to identify diseases in a more rapid, simple and cost-effective manner. Velogene is the first FDA-cleared probe asay for detection of the mecA gene in staphylococcus aureus isolated from a culture. ID Vaccine, a subsidiary of the company, is currently testing a vaccine for group A streptococcus in a human clinical trial partnership with the National Institutes of Health (NIH). The NIH is also providing research funding for the development of a vaccine for HIV/AIDS. Through a partnership with Pasteur Merieux, Serums and Vaccins S.A., the largest vaccine firm in the world, ID Vaccine is furthering its efforts in developing a vaccine for tuberculosis. E.coli research efforts are being conducted alongside the University of British Columbia. ID Biomedical recently announced positive results on its two Phase II Clinical Trials of FluINsure, its intranasally delivered influenza vaccine. The firm also received a favorable response from the U.K.'s Medicines Control Agency to conduct a Phase II human challenge study for the FluINsure vaccine. As a result, the company will pursue its planned Phase II safety, immunogenicity and challenge studies in London, England. The firm's corporate culture encourages leadership, and ID Biomedical claims to empower its workers with decision-making skills. Education upgrades and the acquisition of new skills are encouraged within the workplace. Competitive compensation and benefit packages are offered, and job availability information can be obtained through the firm's web site.

BRANDS/DIVISIONS/AFFILIATES: Velogene ID Vaccine StreptAvax FluINsure Cycling Probe Technology

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Anthony F. Holler, CEO Todd R. Patrick, COO Anthony F. Holler, Pres. Todd R. Patrick, CFO Ame L. Holden, Mktg. Dir. Dawn Caiarelli, Human Resources George H. Lowell, Chief Scientific Officer Louis Fries, Clinical and Regulatory Affairs Deborah L. Bowers, Corp. Sec. Dean Linden, Mgr.-Corp. Comm. Robert N. Bryan, VP-Genomics Research and Dev. David S. Burt, VP-Vaccine Research Barbara Alford-Cassel, VP-Quality Systems Mark Reddish, VP-Product Dev.

Phone: 604-431-9314 Fax: 604-431-9378 Toll-Free: Address: 1510-800 W. Pender, Vancouver, BC V6C 2V6 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $6,000 ( 6 months) 2002 Profits: $-3,400 ( 6 months) Stock Ticker: IDBE 2001 Sales: $1,600 2001 Profits: $-9,200 Employees: 30 2000 Sales: $8,900 2000 Profits: $ 300 Fiscal Year Ends: 12/31 1999 Sales: $ 200 1999 Profits: $-4,500 1998 Sales: $ 100 1998 Profits: $-5,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Effective testing technologies/Development partnerships.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



IDEC PHARMACEUTICALS CORP

www.idecpharm.com


Y Y



Profits: 25


TYPES OF BUSINESS:


Y Y


Drugs-Cancer, Autoimmune Disease and Inflammatory Disease Biopharmaceuticals Contract Drug Manufacturing Contract Drug Development Consulting and Services

IDEC Pharmaceuticals researches and develops drug therapies for the treatment of cancer, autoimmune and inflammatory diseases. The firm’s products focus on acting through the immune system's mechanisms by binding to specific, readily targeted immune cells in the patient's blood or lymphatic system. IDEC also provides contract manufacturing services in which it supports other companies’ manufacturing needs, including quality assurance and control, engineering, regulatory affairs, legal services and validation services. The company manufactures Rituxan, a treatment for non-Hodgkin’s lymphoma (immune system tumors). Rituxan was the first monoclonal antibody approved by the FDA to treat cancer and has achieved sales revenues of over $400 million annually. IDEC recently received FDA approval for ZEVALIN, a radioimmunotherapy that it hopes will supplement Rituxan as another drug targeting cancer. In addition, the firm has a number of drugs under various stages of development, including IDEC-131 for the treatment of systemic lupus, IDEC-151 for rheumatoid arthritis, IDEC-114 for psoriasis and IDEC-152 for asthma. In recent news, the FDA has approved the expanded use of Rituxan for the treatment of low-grade non-Hodgkin's Lymphoma. IDEC is pursuing this new market expansion opportunity in conjunction with Genentech, Inc., a biotechnology company that develops, manufactures and markets human pharmaceuticals. In another development, IDEC recently extended its collaborative agreement with Mitsubishi Pharma Corporation to support clinical development of IDEC-114 in psoriasis. Under the terms of the agreement Mitsubishi Pharma will share in the costs of the clinical development of the product and will conduct parallel clinical trials in psoriasis in Japan. The firm offers its employees vision care benefits as well as financial assistance for continuing education. Credit union membership and recreation discounts to attractions and events are also offered.

BRANDS/DIVISIONS/AFFILIATES: Rituxan ZEVALIN PRIMATIZED PROVAX Taisho Pharmaceuticals PAGE-4 Plasmid DNA Genentech, Inc. Mitsubishi Pharma Corporation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William H. Rastetter, CEO William R. Rohn, COO William H. Rastetter, Pres. Phillip M. Schneider, CFO Louann Lee, Associate Dir.-Human Resources Nabil Hanna, Chief Scientific Officer Paul Grint, Chief Medical Officer Kenneth J. Woolcott, VP-General Counsel Connie L. Matsui, VP-Planning & Resource Dev. Wolfgang Berthold, Sr. VP-Biopharmaceutical Sciences John Geigert, VP-Quality Christine A. White, VP-Clinical Oncology & Hematology Mark C. Wiggins, VP-Bus. Dev.

Phone: 858-431-8500 Fax: 858-431-8750 Toll-Free: Address: 3030 Callan Rd., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $280,570 ( 9 months) 2002 Profits: $103,496 ( 9 months) Stock Ticker: IDPH 2001 Sales: $272,700 2001 Profits: $101,700 Employees: 692 2000 Sales: $154,700 2000 Profits: $48,100 Fiscal Year Ends: 12/31 1999 Sales: $118,000 1999 Profits: $43,200 1998 Sales: $87,000 1998 Profits: $21,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $515,070 Bonus: $239,121 Stock Purch. Plan: Y Second Exec. Salary: $375,842 Bonus: $141,467 ADVANTAGE: Focused on developing targeted therapies for the treatment of cancer and autoimmune diseases.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



IDEXX LABORATORIES INC

www.idexx.com




Y Y

TYPES OF BUSINESS:

Profits: 1


Y


Y


Veterinary Laboratory Testing and Consulting Services-Labs/Testing Diagnostics Veterinary Mail Order Pharmacy Test Kits and Diagnostics for Animals Consulting Services Practice Management Software Computed Radiography Systems

IDEXX Laboratories is a worldwide leader in providing diagnostic, detection and information products for the animal health industry. Products and services include biology and chemistry-based detection systems, laboratory testing services, veterinary practice information management software systems and Internet portal and application service providers. The company’s test kits, which diagnose animal diseases such as feline leukemia viruses in cats and heartworm diseases in dogs, are based on immunoassay technology that utilizes antibodyantigen reactions. The firm also operates VetConnect.com, an Internet network for veterinarians and their clients. It provides online access to veterinary textbooks, e-commerce between businesses and access to test results from the company’s laboratories. In addition, IDEXX provides rapid microbiological test kits for evaluating milk safety and water quality. The company’s Colilert test is used by over 90% of U.S. state health laboratories to detect the E. coli bacteria in water. IDEXX’s acquisition of U.K.-based Genera Pharmaceuticals helped strengthen the company’s water testing division. In recent news, the firm’s milk residue testing system received U.S. FDA approval. The Parallux Beta Lactam Assay is the only rapid residue test in the world able to detect all six beta lactam antibiotic residues at FDA tolerance levels in a single test. In another development, IDEXX Veterinary Services, Inc., a subsidiary of the company, entered the digital radiography business through an agreement with Orex Computed Radiography, Ltd. Under the agreement, computed radiography products developed and manufactured by Orex will be sold exclusively in the worldwide veterinary market by IDEXX. The computed radiography system eliminates the need for conventional film and chemicalbased darkroom processing and allows veterinarians to digitally store, enhance and transmit images. IDEXX offers its workers performance bonuses, a tuition assistance program, an employee referral program and personal growth leave.

BRANDS/DIVISIONS/AFFILIATES: Colilert Genera Pharmaceuticals Cardiopet Incorporated VetConnect, Inc. TD Acquisition Corp. VetTest IDEXX Veterinary Services, Inc. Orex Computed Radiography, Ltd.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jonathan W. Ayers, CEO Jonathan W. Ayers, Pres. Merilee Raines, VP-Finance Jennine Cannizzo, VP-Human Resources Erwin F. Workman, Jr., Exec. VP/Chief Scientific Officer Conan R. Deady, VP/Sec. Conan R. Deady, VP/General Counsel Merilee Raines, Treas. Roland H. Johnson, VP Louis W. Pollock, Sr. VP Robert S. Hulsy, VP Salvator S. Fratoni, VP

Phone: 207-856-0300 Fax: 207-856-0346 Toll-Free: Address: One IDEXX Dr., Westbrook, ME 04092 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $290,949 ( 9 months) 2002 Profits: $27,792 ( 9 months) Stock Ticker: IDXX 2001 Sales: $386,100 2001 Profits: $37,600 Employees: 2,170 2000 Sales: $367,400 2000 Profits: $36,600 Fiscal Year Ends: 12/31 1999 Sales: $358,400 1999 Profits: $32,600 1998 Sales: $321,700 1998 Profits: $-15,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $500,000 Stock Purch. Plan: Y Second Exec. Salary: $305,135 ADVANTAGE: Vast line of products and services/Worldwide distribution.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $280,000 Bonus: $134,400

Northeast: Y

International: Y



IGEN INTERNATIONAL INC

www.igen.com



Y Y


Y Y

TYPES OF BUSINESS:

Profits: 17




Equipment-Diagnosis Genomics Proteomics

IGEN International, Inc. develops and markets products that incorporate its proprietary electrochemiluminescence technology (ORIGEN), which permits the detection and measurement of biological substances. The product offers a unique combination of speed, sensitivity, flexibility and throughput in a single platform. ORIGEN is incorporated into instrument systems and related consumable reagents, and the firm offers assay development and other services used to perform analytical testing. Products based on this technology address markets including life science (drug discovery and development), clinical testing (in vitro diagnostic testing) and industrial testing of food and environmental samples for safety and quality assurance, as well as products for fighting bioterrorism, agricultural products and animal health testing. IGEN's products are sold and placed primarily through its licensing arrangement with Roche Diagnostics, the leading provider of clinical diagnostics products in the world. Roche's immunoassay systems include Elecsys 1010 and Elecsys 2010. IGEN's M-SERIES System is a product line for use by pharmaceutical and biotechnology companies in drug discovery and development. The system is used in all phases of discovery, including validating targets identified through genomics, screening of compounds generated through combinatorial chemistry, re-testing and optimization of lead compounds and clinical trial testing of drug candidates. M-SERIES products include the modular TRICORDER detection tool and the 384 Analyzer. IGEN is also commercializing the PATHIGEN panel of tests for salmonella and other food and water disease-causing pathogens. Recently, ORIGEN technology was adopted in a new ultra-sensitive test for the detection of hepatitis B virus mutants. In other news, the company launched a new M-SERIES application to facilitate the development of monoclonal antibody therapies.

BRANDS/DIVISIONS/AFFILIATES: PATHIGEN ORIGEN TRICORDER M-SERIES ORI-TWIST ORI-TAG BioSoftware Elecsys

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Samuel J. Wohlstadter, CEO Richard J. Massey, COO Richard J. Massey, Pres. George V. Migausky, VP/CFO Samuel J. Wohlstadter, Chmn.

Phone: 301-869-9800 Fax: 301-947-6990 Toll-Free: 800-336-4436 Address: 16020 Industrial Dr., Gaithersburg, MD 20877 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $42,000 (12 months) 2002 Profits: $-42,500 (12 months) Stock Ticker: IGEN 2001 Sales: $31,362 2001 Profits: $-43,253 Employees: 336 2000 Sales: $20,700 2000 Profits: $-32,400 Fiscal Year Ends: 3/31 1999 Sales: $14,900 1999 Profits: $-13,300 1998 Sales: $13,400 1998 Profits: $-11,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Unique technology.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $250,000 Bonus: $200,000

Northeast: Y

International: Y



ILEX ONCOLOGY INC

www.ilexoncology.com

Industry Group Code: 325412 Ranks w ithin this company's industry group: Sales: 88 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y Y



Y Y

TYPES OF BUSINESS:

Profits: 236



Y Y


Drugs-Cancer Anticancer Drug Development Contract Research Services Small-Scale Contract Manufacturing Clinical Trials Monitoring Clinical Results Submission Services

ILEX Oncology manufactures drugs and offers services aimed at the prevention and treatment of cancer. Through its ILEX Products division, the company researches and develops a line of therapeutic drugs, which include CAMPATH for the treatment of chronic lymphocyctic leukemia and multiple sclerosis, CLOFAREX for acute/pediatric leukemias and Apomine for solid tumors. The firm’s ILEX Oncology Services subsidiary provides pharmaceutical and biotechnology companies with contract research drug development services, n i cluding chemistry and toxicology services, small-scale manufacturing for clinical trials, clinical protocol organization design, monitoring clinical trials and preparation of regulatory submissions. ILEX also conducts drug development research, targeted medicinal chemistry and preclinical studies in the fields of angiogenesis inhibition and apoptosis. The firm is developing a pipeline of compounds to treat both advanced-stage cancers and early-stage cancers or premalignant conditions. The diversification of its products is one of its key strategies, as is maintaining one of the most experienced drug development organizations for anticancer drugs in the industry. Another strategic advantage is that ILEX office locations in both the U.S. and Europe enable the company to conduct global clinical trials and process regulatory applications simultaneously in both markets. Recently, ILEX Oncology signed a sublicensing agreement with Ventana Medical Systems to commercialize CAMPATH. The company also launched a Phase I/II trial to evaluate the effects of Apomine in postmenopausal women with osteoporosis.

BRANDS/DIVISIONS/AFFILIATES: CAMPATH ILEX Oncology Services, Inc. OXYPRIM ILX-295501 CLOFAREX ILX23-7553 Apomine Symphar S.A.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jeffrey H. Buchalter, CEO Ze'ev Shaked, Exec. VP/COO Jeffrey H. Buchalter, Pres. Mark P. Mellin, Sr. VP/CFO John Barnes, Sr. Dir.-Human Resources Glenn C. Rice, VP-Research, ILEX Products Don York, Sr. Dir.-IT Terrence A. Rugg, VP-Medical Affairs, ILEX Oncology Services Ronald G. Tefteller, VP/General Counsel Michael T. Dwyer, Sr. VP-Admin. Ian W.D. Clements, VP-Corp. Dev. and Commercial Oper. Corey H. Levenson, Sr. Dir-Tech. Assessment Craig A. Tooman, Sr. VP-Corp. Comm. Timothy M. Ruane, Sr. VP-Bus. Mgmt. Al Jecminek, VP-Licensing and Intellectual Property William D. Mikrut, VP-Clinical Oper. Kathleen Heck, Pres., ILEX Oncology Services Craig L. Bentzen, VP-Research, Europe

Phone: 210-949-8200 Fax: 210-949-8210 Toll-Free: Address: 4545 Horizon Hill Blvd., San Antonio, TX 78229 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $23,618 ( 9 months) 2002 Profits: $-35,013 ( 9 months) Stock Ticker: ILXO 2001 Sales: $24,600 2001 Profits: $-121,000 Employees: 310 2000 Sales: $27,600 2000 Profits: $-39,000 Fiscal Year Ends: 12/31 1999 Sales: $18,100 1999 Profits: $-46,100 1998 Sales: $14,300 1998 Profits: $-21,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $3,250,000 Bonus: $90,000 Stock Purch. Plan: Y Second Exec. Salary: $245,000 Bonus: $76,037 ADVANTAGE: Promising company with several landmark drugs waiting for FDA approval/Multiple revenue streams.

OTHER THOUGHTS:



West:

Southwest: Y

Midwest:

Southeast:



Northeast: Y

International: Y



ILLUMINA INC

www.illumina.com




Profits: 2


TYPES OF BUSINESS:

Y Y Y



Instruments-Genetic Variation Measurement Array Technology

Illumina, Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The firm's tools provide information that can be used to improve drugs and therapies, customize diagnoses and treatments and cure disease. Its patented BeadArray technology uses fiber optics to achieve a level of array miniaturization that allows for a new scale of experimentation. Arrays are collections of miniaturized test sites that permit many tests, or assays, to be performed in parallel. Illumina arranges its arrays in patterns that match the wells of industry-standard microtiter plates, allowing higher throughput than other technologies. The company's complementary Oligator technology permits parallel synthesis of the millions of pieces of DNA necessary to perform large-scale genetic analysis. These technologies are cost-effective, flexible and accurate. Illumina hopes to make BeadArray the industry standard for array products and services, by focusing on emerging high-growth markets, rapidly commercializing the technology, expanding its product lines and strengthening its technological leadership. The first implementation of BeadArray technology is Array of Arrays, a disposable cassette with 96 fiber optic bundles, each of which will perform up to 2,000 unique assays. One Array of Arrays, therefore, can perform up to 192,000 assays. The firm is also developing gene expression profiling products and laser scanning instruments. The company has partnered with Chevron to develop a BeadArray designed to perform leak detection and discrimination of gasoline grades in the petroleum and petrochemical industries, an agreement that was extended in early 2002. In recent news, Illumina was chosen by the National Institutes of Health to be one of five U.S. research groups participating in the International HapMap Project, a global consortium aimed at creating a detailed map of genetic variation. Illumina offers its emloyees flexible spending accounts, an educational assistance program, stock options, referral bonuses and medical, dental and vision insurance.

BRANDS/DIVISIONS/AFFILIATES: BeadArray Sentrix Array of Arrays Oligator International HapMap Project

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jay T. Flatley, CEO Jay T. Flatley, Pres. Timothy M. Kish, VP/CFO Susan Eddins, Head-Worldwide Mktg. Paulette Cabral, VP-Human Resources David L. Barker, VP/Chief Scientific Officer Robert C. Kain, VP- Eng. David C. Douglas, VP-Mfg. John Stuelpnagel, Sr. VP-Oper. Mark S. Chee, VP-Genomics/Research Fellow Michal Lebl, Sr. Dir.-Automation Noemi C. Espinosa, VP-Intellectual Property Arnold Oliphant, VP-Scientific Oper.

Phone: 858-202-4500 Fax: 858-202-4545 Toll-Free: 800-809-4566 Address: 9885 Towne Centre Dr., Ste. 200, San Diego, CA 92121-1975 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $6,154 ( 9 months) 2002 Profits: $-32,715 ( 9 months) Stock Ticker: ILMN 2001 Sales: $2,500 2001 Profits: $-24,800 Employees: 179 2000 Sales: $1,300 2000 Profits: $-18,600 Fiscal Year Ends: 12/31 1999 Sales: $ 500 1999 Profits: $-5,500 1998 Sales: $ 1998 Profits: $-1,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $299,519 Stock Purch. Plan: Y Second Exec. Salary: $225,000 ADVANTAGE: Unique BeadArray technology/Tools for large-scale genomic studies.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $82,500 Bonus: $11,250

Northeast:

International:



IMCLONE SYSTEMS INC

www.imclone.com


Y



Y

TYPES OF BUSINESS:

Profits: 232




Drugs-Cancer Diagnostic Products Vaccines

ImClone Systems, Inc. is a biopharmaceutical company engaged in the research and development of novel cancer treatments. The company focuses on three strategies for treating cancer: growth factor inhibitors, therapeutic cancer vaccines and angiogenesis inhibitors. The firm’s lead product candidate is IMC-C225, which is currently in pivotal trials for treating head and neck cancer. Upon approval, ImClone intends to market IMC-C225 in the United Sates and Canada. The company will rely on its development and marketing partner, Merck KGaA, to market the drug outside North America. The next most advanced product candidate is BEC2, a cancer vaccine. In partnership with Merck KGaA, the firm is testing the vaccine for preventing recurrence or progression of smallcell lung cancer. The company is also developing inhibitors of angiogenesis, which could be used to treat various kinds of cancer and other diseases. Its lead clinical candidate for angiogenesis inhibition is IMC-1C11. In addition to the development of its lead product candidates, ImClone continues to conduct new product research, both independently and in collaboration with academic and corporate partners. These partners include CombiChem and Memorial Sloan-Kettering Cancer Center. The company also develops diagnostic products and vaccines for certain infectious diseases. ImClone has also entered into an agreement with Bristol-Myers Squibb to co-develop and co-promote IMC-C225, an investigational cancer drug, in the U.S., Canada and Japan. ImClone recently underwent a restructuring that included new top management, due in part to a series of stock scandals and the problems some of its products have had with the FDA. The company offers its employees comprehensive health insurance as well as tuition reimbursement.

BRANDS/DIVISIONS/AFFILIATES: IMC-C225 BEC2 IMC-1C11 Merck KGaA

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Harlan W. Waksal, CEO Harlan W. Waksal, COO Harlan W. Waksal, Pres. Daniel S. Lynch, VP-Finance/CFO Ronald A. Martell, VP-Mktg. and Sales Lisa Cammy , Dir.-Human Resources Peter Bohlen, Sr. VP-Research Charles Dunne, VP-MIS and Facilities Gary Paulter, VP-Eng. and Facilities Richard P. Crowley , VP-Mfg. Daniel S. Lynch, Corp. Sec. John B. Landes, General Counsel Paul A. Goldstein, VP-Financial Oper. Michael Howerton, VP-Bus. Dev. Andrea F. Rabney, VP-Corp. Comm. Peter R. Borzilleri, VP- Internal Audit Michael N. Needle, VP- Clinical Affairs Larry Witte, VP-Research Lily Waiyee Lee, VP-Regulatory and Biostatistics

Phone: 212-645-1405 Fax: 212-645-2054 Toll-Free: Address: 180 Varick St., New York, NY 10014 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $45,150 ( 9 months) 2002 Profits: $-115,115 ( 9 months) Stock Ticker: IMCL 2001 Sales: $33,200 2001 Profits: $-102,200 Employees: 399 2000 Sales: $1,400 2000 Profits: $-70,400 Fiscal Year Ends: 12/31 1999 Sales: $2,100 1999 Profits: $-34,600 1998 Sales: $4,200 1998 Profits: $-21,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $550,000 Stock Purch. Plan: Second Exec. Salary: $451,404 ADVANTAGE: Innovative cancer treatments/Partnership with Merck KGaA.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $545,000 Bonus: $450,000

Northeast: Y

International:



IMMTECH INTERNATIONAL

www.immtech-international.com


Y



Profits: 120


TYPES OF BUSINESS:



Drugs-Dications

Immtech International, a development-stage pharmaceutical company, focuses on the discovery and commercialization of therapeutics for the treatment of patients afflicted with opportunistic infectious diseases, cancer or compromised immune systems, such as people infected with HIV. The company has a development program with a specific focus on new drugs to treat fungal diseases, based on a technology platform for the design of a class of pharmaceutical compounds referred to as dications. Dicationic compounds have two positively charged ends held together by a neutrally charged chemical linker group. The unique structure of the compounds with positive charges on the ends (shaped like molecular barbells) allows them to bind to the negatively charged surface in the minor groove of the organism's DNA (like a Band-aid), preventing life-sustaining enzymes from attaching to the DNA's active sites. Once a site is occupied by one of Immtech’s compounds, the necessary enzyme cannot bind to the DNA, preventing the organism from dividing, thereby stopping the spread of the related disease. Immtech has formed alliances with the World Health Organization, National Center for Infectious Diseases, National Institute of Health and the Swiss Tropical Institute. Several research agreements with the University of North Carolina at Chapel Hill, Duke University, Auburn University and Georgia State University are in place, helping Immtech further its goals. Recently, Immtech International announced that several of its compounds have shown activity in treating infections.


CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. T. Stephen Thompson, CEO T. Stephen Thompson, Pres. Gary C. Parks, CFO Richard R. Tidwell, Dir.-Research Consortium Partick D. Yeramian, Medical Dir. Gary C. Parks, Corp. Sec. Mary E. Garcia, Project Dir. Cecilia Chan, Exec. VP-Bus. Dev. Gary C. Parks, Treas. James L. Allen, VP-Regulatory Affairs Phil Bak, Mgr.-Intranet Systems and Market Research Rostyk Mandzij, Laboratory Mgr.

Phone: 847-573-0033 Fax: 847-573-8288 Toll-Free: 877-898-8038 Address: 150 Fairway Dr., Ste. 150, Vernon Hills , IL 60061 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,500 (12 months) 2002 Profits: $-3,300 (12 months) Stock Ticker: IMMT 2001 Sales: $1,354 2001 Profits: $-9,863 Employees: 13 2000 Sales: $ 400 2000 Profits: $-11,400 Fiscal Year Ends: 3/31 1999 Sales: $ 300 1999 Profits: $-1,800 1998 Sales: $ 100 1998 Profits: $-1,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Expertise in dicationic compounds.

OTHER THOUGHTS:




West:

Southwest:

Midwest: Y

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



IMMUCELL CORPORATION

www.immucell.com


Y



Y

TYPES OF BUSINESS:

Profits: 58




Drugs-Bovine Health Dairy Supplies Diagnostics

ImmuCell Corporation is a biotechnology company striving to commercialize proprietary technologies to help dairy and beef producers and their veterinarians to manage disease and reproduction in their herds. The company invested in an addition to its facility in Portland, Maine and the necessary manufacturing equipment to expand production of First Defense and to bring the production of Wipe Out Dairy Wipes in-house. Wipe Out Dairy Wipes are pre-moistened towelettes that are treated with nisin to clean, sanitize and dry the teat area of a cow in advance of milking. The company has also initiated commercial sales of its internally developed California Mastitis Test. This test can be performed cow-side for early detection of mastitis. Mastik helps veterinarians and dairy producers quickly select the antibiotic most likely to be effective in the treatment of individual cases of mastitis. The product can usually provide this answer in less than one day, which is dramatically faster than other commonly used antibiotic susceptibility tests. ImmuCell divested its nonanimal health related assets by licensing certain nutritional rights to its DiffGAM technology to an outside party and by entering into an option agreement to sell its ownership interest in its lactoferrin-producing joint venture. The company is involved in collaborations with The University of Pennsylvania, Michigan State University, University of Nebraska, Baylor College of Medicine, Clemson University, New England Medical Center and Tufts School of Veterinary Medicine. Recently, the company was awarded a one-year grant from the U.S. Department of Health and Human Services to enhance the development of MastOut, a non-antibiotic product for the treatment of mastitis.

BRANDS/DIVISIONS/AFFILIATES: First Defense California Mastitis Test Mastik MastOut Tip-Test Johne's Wipe Out Dairy Wipes DiffGAM

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael F. Brigham, CEO Michael F. Brigham, Pres. Michael F. Brigham, CFO Stafford C. Walker, Chief Mktg. Officer Michael F. Brigham, Human Resources Joseph H. Crabb, Chief Scientific Officer Michael F. Brigham, Corp. Sec. Michael F. Brigham, Treas.

Phone: 207-878-2770 Fax: 207-878-2117 Toll-Free: Address: 56 Evergreen Dr., Portland, ME 04103 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months . 2002 Sales: $4,488 ( 9 months) 2002 Profits: $ 177 ( 9 months) Stock Ticker: ICCC 2001 Sales: $6,400 2001 Profits: $ 400 Employees: 30 2000 Sales: $5,600 2000 Profits: $2,200 Fiscal Year Ends: 12/31 1999 Sales: $4,900 1999 Profits: $ 600 1998 Sales: $4,500 1998 Profits: $- 100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $127,833 Bonus: $6,000 Stock Purch. Plan: Second Exec. Salary: $127,833 Bonus: $6,000 ADVANTAGE: Several unique technologies with potential to serve multiple markets/Diagnostics expertise.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



IMMUNE RESPONSE CORP (THE)

www.imnr.com



Y Y


Profits: 145


TYPES OF BUSINESS:



Drugs-Autoimmune Disease Drugs-Cancer

Immune Response is a biopharmaceutical firm devoted to the development of immune-based therapies for the treatment of HIV, autoimmune diseases and cancer. All of the company’s products are currently under development. At the forefront is Remune, which stimulates cellular immune responses that may slow replication of the HIV virus in infected individuals. Other conditions targeted by Immune Response are rheumatoid arthritis, psoriasis, multiple sclerosis, colon cancer, brain cancer, prostate cancer, melanoma, hepatitis and hemophilia. In addition, the company is working on a delivery system to enable the injection of genes for delivery to the liver. Once delivered, the genes could direct the production of proteins that can treat a disease condition. Immune Response has concentrated on developing its product line, with particular attention to Remune. The drug appears to activate T-cells against the HIV virus when used in conjunction with other antiviral medications. In another finding, the firm reported that the drug also showed promise as a possible universal immunogen, fighting various strains of the HIV virus. At the same time, Immune Response has been working on other developments, recently announcing the creation of a Factor VIII gene that could improve gene therapy for hemophilia patients. In addition, Ravax is being designed to stimulate the immune system of a rheumatoid arthritis patient to control the T cells that initiate the disease. In recent news, Immune Response announced positive results from the Canadian HIV Trials Network regarding Remune and its potential relief from side effects of certain therapies to HIV infected patients.

BRANDS/DIVISIONS/AFFILIATES: Remune Ravax

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ronald B. Moss, Pres. Michael L. Jeub, VP-Finance/CFO Bjorn K. Lydersen, VP-Mfg. Oper. James B. Gavin, Chmn.

Phone: 760-431-7080 Fax: 760-431-8636 Toll-Free: Address: 5935 Darwin Ct., Carlsbad, CA 92008 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 33 ( 9 months) 2002 Profits: $-18,913 ( 9 months) Stock Ticker: IMNR 2001 Sales: $10,000 2001 Profits: $-16,300 Employees: 99 2000 Sales: $7,400 2000 Profits: $-24,500 Fiscal Year Ends: 12/31 1999 Sales: $20,800 1999 Profits: $-15,000 1998 Sales: $17,700 1998 Profits: $-18,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $395,040 Stock Purch. Plan: Second Exec. Salary: $229,223 ADVANTAGE: Promising new company with strong research and development targeting HIV.

OTHER THOUGHT S:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



IMMUNEX CORP

www.immunex.com


Y



Profits: 20


TYPES OF BUSINESS:



Drugs-Cancer, Autoimmune Disease and Infectious Disease

Immunex, a subsidiary of Amgen, is a biopharmaceutical company that develops drugs based on immune system science for the treatment of inflammatory, infectious and cardiovascular diseases, cancer, asthma and rheumatoid arthritis. Immunex draws from a vast array of scientific expertise in the fields of immunology, cytokine biology, vascular biology, antibody-based therapeutics and small molecule research. Many of the firm’s current and potential biotechnology products are recombinant analogs of cytokines and cytokine receptors. Cytokines are protein messengers that coordinate the functions of immune cells as well as other types of cells and tissues. The company’s recombinant cytokine products primarily expand and activate immune cell populations, providing a normal immune response. The firm’s approved products include ENBREL (a TNF receptor that reduces inflammatory activity in rheumatoid arthritis), LEUKINE (a yeast-derived colony that fights infections following bone marrow transplants and chemotherapy for acute myelogenous leukemia) and NOVANTRONE (a line of drugs for the treatment of various cancers, including prostate cancer). In addition, Immunex has a number of drugs that are currently under development, including IL-4 for asthma, AVREND for kidney cancer and MOBISTA for various cancers. The company has concentrated its expansion toward exploring new opportunities through research and development collaborations. In recent company news, Immunex was acquired by Amgen for $16 billion. The company provides comprehensive training for employees to develop personal, computer, managerial and organizational skills. Immunex’s headquarters in Seattle, Washington houses an on-site, fully equipped fitness center that is available to all employees and their spouses. All locations offer private lactation rooms for working mothers.

BRANDS/DIVISIONS/AFFILIATES: LEUKINE NOVANTRONE THIOPLEX AMICAR ENBREL NUVANCE Amgen American Home Products Corporation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Edward V. Fritzky, CEO Peggy V. Phillips, COO Edward V. Fritzky, Pres. David A. Mann, CFO Philip Laub, VP-Human Resources Douglas E. Williams , Chief Tech. Officer Barry G. Pea, Corp. Sec. Barry G. Pea, General Counsel Efi Cohen-Arazi, Sr. VP-Supply Oper. Deborah Helleson, VP-Bus. Dev. David A. Mann, Treas. Michael Aguir, VP-Finance Daniel Burge, VP-Clinical Dev. Kendall Mohler, VP-Biological Sciences Thomas O. Daniel, Sr. VP-Discovery Research

Phone: 206-587-0430 Fax: 206-587-0606 Toll-Free: Address: 51 University St., Seattle, WA 98101 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $986,800 2001 Profits: $170,000 Employees: 1,618 2000 Sales: $861,800 2000 Profits: $154,400 Fiscal Year Ends: 12/31 1999 Sales: $541,700 1999 Profits: $44,300 1998 Sales: $243,500 1998 Profits: $1,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Will be acquired by Amgen.

OTHER THOUGHTS:




West: Y

Southwest: Y

Midwest: Y

Bonus: $ Bonus: $

Southeast: Y



Northeast: Y

International:



IMMUNOGEN INC

www.immunogen.com

Industry Group Code: 325412 Ranks within this company's industry group: Sales: 151

Profits: 139

Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y




TYPES OF BUSINESS:



Drugs-Cancer Tumor-Activated Prodrugs

Biopharmaceutical firm ImmunoGen develops tumoractivated prodrugs (TAPs), which are small-moleculebased anti-cancer agents that deliver chemotherapy to cancerous cells. TAP technology involves the attachment of a potent drug to humanized monoclonal antibodies that target cancer cells. The company is currently focused on developing TAPs for colorectal and small-cell lung cancers. Through its Apoptosis Technology subsidiary, the company also develops technologies aimed at luring cancerous cells to induce their own deaths. ImmunoGen is focused on the eventual goal of marketing its products, all of which are under development and have demonstrated promise in preclinical studies. The firm and British Biotech recently completed the Phase I portion of their clinical study of huN901-DM, a monoclonal antibodybased chemotherapy agent designed for the treatment of small-cell lung cancer. In other news, ImmunoGen earned a milestone payment from Millennium Pharmaceuticals, Inc. for the initiation of clinical trials with an anticancer product candidate developed by Millennium. The product is a tumor-activated prodrug composed of Millennium's MLN591 antibody and ImmunoGen's DM1 effector molecule. Thus far, four DM1-based TAP products have entered clinical testing: two developed by ImmunoGen and two by companies that licensed the firm’s TAP technology.

BRANDS/DIVISIONS/AFFILIATES: Apoptosis Technology, Inc. DM1

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mitchel Sayare, CEO Mitchel Sayare, Pres. Gregg D. Beloff, CFO Linda Bono, VP-Human Resources Walter A. Blattler, Exec. VP-Science and Tech. Kathleen A. Carroll, VP-Admin. Pauline Jen Ryan, VP-Bus. Dev. Kathleen A. Carroll, Treas. John M. Lambert, Sr. VP-Pharmaceutical Dev.

Phone: 617-995-2500 Fax: 617-995-2510 Toll-Free: Address: 128 Sidney St., Cambridge, MA 02139 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $5,900 (12 months) 2002 Profits: $-14,600 (12 months) Stock Ticker: IMGN 2001 Sales: $4,479 2001 Profits: $-15,290 Employees: 76 2000 Sales: $11,600 2000 Profits: $- 200 Fiscal Year Ends: 6/30 1999 Sales: $3,700 1999 Profits: $-4,100 1998 Sales: $ 500 1998 Profits: $-7,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $360,000 Stock Purch. Plan: Second Exec. Salary: $260,000 ADVANTAGE: Expertise in tumor-activated prodrugs (TAPs).

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $130,000 Bonus: $50,000

Northeast: Y

International:



IMMUNOMEDICS INC

www.immunomedics.com




Y

TYPES OF BUSINESS:

Profits: 12




Diagnostics

Immunomedics develops, manufactures and markets diagnostic imaging and therapeutic products for the detection of cancer and various other diseases. The company’s products are created from monoclonal antibodies and fragments to deliver radioisotopes, chemotherapeutic agents and toxins to tumors. Diagnostic imaging products manufactured by Immunomedics include CEA-Scan, for the detection of colorectal, lung and breast cancers, and LeukoScan, for the detection of infections and inflammatory bowel disease. CEA-Scan has been approved in the U.S., Canada and Europe, and LeukoScan has been approved in Europe. Products under development include LymphoScan (epratuzumab), for the detection of nonHodgkin’s lymphoma, and AFP-Scan, for the diagnosis of primary liver and germ -cell cancers. Immunomedics granted a license to Amgen, Inc. to further develop and commercialize the unlabeled form of epratuzumab in North America and Australia. Amgen is currently evaluating this compound in Phase II and Phase III clinical trials for the treatment of patients with non-Hodgkin's lymphoma. Recently, Immunomedics announced the CEA patent portfolio has been licensed to Medix Biochemica and to Beckman-Coulter, Daiichi Pure Chemicals and Dako. Immunomedics provides comprehensive benefits to its employees, including tuition reimbursement and time-off benefits.

BRANDS/DIVISIONS/AFFILIATES: IMG Technologies CEA -Scan LeukoScan LymphoCide CEA -Cide LymphoScan AFP-Scan

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Cynthia L. Sullivan, CEO Cynthia L. Sullivan, Pres. Gerard G. Gorman, VP/CFO David M. Goldenberg, Chief Scientific Officer Ivan D. Horak, Exec. VP-Research and Dev. David M. Goldenberg, Chmn.

Phone: 973-605-8200 Fax: 973-605-8282 Toll-Free: Address: 300 American Rd., Morris Plains , NJ 07950 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $14,300 (12 months) 2002 Profits: $-3,700 (12 months) Stock Ticker: IMMU 2001 Sales: $11,229 2001 Profits: $-4,750 Employees: 85 2000 Sales: $3,200 2000 Profits: $-9,600 Fiscal Year Ends: 6/30 1999 Sales: $6,000 1999 Profits: $-11,300 1998 Sales: $7,600 1998 Profits: $-11,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Innovative imaging technology.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $125,000 Bonus: $137,500

Northeast: Y

International: Y



IMPAX LABORATORIES INC

www.impaxlabs.com


Y Y



Profits: 171


TYPES OF BUSINESS:



Drugs-Generic Drug Delivery Technologies Branded Drugs

IMPAX Laboratories, Inc., formed by the merger of Impax Pharmaceuticals and Global Pharmaceutical Corp., is a technology-based, specialty pharmaceutical company focused on the development and commercialization of generic and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. In the generic market, the firm is primarily focusing on selected controlled-release versions of brand-name drugs. In the brand-name drugs market, the company is developing products for the treatment of central nervous system disorders. Its product portfolio consists of development-stage projects to which IMPAX is applying its formulation and development expertise to produce modified versions of currently marketed drugs. The company plans to market branded products through the IMPAX Pharmaceuticals division and generic products through the Global Pharmaceuticals division. IMPAX has developed several proprietary controlled-release delivery technologies that can be utilized with a variety of oral dosage forms and drug release rates. These include the concentric multiple-particulate delivery system, the timed multiple-action delivery system and the dividable multipleaction delivery system. The firm markets approximately 20 generic pharmaceuticals. Generic products include controlled-release versions of Prilosec, Claritin, Allegra, Tricor and Wellbutrin. The company also has three branded projects under development. Recently, IMPAX received final approval for Omeprazole delayed-release capsules, a generic version of Prilosec. The company also received approval for a generic version of Flumadine flu treatment.

BRANDS/DIVISIONS/AFFILIATES: Global Pharmaceutical Corp. Impax Pharmaceuticals Bupropion Fenofibrate Omeprazole Loratadine Oxycodone

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Charles Hsaio, Co-CEO Larry Hsu, COO Larry Hsu, Pres. Cornel C. Spiegler, CFO David S. Doll, Sr. VP-Sales and Mktg. Joseph A. Storella, VP-Oper. Barry R. Edwards, Co-CEO May Chu, VP-Quality Affairs

Phone: 510-476-2000 Fax: 510-471-3200 Toll-Free: Address: 30831 Huntwood Ave., Hayward, CA 94544 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $15,860 ( 9 months) 2002 Profits: $-16,569 ( 9 months) Stock Ticker: IPXL 2001 Sales: $6,600 2001 Profits: $-25,100 Employees: 150 2000 Sales: $10,200 2000 Profits: $-25,000 Fiscal Year Ends: 12/31 1999 Sales: $1,200 1999 Profits: $-8,900 1998 Sales: $4,400 1998 Profits: $-5,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $195,000 Stock Purch. Plan: Second Exec. Salary: $195,000 ADVANTAGE: Innovative drug delivery technology/Niche multi-source pharmaceuticals.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $102,395 Bonus: $102,395

Northeast: Y

International:



IMS HEALTH INC

www.imshealth.com




Profits: 1


TYPES OF BUSINESS:

Y


Y Y


Software-Sales Management and Market Research Pharmaceutical Sales Tracking Health Care Databases Consulting Services Doctor Profiling Industry Audits

IMS Health, Inc. is one of the world’s leading providers of information solutions to the pharm aceutical and health care industries. Key services offered by the company include market research for prescription and over-thecounter pharmaceutical products, sales management information to optimize sales force productivity and consulting services to assist in decision-making. IMS Health provides syndicated pharmaceutical, medical, hospital, promotional and prescription audits. In addition, the company performs sales territory reports, prescription tracking reports and doctor profiling services. Customers of the firm include major pharmaceutical manufacturers, biotechnology firms, financial analysts, government and regulatory agencies, researchers and educators. IMS Health utilizes powerful database management tools in processing approximately 165 billion pharmaceutical records every month. The firm captures data on over 70% of all prescriptions worldwide, with operations in over 100 countries. In addition, IMS Health owns a majority stake in Cognizant Technology Solutions (CTS), which delivers full life cycle solutions for complex software development and maintenance problems that companies face as they transition to e-business. Solutions of CTS include application development and integration, application management and reengineering services. The company also holds majority ownership in Enterprise Associates, L.L.C., a venture capital unit focusing on investments in emerging businesses. IMS Health recently sold its subsidiary Erisco Managed Care Technologies to the TriZetto Group, Inc. for a 33% stake in TriZetto.

BRANDS/DIVISIONS/AFFILIATES: Cognizant Technology Solutions Erisco Managed Care Technologies Synavant, Inc. TriZetto Group, Inc., The Enterprise Associates, L.L.C. Growth Analyser Pharmacast Therapy Reports

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David M. Thomas, CEO David M. Thomas, Pres. Nancy E. Cooper, CFO Leslye G. Katz , Controller Robert H. Steinfeld, Corp. Sec. Robert H. Steinfeld, General Counsel Mathew L. Friedman, Treas. Kenny Keimatsu, CEO, IMS Health Japan Gary W. Noon, Pres., IMS Health North America Murray L. Aitken, Sr. VP-Services & Consulting Giles Pajot, Exec. VP

Phone: 203-319-4700 Fax: 203-319-4701 Toll-Free: Address: 1499 Post Rd., Fairfield, CT 06430 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $684,400 ( 6 months) 2002 Profits: $121,200 ( 6 months) Stock Ticker: RX 2001 Sales: $1,332,900 2001 Profits: $185,400 Employees: 5,428 2000 Sales: $1,424,400 2000 Profits: $120,800 Fiscal Year Ends: 12/31 1999 Sales: $1,398,000 1999 Profits: $276,100 1998 Sales: $1,186,500 1998 Profits: $220,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $750,000 Stock Purch. Plan: Second Exec. Salary: $465,072 ADVANTAGE: Focus on maintaining and mining massive health-related databases.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $750,000 Bonus: $143,159

Northeast: Y

International: Y



INCARA PHARMACEUTICALS

www.incara.com


Y



Profits: 161


TYPES OF BUSINESS:



Drugs-Inflammatory Bowel Disease Catalytic Antioxidants Tissue Protection, Repair and Regeneration

Incara Pharmaceuticals Corp. is developing therapies focused on tissue protection, repair and regeneration. In the past, the company has focused on developing adult liver stem and progenitor cell therapy, referred to as liver progenitor cell therapy, for the treatment of liver failure. This stem and progenitor cell program was established with the acquisition of Renaissance Cell Technologies, which subsequently became Incara Cell Technologies, Inc. Incara is also conducting research on a series of catalytic antioxidant molecules that may provide strategic opportunities for collaboration with larger companies in areas such as stroke and the prevention of side effects induced by radiation in cancer therapy. Antioxidants destroy free radicals, a class of reactive molecules that damage healthy cells and are believed to play a role in many conditions involving tissue injury and inflammation. The catalytic antioxidant program was established with the acquisition of Aeolus Pharmaceuticals, Inc. Incara is currently developing AEOL 10150 as a potential treatment for stroke. The company has also developed catalytic antioxidants for applications in its liver cell therapy program. Incara is conducting a Phase II/III study of an ultra-low molecular weight heparin, OP2000, for the treatment of ulcerative colitis, a form of inflammatory bowel disease, in conjunction with Elan Corp. In 2001, the company formed Incara Development, Ltd. to develop this therapy. The firm's liver cell technology has potential application in the development of a liver assist device, or LAD. LADs are external devices designed to provide liver function for a few days, providing time for a patient's own liver to recover from failure or function until a transplant is available. In recent news, Incara announced that subsidiary Incara Cell Technologies sold substantially all of its liver cell assets to Vesta Therapeutics, Inc. In accordance with the sale, Incara will place focus on its catalytic antioxidants program. In addition, the firm announced continuing significant cash flow problems in 2002.

BRANDS/DIVISIONS/AFFILIATES: OP2000 Incara Cell Technologies, Inc. Aeolus Pharmaceuticals, Inc. AEOL 10150 AEOL 10113 Incara Development, Ltd. Renaissance Cell Technologies

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Clayton I. Duncan, CEO Clayton I. Duncan, Pres. Richard W. Reichow , Exec. VP/CFO David P. Ward, Exec. VP-Research and Dev. W. Bennett Love, VP-Corp. Planning W. Bennett Love, VP-Corp. Comm. Richard W. Reichow , Treas. John P. Richert, VP-Market Dev.

Phone: 919-558-8688 Fax: 919-558-8686 Toll-Free: Address: 79 TW Alexander Dr., Research Triangle Park, NC 27709 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 40 ( 9 months) 2002 Profits: $-8,789 ( 9 months) Stock Ticker: INCR 2001 Sales: $ 100 2001 Profits: $-22,200 Employees: 25 2000 Sales: $ 100 2000 Profits: $-6,700 Fiscal Year Ends: 9/30 1999 Sales: $2,100 1999 Profits: $-19,600 1998 Sales: $6,100 1998 Profits: $-19,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $352,500 Stock Purch. Plan: Y Second Exec. Salary: $270,875 ADVANTAGE: The firm is struggling due to a lack of cash.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $132,000 Bonus: $93,060

Northeast: Y

International:



INCYTE GENOMICS INC

www.incyte.com



Y


Y

TYPES OF BUSINESS:

Profits: 35




Research-Genetic Information (Drug Discovery) Genomic Databases Gene Expression Services DNA Screening and Cloning

Incyte Genomics owns the largest commercial portfolio of issued U.S. patents covering human, full-length genes , the proteins they encode and the antibodies directed against them. The company has reorganized its business, moving away from genomic information-based products and services. Instead, the firm intends to use its intellectual property and genomic inform ation to become a leader in therapeutic small molecule, secreted protein and antibody discoveries. In order for the company to increase its focus on therapeutic discovery and development programs, it suspended a number of commercial activities, including microarray-related products and services, genomic screening, public domain clone products and services and contract sequencing services. Current products include information databases, intellectual property licensing and full-length clones. Incyte has developed a leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. These technologies primarily consist of genomic databases and pharmaceutically relevant intellectual property licenses, which help pharmaceutical and biotechnology researchers in their therapeutic discovery and development efforts. These efforts include gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. The company operates three sequence databases of gene information: LifeSeq Gold for humans, ZooSeq for animals and LifeExpress, a gene and protein expression database. The firm maintains research services that enable life science researchers to query and analyze these databases online, utilizing features such as Workbench that let users keep track of their research. Furthermore, the company offers technology for the analysis of single nucleotide polymorphisms, which are genetic variations that could potentially lead to specific diseases or conditions.

BRANDS/DIVISIONS/AFFILIATES: Proteome LifeSeq Gold Database PathoSeq Database ZooSeq Database LifeExpress Database LifeTools LifeProt diaDexus

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul A. Friedman, CEO Michael D. Lack, COO Robert Stein, Pres. John Vuko, CFO James R. Neal, Exec. VP-Sales & Mktg. Laurie Brown, VP-Human Resources Robert Stein, Chief Scientific Officer Ken Jacobsen, Sr. VP-Info. Sciences Tim Henn, Corp. Controller E. Lee Bendekgey, Exec. VP/General Counsel Jim Merryweather, Exec. VP-Bus. Dev. Robert Venema, Treas. Randy Harris, Sr. VP-Sales Jeffrey J. Seilhamer, Sr. VP-Discovery Ingrid Akerblom, VP-Informatics Cate Sabatini, VP-Customer Support

Phone: 650-855-0555 Fax: 650-855-0572 Toll-Free: Address: 3160 Porter Dr., Palo Alto, CA 94304 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $80,463 ( 9 months) 2002 Profits: $-69,393 ( 9 months) Stock Ticker: INCY 2001 Sales: $219,300 2001 Profits: $-183,200 Employees: 585 2000 Sales: $194,200 2000 Profits: $-29,700 Fiscal Year Ends: 12/31 1999 Sales: $157,000 1999 Profits: $-26,800 1998 Sales: $134,800 1998 Profits: $3,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $394,850 Bonus: $408,234 Stock Purch. Plan: Second Exec. Salary: $309,560 Bonus: $240,290 ADVANTAGE: Operates sequence databases of gene information for humans, animals, and bacterial and fungal genomes.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Southeast:



Northeast: Y

International: Y



INFORMAX INC

www.informaxinc.com




Profits: 6


TYPES OF BUSINESS:

Y


Y


Software-Bioinformatics Consulting Services

InforMax, Inc. is a leading global provider of informatics software solutions to the life sciences industry. Informatics applies the advances that have taken place in mathematical, computer and life sciences to accelerate and enhance the research of scientific communities. The firm's high-throughput research strategy combines software solutions, consulting services and scientific expertise to provide the enabling technology for drug discovery and development customers. Its software helps companies manage, analyze and interpret the enormous amount of genomic, proteomic and other biomolecular data generated in recent years. InforMax's customers include Pfizer, Procter & Gamble, Merck & Company and the National Institutes of Health. The firm's software includes the Vector NTI suite, the most widely used desktop software for enhancing lab productivity, and GenoMax, a modular family of analytical programs for the analysis of biomolecular data. Vector Enterprise is designed for biologists working in larger research groups or working collaboratively with others on sequence analysis projects. Other products in the Vector suite include Vector NTI Advance, Vector PathBlazer, Vector Xpression and LabShare. InforMax is also licensed to distribute software from companies including Biomax Informatics and AxCell Biosciences Corp. In recent news, the firm signed an agreement with SciTech to collaborate on an innovative data pipelining and automation product line. In addition, Invitrogen Corp., which makes products for life sciences discovery, development and production, agreed to acquire InforMax.

BRANDS/DIVISIONS/AFFILIATES: GenoMax GelPRO ArrayPRO Vector NTI Advance Vector Xpression Vector PathBlazer LabShare Invitrogen Corp.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Andrew Whiteley, CEO John M. Green, COO Andrew Whiteley, Pres. John M. Green, CFO Janet L. Lambert, VP-Mktg. Stephen E. Lincoln, Exec. VP-Product Dev./Chief Scientific Officer Janet L. Lambert, VP-Bus. Dev. John Lippert, VP-Sales Constantine Saris, VP-Global Services Andrew Whiteley, Chmn.

Phone: 240-747-4000 Fax: 240-747-4010 Toll-Free: 800-357-3114 Address: 7600 Wisconsin Ave., Bethesda, MD 20814 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $10,600 ( 9 months) 2002 Profits: $-19,000 ( 9 months) Stock Ticker: INMX 2001 Sales: $25,200 2001 Profits: $-21,400 Employees: 2000 Sales: $17,147 2000 Profits: $-10,674 Fiscal Year Ends: 12/31 1999 Sales: $10,000 1999 Profits: $-1,300 1998 Sales: $4,126 1998 Profits: $- 567


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $399,948 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $350,000 Bonus: $ ADVANTAGE: Makers of a wide range of biotech software for use in computer systems from PCs up to enterprise level systems.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast: Y

International: Y



INKINE PHARMACEUTICAL CO

www.inkine.com


Y



Profits: 140


TYPES OF BUSINESS:



Drugs-Cancer and Autoimmune Diseases Colonoscopy Preparation Products Bowel Disease Treatments

InKine Pharmaceutical Company, Inc., formerly Panax Pharmaceutical Company, was formed to focus on the development of new pharmaceutical compounds identified in and isolated from plants. In 1996, the firm changed its strategy and has redirected its efforts toward expanding its pipeline of commercially viable pharmaceutical products by licensing or acquiring products developed for the treatment of certain diseases. The company's products and technologies include Visicol tablets, which clean the colon and act as a laxative; a group of technologies that down- or up-regulate Fc receptors on macrophages and other cells to treat autoimmune disorders and other diseases; a group of technologies for the inhibition and prevention of tumor metastasis; and IBStat, an immediaterelease antispasmodic product used for a variety of indications. In late 2000, Visicol received FDA approval for the cleansing of the bowels as a preparation for colonoscopy. In 2001, InKine began marketing the product in partnership with Procter and Gamble Pharmaceuticals. The firm has since developed an improved formulation of the drug. The company also began marketing IBStat in partnership with Morton Grove Pharmaceuticals in 2001. Product candidates in the Fc receptor family of technologies include Colirest, a potential treatment for inflammatory bowel disease, and Hematrol, a potential treatment for idiopathic thrombocytopenic purpura (ITP). Other potential applications include rheumatoid arthritis, lupus and Graves disease. These products are undergoing Phase II and III clinical trials. Colirest is also being tested for Crohn's disease and ulcerative colitis. In addition, InKine has licensed Thrombospondin Technology, a cancer treatment formed by a series of peptide molecules. The technology is in preclinical development. Recently, InKine released the results of study showing a 92% patient preference for Visicol tablets as a colonoscopy preparation over liquid preparations.

BRANDS/DIVISIONS/AFFILIATES: Panax Pharmaceutical Company, Ltd. Visicol CBP-2011 Hematrol Colirest IBStat Thrombospondin Technology

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Leonard S. Jacob, CEO Robert F. Apple, Sr. VP/CFO Martin Rose, Exec. VP-Research and Dev. Barbara T. Nagle, VP-Clinical Oper. James L. Bergey, Sr. VP-Bus. Dev. Sandra Davis Jacob, Investor Rel. Monroe I. Klein, Sr. VP-Regulatory Affairs

Phone: 215-283-6850 Fax: 215-283-4600 Toll-Free: Address: 1787 Sentry Pkwy. W, Bldg. 18, Ste. 440, Blue Bell, PA 19422 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $5,206 ( 9 months) 2002 Profits: $-5,809 ( 9 months) Stock Ticker: INKP 2001 Sales: $4,300 2001 Profits: $-15,300 Employees: 12 2000 Sales: $ 100 2000 Profits: $-9,700 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-9,600 1998 Sales: $ 100 1998 Profits: $-9,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $351,667 Stock Purch. Plan: Y Second Exec. Salary: $222,500 ADVANTAGE: Focus on products for colon treatment.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



INSITE VISION INC

www.insitevision.com


Y



Y

TYPES OF BUSINESS:




Drugs-Ophthalmic Drug Delivery Systems Eye Disease Diagnostics

InSite Vision, Inc. is an ophthalmic product development company focusing on genetically based tools for the diagnosis, prognosis and management of glaucoma, as well as other ophthalmic pharmaceutical products based on its proprietary DuraSite eyedrop-based drug delivery technology. DuraSite is a patented delivery system comprising a cross-linked carboxyl-containing polymer that incorporates the drug to be delivered to the eye. The drop remains in the eye for up to several hours, during which time the active drug ingredient is gradually released. The first product utilizing this technology, AquaSite dry eye treatment, was launched as an over-the-counter medication by CIBA Vision. The firm also has retinal programs that include both a therapeutic agent and a retinal drug delivery technology. The company is focusing current efforts on launching its OcuGene glaucoma genetic test based on expanding ISV-900 technology; developing ISV-205, ISV-403 and ISV-401 formulations of DuraSite; and developing ISV-014, a retinal drug delivery device. InSite's glaucoma genetics program is focused on discovering genes associated with glaucoma. OcuGene, the first of the tools based on this program, is in the launch stage. InSite belongs to collaborative agreements with organizations including Quest Diagnostics, Bausch and Lomb and the University of Connecticut Health Center. In recent news, the firm reported favorable FDA Phase II results for ISV-401 as a treatment for bacterial conjunctivitis. InSite plans to enter Phase III trials of the product in 2003.

BRANDS/DIVISIONS/AFFILIATES: AquaSite OcuGene IV-205 ISV-401 ISV-403 DuraSite ISV-900

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. S. Kumar Chandrasekaran, CEO S. Kumar Chandrasekaran, Pres. S. Kumar Chandrasekaran, CFO Erwin C. Si, Sr. Dir.- Preclinical Research Sandra C. Heine, Sr. Dir.-Admin. and Finance Lyle M. Brown, VP-Dev. and Oper. David F. Heniges, VP/Mgr.-Commercial Opportunities Cheryl E. Chen, Sr. Dir.-Clinical Oper. T. Raymond Chen, Sr. Dir.-Regulatory and Quality Assurance Samir D. Roy, Sr. Dir.-Formulation Dev. and Oper.

Phone: 510-865-8800 Fax: 510-865-5700 Toll-Free: Address: 965 Atlantic Ave., Almeda, CA 94501 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 26 ( 9 months) 2002 Profits: $-8,678 ( 9 months) Stock Ticker: ISV 2001 Sales: $ 2001 Profits: $-9,600 Employees: 39 2000 Sales: $4,513 2000 Profits: $-3,443 Fiscal Year Ends: 12/31 1999 Sales: $4,800 1999 Profits: $1,100 1998 Sales: $ 16 1998 Profits: $-8,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $350,000 Stock Purch. Plan: Y Second Exec. Salary: $192,000 ADVANTAGE: Unique eyedrop technology/High-profile partnerships.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:




Northeast:

International:



INSMED INCORPORATED

www.insmed.com


Y



Profits: 193


TYPES OF BUSINESS:



Drugs-Metabolic and Endocrine Disease Drugs-Bone, Muscle and Tissue Restoration

Insmed, Inc. discovers and develops pharmaceutical products for the treatment of metabolic and endocrine diseases primarily associated with insulin resis tance. Its former lead product candidate, INS-1, is an orally active insulin sensitizer that restores tissue sensitivity to the hormone. The company has developed the product for the treatment of type 2 diabetes and polycystic ovary syndrome (PCOS). The company's second product candidate, SomatoKine, is a recombinant protein under development as an injectable insulin sensitizer targeted at the management of both type 1 and 2 diabetes. In 2002, Insmed announced positive results from a Phase II trial of dose-ranging SomatoKine in patients with type 2 diabetes. The company's business strategy includes retaining commercial rights to its products; establishing corporate partnerships in its target markets; outsourcing manufacturing to deploy resources efficiently; and acquiring additional products and technologies. In addition, Insmed continues preclinical studies of IGFBP-3, a biotherapeutic with potential as an anti-tumor therapy. In recent news, Insmed acquired the regulatory files for Insulin-like Growth Factor-1 (IGF-1) from Pharmacia Corp. The company plans to use the portfolio to expedite the development and approval process of SomatoKine. In other news, Insmed announced structural changes to focus on the development of SomatoKine and IGFBP-3. The firm will discontinue internal development of INS-1.

BRANDS/DIVISIONS/AFFILIATES: Celtrix Pharmaceuticals Insmed Pharmaceuticals INS-1 SomatoKine IGFBP-3

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Geoffrey Allan, CEO Geoffrey Allan, Pres. Kevin P. Tully, CFO Kevin P. Tully, Controller Mary Callan, VP-Corp. Dev. Kevin P. Tully, Treas. Fredrick L. Dunn, VP-Clinical Dev. Ronald D. Gunn, VP-Bus. Dev. Lewis J. Stuart, VP-Commercial Dev.

Phone: 804-565-3000 Fax: 804-565-3500 Toll-Free: Address: 4851 Lake Brook Dr., Glen Allen, VA 23058 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,929 ( 9 months) 2002 Profits: $-17,920 ( 9 months) Stock Ticker: INSM 2001 Sales: $ 300 2001 Profits: $-37,200 Employees: 60 2000 Sales: $ 100 2000 Profits: $79,900 Fiscal Year Ends: 12/31 1999 Sales: $ 700 1999 Profits: $-7,800 1998 Sales: $ 100 1998 Profits: $-4,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $380,000 Stock Purch. Plan: Y Second Exec. Salary: $200,000 ADVANTAGE: Acquisition of Celtrix Pharmaceuticals.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:




Northeast: Y

International:



INSPIRE PHARMACEUTICALS INC

www.inspirepharm.com


Y



Y

TYPES OF BUSINESS:

Profits: 164


Y



Drugs-Respiratory and Ocular Diagnostic Aids

Inspire Pharmaceuticals discovers and develops drugs to treat diseases characterized by deficiencies in the body's innate defense mechanisms of mucosal hydration and mucociliary clearance, as well as other non-mucosal disorders. Its product candidates in clinical trials are based on proprietary technology related to P2Y receptors, which coordinate mechanisms of mucosal hydration and mucociliary clearance. Lead products target respiratory and ophthalmic diseases with inadequate treatments. These product candidates include INS365, for the treatment of dry eye disease and allergic rhinitis; INS316, a diagnostic aid for lung cancer and lung infection; and INS37217, for the treatment of cystic fibrosis, retinal disease and upper respiratory disorders. INS365 is being developed as an eye drop and may be one of the first FDA-approved, pharmacologically effective agents to treat the symptoms of dry eye, help prevent long-term corneal damage and improve ocular surface health. It has also been in development as an inhaled product to clear up mucus in the airways of bronchitis sufferers. INS37217 is being developed as an intra-ocular injection for retinal disease; an inhaled product to mitigate the underlying iontransport defect in the airways of cystic fibrosis patients; and as an intranasal spray treatment for disorders in which mucociliary clearance in impaired. Through a development and marketing agreement with Allergan, Inspire receives royalties on global sales of Allergan's Restasis product. Inspire has also collaborated with companies including Kissei Pharmaceutical Co., Genentech, Inc. and Santen Pharmaceutical Co. Recently, the firm announced that it will discontinue development of INS365 as a respiratory treatment for bronchitis to focus on dry eye and allergic rhinitis programs. The company also announced positive results in Phase II clinical trials of INS37217 for allergic rhinitis.

BRANDS/DIVISIONS/AFFILIATES: INS316 INS365 INS37217 Restasis

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Christy L. Shaffer, CEO Gregory J. Mossinghoff, Pres. Joseph K. Schachle, VP-Mktg. and Sales Janet L. Rideout, Chief Scientific Advisor Gregory J. Mossinghoff, Corp. Sec. Mary Bennett, VP-Oper. Donald Kelllerman, Sr. VP-Dev. Mary Bennett, VP-Comm. Lisa LaVange, VP-Biostatics and Data Mgmt. Benjamin R. Yerxa, VP-Discovery Richard Evans, VP-Pharmaceutical Dev.

Phone: 919-941-9777 Fax: 919-941-9797 Toll-Free: Address: 4222 Emperor Blvd., Ste. 470, Durham , NC 277038466 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $3,783 ( 9 months) 2002 Profits: $-16,174 ( 9 months) Stock Ticker: ISPH 2001 Sales: $7,300 2001 Profits: $-23,100 Employees: 56 2000 Sales: $5,400 2000 Profits: $14,000 Fiscal Year Ends: 12/31 1999 Sales: $1,100 1999 Profits: $-8,900 1998 Sales: $ 400 1998 Profits: $-7,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $245,716 Stock Purch. Plan: Second Exec. Salary: $186,375 ADVANTAGE: Multiple products in development/Good partnerships.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Bonus: $70,000 Bonus: $60,000

Northeast:

International:



INTEGRA LIFESCIENCES CORP

www.integra-ls.com


Y


Y


Profits: 8


TYPES OF BUSINESS:



Drugs-Human Tissue Skin Replacement Products Absorbable Medical Products Neuroscience Tissue Regeneration Technology

Integra Lifesciences Corporation develops, manufactures and markets medical devices, implants and biomaterials dealing with human tissue regeneration. Subsidiary Integra NeuroSciences is a leading provider of implants, instruments and monitors used in neurosurgery, neurotrauma and related critical care. This segment addresses trauma cases and hydrocephalus through its established market positions in ICP monitoring, neurosurgical shunting, neuroendoscopy and specialty neurosurgical instrumentation. Integra NeuroSciences is currently responsible for more than 3,000 ICP monitors installed worldwide. Through acquisitions and internal growth, Integra has rapidly grown its NeuroSciences business into a leading provider of devices for the neurosurgery market. The firm recently expanded the division with the acquisition of NeuroSupplies, Inc., a specialty distributor of disposables and supplies for neurologists, pulmonologists and other physicians. Integra LifeSciences, the company’s other business segment, develops and manufactures a variety of medical products and devices, focusing on products used to treat soft tissue and orthopedic conditions. The firm recently added Satelec Medical, a French manufacturer of the Dissectron ultrasonic surgical aspirator console and a broad line of related handpieces, to its LifeSciences division.

BRANDS/DIVISIONS/AFFILIATES: Integra NeuroSciences Integra LifeSciences NeuroSupplies, Inc. Satelec Medical Dissectron

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stuart M. Essig, CEO David B. Holtz, VP-Finance Debbie Leonetti, VP-Mktg. Wilma Davis, VP-Human Resources Michael D. Pierschbacher, Sr. VP-Research and Dev. Judith E. O'Grady, Sr. VP-Clinical Affairs John B. Henneman III, Chief Admin. Officer Linda Littlejohns, VP-Clinical Dev. David B. Holtz, Treas. Bob Paltridge, VP-North American Sales Judith E. O'Grady, Sr. VP-Regulatory/Quality Ass. Michael D. Pierschbacher, Dir.-Corp. Research Ctr. Don Nociolo, VP-Oper.

Phone: 609-275-0500 Fax: 609-799-3297 Toll-Free: Address: 311 Enterprise Dr., Plainsboro, NJ 08536 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $82,561 ( 9 months) 2002 Profits: $9,903 ( 9 months) Stock Ticker: IART 2001 Sales: $87,700 2001 Profits: $26,200 Employees: 600 2000 Sales: $71,600 2000 Profits: $-11,400 Fiscal Year Ends: 12/31 1999 Sales: $42,900 1999 Profits: $-6,000 1998 Sales: $17,600 1998 Profits: $-12,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $325,000 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $270,000 Bonus: $ ADVANTAGE: A leading provider of implants, instruments and monitors used in neurosurgery, neurotrauma and related critical care.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast: Y

International: Y



INTERFERON SCIENCES INC

www.interferonsciences.com


Y



Profits: 100


TYPES OF BUSINESS:



Drugs-Alpha Interferon-Based

Interferon Sciences, Inc. is a biopharmaceutical company engaged in the study, manufacture and sale of pharmaceutical products based on its highly purified, multi-species, natural source alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. Researchers have identified four major classes of human interferon: alpha, beta, gamma and omega. The company’s three ALFERON products contain a form of alpha interferon. Alpha interferons are manufactured commercially in three ways: by genetic engineering, by cell culture and from human white blood cells. The firm’s ALFERON N Injection (interferon alfa-n3) product has been approved by the FDA for the treatment of certain types of genital warts. In addition, Interferon Sciences has been studying its potential use in the treatment of HIV, hepatitis C and other indications. The company has also been studying ALFERON N Gel and ALFERON LDO, the firm’s topical and oral formulations of natural alpha interferon, for the potential treatment of viral and immune system diseases. The production of natural alpha interferon is dependent upon a supply of human white blood cells and other essential materials. Interferon Sciences obtains white blood cells from FDA-licensed blood donor centers. The firm is currently engaged in discussions with potential corporate partners regarding the further investigation of its ALFERON N product as a potential treatment in patients afflicted with multiple sclerosis. For Interferon to operate profitably, it needs to sell significantly more ALFERON N Injection, which will depend mainly on the expansion of existing markets and/or successful attainment of FDA marketing approval for additional indications.

BRANDS/DIVISIONS/AFFILIATES: ALFERON N ALFERON LDO ALFERON N GEL

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Lawrence M. Gordon, CEO Stanley G. Schutzbank, Pres. Donald W. Anderson, CFO Pat Thunell, Dir.-Human Resources Mei-June Liao, VP-Research and Dev. Donald W. Anderson, Controller James R. Knill, VP- Medical Affairs Donald W. Anderson, Corp. Sec.

Phone: 732-249-3250 Fax: 732-249-6895 Toll-Free: 888-728-4372 Address: 783 Jersey Ave., New Brunswick, NJ 08901-3660 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,647 ( 9 months) 2002 Profits: $-3,373 ( 9 months) Stock Ticker: IFSC 2001 Sales: $1,500 2001 Profits: $-7,200 Employees: 38 2000 Sales: $1,100 2000 Profits: $-3,000 Fiscal Year Ends: 12/31 1999 Sales: $2,300 1999 Profits: $-3,600 1998 Sales: $2,000 1998 Profits: $-21,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Focus on alpha interferons.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



INTERMUNE PHARMACEUTICALS INC Industry Group Code: 325412 Ranks within this company's industry group: Sales: 70 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



www.intermune.com Profits: 235


TYPES OF BUSINESS:



Drugs-Chronic Granulomatous Disease and Osteoporosis Drugs-Infectious Disease

InterMune Inc. develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders. The company currently markets three products: Actimmune, Infergen and Amphotec. InterMune has the exclusive license rights in the United States to Actimmune (interferon gamma-1b injection) for a range of indications, including chronic granulomatous disease, osteoperosis, idiopathic pulmonary fibrosis, mycobacterial infections, systemic fungal infections and cystic fibrosis. The company currently markets Actimmune for chronic granulomatous disease. Interferon gamma-1b, the active ingredient in Actimmune, is a human protein that plays a key role in preventing the formation of excessive scar, or fibrotic, tissue and is a potent stimulator of the immune system. The company markets Infergen in the United States and Canada for the treatment of chronic hepatitis C infections and Amphotec worldwide for the treatment of invasive aspergillosis. InterMune is also developing the product Oritavancin for the treatment of Gram-positive bacterial infections, a major cause of bloodstream and skin infections. In recent news, InterMune announced an agreement with Inhale Therapeutic Systems, Inc., to use its technology to develop a PEG-Infergen version for the treatment of chronic hepatitis C infections.

BRANDS/DIVISIONS/AFFILIATES: Actimmune Infergen Amphotec Oritavancin

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. W. Scott Harkonen, CEO W. Scott Harkonen, Pres. Sharon Surrey-Barbari, CFO/Sr. VP-Finance David Cory, Sr. VP-Sales and Mktg. James E. Pennington, VP-Scientific Affairs James E. Pennington, VP-Medical Affairs Stephen N. Rosenfield, VP/Corp. Sec. Stephen N. Rosenfield, General Counsel Sharon Surrey-Barbari, Sr. VP-Admin. John J. Wulf, VP-Corp. Dev. Peter Van Vlasselaer, Sr. VP-Tech. Oper. Marianne Armstrong, Sr. VP-Global Regulatory Oper. Marianne Armstrong, Sr. VP-Corp. Compliance Christine W. Czarniecki, VP-Regulatory Affairs W. Scott Harkonen, Chmn.

Phone: 415-466-2200 Fax: 415-466-2300 Toll-Free: Address: 3280 Bayshore Blvd., Brisbane, CA 94005 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $72,647 ( 9 months) 2002 Profits: $-118,705 ( 9 months) Stock Ticker: ITMN 2001 Sales: $40,000 2001 Profits: $-118,200 Employees: 210 2000 Sales: $11,200 2000 Profits: $-24,200 Fiscal Year Ends: 12/31 1999 Sales: $ 600 1999 Profits: $-6,300 1998 Sales: $ 1998 Profits: $-6,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Exclusive U.S. rights to Actimmune.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:




Northeast:

International:



INTERNATIONAL ISOTOPES

www.intisoid.com


Y



Profits: 78


TYPES OF BUSINESS:



Drugs-Radioactive Isotopes Radiopharmaceuticals

Currently in development, International Isotopes aims to become the first independent commercial manufacturer of radioisotopes and radiopharmaceuticals. Radioisotopes can be used for a number of functions, including the diagnosis of thyroid and prostate cancers, tumor irradiation, heart function diagnosis and bone pain palliation. One of International Isotopes’ currently manufactured products is the iodine-125 implantable radiation brachytherapy seed, licensed from Imagyn Medical Technologies for the treatment of prostate cancer. The company’s major asset, the proton linear accelerator (LINAC), was acquired from the defunct Superconducting Super Collider project and is crucial to the efficient production of radioisotopes. International Isotopes’ is committed toward the eventual release of a full line of radioisotopes. Other projects include production of high specific activity Cobalt-60 for a variety of medical device applications; contract manufacturing of a full range of test and calibration sources for nuclear medicine or gamma camera operational testing; and the processing of topaz gemstone that has undergone irradiation for color enhancement. International Isotopes recently received approval to manufacture dose calibrator and rod sources for nuclear medicine imaging. The firm is the exclusive contract manufacturer to RadQual, LLC for these products. In collaboration with RadQual, International Isotopes has also developed alternative packaging options for the medical flood source in an effort to offer greater flexibility and value.

BRANDS/DIVISIONS/AFFILIATES: LINAC International Isotopes Idaho, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steve Laflin, CEO Steve Laflin, Pres. Sandra Wood, CFO Sandra Wood, VP-Human Resources Darin Lords, Eng. and Quality Control Tanya Fox, Admin. Sandra Wood, Chief Acc. Officer John Miller, Radiation and Industrial Safety Officer Kent Coleman, Oper. Supervisor

Phone: 208-524-5300 Fax: 208-524-1411 Toll-Free: 800-699-3108 Address: 4137 Commerce Circle, Idaho Falls , ID 83401 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: INIS.PK 2001 Sales: $2,200 2001 Profits: $-2,800 Employees: 13 2000 Sales: $2,800 2000 Profits: $-9,700 Fiscal Year Ends: 12/31 1999 Sales: $3,700 1999 Pr ofits: $14,100 1998 Sales: $2,000 1998 Profits: $-5,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $106,885 Stock Purch. Plan: Second Exec. Salary: $99,567 ADVANTAGE: Owns the proton linear accelerator which is crucial to isotope production.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



INTRABIOTICS PHARMACEUTICALS Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



www.intrabiotics.com Profits: 217 Computers: Hardware: Software: Arrays: Database Management:

TYPES OF BUSINESS:



Drugs-Infectious Disease

Intrabiotics is a biopharmaceutical company researching and developing new antibacterial and antifungal drugs to treat and prevent infectious diseases, with an especially strong focus on multi-drug resistant microbes. The company is currently developing an oral solution for countering oral mucositis, which is characterized by mouth ulcers from cancer therapies. It is also being tested for the prevention of ventilator-associated pneumonia and the treatment of respiratory infections in cystic fibrosis patients. Intrabiotics is currently in Phase III clinical trials for reduction in the incidence and severity of ulcerative oral mucositis . It has completed a Phase IIa study of iseganan HCl oral solution for the prevention of ventilatorassociated pneumonia and a Phase I study of iseganan HCl solution for inhalation in cystic fibrosis patients. The company is conducting research focused on discovering and developing compounds with novel chemical structures and mechanisms of antimicrobial activity against bacteria or fungi. It has two programs in the preclinical research stage, IB-880 and IB-863, which it intends to out-license for further research and development.

BRANDS/DIVISIONS/AFFILIATES: IB-880 IB-863 PolyPeptide Laboratories

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ernest Mario, CEO Henry J. Fuchs, COO Henry J. Fuchs, Pres. Eric J. Bjerkholt, Sr. VP/CFO Jim Butler, Sr. VP-Mktg. & Sales Del Nordstrom, VP-Bus. Dev. Steve Ketchum, VP-Regulatory Affairs Natalie L. McClure, Sr. VP-Product Dev. Al Burnette, VP-Sales Leisa Dennehy, VP-Mktg. Ernest Mario, Chmn.

Phone: 650-526-6800 Fax: 650-969-0663 Toll-Free: Address: 1245 Terra Bella Ave., Mountain View, CA 94043 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-24,200 ( months) Stock Ticker: IBPI 2001 Sales: $ 2001 Profits: $-67,400 Employees: 31 2000 Sales: $ 100 2000 Profits: $-45,600 Fiscal Year Ends: 12/31 1999 Sales: $7,900 1999 Profits: $-23,100 1998 Sales: $6,400 1998 Profits: $-17,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $330,000 Stock Purch. Plan: Second Exec. Salary: $250,000 ADVANTAGE: Intensive research and development in antibacterial and antifungal drugs.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $50,000 Bonus: $25,000

Northeast:

International:



INTROGEN THERAPEUTICS INC

www.introgen.com


Y Y



Profits: 129


TYPES OF BUSINESS:



Drugs-Cancer Adenoviral Delivery System

Introgen Therapeutics is a leading developer of gene therapy products for the treatment of cancer. The company is capitalizing on significant advances in the understanding of the human genome and the role that genetic function plays in the development of cancer. Introgen’s drug discovery and development programs have resulted in innovative approaches in which therapeutic genes are used to treat cancer by directly addressing the genetic abnormalities associated with the disease. The company is 20% owned by Aventis. Introgen’s subsidiary, Gendux AB, has established business operations in Europe. The firm’s lead product candidate, INGN 201, combines the naturally occurring p53 tumor suppressor gene with Introgen’s clinically proven adenoviral delivery system. The critical importance of the p53 gene in controlling tumor growth indicates that INGN 201 is applicable to multiple cancers. Introgen is beginning pivotal Phase III clinical studies of INGN 201 in head and neck cancer and conducting a Phase II clinical trial in non-small cell lung cancer. It is also conducting several Phase I clinical trials in additional cancer indications. To date, Introgen has treated over 400 patients with a total of over 3,000 doses of INGN 201, establishing a broad safety profile. Introgen is developing INGN 201 and other p53 products as part of a collaboration agreement with Aventis Pharma. In recent news, the firm was granted the exclusive license to a patent related to breast cancer study from Aventis Pharmaceuticals.

BRANDS/DIVISIONS/AFFILIATES: INGN 201 Gendux AB Aventis Diminishing Viral Gene Expression

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David G. Nance, CEO David G. Nance, Pres. James W. Albrecht, Jr., CFO Dale Petty, VP-Human Resources Jack A. Roth, Chief Medical and Scientific Advisor James A. Merritt, Chief Medical Officer Shawn L. Gallagher, VP-Production and Tech. J. David Enloe, Jr., VP-Oper. G. Thomas Finnegan, VP-Corp. Bus. Dev. C. Channing Burke, VP- Corp. Comm. Sunil Chada, Dir.-Research and Dev. Keith Coffee, Dir.-Clinical Sciences David L. Parker, VP-Intellectual Property Max W. Talbott, Sr. VP-Worldwide Commercial Dev.

Phone: 512-708-9310 Fax: 512-708-9311 Toll-Free: Address: 301 Congress Ave., Ste. 1850, Austin, TX 78701 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,004 ( 9 months) 2002 Profits: $-20,496 ( 9 months) Stock Ticker: INGN 2001 Sales: $ 300 2001 Profits: $-12,300 Employees: 53 2000 Sales: $8,400 2000 Profits: $-7,700 Fiscal Year Ends: 6/30 1999 Sales: $8,200 1999 Profits: $-2,600 1998 Sales: $11,100 1998 Profits: $-2,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $163,854 Stock Purch. Plan: Y Second Exec. Salary: $108,333 ADVANTAGE: Multiple cancer therapies in clinical trials.

OTHER THOUGHTS:



West:

Southwest: Y

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International: Y



INVITROGEN CORPORATION

www.invitrogen.com




Y

TYPES OF BUSINESS:

Profits: 31




Diagnostics-Gene Cloning Kits

Invitrogen develops, manufactures and markets research tools in kit form and provides other research products to customers engaged in life sciences research and the commercial manufacture of genetically engineered products. The company is a leading supplier of over 700 research kits and reagents that simplify and improve gene cloning, gene expression and gene analysis techniques. The company’s TOPO TA Cloning Kits reduce the time required for a key step in the gene cloning process (ligation reaction) from 12 hours to five minutes while increasing the success rate from 50% to over 90%. Other cloning kits manufactured by the company include the FastTrack 2.0 Kit (isolation of pure, full-length mRNA directly from cells or tissues), Discovery Line (RNA and DNA libraries created from hard-to-obtain human tissue sources) and Echo Cloning System (usage of recombination for rapid DNA cloning into multiple expression vectors). Additionally, it supplies sera, cell and tissue culture media and reagents used in life sciences research, as well as in processes to grow cells in the laboratory and produce pharmaceuticals and other materials. Invitrogen has been involved in a number of acquisitions and mergers. The company recently announced it has completed the acquisition of InforMax, Inc., a provider of bioinformatics software.

BRANDS/DIVISIONS/AFFILIATES: TOPO TA Cloning Kit FastTrack 2.0 Kit Novex Electrophoresis GmbH Life Technologies, Inc. Discovery Line Zero Blunt PCR Cloning Kit InforMax, Inc. Ethrog Biotechnologies

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Lyle C. Turner, CEO/Pres. Lewis J. Shuster, COO Lyle C. Turner, Pres. C. Eric Winzer, CFO Alison Rowland, VP-Mktg. L. James Runchey, VP-Human Resources John Carrino, VP-Research and Dev. William Needles, VP/CIO Ann M. McCormick, VP- Mfg. Oper. John A. Cottingham, VP/Corp. Sec. John A. Cottingham, VP/General Counsel John D. Thompson, VP-Corp. Dev. Paul Goodson, VP-Investor Rel. Daryl J. Faulkner, VP-Europe James R. Glynn, Exec. VP August Sick, VP-Bus. Dev. Albie Neal, VP-Asia Pacific Lyle C. Turner, Chmn. Daryl J. Faulkner, Sr. VP-Intl. Oper.

Phone: 760-603-7200 Fax: 760-603-7201 Toll-Free: Address: 1600 Faraday Ave., Carlsbad, CA 92008 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $486,800 ( 9 months) 2002 Profits: $37,500 ( 9 months) Stock Ticker: IVGN 2001 Sales: $629,300 2001 Profits: $-147,700 Employees: 2,726 2000 Sales: $246,200 2000 Profits: $-54,300 Fiscal Year Ends: 12/31 1999 Sales: $92,900 1999 Profits: $9,200 1998 Sales: $70,600 1998 Profits: $5,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Merger with Life Technologies.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:



Bonus: $20,820 Bonus: $19,688

Northeast:

International: Y



IOMED INC

www.iomed.com


Y



Profits: 2


TYPES OF BUSINESS:



Drug Delivery Systems Local Inflammation Therapies Ophthalmic Therapies

IOMED, Inc. is a leader in the development, manufacture and sale of active drug transport systems primarily used to treat acute local inflammation in the sports and occupational medicine and physical therapy markets. The firm seeks opportunities to market or develop new products, as well as collaborative agreements to develop its non-invasive drug technology. Its proprietary technologies are in various stages of research and product development for the treatment of inflammation and ophthalmic diseases. These products are used in the sitespecific, non-invasive administration of soluble salts or other drugs into the body as an alternative to hypodermic injection, to avoid the pain of needle insertion, to minimize the infiltration of carrier fluids and to avoid damage caused by needles in traum atized tissue. IOMED markets two iontophoretic system products used to deliver corticosteroids for local inflammation conditions and to deliver Iontocaine, the firm's topical solution for local dermal anesthesia. The firm's patented Phoresor System is designed for clinical use and is comprised of a reusable dose controller and single-use, disposable transdermal patch kits. Patch kits include IOGEL, TransQ and Anestrode. In addition, the company markets Numby Stuff, an Iontocaine product primarily for use in the pediatrics market. Products in development include IontoDex, designed for patient in-home use in the treatment of local inflammation. IOMED has also developed the OcuPhor platform for safe and effective administration of therapeutics to the back of the eye. In recent news, the firm began distributing Liquid Ice in North America. The product, manufactured by Americool, is a reusable, self-contained cooling and compression wrap. IOMED offers its employees health care coverage, life insurance, educational assistance and other benefits.

BRANDS/DIVISIONS/AFFILIATES: Phoresor System Iontocaine IOGEL Numby Stuff TransQ IontoDex GelSponge OcuPhor

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert J. Lollini, COO Robert J. Lollini, CFO Timothy B. Lucas , Dir.-Nat'l Sales Mary A. Crowther, VP-Human Resources Greg A. Fischer, Exec. VP-Mfg. and Product Dev. Mary A. Crowther, VP-Admin. Services Jessica Barrett, Dir.-Product Mktg. Peter J. Wardle, Chmn.

Phone: 801-975-1191 Fax: 801-972-9072 Toll-Free: 800-621-3347 Address: 2441 S. 3850 West, Ste. A, Salt Lake City, UT 84120 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $11,800 (12 months) 2002 Profits: $-2,400 (12 months) Stock Ticker: IOX 2001 Sales: $11,395 2001 Profits: $-7,876 Employees: 76 2000 Sales: $10,800 2000 Profits: $-1,200 Fiscal Year Ends: 6/30 1999 Sales: $10,500 1999 Profits: $ 100 1998 Sales: $10,300 1998 Profits: $-1,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $200,000 Stock Purch. Plan: Second Exec. Salary: $160,000 ADVANTAGE: Expertise in the use of electrical currents for drug delivery.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



ISIS PHARMACEUTICALS INC

www.isip.com


Y



Profits: 223


TYPES OF BUSINESS:



Drugs-Cytomegalovirus Retinitis Antisense Technology

Isis Pharmaceuticals is a pioneer of antisense technology, which is based on the direct application of gene sequence information to fight various diseases. The company developed Vitravene, the first antisense drug, to fight CMV retinitis. Isis also has 13 other antisense compounds in its pipeline, with eight being tested in human clinical trials, including ISIS 3521, ISIS 5132 and ISIS 2503 for the treatment of solid tumors, ISIS 2302 for various inflammatory diseases and ISIS 14803 for the hepatitis C virus. Isis is expanding the therapeutic opportunities for antisense drugs by developing a variety of formulations to enhance patient convenience and compliance. The company’s second-generation drugs, which represent approximately half of the drugs in development, may be able to be dosed as infrequently as once per month. The firm is also making progress on oral formulations for its second-generation drugs. The company’s GeneTrove division uses antisense technology as a tool to provide information for various pharmaceutical companies about human genes, including their function, behavior and effectiveness in fighting diseases. At the same time, the firm’s Ibis Therapeutics division focuses on the discovery of small molecules that bind to RNA and serve as drugs. This division’s initial area of focus is discovering novel antibacterials, but it plans to extend its focus towards discovering treatments for cancer, central nervous system disease and inflammation as well as degenerative diseases of aging. Isis Pharmaceuticals recently entered a series of alliances designed to market and develop company products. Isis has been successful in creatively structuring corporate alliances in which the company maintains complete ownership of its technology; diminishes the risks inherent in developing, launching and supporting drugs in large and competitive therapeutic markets; and shares significantly in the commercial potential of its drugs.

BRANDS/DIVISIONS/AFFILIATES: Ibis Therapeutics Elan Corporation GeneTrove Vitravene ISIS 2503

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stanley T. Crooke, CEO B. Lynne Parshall, CFO Richard L. Fatt, VP-Strategic Planning & Mktg. Patricia Lowenstam, VP-Human Resources C. Frank Bennett, VP-Antisense Research John McNeil, VP-Informatics F. Andrew Dorr, Chief Medical Officer Grantland E. Bryce, General Counsel Jennifer Giottonini, VP-Bus. Dev. Karen Lundstedt, VP-Corp. Comm. Karen Lundstedt, VP-Investor Rel. Elizabeth L. Hougen, VP-Finance Gregory Hardee, VP-Pharmaceutical Dev. Brett Monia, VP-Antisense Drug Discovery James McArdle, VP-Analytical Dev. & Quality

Phone: 760-931-9200 Fax: 760-931-9639 Toll-Free: Address: 2292 Faraday Ave., Carlsbad, CA 92008 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $58,320 (12 months) 2002 Profits: $-56,413 (12 months) Stock Ticker: ISIS 2001 Sales: $53,300 2001 Profits: $-73,800 Employees: 434 2000 Sales: $37,300 2000 Profits: $-53,500 Fiscal Year Ends: 12/31 1999 Sales: $33,900 1999 Profits: $-59,200 1998 Sales: $39,200 1998 Profits: $-43,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $450,009 Stock Purch. Plan: Y Second Exec. Salary: $358,883 ADVANTAGE: Combination of work in molecular biology and antisense technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $432,000 Bonus: $282,620

Northeast:

International: Y



IVAX CORPORATION

www.ivax.com


Y Y



Profits: 15


TYPES OF BUSINESS:



Drugs-Generic Nutraceuticals Veterinary Products Oncology Drugs Respiratory Drugs Over the Counter Drugs

IVAX Corporation is a holding company whose subsidiaries are among the leading manufacturers of generic and proprietary drug products in the world. IVAX has operations in over 30 countries across the globe. In its proprietary drugs division, the company has an especially strong focus on respiratory and oncology drugs, including its Easi-Breathe device and Paxene, an injectable anticancer drug. Other proprietary drugs include Elmiron, which is used for the treatment of interstital cystitis, a chronic urinary bladder disease primarily affecting women. IVAX also manufactures and markets 56 generic prescriptions in the U.S. and more than 110 generic prescription and over-the-counter drugs in the U.K. In addition, the firm’s subsidiaries produce veterinary products, neutraceuticals (including herb extracts) and diagnostic reagents and instruments. DVM Pharmaceuticals, an IVAX subsidiary, formulates, packages and distributes various veterinary products, primarily neutraceutical and dermatological products for small companion animals. Currently, the company’s research and development efforts are focused on increasing IVAX’s proprietary drug product base. New drugs under development include an oral form of Paxene called Paxoral, a product for the treatment of multiple sclerosis, a patented drug for allergic disorders, a product for the treatment of severe epilepsy and a compound for the treatment of brain cancer. Other research and development areas are focused on formulating compounds for the treatment of diseases including asthma, cystic fibrosis, Parkinson’s disease and Alzheimer’s disease. The company offers its employees dental, medical and vision plans, as well as educational assistance and employee assistance programs.

BRANDS/DIVISIONS/AFFILIATES: IVAX Pharmaceuticals, Inc. Goldcaps, Inc. Diamedix Corporation DVM Pharmaceuticals, Inc. Paxoral Elvetium S.A. Paxene Easi-Breathe

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Phillip Frost, CEO Neil Flanzraich, Pres. Thomas E. Beier, Sr. VP-Finance/CFO J. Michael Lopez, VP-Human Resources Jane Hsiao, Chief Tech. Officer Steven Rubin, Corp. Sec. Steven Rubin, General Counsel Isaac Kaye, Deputy CEO Robert Prego, Sr., VP-Latin America

Phone: 305-575-6000 Fax: 305-575-6055 Toll-Free: Address: 4400 Biscayne Blvd., Miami, FL 33137 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $872,021 ( 9 months) 2002 Profits: $85,985 ( 9 months) Stock Ticker: IVX 2001 Sales: $1,215,400 2001 Profits: $243,200 Employees: 8,175 2000 Sales: $793,400 2000 Profits: $131,000 Fiscal Year Ends: 12/31 1999 Sales: $656,500 1999 Profits: $70,700 1998 Sales: $625,700 1998 Profits: $71,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $735,000 Stock Purch. Plan: Y Second Exec. Salary: $692,003 ADVANTAGE: Focus on respiratory and oncology drugs.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $487,500 Bonus: $402,750

Northeast: Y

International: Y



JOHNSON & JOHNSON

www.jnj.com


Y Y



Y Y

TYPES OF BUSINESS:

Profits: 3




Drugs-Personal Health Care and Hygiene Products Manufac turer Sterilization Products Surgical Products Pharmaceuticals Skin Care Products Self Diagnostic Products Drug Research and Development Medical Equipment

Johnson and Johnson (J&J), founded in 1886, is one of the world’s largest, most comprehensive and broadly based manufacturers of health care products. The company has more than 197 companies in 54 countries and markets its products in almost every country in the world. J&J’s worldwide operations are divided into three segments: consumer, pharmaceutical and medical devices and diagnostics. The company’s principal consumer goods are personal care and hygiene products, including nonprescription drug, adult skin and hair care, baby care, oral care, first aid and sanitary protection products. Major brands in this segment include Mylanta, Band-Aid, Reach, Tylenol, Aveeno, Immodium A-D and Monistat. The pharmaceutical segment covers a wide spectrum of health fields, including antifungal, antiinfective, cardiovascular, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, psychotropic and women’s health. Major prescription drugs in this segment include Orthoclone OKT3 to treat organ transplant rejection; Risperdal, an antipsychotic used to treat schizophrenia; and Remicade, for the treatment of Crohn’s Disease and rheumatoid arthritis. In the medical devices and diagnostics segment, J&J makes a number of professional products including suture and mechanical wound closure products, surgical instruments, disposable contact lenses, joint replacement products, intravenous catheters and medical equipment. J&J has been involved in a number of strategic acquisitions, including Atrionix, Heartport and BabyCenter. Moreover, the company recently merged with ALZA, a research-based pharmaceutical company and a leader in drug delivery technologies. J&J offers its employees on-site childcare at many locations, a hotline with childcare advice and reimbursement for adoption fees. Major sites also offer on-site fitness centers. Working Mother Magazine recently ranked the firm among the Best Companies for Working Mothers for the 16th consecutive year.

BRANDS/DIVISIONS/AFFILIATES: Band-Aid Tylenol Reach Mylanta Atrionix Baby Center ALZA Corporation Heartport

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ralph S. Larsen, CEO Robert J. Darretta, VP-Finance JoAnn H. Heisen, CIO Roger S. Fine, General Counsel Russell C. Deyo, VP-Admin. Christian A. Koffman, Consumer and Personal Care Group Brian D. Perkins, Consumer Pharmaceuticals & Nutritionals Group Robert G. Savage, Pharmaceuticals Group

Phone: 732-524-0400 Fax: 732-524-3300 Toll-Free: 800-328-9033 Address: One Johnson & Johnson Plaza, New Brunswick, NJ 08933 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $26,895,000 ( 9 months) 2002 Profits: $5,213,000 ( 9 months) Stock Ticker: JNJ 2001 Sales: $33,004,000 2001 Profits: $5,668,000 Employees: 101,800 2000 Sales: $30,129,000 2000 Profits: $5,023,000 Fiscal Year Ends: 12/31 1999 Sales: $28,267,000 1999 Profits: $4,258,000 1998 Sales: $24,642,000 1998 Profits: $3,111,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,525,000 Bonus: $1,610,868 Stock Purch. Plan: Y Second Exec. Salary: $1,050,000 Bonus: $1,113,508 ADVANTAGE: Johnson & Johnson is the world's largest and most comprehensive manufacturer of health care products serving the consumer, pharmaceutical and professional markets.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Northeast: Y

International: Y



K V PHARMACEUTICAL CO

www.kvpharma.com


Y Y



Profits: 39


TYPES OF BUSINESS:



Drugs-Generic Drug Delivery Processes and Systems Drugs-Branded Drug Taste Improvement Systems Raw Materials for the Drug Industry

KV Pharmaceuticals develops a wide variety of drug delivery systems, including controlled-released, oral and topic site-specific treatments, tablets and taste-masking systems. The company’s controlled-release systems, which include Meter Release and Micro Release, are designed to release drugs at specific time intervals. KV’s site-specific treatments and tablets isolate drugs to a specific area of the body to increase their effectiveness. The company’s taste-masking systems are aimed at improving the taste of otherwise unpleasant-tasting drugs. These systems include Liquette, FlavorTech and Micromask. In addition, through its ETHEX subsidiary, the company manufactures generic products and markets them to national drug store chains and distributors across the country. ETHEX’s current product line consists of more than 70 products and focuses on four main therapeutic areas: women’s health, cardiovascular, pain management and respiratory. The company established Ther-RX to market brand name pharmaceutical products that KV develops internally using its proprietary technologies. Through its Particle Dynamics, Inc. subsidiary, KV develops, manufactures and markets technologically enhanced raw material products for the pharmaceutical, nutritional, food and personal care industries. The firm has been recognized by many leading financial publications. Forbes ranked KV as one of America’s 200 Best Small Companies for 2001. The company was also ranked by BusinessWeek as one of the top 100 Hot Growth Companies.

BRANDS/DIVISIONS/AFFILIATES: ETHEX Corporation Ther-RX Corporation Liquette Particle Dynamics, Inc. Meter Release Micro Release FlavorTech Micromask

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Marc S. Hermelin, CEO Gerald R. Mitchell, CFO Alan G. Johnson, Sr. VP-Strategic Planning Catherine Biffignani, VP-Corp. Comm. Catherine Biffignani, VP-Investor Rel. Gerald R. Mitchell, Treas. Raymond F. Chiostri, Pres./CEO, Particle Dynamics Alan G. Johnson, Sr. VP-Corp. Growth

Phone: 314-645-6600 Fax: 314-567-1096 Toll-Free: Address: 2503 S. Hanley Rd., St. Louis , MO 63144 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $109,709 ( 9 months) 2002 Profits: $5,318 ( 9 months) Stock Ticker: KVA 2001 Sales: $182,900 2001 Profits: $23,600 Employees: 637 2000 Sales: $146,000 2000 Profits: $24,300 Fiscal Year Ends: 3/31 1999 Sales: $114,900 1999 Profits: $23,300 1998 Sales: $98,486 1998 Profits: $11,304


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: ADVANTAGE: Acquisition of existing drugs.

OTHER THOUGHTS:




West:

Southwest:

Midwest: Y

Southeast:



Bonus: $1,103,000 Bonus: $25,000

Northeast:

International:



KENDLE INTERNATIONAL INC

www.kendle.com




Y Y

TYPES OF BUSINESS:

Profits: 8



Y Y


Research & Development-Clinical Trials Statistical Analysis Medical Technical Writing Consulting

Kendle International is a contract research organization providing drug research and development services in the pharmaceutical and biotechnology industries. Services offered by the company include clinical trial management, clinical data management, statistical analysis, medical technical writing, regulatory/validation consulting and representation and medical communications services. Kendle runs a state-of-the-art clinical pharmacology unit in The Netherlands, where it offers services for drugs undergoing Phase I and IIA clinical trials. Furthermore, through its Health Care Communications subsidiary, the firm provides organizational, meeting management and publication services to various professional associations and pharmaceutical companies. The firm’s proprietary software, TrialWare, enables clinical trial data to be processed faster through automated workflow, parallel processing and standardization. Kendle’s clinical trial information web service, TrialWeb, offers customized browser-based access to project data on a real-time basis, providing customers with enhanced knowledge management capabilities. The company also owns Kendle College, an in-house corporate university that runs seminars and training programs that focus on the organization of clinical trials. Kendle has been working to expand its overseas operations with strategic acquisitions of foreign contract research organizations. The company recently expanded its overseas presence into Central Europe with the opening of a branch office in Poland. In other news, Kendle acquired Clinical and Pharmacologic Research, Inc., which specializes in Phase I bioequivalence studies for the generic drug industry. Kendle offers its employees stock options, a profit-sharing plan, flexible work schedules, business casual dress and continuing education through its corporate university and tuition reimbursement program.paid time off, business casual dress and the option to telecommute. Additionally, senior personnel are eligible for a management bonus. The company prides itself on fostering a progressive work/life environment. Full or part-time associates who work at least 24 hours a week are eligible for benefits.

BRANDS/DIVISIONS/AFFILIATES: ACER/EXCEL, Inc. SYNERmedica U-Gene Reasearch BV Health Care Communications, Inc. TrialWeb Clinical and Pharmacologic Research, Inc. TrialWeb TrialWare

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Candace K. Kendle, CEO Christopher C. Bergen, COO Christopher C. Bergen, Pres. Timothy M. Mooney, CFO Thomas Stilgenbauer, Chief Mktg. Officer Timothy M. Mooney, Treas.

Phone: 513-381-5550 Fax: 513-381-5870 Toll-Free: 800-733-1572 Address: 1200 Carew Tower, 441 Vine St., Cincinnati, OH 45202 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $164,578 ( 9 months) 2002 Profits: $3,653 ( 9 months) Stock Ticker: KNDL 2001 Sales: $154,300 2001 Profits: $4,200 Employees: 1,800 2000 Sales: $120,500 2000 Profits: $-2,100 Fiscal Year Ends: 12/31 1999 Sales: $117,200 1999 Profits: $7,700 1998 Sales: $89,500 1998 Profits: $7,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $255,410 Bonus: $33,518 Stock Purch. Plan: Y Second Exec. Salary: $222,095 Bonus: $22,669 ADVANTAGE: Developing web-enabled technologies to aid drug development research/Steady growth.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Southeast:



Northeast: Y

International: Y



KING PHARMACEUTICALS INC

www.kingpharm.com


Y Y



Profits: 17


TYPES OF BUSINESS:



Drugs-Diversified Vaccines Prescription Pharmaceutical Products Contract Manufacturer Biologicals

King Pharmaceuticals manufactures branded pharmaceutical products that cover four therapeutic areas, including vaccines and biologicals, cardiovascular, antiinfective and women’s health. The primary cardiovascular product offered by the company is Altace, an angiotensin converting enzyme inhibitor that serves as a drug treatment for hypertension. King also manufactures Lorabid, a treatment for patients with mild to moderate infections caused by bacteria in the respiratory tract and the skin. The firm produces labor-inducing drug Pitocin and Anusol-HC, a treatment for hemorrhoids. In addition, the company currently has Fluogen, a trivalent influenza virus vaccine, under development. The company acquires branded products from larger pharmeceutical companies. For example, King has obtained an exclusive license from Novavax, Inc. to promote, market, distribute and sell Estrasorb, used in transdermal estrogen replacement therapy. Additionally, King and Novava x agreed to comarket King’s oral contraceptive product Nordette, in the U.S. and Puerto Rico. The firm has acquired three branded prescription pharmaceutical products, along with a fully paid license to a fourth product, from Bristol-Myers Squibb Company. These products complement and expand the company’s existing cardiovascular, women's health, and endocrinology product lines. As part of the acquisition, King has entered into manufacturing and supply agreements with Bristol-Myers Squibb Company. In other news, the firm recently received approval from the U.S. Food and Drug Administration for its new drug application for Levoxyl tablets. Levoxyl is a synthetic hormone used for the treatment of hypothyroidism and suppression of thyroid-stimulating hormone and represents a new revenue source for the company.

BRANDS/DIVISIONS/AFFILIATES: Anusol-HC Jones Pharma, Inc. Medco Research, Inc. Levoxyl Lorabid Altace Novavax, Inc. Pitocin

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John M. Gregory, CEO Jefferson J. Gregory, COO Jefferson J. Gregory, Pres. James R. Lattanzi, CFO Michael R. Hilton, VP-Sales and Mktg. Diane Holbrook, Exec. VP-Human Resources R. Henry Richards, Exec. VP-Medical Affairs Moises Saporta, VP-Mfg. John A. A. Bellamy , Exec. VP- General Counsel James E. Gregory, Exec. VP-Prod. & Admin., Bristol Facility Ronald C. Siegfried, Exec. VP-Dev. Kyle P. Macione, Exec. VP-Corp. Affairs Kyle P. Macione, Exec. VP-Investor Rel. Joseph R. Gregory, Pres./COO- Monarch Pharmaceuticals Terri D. White-Gregory, Exec. VP-Financial Analyst Ernest C. Bourne, Pres.-King Int'l

Phone: 423-989-8000 Fax: 423-274-8677 Toll-Free: 800-776-3637 Address: 501 5th St., Bristol, TN 37620 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $856,303 ( 9 months) 2002 Profits: $233,146 ( 9 months) Stock Ticker: KG 2001 Sales: $872,300 2001 Profits: $218,000 Employees: 1,843 2000 Sales: $620,200 2000 Pr ofits: $64,509 Fiscal Year Ends: 12/31 1999 Sales: $512,500 1999 Profits: $99,937 1998 Sales: $294,400 1998 Profits: $83,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $455,810 Bonus: $100,000 Stock Purch. Plan: Second Exec. Salary: $450,810 Bonus: $75,000 ADVANTAGE: Great success at acquiring and promoting existing drug products/Acquisition of Jones Pharma.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast: Y



Northeast:

International:



KOS PHARMACEUTICALS INC

www.kospharm.com


Y


Y


Y

TYPES OF BUSINESS:

Profits: 47




Drugs-Cardiovascular Drugs-Respiratory Diseases Drug Delivery Systems

Kos Pharmaceuticals, Inc. (Kos) develops and produces proprietary prescription products for the treatment of chronic cardiovascular and respiratory diseases. The company markets Niaspan, for the treatment of cholesterol disorders, as well as Mavik and Tarka (through a joint effort with Knoll Pharmaceutical), used in the treatment of hypertension. In addition, the firm has a number of products under development, including a device utilizing aerosolized inhalation formulations, Nicostation (a drug to complement Niaspan by treating mixed lipid disorders), isosorbide-5-mononitrate (a treatment for angina pectoritis) and a solid-dose drug delivery system that will formulate compounds. Kos has concentrated its expansion on improving its position in the $14-billion cardiovascular pharmaceuticals market. The firm is currently looking into new applications for its solid-dose technology of gastric retention delivery systems designed for pharmaceutical products. Kos continues to develop new inhalation delivery technologies for the treatment of diabetes and respiratory diseases. The company anticipates developing biotherapeutic compounds in order to complement in vitro and in vivo data demonstrating the performance and efficacy of delivering proteins via the lungs. Kos is also working on a line of inhalation devices including a breath-coordinated inhaler, a breath-actuated inhaler and a spacerless MDI device that generates low plume force. These products will offer a variety of benefits. In recent news, the company was granted a third U.S. patent for the unique pharmacokinetic features of its Niaspan and Advicor cholesterol drugs. The company also recently entered into an alliance with the American Heart Association to provide personalized treatment information via the Internet to patients with cholesterol disorders. The company provides its employees with tuition reimbursement, vision and dental care and an employee assistance program.

BRANDS/DIVISIONS/AFFILIATES: Tarka Advicor Nicostation Niaspan Mavik

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Adrian Adams , CEO Adrian Adams , Pres. Christopher Kiritsy, CFO Robert E. Baldini, Chief Sales and Mktg. Officer Susan Taylor, VP-Human Resources David J. Bova, Sr. VP-Research and Dev. Christopher Rieder, VP-IT Juan Rodriguez, VP/Controller Mark McGovern, VP-Medical Affairs Richard King, Sr. VP-Commercial Oper. Christopher Kiritsy, VP-Bus. Dev. Frederick Sexton, Sr. VP-Product Dev. Marvin Blanford, VP-Compliance Eugenio Cefali, VP-Clinical Dev. David Heatherman, VP- Managed Care

Phone: 305-577-3464 Fax: 305-577-4596 Toll-Free: Address: 1001 Brickell Bay Dr., 25th Fl., Miami, FL 33131 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $117,677 ( 9 months) 2002 Profits: $-26,905 ( 9 months) Stock Ticker: KOSP 2001 Sales: $91,400 2001 Profits: $2,400 Employees: 580 2000 Sales: $60,200 2000 Profits: $-35,300 Fiscal Year Ends: 12/31 1999 Sales: $36,300 1999 Profits: $-54,600 1998 Sales: $13,000 1998 Profits: $-79,200


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $395,600 Bonus: $400,000 Stock Purch. Plan: Y Second Exec. Salary: $250,000 Bonus: $175,000 ADVANTAGE: Concentrated expans ion within the cardiovascular market/Expertise in inhalation delivery technologies.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Northeast: Y

International:



KOSAN BIOSCIENCES INC

www.kosan.com


Y


Clinical: Trials : Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:

Profits: 160


TYPES OF BUSINESS:



Drugs-Polyketide Manipulation Cancer Treatments Treatments for Infectious Disease Gastrointestinal Motility Treatments

Kosan Biosciences, Inc. is a biotechnology company using its proprietary technologies to develop drug candidates from an important class of natural product compounds known as polyketides. Polyketides are naturally made in very small amounts in microorganisms and are difficult to make or modify chemically. The company is able to create, modify and produce the compounds in ways that chemists generally cannot. Because polyketides have been a rich source of marketed drugs, the firm hopes to create a pipeline of potential drug candidates from its novel compounds. Kosan makes improved versions of known polyketide pharmaceutical products and changes existing products to create new products in other therapeutic areas. Part of the firm's strategy is to form collaborative relationships to move its drug candidates into and through clinical trials and to market, prepare and screen its polyketide libraries to create new products. The four components of Kosan's technology platform are polyketide gene alteration, chemo-biosynthesis, heterologous over-expression and combinatorial biosynthesis. Currently, the firm is focusing its development efforts on treatments for cancer, infectious diseases and gastrointestinal motility disorders. Kosan maintains a research agreement with The R. W. Johnson Pharmaceutical Research Institute in the area of infectious disease. The company has also collaborated with the Sloan-Kettering Institute for Cancer Research to develop epothilone compounds for cancer treatment. In recent news, Kosan announced results from a Phase I trial of KOS-862, an epothilone product that inhibits cancer cells. The company also signed two research and development agreements with the National Cancer Institute to develop geldanamycin analogs, which sensitize cancer cells to anticancer agents. Kosan offers its employees benefits including medical, dental and vision plans, life insurance, stock options, referral bonuses and commuter checks, as well as annual company events.

BRANDS/DIVISIONS/AFFILIATES: KOS-862

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Daniel V. Santi, CEO Michael S. Ostrach, COO Michael S. Ostrach, Pres. Susan M. Kanaya, CFO/Sr. VP-Finance Peter Licari, VP-Process Sciences Robert Johnson, Sr. VP-Medical Affairs Robert Johnson, Sr. VP-Corp. Dev. David C. Myles, Exec. Dir.-Chemistry C. Richard Hutchinson, VP-New Tech. Leonard Katz , VP-Biological Sciences

Phone: 510-732-8400 Fax: 510-732-8401 Toll-Free: Address: 3832 Bay Center Pl., Hayward, CA 94545 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $4,060 ( 9 months) 2002 Profits: $-17,690 ( 9 months) Stock Ticker: KOSN 2001 Sales: $5,200 2001 Profits: $-21,900 Employees: 98 2000 Sales: $4,200 2000 Profits: $-15,100 Fiscal Year Ends: 12/31 1999 Sales: $5,300 1999 Profits: $-4,400 1998 Sales: $1,200 1998 Profits: $-3,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Gene manipulation technology.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:



Bonus: $100,000 Bonus: $12,500

Northeast:

International:



LA JOLLA PHARMACEUTICAL

www.ljpc.com


Y




TYPES OF BUSINESS:



Drugs-Autoimmune & Inflammatory Disease

La Jolla Pharmaceutical Company (LJPC) is a biopharmaceutical company focused on the research and development of highly specific therapeutic products for the treatment of certain life-threatening antibody-mediated diseases, including autoimmune conditions such as lupus. The firm's drug candidates, called Toleragens, are designed to treat the underlying cause of these diseases, rather than only the symptoms, without the severe negative side effects caused by suppression of the immune system. The company's proprietary Tolerance Technology program targets and suppresses antibodies without affecting the protective functions of the immune system. LJPC's clinical drug candidate for the treatment of lupus is known as LJP 394 and is currently undergoing FDA Phase III trials. Its candidate for antibody-mediated thrombosis, LJP 1082, is being evaluated in Phase I and II trials. In addition to completing development of LJP 394 for lupus patients, the company plans to apply its technology to other life-threatening conditions, including stroke and heart attack. LJPC has nearly 100 issued patents and more than 80 pending patent applications for its various technologies and drug candidates. Recently, the company announced the results of Phase I and II trials of LJP 1082 antibody-mediated stroke, deep vein thrombosis and recurrent miscarriage.

BRANDS/DIVISIONS/AFFILIATES: Toleragens LJP 394 LJP 920 LJP 1082 Tolerance Technology

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen B. Engle, CEO David Duncan, Jr., CFO William J. Welch, VP-Mktg. and Sales Theodora Reilly, VP-Human Resources Matthew D. Linnik, Exec. VP-Research/Chief Scientific Officer Gail A. Sloan, Controller/Sr. Dir.-Finance Bruce K. Bennett, Jr., VP-Mfg. Gail A. Sloan, Corp. Sec. Andrew Wiseman, Sr. Dir.-Bus. Dev. Andrew Wiseman, Sr. Dir.-Investor Rel. Karen Church, VP-Regulatory Affairs Kenneth R. Heilbrunn, VP-Clinical Dev. Paul C. Jenn, VP- Product Dev. Stephen B. Engle, Chmn.

Phone: 858-452-6600 Fax: 858-452-6893 Toll-Free: Address: 6455 Nancy Ridge Dr., San Diego, CA 92121-2249 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ ( 9 months) 2002 Profits: $-30,200 ( 9 months) Stock Ticker: LJPC 2001 Sales: $ 2001 Profits: $-24,700 Employees: 118 2000 Sales: $ 100 2000 Profits: $-13,800 Fiscal Year Ends: 12/31 1999 Sales: $4,700 1999 Profits: $-9,100 1998 Sales: $8,600 1998 Profits: $-7,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $345,655 Stock Purch. Plan: Second Exec. Salary: $203,400 ADVANTAGE: Development of landmark Tolerance Technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $109,252 Bonus: $57,456

Northeast:

International:



LABORATORIO CHILE SA

www.labchile.com


Y




TYPES OF BUSINESS:



Drugs-Veterinary and Generic Dermatological Pr oducts Cardiovascular Medications Consumer Products

Laboratorio Chile (LabChile), a subsidiary of U.S. generic drug manufacturer IVAX, is a major producer of pharmaceuticals for both humans and animals. The firm has subsidiaries in Argentina, Brazil, Columbia and Peru. LabChile serves both the institutional and retail sectors of its industry. The company also produces human antibiotic, cardiovascular and dermatological products, including offpatent branded and generic drugs. The firm’s veterinary products include vaccines for livestock and antibiotics. Beyond the pharmaceutical industry, LabChile produces such consumer products as MacroSweet, an artificial sweetener, and Freshmel, a brand of antiseptic throat lozenges. The firm has partnered with Schering Plough in a manufacturing agreement for two of its compounds. The firm’s Chilean operations encompass the sales of 906 branded prescription, generic, over-the-counter, clinical and veterinary products, as well as the exportation of these products to 15 countries. In Argentina, the firm produces 82 brands of central nervous system, cardiovascular, alimentary tract and metabolism medications through its Laboratorios Armstrong and Synchro facilities. Peruvian operations, which are conducted through LabChile’s Newpharm S.A. subsidiary, include the institutionally geared commercialization and distribution of 173 different LabChile products. LabChile’s products are primarily sold in Chile, Bolivia, Ecuador, Peru, Panama and Paraguay.

BRANDS/DIVISIONS/AFFILIATES: MacroSweet LabChile Farmasalud S.A. Laboratorios Armstrong Farma Systems S.A. Newpharm S.A. Pharmtrade S.A. IVAX Corporation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Benjamín Alliende Rodríguez, Mgr.-Finance Claudio Garcia Ascenci, Mgr.-Human Resources Fernando Lopez Lago, Mgr.-Info. Systems Benjamín Alliende Rodríguez, Mgr-Admin. Hernán Pfeifer Frenz , General Mgr. Neil Flanzraich, Chmn.

Phone: +56-2-365-5000 Fax: +56-2-365-5100 Toll-Free: 800-633-1322 Address: Avenida Maraton 1315, Nunoa, Santiago, Chile

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $42,900 2000 Profits: $5,700 Fiscal Year Ends: 12/31 1999 Sales: $176,600 1999 Profits: $19,700 1998 Sales: $184,700 1998 Profits: $19,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Nearly 1,000 products in production.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



LARGE SCALE BIOLOGY CORP

www.lsbc.com


Y


Y Y


Y

TYPES OF BUSINESS:

Profits: 22




Research & Development in Life Sciences Proteomics Genomics Drug Development

Large Scale Biology Corp. (LSBC) develops therapeutic products using its proprietary technology and expertise in proteins. The company's technological focus is in three areas: proteomics, functional genomics and the production of proteins for commercial applications. Product categories of strategic importance to LSBC include cancer vaccine immunotherapy and other vaccines for the treatment and prevention of infectious diseases; products and processes for treatment of a variety of diseases in the medical field of hematology; and the low-cost production of complex human proteins in genetically engineered host plants for its own products and in partnership with others. Products the company is working on include a therapeutic vaccine for the treatment of non-Hodgkin's lymphoma, a novel product for stimulation and expansion of stem cell precursors and a proprietary form of human alphagalactosidase for the treatment of Fabry disease. LSBC's technologies include methodologies for the analysis of genes and proteins and for the completion of that analysis in an automated, high-throughput fashion. The firm also owns unique systems for manufacturing proteins in research and commercial quantities to pharmaceuticalgrade purity standards. In the year 2001, the company reported positive results in a Phase I clinical trial for its non-Hodgkin's lymphoma vaccine; established new research collaborations, including agreements with the Stanley Foundation Research Programs and Stanford University; completed upgrades to its Owensboro, Kentucky bioprocessing facility; and obtained 13 new patents. The company provides employees with medical, dental and vision insurance, flexible spending accounts, an employee assistance plan, stock options and banking benefits.

BRANDS/DIVISIONS/AFFILIATES: Large Scale Proteomics Corp. ProGEx Kepler GENEWARE

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert L. Erwin, CEO David R. McGee, Sr. VP/COO John D. Fowler, Jr., Pres. Ronald J. Artale, CFO/Sr. VP-Finance Laurence K. Grill, Sr. VP/Chief Scientific Officer Gary Wolfe, VP-Informatics Systems R. Barry Holtz, Sr. VP-Biopharmaceutical Mfg. John S. Rakitan, Corp. Sec. John S. Rakitan, Sr. VP/General Counsel Daniel Tuse, VP-Bus. Dev. and Pharmaceuticals Daniel J. Moriarty, VP-Corp. Affairs Carol Higgins, Investor Rel. Michael D. Centron, Treas. Sandra Steiner, VP-Proteomics Programs Guy della-Cioppa, VP-Genomics and Dev. John Taylor, VP-Software Dev. and Bioinformatics Robert J. Walden, Sr. VP/Mgr.-Proteomics

Phone: 707-446-5501 Fax: 707-446-3917 Toll-Free: Address: 3333 Vaca Valley Pkwy., Ste. 1000, Vacaville, CA 95688 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,600 ( 9 months) 2002 Profits: $-25,900 ( 9 months) Stock Ticker: LSBC 2001 Sales: $17,700 2001 Profits: $-20,700 Employees: 169 2000 Sales: $23,300 2000 Profits: $-16,300 Fiscal Year Ends: 12/31 1999 Sales: $16,100 1999 Profits: $-34,900 1998 Sales: $3,400 1998 Profits: $-8,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $293,000 Stock Purch. Plan: Y Second Exec. Salary: $238,000 ADVANTAGE: A leader in the integrated discovery, production and application of proteins.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast: Y



Bonus: $ Bonus: $

Northeast: Y

International:



LEXICON GENETICS INC

www.lexgen.com



Y


Profits: 26


TYPES OF BUSINESS:



Research & Development-Genetics Genetic Databases Drug Discovery

Genomics firm Lexicon Genetics is devoted to determining gene functions for drug discovery through the use of knockout mouse technology. The technology alters the DNA of various genes in mouse cells to determine the function of the disrupted gene. The company maintains the OmniBank database and mouse clone library where tens of thousands of embryonic cell clones are catalogued and stored. Through its Internet exchange, Lexgen.com, Lexicon allows researchers to view the DNA sequence of each cell clone online. Companies using the OmniBank online database include German pharmaceutical firm Boehringer Ingelheim, The R.W. Johnson Pharmaceutical Research Institute and American Home Products. The firm also operates the Human Gene Trap database, which documents the DNA sequences of over 50,000 human genes. LexVision is a program under which the company is determining the functions of human genes that could serve as possible targets for pharmaceuticals. Lexicon recently issued a non-exclusive license to Biogen, Inc. for the use of its patented isogenic DNA gene targeting technologies in Biogen's internal research programs. The firm also granted a non-exclusive license to Millennium Pharmaceuticals, Inc. covering the use of Lexicon's isogenic DNA technology. Millennium will use the technology in its drug discovery and target validation programs. In other news, the company was issued a sixth U.S. patent in the field of gene trapping. Lexicon was also awarded two patents covering the full-length sequences of potential drug targets discovered through its gene discovery programs. The firm offers its employees relocation assistance, an educational assistance plan and reimbursement accounts for child care and vision coverage.

BRANDS/DIVISIONS/AFFILIATES: OmniBank LexVision Lexgen.com Seek Target Validation (S-T-V) Program Lexicon Pharmaceuticals Human Gene Trap

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Arthur T. Sands, CEO Arthur T. Sands, Pres. Julia P. Gregory, CFO Walter F. Colbert, Sr. VP-Human Resources Brian P. Zambrowicz, Exec. VP-Research David Kimball, VP- Medicinal Chemistry Jeffrey L. Wade, Exec. VP/General Counsel Ray B. Webb, VP-Finance and Admin. Randall B. Riggs, Sr. VP-Bus. Dev. Carol L. Hensley, VP-Corp. Comm. Alan J. Main, Sr. VP-Lexicon Pharmaceuticals James R. Piggott, Sr. VP-Pharmaceutical Biology Lance K. Ishimoto, VP-Intellectual Property Christophe Person, VP-Informatics

Phone: 281-863-3000 Fax: 281-863-8088 Toll-Free: Address: 8800 Technology Forest Pl., The Woodlands , TX 77381-1160 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $25,080 ( 9 months) 2002 Profits: $-45,808 ( 9 months) Stock Ticker: LEXG 2001 Sales: $30,600 2001 Profits: $-35,200 Employees: 507 2000 Sales: $14,500 2000 Profits: $-26,000 Fiscal Year Ends: 12/31 1999 Sales: $4,700 1999 Profits: $-12,500 1998 Sales: $2,200 1998 Profits: $-7,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $400,000 Stock Purch. Plan: Second Exec. Salary: $260,000 ADVANTAGE: Provides Internet access to major databases of cell clones for genomic study.

OTHER THOUGHTS:



West:

Southwest: Y

Midwest:

Southeast:



Bonus: $250,000 Bonus: $125,000

Northeast: Y

International:



LIFECELL CORPORATION

www.lifecell.com


Y


Y


Profits: 1


TYPES OF BUSINESS:



Drugs-Tissue Grafting Biomedical Products Skin Replacement Technology

LifeCell Corporation specializes in regenerative medicine, developing and manufacturing products geared toward the repair, replacement and preservation of human tissues. The company has developed and patented several proprietary technologies, including a method for producing an extracellular tissue matrix, a method for cell preservation through signal transduction and a method for freeze-drying biological cells and tissues without damage. LifeCell markets three major products based on these tissue matrix technologies: Alloderm and Cymetra for burns and plastic reconstructive surgery and Repliform for the urogynecology market (treatment of urinary incontinence). The versatile Alloderm is one of the only transplant tissue products on the market promoting the regeneration of normal human soft tissue. In addition, the firm has a number of products currently under development, including a small-diameter vascular graft, orthopedic applications of its acellular dermal matrix and Thrombosol, a formulation for extended storage of platelets.

BRANDS/DIVISIONS/AFFILIATES: Alloderm Cymetra Repliform Thrombosol

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul G. Thomas, CEO Paul G. Thomas, Pres. Fenel M. Eloi, Sr. VP/CFO Patrick N. Bergstedt, VP-Sales & Mktg. Judy Colyn, Mgr.-Human Resources Stephen A. Livesey , Chief Science Officer William E. Barnhart, VP-Oper.

Phone: 908-947-1100 Fax: 908-947-1200 Toll-Free: Address: 1 Millennium Way, Branchburg, NJ 08876 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $25,155 ( 9 months) 2002 Profits: $ 994 ( 9 months) Stock Ticker: LIFC 2001 Sales: $27,800 2001 Profits: $-2,100 Employees: 138 2000 Sales: $22,772 2000 Profits: $-7,138 Fiscal Year Ends: 12/31 1999 Sales: $12,700 1999 Profits: $-9,200 1998 Sales: $8,000 1998 Profits: $-7,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $288,750 Stock Purch. Plan: Second Exec. Salary: $220,584 ADVANTAGE: Expertise in human tissue regeneration.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $129,938 Bonus: $56,249

Northeast: Y

International:



LIFECORE BIOMEDICAL INC

www.lifecore.com



Y


Profits: 18


TYPES OF BUSINESS:



Dental Implants Tissue Regeneration Products Surgical Devices

Lifecore Biomedical develops and manufactures medical and surgical devices, which are used in a wide range of fields including dentistry, general surgery, ophthalmology, drug delivery, veterinary and wound care management. The company’s hyaluronates division focuses on hyaluronates products (carbohydrates that moisturize soft tissues in the body), including INTERGEL, a product aimed at reducing post-surgical adhesions. The oral restorative division offers a range of titanium -based dental implants that replace lost or extracted teeth. In addition, the division also manufactures tissue regeneration products for the restoration of soft tissue after deterioration from periodontal disease. Lifecore Biomedical has increased its international operations, most notably through the creation of a subsidiary based in Stockholm, Sweden that enables the firm to distribute its products throughout the Scandinavian region. The company is working to develop increased strategic alliances with market leaders. Current partners include Alcon Labs, Johnson and Johnson, Gynecare and the Musculoskeletal Transplant Foundation.

BRANDS/DIVISIONS/AFFILIATES: Implant Support Systems, Inc. CAPSET Calcium Sulfate Barrier TefGen Regenerative Membranes INTERGEL Adhesion Prevention Solution

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James W. Bracke, CEO James W. Bracke, Pres. Dennis J. Allingham, Exec. VP/CFO Andre P. Decarie, VP-Mktg. & Sales Julia Jensen, Human Resources Colleen M. Olson, VP-Corp. Admin. Oper. Brian J. Kane, VP-New Bus. Dev. Dennis J. Allingham, General Mgr.-Hyaluronate & Oral Restorative Div.

Phone: 612-368-4300 Fax: 612-368-3411 Toll-Free: Address: 3515 Lyman Blvd., Chaska, MN 55318 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $38,800 (12 months) 2002 Profits: $-4,700 (12 months) Stock Ticker: LCBM 2001 Sales: $34,100 2001 Profits: $-3,700 Employees: 200 2000 Sales: $32,800 2000 Profits: $-1,600 Fiscal Year Ends: 6/30 1999 Sales: $27,300 1999 Profits: $1,600 1998 Sales: $25,600 1998 Profits: $ 200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: International expansion.

OTHER THOUGHTS:




West:

Southwest:

Midwest: Y

Southeast:



Bonus: $35,178 Bonus: $22,386

Northeast:

International: Y



LIGAND PHARMACEUTICALS INC

www.ligand.com


Y



Profits: 199


TYPES OF BUSINESS:



Drugs-Cancer Small Molecule Drugs

Ligand Pharmaceuticals develops new drugs that address a wide variety of medical needs, including cancer, skin diseases, hormone-related diseases, osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases. The company’s products include Panretin gel, a topical treatment used to treat lesions stemming from AIDS-related Kaposi’s sarcoma, and Ontak and Targretin are prescribed for patients with cutaneous T-cell lymphoma. In addition, the company has a number of drugs in development, including pain reliever Morphelan and its tissue selective androgen receptor modulators for hormone replacement therapy. Ligand’s business strategy includes forming collaborative partnerships with other established pharmaceutical companies. The firm currently has alliances with the likes of Pfizer, Allergan, GlaxoSmithKline, Eli Lilly and Bristol-Myers Squibb. Cooperative products currently under development include drugs that treat osteoporosis, breast cancer, cardiovascular disease, type II diabetes and inflammatory diseases. Ligand Pharmaceuticals has been working on developing its overseas operations, concentrating its efforts on Europe. European authorities recently granted a marketing authorization for Panretin, the first of the company’s products to be approved for distribution in Europe. In anticipation of the approval, the company signed a major multi-million dollar deal with Italian pharmaceutical company Alfa Wasserman to market Ligand products in Italy. At the same time, Ligand has also concentrated expansion efforts toward the development of new products, having recently received FDA approval for the gel version of Targretin, which will be fourth in the company’s product line.

BRANDS/DIVISIONS/AFFILIATES: Glycomed, Inc. Allergan Ligand Retinoid Therapeutics, Inc. Seragen Inc. Targretin ONTAK Panretin Morphelan

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David E. Robinson, CEO David E. Robinson, Pres. Paul V. Maier, Sr. VP/CFO William A. Pettit, Sr. VP-Human Resources & Admin. Andres Negro-Vilar, Chief Scientific Officer/Sr. VP-Research Gian Aliprandi, VP/Sr. Corp. Controller Warner R. Broaddus , Corp. Sec. Warner R. Broaddus , General Counsel Phillip A. Duffy, VP-Tech. Oper. Russell L. Allen, VP-Corp. Dev. & Strategic Planning Steven D. Reich, Sr. VP-Clinical Research Eric S. Groves, VP-Project Mgmt.

Phone: 858-550-7500 Fax: 858-550-7506 Toll-Free: Address: 10275 Science Center Dr., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $69,317 ( 9 months) 2002 Profits: $-25,868 ( 9 months) Stock Ticker: LGND 2001 Sales: $76,300 2001 Profits: $-43,000 Employees: 351 2000 Sales: $48,110 2000 Profits: $-72,376 Fiscal Year Ends: 12/31 1999 Sales: $38,285 1999 Profits: $-74,719 1998 Sales: $17,673 1998 Profits: $-117,886


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $573,945 Stock Purch. Plan: Second Exec. Salary: $369,550 ADVANTAGE: A leader in the discovery and development of small-molecule drugs.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



LION BIOSCIENCE AG

www.lionbioscience.com




Profits: 4


TYPES OF BUSINESS:

Y



Software-Genetic Analysis Research-Nuclear Receptor Genes Life Science Informatics Professional Services

LION Bioscience manufactures research and development data and information analysis software for the life sciences and health care industries. LION has established alliances in informatics and genomics with several leading health care companies, including Aventis, Bayer, Celera, DuPont, Glaxo Wellcome, Merck, Nestle, Novartis, Pharmacia and Upjohn and SmithKline Beecham. LION’s Life Science Informatics operations are focused on developing and implementing innovative integration solutions, with the aim of improving productivity and performance in the areas of life science research and development. The LION DiscoveryCenter is a powerful integration platform that provides a single point of access to drug discovery data, applications and related documents in a user-friendly desktop interface. LION Lead Engine is another application component that provides a comprehensive chemistry solution for lead identification and optimization as well as preclinical testing and analysis. The LION Lead Engine provides the ability to identify leads faster, while allowing researchers to optimize leads of higher quality more quickly. LION SolutionCenter Professional Services provides customized solutions for clients’ specific needs, including integrating proprietary and third-party databases and applications; developing customized views and interfaces; and integrating internal data visualization resources. The firm’s Integrated Drug Discovery and Diagnostics business formerly integrated information technology solutions with high-throughput technologies. LION recently discontinued its drug discovery business in order to focus on providing comprehensive integration and decision support solutions for the life science industry. As a result, 86 full-time positions were discontinued. In other news, the firm and IBM recently agreed to offer subscription-based hosted computing services to life sciences companies performing drug-related research. The company has locations in Germany, the U.K., Japan and the United States. Employees need not necessarily speak a foreign language in order to work for the company in foreign locations.

BRANDS/DIVISIONS/AFFILIATES: SRS Prisma LION DiscoveryCenter LION Lead Engine LION SolutionCenter Trega Biosciences IBM

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Friedrich von Bohlen, CEO Klaus J. Sprockamp, COO Martin Hollenhorst, CFO Werner Eberhardt, VP-Mktg. Jan Mous, Chief Scientific Officer Reinhard Schneider, CIO Sven Riethmuller, General Counsel Rupert Luck, Sr. Dir-Global Admin. Daniel Keesman, Chief Bus. Officer Gunter Dielman, VP-Investor Rel. Claus Kremoser, VP-Drug Delivery Jurgen Mertens, VP-IT Consulting Hartmut Voss, VP-Scientific Content Thomas Hein, VP-Professional Services

Phone: +49-6221-4038-0 Fax: +49-6221-4038-101 Toll-Free: Address: Waldhofer Strasse 98, Heidelberg, 69123 Germany

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $35,200 (12 months) 2002 Profits: $-47,600 (12 months) Stock Ticker: LEON 2001 Sales: $10,000 2001 Profits: $-12,356 Employees: 441 2000 Sales: $8,700 2000 Profits: $-10,700 Fiscal Year Ends: 3/31 1999 Sales: $3,900 1999 Profits: $-3,800 1998 Sales: $ 800 1998 Profits: $-1,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Software expertise for the preclinical phase of drug development.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



LORUS THERAPEUTICS INC

www.lorusthera.com


Y




TYPES OF BUSINESS:



Drugs-Cancer Antisense Compounds Low -Molecular Weight Compounds

Toronto-based Lorus Therapeutics, Inc., formerly Imutech Pharma, is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products and technologies for use in the treatment of cancer. The firm is engaged in basic drug discovery research in addition to acquisitions of promising novel technologies from other companies and research institutions. Taking a multi-mechanistic approach to cancer treatment, the company concentrates on the discovery and development of different classes of anticancer compounds, focusing on distinct molecular entities that act against specific cellular targets associated with the development and progression of cancer. Lorus's research programs include biology-based discovery research; preclinical development in toxicology, drug metabolism and phamacokinetics; and clinical development with an emphasis on Phase I and II trials. Currently, the firm is investigating three strategies: oligonucleotides, particularly antisense molecules; low molecular weight compounds; and immune modulating natural product mixtures. Products in development include GTI 2040 and GTI 2501, antisense compounds; analogs of the antifungal agent clotrimazole; and Virulizin, an immunotherapy product with indications for pancreatic cancer, malignant melanoma, Kaposi's sarcoma, lung cancer, breast cancer and uterine, ovarian and cervical cancers. Virulizin is currently in Phase III clinical trials. Recently, Lorus was issued a U.S. patent for the drug. The firm also renewed its emergency drug program to supply the anticancer product to patients with advanced pancreatic cancer.

BRANDS/DIVISIONS/AFFILIATES: Imutec Pharma NuChem Virulizin GTI 2040 GTI 2501 NC 381

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jim A. Wright, CEO James T. Parsons, VP-Finance/CFO Aiping H. Young, Sr. VP/Chief Tech. Officer Shane A. Ellis, Corp. Sec. Shane A. Ellis, VP-Legal Affairs James T. Parsons, VP-Admin. Geoffery S. Collett, VP-Corp. Dev. Suzanne Cadden, VP-Regulatory and Clinical Affairs

Phone: 416-798-1200 Fax: 416-798-2200 Toll-Free: Address: 2 Meridian Rd., Toronto, Ontario M9W 4Z7 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $ (12 months) 2002 Profits: $-8,800 (12 months) Stock Ticker: Foreign 2001 Sales: $ 2001 Profits: $-9,800 Employees: 21 2000 Sales: $ 2000 Profits: $-5,619 Fiscal Year Ends: 5/31 1999 Sales: $ 1999 Profits: $-3,021 1998 Sales: $ 1998 Profits: $-3,096


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Purchased rights to NuChem Analogs.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



LUMINEX CORPORATION

www.luminexcorp.com




Y

TYPES OF BUSINESS:

Profits: 25




Bioassay Devices Microspheres

Luminex manufactures and markets a technology platform based on bioassays, which are used in the life sciences industry to detect biochemicals, proteins and genes in samples for the purpose of drug discovery, genetic analysis, pharmacogenomics and clinical diagnostics. The company’s LabMAP system performs up to 100 bioassays on a single drop of fluid through Luminex 100, an instrument combining diode lasers, digital signal processors and other software. The firm also manufactures development microspheres (used to discover and optimize characteristics of individual biomolecular interactions), calibration microspheres (used to assure consistency in measurements) and multi-analyte microspheres (which enable reactions and controls to be mixed and measured after they are optimized). Luminex has concentrated its expansion toward exploring new ventures through alliances and collaborations. The firm recently entered into three agreements with Bayer Diagnostics, a division of Bayer Corporation. The contracts cover a license harmony and related supply agreement for Luminex's xMAP technology, as well as a multi-year agreement relating to the development of a new cellular analyzer. Part of the license agreement grants Bayer Diagnostics the right to develop and distribute invitro diagnostic products based on Luminex technology. Bayer will also design and market a new cellular analyzer based on in-house and Luminex technology and software. Luminex will manufacture the instrument platform and receive royalties from the commercialization of Bayer's product based on the cellular analyzer, as well as revenue from the sale of the instruments. In other news, Luminex was recently named the highest-ranking life sciences company on the 2002 Deloitte & Touche Technology Fast 500, a ranking of the fastest growing technology companies in North America.

BRANDS/DIVISIONS/AFFILIATES: Luminex 100 Luminex XYP LumAvidin LabMAP xMAP Bayer Diagnostics

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas W. Erickson, CEO Thomas W. Erickson, COO Mark B. Chandler, Pres. James L. Persky, VP/CFO James E. Schepp, VP-Mktg. and Sales Eddie Chien, Human Resources Ralph L. McDade, VP-Scientific Affairs Harriss T. Currie, Controller Michael D. Spain, Chief Medical Officer Oliver H. Meek, VP-Mfg. Randel S. Marfin, VP-Bus. Dev. James L. Persky, Treas. James W. Jacobson, VP-Tech. Oper.

Phone: 512-219-8020 Fax: 512-219-5195 Toll-Free: 888-219-8020 Address: 12212 Technology Blvd., Austin, TX 78727 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $9,046 ( 9 months) 2002 Profits: $-18,022 ( 9 months) Stock Ticker: LMNX 2001 Sales: $20,900 2001 Profits: $-15,700 Employees: 183 2000 Sales: $8,600 2000 Profits: $-12,500 Fiscal Year Ends: 12/31 1999 Sales: $3,100 1999 Profits: $-9,200 1998 Sales: $ 400 1998 Profits: $-5,600

SALARIES/BENEFIT S: Pension Plan: Savings Plan: Y

COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Advanced bioassay technology.

OTHER THOUGHTS:




West:

Southwest: Y

Midwest:

Southeast:



Bonus: $35,000 Bonus: $20,000

Northeast:

International:



LYNX THERAPEUTICS INC

www.lynxgen.com




Profits: 20


TYPES OF BUSINESS:

Y Y Y



DNA Cloning and Analysis Technology Proteomics Technology

Lynx Therapeutics, Inc. is a leader in the development and application of novel technologies for the discovery of gene expression patterns and genomic variations important to the pharmaceutical, biotechnology and agricultural industries. The firm's proprietary cloning procedure, Megaclone, forms the foundation of these technologies. Megaclone transforms a sample containing millions of DNA molecules into one made up of millions of microbeads, each of which carries approximately 100,000 copies of one of the DNA molecules in the sample. The procedure enables the DNA molecules to be analyzed simultaneously in various applications. In addition, it eliminates the need to store and handle millions of individual DNA clones. Applications based on Megaclone include Massively Parallel Signature Sequencing (MPSS), which generates gene sequence information from microbeads; Megasort, which enables researchers to focus on potential target genes by permitting the direct physical isolation of nearly all the genes differentially expressed between samples; and Megatype, which enables a single experiment to yield the disease- or trait-associated single nucleotide polymorphisms (SNPs) that differentiate large populations of genomes. Lynx is also developing a proteomics technology, Protein ProFiler, which is expected to provide high-resolution analysis of complex mixtures of proteins from cells or tissues. The company formed Axaron Bioscience as a joint venture with BASF to employ Lynx's technology in neuroscience, toxicology and microbiology research programs. In recent news, Lynx formed a two-year collaborative research agreement with the University of California at Davis to study gene expression in the Arabidopsis plant. Lynx offers its employees a benefits package including educational assistance, stock options, a casual dress code, an employee referral plan, health club membership, flexible spending accounts, flu shots and medical, dental and vision plans. Additional benefits include free snacks, subsidized lunches, sports teams and weekly massages.

BRANDS/DIVISIONS/AFFILIATES: Megasort Megatype Megaclone Lynx Therapeutics GmbH Axaron Bioscience AG Protein ProFiler Massively Parallel Signature Sequencing (MPSS)

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kevin P. Corcoran, CEO Kevin P. Corcoran, Pres. Edward C. Albini, CFO Kathy A. San Roman, VP-Human Resources John E. Wiktorowicz, Dir.-Proteomics Edward C. Albini, Corp. Sec. Kathy A. San Roman, VP-Admin. Elizabeth S. Song, Dir.-Bus. Dev. and Alliances Mgmt. Thomas J. Vasicek, VP-Bus. Dev. Jen-i Mao, VP-Genetic Analysis Daixing Zhou, Dir.-Bioinformatics Sarah McCurdy, Mgr.-Bus. Dev. and Commercialization

Phone: 510-670-9300 Fax: 510-670-9302 Toll-Free: Address: 25861 Industrial Blvd., Hayward, CA 94545 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $12,708 ( 9 months) 2002 Profits: $-12,510 ( 9 months) Stock Ticker: LYNX 2001 Sales: $19,300 2001 Profits: $-16,700 Employees: 182 2000 Sales: $12,600 2000 Profits: $-13,300 Fiscal Year Ends: 12/31 1999 Sales: $12,900 1999 Profits: $-6,700 1998 Sales: $7,000 1998 Profits: $-4,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $290,192 Stock Purch. Plan: Y Second Exec. Salary: $209,796 ADVANTAGE: Unique cloning technology/High-profile partnerships for drug development.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International: Y



MACROCHEM CORPORATION

www.macrochem.com


Y



Profits: 6


TYPES OF BUSINESS:



Drug Delivery Technology SEPA -enhanced Pharmaceuticals

MacroChem primarily specializes in the development of pharmaceutical products for commercialization through SEPA (Soft Enhancer of Percutaneous Absorption), a patented topical drug delivery technology. SEPA compounds, when properly combined with drugs, provide pharmaceutical formulations (creams, gels, solutions, etc.) that enhance the transdermal delivery of drugs into the skin or into the bloodstream and can also be used in patch formats in transdermal delivery of selected pharmaceuticals. Transdermal delivery provides an alternative to other methods of drug administration (injection, oral dosage forms, inhalation, etc.). The company has its own facility for the in vitro testing of drug formulations containing SEPA and therefore is less dependent on outside laboratories for this type of testing. SEPA compounds can be used with a broad variety of new and existing drugs to enhance their commercial value. The therapeutic effectiveness and improved convenience of a transdermal SEPA product may substantially expand the existing market for a drug, making SEPA technology a keystone element in pharmaceutical expansion. In addition, a formulation containing SEPA compounds may prove to be a superior alternative to existing methods of administering certain drugs. MacroChem is presently developing specific SEPA formulations for use with non-proprietary and proprietary drugs manufactured by pharmaceutical companies. It plans to commercialize these products through the formation of partnerships, strategic alliances and license agreements. Topiglan is a topical drug being developed for the treatment of male erectile dysfunction. The company was recently issued a patent for EcoNail, an antifungal nail lacquer.

BRANDS/DIVISIONS/AFFILIATES: SEPA Topiglan Benefen MacroDerm EcoNail Topiglan

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert J. Palmisano, CEO Robert J. Palmisano, Pres. Bernard R. Patriacca, CFO Mel Snyder, VP-Mkt. Dev. Thomas C.K. Chan, VP-Research and Tech. Kenneth L. Rice, Jr., Corp. Sec. Kenneth L. Rice, Jr., Treasurer Paul J. Schechter, VP-Drug Dev. and Regulatory Affairs John L. Zabriskie, Chmn.

Phone: 781-862-4003 Fax: 781-862-4338 Toll-Free: Address: 110 Hartwell Ave., Lexington, MA 02421-3134 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 43 ( 9 months) 2002 Profits: $-5,881 ( 9 months) Stock Ticker: MCHM 2001 Sales: $ 800 2001 Profits: $-12,300 Employees: 32 2000 Sales: $ 600 2000 Profits: $-9,700 Fiscal Year Ends: 12/31 1999 Sales: $ 500 1999 Profits: $-6,800 1998 Sales: $ 300 1998 Profits: $-4,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $217,000 Stock Purch. Plan: Second Exec. Salary: $185,000 ADVANTAGE: Topical drug delivery technology that can enhance efficacy of existing drugs.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



MALLINCKRODT INC

www.mallinckrodt.com


Y



Y Y

TYPES OF BUSINESS:




Drugs Imaging Agents Medical Gases Catheters Respiratory Products Diagnostics Anesthesia Devices

Mallinckrodt develops and manufactures a wide range of medical products and devices, primarily used by hospitals for diagnostic and treatment purposes. The company’s imaging group produces a full line of imaging agents and radiopharmaceuticals, including ultrasound and MRI contrast agents, catheters for diagnosis and therapy and x-ray contrast media. Through its respiratory segment, the firm offers a variety of products, including anesthesia devices, medical gases, oxygen therapy and asthma management products, sleep diagnostics and therapy devices and blood analysis products. Mallinckrodt’s pharmaceuticals division is focused on providing pain relief and addiction therapy, with a product line that includes codeine, phosphate, morphine sulfate, naltrexone (for alcohol addiction) and methylphenidate (for attention deficit hyperactivity disorder). Mallinckrodt has been working toward the development and release of new products. The company recently received FDA approval for its OxiFirst Fetal Oxygen Monitoring System, widely hailed to be the first major breakthrough in obstetrical monitoring since the 1960s, which will enable obstetricians to monitor fetus oxygenation during labor and delivery. The firm also received approval for its Liebel-Flarsheim brand Optistar MR contrast power injectors, which introduce contrast media into the body. Mallinckrodt is a subsidiary of Tyco International, Ltd.

BRANDS/DIVISIONS/AFFILIATES: Accucomp, Ltd. Accufusion, Ltd. Carnforth Limited Tyco International HemoCue Optistar MR Liebel-Flarsheim Company OxiFirst

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. C. Ray Holman, CEO Michael A. Rocca, Sr. VP/CFO Bruce K. Crockett, VP-Human Resources William B. Stone, Chief Tech. Officer Douglas A. McKinney, VP/Controller Adeoye Y. Olukotun, VP-Medical & Regulatory Affairs Roger A. Keller, VP/General Counsel Barbara A. Abbett, VP-Comm. Frank A. Voltolina, VP/Treas. Douglass B. Given, Sr. VP Ashok Chawla, Sr. VP/Pres.-Global Bus. Group

Phone: 314-654-2000 Fax: 314-654-5380 Toll-Free: Address: 675 McDonnell Blvd., Hazelwood, MO 63042 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 12,265 2000 Sales: $2,652,800 2000 Profits: $205,000 Fiscal Year Ends: 6/30 1999 Sales: $2,581,200 1999 Profits: $196,200 1998 Sales: $2,367,000 1998 Profits: $-291,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Expertise in diagnostic equipment.

OTHER THOUGHTS:




West: Y

Southwest: Y

Midwest: Y

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



MARTEK BIOSCIENCES CORP

www.martekbio.com


Y Y



Profits: 8


TYPES OF BUSINESS:



Drugs-Nutritional Oils Pharmaceutical Products Dietary Supplements Fluorescent Products

Martek Biosciences Corp. has pioneered the commercial development of microalgae into a portfolio of high-value products and product candidates consisting of nutritional products, advanced detection systems and other products. The company has developed production methods and intellectual property for two important fatty acids, DHA and ARA, which may help develop the eyes and central nervous systems of newborns and promote adult mental and cardiovascular health. Martek is investigating the potential benefit of DHA supplementation on cardiovascular health and breast cancer, as well as on cystic fibrosis and visual and neurological disorders. Currently, the firm is targeting the infant formula market and the adult nutritional market for its nutritional oils. Martek has licensed its DHASCO and ARASCO oil blends to a number of companies in the infant formula market, including Abbott Laboratories and Mead Johnson Nutritionals. Martek also produces Neuromins, a DHA dietary supplement, and Neuromins PL, a DHA supplement specifically designed for pregnant and lactating women. These products are distributed through marketing agreements with firms including Natrol, Inc., Source Naturals, Inc., Nature's Way and Neutraceutical Corp. The products are sold at outlets such as Safeway, Vitamin World, Eckerd's and Savon. Martek also sells bulk DHA oil and powder for applications such as children's chewables and nutritional drinks. In addition, the firm develops fluorescent marker products from microalgae with potential applications in automated biological screening. The markers bring greater speed, sensitivity and simplicity to existing tes ts and applications. These dye products include SureLight, CryptoLight and SensiLight. In addition, Martek's genomics group is developing technologies that may allow the firm to transfer DHA-producing genetic material of microalgae into agricultural products such as corn. Recently, Abbott launched the first soy-based infant formula in the U.S. to contain DHA and ARA.

BRANDS/DIVISIONS/AFFILIATES: DHASCO OmegaTech, Inc. ARASCO Neuromins Formulaid CryptoLight SensiLight SureLight

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Henry Linsert, Jr., CEO Richard J. Radmer, Pres. Peter L. Buzy, CFO Jerome C. Keller, Sr. VP-Sales and Mktg. Richard J. Radmer, Chief Scientific Officer George P. Barker, Sr. VP/Corp. Sec. George P. Barker, General Counsel Thomas C. Fisher, Sr. VP-Oper. Peter L. Buzy, Treas.

Phone: 410-740-0081 Fax: 410-740-2985 Toll-Free: Address: 6480 Dobbin Rd., Columbia, MD 21045 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $30,937 ( 9 months) 2002 Profits: $-24,608 ( 9 months) Stock Ticker: MATK 2001 Sales: $18,800 2001 Profits: $-13,700 Employees: 166 2000 Sales: $9,700 2000 Profits: $-15,700 Fiscal Year Ends: 10/31 1999 Sales: $6,100 1999 Profits: $-14,800 1998 Sales: $6,900 1998 Profits: $-13,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $286,167 Stock Purch. Plan: Second Exec. Salary: $182,400 ADVANTAGE: Microalgae expertise/Partnership with Abbott Labs.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast: Y



Bonus: $82,700 Bonus: $52,360

Northeast: Y

International:



MATRITECH INC

www.matritech.com




Y

TYPES OF BUSINESS:

Profits: 14




Diagnostics-Cancer Diagnostic Tests for Bladder and Cervical Cancer

Matritech, Inc. develops, manufactures and markets innovative cancer diagnostic products based on its proprietary nuclear matrix protein (NMP) technology. The nuclear matrix, a three-dimensional protein framework within the nucleus of cells, plays a fundamental role in determining cell type by physically organizing the contents of the nucleus, including DNA. The company has demonstrated that there are differences in the types and amounts of NMPs found in cancerous and normal tissue and believes the detection of such differences provides important diagnostic information about cellular abnormalities, including cancer. Using its technologies, Matritech has developed non-invasive and minimally invasive cancer diagnostic tests for bladder and cervical cancer and is developing additional tests for breast, colon and prostate cancer. The firm's NMP22 Test Kit for bladder cancer, the first product based on NMP technology, was cleared for sale in the U.S. in 1996. The kit has also been approved for sale in Japan, China and several other countries worldwide. In 2001 the company developed a point-of-care format known as NMP22 BladderChek. Timm Medical Technologies owns the exclusive rights to distribute this product to U.S. urologists. Matritech has also developed the NMP22 Bladder Cancer Test Automated Format. NMP179 is currently in development as a diagnostic test for cervical cancer and precancer. NMP66 is the company's breast cancer product, and NMP48 is in development for prostate cancer. The firm is also developing NMP35 for colon cancer testing. In recent news, Matritech and Sysmex Corp., the largest diagnostic company in Japan, announced a partnership to develop an automated pap smear test to make use of the NMP179 biomarker.

BRANDS/DIVISIONS/AFFILIATES: NMP22 Test Kit Matritech Europe NMP66 NMP Technology NMP22 BladderChek NMP35 NMP48 NMP179

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen D. Chubb, CEO David L. Corbet, COO David L. Corbet, Pres. Richard A. Sandberg, CFO/VP-Finance John Quigley, VP-Mktg. and Sales Ying-Jye Wu, VP-Research and Dev. Stephen H. Ip, VP- Corp. Dev. Melodie R. Domurad, VP-Clinical and Regulatory Affairs

Phone: 617-928-0820 Fax: 617-928-0821 Toll-Free: Address: 330 Nevada St., Newton, MA 02160 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,449 ( 9 months) 2002 Profits: $-6,179 ( 9 months) Stock Ticker: NMPS 2001 Sales: $2,300 2001 Profits: $-8,700 Employees: 44 2000 Sales: $1,200 2000 Profits: $-6,800 Fiscal Year Ends: 12/31 1999 Sales: $ 600 1999 Profits: $-6,100 1998 Sales: $1,000 1998 Profits: $-7,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $238,915 Stock Purch. Plan: Second Exec. Salary: $200,769 ADVANTAGE: Proprietary, non-invasive cancer diagnostic technology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $35,700 Bonus: $25,000

Northeast: Y

International: Y



MATRIX PHARMACEUTICAL

www.matx.com


Y




TYPES OF BUSINESS:



Drugs-Cancer Aqueous -Based Protein Gel Systems

Matrix Pharmaceuticals develops drug candidates for cancer in the form of aqueous -based protein gel systems that deliver water-soluble chemotherapeutic agents. The company covers a wide variety of fields, including tumor biology and physiology, advanced imaging techniques, pharmaceutical chemistry, polymer chemistry, analytical chemistry and biochemistry. One of the company’s main products, IntraDose, is currently under development as an injectable gel for solid tumors in the head and the neck. Another product under development, FMdC, is part of the anticancer class of nucleoside analogs that target solid tumors and cancers of blood cell origin. Matrix's MPI 5020 Radiopotentiator utilizes aqueous protein gel technology to enhance the effects of radiation treatment for solid tumors. In a major development, Chiron Corporation acquired Matrix in early 2002. California-based Chiron is a global pharmaceutical company that develops and commercializes high-value products, with a strategic focus on cancer and infectious disease. The firm commercializes its products through three business units: biopharmaceuticals, vaccines and blood testing.

BRANDS/DIVISIONS/AFFILIATES: IntraDose MPI 5020 Radiopotentiator FMdC Chiron Corporation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael D. Casey, CEO Michael D. Casey, Pres. Jeanette Fritzsky, VP-Sales and Mktg. Lori Gillespie, Human Resources Coordinator Richard E. Jones, VP-Research and Dev. Ronald P. Lucas, VP-Oper. Harry D. Pedersen, VP-Corp. Dev. Richard D. Leavitt, Sr. VP-Medical and Regulatory Affairs Dennis M. Brown, VP-Discovery Research

Phone: 510-742-9900 Fax: 510-742-8510 Toll-Free: Address: 34700 Campus Dr., Fremont, CA 94555 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $1,500 2000 Profits: $23,300 Fiscal Year Ends: 12/31 1999 Sales: $ 400 1999 Profits: $-21,000 1998 Sales: $ 1998 Profits: $-21,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Focus on using advanced technologies to create cancer therapies.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International:



MAXIM PHARMACEUTICALS

www.maxim.com


Y

Other: AgriBio: Genomics: Proteomics: Tissue Replac ement: Cell Transplantation:


Profits: 195


TYPES OF BUSINESS:



Drugs-Cancer Drugs-Hepatitis Topical Therapies

Maxim Pharmaceuticals, Inc. is a global biopharmaceutical company with a diverse pipeline of therapeutic candidates for life-threatening cancers and hepatitis. Its lead drug candidate, Ceplene, is designed to prevent or reverse damage associated with oxidative stress, thereby protecting immune cells and other critical cells and tissue. Ceplene has the potential to be used in a broad range of diseases in which oxidative stress plays a role, including advanced metastatic melanoma, acute myelogenous leukemia, renal cell carcinoma (kidney cancer) and hepatitis C. In addition, Maxim has initiated clinical trials to develop the drug as a treatment for non-viral liver diseases, including cirrhosis. The firm has also developed a high-throughput screening system that is targeted to the identification of compounds that can modulate programmed cell death, or apoptosis. Compounds generated by this technology include the MX2105 series of anti-cancer drug candidates, licensed to Shire-BioChem. The firm also has a collaboration with Celera Genomics, whereby Maxim has screened approximately 400,000 of Celera's compounds to identify anti-cancer effects. Maxim's MaxDerm technology is designed for the treatment of medical conditions for which topical therapy is appropriate, such as oral mucositis, burns, herpes, shingles and related conditions. Pilot clinical studies of a topical histamine gel based on MaxDerm technology have showed efficacy in patients with herpes labialis (cold sores). Further studies will test the drug for indications including radiation dermatitis, a painful side effect of radiation therapy, and aphthous stomatitis (canker sores). Recently, the firm announced the results of pre-clinical studies suggesting that Ceplene can accelerate recovery from alcohol-induced liver damage.

BRANDS/DIVISIONS/AFFILIATES: Cytovia MaxDerm Ceplene MX2167 MX8899 MX126374 MX2105

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Larry G. Stambaugh, CEO Larry G. Stambaugh, Pres. Dale A. Sander, CFO Pam Gleason, VP-Human Resources Kurt R. Gehlsen, Chief Scientific Officer/Sr. VP-Research Dale A. Sander, Corp. Sec. Karl-Hermann Bremeyer, VP-European Oper. Dale A. Sander, Sr. VP-Corp. Dev. Philippe G. Prokocimer, VP-Drug Dev.

Phone: 619-453-4040 Fax: 619-453-5005 Toll-Free: Address: 8899 University Center Ln., Ste. 400, San Diego, CA 92122 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,800 ( 9 months) 2002 Profits: $-53,300 ( 9 months) Stock Ticker: MAXM 2001 Sales: $3,200 2001 Profits: $-37,300 Employees: 132 2000 Sales: $1,400 2000 Profits: $-77,500 Fiscal Year Ends: 9/30 1999 Sales: $1,100 1999 Profits: $-39,200 1998 Sales: $ 200 1998 Profits: $-21,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Collaboration with Celera Genomics.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:



Bonus: $65,000 Bonus: $30,000

Northeast:

International:



MAXYGEN INC

www.maxygen.com




Y

TYPES OF BUSINESS:

Profits: 31




Research & Development-Molecular Evolution DNA Sequences

Maxygen is a leading supplier of directed evolution technology for optimization of genes for the development of products in protein pharmaceuticals, vaccines, agriculture and chemicals. The company’s proprietary technologies, known as MolecularBreeding, combine advanced molecular biology techniques with those of classical breeding to develop protein pharmaceuticals, preventative and therapeutic vaccines, chemicals and agriculture. Components of MolecularBreeding include DNAShuffling, a proprietary process for recombining genes into a library of novel DNA sequences, and MaxyScan, a series of screening capabilities for the identification of desired properties from the library. Maxygen believes its technology provides distinctive advantages over traditional biotechnology by shortening time required to generate lead product candidates, lowering costs associated with research and expanding the potential for discovery. The firm is looking to evaluate opportunities in other fields, including antibody engineering, nutraceuticals, natural products, gene therapy and liquid fuels. Maxygen is currently pursuing more than 40 potential products with its issued patents and more than 450 pending patent applications. The firm has alliances with 11 companies that are market leaders in their respective industries, including Lundbeck, the International AIDS Vaccine Initiative (IAVI), Novozymes, DuPont, Chevron, Pfizer, Syngenta and Hercules. Maxygen is focused on developing products for a number of applications, including the treatment of multiple forms of cancer, infectious diseased such as HIV and hepatitis, allergies and antoimmune diseases. In the chemical sector, the firm is developing biocatalytic processes that could increase yields and decrease manufacturing costs for biotechnology products. In agriculture, Maxygen hopes its technology will increase the quantity and quality of crop yields, such as enhancing the nutritional value of human food or animal feed.

BRANDS/DIVISIONS/AFFILIATES: MolecularBreeding DNAShuffling MaxyScan

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Russell J. Howard, CEO Simba Gill, Pres. Lawrence Briscoe, CFO Howard A. Simon, VP-Human Resources Willem P.C. Stemmer, VP-Research Michael Rabson, General Counsel Pierre Pujol, VP- Corp. Bus. Dev. John Bedbrook, Pres., Agriculture Alan Shaw , Pres., Chemicals Keith Powell, Chief Tech. Officer Russell J. Howard, Pres., Vaccines

Phone: 650-298-5300 Fax: 650-364-2715 Toll-Free: Address: 515 Galveston Dr., Redwood City, CA 94063 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $31,652 ( 9 months) 2002 Profits: $-24,995 ( 9 months) Stock Ticker: MAXY 2001 Sales: $30,500 2001 Profits: $-45,000 Employees: 308 2000 Sales: $24,500 2000 Profits: $-59,600 Fiscal Year Ends: 12/31 1999 Sales: $14,000 1999 Profits: $-11,300 1998 Sales: $2,700 1998 Profits: $-8,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: MolecularBreeding technology.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:



Bonus: $57,750 Bonus: $49,500

Northeast:

International: Y



MDS INC

www.mdsintl.com




Y Y Y

TYPES OF BUSINESS:

Profits: 2



Y


Laboratory Services Research Services Imaging Agents Medical and Surgical Supplies Sterilization Systems Venture Capital

MDS is a global biotechnology firm operating in health, life sciences and proteomics, with operations in 23 countries around the world, including locations in North America, Europe, Asia and Africa. The health segment, which includes MDS Pharma Services, MDS Sciex and MDS Nordion, provides laboratory services; access to anatomical, clinical and genetic information; laboratory management; and distribution of medical products to health care institutions. Customers include hospitals, health care professionals and long-term care facilities. In 2001, this segment began construction of a $20-million cyclotron in Vancouver to meet increased demand for medical isotopes. The division also expanded its agreement with PerkinElmer to develop mass spectrometry equipment. The life sciences segment provides specialized analytical instruments used in drug and biopharmaceutical development; drug discovery and development services; radiation treatment and oncology information management; nuclear medicines for diagnostic and therapeutic applications; and sterilization technology for medical devices and other products. This segment has recently expanded to offer new genetic and other tests. The proteomics division supplies functional proteomics capabilities that revolutionize the way pharmaceutical and biotechnology companies discover and develop new drugs. In 2001, MDS Proteomics formed several new partnerships, including collaborations with Abgenix to develop and commercialize antibody drugs; with Agilent Technologies to develop protein analysis technologies; and with IBM Life Sciences to perform research in bioinformatics. MDS also owns 47% of MDS Capital Corp., which manages seven funds totaling $800 million. The company offers its employees an on-site fitness center, aerobics, yoga and strength training classes, nature trails for jogging and walking and 52 acres of trees and wildlife to enjoy. MDS also sponsors organized sports, such as soccer, volleyball and hockey.

BRANDS/DIVISIONS/AFFILIATES: MDS Nordion MDS Sciex MDS Laboratory Services MDS Pharma Services MDS Matrix MDS Capital Corp. MDS Proteomics Source Medical

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John A. Rogers, CEO John A. Rogers, Pres. Gary W. Goertz , CFO/Exec. VP-Finance Alan D. Torrie, Exec. VP-Global Markets and Tech. Andrea C. Bodnar, VP/CIO Douglas J.P. Squires, Pres., MDS Pharma Services Peter E. Brent, Sr. VP/Corp. Sec. Peter E. Brent, General Counsel Robert W. Breckon, Sr. VP-Strategy and Corp. Dev. Kerry A. Thomas, VP-Strategic e-Bus. Initiatives Sharon Mathers, VP-Corp. Comm. Sharon Mathers, VP-Investor Rel. James M. Reid, Exec. VP-Organization Dynamics John A. Morrison, Group Pres.-Health Care Provider Markets Mary E. Federau, Sr. VP-Talent Dev. R. Ian Lennox, Group Pres.- Pharmaceutical and Biotech Markets

Phone: 416-675-7661 Fax: 416-675-0688 Toll-Free: 888-637-7222 Address: 100 International Blvd., Toronto, Ontario M9W 6J6 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $834,865 ( 9 months) 2002 Profits: $50,713 ( 9 months) Stock Ticker: MDZ 2001 Sales: $1,031,000 2001 Profits: $46,000 Employees: 10,000 2000 Sales: $938,700 2000 Profits: $22,000 Fiscal Year Ends: 10/31 1999 Sales: $774,200 1999 Profits: $51,600 1998 Sales: $650,700 1998 Profits: $11,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Vast array of products and services.

OTHER THOUGHTS:




West: Y

Southwest: Y

Midwest: Y

Bonus: $ Bonus: $

Southeast: Y



Northeast: Y

International: Y



MEDAREX INC

www.medarex.com


Y



Profits: 77


TYPES OF BUSINESS:



Drugs-Human Monoclonal Antibodies Therapeutic Products

Medarex is a leading biopharmaceutical company devoted to the production of human monoclonal antibody-based therapeutics to fight various diseases. The firm’s UltiMab Human Antibody Development System uses transgenic mice in which mouse-derived antibody gene expression is suppressed and effectively replaced with human antibody gene expression. With UltiMab, the company can create all types of antibodies that are fully human, with no mouse protein sequences embedded in the genetic code. Consequently, UltiMab antibodies are less likely to be rejected by a human patient. In addition, the antibodies are more likely to have favorable safety profiles and be eliminated less rapidly from the human body, potentially reducing the frequency and amount of dosing required to affect disease targets. The company has a variety of product candidates that are currently in clinical development, including MDX-33 for idiopathic thrombocytopenia purpura (ITP); MDX-010 for prostate cancer, malignant melanoma and melanoma vaccines, MDX-44 for psoriasis; IDM-1 for ovarian cancer; and HuMax-CD4 for rheumatoid arthritis. The firm is also developing antibodies to treat anti-inflammatory diseases, lymphoma, breast and other cancers. The UltiMab technology is licensed to pharmaceutical and biotechnology companies that also pay royalties on commercial sales of their products. Medarex has entered a spate of strategic alliances, most of which are aimed at research and development opportunities for new antibodies. Over 41 pharmaceutical and biotechnology companies have partnered with Medarex to jointly develop and commercialize products. These companies include industry leaders such as Amgen, Inc., Centocor, Inc., Eli Lilly & Company, Human Genome Sciences, Inc., Immunex Corporation, Novartis Pharma AG, Novo Nordisk A/S and Schering AG. The company owns a major interest in Genmab, a Danish biotechnology company.

BRANDS/DIVISIONS/AFFILIATES: UltiMab Human Antibody Development System KM-Mouse HuMax-CD4 Trans-Phage Technology Genmab MDX-33 MDX-44 IDM-1

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Donald L. Drakeman, CEO Donald L. Drakeman, Pres. Christian S. Schade, Exec. VP-Finance & Admin. Nancy Dawley , Human Resources Nils Lonberg, Sr. VP-Science Geoffrey M. Nichol, Sr. VP-Product Devel. Randall T. Curnow , Sr. VP/Chief Medical Officer W. Bradford Middlekauff, Corp. Sec. W. Bradford Middlekauff, VP/General Counsel Yashwant M. Deo, Sr. VP-Oper. Ronald A. Pepin, Sr. VP-Bus. Dev. Michael A. Appelbaum, Treas. Ernst Schweizer, Pres., Medarex Europe

Phone: 609-430-2880 Fax: 609-430-2850 Toll-Free: Address: 707 State Rd., Princeton, NJ 08540-1437 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $33,484 ( 9 months) 2002 Profits: $-117,925 ( 9 months) Stock Ticker: MEDX 2001 Sales: $42,300 2001 Profits: $-2,700 Employees: 297 2000 Sales: $22,500 2000 Profits: $3,300 Fiscal Year Ends: 12/31 1999 Sales: $9,900 1999 Profits: $-17,000 1998 Sales: $6,800 1998 Profits: $-22,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: UltiMab mouse technology.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:



Bonus: $480,000 Bonus: $200,000

Northeast: Y

International: Y



MEDICIS PHARMACEUTICAL CORP

www.medicis.com


Y



Profits: 33


TYPES OF BUSINESS:



Drugs-Dermatological

Medicis Pharmaceutical Corp. is a leading provider of pharmaceuticals for various dermatological conditions. The company markets a wide range of prescription products, which include DYNACIN and TRIAZ for acne, LUSTRA for skin dyschromia, OVIDE for head lice, NOVCACET for acne rosacea, LOPROX for seborrheic dermatitis and LIDEX and SYNALAR for inflammatory and hyperproliferative skin diseases. The firm’s primary nonprescription product is its ESOTERICA line of topical creams for minor skin discoloration conditions such as age spots, uneven skin tones, dark patches, blotches and freckles. Medicis also sells PLEXION, a prescription cleanser for treating acne rosacea. In addition, Medicis operates SunAndSkin.com, a web site devoted to promoting skin care awareness and providing information about the effects of the sun on the skin. The firm recently completed its acquisition of Ascent Pediatrics, which develops child-appropriate doses of existing prescription drugs.

BRANDS/DIVISIONS/AFFILIATES: ESOTERICA PLEXION SunAndSkin.com Ascent Pediatrics DYNACIN LUSTRA LIDEX TOPICORT

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jonah Shacknai, CEO Mark A. Prygocki, CFO Richard J. Havens, Sr. VP-Sales and Mktg. Adriane Young, Dir.-Human Resources Mitchell S. Wortzman, Sr. VP-Research and Dev. Joseph P. Cooper, Sr. VP-Mfg. and Distribution Mark A. Prygocki, Corp. Sec. Jin Sun Kim, General Counsel Joseph P. Cooper, Exec. VP-Bus. Dev. Libby Retherford, Dir.-Corp. Comm. Mark A. Prygocki, Treas.

Phone: 602-808-8800 Fax: 602-808-0822 Toll-Free: Address: 8125 N. Hayden Rd., Scottsdale, AZ 85258 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $212,800 (12 months) 2002 Profits: $50,000 (12 months) Stock Ticker: MRX 2001 Sales: $167,800 2001 Profits: $40,400 Employees: 188 2000 Sales: $139,100 2000 Profits: $43,000 Fiscal Year Ends: 6/30 1999 Sales: $116,900 1999 Profits: $41,400 1998 Sales: $77,600 1998 Profits: $-12,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Focus on dermatological drugs.

OTHER THOUGHTS:




West:

Southwest: Y

Midwest:

Southeast:



Bonus: $550,000 Bonus: $255,000

Northeast:

International:



MEDIMMUNE INC

www.medimmune.com

Industry Group Code: 325412 Ranks within this company's industry group: Sales: 30

Profits: 22

Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y




TYPES OF BUSINESS:



Drugs-Infectious Disease Drugs for Transplant Patients Oncology Drugs

MedImmune is a biotechnology company engaged in the development and production of pharmaceuticals for infectious diseases and transplantation operations. The company’s Synagis drug (for the treatment of respiratory syncytial virus) is the only monoclonal antibody approved for an infectious disease and has become a primary pediatric product for the prevention of RSV, a major cause of viral pneumonia and brochiolitis in infants and children. In addition, the firm markets CytoGam, a treatment for the cytomegalovirus disease arising from organ transplant complications. Other products include Ethyol for the reduction of toxicities from cancer chemotherapy and radiotherapy, NeuTrexin for the treatment of pneumonia in AIDS patients and Hexalen for the treatment of advanced forms of ovarian cancer. MedImmune has eight additional products in various stages of clinical testing. The company’s subsidiary, MedImmune Oncology, has offices in the U.S. and the Netherlands and primarily conducts the clinical development activities for cancer-focused products. The firm recently announced that it has entered into a research collaboration and worldwide exclusive licensing agreement with Genaera Corporation, a biopharmaceutical company focused on developing medicines from genomics and natural products for the treatment of serious diseases. The two companies will work together on developing and commercializing antibodies that prevent symptoms of asthma and other respiratory diseases.

BRANDS/DIVISIONS/AFFILIATES: CytoGam RespiGam Synagis U.S. Bioscience, Inc. MedImmune Oncology, Inc. Ethyol NeuTrexin Hexalen

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David M. Mott, CEO Melvin D. Booth, COO Melvin D. Booth, Pres. Gregory S. Patrick, CFO Armando Anido, Sr. VP-Mktg. & Sales James F. Young, Pres.-Research and Dev. Franklin H. Top, Jr., Exec. VP/Medical Dir. Michael S. Richman, Sr. VP-Admin. Michael S. Richman, Sr. VP-Corp. Dev. Edward M. Connor, Sr. VP-Clinical Dev.

Phone: 301-417-0770 Fax: 301-527-4200 Toll-Free: Address: 35 W. Watkins Mill Rd., Gaithersburg, MD 20878 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $465,989 ( 9 months) 2002 Profits: $-1,182,606 ( 9 months) Stock Ticker: MEDI 2001 Sales: $618,700 2001 Profits: $149,000 Employees: 877 2000 Sales: $540,500 2000 Profits: $111,200 Fiscal Year Ends: 12/31 1999 Sales: $383,400 1999 Profits: $93,400 1998 Sales: $227,200 1998 Profits: $47,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $737,512 Stock Purch. Plan: Y Second Exec. Salary: $725,000 ADVANTAGE: Makes the primary pediatric product for the prevention of RSV.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $800,000 Bonus: $900,000

Northeast: Y

International: Y



MEDIMMUNE VACCINES

www.aviron.com


Y




TYPES OF BUSINESS:



Drugs-Vaccines Influenza Vaccines Croup Vaccines Mononucleosis Vaccines

MedImmune Vaccines, formerly Aviron, is a biopharmaceutical company focused on the prevention of disease through innovative vaccine technology. MedImmune Vaccines is a subsidiary of MedImmune, Inc. The firm focuses on product development and commercialization efforts for its lead product candidate, FluMist, an investigational live virus vaccine for influenza delivered as a nasal spray. A biologic license application relating to FluMist is currently pending before the Food and Drug Administration. The company’s goal is to become a leader in the discovery, development, manufacture and marketing of innovative vaccines that are safe, effective and economical enough to merit their use in immunization programs targeting the general population. Its vaccine programs are based both on techniques for producing weakened live virus vaccines and on the company's proprietary genetic engineering technologies. Since the influenza virus changes and becomes less susceptible to vaccines each year, MedImmune Vaccines develops techniques that are useful for updating the vaccine yearly, according to recommendations of the CDC and the FDA. MedImmune Vaccines is also developing vaccines for croup and mononucleosis, jointly with GlaxoSmithKline. These vaccines are currently in clinical trials. In addition, the company has started developing drugs for the treatment of cytomegalovirus (CMV). CMV is the leading infectious cause of birth defects in the U.S.; there is currently no vaccine available for the virus.

BRANDS/DIVISIONS/AFFILIATES: FluMist Aviron MedImmune, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. C. Boyd Clark, CEO C. Boyd Clark, Pres. Mike Makris, VP/Controller

Phone: 650-919-6500 Fax: 650-919-6610 Toll-Free: Address: 297 N. Bernardo Ave., Mountain View, CA 94043-5205 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $14,000 2001 Profits: $-127,300 Employees: 585 2000 Sales: $32,242 2000 Profits: $-77,511 Fiscal Year Ends: 12/31 1999 Sales: $22,200 1999 Profits: $-61,900 1998 Sales: $ 700 1998 Profits: $-54,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Focus on flu therapy.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International:



MEDTOX SCIENTIFIC INC

www.medtox.com




Y Y

TYPES OF BUSINESS:

Profits: 5




Services-Labs Substance Abuse Testing Services Hazardous Materials Exposure Monitoring Clinical Drug Testing Forensic Analysis On-Site Occupational Testing Products

Medtox Scientific provides laboratory testing services in forensic and clinical toxicology as well as heavy metal analyses. In addition, the company develops and manufactures on-site diagnostic screening products that can detect substances in humans, food, animals and the environment. The firm’s Ez-Screen and Ez-Quant tests are used to detect toxins that contaminate corn, wheat, rye, barley and other agricultural products consumed by humans. Medtox provides a wide range of laboratory services, including therapeutic drug monitoring, emergency toxicology, occupational testing, forensic analysis and on-site drug screening tests. The company’s Profile-II and Verdict-II are used for detecting cannabinoids (THC), cocaine, opiates, amphetamines and phencyclidine (PCP) in human urine. The firm also performs gas chromatography/mass spectrometry on infants’ stools to test for the presence of various drugs that may have resulted from maternal drug abuse. Medtox recently acquired Leadtech Corp., a clinical laboratory that primarily examines lead concentrations in the blood of pediatric patients. With the recent terrorist incidents involving anthrax, Medtox is focusing its efforts on testing for biological agents and toxins. The company recently announced that it has collaborated in the past with the Department of Defense on projects for the development and manufacture of test kits for the detection of several biological agents and toxins, including anthrax. These products are currently inactive, but the technology, expertise and manufacturing capabilities remain within the company.

BRANDS/DIVISIONS/AFFILIATES: EDITEK, Inc. Princeton Diagnostic Laboratories of America, Inc. Profile Verdict Ez-Screen Ez-Quant Leadtech Corp.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard J. Braun, CEO Richard J. Braun, Pres. James Schoonover, Chief Mktg. Officer Susan Puskas, VP-Human Resources Kevin J. Wiersma, COO, Laboratory Div. B. Mitchell Owens , COO, Diagnostics Div. Jennifer Collins, VP/Laboratory Dir. Susan Puskas, VP-Quality Assurance and Regulatory Affairs

Phone: 612-636-7466 Fax: 651-636-5351 Toll-Free: 800-832-3244 Address: 402 W. County Rd. D, St. Paul, MN 55112 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $39,901 ( 9 months) 2002 Profits: $12,813 ( 9 months) Stock Ticker: TOX 2001 Sales: $49,100 2001 Profits: $2,500 Employees: 455 2000 Sales: $42,900 2000 Profits: $-2,600 Fiscal Year Ends: 12/31 1999 Sales: $35,000 1999 Profits: $1,400 1998 Sales: $29,600 1998 Profits: $-2,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $250,000 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $140,000 Bonus: $ ADVANTAGE: Able to offer a complete line of testing and analysis services, including on-site services for major employers.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Northeast: Y

International:



MERCK & CO INC

www.merck.com


Y



Profits: 2


TYPES OF BUSINESS:


Y


Drugs-Manufacturer Human Health Products and Services Animal Health Products and Services Pharmaceutical Benefits Management

Merck & Co., Inc. is a leading global research-driven pharmaceutical company that manufactures a broad range of products and provides pharmaceutical benefit services through subsidiary Merck-Medco Managed Care, L.L.C. Merck’s products include therapeutic and preventative agents generally sold by prescription, as well as medications used to control and alleviate disease in livestock, small animals and poultry. The company makes drugs that treat ailments associated with American eating habits, including high cholesterol, hypertension and heart failure. These products make up about one-third of the company’s sales. Merck’s top-selling cholesterol drugs are Zocor and Mevacor, and its primary hypertension drugs are Vasotec and Prinivil. Every month, Merck’s web site offers quizzes and information, called InfoParks, on different diseases, such as HIV, heart disease and hepatitis. The firm ascribes its current financial success to five key medicines: Vioxx, a once-a-day medicine for both osteoarthritis and acute pain; Zocor, a prescription drug which controls cholesterol levels; Cozaar and Hyzaar, high blood pressure medicines; and Fosamax, which prevents postmenopausal osteoporosis. Fosamax Once Weekly, the first and only once-a-week oral treatment for osteoperosis is currently the number one medicine in this market. In addition, Merck’s Singulair, a leukotriene antagonist, is the world’s fastest growing asthma medicine. Merck offers its employees on-site fitness facilities with personal trainers, day-care and summer camp programs and extensive training. The company also offers on-site auto maintenance and video rentals for employees at its headquarters location. Additionally, employees may receive scholarships, tuition reimbursement and financial planning assistance. Notably, over 50% of managers and supervisors are female.

BRANDS/DIVISIONS/AFFILIATES: Merck-Medco Managed Care, L.L.C. Mevacor Vasotec Comvax Ivomec Pepcid Singular Fosamax

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Raymond V. Gilmartin, CEO Raymond V. Gilmartin, Pres. Judy C. Lewent, Sr. VP/CFO Wendy Yarno, Sr. VP-Human Resources Edward M. Scolnick, Exec. VP-Science & Tech. Richard C. Henriques, Jr., VP/Controller Bernard J. Kelley, Pres., Merck Mfg. Div. Kenneth C. Frazier, Sr. VP/General Counsel Linda M. Distlerath, VP-Public Affairs Caroline Dorsa, VP/Treas. Edward M. Scolnick, Pres., Merck Research Laboratories David W. Anstice, Pres., Human Health-The Americas Per Wold-Olsen, Pres., Human Health- Europe, Middle East, Africa Richard T. Clark, Pres., Merck-Medco

Phone: 908-423-1000 Fax: 908-735-1253 Toll-Free: Address: One Merck Dr., Whitehouse Station, NJ 08889-0100 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $37,871,900 ( 9 months) 2002 Profits: $5,259,700 ( 9 months) Stock Ticker: MRK 2001 Sales: $47,716,000 2001 Profits: $7,282,000 Employees: 78,100 2000 Sales: $40,363,200 2000 Profits: $6,821,700 Fiscal Year Ends: 12/31 1999 Sales: $32,714,000 1999 Profits: $5,890,500 1998 Sales: $26,898,200 1998 Profits: $5,248,200


COMPET ITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $1,383,338 Stock Purch. Plan: Second Exec. Salary: $820,000 ADVANTAGE: World class drug firm with massive research capabilities.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $1,500,000 Bonus: $825,000

Northeast: Y

International: Y



MGI PHARMA INC

www.mgipharma.com


Y



Profits: 188


TYPES OF BUSINESS:



Drugs-Oncology and Rheumatology

MGI PHARMA is a pharmaceutical company concentrating on the acquisition, development and marketing of drugs for the treatment of cancer and rheumatology disorders. The company’s Salagen tablets, which account for almost all of the company's sales, are a treatment for radiationinduced xerostomia (chronic dry mouth) in patients of head and neck cancer and of Sjogren’s syndrome. Sjogren’s syndrome is an automimmune disease that damages moisture-producing glands. In addition, the firm manufactures Azulfidine EN-tabs and Riadura for rheumatoid arthritis patients, Luxiq foam for corticosteroidresponsive scalp dermatoses in psoriatic arthritis patients and Didronel I.V. Infusion for hypercalcemia of malignancy in various cancer patients. MGI PHARMA has formed several alliances aimed at research and marketing opportunities. Recently, the company was named to Deloitte & Touche's prestigious Fast 50 program, which is a ranking of the 50 fastest-growing technology companies in Minnesota. In other news, the firm and Helsinn Healthcare SA, a privately owned Swiss pharmaceutical group, announced that the FDA accepted their new drug application to market Palonosetron. The drug is used in the prevention of chemotherapy-induced nausea and vomiting. The firm provides employees with a continuing education program, credit union membership, discount off-site airport parking and discounted tickets for entertainment and cultural activities.

BRANDS/DIVISIONS/AFFILIATES: Didronel I.V. Infusion Azulfidine EN-tabs Ridaura Palonosetron Salagen Irofulven MethylGene Luxiq

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Charles N. Blitzer, CEO Leon O. Moulder, Jr., COO Leon O. Moulder, Jr., Pres. William C. Brown, CFO Alan R. Caplan, VP-Sales Edgar F. Timberlake, VP-Human Resources John R. MacDonald, Sr. VP-Research and Dev. William C. Brown, Controller Michael T. Cullen, Jr., Chief Medical Officer Robert M. Johnson, VP-Pharmaceutical Mfg. Robert M. Johnson, VP-Int'l Oper. Leon O. Moulder, Exec. VP John R. MacDonald, Dir.-Pharmacology and Toxicology

Phone: 952-346-4700 Fax: 952-346-4800 Toll-Free: Address: 5775 W. Old Shakopee Rd., Ste. 100, Bloomington, MN 55437 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $25,537 ( 9 months) 2002 Profits: $-24,576 ( 9 months) Stock Ticker: MOGN 2001 Sales: $33,000 2001 Profits: $-34,800 Employees: 167 2000 Sales: $25,200 2000 Profits: $-19,500 Fiscal Year Ends: 12/31 1999 Sales: $24,700 1999 Profits: $4,700 1998 Sales: $16,800 1998 Profits: $ 400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Rapid revenue growth.

OTHER THOUGHTS:




West:

Southwest:

Midwest: Y

Southeast:



Bonus: $149,850 Bonus: $65,350

Northeast:

International:



MICROLOGIX BIOTECH INC

www.mbiotech.com


Y

Other: AgriBio: Genomics: Proteomics: Tissue Replac ement: Cell Transplantation:


Profits: 102


TYPES OF BUSINESS:



Drugs-Antibiotic-Resistant Disease

Micrologix Biotech, Inc. is a biopharmaceutical company focusing on the discovery, development and commercialization of innovative drugs to treat lifethreatening diseases. The company’s drug candidates are based on the development of improved derivatives of naturally occurring peptide compounds found in the defense systems of virtually all life forms. Currently, the firm is in Phase III clinical trials for MBI 226, its novel lead antimicrobial drug product. The trials are designed to demonstrate whether the drug reduces the incidence of life-threatening bacterial and fungal bloodstream infections related to the use of central venous catheters in seriously ill patients. Moreover, the company has completed the first Phase II clinical trial for MBI 594AN, a novel drug candidate for the treatment of acne. The activity of MBI 594AN will be assessed based on acne lesion counts and physician assessment of each patient during the study. In addition, the safety, tolerability and systemic absorption of the drug will be assessed in 18 acne patients in a five-day open label study. Recently, the company acquired a portfolio of antiviral technologies and product candidates owned and being developed by Origenix Technologies, Inc. In other news, Micrologix announced it has entered into a collaboration and license agreement with Hybridon, Inc., to develop a drug for the treatment of human papillomavirus (HPV).

BRANDS/DIVISIONS/AFFILIATES: MBI 226 MBI 594AN

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James Demesa, CEO James Demesa, Pres. Arthur J. Ayers, VP-Finance/CFO Jacob J. Clement, Sr. VP-Science and Tech./Chief Science Officer R. Hector MacKay-Dunn, Corp. Sec. K. David Campagnari, VP-Oper. William D. Milligan, Sr. VP-Corp. Dev./Chief Bus. Officer Arthur J. A yers, Mgr.-Investor Rel. Nancy S. Coulson, Sr. VP-Product Dev. C. Robert Cory, VP-Bus. Dev. Richard Coulson, VP-Tech. Dev. H. David Friedland, VP-Clinical Dev.

Phone: 604-221-9666 Fax: 604-221-9688 Toll-Free: 800-665-1968 Address: 3650 Westbrook Mall, Vancouver, BC V6S 2L2 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Foreign 2001 Sales: $2,059 2001 Profits: $-7,456 Employees: 49 2000 Sales: $ 651 2000 Profits: $-5,514 Fiscal Year Ends: 4/30 1999 Sales: $ 400 1999 Profits: $-4,143 1998 Sales: $ 506 1998 Profits: $-3,426


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Expertise in peptide compounds/Several products undergoing clinical trials.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International: Y



MILLENNIUM PHARMACEUTICALS INC Industry Group Code: 325412 Ranks within this company's industry group: Sales: 39 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y


Y


www.mlnm.com

Profits: 237


TYPES OF BUSINESS:



Drugs-Gene-Based Discovery Platform Pharmacogenomics Diagnostics Life Science-based Products

Millennium Pharmaceuticals researches small molecule, biotherapeutic and predictive medicine products. The company integrates large-scale genetics, genomics, highthroughput screening and informatics to create a drug discovery platform that accelerates the development of therapeutic and diagnostic products. The platform identifies important genes, determines their functions, validates drug and product development targets, formulates assays based on these targets and identifies product candidates. The company’s three primary fields of emphasis are cancer, metabolic diseases (such as obesity) and inflammation. In addition, Millennium has significant programs in infectious diseases, cardiovascular diseases and diseases of the central nervous system. The firm focuses on developing small-molecule drugs, which are typically formulated into pills for oral consumption, as well as proteins and monoclonal antibodies, which are typically only available in injectable form. The company licenses its platform to various pharmaceutical and biotechnological firms in exchange for royalties. The firm recently merged with COR Theraputics, Inc. As part of the merger, Millennium acquired Integrilin, a drug that treats acute coronary problems. The firm also received substantial research and development capabilities in the areas of cardiovascular disease and oncology. The firm’s Millennium University offers employees a variety of in-house workshops and off-site seminars designed to enhance career development at the company. Employees are eligible for bonus opportunities depending on Millenium’s achievement of various goals as well as individual performance.

BRANDS/DIVISIONS/AFFILIATES: Millennium Predictive Medicine, Inc. LeukoSite, Inc. CAMPATH LDP-02 LDP-977 Integrilin COR Therapeutics, Inc. Cambridge Discovery Chemistry

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mark J. Levin, CEO Kevin Starr, COO Kevin Starr, CFO Linda K. Pine, Sr. VP-Human Resources Charles J. Homcy, VP-Research and Dev. James A. Nash, Sr. VP-Worldwide Mfg. John B. Douglas, III, General Counsel Paul Hamelin, Sr. VP-Commercial Oper. Alan L. Crane, Sr. VP-Corp. Dev. Clare Midgley, VP-Corp. Comm. Robert Tepper, Chief Scientific Officer Kevin Starr, Exec. VP-Bus. Oper. Kenneth J. Conway, Pres., Millennium Predictive Medicine, Inc. John Maraganore, Sr. VP-Strategic Product Dev.

Phone: 617-679-7000 Fax: 617-374-7788 Toll-Free: Address: 75 Sidney St., Cambridge, MA 02139 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $256,208 ( 9 months) 2002 Profits: $-510,479 ( 9 months) Stock Ticker: MLNM 2001 Sales: $246,200 2001 Profits: $-192,000 Employees: 1,900 2000 Sales: $196,300 2000 Profits: $-309,600 Fiscal Year Ends: 12/31 1999 Sales: $183,700 1999 Profits: $-352,000 1998 Sales: $133,700 1998 Profits: $10,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $405,997 Stock Purch. Plan: Y Second Exec. Salary: $328,557 ADVANTAGE: Lucrative R&D alliance with Abbott Labs and Bayer.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $365,765 Bonus: $275,626

Northeast: Y

International: Y



MILLIPORE CORP

www.millipore.com




Y

TYPES OF BUSINESS:

Profits: 1



Y


Instruments-Fluid Analysis, Identification and Purification Chromatography Technologies Validation Services

Millipore Corp. is a multinational bioscience company that provides technologies, tools and services for the discovery, development and production of new therapeutic drugs. Its products serve the worldwide life science research, biotechnology and pharmaceutical industries. Millipore's products are based on a variety of enabling technologies, including its membrane filtration and chromatography technologies. In life science research, the company offers products for genomics, proteomics, drug discovery and general laboratory applications. For its other industry markets, the firm offers products for development, scale-up, production and quality assurance of therapeutics, as well as validation services. In 2000, the company spun off its microelectronics business into Mykrolis Corporation. Millipore sells approximately 5,500 products, not including spare parts, which are listed in its catalogs and sold as standard items, systems or devices. The company also assembles custom products for special applications. Products include membranes, filter devices and ancillary equipment and supplies, laboratory water purification systems, cartridge filters and housing of various sizes and configurations, process liquid chromatography media and systems, process filtration systems and media-based sample preparation devices and kits. Products based on the firm's proprietary size exclusion membrane technology have been introduced to improve speed, automation and cost-effectiveness of a number of DNA-based separations for sequencing, plasmid prep, diagnostic and microarray applications. Millipore's products are used in manufacturing and research operations to isolate and purify specific components of fluid streams for analysis, to concentrate identified compounds for further processing and to purify critical fluids. Millipore has been featured in Working Mother magazine as one of the Top 100 Companies for Working Mothers for several consecutive years.

BRANDS/DIVISIONS/AFFILIATES: MultiScreen Opticap Millipore MicroElectronics, Inc. Mykrolis Corporation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Francis J. Lunger, CEO Francis J. Lunger, Pres. Kathleen B. Allen, VP/CFO Kathleen M. Stearns, VP-Human Resources Vinay Goel, VP-Membrane Tech. Div. J. Edward Lary, VP-Mfg. Oper. Jeffrey Rudin, VP/General Counsel Kevin D. Sanborn, VP-Strategic Planning Geoffrey Helliwell, Treas. Dominique F. Baly, Pres.-Laboratory Water Div. William C. Emhister, Pres.-Life Science Div. Susan Vogt, Pres.-Biopharmaceutical Div.

Phone: 781-533-6000 Fax: 781-533-3110 Toll-Free: Address: 80 Ashby Rd., Bedford, MA 01730-2271 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $518,372 ( 9 months) 2002 Profits: $63,795 ( 9 months) Stock Ticker: MIL 2001 Sales: $656,900 2001 Profits: $31,200 Employees: 4,160 2000 Sales: $954,000 2000 Profits: $119,000 Fiscal Year Ends: 12/31 1999 Sales: $771,200 1999 Profits: $64,300 1998 Sales: $699,300 1998 Profits: $4,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $667,849 Stock Purch. Plan: Second Exec. Salary: $262,871 AD VANTAGE: A leader in the field of separations technology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



MIRAVANT MEDICAL TECHNOLOGIES Industry Group Code: 325412 Ranks within this company's industry group: Sales: 145 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Y

TYPES OF BUSINESS:

www.miravant.com Profits: 146




Drugs-Photodynamic Therapy Medical Devices

Miravant Medical Technologies develops drugs and medical devices for use in its proprietary PhotoPoint photodynamic therapy technology, which integrates lightactivated drugs and light-producing devices to achieve photochemical destruction of diseased cells. The company makes use of light technologies, including software-controlled microchip diodes, light-emitting diodes (LED) and arrays, to manufacture light sources and light delivery devices for PhotoPoint. The firm has developed SnET2, a PhotoPoint synthetic compound that helps transform light energy into chemical energy and has also assembled the PhotoPoint System for Opthalmology, which is used for eye examination and treatment. The company is developing PhotoPoint systems for a wide range of other areas, including oncology, cardiovascular disease and dermatology. As part of a joint venture with the Pharmacia Corporation, Miravant has been working on clinical trials for using PhotoPoint SnET2 for treating agerelated macular degeneration, a leading cause of blindness in the U.S. The company recently has completed two Phase III clinical trials. Miravant also released positive results from preclinical studies of its PhotoPoint treatment for the prevention of restenosis, a complication arising from balloon angioplasty for obstructive coronary artery disease. Phase II clinical trials are underway for the developmental product MV94411, a topical gel for psorisis.

BRANDS/DIVISIONS/AFFILIATES: PhotoPoint SnET2 Pharmacia Corporation MV94411

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gary S. Kledzik, CEO David E. Mai, Pres. John M. Philpott, CFO Susan Kennedy , Human Resources Tom Herrick, Investor Relations Robert W. Scott, Pres., Miravant Cardiovascular, Inc. Glenn A. Wilson, VP-Pharmaceuticals Allan H. Mizoguchi, VP-Regulatory Affairs Gary S. Kledzik, Chmn.

Phone: 805-685-9880 Fax: 805-685-7981 Toll-Free: Address: 336 Bollay Dr., Santa Barbara, CA 93117 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,600 ( 9 months) 2002 Profits: $-14,100 ( 9 months) Stock Ticker: MRVT.OB 2001 Sales: $4,700 2001 Profits: $-16,400 Employees: 113 2000 Sales: $5,000 2000 Profits: $-26,000 Fiscal Year Ends: 12/31 1999 Sales: $14,600 1999 Profits: $-22,300 1998 Sales: $10,200 1998 Profits: $-28,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $384,313 Stock Purch. Plan: Second Exec. Salary: $295,625 ADVANTAGE: Proprietary photodynamic technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



MOLECULAR BIOSYSTEMS INC

www.allp.com




Y

TYPES OF BUSINESS:




Ultrasound Imaging Agents

Molecular Biosystems, Inc. is the developer of OPTISON, the only approved intravenous ultrasound contrast agent marketed in the United States and Europe. The firm has operated in the ultrasound imaging industry for over two decades. Molecular Biosystems operates as a subsidiary of Alliance Pharmaceutical, a developer of therapeutic and diagnos tic products. OPTISON, an ultrasound contrastimaging agent, consists of gas -filled human serum albumin microspheres. The product is utilized through injection into an arm vein, passing microspheres through the bloodstream to the right atrium and ventricle of the heart (areas with the greatest clinical import in heart disease diagnosis). OPTISON is the first perfluorocarbonbased agent to receive final marketing authorization by the European Agency for the Evaluation of Medicinal Products for use in patients with suspected or known cardiovascular disease. Aside from its beneficial usage as a cardiovascular diagnostic agent, OPTISON may also prove useful in screening high-risk patients prior to general surgery or other potentially stressful treatment regimens . A surgeon may use the product to assess whether an elderly or weakened patient is capable of undergoing a particular surgery or treatment without a cardiac incident.

BRANDS/DIVISIONS/AFFILIATES: OPTISON ORALEX Chugai Pharmaceutical Palatin Technologies Amersham Alliance Pharmaceutical Corp.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bobba Venkatadri, CEO Bobba Venkatadri, Pres. Elizabeth L. Hougen, CFO Laura Gross, VP-Human Resources

Phone: 858-812-7001 Fax: 858-455-3465 Toll-Free: Address: 10030 Barnes Canyon Rd., San Diego, CA 92121-2789 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $8,525 2000 Profits: $7,568 Fiscal Year Ends: 3/31 1999 Sales: $9,581 1999 Profits: $-21,200 1998 Sales: $6,200 1998 Profits: $-21,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Manufactures the only approved intravenous ultrasound contrast agent in the U.S. and Europe.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



MOLECULAR DEVICES CORP

www.moleculardevices.com




Y

TYPES OF BUSINESS:

Profits: 20




Supplies-Drug Discovery Automation Bioanalytical Measurement Systems

Molecular Devices Corporation (MDC) is a leading developer of high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Its systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics, proteomics and combinatorial chemistry by facilitating the costeffective identification and evaluation of drug candidates. MDC offers products in two categories: drug discovery and life sciences research. In drug discovery, the firm manufactures the Fluorometric Imaging Plate Reader and the Analyst, Acquest and ScreenStation systems. These products provide a wide array of solutions for both biochemical and cell-based research in the highthroughput screening and lead optimization market segments. Its life sciences research products include the Maxline family of microplate readers, the FlexStation system, the Skatron liquid handling systems and the Threshold system. MDC recently agreed to acquire Cytion SA, a firm developing systems that analyze ion channels through automated patch clamping, an area of significant interest to pharmaceutical companies and other life sciences researchers.

BRANDS/DIVISIONS/AFFILIATES: Cytion SA Fluorometric Imaging Plate Reader Analyst System Acquest System ScreenStation System Maxline Microplate Readers FlexStation System IonWorks

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph D. Keegan, CEO Joseph D. Keegan, Pres. Tim Harkness, CFO Stephen J. Oldfield, VP-Worldwide Mktg. Patricia C. Sharp, VP-Human Resources Gillian M.K. Humphries, VP-Research Andrew T. Zander, VP-Eng. Robert J. Murray, VP-Oper. Thomas J. O'Lenic, VP-North American Sales and Service John S. Senaldi, Gen. Mgr.-IonWorks

Phone: 408-747-1700 Fax: 408-747-3601 Toll-Free: 800-635-5577 Address: 1311 Orleans Dr., Sunnyvale, CA 94089 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $71,972 ( 9 months) 2002 Profits: $4,198 ( 9 months) Stock Ticker: MDCC 2001 Sales: $92,200 2001 Profits: $-5,200 Employees: 370 2000 Sales: $96,000 2000 Profits: $-4,900 Fiscal Year Ends: 12/31 1999 Sales: $71,900 1999 Profits: $3,700 1998 Sales: $52,200 1998 Profits: $1,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $357,268 Stock Purch. Plan: Y Second Exec. Salary: $219,450 ADVANTAGE: The company is an innovator in the production of bioanalytical systems.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International: Y



MONSANTO CO

www.monsanto.com



Y


Profits: 2


TYPES OF BUSINESS:



Chemicals-Agricultural Herbicides Seeds

Monsanto Company, originally formed as a subsidiary of Pharmacia Corporation, is a global provider of technologybased solutions and agricultural products for growers and downstream customers, such as grain processors, food companies and consumers, in agricultural markets. The firm's herbicides, seeds and related biotechnology trait products can be combined to provide growers with integrated solutions to produce higher-yield crops while controlling weeds, insects and diseases more efficiently and cost-effectively. The company's principal agricultural products include Roundup herbicide for agricultural and industrial applications; Harness and Degree herbicides for control of pre-emergent annual grass and broadleaf weeds in corn; Lasso herbicides for grass and weeds in corn, soybean, peanut and sorghum crops; Maverick herbicide for control of grassy weeds in wheat; Machete herbicide for control of grass and weeds in rice, barley and wheat; Avadex and Far-Go herbicides for wheat, barley, peas and lentils; Permit, Manage and Sempra herbicides for weeds in corn, cotton and sugarcane; Posilac, which increases milk production in dairy cows; and Monsanto Choice Genetics swine genetics products. Monsanto also provides Roundup lawn and garden products for the residential market. In addition, the company offers EnviroChem engineering and construction management services. The firm's seeds and genomics products include Roundup Ready, Bollgard, YieldGard, Agroceres, Asgrow and Hartz traits and seeds. Recently, Monsanto and Dow AgroSciences reached an agreement that will provide farmers worldwide with greater access to a range of agricultural products and technologies, including Roundup Ready corn, soybeans, cotton and canola. Monsanto offers its employees health, disability and life insurance and a cash balance pension plan.

BRANDS/DIVISIONS/AFFILIATES: Pharmacia Corporation Roundup Harness Degree Lasso Maverick Machete Avadex

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frank V. AtLee, Chm./Interim CEO Hugh Grant, Exec. VP/COO Terrell K. Crews, Exec. VP/CFO John M. Murabito, Sr. VP-Human Resources Robert T. Fraley, Exec. VP/Chief Tech. Officer Janet M. Holloway , CIO Richard Clark, VP/Controller Mark Leidy, VP-Mfg. Charles Burson, Exec. VP/Corp. Sec. Charles Burson, General Counsel Jerry Steiner, VP-Strategy Sarah Hull, Sr. VP-Public Affairs Carlos Popik, V P-Latin America Carl Casale, VP-North America Steven L. Engelberg, Sr. VP-Gov't Affairs Cheryl Morley, Pres.-Animal Agricultural Group Philippe Castaing, Mgr.-Europe and Africa

Phone: 314-694-1000 Fax: 314-694-8394 Toll-Free: Address: 800 N. Lindbergh Blvd., St. Louis , MO 63167 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $3,453,000 ( 9 months) 2002 Profits: $-1,754,000 ( 9 months) Stock Ticker: MON 2001 Sales: $5,462,000 2001 Profits: $295,000 Employees: 14,600 2000 Sales: $5,493,000 2000 Profits: $149,000 Fiscal Year Ends: 12/31 1999 Sales: $5,248,000 1999 Profits: $150,000 1998 Sales: $4,448,000 1998 Profits: $-125,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $867,312 Stock Purch. Plan: Y Second Exec. Salary: $561,539 ADVANTAGE: Leading international agricultural products company.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $357,000 Bonus: $198,000

Northeast: Y

International: Y



MYLAN LABORATORIES INC

www.mylan.com


Y



Profits: 36


TYPES OF BUSINESS:



Drugs-Generic Branded Drugs for Cardiology, Dermatology and Neurology

Mylan Laboratories is a fully-integrated pharmaceuticals company, developing and marketing both generic and branded prescription drugs. Among the products currently being developed by the company are a treatment for migraine headaches, a drug for symptoms of Parkinson’s disease and a wound care product for the treatment of diabetic foot ulcers. The firm markets an extensive line of generic products h t rough three business units: Mylan Pharmaceuticals, Mylan Technologies and UDL Laboratories. Mylan manufactures and markets approximately 115 generic pharmaceuticals in capsule or tablet forms. The firm markets an additional 72 generic products under supply and distribution agreements with other pharmaceutical companies. Mylan’s most profitable generic product, Nifedipine ER (Procardia XL), is used for the treatment of hypertension and angina. The company’s branded products portfolio includes Maxzide, Digitek and Nitrek for the treatment of various heart conditions and Avita, Mentax and Anticin for the skin. Mylan’s branded segment operates primarily through its Beretek Pharmaceuticals subsidiary. Through Mylan Technologies subsidiary, parent company Mylan develops components for drug delivery systems and dressings, including MEDIFILM (medical and wound care films), MEDIFLEX (transdermal backing materials), MEDIRELEASE (release liners) and MEDIDERM (skin contact adhesive laminates). Mylan has been working on expanding its product line, especially with its generic pharmaceutical offerings. The company recently acquired a new drug application for the sale of Butorphanol Tartrate Nasal Spray, the generic equivalent Stadol NS, which is used for the management of pain.

BRANDS/DIVISIONS/AFFILIATES: Bertek Pharmaceuticals, Inc. Mylan Pharmaceuticals Mylan Technologies UDL Laboratories, Inc. Maxzide Digitek Nitrek Mentax

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Milan Puskar, CEO C.B. Todd, COO C.B. Todd, Pres. Edward J. Borkowski, CFO John P. O'Donnell, VP-Research & Quality Control Thomas S. Clark, VP-Corp. Medical Affairs Roger L. Foster, Corp. Sec. Roger L. Foster, General Counsel Patricia A. Sunseri, VP-Investor & Public Rel. Dana G. Barnett, Exec. VP Sharad K. Govil, Pres., Mylan Technologies Louis J. DeBone, Pres., Mylan Pharmaceuticals Harry Korman, Pres., UDL Laboratories

Phone: 412-232-0100 Fax: 412-232-0123 Toll-Free: Address: 1030 Century Bldg., 130 7th St., Pittsburgh, PA 15222 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,104,100 (12 months) 2002 Profits: $260,300 (12 months) Stock Ticker: MYL 2001 Sales: $846,700 2001 Profits: $37,100 Employees: 2,220 2000 Sales: $790,100 2000 Profits: $154,200 Fiscal Year Ends: 3/31 1999 Sales: $721,100 1999 Profits: $115,400 1998 Sales: $555,400 1998 Profits: $100,777


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: ADVANTAGE: A fully integrated pharmaceutical firm.

OTHER THOUGHTS:

Top Exec. Salary: $1,000,000 Second Exec. Salary: $550,000



West:

Southwest:

Midwest: Y

Southeast: Y



Bonus: $500,000 Bonus: $450,000

Northeast: Y

International:



MYRIAD GENETICS INC

www.myriad.com


Y


Y


Y

TYPES OF BUSINESS:

Profits: 13




Diagnosis and Testing Products

Myriad Genetics, Inc. is a genomics company focused on the development of therapeutic and diagnostic products based on the discovery of major common human disease genes and their biological pathways. The company utilizes analyses of extensive family histories and genetic material, as well as a number of proprietary technologies, to identify inherited gene mutations, which increase the risk to individuals of developing these diseases. The firm developed ProNet, a proprietary high-throughput assay to identify protein-protein interactions, in a five-year, $51million collaboration with Schering AG. The discovery of disease-predisposing genes and their biochemical pathways provides Myriad with three significant commercial opportunities: the development of therapeutic products for the treatment and prevention of major diseases associated with them; the marketing of subscriptions to the ProNet database of protein interactions; and the development and marketing of molecular diagnostic and information services for the identification of individuals who are genetically predisposed to disease. Subsidiary Myriad Pharmaceuticals, Inc., formed in 1999, develops therapeutic lead compounds and markets them to pharmaceutical companies. Subsidiary Myriad Genetic Laboratories develops and markets proprietary molecular diagnostic products in the areas of predictive medicine and personalized medicine. Myriad also develops therapeutic products in conjunction with its strategic partners, including Bayer Corporation, Eli Lilly and Company, Monsanto Company, Novartis Corporation and Schering. In recent news, Myriad and Genetic Technologies, Ltd. announced a strategic alliance under which they will cross-license certain technologies related to the identification of non-coding DNA alterations and the assessment of inherited human diseases. Myriad will receive a broad, non-exclusive license to Genetic Technologies' non-coding DNA analysis and mapping patents for all applications in human therapeutics and diagnostics.

BRANDS/DIVISIONS/AFFILIATES: Myriad Genetic Laboratories Myriad Pharmaceuticals, Inc. ProNet

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Peter D. Meldrum, CEO Peter D. Meldrum, Pres. Jay M. Moyes, CFO Mark H. Skolnick, Chief Scientific Officer Richard Marsh, General Counsel S. George Simon, VP-Bus. Dev. William A. Hockett, III, V P-Corp. Comm. Gregory C. Critchfield, Pres., Myriad Genetic Laboratories Adrian N. Hobden, Pres., Myriad Pharmaceuticals, Inc. Sudhir Saharabudhe, Exec. VP-Research

Phone: 801-584-3600 Fax: 801-584-3640 Toll-Free: Address: 320 Wakara Way, Salt Lake City, UT 84108 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $53,800 (12 months) 2002 Profits: $-14,000 (12 months) Stock Ticker: MYGN 2001 Sales: $45,200 2001 Profits: $-7,200 Employees: 452 2000 Sales: $34,000 2000 Profits: $-8,700 Fiscal Year Ends: 6/30 1999 Sales: $25,300 1999 Profits: $-10,000 1998 Sales: $23,200 1998 Profits: $-9,800


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $350,562 Stock Purch. Plan: Second Exec. Salary: $260,562 ADVANTAGE: Excellent partnerships/Success in research projects.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $110,761 Bonus: $84,961

Northeast:

International:



NABI BIOPHARMACEUTICALS

www.nabi.com


Y



Profits: 26


TYPES OF BUSINESS:



Drugs-Infectious Disease and Autoimmune Disorder Therapeutic Treatment of Infectious Disease Therapeutic Treatment of Immunological Disorders Biopharmaceuticals Human Plasma

Nabi Biopharmaceuticals, formerly Nabi, is a vertically integrated research and development biopharmaceutical company that focuses on serious, unmet medical needs. The firm has a broad product portfolio and significant research capabilities focused on the development and commercialization of drugs that prevent and treat infectious, autoimmune and addictive diseases. The company currently markets four biopharmaceutical products. Nabi-HB prevents hepatitis B infections, which affect approximately 350 million people worldwide. WinRho SDF treats acute, chronic and HIV-related immune thrombocytopenia purpura, an autoimmune disease that manifests itself in abnormally low platelet levels resulting in excessive bleeding. Autoplex T is used in the treatment of hemophilia A, a blood clotting dis order. Cancer patients who develop hyperuricemia following chemotherapy use Aloprim to treat the condition, which affects more than 90,000 patients in the U.S. Nabi controls an extensive pipeline of biopharmaceutical products that are currently under development. One product under development, NicVAX, is expected to help smokers quit. NicVAX is an experimental vaccine that induces the production of high levels of nicotine-specific antibodies. Once these antibodies bind to nicotine molecules, they are unable to cross the blood/brain barrier to bind and activate the neuroreceptors, which provide the positive reinforcement from smoking. NicVAX has been shown to reduce nicotine levels in the brains of rats by 64% compared to control subjects, as well as prevent nicotine-induced blood pressure increases. The company recently sold its antibody collection business. Nabi offers its employees medical, dental, vision and life insurance, as well as a discount prescription program. Employees receive flexible spending accounts, access to one of three full-service credit unions, an employee assistance program, a smoking cessation program, an employee referral program, business casual dress, Costco membership and discount prices for commuter services. In addition, tuition assistance is available.

BRANDS/DIVISIONS/AFFILIAT ES: BioMune Corporation Autoplex T H-BIG PBI Aloprim NicVAX Collaborative BioAlliance StaphVAX

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David J. Gury, CEO Thomas H. McLain, COO David J. Gury, Pres. Mark L. Smith, Sr. VP-Finance/CFO Gary A. Siskowski, Sr. VP-Mktg. & Sales C. Thomas Johns, Sr. VP-Mfg. Oper. David M. Muth, Sr. VP-Bus. Oper. Mark A. Soufleris , VP-Investor Rel. Robert B. Naso, Sr. VP-Quality, Regulatory & Product Dev. Mark A. Soufleris , VP-Public Rel.

Phone: 561-989-5800 Fax: 561-989-5801 Toll-Free: Address: 5800 Park of Commerce Blvd. NW, Boca Raton, FL 33487 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $137,871 ( 9 months) 2002 Profits: $ 985 ( 9 months) Stock Ticker: NABI 2001 Sales: $234,800 2001 Profits: $104,700 Employees: 615 2000 Sales: $228,800 2000 Profits: $4,400 Fiscal Year Ends: 12/31 1999 Sales: $233,600 1999 Profits: $3,300 1998 Sales: $243,100 1998 Profits: $-21,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $476,808 Stock Purch. Plan: Y Second Exec. Salary: $252,192 ADVANTAGE: NABI is one of the world's largest suppliers of source and specialty plasma.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $900,302 Bonus: $419,965

Northeast: Y

International: Y



NANOGEN INC

www.nanogen.com



Y


Profits: 3


TYPES OF BUSINESS:

Y



Chips-DNA Analysis Genomics Research

Nanogen, Inc. integrates advanced microelectronics and molecular biology into a core platform with broad and diverse commercial applications. The firm hopes to become a leading provider of molecular diagnostic tests. Its primary areas of focus are genomics, biomedical research, medical diagnostics, forensics and drug discovery. Nanogen's NanoChip System is a bioassay system consisting of the NanoChip Molecular Biology Workstation, comprised of automated instruments, and the NanoChip Cartridge, a consumable cartridge with a proprietary semiconductor microchip. The subsystem instruments include a microchip loader, a fluorescent array scanner, a fluidics station and computer hardware and software systems. The NanoChip system provides a flexible tool for the rapid, precise identification and analysis of biological test samples containing charged molecules, such as DNA. In addition to DNA applications, the firm's platform technology is applicable in antigenantibody, enzyme-substrate, cell-receptor and cell separation technologies. Diagnostics applications include pharmacogenomics and infectious diseases. The NanoChip workstation was initially targeted toward clinical researchers performed genetic analysis, but the company has since expanded its targeted customers to include more production-oriented customers. In 2001, Nanogen and Aventis formed a new company, Nanogen Recognomics, to research and develop new products and applications for the NanoChip system. Nanogen has offices in California, the Netherlands and Germany. In recent news, the firm announced that it placed 10 NanoChip workstations in the third quarter of 2002, bringing the total number of placements to 28. This number includes five systems at major clinical reference laboratories. The company offers its employees vision, dental, life and short- and long-term disability coverage. Nanogen also provides educational assistance and an employee assistance program. In addition, the company hosts biweekly socials with free food and beverages.

BRANDS/DIVISIONS/AFFILIATES: NanoChip Nanogen Europe KnowledGENE.com Nanogen Recognomics

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Randy White, CEO Bruce A. Huebner, COO Bruce A. Huebner, Pres. Gerard Wills, CFO William Franzblau, Corp. Sec. William Franzblau, VP-Legal Affairs David Macdonald, Sr. VP-Oper. Ira Marks, VP-Bus. Dev. Gerard Wills, Treas.

Phone: 858-410-4600 Fax: 858-410-4848 Toll-Free: 877-626-6436 Address: 10398 Pacific Center Ct., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $5,035 ( 9 months) 2002 Profits: $-24,277 ( 9 months) Stock Ticker: NGEN 2001 Sales: $11,200 2001 Profits: $-32,500 Employees: 194 2000 Sales: $11,600 2000 Profits: $-18,300 Fiscal Year Ends: 12/31 1999 Sales: $8,100 1999 Profits: $-25,200 1998 Sales: $7,600 1998 Profits: $-20,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $365,000 Stock Purch. Plan: Y Second Exec. Salary: $290,000 ADVANTAGE: Technology with potential uses in multiple industries.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $345,000 Bonus: $115,000

Northeast:

International: Y



NAPRO BIOTHERAPEUTICS INC

www.naprobio.com


Y



Profits: 174


TYPES OF BUSINESS:



Drugs-Cancer Cancer Chemotherapeutic Technology

NaPro BioTherapeutics, Inc. is a biopharmaceutical company that develops natural-product pharmaceuticals. The company focuses on the development and manufacture of cancer chemotherapeutic technology. NaPro’s frontline product is Paclitaxel, which is a natural anti-cancer compound. This product was recognized by the NCI (National Cancer Institute) for exhibiting cytotoxic activity toward harmful leukemia cells as well as slowing some tumor growth. At this time, Paclitaxel is only administered intraveniously. Pre-clinical development is currently underway to present an oral form of Paclitaxel. This breakthrough would decrease the dangers of administering the product through intravenous delivery. NaPro has joined forces with Abbott Laboratories and F.H. Faulding & Co., Ltd. to increase development and marketing of Paclitaxel in the United States and worldwide. The firm also is united with F.H. Faulding & Co., Ltd. to establish sales and manufacturing in Australia, New Zealand and Southeast Asia, with Tzamal Pharma for the development and distribution in Israel and with JCR Pharmaceuticals Co., Ltd. for the supply and distribution in Japan. The company is currently evaluating the purchase of new products and technologies in the natural products field. It is developing new anti-cancer compounds, NaPro 80239 for use in hematological cancer, NaPro 80661 and NaPro 82739 for solid tumors and NaPro 102339 for a directed drug delivery product. In recent news, NaPro introduced a new gene editing technology that will provide researchers with genes prepared for testing and evaluation.

BRANDS/DIVISIONS/AFFILIATES: Paclitaxel F.H. Faulding & Co., Ltd. Abbott Laboratories Tzamal Pharma JCR Pharmaceuticals Co., Ltd. NaPro 80239 NaPro 80661 NaPro 102339

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Leonard P. Shaykin, CEO Sterling K. Ainsworth, Pres. Gordon H. Link, VP-Finance/CFO Patricia A. Pilia, Exec. VP-Bioresearch/Tech. Brian McCudden, VP-Mfg. Patricia A. Pilia, Sec. Kai Larson, VP-General Counsel David L. Denny, VP-Oper. Patricia A. Pilia, Treas. James D. McChesney, VP-Natural Products Chemistry Sterling K. Ainsworth, Chief Scientific Officer Gordon H. Link, Pres.-Genomics Division Brenda P. Fielding, VP-Regulatory Affairs Leonard P. Shaykin, Chmn.

Phone: 303-530-3891 Fax: 303-530-1296 Toll-Free: 800-976-2776 Address: 6304 Spine Rd., Unit A, Boulder, CO 80301 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $24,546 ( 9 months) 2002 Profits: $-7,552 ( 9 months) Stock Ticker: NPRO 2001 Sales: $15,700 2001 Profits: $-25,800 Employees: 189 2000 Sales: $8,100 2000 Profits: $-16,600 Fiscal Year Ends: 12/31 1999 Sales: $7,600 1999 Profits: $-9,000 1998 Sales: $5,000 1998 Profits: $-2,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $259,423 Stock Purch. Plan: Second Exec. Salary: $239,331 ADVANTAGE: Clinical success/International distribution.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $100,000 Bonus: $200,000

Northeast:

International: Y



NASTECH PHARMACEUTICAL CO INC Industry Group Code: 325412 Ranks within this company's industry group: Sales: 165 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y Y



www.nastech.com Profits: 110


TYPES OF BUSINESS:



Drugs-Nasally Administered Drug Delivery Systems

Nastech Pharmaceutical Company, Inc. is a leader in nasal drug delivery technology. Historically, its core technical competency has involved the research, development and manufacture of nasally administered prescription pharmaceuticals. The company investigates the commercial weaknesses of pharmaceutical products currently available in oral, injectable or other dosage forms and determines the advantages of alternative drug delivery systems for the same drug. For example, nasal delivery can provide faster absorption into the blood stream than oral products, resulting in faster onset of action. Other possible advantages include lower doses, fewer side effects, greater safety and efficacy, greater convenience and lower overall costs. Nastech has a commercial interest in two nasal drug products, both of which are approved for sale in the U.S. The company has a licensing agreement with the Bristol-Myers Squibb Company for Stadol NS, an opioid pain relief medication in a convenient, self-administered form. Nastech's other nasal product is Nascobal, a vitamin B-12 product with benefits over injectable therapy for chronic B-12 deficiency anemia. Nascobal has been marketed by Schwartz Pharma, Inc. The firm has also developed nasally administered apomorphine treatment for male and female sexual dysfunction. Nastech is also developing products including a patch treatment for motion sickness; an MASCT device for the treatment of breast cancer; and injectable treatments for conditions including cancer, hepatitis, multiple sclerosis and growth deficiency. The firm acquired the MASCT (Mammary Aspiration Specimen Cytology Test) device through its merger with Atossa Healthcare, Inc. in 2000. Nastech maintains strategic alliances with organizations including the University of Kentucky Research Foundation, Cambridge Laboratories and Questcor Pharmaceuticals. Recently, the company reacquired the rights to Nascobal from Schwartz Pharma.

BRANDS/DIVISIONS/AFFILIATES: Stadol NS Nascobal Atossa Healthcare, Inc. STA-T Technology

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steven C. Quay, CEO Steven C. Quay, Pres. Gregory L. Weaver, CFO Gerard A. Cignarella, Sr. Dir.-Global Mktg. Helena Messina, Dir.-Human Resources Gordon Brandt, Exec. VP-Science and Clinical Dev. David E. Wormuth, Sr. VP-Oper. Gerard A. Cignarella, Sr. Dir.-Bus. Dev. Matthew D. Haines, Dir.-Corp. Comm. Dilip M. Worah, Chief Scientific Officer

Phone: 425-908-3600 Fax: 425-908-3650 Toll-Free: Address: 3450 Monte Villa Pkwy. , Bothell, WA 98021 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $7,166 ( 9 months) 2002 Profits: $-7,673 ( 9 months) Stock Ticker: NSTK 2001 Sales: $2,600 2001 Profits: $-9,200 Employees: 42 2000 Sales: $4,800 2000 Profits: $-9,700 Fiscal Year Ends: 12/31 1999 Sales: $5,600 1999 Profits: $-8,400 1998 Sales: $9,600 1998 Profits: $- 900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $300,000 Stock Purch. Plan: Second Exec. Salary: $215,000 ADVANTAGE: Ability to create additional value in drugs developed by other firms.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $41,231 Bonus: $84,587

Northeast: Y

International:



NEOGEN CORPORATION

www.neogen.com




Y

TYPES OF BUSINESS:

Profits: 5




Diagnostic Test Kits Food Safety Test Kits Animal Health Test Kits Pharmacology Test Kits Agricultural Test Kits

Neogen Corporation develops, manufactures and markets a diverse line of products for food and animal safety. The company provides more than 200 diagnostic test kits that detect food-borne bacteria, natural toxins, food allergens, drug residues, pesticide residues, plant diseases and sanitation concerns. Neogen’s food safety division develops and markets one-stop solutions to keep food and feed safe from contamination. The company’s Acumedia subsidiary produces culture media that is used in a variety of food safety tests, such as food-borne pathogen detection. Neogen’s animal safety division manufactures and markets pharmaceuticals, vaccines, topicals and diagnostic products to the professional animal care market. The firm’s Ideal Instruments subsidiary provides more than 200 precision instruments to the veterinary market. Ideal’s needles and syringes accurately deliver drugs to animals, reducing residues in meat and milk. Other instruments offered by the subsidiary are used in animal obstetrics and surgery, as well as in animal health administration. In recent news, the company opened a sales and distribution center in Shanghai, China. The expansion allows Neogen to better serve the expanding food safety market, as well as more closely oversee its current Chinese animal safety operations. Neogen was recently named to Fortune Small Business’s list of the 100 fastest-growing, publicly held small companies in America.

BRANDS/DIVISIONS/AFFILIATES: Ideal Instruments Agdia, Inc. AmVet Pharmaceuicals ISO-GRID Gene-Trak DNA Acumedia QA Life Sciences Veritox

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James L. Herbert, CEO Lon M. Bohannon, COO James L. Herbert, Pres. Richard R. Current, CFO Joseph M. Madden, VP-Scientific Affairs Gerald S. Traynor, VP-Mfg. Thomas H. Reed, Corp. Sec. Lon M. Bohannon, VP-Admin. Anthony E. Maltese, Mgr.-Corp. Dev. Mark A. Mozola, VP-Research and Dev. Terri A. Morrical, VP/General Mgr. Gerald S. Traynor, VP-Instrument Dev.

Phone: 517-372-9200 Fax: 517-372-9027 Toll-Free: 800-234-5333 Address: 620 Lesher Pl., Lansing, MI 48912 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $41,100 (12 months) 2002 Profits: $3,900 (12 months) Stock Ticker: NEOG 2001 Sales: $34,900 2001 Profits: $3,200 Employees: 250 2000 Sales: $23,500 2000 Profits: $3,100 Fiscal Year Ends: 5/31 1999 Sales: $22,200 1999 Profits: $2,300 1998 Sales: $18,500 1998 Profits: $2,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Steady, profitable growth.

OTHER THOUGHTS:




West:

Southw est:

Midwest: Y

Southeast: Y



Bonus: $106,000 Bonus: $21,400

Northeast: Y

International: Y



NEOPROBE CORPORATION

www.neoprobe.com




Y

TYPES OF BUSINESS:

Profits: 15




Supplies-Intrapoperative Cancer Diagnosis Gamma-Guided Surgical Instruments

Neoprobe devotes its efforts toward the research and clinical development of innovative systems for the intraoperative diagnosis and treatment of cancers. The company recently expanded its product portfolio through the acquisition of Biosonix, Ltd., which later changed its name to Cardiosonix Ltd. Cardiosonix is developing and commercializing a unique line of blood flow measurement devices for a variety of diagnostic and surgical applications that uses an Angle-independent Doppler Blood Flow (ADBF) technology. Its three products include Quantix/ND, Quantix/OR, and Quantix/TE. Research and development efforts of Neoprobe have included market launch activities related to gamma radiation detection instrumentation, used in the application of intraoperative lymphatic mapping (ILM), and to an activated cellular therapy (ACT) for the treatment of certain cancers and viral diseases. Surgeons use lymphatic mapping to help trace the lymphatic patterns in a cancer patient to evaluate potential tumor drainage and cancer spread. Neoprobe’s patented gamma detection systems consist of hand-held detector probes and a control unit. The neo2000 Gamma Detection System is the third generation of the company's gamma detection systems. The firm entered into a distribution arrangement with Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, to distribute Neoprobe’s line of gamma guided surgical instruments on an exclusive worldwide basis. Lymphoseek is being developed as a radioactive tracing agent to be used with these gamma detection devices. In recent news, Neoprobe announced the launch of Cardiosonix Quantix/ND in Germany, the United Kingdom and Switzerland.

BRANDS/DIVISIONS/AFFILIATES: Cardiosonix Ltd. Biosonix, Ltd. neo2000 Gamma Detection System Lymphoseek Quantix/ND Angle-independent Doppler Blood Flow Technology Quantix/OR Quantix/TE

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David C. Bupp, CEO David C. Bupp, Pres. Brent Larson, CFO/VP-Finance Richard C. Orahood, Medical Dir. Carl M. Bosch, VP-Instrument Dev. Roger Brown, VP-Regulatory Affairs/Quality Assurance

Phone: 614-793-7500 Fax: 614-793-7520 Toll-Free: 800-793-0079 Address: 425 Metro Place N., Ste. 300, Dublin, OH 43017-1367 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,216 ( 9 months) 2002 Profits: $-2,799 ( 9 months) Stock Ticker: NEOP.OB 2001 Sales: $7,600 2001 Profits: $ Employees: 35 2000 Sales: $9,700 2000 Profits: $1,800 Fiscal Year Ends: 12/31 1999 Sales: $9,446 1999 Profits: $-4,174 1998 Sales: $5,833 1998 Profits: $-28,033


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $310,000 Stock Purch. Plan: Second Exec. Salary: $131,250 ADVANTAGE: New relationship with Ethicon Endo-Surgery.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $46,500 Bonus: $20,250

Northeast:

International:



NEORX CORPORATION

www.neorx.com


Y



Profits: 167


TYPES OF BUSINESS:



Drugs-Cancer and Heart Disease Drug Delivery Devices Radiopharmaceutical Technologies

NeoRx Corporation develops innovative therapeutic biopharmaceuticals primarily for the treatment of cancer and cardiovascular and inflammatory diseases. As part of its operating strategy, the firm seeks to form alliances for developing and commercializing its Skeletal Targeted Radiotherapy and Pretarget platforms. NeoRx also outlicenses intellectual property rights from its portfolio of over 100 U.S. patents, which includes more than 25 patents relating to its Pretarget technology platform. Its portfolio also consists of cardiovascular drug delivery devices and antibody, radiopharmaceutical, ligand-linker and targeting technologies for imaging and therapeutics. In addition, the firm seeks to acquire or in-license novel lead compounds for cancer or related disorders, especially small-molecule, antibody or peptide product candidates in preclinical or early clinical testing. As part of its cancer treatment program, NeoRx has conducted clinical trials of its Skeletal Targeted Radiation product, combined with chemotherapy, in patients with multiple myeloma. The company's goal is to improve the effectiveness and reduce toxicities of current therapeutic methods. NeoRx’s focus is on toxic agents (regarding tumors) and on catering to unmet healthcare needs related to cancer. Products that the company develops target metastatic cancer and attempt to reduce the risk that cancer has spread. The firm recently announced additional workforce reductions, as part of its previously announced program to conserve cash by focusing on clinical development of Skeletal Targeted Radiotherapy. In other news, NeoRx sold IDEC Pharmaceuticals Corporation certain intellectual property and granted it certain licenses and option rights. The intellectual property sold includes a portfolio of the firm’s U.S. and international patents and certain associated technology and know-how relating to antibody-based therapeutics and ligand-linker technology.

BRANDS/DIVISIONS/AFFILIATES: International Isotopes, Inc. Holmium-166 DOTMP Pretarget Skeletal Targeted Radiotherapy

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Douglass B. Given, CEO Wolfgang Oster, COO Douglass B. Given, Pres. Richard Anderson, CFO Linda T. Findlay, VP-Human Resources Richard Ghalie, VP-Medical Richard Anderson, Corp. Sec. Richard Ghalie, VP-Regulatory Affairs

Phone: 206-281-7001 Fax: 206-284-7112 Toll-Free: Address: 410 W. Harison St., Seattle, WA 98119-4007 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,036 ( 9 months) 2002 Profits: $-25,987 ( 9 months) Stock Ticker: NERX 2001 Sales: $2,900 2001 Profits: $-23,800 Employees: 119 2000 Sales: $3,500 2000 Profits: $-11,400 Fiscal Year Ends: 12/31 1999 Sales: $ 600 1999 Profits: $-12,000 1998 Sales: $9,100 1998 Profits: $-4,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $234,202 Stock Purch. Plan: Y Second Exec. Salary: $192,385 ADVANTAGE: Focus on therapies with lessened side effects.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest:

Southeast:



Bonus: $50,000 Bonus: $17,500

Northeast:

International:



NEOSE TECHNOLOGIES INC

www.neose.com


Y



Profits: 133


TYPES OF BUSINESS:



Drugs-Proprietary Biological Technologies Complex Carbohydrate Manufacturing

Neose Technologies, Inc. develops proprietary technologies for the synthesis and manufacture of complex carbohydrates. Its enzymatic technology platform makes feasible the synthesis and modification of a wide range of complex carbohydrates, or chains of simple sugar molecules that can be joined together in many different com binations. The platform enables the production and manipulation of these molecules as either stand-alone molecules or carbohydrate structures attached to recombinant therapeutic glycoproteins and glycolipids. The firm's GlycoAdvance program uses this technology to complete the human carbohydrate structures on therapeutic glycoproteins. This technology could potentially result in improved clinical activity and enhanced drug development flexibility. Neose is pursuing partnerships for GlycoAdvance with pharmaceutical and biotechnology companies that are developing or marketing glycoprotein drugs, such as monoclonal antibodies. Currently, the company is developing, in partnership with Wyeth Pharmaceuticals, a glycoprotein product to treat inflammation and thrombosis associated with acute coronary syndrome and reperfusion injury. The drug is in Phase II clinical trials for heart attack. The GlycoTherapeutics program enables the development of carbohydrate-based therapeutics. Neose has partnered with Neuronyx, Inc. to develop treatments for Parkinson's disease and other neurological diseases based on this platform. The GlycoActives program enables the development of novel carbohydrate food and nutritional ingredients. The firm has entered into a joint venture with NcNeil Nutritionals to explore the enzymatic production of complex carbohydrates for use as bulking agents. In recent news, the company signed a research agreement with Monsanto Company to investigate GlycoAdvance technology in monoclonal antibodies produced in plants. Neose also signed a second research agreement with Novo Nordisk to use GlycoPEGylation technology in therapeutic proteins.

BRANDS/DIVISIONS/AFFILIATES: GlycoAdvance GlycoTherapeutics GlycoActives GlycoPEGylation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. C. Boyd Clark, CEO C. Boyd Clark, Pres. Robert I. Kriebel, Sr. VP/CFO Victor Sarantschin, Dir.-Tech. Mktg. Sandy Keller, Mgr.-Human Resources Admin. Robert Bayer, Sr. Dir.-Research Joseph P. Brennan, Dir.-Info. Systems Chester A. Myers, VP-Pharmaceutical Dev. W. Kevin Pelin, V P-Mfg. Debra J. Poul, VP/General Counsel Joseph J. Villafranca, Sr. VP-Oper. and Pharmaceutical Dev. George J. Vergis, VP-Bus. and Commercial Dev. Barbara Krauter, Investor Rel. Associate David A. Zoph, Exec. VP-New Product Dev. A. Brian Davis, VP-Finance Marjorie Hurley, VP-Regulatory Affairs and Project Mgmt. Valerie Mulligan, Sr. Dir.-Quality Assurance

Phone: 215-315-9000 Fax: 215-315-9100 Toll-Free: Address: 102 Witmer Rd., Horsham , PA 19044 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $4,519 ( 9 months) 2002 Profits: $-20,040 ( 9 months) Stock Ticker: NTEC 2001 Sales: $1,300 2001 Profits: $-13,300 Employees: 111 2000 Sales: $4,600 2000 Profits: $-8,500 Fiscal Year Ends: 12/31 1999 Sales: $ 400 1999 Profits: $-13,300 1998 Sales: $ 400 1998 Profits: $-11,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $294,866 Stock Purch. Plan: Y Second Exec. Salary: $288,354 ADVANTAGE: Expertise in the synthesis of complex carbohydrates.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $147,433 Bonus: $144,177

Northeast: Y

International:



NEUROBIOLOGICAL TECHNOLOGIES INC Industry Group Code: 325412 Ranks within this company's industry group: Sales: 144 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



www.ntii.com

Profits: 50


TYPES OF BUSINESS:



Drugs-Neurological Disease

Neurobiological Technologies, Inc. (NTI) is a drug development company focused on the clinical development and approval of neuroscience drugs. It creates neuroprotective and neuromodulatory agents, which inhibit or modulate the impairment process of brain cells, to treat progressive natural and acquired neurological disorders. The company entered into an alliance with Merz+ Co. GmbH&Co. of Germany to further the development of Memantine, a product successfully proven to treat dementia (a progressive loss of memory). Researchers found that Memantine improves cognitive, psychological, social and motor functions impaired by dementia. Merz + Co. entered into an agreement with Forest Laboratories, Inc. for the development and marketing of Memantine in the United States and H. Lundbeck A/S to market Memantine in certain European countries, Canada, Australia and South Africa. NTI is also evaluating XERECEPT for treatment of peritumoral brain edema (swelling of brain tissue due to tumor). This product has been found to be safer than alternative treatments currently used. By decreasing swelling, the drug is designed to improve the quality of life for brain cancer patients suffering from dysfunctions due to edema. Recently, the company completed Phase II trial of development and research activities for XERECEPT. This product was granted orphan drug status, which makes it eligible for federal research grants. In recent news, a New Drug Application was filed for the product Memantime in the treatment of Alzheimer’s disease. The drug has positive clinical trial results when used in collaboration with Aricept, a drug licensed by Eisai Co., Ltd.

BRANDS/DIVISIONS/AFFILIATES: Merz+ Co. GmbH&Co. Memantine XERECEPT

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul E. Freiman, CEO Paul E. Freiman, Pres. Paul E. Freiman, CFO Lisa U. Carr, VP- Medical Affairs Stephen C. Ferruolo, Corp. Sec. Abraham E. Cohen, Chmn.

Phone: 510-262-1730 Fax: 510-262-0204 Toll-Free: Address: 3260 Blume Drive, Ste. 500, Richmond, CA 94806 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $ (12 months) 2002 Profits: $-4,300 (12 months) Stock Ticker: NTII 2001 Sales: $4,781 2001 Profits: $1,588 Employees: 10 2000 Sales: $ 100 2000 Profits: $-3,115 Fiscal Year Ends: 6/30 1999 Sales: $ 100 1999 Profits: $-3,600 1998 Sales: $2,100 1998 Profits: $-2,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $200,000 Stock Purch. Plan: Y Second Exec. Salary: $123,200 ADVANTAGE: Exciting product for the treatment of dementia.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $150,000 Bonus: $30,000

Northeast:

International: Y



NEUROCRINE BIOSCIENCES INC

www.neurocrine.com


Y



Profits: 192


TYPES OF BUSINESS:



Drugs-Neurological and Immune Disorder Therapeutic Disease Treatment

Neurocrine Biosciences, Inc. is a leading neuroimmunology company focused on the discovery and development of therapeutics to treat diseases and disorders of the central nervous and immune systems. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction of central nervous , immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes. The firm recently announced the extension of its research collaboration with Wyeth, which has focused on the excitatory amino acid transporter sub-type, EAAT-3. The EEAT-3 has applications to treat schizophrenia, Alzheimer’s and other nervous system disorders.

BRANDS/DIVISIONS/AFFILIATES: Taisho Pharmaceutical NBI 6024 Neuroscience Pharma

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gary A. Lyons, CEO Gary A. Lyons, Pres. Paul W. Hawran, CFO Cynthia J. Thomas, VP-Human Resources Henry Pan, Chief Medical Officer Margaret E. Valeur-Jensen, Corporate Sec. Margaret E. Valeur-Jensen, General Counsel D. Bruce Campbell, Sr. VP-Dev. Henry Pan, Exec. VP-Clinical Dev. Paul J. Conlon, VP-Drug Discovery John Saunders, VP-Medicinal Chemistry Kevin C. Gorman, VP-Bus. Dev.

Phone: 858-658-7600 Fax: 858-658-7601 Toll-Free: Address: 10555 Science Center Dr., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $14,167 ( 9 months) 2002 Profits: $-55,749 ( 9 months) Stock Ticker: NBIX 2001 Sales: $41,200 2001 Profits: $-36,900 Employees: 222 2000 Sales: $14,600 2000 Profits: $-28,800 Fiscal Year Ends: 12/31 1999 Sales: $16,800 1999 Profits: $-16,800 1998 Sales: $16,000 1998 Profits: $-20,000

SALARIES/BENEFIT S: Pension Plan: Savings Plan: Y

COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $405,000 Bonus: $200,000 Stock Purch. Plan: Y Second Exec. Salary: $273,000 Bonus: $100,000 ADVANTAGE: Neocrine utilizes advanced technologies to enhance its drug discovery capabilities.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



NEUROGEN CORP

www.neurogen.com


Y



Profits: 172


TYPES OF BUSINESS:



Drugs-Neurological and Psychiatric Small Molecule Drugs

Neurogen Corp. is a leading small molecule drug discovery and development company targeting new drug candidates to improve the lives of patients suffering from neurological, inflammatory, pain and metabolic disorders. The firm has generated a portfolio of new drug programs through its fully integrated, proprietary drug discovery platform. Its Accelerated Intelligent Drug Discovery (AIDD) process and its expertise in cellular function assays allow the company to rapidly and cost-effectively identify active compounds during the drug discovery process. AIDD is an integrated system of hardware, software and processes that allows scientists to improve on the trial and error approach traditionally associated with discovery and development, through iterative application of screening, computational modeling and synthesis. The system works in tandem with its focused compound library and Virtual Screening on its Virtual Library, with several hundred billion virtual compounds. Neurogen has discovered 10 small molecule candidates that the firm and its partners are leading through human clinical trials. Two of these candidates, for the treatment of Alzheimer's disease and insomnia, are being tested by Pfizer, Inc. The company is also testing products for inflammatory disorders, Parkinson's disease, anxiety and depression, pulmonary disease, stress, pain and obesity. The company has also formed a licensing and research agreement with Aventis. Recently, Neurogen announced the results from a Phase II clinical study of NGD 97-1 for the treatment of Alzheimer's disease. The company also recently reduced its workforce by approximately 10% in order to enhance efficiency.

BRANDS/DIVISIONS/AFFILIATES: Accelerated Intelligent Drug Discovery Virtual Screening Virtual Library NGD 97-1

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William Koster, CEO William Koster, Pres. Alan Hutchison, Exec. VP-Discovery Research Kenneth R. Shaw , Sr. VP-Chemistry and Pharmaceutical Dev. Stephen R. Davis, Exec. VP/Chief Bus. Officer Edmund P. Harrigan, Exec. VP/Chief Dev. Officer James E. Krause, Sr. VP-Biology Charles J. Manly, VP-Discovery Tech. James V. Cassella, VP-Clinical Research and Dev.

Phone: 203-488-8201 Fax: 203-481-8683 Toll-Free: Address: 35 NE Industrial Rd., Branford, CT 06405 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $12,417 ( 9 months) 2002 Profits: $-19,220 ( 9 months) Stock Ticker: NRGN 2001 Sales: $11,500 2001 Profits: $-25,400 Employees: 200 2000 Sales: $20,400 2000 Profits: $-15,500 Fiscal Year Ends: 12/31 1999 Sales: $10,200 1999 Profits: $-14,600 1998 Sales: $11,100 1998 Profits: $-9,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $285,107 Stock Purch. Plan: Second Exec. Salary: $274,152 ADVANTAGE: Focus on small molecule research/Alliance with Pfizer.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:




Northeast: Y

International:



NEXMED INC

www.nexmed.com


Y Y



Profits: 144


TYPES OF BUSINESS:



Drugs Transdermal Drug Delivery Systems Sexual Dysfunction Products Medical Devices

NexMed, Inc. is a pharmaceutical and medical technology company that develops and commercializes therapeutic products based on proprietary delivery systems. Currently, the company is focusing its efforts on new and patented topical pharmaceutical products based on a penetration enhancement drug delivery technology known as NexACT, which has the potential to allow active drugs to be better absorbed through the skin. The firm is developing topical treatments in forms including cream, gel, patch and tape. Principal product candidates include Alprox-TD and Femprox creams for the treatment of male erectile dysfunction and female sexual arousal disorder, respectively. Alprox-TD has been launched in China under the trademark Befar. NexMed is also in the early stages of developing a topical treatment for nail fungus, a topical non-steroid anti-inflammatory drug and a topical anti-emetic treatment for the prevention of nausea and vomiting associated with post-operative surgical procedures and cancer chemotherapy. Another product in development is the Viratrol device, a therapeutic medical product for the treatment of herpes simplex diseases without the use of drugs. The device is hand-held and non-invasive, designed to treat herpes lesions with minute electrical currents. In recent news, NexMed announced that it is pursuing European marketing approval for AlproxTD. In addition, the firm is completing two U.S. Phase III trials for the product. NexMed offers its employees competitive salaries, medical and dental insurance and stock option plans.

BRANDS/DIVISIONS/AFFILIATES: NexACT Viratrol Femprox Alprox -TD Befar NexMed International, Ltd.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Y. Joseph Mo, CEO Y. Joseph Mo, Pres. James L. Yeager, Sr. VP-Scientific Affairs Kenneth F. Anderson, VP-Commercial Dev. Vivian H. Liu, VP-Corp. Affairs

Phone: 609-208-9688 Fax: 609-208-1868 Toll-Free: Address: 350 Corporate Blvd., Robbinsville, NJ 08691 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 145 ( 9 months) 2002 Profits: $-19,395 ( 9 months) Stock Ticker: NEXM 2001 Sales: $ 100 2001 Profits: $-16,200 Employees: 83 2000 Sales: $ 100 2000 Profits: $-8,707 Fiscal Year Ends: 12/31 1999 Sales: $1,492 1999 Profits: $-2,491 1998 Sales: $5,709 1998 Profits: $-4,823


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $225,000 Stock Purch. Plan: Second Exec. Salary: $195,000 ADVANTAGE: Unique set of products focused on proprietary delivery technologies.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $80,000 Bonus: $62,000

Northeast: Y

International: Y



NORTH AMERICAN SCIENTIFIC

www.nasi.net


Y



Y

TYPES OF BUSINESS:

Profits: 16



Y


Radioactive Seeds (Prostate Cancer) Radioactive Implant Therapeutics Imaging Technology Calibration and Control Products Environmental Monitoring Brachytherapy

North American Scientific, Inc. (NASI) designs, develops and produces innovative radioisotopic products, including brachytherapy seeds and radiopharmaceuticals, for the treatment and diagnosis of disease. The firm has applied its expertise in radioisotopes to develop and market products for medical, environmental, research and industrial applications. Since 1996, NASI has focused primarily on medical markets. The company's first two therapeutic products are brachytherapy seeds for the treatment of prostate cancer, marketed under the trademarks IoGold and PdGold by Mentor Corporation, the firm's distribution partner. In 2000, the company acquired Boston-based Theseus Imaging Corp., expanding NASI's products into larger markets. Theseus's primary product candidate is Apomate, an in vivo nuclear medicine imaging agent that targets cell death. The drug is in clinical trials for applications including determining response to chemotherapy, assessing the location and extend of heart attack damage and detecting heart transplant rejection. NASI's other products include radiation calibration and reference source products and Prospera, a line of high-activity brachytherapy seeds for use in the treatment of ocular melanoma and other solid tumor applications. In recent news, subsidiary Theseus Imaging announced plans to submit a new drug application to the FDA for its Hynic-Annexin V program.

BRANDS/DIVISIONS/AFFILIATES: Mentor Corporation Gold Standard Theseus Imaging Corp. Prospera Apomate IoGold PdGold Hynic-Annexin V

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. L. Michael Cutrer, CEO L. Michael Cutrer, Pres. Alan I. Edrick, Sr. VP/CFO George Jones, Exec. VP-Sales and Mktg. Allan M. Green, Chief Tech. Officer David Stiles, VP-Brachytherapy Sales and Mktg. Irwin J. Gruverman, Chmn.

Phone: 818-734-8600 Fax: 818-734-8606 Toll-Free: Address: 20200 Sunburst St., Chatsworth, CA 91311 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $15,160 ( 9 months) 2002 Profits: $-5,103 ( 9 months) Stock Ticker: NASI 2001 Sales: $19,300 2001 Profits: $-2,000 Employees: 61 2000 Sales: $17,500 2000 Profits: $-6,000 Fiscal Year Ends: 10/31 1999 Sales: $12,800 1999 Profits: $3,400 1998 Sales: $5,800 1998 Profits: $1,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $290,000 Stock Purch. Plan: Y Second Exec. Salary: $200,000 ADVANTAGE: Unique method for delivery of radioactive therapy.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $75,000 Bonus: $40,000

Northeast: Y

International:



NORTHFIELD LABORATORIES

www.northfieldlabs.com


Y




TYPES OF BUSINESS:



Drugs-Blood Substitute

Northfield Laboratories, Inc. is a leader in the development of a safe and effective alternative to transfused blood for use in the treatment of acute blood loss. Its PolyHeme blood substitute product is a solution of chemically modified hemoglobin derived from human blood. Clinical studies indicate that PolyHeme carries as much oxygen and loads and unloads oxygen in the same manner as transfused blood. Therefore the product is potentially effective as a resuscitative fluid in the treatment of hemorrhagic shock resulting from extensive blood loss. The firm's method of manufacturing the product is designed to eliminate risk of transmission of diseases such as AIDS or hepatitis. PolyHeme is universally compatible and does not require blood typing prior to infusion. It also has an extended shelf life compared to blood. Under refrigerated conditions, the product has a shelf life in excess of 12 months. Northfield has conducted clinical trials of PolyHeme at multiple U.S. locations in trauma and emergency situation applications. It has also been tested in elective surgical applications. The firm has entered into licensing agreements with Pharmacia Corp. and Hemocare, Ltd. to manufacture and distribute the product both inside and outside the U.S., in areas including European, Middle Eastern and African countries. Northfield owns five patents relating to PolyHeme. Recently, Northfield proposed ambulance trials to assess the role of PolyHeme in treating severely injured patients before they reach a hospital.

BRANDS/DIVISIONS/AFFILIATES: PolyHeme

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steven A. Gould, CEO Jack J. Kogut, VP-Finance Marc D. Doubleday, VP-Process Eng. Robert L. McGinnis, VP-Mfg. Dev. Jack J. Kogut, Corp. Sec. John A. Dybas, Jr., VP-Comm. Jack J. Kogut, Treas. John A. Dybas, Jr., VP-Regulatory Affairs

Phone: 847-864-3500 Fax: 847-864-3577 Toll-Free: Address: 1560 Sherman Ave., Ste. 1000, Evanston, IL 602014800 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note : Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $ (12 months) 2002 Profits: $-10,700 (12 months) Stock Ticker: NFLD 2001 Sales: $ 100 2001 Profits: $-10,174 Employees: 58 2000 Sales: $ 100 2000 Profits: $-9,200 Fiscal Year Ends: 5/31 1999 Sales: $ 100 1999 Profits: $-7,400 1998 Sales: $ 100 1998 Profits: $-5,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $298,682 Stock Purch. Plan: Second Exec. Salary: $281,525 ADVANTAGE: Effective blood substitute for patients suffering from acute blood loss.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $147,487 Bonus: $139,024

Northeast:

International:



NOVARTIS AG

www.novartis.com


Y



Profits: 5


TYPES OF BUSINESS:



Drugs-Diversified Therapeutic Drug Discovery Therapeutic Drug Manufacturing Generic Drugs Branded Pharmaceuticals Over-the-Counter Drugs Nutritionals Soft Contact Lenses

Novartis is engaged in research and development and is a leader in life sciences with a strong focus on improving the well being of animals, plants, crops and humans. It operates in five principle business segments: pharmaceuticals, generics, consumer health, CIBA Vision and animal health. Through its pharmaceuticals division, Novartis develops, manufactures and markets prescription medicines. Its generics division competes in two segments: finished dosage forms and active pharmaceutical ingredients and their intermediates. Finished dosage forms are sold to pharmacies, hospitals and other health care outlets, while active ingredients and their intermediates for pharmaceutical and biotechnological substances are sold to industrial customers. Consumer health operates in the over-thecounter self-medication, health and functional nutrition and medical nutrition units. Novartis recently began the divestiture of certain parts of its health and functional food business in order to increase its focus on pharmaceuticals. CIBA Vision is a world leader in the research, development and manufacturing of eye care products, namely soft contact lenses, lens care products and ophthalmic surgical products. Through its animal health division, Novartis enhances and extends the life of companion animals and improves the health and productivity of farm animals. This business unit recently purchased Grand Laboratories, Inc. and ImmTech Biologics, Inc., both engaged in the development of vaccines for cattle and pigs. Novartis recently established the Novartis Institute for Biomedical Research, Inc. in Cambridge, Massachusetts. All worldwide research activities performed in Europe, the U.S. and Japan will be led by the Institute. The firm will open a new $750 million, 1,000 employee lab in Cambridge, MA in 2004. Novartis provides medical, dental and vision insurance to employees, in addition to childcare and elderly care support, educational advancement support and family care support. Novartis also offers health and fitness programs and counseling services.

BRANDS/DIVISIONS/AFFILIATES: CIBA Vision Grand Laboratories, Inc. ImmTech Biologics, Inc. Novartis Institute for Biomedical Research, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Daniel Vasella, CEO Daniel Vasella, Pres. Raymund Breu, CFO Norman Walker, Exec. Dir.-Human Resources Ingrid Duplain, Corp. Sec. Urs Barlocher, Dir.-Legal and General Affairs Gilbert Wenzel, Dir.-Strategic Planning Karen J. Huebscher, Global Head of Investor Rel. Christian Seiwald, CEO-Generics Glen Bradly, CEO, CIBA Vision Hans-Beat Gurtler, CEO, Animal Health Al Piergallini, CEO, Consumer Health Thomas Ebeling, CEO, Novartis Pharma AG

Phone: +41-61-324-1111 Fax: +41-61-324-8001 Toll-Free: Address: Lichtstrasse 35, Basel, CH-4002 Switzerland

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $15,346,000 ( 9 months) 2002 Profits: $3,546,000 ( 9 months) Stock Ticker: NVS 2001 Sales: $19,070,000 2001 Profits: $4,181,000 Employees: 68,000 2000 Sales: $21,312,500 2000 Profits: $4,291,666 Fiscal Year Ends: 12/31 1999 Sales: $19,324,404 1999 Profits: $3,963,690 1998 Sales: $18,870,238 1998 Profits: $3,577,381


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: A combination of acquisitions and strong research have made this one of the most promising pharma companies in the world.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International: Y



NOVAVAX INC

www.novavax.com


Y



Y

TYPES OF BUSINESS:

Profits: 117




Drugs-Bacterial and Viral Infection Hormone Replacement Therapies Contract Research Services

Novavax is a fully integrated specialty pharmaceutical company focused on the research, development and commercialization of products utilizing its proprietary drug delivery and vaccine technologies for large and growing markets, concentrating on the areas of women's health care and infectious diseases. It lead product candidate, ESTRASORB, is the first transdermal lotion for estrogen replacement therapy for which a new drug application has been accepted by the FDA. In Phase II and III clinical trials, the product significantly reduced hot flashes in menopausal women. The drug offers additional advantages over other estrogen replacement therapies, including ease of use, rapid onset and a lower incidence of skin irritation and nausea. Novavax's drug delivery technologies involve the use of its patented oil and water emulsions, which can be used as vehicles for the transdermal and injectable delivery of a variety of drugs and other therapeutic products, including hormones, antibacterial and anti-viral products and vaccine adjuvants. Other product candidates include ANDROSORB, a transdermal testosterone lotion in Phase II trials; ANDROJect, a long-acting subcutaneous formulation of testosterone; and a transdermal progestin lotion in preclinical development. The firm also conducts research and development on preventative and therapeutic vaccines for a variety of infectious diseases. Products that the com pany currently markets include Nestabs prescription prenatal vitamins, Gynodiol oral estrogen replacement therapy, AVC cream and suppositories for vaginal bacterial infection and Nordette birth control pills. Novavax's products are based on its platform technologies, which include Novasomes, non-phospholipid liposomes used as adjuvants to enhance vaccine effectiveness; and Sterisomes, subcutaneous injections which deliver long-acting drug effect. In recent news, a Phase III trial for ESTRASORB showed the product effective in reducing vasomotor symptoms in postmenopausal women.

BRANDS/DIVISIONS/AFFILIATES: ESTRASORB ANDROSORB Nestabs Gynodiol AVC Cream Analpram HC ANDRO-Ject Sterisomes

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Mitchell J. Kelly, CEO Mitchell J. Kelly, Pres. Dennis W. Genge, VP/CFO D. Craig Wright, Chief Scientific Officer Ann O. McGeehan, General Counsel Dennis W. Genge, Treas. Marvin A. Heuer, VP-Scientific and Regulatory Affairs Dennis O'Donnell, Chmn.

Phone: 301-854-3900 Fax: 301-854-3901 Toll-Free: Address: 8320 Guilford Rd., Ste. C, Columbia, MD 21046 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $13,306 ( 9 months) 2002 Profits: $-17,552 ( 9 months) Stock Ticker: NVAX 2001 Sales: $24,100 2001 Profits: $-9,700 Employees: 173 2000 Sales: $2,500 2000 Profits: $-12,200 Fiscal Year Ends: 12/31 1999 Sales: $1,200 1999 Profits: $-4,500 1998 Sales: $ 700 1998 Profits: $-4,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $266,782 Stock Purch. Plan: Second Exec. Salary: $210,171 ADVANTAGE: Ability to create an early revenue stream by offering contract research.

OTHER THOUGHTS:


Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/M inorities:

West:

Southwest:

Midwest:

Southeast:



Bonus: $250,000 Bonus: $75,000

Northeast: Y

International:



NOVEN PHARMACEUTICALS

www.noven.com


Y



Profits: 42


TYPES OF BUSINESS:



Transdermal Drug Delivery Systems Women's Health Products Pain Management Products

Noven Pharmaceuticals, Inc. is a leader in the development and manufacture of advanced transdermal drug delivery products and technologies and prescription transdermal products. Its principal commercialized products are transdermal drug delivery systems, utilizing its DOT Matrix technology, for use in hormone replacement therapy. The firm's first product was an estrogen patch for the treatment of menopausal symptoms, marketed under the name Vivelle in the U.S. and Canada and under the name Menorest in Europe and other markets. The company also launched the smallest transdermal estrogen patch ever approved by the U.S. FDA, Vivelle-Dot. The product is currently marketed in several foreign countries and began marketing under the name Estradot in the U.S. in 2002. Noven also developed a combination estrogen/progestin transdermal patch for the treatment of menopausal symptoms, marketed under the name CombiPatch in the U.S. and Estalis in Europe and other markets. The firm is currently developing a range of products, including MethyPatch, a transdermal delivery system for the treatment of attention deficit hyperactivity disorder. Other areas of focus include central nervous system conditions and pain management. In addition, Noven has partial ownership of a joint venture formed in partnership with Novartis Pharmaceuticals, called Vivelle Ventures, doing business under the name Novogyne Pharmaceuticals. The company markets Vivelle, Vivelle-Dot and CombiPatch in the U.S. In recent news, the FDA accepted a new drug application for MethyPatch.

BRANDS/DIVISIONS/AFFILIATES: Vivelle Menorest Vivelle-Dot CombiPatch Estalis MethyPatch Estradot Novogyne Pharmaceuticals

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert C. Strauss, CEO Robert C. Strauss, Pres. James B. Messiry, VP/CFO W. Neil Jones, VP-Mktg. and Sales Juan A. Mantelle, VP/Chief Tech. Officer Jeffery P. Eisenberg, Corp. Sec. Jeffery P. Eisenberg, General Counsel Paven Handa, Exec. Dir.-Bus. Dev. Joseph C. Jones, VP-Corp. Affairs Jeffery P. Eisenberg, VP-Strategic Alliances

Phone: 305-253-5099 Fax: 305-251-1887 Toll-Free: Address: 11960 SW 144th St., Miami, FL 33186 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $42,089 ( 9 months) 2002 Profits: $10,859 ( 9 months) Stock Ticker: NOVN 2001 Sales: $45,900 2001 Profits: $12,100 Employees: 252 2000 Sales: $42,900 2000 Profits: $19,600 Fiscal Year Ends: 12/31 1999 Sales: $31,600 1999 Profits: $10,500 1998 Sales: $21,800 1998 Profits: $-4,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $485,100 Stock Purch. Plan: Second Exec. Salary: $220,500 ADVANTAGE: Growing line of unique therapies based on transdermal delivery.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Bonus: $ Bonus: $

Northeast:

International:



NOVO-NORDISK AS

www.novonordisk.com


Y



Profits: 12


TYPES OF BUSINESS:



Drugs-Diabetes Drugs-Women's Health Drugs-Growth Disorders Drugs-Industrial Enzymes Insulin Delivery Systems Hormone Replacement Therapy

Based in Denmark, Novo Nordisk is a global, focused health care company with a broad diabetes product portfolio, including insulin delivery systems. The firm is also engaged in areas including hemostasis management, human growth hormone and hormone replacement therapy. The company manufactures and markets pharmaceutical products and services that are designed to make a significant difference to patients, the medical profession and society. Novo Nordisk's range of diabetes products includes easy-to-use pen devices for injecting insulin. The firm also offers diabetes services, such as educational and training materials for both patients and health care professionals. The company's NovoSeven product, a treatment for hemophilia, is a recombinant coagulation factor that enables coagulation to proceed in the absence of natural factors. Currently, a NovoSeven plant is under construction in Denmark. Novo Nordisk also manufactures Norditropin SimpleXx, a human growth hormone for the treatment of growth hormone deficiency in children and adults, Turner syndrome and other conditions, available in the company's dedicated pen system. The NordiPenMate device is an auto-insertion tool for people with a phobia of needles. The firm also manufactures post-menopausal hormone replacement therapy products, including Activelle, Kliogest, Trisequens, Estrofem and Vagifem. In recent news, Novo Nordisk submitted a new drug application to the U.S. FDA for NN304, or insulin detemir, a new long-lasting insulin analog. In other news, the company's Novo Nordisk Canada subsidiary signed a distribution agreement for GlucaGen with Paladin Labs, Inc.

BRANDS/DIVISIONS/AFFILIATES: NovoPenMate NovoSeven Norditropin SimpleXx Activelle Kliogest Trisequens Estrofem Vagifem

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Lars Rebien Sorensen, CEO Kare Schultz, Exec. VP/COO Lars Rebien Sorensen, Pres. Jesper Brandgaard, Exec. VP/CFO Lars Almblom Jorgensen, Exec. VP/Chief of Staff Mads Krogsgaard Thomsen, Exec. VP/Chief Science Officer Mike Rulis, VP-Media Rel. Lise Kingo, Exec. VP Hans Gliese, Sr. VP-Dev. Peter Aurup, VP-U.S. Drug Dev.

Phone: +45-4444-8888 Fax: +45-4449-0555 Toll-Free: Address: 2880 Novo Alle, Basgvaerd, DK-2880 Denmark

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,269,000 ( 9 months) 2002 Profits: $359,000 ( 9 months) Stock Ticker: NVO 2001 Sales: $2,839,000 2001 Profits: $461,000 Employees: 16,141 2000 Sales: $2,437,000 2000 Profits: $417,000 Fiscal Year Ends: 12/31 1999 Sales: $1,924,000 1999 Profits: $288,000 1998 Sales: $1,599,000 1998 Profits: $223,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: A leader in insulin protection.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast: Y



Northeast: Y

International: Y



NPS PHARMACEUTICALS INC

www.npsp.com


Y



Profits: 206


TYPES OF BUSINESS:



Drugs-Hyperparathyroidism, Osteoporosis and Neurological Damage Small Molecule Drugs

NPS Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs and recombinant proteins. Its current product candidates are primarily for the treatment of bone and mineral disorders, gastrointestinal disorders and central nervous system disorders. NPS has two programs which treat osteoporosis. Its PREOS hormone is currently being developed within the company to treat the disorder, and the firm is working with GlaxoSmithKline to pursue calcilytic compounds as a separate form of treatment. NPS is presently developing the hormone ALX-0600 for the treatment of the gastrointestinal disorder short bowel syndrome. The company is evaluating the results of its latest trial with the treatment. The firm has recently entered into an agreement with AstraZeneca under which it will collaborate exclusively on the development of metabotropic glutamate receptor subtypes which can treat central nervous system disorders such as chronic pain. It also collaborates with Janssen on glycine reuptake inhibitors to identify prospective drug candidates for schizophrenia and dementia.

BRANDS/DIVISIONS/AFFILIATES: PREOS ALX-0600 GlaxoSmithKline AstraZeneca Janssen

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Hunter Jackson, CEO Hunter Jackson, Pres. Robert K. Merrell, CFO G. Thomas Heath, Sr. VP-Mktg. and Sales N. Patricia Freston, VP-Human Resources Edward F. Nemeth, Chief Scientific Officer James U. Jensen, Sec. James U. Jensen, VP-Legal Affairs David L. Clark, VP-Oper. James U. Jensen, VP-Corp. Dev. David L. Clark, VP-Corp. Comm. Robert K. Merrell, Treas. Alan L. Mueller, VP-Discovery Research Thomas B. Marriott, VP-Dev. Research

Phone: 801-583-4939 Fax: 801-583-4961 Toll-Free: Address: 420 Chipeta Way, Salt Lake City, UT 84108 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,021 ( 9 months) 2002 Profits: $-61,433 ( 9 months) Stock Ticker: NPSP 2001 Sales: $10,400 2001 Profits: $-50,000 Employees: 146 2000 Sales: $7,600 2000 Profits: $-32,100 Fiscal Year Ends: 12/31 1999 Sales: $3,400 1999 Profits: $-35,700 1998 Sales: $3,600 1998 Profits: $-17,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $383,300 Stock Purch. Plan: Second Exec. Salary: $218,181 ADVANTAGE: Niche therapy focus/Strategic alliances.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $149,122 Bonus: $5,100

Northeast:

International: Y



NUTRITION 21 INC

www.nutrition21.com


Y Y



Profits: 1


TYPES OF BUSINESS:



Drugs-Dietary Cardiovascular and Diabetes Treatments Nutritional Ingredients

Nutrition 21, Inc., formerly AMBI, Inc., aspires to become the leading nutrition company specializing in branded therapeutic nutrition supplements for disease-specific conditions. The firm's first branded product, Diachrome, will be positioned to aid in the dietary management of diabetes and marketed with the support of health care professionals. The company has commissioned its fourth clinical trial to validate the products' efficacy and pharmaco-economic benefits. In the past, Nutrition 21's chromium -based patent portfolio has supported a profitable ingredient business that concentrates on sales of a USDA-invented and researched picolinate form of chromium, sold under the Chromax brand name to vitamin and supplement manufacturers for human and animal applications. It is one of the most widely used ingredients in supplements marketed for weight control purposes. Other ingredients sold by the firm include Selenomax and Magnemax. With the acquisition of Optimum Lifestyle in 1999, Nutrition 21 acquired the Lite Bites brand and branched into the sale of branded consumer products. The company sells the Lite Bites Fat Fighting System, which is based on Chromax, on televised shopping programs through an alliance with QVC. Over the past three years, Nutrition 21 has funded a robust clinical development program to better understand chromium's mechanism of action and its relevance to insulin-mediated metabolic systems. Through this effort the firm has identified newly patented combinations of chromium and new food systems that can be enhanced by the inclusion of its ingredient systems. In recent news, the company entered into a partnership with Leiner Health Products to market and sell Lite Bites nutrition bars in national mainstream retail channels.

BRANDS/DIVISIONS/AFFILIATES: AMBI, Inc. Optimum Lifestyle, Inc. Diachrome Chromax Lite Bites Selenomax SelenoPure Magnemax

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gail Montgomery, CEO Gail Montgomery, Pres. Alan J. Kirschbaum, Sr. VP-Finance/Principal Financial Officer Benjamin T. Sporn, Sr. VP/Corp. Sec. Benjamin T. Sporn, General Counsel Alan J. Kirschbaum, Treas.

Phone: 914-701-4500 Fax: 914-696-0860 Toll-Free: Address: 4 Manhattanville Rd., Purchase, NY 10577-2197 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $14,700 (12 months) 2002 Profits: $-6,000 (12 months) Stock Ticker: NXXI 2001 Sales: $23,252 2001 Profits: $1,065 Employees: 23 2000 Sales: $32,800 2000 Profits: $6,500 Fiscal Year Ends: 6/30 1999 Sales: $28,300 1999 Profits: $5,900 1998 Sales: $20,800 1998 Profits: $1,100


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Steady growth/Focus on cardiovascular health and diabetes treatments.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



ONYX PHARMACEUTICALS INC

www.onyx-pharm.com


Y



Profits: 178


TYPES OF BUSINESS:



Drugs-Cancer Small-Molecule Drugs Therapeutic Viruses

Onyx Pharmaceuticals, Inc. develops innovative products for the treatment of cancer utilizing two technology platforms, small molecules and therapeutic viruses. Its product candidates include ONYX-015, ONYX-411 and Armed Therapeutic Viruses. In addition, the company is developing a novel small-molecule compound, BAY 439006, in partnership with Bayer Corp. ONYX-015 is a human virus genetically engineered to selectively replicate in and kill cancer cells based on the mutation or loss of function of a specific tumor suppressor gene. The product is currently in Phase III clinical trials for head and neck cancer, as well as Phase I/II trials for liver metastases of colorectal cancer. The firm has partnered with WarnerLambert to develop and commercialize this product. BAY 43-9006 is designed to block the inappropriate growth signals in tumor cells by inhibiting the enzyme that is activated to induce cancer cell growth. The drug is Phase I/II clinical trials for the treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). Onyx is initiating trials of the product in patients with various tumor types. The company is also developing human viruses that kill cancer cells based on mutations of the retinoblas toma tumor suppressor gene. ONYX-411, based on this technology, is in preclinical development for multiple tumor types. Onyx is also researching smallmolecule cell cycle programs and inflammation programs for tumors and acute and chronic inflammatory disease. In recent news, the company announced that BAY 439006 is moving toward Phase III trials in 2003. The firm offers its employees health, dental, vision and life insurance, flexible spending accounts, tuition reimbursement, stock options and members hip in a credit union.

BRANDS/DIVISIONS/AFFILIATES: ONYX-015 BAY 43-9006 ONYX-411 ONYX-443 Armed Therapeutic Viruses

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Hollings C. Renton, CEO Hollings C. Renton, Pres. Leonard E. Post, Sr. VP-Research and Dev. Marilyn E. Wortzman, Controller Gregory J. Giotta, VP/Chief Legal Counsel Jeanne Y. Jew , VP-Corp. and Commercial Dev. D. Scott Geyer, Sr. VP-Product Dev. Scott M. Freeman, VP-Clinical Dev. Hollings C. Renton, Chmn.

Phone: 510-222-9700 Fax: 510-222-9758 Toll-Free: Address: 3031 Research Dr., Richmond, CA 94806 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,715 ( 9 months) 2002 Profits: $-32,490 ( 9 months) Stock Ticker: ONXX 2001 Sales: $15,800 2001 Profits: $-27,600 Employees: 85 2000 Sales: $24,200 2000 Profits: $-7,500 Fiscal Year Ends: 12/31 1999 Sales: $13,300 1999 Profits: $-14,800 1998 Sales: $11,300 1998 Profits: $-17,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $355,384 Bonus: $80,000 Stock Purch. Plan: Y Second Exec. Salary: $285,385 Bonus: $17,500 ADVANTAGE: Steady growth/Product line expansion/Unique focus on genetically engineered viruses.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



ORAPHARMA INC

www.orapharma.com


Y



Profits: 173


TYPES OF BUSINESS:



Drugs-Oral Disease Oral Health Care Products Novel Bone Products Soft Tissue Regeneration Products Periodontal Therapeutics Oral Mucositis Treatment Pain Management Systems

OraPharma, Inc. is engaged in the research, development and marketing of oral health care products. The firm is also focused on novel bone and soft tissue regeneration products, next-generation periodontal therapeutics and oral mucositis treatment prevention, a side effect of cancer treatments and pain management systems. The company’s lead product, Arestin microspheres, is indicated as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis. Other technological initiatives that OraPharma currently has underway include new treatments for bone and tissue regeneration, oral complications of cancer therapy and dental pain/trauma. The firm’s patented core technology platform us es a sustained-release drug delivery system that is based on microencapsulation of drugs in bioresorbable polymers. This technology allows for varied rates of drug release by altering polymer degradation patterns and can deliver drugs over periods ranging from one day to several months. The company recently entered into a distribution agreement with Kensey Nash Corporation, a medical device manufacturer specializing in absorbable biomaterials. Under the agreement, OraPharma will exclusively distribute Epi-Guide Periodontal Barrier Matrix and Drilac Surgical Dressing products in the United States and Canada through its direct sales force. In a major development, Johnson & Johnson recently signed a definitive agreement to acquire OraPharma. Once the acquisition is completed, OraPharma will operate as part of the Personal Products Company, a member of the Johnson & Johnson family of companies. Johnson & Johnson has 197 operating companies in 54 countries around the world, selling products in more than 175 countries.

BRANDS/DIVISIONS/AFFILIATES: Arestin American Home Products Epi-Guide Periodontal Barrier Matrix Drilac Surgical Dressing Personal Products Company Johnson & Johnson

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael D. Kishbauch, CEO Michael D. Kishbauch, Pres. James A. Ratigan, CFO Russell A. Secter, VP-Sales & Mktg. Linda Bird, VP-Human Resources J. Ronald Lawter, Chief Scientific Officer/Chief Tech. Officer/VP Jan N. Lessem, VP/Chief Medical Officer James A. Ratigan, Corp. Sec.

Phone: 215-956-2200 Fax: 215-443-9531 Toll-Free: Address: 732 Louis Dr., Warminster, PA 18974 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $14,752 ( 9 months) 2002 Profits: $-19,946 ( 9 months) Stock Ticker: OPHM 2001 Sales: $7,700 2001 Profits: $-25,700 Employees: 124 2000 Sales: $ 100 2000 Profits: $-12,300 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-11,200 1998 Sales: $ 1998 Profits: $-8,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Focus on oral health products.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $49,888 Bonus: $45,218

Northeast: Y

International:



ORASURE TECHNOLOGIES INC

www.orasure.com


Y



Y

TYPES OF BUSINESS:

Profits: 19




Diagnostics DNA Screening Kits Oral Fluid Collection Devices Immunoassays Cryosurgical Products Substance Abuse Tests

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies and diagnostic products including immunoassays and other in vitro diagnostic tests, as well as other medical devices. These products are sold in the U.S. and certain other foreign countries to government agencies, clinical laboratories, physicians' offices, hospitals, commercial and industrial entities and various distributors. The firm's principal platform technologies are the OraSure and Intercept oral fluid collection devices; the OraQuick rapid diagnostic test device; and up-converting phosphor technology (UPT) including its first application, UPlink, a lateral flow testing system for various analytes. OraSure's other products include the Histofreezer portable cryosurgical system, certain immunoassay tests and reagents for insurance risk assessment, substance abuse testing and forensic toxicology applications, or oral fluid Western Blot confirmatory test for HIV-1 and the Q.E.D. saliva alcohol test. The OraSure oral fluid collection device is used in conjunction with screening and confirmatory tests for HIV1 antibodies and other analytes. It consists of a small, treated cotton-fiber pad on a nylon handle, which is placed in the mouth for two to five minutes. The device collects oral mucosal transudate (OMT0, a serum -derived fluid that contains higher concentrations of antibodies and analytes than saliva. The product has several advantages over blood- and urine-based testing systems for both health care professionals and patients, including the elimination of needle risk, non-invasive collection method, minimal required training, rapid and efficient collection in any setting and low cost. UPlink is a rapid point-of-care system that provides quantitative results in about 10 minutes on a variety of samples, including oral fluid, blood, serum, urine and stool samples. OraSure is currently developing the product for additional applications with Meridian Diagnostics, Inc. In recent news, the firm received FDA approval for the OraQuick Rapid HIV-1 test.

BRANDS/DIVISIONS/AFFILIATES: UPlink AUTO-LYTE Histofreezer OraQuick HIV OraSure HIV -1 MICRO-PLATE Intercept Q.E.D. Saliva Alcohol Test

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael J. Gausling, CEO Michael J. Gausling, Pres. Ronald H. Spair, Exec. VP/CFO Joseph E. Zack, Exec. VP-Mktg. and Sales R. Sam Niedbala, Exec. VP/Chief Science Officer Mark L. Kuna, Controller Jack E. Jerrett, VP/Corp. Sec. Jack E. Jerrett, General Counsel P. Michael Formica, Sr. VP-Oper. Salvatore J. Salamone, Sr. VP-Product Dev. Richard D. Hooper, VP-Finance

Phone: 610-882-1820 Fax: 610-882-1830 Toll-Free: Address: 150 Webster St., Bethlehem , PA 18015 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $23,762 ( 9 months) 2002 Profits: $-3,261 ( 9 months) Stock Ticker: OSUR 2001 Sales: $32,600 2001 Profits: $-3,700 Employees: 2000 Sales: $28,788 2000 Profits: $-12,747 Fiscal Year Ends: 12/31 1999 Sales: $24,046 1999 Profits: $-4,233 1998 Sales: $20,444 1998 Profits: $-2,374


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $274,461 Stock Purch. Plan: Second Exec. Salary: $225,211 ADVANTAGE: A leading maker of oral specimen kits and fluid collection kits.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



ORCHID BIOSCIENCES INC

www.orchid.com



Y


Y

TYPES OF BUSINESS:

Profits: 34


Y Y



Research-Bioinformatics Genetic Technology Diagnostics Transplantation Pharmacogenetic Testing Genetic Databases Genotyping Instrument Hardware Reagents

Orchid BioSciences is engaged in the development and commercialization of technologies, products and services designed to measure and analyze information related to genetic diversity, or the genetic variability that distinguishes one organism from another. The firm has established a portfolio of business units that provide products and services focusing on the analysis of genetic variability through genotyping, the measurement of genetic variability in a person, plant or animal individual. This data is used in the field of identity genomics for paternity and forensics identification testing, as well as by health care providers in organ trans plantation compatibility testing. It is also used in genetic disease susceptibility testing and to help physicians manage treatment regimens. Orchid focuses on applications including SNP (single nucleotide polymorphism) genotyping and pharmacogenetics. The firm's business units include Orchid Life Sciences, which develops and markets products and services for SNP genotyping to life sciences and biomedical researchers and pharmaceutical, agricultural, diagnostic and biotechnology companies; Orchid Identity Genomics, which provides DNA testing for paternity and forensics determinations to government authorities as well as individuals and organizations (through Orchid GeneScreen and Orchid Cellmark); Orchid Diagnostics, which provides products and services for genetic testing; and Orchid GeneShield, which develops programs designed to accelerate the adoption and use of personalized medicine by patients and physicians. At the core of Orchid's technologies is its proprietary SNP-IT primer extension technology, a method of isolating the precise location of the site of a suspected SNP and utilizing the inherent accuracy of DNA polymerase to determine the presence or absence of the SNP. SNP-IT products include SNPcode and SNPstream. In recent news, the company introduced the ChromosomeBrowser web tool for interactive SNP genotyping applications. The company offers its employees credit union membership and alternative work schedules.

BRANDS/DIVISIONS/AFFILIATES: Orchid Biocomputer Orchid Diagnostics Orchid GeneScreen Orchid Cellmark Orchid GeneShield Orchid Life Sciences SNPstream SNPware

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dale R. Pfost, CEO Dale R. Pfost, Pres. Andrew P. Savadelis, CFO/Sr. VP-Finance Michael T. Boyce-Jacino, Chief Scientific Officer/VP-Life Sciences Donald R. Marvin, Sr. VP/Mgr.-Diagnostics Russell T. Granzow , VP-Corp. Bus. Dev. and Strategy Mark D. Stolorow , Exec. Dir.-Orchid Cellmark Keith W. Brown, Sr. VP/Mgr.-Identity Genomics Christopher S. Smith, Exec. Dir.-Orchid GeneScreen M. Lee Morse, VP/Mgr.-Orchid GeneShield

Phone: 609-750-2200 Fax: 609-750-6400 Toll-Free: Address: 4390 U.S. Rte. One, Princeton, NJ 08540 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results w ere not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $49,252 ( 9 months) 2002 Profits: $-45,016 ( 9 months) Stock Ticker: ORCH 2001 Sales: $31,200 2001 Profits: $-84,700 Employees: 595 2000 Sales: $18,400 2000 Profits: $-47,900 Fiscal Year Ends: 12/31 1999 Sales: $1,800 1999 Profits: $-28,200 1998 Sales: $2,800 1998 Profits: $-11,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $365,750 Stock Purch. Plan: Second Exec. Salary: $291,500 ADVANTAGE: Excellent potential for new uses of its diagnostics technology.

OTHER THOUGHTS:



West:

Southwest: Y

Midwest:

Southeast:



Bonus: $79,233 Bonus: $96,250

Northeast: Y

International: Y



ORGANOGENESIS INC

www.organogenesis.com



Y


Profits: 9


TYPES OF BUSINESS:



Tissue Replacement Products Human Connective Tissue Development Liver Assist Device Wound Dressing Products

Organogenesis Inc. is a tissue-engineering firm that designs, develops and manufactures medical products containing living cells and/or natural connective tissue. The firm is the developer and manufacturer of the only mass-produced medical product containing living human cells marketed in the United States. The product development program includes living tissue replacements, cell-based organ assist devices and other tissueengineered products. The Apligraph living cell substitute, the company’s lead product, is designed for the treatment of venous leg ulcers due to poor blood circulation. Apligraph contains living human skin cells, keratinocytes and fibroblasts, which are organized in an epidermal and dermal layer. Graftpatch is another product by Organogenesis used for soft tissue reinforcement. The firm is currently developing Vitrix, which is a dermal and connective tissue replacement for wound repair and surgery. Another milestone for the company is the development of Testskin II. In clinical studies, the product, used in vitro, stimulates the generation of certain skin cell types and produces collagen fibrils. Organogenesis is also developing a liver assist device designed to keep a patient alive until a donor liver becomes available. The company recently received FDA marketing clearance for PuraPly, a wound dressing product, and FortaFlex Surgical Sling, a bioengineered tissue support product. In mid 2002, the firm filed for bankruptcy protection.

BRANDS/DIVISIONS/AFFILIATES: Apligraph Novartis Pharmaceuticals Corporation Graftpatch Vitrix Testskin II FortaFlex PuraPly Surgical Sling

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Steven B. Bernitz , CEO Steven B. Bernitz , Pres. Gary S. Gillheeney, CFO Nancy L. Parenteau, Sr. VP-Research & Dev. Michael L. Sabolinski, Exec. VP-Medical and Reg. Affairs Gary S. Gillheeney, Corp. Sec. Jeff Dow , General Counsel John J. Arcari, VP-Admin. Gary S. Gillheeney, VP-Corp. Dev. Gary S. Gillheeney, Treas. Paul J. DiCicco, VP-Oper. Michael L. Sabolinski, Chief Scientific Officer

Phone: 781-575-0775 Fax: 781-575-0440 Toll-Free: Address: 150 Dan Rd., Canton, MA 02021 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 3 months. 2002 Sales: $2,900 ( 3 months) 2002 Profits: $-7,400 ( 3 months) Stock Ticker: ORG 2001 Sales: $10,300 2001 Profits: $-30,100 Employees: 182 2000 Sales: $10,200 2000 Profits: $-28,600 Fiscal Year Ends: 12/31 1999 Sales: $2,700 1999 Profits: $-28,400 1998 Sales: $7,900 1998 Profits: $-14,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $277,420 Bonus: $56,000 Stock Purch. Plan: Second Exec. Salary: $229,836 Bonus: $30,000 ADVANTAGE: Many potential uses for its skin replacement products/Filed for bankruptcy in 2002.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



ORPHAN MEDICAL INC

www.orphan.com


Y



Profits: 94


TYPES OF BUSINESS:



Drugs-Rare Disease Antidotes Oncology Support Drugs Sleep Disorder Treatment

Orphan Medical, Inc. acquires, develops and markets pharmaceutical products of high medical value for patients within selected therapeutic areas, currently concentrating on antidotes, oncology support and sleep disorders. The company's lead antidote and oncology support products are Antizol and Busulfex, respectively, and are available commercially in the United States and several foreign countries. Xyrem is Orphan's lead product in the sleep disorders area. The firm also manufactures and distributes Cystadane and Sucraid, which treat two rare congenital diseases. Antizol-Vet is marketed through separate channels to the veterinary community. Orphan utilizes a targeted marketing approach, focusing on areas characterized by well-defined patient populations treated by well-defined groups of specialists, which makes a large sales force unnecessary because marketing efforts can be focused on a limited number of medical specialists or patients. In recent news, the company announced the commercial launch of is Xyrem product in oral solution form. The drug is being sold through a specialty sales force to sleep centers and other physicians who treat cataplexy patients. It is the first and only approved medication for the treatment of cataplexy, a debilitating symptom of narcolepsy. Express Scripts, a pharmacy benefit management company, was named the exclusive distributor of the drug. Orphan also recently reported that Xyrem prescriptions written to date have exceeded company expectations.

BRANDS/DIVISIONS/AFFILIATES: Antizol Busulfex Xyrem Sucraid Cystadane Elliotts B Solution Antizol-Vet

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John H. Bullion, CEO William Houghton, COO Timothy G. McGrath, VP/CFO Pamela J. Stahl, VP-Commercial Oper. Dayton T. Reardan, VP-Regulatory Affairs Mark D. Perrin, Exec. VP/Chief Commercial Officer John H. Bullion, Chmn.

Phone: 612-513-6900 Fax: 612-541-9209 Toll-Free: 888-867-7426 Address: 13911 Ridgedale Dr., Ste. 250, Minnetonka, MN 55305 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $11,337 ( 9 months) 2002 Profits: $-6,523 ( 9 months) Stock Ticker: ORPH 2001 Sales: $11,300 2001 Profits: $-6,000 Employees: 66 2000 Sales: $11,200 2000 Profits: $-6,100 Fiscal Year Ends: 12/31 1999 Sales: $6,500 1999 Profits: $-5,200 1998 Sales: $5,000 1998 Profits: $-8,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $256,938 Bonus: $128,131 Stock Purch. Plan: Second Exec. Salary: $200,000 Bonus: $109,635 ADVANTAGE: Focus on therapies for rare diseases/Ability to capitalize on drug therapies developed by other companies.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Northeast:

International:



OSI PHARMACEUTICALS INC

www.osip.com


Y



Profits: 166


TYPES OF BUSINESS:



Drugs-Small Molecule Cancer Treatments

OSI Pharmaceuticals is a leading biopharmaceutical company primarily focused on the discovery, development and commercialization of innovative products for the treatment of cancer. It has built a pipeline of discovery programs and drug candidates addressing major, unmet needs in cancer and selected opportunities arising from its drug discovery research programs that represent significant commercial opportunities outside of cancer. The firm has three candidates in clinical trials and seven projects with candidates in late-stage preclinical development. In late 2001, OSI acquired the oncology assets of Gilead Sciences, Inc., providing the company with three additional oncology candidates in clinical trials, as well as a first-class oncology clinical development team and strong toxicology groups. OSI's most advanced drug candidate, Tarceva, is a small molecule inhibitor of the epidermal growth factor receptor, the protein product of which is overexpressed in many solid tumor cancers. Tarceva is an oral, once-a-day drug with utility in treating a wide range of tumor types, including lung cancer, head and neck cancer and ovarian cancer. The drug is currently in Phase III clinical trials. Other oncology products in development include GS7904L, a liposomal thymidycate; OSI-211, a liposomal lurtotecan; and OSI760 and OSIC-0961370, adenosine receptor inhibitors. OSI's other research programs include the areas of diabetes, respiratory diseases, cholesterol lowering and cosmeceuticals. Recently, the company announced several restructuring adjustments designed to refocus efforts on oncology, including staff reductions. In addition, the company recently initiated two Phase II trials of OSI211 for ovarian and small-cell lung cancer. OSI offers its employees medical, dental and life insurance, stock options, tuition reimbursement, flexible spending plans, an employee assistance program and employee functions and activities.

BRANDS/DIVISIONS/AFFILIATES: Tarceva Aston Molecules Gilead Sciences, Inc. OSI-760 OSIC-0961370 GS7904L OSI-211

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Colin Goddard, CEO Robert L. Van Nostrand, VP/CFO Linda E. Amper, VP-Human Resources Nicholas G. Bacopoulos, Pres., Research and Dev. Raymond Bendele, VP- Pharmaceutical Dev. Barbara Wood, General Counsel Linda E. Amper, VP-Bus. Admin. Geoffrey Cooper, VP-Bus. Dev. John A. Slack, VP-Dev. Neil Gibson, VP-Research Nicole Onetto, Exec. VP-Oncology Arthur M. Bruskin, VP-Strategic Planning Jim McCormack, VP-U.K. Research

Phone: 631-962-2000 Fax: 631-752-3880 Toll-Free: Address: 58 S Service Rd., Ste. 110, Melville, NY 11747 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $17,172 ( 9 months) 2002 Profits: $-196,337 ( 9 months) Stock Ticker: OSIP 2001 Sales: $26,000 2001 Profits: $-23,700 Employees: 383 2000 Sales: $28,700 2000 Profits: $-16,300 Fiscal Year Ends: 9/30 1999 Sales: $22,700 1999 Profits: $-9,800 1998 Sales: $19,500 1998 Profits: $-10,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $488,769 Stock Purch. Plan: Y Second Exec. Salary: $304,856 ADVANTAGE: Expertise in identifying small molecule drug candidates for further development.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $250,000 Bonus: $60,000

Northeast: Y

International: Y



OXFORD GLYCOSCIENCES PLC

www.ogs.com


Y


Y


Y

TYPES OF BUSINESS:

Profits: 27




Drug Research-Proteomics Proteomics Services Proteomics Data Drugs

Oxford GlycoSciences, Plc (OGS) is a leader in the emerging field of proteomics. The company uses proteomics as well as genomics to create an innovative, proprietary drug discovery platform that allows the systematic separation, identification and characterization of proteins on an industrial scale. OGS has drug research discovery programs in cancer, infectious disease and glycolipid storage disorders. The company’s most advanced drug candidate, Vevesca (formerly known as OGT 918) is a small molecule for the oral treatment of Gaucher’s disease. Vevesca is currently undergoing clinical trials and has received fast-track designation by the FDA. In addition to creating drug and diagnostic products, OGS provides proteomics services and data to the pharmaceutical and life sciences industries. A number of major companies and research institutions have entered into collaborations with the company to access its proteomics platform for discovery and development. These include Medarex, NeoGenesis, Pfizer, Merck, Bayer and Biolnvent. In recent news, OGS announced that the European Commission has granted marketing authorization for Zavesca the first oral treatment for patients with mild to moderate type 1 Gaucher disease for whom Enzyme Replacement Therapy (ERT) is unsuitable. 62 of the company's 172 employees hold PhDs or other advanced degrees. Approximately 141 employees are employed in research and development activities.

BRANDS/DIVISIONS/AFFILIATES: LifeExpress Vevesca Zavesca OGT 918

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David Raymond Ebsworth, CEO Denis Mulhall, CFO Raj Bhikhu Parekh, Chief Scientific Officer Andrew Lyall, CIO Chris Moyses, Chief Medical Officer John Edward Ilett, Corp. Sec. G. Kirk Raab, Chmn.

Phone: +44-1235-208000 Fax: +44-1235-208020 Toll-Free: Address: The Forum, 86 Milton Park, Abingdon Oxon, OX14 4RY UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: OGSI 2001 Sales: $19,500 2001 Profits: $-36,900 Employees: 186 2000 Sales: $13,300 2000 Profits: $-23,300 Fiscal Year Ends: 12/31 1999 Sales: $14,100 1999 Profits: $-15,700 1998 Sales: $8,500 1998 Profits: $-14,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $330,000 Stock Purch. Plan: Second Exec. Salary: $175,000 ADVANTAGE: A leader in the emerging field of proteomics.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $22,000 Bonus: $16,000

Northeast:

International: Y



OXIGENE INC

www.oxigene.com


Y



Profits: 84


TYPES OF BUSINESS:



Drugs-Cancer Anti-Inflammatory Agents DNA Repair Measurement and Stimulation

OXiGENE, Inc. is an international biopharmaceutical company engaged principally in research into and the development of products for use in the treatment of cancer. Historically, the company's activities have been directed primarily towards products designed to complement and enhance the clinical efficacy of radiation and chemotherapy, which are the most common and traditional forms of non-surgical cancer treatment. Its operating strategy is to in-license complementary compounds from academic institutions, lead the compounds through early-stage clinical trials and seek to negotiate contracts with pharmaceutical companies to develop, market and manufacture any resulting commercial drug or clinical products. Recently, OXiGENE has begun to investigate certain of its development-stage products for applications such as direct cancer treatment agents or anti-inflammatory agents or in the treatment of fungal or other infectious diseases, as well as for DNA repair measurement and stimulation. Currently, OXiGENE has, in various stages of clinical development, therapeutic product candidates that derive from three principal technology platforms. Its flagship drug, Combrestatin, eliminates tumors by destroying the blood vessels that enable the tumor to grow. Other products include Cordycepin, a treatment for leukemia, and Declopramide, a treatment that inhibits the DNA repair process for tumors, thus making them more vulnerable to the effects of chemotherapy and radiation. In a step that should contribute to the advancement of vision-related research on its lead vascular targeting compound, Combretastatin A4 Prodrug, the firm recently entered into a research agreement with The Foundation Fighting Blindness, Inc., a nationwide charitable organization whose mission is to discover the causes, treatments and cures for retinal degenerative diseases. The company offers its employees flexible work schedules.

BRANDS/DIVISIONS/AFFILIATES: Declopramide Cordycepin Combrestatin Combrestatin A4 Prodrug

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frederick Driscoll, CEO Frederick Driscoll, Pres. Bo Haglund, CFO Kristen Wilson, VP-Human Resources Dai Chaplin, VP- Research Scott L. Young, VP-Clinical and Regulatory Affairs

Phone: 617-673-7800 Fax: 617-924-9229 Toll-Free: Address: 321 Arsenal St., Watertown, MA 02472 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 223 ( 9 months) 2002 Profits: $-8,575 ( 9 months) Stock Ticker: OXGN 2001 Sales: $9,000 2001 Profits: $-4,100 Employees: 14 2000 Sales: $3,600 2000 Profits: $-9,100 Fiscal Year Ends: 12/31 1999 Sales: $2,600 1999 Profits: $-10,400 1998 Sales: $2,000 1998 Profits: $-11,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $318,602 Stock Purch. Plan: Second Exec. Salary: $271,885 ADVANTAGE: Now exploring multiple applications of its therapy technology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:




Northeast: Y

International:



OXIS INTERNATIONAL INC

www.oxis.com


Y



Y

TYPES OF BUSINESS:

Profits: 81




Drugs-Stress-Related Disease Small-Molecule Drugs Diagnostics Specialty Chemicals

OXIS International, Inc. is a biopharmaceutical company engaged in the development of diagnostic and therapeutic products and new technologies applicable to conditions and/or diseases associated with oxidative stress, or an excess of free radicals. The firm is structured into two subsidiaries, OXIS Health Products, Inc. (OHP) and OXIS Therapeutics, Inc. (OTI). OHP, with over 140 research products for sale, carries out the firm's commercial health products business through the marketing of research and commercial diagnostic assays and fine chemicals to research and clinical laboratories and other customers. The subsidiary does business as OxisResearch. Its diagnostic products include 26 assays to measure markers of oxidative stress. The company has also manufactured 14 commercial therapeutic drug-monitoring assays based on fluorescence polarization immunoassay technology. In addition, OHP markets proteins, antibodies, controls and specialty chemicals. OTI carries out OXIS's pharmaceutical and nutraceutical discovery business and is focused on new drugs to treat diseases associated with tissue damage from free radicals and reactive oxygen species (ROS). OXIS's lead drug candidate is BXT-51072, which has completed a Phase II clinical trial for inflammatory bowel disease. Other products in its portfolio include three classes of small molecular weight antioxidant molecules and an SOD product for veterinary research and human clinical application in Spain.

BRANDS/DIVISIONS/AFFILIATES: OXIS Health Products, Inc. OxisResearch OXIS Therapeutics, Inc. Palosein BXT-51072 OxyScan System

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ray R. Rogers, CEO Sharon Ellis, COO Ray R. Rogers, Pres. Sharon Ellis, CFO Ray R. Rogers, Chmn.

Phone: 503-283-3911 Fax: 503-283-4058 Toll-Free: 800-547-3686 Address: 6040 N. Cutter Circle, Ste. 317, Portland, OR 97217 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,575 ( 9 months) 2002 Profits: $- 657 ( 9 months) Stock Ticker: OXIS 2001 Sales: $3,000 2001 Profits: $-3,500 Employees: 15 2000 Sales: $3,500 2000 Profits: $-4,600 Fiscal Year Ends: 12/31 1999 Sales: $7,200 1999 Profits: $-4,400 1998 Sales: $5,100 1998 Profits: $-7,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $255,000 Stock Purch. Plan: Second Exec. Salary: $215,000 ADVANTAGE: Offers a wide variety of research and diagnostic products.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



PACIFIC BIOMETRICS INC

www.pacbio.com




Y Y Y

TYPES OF BUSINESS:

Profits: 7



Y Y


Clinical Trials Laboratory Services Data Management Diagnostic Technology DNA Amplification Systems

Pacific Biometrics, Inc. provides specialty reference laboratory services to the pharmaceutical and diagnostics industries. Previously, the company was engaged in the development and commercialization of non-invasive technologies for use in diagnostics to improve the detection and management of chronic disease. These efforts have been terminated due to the firm's inability to obtain FDA approval for its OsteoPatch product and lack of necessary funding. The firm also developed two patented platform technologies that permit the use of sweat and saliva as diagnostic fluids, SweatPatch and SalivaSac. Pacific's Seattle-based reference laboratory is a technical leader in cardiovascular disease and lipids. Services include development of reference methods and clinical trial protocols and contract research and development. The company also provides expertise in the field of osteoporosis assessments through its work with diagnostic manufacturers of assays for bone markers. In mid-2002, Pacific agreed to purchase certain technology, intellectual property and equipment from Saigene Corporation. These assets were associated with DNA amplification, cell viability and related processes. Through this transaction, Pacific acquired the LIDA (Logarithmic Isothermal DNA Amplification) technology platform, which rapidly replicates DNA without the need for expensive lab equipment and procedural steps as required with many other amplification systems. A high percentage of genebased commercial and research assays require this kind of system. Pacific also acquired Saigene's cell viability platform, which may be the first molecular method of its kind to rapidly distinguish live cells from dead cells.

BRANDS/DIVISIONS/AFFILIATES: Saigene Corporation Pacific Biometrics Research Foundation OsteoPatch LIDA SweatPatch SalivaSac

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ronald R. Helm, CEO Ronald R. Helm, CFO Elizabeth T. Leary, Chief Scientific Officer Tonya Aggoune, Mgr.-Info. Systems Mario Ehlers, Chief Medical Officer Janice O'Connor, Dir.-Bus. Dev. Ronald R. Helm, Treas. Tim Carlson, Dir.-Laboratory Services Dave Sweezy, Mgr.-Quality Assurance

Phone: 206-298-0068 Fax: 206-298-9838 Toll-Free: 800-767-9151 Address: 220 W Harrison St., Seattle, WA 98119 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $4,400 (12 months) 2002 Profits: $ 900 (12 months) Stock Ticker: PBMI 2001 Sales: $1,900 2001 Profits: $ 200 Employees: 18 2000 Sales: $1,400 2000 Profits: $- 900 Fiscal Year Ends: 6/30 1999 Sales: $1,500 1999 Profits: $-6,100 1998 Sales: $2,500 1998 Profits: $-4,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $72,000 Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Diversified growth potential through its diagnostics technologies.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International:



PALATIN TECHNOLOGIES INC

www.palatin.com


Y



Y

TYPES OF BUSINESS:

Profits: 122




Drugs-Male Erectile Dysfunction Peptide Technology Diagnostic Imaging Products

Palatin Technologies, Inc. is a development-stage biopharmaceutical company committed to the discovery, development and commercialization of novel therapeutics. The firm concentrates its efforts on three products. PT141 is a nasally administered peptide for the treatment of sexual dysfunction. The nasal mode of administration is non-invasive and fast-acting. Palatin has completed Phase I and II studies of the product in male patients and a Phase I study in female patients. LeuTech is a radiolabeled monoclonal antibody that binds to white blood cells that collect at sites of infection, thus enabling the infection to be easily and rapidly imaged and detected with a gamma camera. The company is testing the product for detection of infections including osteomyelitis, fever of unknown origin, post-surgical abscess and inflammatory bowel disease, in Phase II studies. Palatin's MIDAS (metal ion-induced distinctive array of structures) platform for drug design and discovery provides a rapid and efficient process to transform peptides into either peptidomimetic therapeutic leads or small-molecule therapeutic leads. The company is engaged in research and development using this technology to diagnose infections and treat sexual dysfunction, obesity and inflammation. The technology may have applications in other areas such as immune disorders, cancer and cardiology. MIDAS compounds PT-15 and PL-2299 are currently in preclinical development. Recently, preclinical studies of PT-141 showed significant, selective increase in sexual behavior in female rodents. The company offers its employees benefits including medical, prescription drug, life, maternity and dental insurance; an incentive stock option plan; and flexible work schedules.

BRANDS/DIVISIONS/AFFILIATES: LeuTech PT-141 MIDAS PT-15 PL-2299

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Carl Spana, CEO Carl Spana, Pres. Stephen T. Wills, Exec. VP/CFO Perry Molinoff, Exec. VP-Research and Dev. Stephen T. Wills, Treas. Shubh Sharma, VP/Chief Tech. Officer

Phone: 609-495-2200 Fax: 609-495-2201 Toll-Free: Address: 4-C Cedar Brook Dr., Cranbury, NJ 08512 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 300 ( 9 months) 2002 Profits: $-16,100 ( 9 months) Stock Ticker: PTN 2001 Sales: $1,788 2001 Profits: $-10,599 Employees: 33 2000 Sales: $5,100 2000 Profits: $-8,200 Fiscal Year Ends: 6/30 1999 Sales: $ 600 1999 Profits: $-12,000 1998 Sales: $ 100 1998 Profits: $-9,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $291,042 Stock Purch. Plan: Second Exec. Salary: $226,833 ADVANTAGE: Unique peptide technologies and diagnostics.

OTHER T HOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



PALIGENT INC Industry Group Code: 325412 Ranks within this company's industry group: Sales: 222 Drugs: Drugs: Contract Manufacturing: Drug Delivery Sy stems: Nutriceuticals:

Y



Profits: 69


TYPES OF BUSINESS:



Drugs-HIV and Infectious Disease

Paligent, Inc. (formerly Procept, Inc.), a biotechnology company, is focused on the development and commercialization of innovative drugs for the treatment of infectious diseases and cancer. In 2000, the firm outlicensed its two biotechnology compounds, PRO 2000 Gel and O6-BG. These products have been under development for several years. PRO 2000 Gel is under development as a microbicide to prevent HIV and other sexually transmitted pathogens, including chlamydia, gonorrhea and herpes. The product comes in the form of a vaginal topical gel. Interneuron Pharmaceuticals holds the exclusive rights to market PRO 2000 Gel. O6-BG is a chemosensitizer designed to overcome resistance to O6alkylating agents, a class of commonly used chemotherapeutics. In preclinical studies , the product increased anti-tumor activity of these agents in the brain, colon and prostate. The drug has potential applications in brain cancer, lymphoma, gastrointestinal cancers and melanoma. In 2001, Paligent disposed of its Internet business, HeavenlyDoor.com, Inc., which provided products and services for the funeral industry. This action, coupled with its out-licensing, significantly reduced the firm's operating costs. The company also sold its biotechnology equipment, closed its Cambridge, Massachusetts facility and eliminated the majority of its staff. Currently Paligent is seeking business opportunities to maximize its value.

BRANDS/DIVISIONS/AFFILIATES: HeavenlyDoor.com, Inc. Procept, Inc. PRO 2000 Gel O6-BG

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Salvatore A. Bucci, CEO Salvatore A. Bucci, Pres. Michael S. Weiss, Corp. Sec. Michael S. Weiss, Chmn.

Phone: 212-453-3111 Fax: 212-983-2379 Toll-Free: Address: 369 Lexington Ave., New York, NY 02139 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 7 ( 9 months) 2002 Profits: $- 792 ( 9 months) Stock Ticker: PGNT 2001 Sales: $ 100 2001 Profits: $-1,700 Employees: 2 2000 Sales: $ 254 2000 Profits: $-47,985 Fiscal Year Ends: 12/31 1999 Sales: $ 280 1999 Profits: $-14,795 1998 Sales: $ 330 1998 Profits: $-3,291


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $200,000 Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Refocusing as a provider of funeral arrangements.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:




Northeast: Y

International:



PANVERA LLC

www.aurorabio.com



Y


Y Y

TYPES OF BUSINESS:




Research-Drug Discovery Genomics High-Throughput Chemical Research

Aurora Biosciences, a subsidiary of Vertex Pharmaceuticals, designs, develops and commercializes advanced drug discovery technologies, services and instrumentation to accelerate the discovery of new medicines. The company’s technology platform provides an advanced way to identify commercially useful targets, enable rapid assay development and rapidly test compounds for use as potential new medicines that act upon those targets. Aurora is launching a proprietary large-scale biology program to identify proteins involved in disease (targets), rapidly incorporate these targets into tests, or assays, that measure activity in targets and then rapidly screen hundreds of thousands of compounds against these assays to identify potential drugs. The firm’s ultra-high throughput screening system, known as the UHTSS, is designed to screen over 100,000 compounds per day against targets. Aurora was awarded a Phase II Small Business Innovation Research grant from the National Institutes of Health in 2000. The $1 million grant was awarded for the company’s determination to develop models that will test whether or not certain drugs have unfavorable interactions in metabolic pathways. Aurora works with Bristol-Myers Squibb, Eli Lilly, Merck and Pfizer on a number of its projects, including the development of its UHTSS system.

BRANDS/DIVISIONS/AFFILIATES: Vertex Pharmaceuticals UHTSS

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas G. Klopack, COO Michael G. Wokasch, Pres. John R. Pashkowsky, VP-Finance Scott Beckey , VP-Strategic Sales Software and Systems Pamela Fritz, Sr. Dir.-Human Resources Peter J. Coassin, VP-Instrumentation/Research and Dev. John D. Mendlein, General Counsel Michael J. Dunn, VP-Bus. Dev. John R. Pashkowsky, Treas. Harry Stylli, Sr. VP-Commercial Dev. Paul J. England, Sr. VP-Research John D. Mendlein, Chief Knowledge Officer

Phone: 858-404-6600 Fax: 858-404-6714 Toll-Free: Address: 11010 Torreyana Rd., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 103 2000 Sales: $63,800 2000 Profits: $4,400 Fiscal Year Ends: 12/31 1999 Sales: $50,500 1999 Profits: $ 200 1998 Sales: $26,600 1998 Profits: $-18,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Advanced technology in drug discovery research.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International:



PARADIGM GENETICS INC

www.paragen.com



Y


Profits: 19


TYPES OF BUSINESS:



Research-Gene Function Agricultural Gene Research Drug Discovery and Development

Paradigm Genetics is a gene research company with an agricultural focus. The company is currently studying arabidopsis thalania (a product from the mustard family), rice and six filamentous fungi. The firm analyzes gene functions using functional genomics and bioinformatics. Paradigm's Genefunction Factory acts as a laboratory where scientists discover and modify genes, measure the consequences of the manipulated gene modification and determine gene function. The company's FunctionFinder allows integration of gene discovery, gene function determination and gene use identification. Paradigm has entered into a strategic alliance with Bayer for the development of novel herbicides. The company has also allied with Pharmacia for the development of increased crop output and nutritional and human health products. Paradigm is organized around five scientific departments and an informatics division. These departments include plant research, microbial research, DNA technologies, metabolic profiling and biochemistry. Informatics deals with the construction, storage and management of the data flow from scientific research. The firm recently underwent internal restructuring in order to better focus resources on growing its human health care and agricultural businesses. The restructuring included the establishment of distinct business units for health care and agriculture, the realignment of research groups and a reduction of its workforce by approximately 20%. Primarily administrative and research positions were affected by this move. In other news, Paradigm was awarded a five-year toxicogenomics contract by the National Institute of Environmental Health Sciences, to determine how toxicants work and cause damage at the cellular level. The research may result in better methods of risk assessment and compound optimization for both the pharmaceutical and agricultural chemical industries. Finally, due to a series of planned divestitures and expected new contracts, Paradigm is expecting to report its first profitable quarter earlier than had been expected, towards the end of 2003.

BRANDS/DIVISIONS/AFFILIATES: Genefunction Factory FunctionFinder

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Heinrich Gugger, CEO John A. Ryals, Pres. Phil Alfano, CFO Ken Hunt, VP-Mktg. James D. Bucci, VP-Human Resources John Hamer, Chief Scientific Officer Barry Buzogany , Corp. Sec. Barry Buzogany , General Sec. Ian A.W. Howes, VP-Oper. Ken Hunt, VP-Bus. Strategy Jin Sun Kim, VP-Health Care Keith Davis, VP-Agricultural Research Tom Colattsky, VP-Health Care Research

Phone: 919-425-3000 Fax: 919-544-8094 Toll-Free: Address: 108 Alexander Dr., Research Triangle Park, NC 277094528 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $16,351 ( 9 months) 2002 Profits: $-14,157 ( 9 months) Stock Ticker: PDGM 2001 Sales: $24,500 2001 Profits: $-16,000 Employees: 253 2000 Sales: $10,337 2000 Profits: $-17,724 Fiscal Year Ends: 12/31 1999 Sales: $2,197 1999 Profits: $-10,620 1998 Sales: $ 871 1998 Profits: $-4,290


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Heavy emphasis on gene research.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast: Y



Bonus: $44,055 Bonus: $38,295

Northeast:

International:



PAREXEL INTERNATIONAL

www.parexel.com




Y Y

TYPES OF BUSINESS:

Profits: 11



Y Y


Research & Development-Clinical Trial and Data Management, Biostatistical Analysis, and Report Production Clinical Research Medical Marketing Medical Consultation Data Management Publishing Software

Based near Boston, Massachusetts, PAREXEL International Corp. is a leading biopharmaceutical services company, providing a range of knowledge-based contract research, medical marketing, consulting and technology products and services to the worldwide pharmaceutical, biotechnology and medical device industries. One of the largest biopharmaceutical companies in the world, PAREXEL manages 56 locations in 37 countries. The firm's primary objective is to provide solutions for managing the biopharmaceutical product life cycle with the goal of reducing time, risk and cost associated with development and commercialization of new therapies. Products and services include clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, performance improvement, industry training and publishing, web-based portal solutions, interactive voice response systems, electronic data capture solutions, medical diagnostic services and other drug development consulting services. Outsourcing research and development and marketing functions to PAREXEL helps client companies maximize the return on their own research investments. Perceptive Informatics, a majorityowned subsidiary, provides a variety of technology products and services designed to improve clients' product development and commercialization processes. In recent news, PAREXEL announced a collaborative agreement with Dataform, Inc. to co-market electronic regulatory submissions services. In addition, Perceptive Informatics recently acquired Invantage, Inc., a software company providing pharmaceutical and biotechnology products and services.

BRANDS/DIVISIONS/AFFILIATES: PAREXEL Consulting Group Perceptive Informatics, Inc. Barnett International KMI Invantage, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Josef H. von Rickenbach, CEO Carl A. Spalding, COO Carl A. Spalding, Pres. James F. Winschel, CFO/Sr. VP Susan M. Warren, VP-Corp. Mktg. Mark T. Beaudouin, Corp. Sec. Mark T. Beaudouin, General Counsel Ulf Schneider, Sr. VP/Chief Admin. Officer Susan M. Warren, VP-Strategy Jill Baker, Sr. Dir.-Investor Rel. Andrew J. Morffew , Pres., PAREXEL Consulting Group Andrew L. Smith, Pres.-Medical Mktg. Mark A. Goldberg, Pres., Perceptive Informatics Paule A. Dapres, Exec. VP-Clinical Research Services

Phone: 781-487-9900 Fax: 781-487-0525 Toll-Free: Address: 195 West St., Waltham, MA 02154-1163 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $564,900 (12 months) 2002 Profits: $13,200 (12 months) Stock Ticker: PRXL 2001 Sales: $387,560 2001 Profits: $- 825 Employees: 4,640 2000 Sales: $378,200 2000 Profits: $5,500 Fiscal Year Ends: 6/30 1999 Sales: $348,500 1999 Profits: $15,600 1998 Sales: $285,442 1998 Profits: $9,319


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $370,696 Stock Purch. Plan: Y Second Exec. Salary: $254,607 ADVANTAGE: Multifaceted company/Heavy emphasis on clinical research.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $193,125 Bonus: $137,500

Northeast: Y

International: Y



PDK LABS INC

www.pdklabs.com


Y Y




TYPES OF BUSINESS:



Drugs-Generic Over-the-Counter Pharmaceuticals Alertness Aids Dietary Supplements

PDK Labs, Inc. manufactures and distributes over-thecounter (OTC) non-prescription pharmaceutical products and vitamins. The company’s primary line of products includes non-prescription pain relievers, decongestants, bronchodialators and a broad range of vitamins and nutritional supplements. Marketing strategies are implemented through regional distributors, private label distribution and various licensing and supply agreements. Futurebiotics, a subsidiary of PDK Labs, sells multivitamins, specialty supplements, superfood powders and herbal and mineral tonics internationally in South America, Central Europe, Hong Kong, Malaysia, Japan and Scandinavia. The firm’s private label sales contribute to over two-thirds of revenue. Recently, the firm announced it signed an agreement and will merge with PDK Acquisition Corporation. Currently, PDK Labs is involved in an exclusive supply agreement with a company for dietary supplements and a broad range of over-thecounter, non-prescription pharmaceutical products. In addition, the firm has a second exclusive supply and licensing agreement with the same third party where PDK Labs granted an exclusive license to utilize and distribute the brand names Max Brand and Heads Up over-thecounter drugs. PDK Labs entered a supply agreement with Superior Supplements, Inc., in which it has an obligation to purchase $2.5 million in products.

BRANDS/DIVISIONS/AFFILIATES: Futurebiotics, Inc. Max Brand Heads Up Superior Supplements PDK Acquisition Corporation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Reginald Spinello, CEO Reginald Spinello, Pres. Karine Hollander, CFO Pam Klarman, VP-Human Resources

Phone: 631-273-2630 Fax: 631-273-1583 Toll-Free: Address: 145 Ricefield Ln., Hauppauge, NY 11788 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Private 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $ 2000 Profits: $ Fiscal Year Ends: 11/30 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Growing customer network/Merger with PDK Acquisition Corp.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



PENWEST PHARMACEUTICALS CO

www.penw.com


Y



Profits: 143


TYPES OF BUSINESS:



Drugs-Active Ingredient Release Novel Drug Technology Excipients

Penwest Pharmaceuticals Co. is engaged in the research, development and commercialization of novel drug delivery technologies. The firm is also a leader in the design, manufacture and distribution of branded pharmaceutical excipients, the inactive ingredients in tablets and capsules. Penwest’s proprietary TIMERx controlled release drug delivery technology is applicable to a broad range of orally administered drugs, including soluble and insoluble drugs and those with a narrow therapeutic index. Successful drug formulations utilizing the TIMERx system include Nifedipine XL, for hypertension and angina, and Cystrin CR, a controlled release version of oxybutynin for urge incontinence. Part of Penwest’s business strategy is to apply this technology to generic versions of branded controlled release pharmaceuticals. The firm’s ProSolv, a high-functional excipient based on co-processing technology, improves the performance characteristics of tablets. Emcocel, a tabletting binder, is the company’s largest selling product. Other excipients include Emcompress, Emdex, Candex, Explotab and Pruv. In recent news, the FDA approved the first prescription drug using ProSolv, a hypothyroidism treatment developed by MOVA. The company also recently joined Finzelberg to develop a line of herbal formulas using Penwest’s ProSolv technology.

BRANDS/DIVISIONS/AFFILIATES: TIMERx Cystrin CR Nifedipine XL Emcocel Emdex ProSolv Candex Pruv

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Tod R. Hamachek, CEO Jennifer L. Good, VP-Finance/CFO Anand R. Baichwal, Sr. VP-Research and Dev. Paul K. Wotton, VP-Bus. Dev. Stephen J. Berte, Sr. VP/General Mgr.-Excipients Bus.

Phone: 845-878-3414 Fax: 845-878-3484 Toll-Free: 800-431-2457 Address: 2981 Rte. 22, Patterson, NY 12563-9970 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $27,549 ( 9 months) 2002 Profits: $-14,112 ( 9 months) Stock Ticker: PPCO 2001 Sales: $40,000 2001 Profits: $-16,000 Employees: 148 2000 Sales: $42,100 2000 Profits: $-8,800 Fiscal Year Ends: 12/31 1999 Sales: $37,300 1999 Profits: $-7,700 1998 Sales: $29,000 1998 Profits: $-8,800


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $355,000 Bonus: $90,000 Stock Purch. Plan: Second Exec. Salary: $180,000 Bonus: $45,000 ADVANTAGE: Established manufacturer and distributor of excipients to the pharmaceutical and nutritional industries.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Northeast: Y

International: Y



PEREGRINE PHARMACEUTICALS INC www.peregrineinc.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 191 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Profits: 114


TYPES OF BUSINESS:



Drugs-Cancer Monoclonal Antibodies Contract Manufacturing Services

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company primarily engaged in the research, development, manufacture and commercialization of cancer therapeutics and cancer diagnostics through a series of proprietary platform technologies using monoclonal antibodies. Peregrine's main focus is the development of its collateral targeting antibody-based technologies (Collateral Targeting Agents). These agents bind to or target stable structures found in most solid tumors, thereby circumventing the problems encountered by technologies that target the surface of the cancer cell itself. Advantages include circumvention of drug resistance and applicability to a variety of cancer types. Various Collateral Targeting Agents are in all stages of clinical development, including trials for recurrent brain cancer, colorectal cancer, soft-tissue sarcoma and liver cancer. Peregrine's most advanced agent of this type is TNT (Tumor Necrosis Therapy). The first product based on this therapy is Cotara. The company also has a direct tumortargeting antibody, Oncolym, for the treatment of nonHodgkin's B-cell lymphoma. This product, based on Lym 1 Technology, is currently in Phase I/II trials. In early 2002, the firm formed a subsidiary, Avid Bioservices, Inc., to provide an array of contract manufacturing services, including cell culture development, process development and testing of biologics for biopharmaceutical and biotechnology companies. In recent news, the company received European orphan drug status for Cotara for the treatment of glioma. The product had already been granted fast track designation by the U.S. FDA. In addition, Peregrine announced data showing that its Lym 1 antibodies have significant anti-tumor effect on several B-cell lymphoma cancer models.

BRANDS/DIVISIONS/AFFILIATES: Techniclone Corp. Oncolym Avid Bioservices, Inc. Collateral Targeting Agents Cotara Lym-1 Technology TNT

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Edward J. Legere, CEO Steven W. King, COO Edward J. Legere, Pres. Paul J. Lytle, CFO Richard Richieri, VP-Mfg. Paul J. Lytle, Corp. Sec. Terrence G. Chew , Sr. VP-Regulatory and Clinical Affairs K.A. Ajit Simh, VP-Quality Assurance

Phone: 714-508-6000 Fax: 714-838-5817 Toll-Free: Address: 14272 Franklin Ave., Ste. 100, Tustin, CA 92780 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: PPHM 2001 Sales: $ 979 2001 Profits: $-9,535 Employees: 27 2000 Sales: $ 100 2000 Profits: $-14,500 Fiscal Year Ends: 4/30 1999 Sales: $ 100 1999 Profits: $-19,500 1998 Sales: $ 500 1998 Profits: $-11,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $224,808 Stock Purch. Plan: Second Exec. Salary: $206,827 ADVANTAGE: Expertise in collateral targeting for the destruction of tumors.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $117,000 Bonus: $152,500

Northeast:

International:



PFIZER INC

www.pfizer.com


Y



Profits: 1


TYPES OF BUSINESS:



Drugs-Diversified Cardiovascular and Central Nervous System Agents Orthopedic Implants Animal Vaccines Antiseptic and Germicidal Products Anti-fungal Agents for AIDS Patients Over-the-Counter Drugs

Pfizer, Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures and markets innovative medicines for humans and animals. The firm operates in two business segments: pharmaceuticals and consumer products. Pfizer's pharmaceutical division includes prescription pharmaceuticals for treating cardiovascular diseases, infectious diseases, central nervous system disorders, diabetes, erectile dysfunction, allergies, arthritis and other disorders. Major drugs offered by the company include Zoloft and Neurontin for the treatment of central nervous system disorders; Diflucan for the treatment of various fungal infections; Viracept for treatment of HIV infections; and Zithromax, an oral or injectable antibiotic. The pharmaceutical segment also develops products for livestock as well as companion animals, including parasiticides, antibiotics, vaccines and other veterinary items. Pfizer has a number of innovative animal products that are expected to reach the market starting in 2003. The firm’s Revolution topical liquid is the first medicine that can protect against external parasites, gastrointestinal worms and heartworms. In addition, the company’s Capsugel subsidiary is one of the world’s largest producers of two-piece capsules used in manufacturing prescription and over-the-counter pharmaceuticals and nutritional supplements. Pfizer’s consumer products segment markets many of the world’s best-known consumer health brands, including Benadryl, Rolaids, Zantac 75, Visine, Cortizone and BenGay. Recently, the firm received FDA approval for its allergy medicine, Zyrtec-D, an antihistamine with decongestant for the treatment of a broad range of allergies and nasal congestion. In mid 2002, Pfizer announced its intention to acquired rival Pharmacia for $60 billion, creating a giant pharmaceuticals firm with $48 billion in annual revenues and $7 billion in annual research and development. Pfizer offers its workforce medical and dental plans, as well as adoption assistance and product discounts.

BRANDS/DIVISIONS/AFFILIATES: Viagara Zyrtec-D Zoloft Neurontin Viracept Celebrex Pharmacia Lipitor

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Henry A. McKinnell, CEO Henry A. McKinnell, Pres. David L. Shedlarz, Exec. VP/CFO J. Patrick Kelly, Sr. VP-Worldwide Mktg. Robert W. Norton, Sr. VP-Corp. Human Resources George M. Milne, Jr., Exec. VP-Global R & D Loretta V. Cangilosi, VP/Controller C.L. Clemente, Corp. Sec. Paul S. Miller, Exec. VP/General Counsel Frederick W. Telling, VP-Corp. Strategic Planning C.L. Clemente, Exec. VP-Corp. Affairs Richard A. Passoc, VP/Treas. M. Kenneth Bowler, VP-Federal Gov't Regulations Gary N. Jortner, Sr. VP-Product Dev. Alan G. Levin, VP-Finance

Phone: 212-573-2323 Fax: 212-573-7851 Toll-Free: Address: 235 E. 42nd St., New York, NY 10017-5755 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $25,177,000 ( 9 months) 2002 Profits: $6,270,000 ( 9 months) Stock Ticker: PFE 2001 Sales: $32,259,000 2001 Profits: $7,788,000 Employees: 90,000 2000 Sales: $29,574,000 2000 Profits: $3,726,000 Fiscal Year Ends: 12/31 1999 Sales: $27,376,000 1999 Profits: $4,952,000 1998 Sales: $23,231,000 1998 Profits: $4,633,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,516,667 Stock Purch. Plan: Second Exec. Salary: $944,600 ADVANTAGE: Products are available in more than 150 countries/Acquisition of Pharmacia.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $2,780,800 Bonus: $1,062,700

Northeast: Y

International: Y



PHARMACEUTICAL FORMULATIONS INC Industry Group Code: 325412 Ranks within this company's industry group: Sales: 63 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



www.pfiotc.com

Profits: 136


TYPES OF BUSINESS:



Drugs-Generic Contract Manufacturing Antifungal Aerosols Generic Over-the-Counter Products

Pharmaceutical Formulations, Inc. (PFI) is one of the largest publicly traded private label manufacturers and distributors of non-prescription or over-the-counter pharmaceuticals in the United States. Its manufactured products are primarily sold under its customer’s store brands or other private labels or in bulk to companies who repackage the products to sell to small independent retailers or other manufacturers that are not approved by the government to manufacture products. Products distributed by the company include internal analgesics, cough and cold, allergy and sinus and gastrointestinal medicines, laxatives, sleep aides, stimulants and effervescent denture cleaners that are in the form of tablets, caplets or capsules. The firm also sells and markets a line of anti-fungal aerosols and generic overthe-counter products under its own brand names. Health+Cross, Health Pharm, Allefed and Leg Ease, the firm's branded items, account for a small percentage of total revenues. PFI’s customers include Walgreen Co., Price-Costco Wholesale, K-Mart and Revco D.S., Inc. The firm focuses on product quality enhancement, product improvement and new product development.

BRANDS/DIVISIONS/AFFILIATES: Allerfed Leg Ease Health+Cross Health Pharm

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John L. Oram, CEO James Ingram, COO James Ingram, Pres. Walter Kreil, CFO Anthony Cantaffa, VP-Sales & Mktg. Alexander M. Schobel, VP-Research & Dev. Susan Baer, General Counsel Ward Barney , VP-Oper. Brian Barbee, VP-Regulatory Affairs Lenny Luongo, Dir.-Sales Admin. Helen Kushner, Mgr.-Customer Rel.

Phone: 732-985-7100 Fax: 732-819-3330 Toll-Free: Address: 460 Plainfield Ave., Edison, NJ 08818 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $53,600 (12 months) 2002 Profits: $-6,900 (12 months) Stock Ticker: PHFR 2001 Sales: $49,200 2001 Profits: $-14,600 Employees: 344 2000 Sales: $76,600 2000 Profits: $-7,900 Fiscal Year Ends: 6/30 1999 Sales: $82,200 1999 Profits: $-6,600 1998 Sales: $80,800 1998 Profits: $1,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $180,000 Bonus: $7,500 Stock Purch. Plan: Second Exec. Salary: $170,000 Bonus: $ ADVANTAGE: PFI is one of the largest solid dosage generic pharmaceutical manufacturer in the country.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



PHARMACEUTICAL PRODUCT DEVELOPMENT INC www.ppdi.com Industry Group Code: 541710 Ranks within this company's industry group: Sales: 4 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:



Y Y

TYPES OF BUSINESS:

Profits: 1


Y


Y


Contract Research Services Life Science Research and Development Life Science Clinical Consulting Services Novel Therapeutic Drug Development Drug Development Tools Software

Pharmaceutical Product Development, Inc. (PPD) is a global provider of drug discovery and development services to pharmaceutical and biotechnology companies. The company’s subsidiary PPD Discovery is engaged in discovery sciences in pharmaceutical research and development. PPD Development, another subsidiary, is engaged in life science contract research organization services, providing integrated product development resources. That subsidiary also manages PPD Informatics, which provides clinical data consulting services and software solutions for pharmaceutical and biotechnology companies, government and drug development service providers. Along with Informatics, PPD Development also operates PPD Medical Communications, which provides medical information and marketing support services to health care providers and consumers on behalf of pharmaceutical and biotechnology companies. PPD also manages PPD Virtual which provides virtual drug development consulting and management via an innovative risk-sharing model to pharmaceutical companies, biotechnology firms and academic research institutions. The company recently acquired Piedmont Research Center, a cancer research company that performs preclinical evaluations of anticancer therapies. PPD has also agreed to acquire Medical Research Laboratories International, Inc., which operates a central laboratory in Kentucky, and Medical Research Laboratories International BVBA, a Belgian company that operates a central lab in Brussels.

BRANDS/DIVISIONS/AFFILIATES: PPD Development PPD Discovery PPD Informatics PPD Medical Communications PPD Virtual Piedmont Research Center Medical Research Laboratories International, Inc. Medical Research Laboratories International BVBA

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Fredric N. Eshelman, CEO Fred B. Davenport, Jr., Pres. Linda Baddour, CFO Fred B. Davenport, Jr., Sec. Paul S. Covington, Exec. VP-Dev. Paul S. Covington, Treas. Francis J. Casieri, Sr. VP-Global Bus. Dev.

Phone: 910-251-0081 Fax: 910-762-5820 Toll-Free: Address: 3151 S. 17th St., Wilmington, NC 28412 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to ge t the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $439,433 ( 9 months) 2002 Profits: $19,925 ( 9 months) Stock Ticker: PPDI 2001 Sales: $431,500 2001 Profits: $49,200 Employees: 4,375 2000 Sales: $345,300 2000 Profits: $32,300 Fiscal Year Ends: 12/31 1999 Sales: $302,500 1999 Profits: $28,500 1998 Sales: $246,500 1998 Profits: $21,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Wide range of services/Rapid growth.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest: Y

Southeast:



Bonus: $493,125 Bonus: $165,000

Northeast: Y

International: Y



PHARMACEUTICAL RESOURCES INC Industry Group Code: 325412 Ranks within this company's industry group: Sales: 37 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



www.parpharm.com Profits: 31


TYPES OF BUSINESS:



Drugs-Generic

Pharmaceutical Resources, Inc. (PRI) is a holding company that develops, manufactures and distributes a broad line of generic drugs in the United States. The firm operates primarily through subsidiary Par Pharmaceutical, Inc. PRI's product line consists of approximately 120 prescription and over-the-counter drug products, including varying dosage strengths. In addition to its own manufactured products, the company has strategic alliances with several pharmaceutical and chemical companies that provide it with products for sale through distribution, development or licensing agreements. These products are marketed primarily to wholesalers, retail drug store chains, drug distributors and repackagers principally through its own sales staff. Drug products include treatments for central nervous system disorders, cardiovascular drugs, analgesics and anti-inflammatory products, anti-bacterials, anti-diabetics, antihistamines, anti-virals, cholesterol-lowering drugs and ovulation stimulants. Among these are generic versions of Advil, Daypro, Glucophage, Zantac and Clomid. In 2001, the company introduced three new products, including generic versions of Megace and Prozac. In mid-2002, PRI also acquired the rights to five products from Bristol-Meyers Squibb, including Capoten, Capozide, Questran and Questran Light and Sumycin. In late 2001, Par entered into an agreement with Elan Corp. to develop a range of modified-release drugs over a five-year period. In recent news, Par announced that it filed an abbreviated new drug application with the FDA for a generic version of Ultracet acetaminophen tablets. The company was also granted tentative approval for generic Prilosec.

BRANDS/DIVISIONS/AFFILIATES: Par Pharmaceutical, Inc. Acyclovir Akineton BusPIRone HCI Captopril Famotidine Fluoxetine IBU

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kenneth I. Sawyer, CEO Kenneth I. Sawyer, Pres. Dennis J. O'Connor, VP/CFO Dennis J. O'Connor, Corp. Sec. Scott L. Tarriff, CEO/Pres., Par Pharmaceutical, Inc. Kenneth I. Sawyer, Chmn.

Phone: 845-425-7100 Fax: 845-425-7907 Toll-Free: Address: One Ram Ridge Rd., Spring Valley, NY 10977-6714 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $282,500 ( 9 months) 2002 Profits: $60,800 ( 9 months) Stock Ticker: PRX 2001 Sales: $271,000 2001 Profits: $53,900 Employees: 393 2000 Sales: $85,022 2000 Profits: $- 929 Fiscal Year Ends: 9/30 1999 Sales: $80,315 1999 Profits: $-1,774 1998 Sales: $59,705 1998 Profits: $-9,628


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Continual approval of new drugs.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $55,000 Bonus: $50,000

Northeast: Y

International: Y



PHARMACOPEIA INC

www.pcop.com




Y

TYPES OF BUSINESS:

Profits: 17


Y



Research & Development-Drug Discovery Support Molecular Combinational Chemistry Pharmaceutical Software

Pharmacopeia, Inc. is engaged in the design, development, marketing and support of science and technology-based products and services that are intended to improve and accelerate the processes of drug discovery and chemical development. The Drug Discovery Services segment provides services to pharmaceutical and biotechnology companies. Pharmacopeia combines chemistry and high-throughput screening for the development of new drug discovery programs. Moreover, the firm uses its Encoded Combinatorial Libraries on Polymeric Support (ECLiPS) technology to generate small-molecule compound libraries that can be utilized in pharmaceutical research. Recently, the company announced the development of Accelrys, a new subsidiary that controls previously independent software segments. Accelrys is comprised of Molecular Simulations, Synopsys Scientific Systems, Oxford Molecular and the Genetics Computer Group. The firm’s major software sector, Molecular Simulations, provides molecular modeling and simulation software, which facilitates new drug and chemical product discovery and development. In other news, Accelrys recently agreed to acquire Synomics, Ltd., a U.K.-based middleware technology and consulting firm. In addition, Pharmacopeia announced its intentions to purchase and consequently merge with Eos Biotechnology, Inc., a company that offers genomics based drug discovery technology.

BRANDS/DIVISIONS/AFFILIATES: ECLiPS Eos Biotechnology, Inc. Synomics, Ltd. Molecular Simulations, Inc. Oxford Molecular Genetics Computer Group Synopsys Scientific Systems Accelrys Software

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph A. Mollica, CEO Joseph A. Mollica, Pres. John J. Hanlon, Exec. VP/CFO Richard J. Walsh, Sr. VP-Mktg. William J. DeLorbe, VP-Human Resources John J. Baldwin, Chief Science & Tech. Officer Michael G. Lenahan, Exec. V P/General Counsel Richard J. Walsh, Sr. VP-Bus. Dev. Nolan H. Sigal, Sr. VP-Drug Discovery Stephen A. Spearman, Exec. VP/COO-Drug Discovery Michael Stapleton, Exec. VP/COO-Software

Phone: 609-452-3600 Fax: 609-452-3672 Toll-Free: Address: CN 5350, Princeton, NJ 08543-5350 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $87,048 ( 9 months) 2002 Profits: $-17,413 ( 9 months) Stock Ticker: PCOP 2001 Sales: $122,300 2001 Profits: $-14,300 Employees: 800 2000 Sales: $119,400 2000 Profits: $1,200 Fiscal Year Ends: 12/31 1999 Sales: $104,000 1999 Profits: $3,800 1998 Sales: $92,200 1998 Profits: $-10,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $505,833 Stock Purch. Plan: Second Exec. Salary: $284,667 ADVANTAGE: Ability to use state-of-the-art computer technology for new compound discovery.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



PHARMACYCLICS INC

www.pcyc.com


Y


Clinical: Trials : Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:

Y

TYPES OF BUSINESS:

Profits: 185




Drugs-Cancer and Cardiovascular Disease Light Emitting Diodes (LEDs) Photodynamic Therapy Texaphyrins

Pharmacyclics is a pharmaceutical company engaged in the development of products to improve current therapeutic approaches for the treatment of cancer, arteriosclerosis and retinal disease. The firm develops texaphyrins, injected molecules that accumulate in tumor growths. The molecules are then exposed to various energy sources, and the metallic molecules energize and destroy the diseased tissue, leaving minimal damage to healthy cells. Radiation sensitizers increase the cytotoxic effects of radiation when administered with the radiation therapy. The firm's texaphyrin products include Xcytrin, Lutrin, Antrin and Optrin molecules. Pharmacyclics is testing its Optrin injection for the photodynamic therapy in patients who suffer from age-related macular degeneration. The firm is in collaboration with Coherent, Inc. and Laserscope, Inc. regarding the development of a 732-nanometer light to be used in photodynamic therapy studies. The company continues to advance its plans to conduct a second Phase 3 clinical trial, in order to confirm the potential clinical benefits observed in lung cancer patients treated with Xcytrin. As a result, Pharmacyclics expects to soon begin enrolling patients in this trial. In the first set of clinical trials, researchers concluded that Xcytrin, when added to whole brain radiation therapy, significantly prolongs the time to neurologic tumor progression. This decreases deaths in patients with brain metastases from lung cancer. By conducting further trials, the firm is hoping to provide further evidence of the potential benefits of Xcytrin for patients with brain tumors, especially those with lung cancer.

BRANDS/DIVISIONS/AFFILIATES: Rare Earth Medical Lutrin Xcyrin Antrin Optrin Quantum Devices, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard A. Miller, CEO Richard A. Miller, Pres. Leiv Lea, CFO Daniel C. Adelman, VP-Clinical Oper. Cynthia J. Ladd, Sr. VP/General Counsel Timothy G. Whitten, Sr. VP-Commercial Oper. Leiv Lea, VP-Admin. Hugo Madden, VP-Chemical Oper. Markus F. Renschler, VP-Oncology Clinical Dev.

Phone: 408-774-0330 Fax: 408-774-0340 Toll-Free: Address: 995 E. Arques Ave., Sunnyvale, CA 94085 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-36,600 ( months) Stock Ticker: PCYC 2001 Sales: $3,121 2001 Profits: $-30,925 Employees: 176 2000 Sales: $1,600 2000 Profits: $-23,600 Fiscal Year Ends: 6/30 1999 Sales: $2,000 1999 Profits: $-19,200 1998 Sales: $3,500 1998 Profits: $-9,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $330,417 Stock Purch. Plan: Y Second Exec. Salary: $287,714 ADVANTAGE: Expertise in texaphyrins/Strong strategic alliances.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



PHARMOS CORPORATION

www.pharmoscorp.com


Y



Profits: 44


TYPES OF BUSINESS:



Drugs-Neurological Drugs-Inflammatory Disorders Cancer Therapies

Pharmos Corp. is a biopharmaceutical company that discovers and develops new drugs to treat a range of inflammatory and neurological disorders such as traumatic brain injury and stroke. The firm has an extensive portfolio of drug candidates under development, as well as discovery, preclinical and clinical capabilities, including expertise in rational drug design, novel drug delivery technology and high-throughput screening. The company previously had two successful ophthalmic products on the market, Alrex and Lotemax, but these were sold to Bausch & Lomb in 2001. Pharmos's lead central nervous system product, Dexanabinol, is currently undergoing Phase III clinical trials for severe traumatic brain injury. Pharmos has identified several promising new compounds based on its program to develop synthetic relatives of the active ingredient in cannabis. Preclinical investigations are underway for compounds to treat stroke, multiple sclerosis, neuropathic pain and Parkinson's disease. The firm's chemical library consists of two chemically distinct cannabinoid platforms, tricyclic dextrocannabinoids and bicyclic cannabinoids. The two platforms have difference mechanisms of action but have considerable overlap in their therapeutic potential in treating neurological, cardiovascular, autoimmune and inflammatory disorders. The company has also developed a library of new proprietary compounds called Selective Estrogen Receptor Modulators (SERMs), which have been synthesized and screened primarily on the basis of their binding activity to estrogen receptors. These compounds may be active against various forms of cancer, including pancreatic cancer and malignant melanoma. In recent news, Pharmos filed an investigation new drug application with the FDA to begin patient enrollment in a pivotal Phase III trial of Dexanabinol. More than 400 patients have been enrolled in the trial to date.

BRANDS/DIVISIONS/AFFILIATES: Alrex Lotemax Pharmos, Ltd. Dexanabinol SERMs

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Haim Aviv, CEO Gad Riesenfeld, COO Gad Riesenfeld, Pres. Robert W. Cook, Exec. VP/CFO George Fink, VP-Research Nadim Y. Kassem, VP-Clinical and Regulatory Affairs Haim Aviv, Chief Scientist Haim Aviv, Chmn.

Phone: 732-452-9556 Fax: 732-452-9557 Toll-Free: Address: 99 Wood Ave. S, Ste. 311, Iselin, NJ 08830 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to ge t the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-13,440 ( months) Stock Ticker: PARS 2001 Sales: $4,300 2001 Profits: $5,000 Employees: 70 2000 Sales: $5,100 2000 Profits: $-8,000 Fiscal Year Ends: 12/31 1999 Sales: $3,300 1999 Profits: $-4,600 1998 Sales: $1,500 1998 Profits: $-4,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $268,000 Bonus: $80,000 Stock Purch. Plan: Second Exec. Salary: $209,790 Bonus: $42,000 ADVANTAGE: Focus on enhancing molecular structure in specific drug candidates/Major partnerships.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International: Y



PHOTOGEN TECHNOLOGIES INC

www.photogen.com


Y




TYPES OF BUSINESS:



Drugs-Cancer Photoactive Agents Diagnostic Imaging Agents

Photogen Technologies, Inc. is an emerging developmentstage biotechnology company focused on developing minimally invasive products for the treatment and diagnosis of disease. These products are based on several related families of core technologies, which include multi-photon excitation, certain photoactive agents or diagnostic agents and other related technologies. The company has discovered new methods and apparatus for using energy from lasers, X-rays or other sources to selectively activate photoactive agents within tissue sufficient to produce a range of beneficial therapeutic and diagnostic outcomes. These discoveries include methods, materials and devices that are used to produce light or other energy and photoactive agents for the purpose of destroying diseased cells, removing tissue or identifying and diagnosing disease. Photogen’s core technologies are proprietary and protected by issued U.S. and foreign patents or are subject to pending patent applications. Photo-diagnosis com bines a photoactive agent with the appropriate activating energy, the outcome of which is a diagnostic signal or image of tissue. Photoactive or diagnostic agents are drugs, or compounds naturally present in tissue, that react to energy to create a desired therapeutic reaction or diagnostic signal. In recent news, the company refinanced and sold its photodynamic therapy and laser business. Photogen is now focused on the development of diagnostic imaging agents for use in cardiovascular applications and lymphography (the metastasis of cancer into lymph nodes).


CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Taffy J. Williams , CEO Timothy Scott, COO Taffy J. Williams , Pres. Brooks Boveroux , CFO Dan Hamilton, VP-Human Resources Timothy Scott, Sr. Scientist Reinhard Koenig, Sr. VP-Medical Kenneth Sylvester, VP-Mfg. Eric A. Wachter, Corp. Sec. Jay Zimmerman, Clinical Oper. David D. Shaw , VP-Clinical Research and Tech. Dev. Brooks Boveroux , Treas. Dan Hamilton, Mgr.-Finance and Admin.

Phone: 215-862-6860 Fax: 215-862-7139 Toll-Free: Address: 140 Union Square Dr., New Hope, PA 18938 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-6,000 ( months) Stock Ticker: PHGND 2001 Sales: $ 2001 Profits: $-9,700 Employees: 13 2000 Sales: $ 200 2000 Profits: $-10,800 Fiscal Year Ends: 12/31 1999 Sales: $ 200 1999 Profits: $-6,100 1998 Sales: $ 400 1998 Profits: $-2,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $265,000 Bonus: $66,250 Stock Purch. Plan: Second Exec. Salary: $215,000 Bonus: $32,250 ADVANTAGE: Photoactive therapies based on the use of various energy sources in unique ways.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



POLYDEX PHARMACEUTICALS

www.polydex.com


Y Y



Profits: 60


TYPES OF BUSINESS:



Drugs-Veterinary Drug Delivery Products Dextran-Based Products Contraceptives

Based in Canada, Polydex Pharmaceuticals, Ltd. is conducted through two subsidiaries, Polydex Chemicals, Ltd., which itself conducts business through Dextran Products, Ltd., and Chemdex, Inc. The firm also owns Veterinary Laboratories, Inc., which is part of a joint venture with Sparhawk Laboratories, Inc. Polydex controls the joint venture, whose purpose is the manufacture and sale of veterinary pharmaceutical products. In addition, the company owns Novadex International, Inc., based in the Bahamas. This subsidiary's primary asset is a patent for the use of cellulose sulphate in a number of applications, including the development of a new contraceptive gel. Currently, Polydex manufactures and sells dextran and several of its derivatives, including iron dextran and dextran sulfate; veterinary pharmaceutical products and other specialty chemicals; and cosmetic raw materials. Dextran is the generic name applied to certain synthetic compounds formed by bacterial growth on sucrose. Iron dextran is used as a treatment for anemia in pigs. Dextran sulphate is a specialty chemical used in research applications. Other veterinary products include sterile injectable products, tablets and boluses; and internal and external solutions, ointments and powders. The firm is also investigating the potential human application of certain of its products. In recent news, the company announced continued progress in the development of its lead product, Ushercell. Ushercell is a high-molecular-weight cellulose sulphate compound in development as a contraceptive and for the prevention of transmission of sexual disease. The product is nearing late-stage Phase III human clinical trials.

BRANDS/DIVISIONS/AFFILIATES: Sparhawk Veterinary Laboratories, Inc. Dextran Products, Ltd. Polydex Chemicals, Ltd. Chemdex, Inc. Veterinary Laboratories, Inc. Ushercell

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. George G. Usher, CEO George G. Usher, Pres. Sharon L. Wardlaw , CFO Sharon L. Wardlaw , Chief Acc. Officer Sharon L. Wardlaw , Corp. Sec. Sharon L. Wardlaw , Treas. Sharon L. Wardlaw , Pres., Dextran Products Bert Hughes, Pres./CEO, Sparhawk John Bascom, Exec. VP-Sparhawk

Phone: 416-755-2231 Fax: 416-755-0334 Toll-Free: Address: 421 Comstock Rd., Toronto, Ontario M1L 2H5 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $12,200 (12 months) 2002 Profits: $- 200 (12 months) Stock Ticker: Foreign 2001 Sales: $13,828 2001 Profits: $ 131 Employees: 86 2000 Sales: $13,100 2000 Profits: $1,000 Fiscal Year Ends: 1/31 1999 Sales: $11,700 1999 Profits: $ 600 1998 Sales: $9,800 1998 Profits: $ 500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $170,000 Stock Purch. Plan: Second Exec. Salary: $110,000 ADVANTAGE: Growing sales and profits base/Expertise in products based on Dextran.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Bonus: $ Bonus: $

Northeast:

International: Y



PRAECIS PHARMACEUTICALS

www.praecis.com


Y



Profits: 207


TYPES OF BUSINESS:



Drugs-Hormonal Disease (Peptide-based)

Praecis Pharmaceuticals is engaged in peptide-based drug development related to hormone disorder treatment. Its lead product candidate, Plenaxis is being developed for the treatment of hormonally responsive advanced prostate cancer and endometriosis. A new drug application was filed for Plenaxis for the treatment of prostate cancer and the drug has recently completed stage II/III for the treatment of endometriosis. The company is also in stage I development of Apan, a drug candidate for the treatment of Alzheimer's disease. Praecis’s proprietary drug discovery technology, Ligand Evolution to Active Pharmaceuticals (LEAP), was instrumental in the development of Plenaxis and Apan. This technology platform also includes a proprietary drug delivery system known as Rel-Ease. Through its collaboration with Human Genome Sciences, the company has licensed certain rights to CCR5 as a disease target. The LEAP technology is being utilized to discover ligands against CCR5 that may act as inhibitors of HIV entry into T cells. Recently, Praecis announced positive results for the stage II/III study of Plenaxis for the use in endometriosis. Praecis offers its employees a comprehensive benefits package, including a college savings plan, a health club membership and tuition assistance.

BRANDS/DIVISIONS/AFFILIATES: Plenaxis CCR5 Apan LEAP Technology Rel- Ease

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Malcolm L. Geffer, CEO William K. Heiden, COO William K. Heiden, Pres. Kevin F. McLaughlin, CFO/Sr. VP Lena M. Bergfors, VP-Human Resources Marc B. Garnick, Exec. VP- Chief Medical Officer Kevin F. Mc Laughlin, Corp. Sec. Gary F. Musso, VP-Dev. Kevin F. McLaughlin, Treas. William L. Kubasek, VP- Program Dev. Marc B. Garnick, Exec. VP-Chief Regulatory Officer Malcolm L. Geffer, Chmn.

Phone: 781-795-4100 Fax: 781-890-7471 Toll-Free: Address: 830 Winter St., Waltham, MA 02451-1420 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,029 ( 9 months) 2002 Profits: $-32,469 ( 9 months) Stock Ticker: PRCS 2001 Sales: $9,900 2001 Profits: $-54,600 Employees: 127 2000 Sales: $61,200 2000 Profits: $-28,700 Fiscal Year Ends: 12/31 1999 Sales: $61,500 1999 Profits: $9,300 1998 Sales: $39,600 1998 Profits: $5,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $345,313 Stock Purch. Plan: Y Second Exec. Salary: $288,221 ADVANTAGE: Outstanding genome research/LEAP Technology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $110,000 Bonus: $42,000

Northeast: Y

International:



PROCYTE CORPORATION

www.procyte.com


Y Y



Profits: 1


TYPES OF BUSINESS:



Skin, Hair and Wound Care Products Surgical Dressings Veterinary Wound-Care Products Contract Manufacturing

ProCyte is a health care company that develops, manufactures and markets products for wound care, skin health and hair care. Most of the company’s products incorporate its patented copper peptide technology or hydropolymer technology. ProCyte currently focuses on three target markets: dermatology and skin care, including the wound care associated with plastic and cosmetic surgery; hair care; and chronic wound care. ProCyte also continues to emphasize its Complex Cu3 Intensive Repair Creme, Cleanser and Hydrating Gel products, used to treat patients following chemical peels, microdermabrasion and laser treatments, as a complement to its line of prescription and over-the-counter topical drugs, sun protection and anti-aging skin care products. The Complex Cu3 products provide a comprehensive approach to postprocedure care. The company's Pillo Pro Absorbent Dressings provide moisture absorption required following liposuction. ProCyte utilizes the excess capacity of its manufacturing facility by contracting with pharmaceutical and biotechnology clientele to provide processing and other services. ProCyte also markets several veterinary products for wound and skin care, including its Iamin-Vet Skin Care Gel and OsmoCyte-Vet Pillow Wound Dressings. Notably, the firm was recently ranked among the 2002 Deloitte & Touche Technology Fast 500, a ranking of the 500 fastest growing technology companies in North America. ProCyte was also featured as one of the 50 fastest growing technology companies in Washington.

BRANDS/DIVISIONS/AFFILIATES: Neova Therapy Wash Gel 32 Hydro-Lac Lotion Pillo Pro Absorbant Dressings NeovaTherapy Iamin-Vet Skin Care Gel Osmocyte-Vet Pillow Wound Dressings Complex Cu3

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John F. Clifford, CEO John F. Clifford, Pres. Robert W. Benson, CFO Robin L. Carmichael, VP-Mktg. Mark Landis, Controller

Phone: 425-869-1239 Fax: 425-869-1229 Toll-Free: Address: 8511 154th Ave. NE, Bldg. A., Redmond, WA 980523557 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $8,404 ( 9 months) 2002 Profits: $1,345 ( 9 months) Stock Ticker: PRCY 2001 Sales: $9,700 2001 Profits: $- 900 Employees: 39 2000 Sales: $6,600 2000 Profits: $-2,100 Fiscal Year Ends: 12/31 1999 Sales: $4,700 1999 Profits: $-5,300 1998 Sales: $2,600 1998 Profits: $-4,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $269,989 Stock Purch. Plan: Second Exec. Salary: $142,228 ADVANTAGE: Copper peptide technology/Proprietary hydropolymer technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $55,622 Bonus: $26,269

Northeast:

International:



PROGENICS PHARMACEUTICALS

www.progenics.com


Y



Profits: 71


TYPES OF BUSINESS:



Drugs-Cancer Drugs-HIV Small-Molecule Drugs

Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to address the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company applies its expertise in immunology and molecular biology to develop pharmaceuticals to fight viral diseases, such as HIV infection, and cancers, including malignant melanoma and prostate cancer. Progenics is conducting Phase II clinical studies with methylnaltrexone (MNTX), a compound designed to block the side effects of opioid analgesics without interfering with pain palliation. The firm has also initiated Phase II clinical trials of its lead HIV product, PRO 542, a viral-entry inhibitor, and is in preclinical development with PRO 140 and follow-up product candidates. PRO 542 is an antibody-like product designed to neutralize HIV by binding to a glycoprotein on HIV and thereby preventing infection healthy cells, or by binding to and detaching the glycoprotein from the virus. PRO140 is a monoclonal antibody. The firm's most clinically advanced product is GMK, a cancer vaccine in Phase III trials for the treatment of malignant melanoma. In addition, Progenics is developing cancer immunotherapies based on PSMA (prostate specific membrane antigen) technology; ProVax, an HIV vaccine; and DHA-based small-molecule antioxidants to treat stroke. In 2000, Progenics entered into an agreement with Pharmacopeia, Inc. to discover small-molecule HIV therapeutics. The firm also maintains a joint venture agreement with Cytogen Corp. to develop vaccine and antibody-based immunotherapeutic products based on PSMA. In recent news, Progenics was awarded $1 million from the National Cancer Institute to develop novel immunotherapies for prostate cancer. The firm offers its employees tuition reimbursement, comprehensive health care coverage, dental and vision coverage and stock option plans.

BRANDS/DIVISIONS/AFFILIATES: GMK MGV PRO 542 PRO 140 ProVax DHA MNTX PSMA

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul J. Maddon, CEO Ronald J. Prentki, Pres. Robert A. McKinney, VP-Finance Katrina L. Galante, Mgr.-Staffing Paul J. Maddon, Chief Scientific Officer Robert J. Israel, Sr. VP-Medical Affairs Philip K. Yachmetz, VP/Corp. Sec. Philip K. Yachmetz, General Counsel Robert A. McKinney, VP-Oper. and Finance Richard W. Krawiec, VP-Corp. Comm. Richard W. Krawiec, VP-Investor Rel. Robert A. McKinney, Treas. Kenneth G. Surowitz , VP-Quality and Regulatory Affairs Thomas A. Boyd, VP-Preclinical Dev. and Project Mgmt. James H. Conover, VP-Regulatory Affairs William C. Olson, VP-Research and Dev.

Phone: 914-789-2800 Fax: 914-789-2817 Toll-Free: Address: 777 Old Saw Mill River Rd., Tarrytown, NY 10591 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $9,175 ( 9 months) 2002 Profits: $-13,768 ( 9 months) Stock Ticker: PGNX 2001 Sales: $8,900 2001 Profits: $-1,900 Employees: 80 2000 Sales: $14,000 2000 Profits: $-5,900 Fiscal Year Ends: 12/31 1999 Sales: $17,500 1999 Profits: $- 500 1998 Sales: $14,000 1998 Profits: $1,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $460,000 Stock Purch. Plan: Y Second Exec. Salary: $317,000 ADVANTAGE: Good revenue base/Partnerships with major firms.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $110,000 Bonus: $250,000

Northeast: Y

International:



PROTEIN DESIGN LABS INC

www.pdl.com


Y



Profits: 46


TYPES OF BUSINESS:



Drugs-Kidney Transplant Rejection Humanized Monoclonal Antibodies

Protein Design Labs, Inc. (PDL) is a leading developer of humanized monoclonal antibodies for the prevention and treatment of disease. The company’s Zenapax was developed for the prevention of kidney transplant rejection. The product is currently licensed to Hoffman-La Roche, Inc. for marketing in the United States, Europe and other countries. Zenapax is also being tested for the treatment of autoimmune and inflammatory conditions, transplant and cancer. Recently, the company entered an agreement with Exelixis, Inc. to discover and develop cancer-fighting antibodies. Exelixis will provide its model organism genetics technology for identification purposes and PDL will then develop the new antibody drug candidates. In addition, Protein Labs announced favorable results of its SMART Anti-Gamma Interferon antibody Phase I/Phase II trials that are intended to treat Crohn's disease. The company is also conducting Phase II trials in order to review the firm's Remitogen drug effectiveness in cancer patients. Other drugs in the pipeline include Zamyl for acute myeloid leukemia, SMART Anti-L-Selectin for trauma patients, Nuvion for graft-versus -host disease.

BRANDS/DIVISIONS/AFFILIATES: Hoffman-La Roche Zenapax Celltech Chiroscience American Home Products Toagosei Exelixis, Inc. SMART Anti-Gamma Interferon Antibody Remitogen

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Douglas O. Ebersole, Acting CEO Patrick M. Caldwell, VP-Finance Jaisim Shah, VP- Mktg. Frances G. Charlson, VP-Human Resources William R. Benjamin, VP-Research Patrick M. Caldwell, Controller Sergio Garcia-Rodriguez , Corp. Sec. Sergio Garcia-Rodriguez , General Counsel Brett L. Schmidli, Sr. VP-Tech. Oper. Robert L. Kirkman, VP-Bus. Dev. & Corp. Comm. Corine Klingbeil, VP- Preclinical Dev. Douglas O. Ebersole, Sr. VP-Legal & Licensing Lyn D. Olson, VP-Quality and Compliance Mark P. Backer, VP-Tech. Dev.

Phone: 510-574-1400 Fax: 510-574-1500 Toll-Free: Address: 34801 Campus Dr., Fremont, CA 94555 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $35,660 ( 9 months) 2002 Profits: $-6,670 ( 9 months) Stock Ticker: PDLI 2001 Sales: $79,500 2001 Profits: $2,600 Employees: 363 2000 Sales: $63,056 2000 Profits: $ 647 Fiscal Year Ends: 12/31 1999 Sales: $35,754 1999 Profits: $-10,333 1998 Sales: $30,828 1998 Profits: $-9,502


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $486,262 Stock Purch. Plan: Y Second Exec. Salary: $413,786 ADVANTAGE: A leading developer of humanized monoclonal antibodies.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



PROTEIN POLYMER TECHNOLOGIES Industry Group Code: 325412 Ranks within this company's industry group: Sales: 199 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:



Y

TYPES OF BUSINESS:

www.ppti.com Profits: 79




Drugs-Protein Polymers Medical Products Technologies

Protein Polymer Technologies, Inc. (PPT) is a development-stage biotechnology company engaged in the research, development, production and clinical testing of medical products based on its proprietary protein-based biomaterials technology. The company focuses primarily on developing materials technology and products to be used in the surgical repair of human tissue, including surgical adhesives and sealants, soft tissue augmentation products, wound healing matrices, drug delivery devices and surgical adhesion barriers. PPT also developed coating technology that can efficiently modify and improve the surface properties of more traditional biomedical devices. The company initiated human clinical testing of its urethral bulking agent for the treatment of female stress urinary incontinence. The U.S. FDA approved the company's Investigational Device Exemption (IDE), which allows the testing of the safety and effectiveness of the incontinence product in women over the age of 40 who have become incontinent due to the shifting of their bladder or the weakening of the muscle at its base that controls the flow of urine, or both problems combined. The company has established a strategic alliance with Femcare, Ltd. for the commercialization of the incontinence product in Europe and Australia. In the agreement, Femcare is responsible for clinical testing, regulatory approval, and product sales and marketing within these territories, and PPT is responsible for product manufacturing. Recently, PPT and Windamere Venture Partners formed Spine Wave, Inc. to develop a spinal disk repair product. The company offers its employees a 401(k) savings plan and an employee stock purchase plan.

BRANDS/DIVISIONS/AFFILIATES: Spine Wave, Inc. Windamere Venture Partners Investigational Device Exemption (IDE) Femcare, Ltd.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. J. Thomas Parmeter, CEO J. Thomas Parmeter, Pres. Janis Y. Neves , Dir.-Finance and Admin. Joseph Cappello, Chief Tech. Officer Philip J. Davis, Corp. Sec. John E. Flowers, VP-Planning and Oper. Joseph Cappello, VP-Research and Dev. Radine G. Pobuda, Dir.-Quality Systems and Regulatory Affairs Franco A. Ferrari, VP-Laboratory Oper. J. Thomas Parmeter, Chmn.

Phone: 858-558-6064 Fax: 858-558-6477 Toll-Free: Address: 10655 Sorrento Valley Rd., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 588 ( 9 months) 2002 Profits: $-2,353 ( 9 months) Stock Ticker: PPTI 2001 Sales: $ 800 2001 Profits: $-3,100 Employees: 20 2000 Sales: $1,200 2000 Profits: $-2,500 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-4,300 1998 Sales: $ 300 1998 Profits: $-5,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $212,000 Stock Purch. Plan: Y Second Exec. Salary: $137,000 ADVANTAGE: Proprietary protein-based biomaterials technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



QIAGEN NV

www.qiagen.com



Y


Y

TYPES OF BUSINESS:

Profits: 5


Y Y


Y


Supplies-Plasmid Purification Genomics Analysis Nucleic Acid Measurement Technologies Genomics Computer Solutions Synthetic Oligonucleotides

Qiagen is a Netherlands -based company that provides products and services in two segments: genotyping and instruments. Qiagen has operations in Japan, Germany, the U.S., U.K., Switzerland, France, Italy, Australia and Canada. Its genomics segment, represented by Qiagen Genomics in Seattle, focuses on its proprietary nucleic acid measurement technologies platform, including the Masscode tagging system and DNA Reaction Control technology. Qiagen Genomics is the first company that has nucleic acid measurement technologies to offer full service genomics analysis. Another subsidiary, Operon Technologies, is a market-leading synthetic nucleic acid company that manufactures and sells synthetic oligonucleotides, genes and other products to life science researchers around the world. Its instruments segments make tools that are necessary for the extraction and purification of nucleic acids for use in DNA sequencing, drug research and genomics. Qiagen’s patented SolidPhase Anion-Exchange Technology was specifically developed for nucleic acid purification. An anionexchange resin, the QIAprecipitator unit, which allows recovery of DNA without centrifugation, and the QIAfilter unit allow a significantly faster purification procedure. The company offers a huge array of products and services. RNeasy Protect Kits stabilize and isolate high-quality RNA, which is very helpful due to the unstable nature of RNA after extraction. Other products include the MinElute PCR Purification and Gel Extraction Kit, PolyFect Transfection Reagent, PCR and RT-PCR Application Guide, HiSpeed Plasmid Midi Kit and the DyeEx 96 Spin Kit. Recently, Qiagen announced it has entered into a supply agreement with Precision Systems Science Co., Ltd. Under this agreement, Qiagen will purchase from Precision automation components for its nucleic acid, cell purification and protein solutions. In other news, the company announced it has entered into a supply agreement with Affymetrix, Inc. for the use of its GeneCHip arrays.

BRANDS/DIVISIONS/AFFILIATES: Operon Technologies Qiagen Genomics PolyFect Transfection Reagent Rneasy Protect Kits Solid-Phase Anion-Exchange Technology MinElute PCR Purification and Gel Extraction Kit PolyFect Transfection Reagent HiSpeed Plasmid Midi Kit

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Metin Colpan, Managing Dir./CEO Peer M. Schatz, CFO/Managing Dir. Detlev H. Reisner, Chmn.-Supervisory Board

Phone: +31-77-320-8400 Fax: +31-77-320-8409 Toll-Free: Address: Spoorstraat 50, Venlo, 5911 KJ The Netherlands

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $220,159 ( 9 months) 2002 Profits: $21,369 ( 9 months) Stock Ticker: QGENF 2001 Sales: $263,800 2001 Profits: $34,400 Employees: 1,500 2000 Sales: $204,000 2000 Profits: $20,100 Fiscal Year Ends: 12/31 1999 Sales: $158,200 1999 Profits: $13,900 1998 Sales: $120,800 1998 Profits: $13,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Rapidly-growing revenues.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



QLT INC

www.qltinc.com


Y



Profits: 28


TYPES OF BUSINESS:



Drugs-Photodynamic Cancer Treatments Eye Disease Treatments Immune Disorder Treatments

Based in Vancouver, Canada, QLT, Inc. (formerly QLT Photo Therapeutics, Inc.) is a global biopharmaceutical company that focuses on the discovery, development and commercialization of new therapies to treat cancer, eye disease and immune disorders. Its Photofrin product was the world's first approved photodynamic therapy drug and is used in the treatment of a range of cancers. The firm's second-generation photosensitizer, Visudyne, is a treatment for wet age-related macular degeneration (AMD), the leading cause of blindness in people over the age of 50. Visudyne has received approval for AMD in more than 60 countries, in addition to 40 countries for other indications, such as pathological myopia and ocular histoplasmosis. Currently, QLT is developing verteporfin as a treatment for skin cancer, in addition to investigating other compounds, such as tariquidar, which addresses the problem of resistance to chemotherapy drugs and has entered Phase III trials. QLT0074 is the company's thirdgeneration photosensitizer, which is in clinical trials for prostate hyperplasia and male pattern baldness. QLT has collaborative partnerships with Novartis Ophthalmics, Lumenis, Ltd. and Axcan Pharma, Inc., among others. In recent news, the firm streamlined its workforce to concentrate on key development programs, eliminating approximately 18% of its staff. In addition, QLT announced the launch of a Phase III trial using photodynamic therapy for the treatment of multiple basal cell carcinoma. QLT offers its employees comprehensive health and dental coverage, professional development programs and scholarship programs.

BRANDS/DIVISIONS/AFFILIATES: QLT Photo Therapeutics, Inc. Visudyne Photofrin QLT0074

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul Hastings, CEO Paul Hastings, Pres. Michael Doty, Sr. VP/CFO Robert Butchofsky , VP-Mktg. and Sales Planning Linda Lupini, VP-Human Resources Mohammad Azab, Sr. VP-Clinical Research Mohammad Azab, Sr. VP-Medical Affairs Linda Lupini, VP-Admin. William Newell, Sr. VP/Chief Bus. Officer Lawrence Mandt, VP-Quality and Regulatory Affairs Alain Curaudeau, Sr. VP-Project Planning and Mgmt.

Phone: 604-707-7000 Fax: 604-707-7001 Toll-Free: 800-663-5486 Address: 887 Great Northern Way, Vancouver, BC V5T 4T5 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $77,108 ( 9 months) 2002 Profits: $13,461 ( 9 months) Stock Ticker: QLTI 2001 Sales: $81,300 2001 Profits: $76,700 Employees: 400 2000 Sales: $31,900 2000 Profits: $4,000 Fiscal Year Ends: 12/31 1999 Sales: $17,300 1999 Profits: $-21,900 1998 Sales: $8,100 1998 Profits: $-15,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $ Bonus: $ ADVANTAGE: Growing revenues/The world's first approved photodynamic treatment for early -stage curative cancers.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast:

International: Y



QUESTCOR PHARMACEUTICALS

www.questcor.com


Y



Profits: 105


TYPES OF BUSINESS:



Drugs-Hospital Use Specialty Pharmaceuticals Neurological Drugs Gastoenterological Drugs Dietary Supplements

Questcor Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company focused on the development, acquisition and marketing of acute care and critical care hospital and specialty pharmaceuticals and related health care products. Currently, the firm markets five products through its internal sales force in the U.S., as well as a sixth product in Italy through a strategic partner. These products target pediatric neurologists, gastroenterologists, nephrologists, transplant centers and nuclear medicine centers. Questcor's marketed products include HP Acthar Gel, an injectable drug that helps patients with infantile spasm (West syndrome); Ethamolin, an injectable drug used to treat esophageal varices that have recently bled; Glofil-125 and Inulin, injectable agents that assess kidney function by measuring gastrointestinal filtration rate; and VSL#3, a probiotic used as a dietary supplement to promote normal gastrointestinal function. The company has made efforts to reduce spending on research and development and to focus on sales and marketing. Accordingly, Questcor has entered into agreements with several pharmaceutical and biotechnology companies to further the development of technology acquired from its 1999 merger with RiboGene. Fabre Kramer Pharmaceuticals agreed to manage and provide funding for the clinical development of Hypnostat and Panistat, drug candidates for insomnia and panic disorders, respectively. The firm's antifungal drug discovery program has been licensed to Tularik, Inc. Questcor also has the rights to trademarks including Migrastat, Ceresine, Neoflo and Dermaflo. Recently, the company received FDA approval to extend the labeled shelf life of HP Acthar Gel from 12 months to 18 months. The firm also signed an agreement with Beacon Pharmaceuticals to market the product in the U.K. The company offers employees competitive benefits including stock options.

BRANDS/DIVISIONS/AFFILIATES: VSL#3 HP Acthar Gel Glofil-125 Inulin Ethamolin Pramidin Hypnostat Panistat

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Charles J. Casamento, CEO Charles J. Casamento, Pres. Timothy E. Morris, CFO/VP-Finance Rick Storch, Human Resources Timothy E. Morris, VP-Admin. Kenneth R. Greathouse, VP-Commercial Oper.

Phone: 510-400-0700 Fax: 510-400-0799 Toll-Free: Address: 3260 Whipple Rd., Union City, CA 94587 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $11,443 ( 9 months) 2002 Profits: $-2,430 ( 9 months) Stock Ticker: QSC 2001 Sales: $5,700 2001 Profits: $-8,700 Employees: 38 2000 Sales: $3,600 2000 Profits: $-13,800 Fiscal Year Ends: 7/31 1999 Sales: $1,000 1999 Profits: $-6,800 1998 Sales: $2,600 1998 Profits: $-5,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $405,000 Stock Purch. Plan: Second Exec. Salary: $195,267 ADVANTAGE: Significant licensing and marketing agreement.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $192,375 Bonus: $56,100

Northeast:

International:



QUINTILES TRANSNATIONAL CORP

www.quintiles.com




Y Y

TYPES OF BUSINESS:

Profits: 25



Y


Research & Development Sales/Marketing for Pharmaceutical Companies Web-based Products Research Solutions Strategic Alliance Services Clinical Trials

Quintiles Transnational Corporation is a leading provider of full-service contract research, sales and marketing services to the global pharmaceutical, biotechnology and medical device industries. The company provides a broad range of contract services to speed the process from development to peak sales of a new drug or medical device. The firm also offers market research solutions and strategic analyses to support healthcare decisions and policy consulting to governments and other organizations worldwide. Quintiles operates in three primary business segments: Product Development Group, Commercial Services Group and QUINTERNET Informatics. The Product Development Group provides a full range of drug development services from strategic planning and preclinical services to regulatory submission and approval. The Commercial Services Group engages in sales force deployment and strategic marketing services as well as consulting services for its customers. QUINTERNET Informatics offers a broad spectrum of products and services to improve the quality and management of care in the delivery of health-related services. The company recently launched Innovex eHealth Solutions Group, which provides Internet-based sales and marketing services for the pharmaceutical, biotechnology and medical device industries. The premier product of the group is iQLearning, a Web-based system that has the capability to provide a wide range of online products and educational programs for physicians and sales representatives.

BRANDS/DIVISIONS/AFFILIATES: Healtheon/Web MD Innovex Rx Market Monitor Quintiles Academy Japan Pharma Center QUINTERNET Informatics Innovex eHealth Solutions Group iQLearning

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Pamela J. Kirby, CEO James L. Bierman, CFO John S. Russell, General Counsel Greg Connors, Investor Rel. Gregory Porter, CEO, Quintiles Informatics Pat Grebe, Media Rel.

Phone: 919-998-2000 Fax: 919-998-9113 Toll-Free: Address: 4709 Creekstone Dr., Ste. 200, Durham , NC 277093979 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,185,364 ( 9 months) 2002 Profits: $59,066 ( 9 months) Stock Ticker: QTRN 2001 Sales: $1,619,900 2001 Profits: $-33,900 Employees: 17,224 2000 Sales: $1,659,900 2000 Profits: $418,900 Fiscal Year Ends: 12/31 1999 Sales: $1,607,100 1999 Profits: $109,300 1998 Sales: $1,221,800 1998 Profits: $88,600


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $600,000 Bonus: $31,875 Stock Purch. Plan: Second Exec. Salary: $368,749 Bonus: $12,031 ADVANTAGE: Leading provider of full-service contract research, sales and marketing services to the global pharmaceutical, biotechnology, and medical device industries.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Northeast: Y

International: Y



REGENERON PHARMACEUTICALS INC Industry Group Code: 325412 Ranks within this company's industry group: Sales: 90 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



www.regn.com

Profits: 225


TYPES OF BUSINESS:



Drugs-Diversified Protein-Based Drug Development Small Molecule Drug Development

Regeneron Pharmaceuticals, Inc. discovers, develops and commercializes therapeutic drugs for the treatment of serious medical conditions. The company is currently expanding its focus on degenerative neurological diseases to include drug therapies for obesity, rheumatoid arthritis, cancer, allergies, asthma and other disorders. Drug development includes protein-based or small-molecule drugs, as well as developing specific proteins for neurons. Regeneron’s platform technologies are Targeted Genomics, Functionomics and Designer Protein Therapeutics. The firm is involved in a continuing collaboration with Sumitomo in Japan for the development of BDNF, Regeneron’s brain-derived neurotrophic factor. The company is also engaged in a study with partners at the University of California in San Francisco regarding Vascular Endothelial Growth Factor and other inflammatory agents. Recently, Regeneron reported its results from Phase II trials of Axokine, a drug expected to treat obesity. It found that patients who took the treatment maintained weight loss for at least 36 weeks after the end of the trial. Notably, the company came upon the key factors to muscle growth, which were published in the widely recognized Nature and Science journals. These significant findings may lead to therapies that prevent the adverse effects of muscle atrophy. Regeneron is also in collaborative agreements with Merck & Co. and Proctor & Gamble.

BRANDS/DIVISIONS/AFFILIATES: Emisphere AXOKINE Angioprotein-1 Sumitomo BDNF

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Leonard S. Schleifer, CEO Leonard S. Schleifer, Pres. Murray A. Goldberg, Sr. VP-Finance/CFO Richard X. Horne, VP-Human Resources George D. Yancopoulos, Chief Scientific Officer/Sr. VP Randall G. Rupp, Sr. VP-Mfg. Joseph M. Sorrentino, VP/Assoc. General Counsel Murray A. Goldberg, VP-Admin. Ann Acheson, VP-Product Dev. Oper. and Logistics Charles Poole, VP- Investor Rel. Murray A. Goldberg, Treas. George D. Yancopoulos, Pres., Regeneron Research Laboratories Jesse M. Cedarbaum, VP-Clinical Affairs David M. Valenzuela, VP-Genomics & Bioinformatics Randall G. Rupp, VP- Process Science

Phone: 914-347-7000 Fax: 914-347-2113 Toll-Free: Address: 777 Old Saw Mill River Rd., Tarrytown, NY 10591-6707 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $17,076 ( 9 months) 2002 Profits: $-88,684 ( 9 months) Stock Ticker: REGN 2001 Sales: $22,000 2001 Profits: $-76,200 Employees: 575 2000 Sales: $59,300 2000 Profits: $-23,200 Fiscal Year Ends: 12/31 1999 Sales: $34,500 1999 Profits: $-23,100 1998 Sales: $38,300 1998 Profits: $-8,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $538,269 Bonus: $250,000 Stock Purch. Plan: Y Second Exec. Salary: $423,942 Bonus: $100,000 ADVANTAGE: Molecular biology expertise/Lucrative agreements with Merck and Proctor & Gamble.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast: Y

International:



REPLIGEN CORPORATION

www.repligen.com


Y



Profits: 89


TYPES OF BUSINESS:



Drugs-Pediatric Autism Treatment Immune Disorder Treatment Mitochondrial Disease Treatment

Repligen develops innovative therapeutic products for debilitating pediatric diseases. Its drug candidates are secretin for autism, uridine for mitochondrial disease and CTLA4 for immune disorders. These products are synthetic forms of naturally occurring substances that may correct improperly regulated biological processes with minimal toxicity or side effects. They have the potential to produce clinical benefits not attainable with any existing drug in diseases for which there are few alternatives. Repligen's business strategy is to partially fund the development of its proprietary therapeutic products derived from the sales of its specialty pharmaceuticals: rProtein A, used in the purification of antibodies, and SecreFlo, a diagnostic product. SecreFlo is a form of synthetic porcine secretin to aid in the assessment of pancreatic function and the diagnosis of gastrinoma. Repligen intends to market SecreFlo directly to gastroenterologists in the U.S. Secretin is a hormone produced in the small intestine which regulates the function of the pancreas; studies show that the hormone may have beneficial effects in some autistic children, including improvements in social interaction and communication. The firm has completed Phase II clinical trials on synthetic forms of the hormone in autistic children. Repligen licensed the rights to patent applications of uridine as a treatment for mitochondrial disease from the University of California at San Diego. Uridine is a precursor for the synthesis of RNA and DNA. Repligen is also developing CTLA4, a protein fused to a portion of a human antibody molecule, which has been shown to selectively block unwanted immune responses in organ transplantation and several autoimmune diseases. In recent news, the company announced FDA approval for a new application of SecreFlo as an aid in the location and cannulation of the pancreatic ducts in patients undergoing endoscopic procedures. Repligen offers its employees health, dental, life and longterm disability insurance, as well as equity participation.

BRANDS/DIVISIONS/AFFILIATES: SecreFlo CTLA4 rProtein A

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Walter C. Herlihy, CEO Walter C. Herlihy, Pres. James R. Rusche, Sr. VP-Research and Dev. Patrice Rioux, VP-Medical Affairs Daniel P. Witt, VP-Bus. Dev. Richard Boismenu, Sr. Dir.-Immunology and Cell Biology

Phone: 781-250-0111 Fax: 781-250-0115 Toll-Free: 800-622-2259 Address: 41 Seyton St., Bldg. 1, Ste. 100, Waltham, MA 02453 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $4,300 ( 9 months) 2002 Profits: $-4,500 ( 9 months) Stock Ticker: RGEN 2001 Sales: $2,346 2001 Profits: $-5,278 Employees: 40 2000 Sales: $3,500 2000 Profits: $-3,800 Fiscal Year Ends: 3/31 1999 Sales: $2,400 1999 Profits: $-2,500 1998 Sales: $2,400 1998 Profits: $- 800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $242,000 Stock Purch. Plan: Second Exec. Salary: $185,000 ADVANTAGE: Drug for the treatment of autism, a significant market need.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $50,000 Bonus: $7,000

Northeast: Y

International:



RIBOZYME PHARMACEUTICALS

www.rpi.com


Y



Profits: 211


TYPES OF BUSINESS:



Drugs-Cancer Ribozyme Technology Hepatitis Treatments

Ribozyme Pharmaceuticals, Inc. is developing anew class of therapeutics based on engineering molecules called ribozymes, which are sequences of nucleotides. Ribozymes act as molecular scissors by cutting RNA molecules into two ineffective strands, preventing abnormal protein production or viral replication. The molecules are applicable in a broad range of pharmaceutical therapies and are therapeutically precise. Ribozyme is developing four product candidates in clinical and preclinical testing: Angiozyme for the treatment of solid tumors; Heptazyme for chronic hepatitis C; Herzyme for breast and other sold tumor cancers; and HepBzyme for the treatment of hepatitis B. During 2001, the firm initiated Phase II trials of Angiozyme in metastatic breast and colorectal cancer, as well as Phase I and II trials of Heptazyme and Herzyme. HepBzyme is in preclinical testing. Ribozyme is testing these products in partnership with companies including Chiron Corp. and Elan Corp. In addition, the company uses ribozymes for target dis covery and validation to help companies in the life science industry identify genes that cause or contribute to human disease. This technology has been transferred to the German firm Atugen, of which Ribozyme owns approximately 32%. Ribozymes have also shown applicability in the area of molecular diagnostics. Ribozyme has entered into a collaborative agreement with Archemix to explore this area. Recently, the company announced the development of a more stable and potent form of Heptazyme. The firm also announced departmental organizational changes and reductions in staff.

BRANDS/DIVISIONS/AFFILIATES: Heptazyme Herzyme Angiozyme HepBzyme Atugen

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Howard W. Robin, CEO Howard W. Robin, Pres. Marvin Tancer, CFO Nassim Usman, Chief Scientific Officer/VP-Research and Dev. Lawrence Blatt, Corp. Sec. Bharat M. Chowrira, VP-Legal Affairs, Licensing and Patent Counsel Marvin Tancer, VP-Oper. Lawrence Kahn, VP-Bus. Dev. Cathy Robins, Investor Rel. Barry A. Polisky, VP-Research Lawrence Blatt, VP-Admin. and Finance

Phone: 303-449-6500 Fax: 303-449-6995 Toll-Free: Address: 2950 Wilderness Pl., Boulder, CO 80301 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $4,508 ( 9 months) 2002 Profits: $-24,364 ( 9 months) Stock Ticker: RZYM 2001 Sales: $8,300 2001 Profits: $-59,800 Employees: 130 2000 Sales: $15,500 2000 Profits: $-15,900 Fiscal Year Ends: 12/31 1999 Sales: $7,700 1999 Profits: $-10,700 1998 Sales: $9,000 1998 Profits: $-10,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $309,231 Stock Purch. Plan: Y Second Exec. Salary: $288,275 ADVANTAGE: Leading developer of ribozyme technology/Partnerships with leading drug firms.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:




Northeast:

International:



SANGAMO BIOSCIENCES INC

www.sangamo.com



Y


Y

TYPES OF BUSINESS:

Profits: 23




Drug Research and Development-Gene Expression Regulation Transcription Factor Development

Sangamo BioSciences is a leader in the development of new transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The company’s Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins, or ZFPs. By engineering ZFPs so that they can selectively bind to and regulate a target gene, Sangamo has created ZFP transcription factors that can control gene expression and, consequently, cell function. The firm intends to establish Universal Gene Recognition as a broadly used technology platform for commercial applications in pharmaceutical discovery, human therapeutics, DNA diagnostics and agricultural and industrial biotechnology. In recent news, Sangamo announced it was awarded a grant for conducting Phase II research on ZFP technology. The company also established a collaborative agreement with Avigen, Inc. to evaluate its ZFP technology and Avigen’s gene delivery system for the use in chronic pain.

BRANDS/DIVISIONS/AFFILIATES: Universal Gene Recognition Universal GeneTools Avigen, Inc. Rosetta Inpharmatics

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Edward O. Lamphier, II, CEO Edward O. Lamphier, II, Pres. Janet L. Nibel, VP-Finance Carl Pabo, Sr. VP-Chief Scientific Officer Janet L. Nibel, VP-Admin. Peter Bluford, VP-Bus. Dev. Casey Case, VP-Research Eric Rhodes, Sr. Dir.-Commercial Dev.

Phone: 510-970-6000 Fax: 510-236-8951 Toll-Free: Address: 501 Canal Blvd., Ste. A100, Richmond, CA 94804 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,879 ( 9 months) 2002 Profits: $-29,058 ( 9 months) Stock Ticker: SGMO 2001 Sales: $4,900 2001 Profits: $-25,200 Employees: 90 2000 Sales: $3,400 2000 Profits: $-9,100 Fiscal Year Ends: 12/31 1999 Sales: $2,200 1999 Profits: $-3,800 1998 Sales: $2,000 1998 Profits: $-3,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $300,000 Stock Purch. Plan: Y Second Exec. Salary: $180,000 ADVANTAGE: Major partnerships/Unique technology focused on creating DNA binding proteins.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $164,538 Bonus: $50,000

Northeast:

International: Y



SANGSTAT MEDICAL CORP

www.sangstat.com


Y



Profits: 112


TYPES OF BUSINESS:


Y


Drugs-Organ Rejection and Viability Mail-Order Delivery of Drugs Specialty Pharmacy Online Pharmacy Generic Drugs

SangStat Medical Corporation is a global biotechnology company expanding on its transplantation foundation to discover, develop and market high value therapeutic products in immunology, hematology/oncology and autoimmune disease. The company’s subsidiaries include SangStat Europe and SangStat, Canada, Ltd. The firm recently decided to implement a new strategy that focuses significant resources on its pharmaceutical products segment, which consists of four marketed products and three principal product candidates. It also sold its transplantation services segment, The Transplant Pharmacy, to Chronimed. The company is currently marketing the following products: Thymoglobulin, which prevents graft rejection in kidney transplants; Lymphoglobuline, which prevents and treats kidney, heart, pancreas or liver rejection (outside the U.S.); Celsior, which preserves organ viability; and Gengraf, which is copromoted with Abbott Laboratories. Products currently in development include ABX-CBL, an anti-CD 147 antibody for the treatment of steroid resistant Graft-versus -Host disease in co-development with Abgenix, Inc.; and RDP58 for the treatment of ulcerative colitis and Crohn’s disease. In recent news, SangStat announced that it has received approval from the U.S. FDA for its Investigational New Drug application for clinical studies of RDP58. The company has also received a notice of compliance from Canada Health for Thymoglobulin.

BRANDS/DIVISIONS/AFFILIATES: SangStat Europe SangStat, Canada, Ltd. Thymoglobulin Lymphoglobuline Celsior Gengraf Abgenix, Inc. RDP58

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard D. Murdock, CEO Richard D. Murdock, Pres. Stephen Dance, Sr. VP-Finance Steve Aselage, Sr. VP-North America Sales and Mktg. Marlene Perry, Dir.-Human Resources Timothy Fong, VP-Discovery Research Adrian Arima, Sr. VP/General Counsel Ralph Levy, Sr. VP-Oper. Brian Lundstrom, VP-Bus. Dev. Raymond J. Tesi, Sr. VP-Clinical Dev. and Medical Affairs Ross Maclean, VP-Global Regulatory Affairs

Phone: 510-789-4300 Fax: 510-789-4400 Toll-Free: Address: 6300 Dumbarton Circle, Fremont, CA 94555 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $88,361 ( 9 months) 2002 Profits: $5,094 ( 9 months) Stock Ticker: SANG 2001 Sales: $94,500 2001 Profits: $-9,300 Employees: 263 2000 Sales: $63,100 2000 Profits: $-44,300 Fiscal Year Ends: 12/31 1999 Sales: $58,200 1999 Profits: $-33,000 1998 Sales: $19,700 1998 Profits: $-38,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $341,040 Stock Purch. Plan: Second Exec. Salary: $235,333 ADVANTAGE: Disease management approach to transplant biotechnology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $215,935 Bonus: $76,705

Northeast: Y

International: Y



SCHERING-PLOUGH CORP

www.sch-plough.com


Y



Profits: 8


TYPES OF BUSINESS:



Drugs-Allergies and Respiratory Anti-Infective/Anti-Cancer Drugs Dermatologicals Cardiovascular Drugs Animal Health Pharmaceuticals Over-The-Counter Drugs

Schering-Plough Corporation is engaged in the discovery, development, manufacture and marketing of pharmaceutical products through its Pharmaceuticals, Health Care Products, and Animal Health subsidiaries. Schering-Plough Pharmaceuticals manufactures and markets allergy, respiratory, anti-infective, anti-cancer, dermatological and cardiovascular prescription pharmaceuticals. Schering-Plough HealthCare Products markets a number of over-the-counter, foot care and sun care products, including Afrin, Drixocal, Tinactin, Correctol, Dr. Scholl’s and Coppertone. Schering-Plough Animal Health develops and markets a broad range of pharmaceuticals and biologicals for companion animals and animals involved in food production. Recently, the company and NeoGenesis Drug Discovery, Inc. announced a multi-year, multi-target research collaboration to discover small-molecule drug candidates. Under the terms of the agreement, Schering-Plough will make an equity investment in NeoGenesis and provide research and development funding for a maximum of five years. The FDA recently approved the firm’s Peg-Intron and Rebetol combination therapy for the treatment of chronic hepatitis C in patients who have never been treated with interferon alpha. The combined treatment regimen is the first and only pegylated interferon-based combination therapy approved in the United States. The company has also received authorization from the European Commission of the European Union to market Desloratadine tablets as a nonsedating treatment for the symptoms of chronic idiopathic urticaria, such as itching or hives. Schering-Plough Corporation offers its employees tuition reimbursement, scholarships, adoption counseling and referral services, fitness and exercise program memberships and medical and dental insurance. The company also sponsors a number of recreational and social programs for its employees, including basketball teams, walking, running and cycling clubs and tennis tournaments.

BRANDS/DIVISIONS/AFFILIATES: Afrin Drixocal Tinactin Correctol Dr. Scholl's Coppertone Claritin Desloratadine

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard Jay Kogan, CEO Jack L. Wyszomierski, CFO John P. Ryan, Dir.-Human Resources Robert S. Lyons, VP-Corp. Info. Services Thomas A. Kelly, Controller John J. LaRosa, Corp. Sec. Joseph C. Connors, General Counsel Geraldine U. Foster, Sr. VP-Corp. Comm. Geraldine U. Foster, Sr. VP-Investor Rel. E. Kevin Moore, Treas. Daniel A. Nichols, Sr. VP-Taxes Douglas J. Gingerella, VP-Corp. Audits John E. Nine, Pres.-Schering Tech. Oper. Roch F. Doliveux, Pres., Schering-Plough Int'l. Richard de Jongh Osborne, Chmn.

Phone: 908-298-4000 Fax: 908-822-7048 Toll-Free: Address: 2000 Galloping Hill Rd., Kenilworth, NJ 07033-0530 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $7,810,000 ( 9 months) 2002 Profits: $1,662,000 ( 9 months) Stock Ticker: SGP 2001 Sales: $9,802,000 2001 Profits: $1,943,000 Employees: 29,800 2000 Sales: $9,815,000 2000 Profits: $2,423,000 Fiscal Year Ends: 12/31 1999 Sales: $9,116,000 1999 Profits: $2,110,000 1998 Sales: $8,027,000 1998 Profits: $1,756,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $1,430,000 Stock Purch. Plan: Second Exec. Salary: $542,000 ADVANTAGE: Expertise in gene therapy/Excellent brand name recognition.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $ Bonus: $

Northeast: Y

International: Y



SCICLONE PHARMACEUTICALS

www.sciclone.com


Y



Profits: 96


TYPES OF BUSINESS:



Drugs-Chronic Disease Immune System Enhancers Hepatitis Therapies Small-Molecule Therapies

SciClone Pharmaceuticals, Inc. develops and commercializes pharmaceutical and biological therapeutic compounds that are acquired or in-licensed at the stage of late preclinical or early clinical development. SciClone's strategic goal, based on the broad therapeutic potential of its lead drug, ZADAXIN, is to become the preeminent worldwide provider of immune system enhancers (ISEs) as monotherapies and as critical components of combination drug therapies for infectious diseases and cancer. ZADAXIN has been approved for sale primarily as a monotherapy for hepatitis B in 26 countries and has been administered to more than 10,000 patients worldwide. Currently, the company is targeting major market regulatory approval for ZADAXIN as a treatment for conditions including hepatitis C and cancer in global Phase III clinical trials. SciClone is focusing on hepatitis C as the first indication for commercial registration of the drug in the U.S. At present, the largest single market for ZADAXIN is China. ZADAXIN is an immune system enhancer that helps to stimulate, maintain and direct the body's antiviral and anticancer immune response. The firm is also developing a second generation of ISEs, including SCV-07 and its related compounds, which have the potential to be orally active (as opposed to ZADAXIN, which is administered as a subcutaneous injection). In addition, SciClone continues to develop CPX, a novel small-molecule protein-repair therapy for cystic fibrosis. This product is licensed from the National Institutes of Health. Recently, the firm released the results of a study showing that ZADAXIN, in combination with pegylated interferon, had additional benefits in non-responding patients with hepatitis C.

BRANDS/DIVISIONS/AFFILIATES: SciClone Pharmaceuticals International ZADAXIN CPX SCV -07

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Donald R. Sellers, CEO Alfred R. Rudolph, COO Donald R. Sellers, Pres. Richard A. Waldron, CFO Cynthia W. Tuthill, VP-Scientific Affairs Eduardo B. Martins, Medical Dir.

Phone: 650-358-3456 Fax: 650-358-3469 Toll-Free: 800-724-2566 Address: 901 Mariner's Island Blvd., Ste. 205, San Mateo, CA 94404 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $12,294 ( 9 months) 2002 Profits: $-7,420 ( 9 months) Stock Ticker: SCLN 2001 Sales: $13,800 2001 Profits: $-6,200 Employees: 84 2000 Sales: $15,400 2000 Profits: $-1,700 Fiscal Year Ends: 12/31 1999 Sales: $9,400 1999 Profits: $-5,500 1998 Sales: $3,725 1998 Profits: $-21,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $432,000 Stock Purch. Plan: Second Exec. Salary: $216,000 ADVANTAGE: Rapidly growing sales of its hepatitis therapy/Marketing in 20 nations.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $144,000 Bonus: $72,000

Northeast:

International: Y



SCIOS INC

www.sciosinc.com


Y



Profits: 215


TYPES OF BUSINESS:



Drugs-Cardiovascular and Renal Disorder

Scios, Inc. is a biopharmaceutical company developing novel treatments for cardiovascular and inflammatory diseases. The firm’s disease-based technology platform integrates expertise in protein biology with computational and medicinal chemistry to identify novel targets and design small molecule compounds for large markets with unmet medical needs. Scios’s Natrecor for the treatment of acute congestive heart failure (CHF) brought sales in excess of $14 million in 2001. The company is now focused on the development of three products: Natrecor, SCIO-469 (an oral small molecule inhibitor of p38 kinase for the treatment of rheumatoid arthritis) and small molecule inhibitors for TGF-beta receptors (the cytokine implicated in diseases characterized by chronic scar formation, or fibrosis). Scios is part of a marketing alliance with Innovex to commercialize Natrecor in North America. The company has also expanded its research collaboration with Medtronic to clinically evaluate the hemodynamic, endocrine and clinical effects of Natrecor, using information collected during and after infusions of the drug. Additionally, Scios has entered into an agreement with Glaxo Group, Ltd., a division of GlaxoSmithKline (GSK), under which it will license Natrecor to GSK in all European markets. A recent article in the Journal of the American Medical Association supported the use of Natrecor, the firm’s flagship product, for the treatment of CHF. Scios also recently raised its net sales forecast for Natrecor, based on outstanding first quarter sales performance. Scios offers employees medical, vision, dental and life insurance, as well as an employee assistance program.

BRANDS/DIVISIONS/AFFILIATES: California Biotechnology, Inc. Natrecor Fiblast SCIO-469 Biodel Scios Nova, Inc. Gliadel

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard B. Brewer, CEO Richard B. Brewer, Pres. David W. Gryska, Sr. VP-Finance/CFO Thomas L. Feldman, VP-Sales & Mktg. Allison Herd, VP-Human Resources George F. Schreiner, VP/Chief Scientific Officer Darlene P. Horton, VP-Medical Affairs Matthew R. Hooper, VP/General Counsel Elliott B. Grossbard, Sr. VP-Dev. Jane A. Moffitt, VP-Regulatory Affairs Tricia Baldwin, VP-Quality and Product Dev.

Phone: 408-616-8200 Fax: 408-616-8206 Toll-Free: Address: 820 W. Maude Ave., Sunnyvale, CA 94085 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $66,628 ( 9 months) 2002 Profits: $-69,559 ( 9 months) Stock Ticker: SCIO 2001 Sales: $47,300 2001 Profits: $-62,500 Employees: 425 2000 Sales: $12,600 2000 Profits: $-42,500 Fiscal Year Ends: 12/31 1999 Sales: $28,400 1999 Profits: $-20,100 1998 Sales: $44,700 1998 Profits: $-2,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $460,000 Stock Purch. Plan: Second Exec. Salary: $255,000 ADVANTAGE: Expertise in protein-based and small molecule drugs.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $400,000 Bonus: $145,000

Northeast:

International:



SENETEK PLC

www.senetekplc.com


Y



Profits: 57


TYPES OF BUSINESS:



Drugs-Sexual Dysfunction Skincare Technologies Epinephrine Products Cosmetics Biopharmaceuticals

Senetek is a biotechnology company that develops, manufactures and markets proprietary products for the enhancement of quality of life, primarily offering products for the diagnosis and treatment of aging-related health care problems. The company focuses on two business sectors: biopharmaceuticals, in particular therapeutic agents for erectile dysfunction and female sexual dysfunction; and proprietary skincare technologies. In connection with its product development activities, Senetek sponsors research in the life sciences and biotechnology fields. Its Invicorp product employs an easy-to-use, self-administered automatic system that delivers a combination therapy of two specific drugs, vasoactive intestinal polypeptide and phentolamine mesylate, for the treatment of erectile dysfunction. In clinical trials, more than 80% of patients responded successfully to treatment with Invicorp. Another product, Adrenaject, uses an automatic injector syringe to deliver a self-injectable formulation of epinephrine, an emergency antidote for anaphylactic shock, a life-threatening condition triggered by a severe allergic reaction to insect stings, insect bites and certain foods. Senetek recently entered into a worldwide licensing agreement for its Kinetin product with Shaklee Corporation. Shaklee is a subsidiary of Yamanouchi Pharmaceutical, Japan's thirdlargest pharmaceutical company. In other news, the firm signed a marketing and distribution agreement for Invicorp, their leading erectile dysfunction product. New Zealand-based Douglas Pharmaceuticals will market the product and receive rights of first offer on future Senetek products in development. Senetek also entered into a license agreement with Enprani Co., Ltd. of Korea to market and distribute Kinetin.

BRANDS/DIVISIONS/AFFILIATES: Invicorp Kinetin Allercreme Silver Fox Carmé Cosmeceutical Sciences

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frank J. Massino, CEO Andreas O. Tobler, COO Charles Biama, CFO Corena Michnevich, VP-Human Resources Michael Delmage, Chief Tech. Officer Stewart Slade, Corp. Sec. Stewart Slade, VP-European Oper.

Phone: 707-226-3900 Fax: 707-259-6238 Toll-Free: Address: 620 Airpark Rd., Napa, CA 94558 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $8,085 ( 9 months) 2002 Profits: $1,881 ( 9 months) Stock Ticker: SNTK 2001 Sales: $8,900 2001 Profits: $ 400 Employees: 9 2000 Sales: $3,800 2000 Profits: $-4,700 Fiscal Year Ends: 12/31 1999 Sales: $8,300 1999 Profits: $-11,900 1998 Sales: $4,700 1998 Profits: $-22,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $250,000 Bonus: $50,000 Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: Good revenue base/New focus on products for skincare and for the treatment of sexual dysfunction.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



SEPRACOR INC

www.sepracor.com


Y



Profits: 238


TYPES OF BUSINESS:



Drugs-New and Improved Reformulation of Existing Drugs

Sepracor is a specialty pharmaceutical company with a goal to develop and market improved versions of widelyprescribed drugs. These versions, better known as improved chemical entities, feature enhancements such as reduced side effects, increased therapeutic efficacy and improved dosage forms. The company’s portfolio is concentrated on the allergy, asthma, urology, gastroenterology, psychiatry and neurology markets. As part of a co-promotion agreement with Abbott Laboratories, the firm markets asthma drug Xopenex to hospitals, pulmonologists and allergists. Patients taking Xoponex instead of its racemic albuterol predecessor were shown to have improved lung function. Sepracor is also developing allergy medication norastemizole, which could potentially have longer duration of action than traditional non-sedating antihistamines. Furthermore, the firm is conducting Phase III clinical trials for (S)-Oxybutynin, a version of urinary incontinence drug Ditropan that may reduce side effects; Estorra, a drug expected to treat sleep disorders; and the (R,R)-Formoterol compound, which is found as a long-acting bronchodilator inhalation solution. Sepracor’s expansion has been concentrated on running clinical trials for various drugs under development with the eventual goal of marketing them. Drugs or compounds under Phase II reviews include the anti-depressant (R)Sibtramine Metabolite and (S)-Sibutramine Metabolite which treats sexual dysfunction. Additionally, the firm has recently commenced clinical trials for SEP174559, a treatment for anxiety, as well as (S)-Doxazosin, a compound that has been found to treat benign prostatic hyperplasia. Sepracor offers its employees tuition reimbursement, adoption reimbursement and a comprehensive health plan.

BRANDS/DIVISIONS/AFFILIATES: BioSphere Medical, Inc. Versicor, Inc. HemaSure, Inc. Xopenex Abbott Laboratories (R,R)-Formoterol (S)-Oxybutynin Estorra

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Timothy J. Barberich, CEO William J. O'Shea, COO William J. O'Shea, Pres. David P. Southwell, Exec. VP/CFO Shizuko Yamaji, Dir.-Human Resources Paul D. Rubin, Exec. VP-Drug Dev. and Research David P. Sothwell, Corp. Sec. Douglas E. Reedich, Sr. VP-Legal Affairs & Chief Patent Counsel Robert F. Scumaci, Sr. VP-Finance & Admin. Robert F. Scumaci, Treas. Shizuko Yamaji, Dir.-Corp. Admin.

Phone: 508-481-6700 Fax: 508-357-7499 Toll-Free: Address: 111 Locke Dr., Marlborough, MA 01752 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $160,061 ( 9 months) 2002 Profits: $-232,235 ( 9 months) Stock Ticker: SEPR 2001 Sales: $152,100 2001 Profits: $-224,000 Employees: 930 2000 Sales: $85,200 2000 Profits: $-204,000 Fiscal Year Ends: 12/31 1999 Sales: $22,700 1999 Profits: $-183,000 1998 Sales: $10,200 1998 Profits: $-93,300


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Ability to improve existing drugs.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $127,500 Bonus: $210,000

Northeast: Y

International: Y



SEQUENOM INC

www.sequenom.com




Profits: 32


TYPES OF BUSINESS:

Y Y



Chips-DNA Arrays Genotype Analysis Software

Industrial genomics firm SEQUENOM is the developer of MassARRAY, a DNA analysis platform for the evaluation of single nucleotide polymorphisms (SNPs). An SNP is a genetic variation of a DNA sequence that affects gene functions and frequently causes chronic diseases, such as cancer, diabetes and cardiovascular disease. MassARRAY examines samples of DNA and SNPs and compares them to thousands of other samples to determine the effects of a particular SNP. Used to develop pharmaceuticals and agricultural products, MassARRAY integrates a variety of technology, including mass spectrometry, to measure small molecules, SpectroChips that vaporize biomolecules to prepare them for MassARRAY analysis, BioMass assays that provide analytic information and the SpectroTyper software bioinformatics system that records genotype information. SEQUENOM recently acquired Axiom Biotechnologies, a privately held San Diego-based biotechnology company. Axiom has core competence and proprietary technologies in the fields of functional biology and lead compound optimization. The firm also has a large, well-characterized cell bank of over 100 human cell types representing all major tissues in the human body. This cell line repository can be used for the functional validation of candidate genes and for bioassays in drug discovery. Axiom has internal discovery programs including early-stage compounds in two disease areas. In other news, SEQUENOM launched a high-performance SNP discovery application for its MassARRAY platform. The company is also in the process of developing a high-precision gene expression profiling application for the platform.

BRANDS/DIVISIONS/AFFILIATES: MassARRAY MassEXTEND SpectroCHIP SpectroTYPER SpectroJET Axiom Biotechnologies

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Toni Schuh, CEO Delbert F. Foit, Jr., COO Toni Schuh, Pres. Stephen L. Zaniboni, CFO Kimberly Ellstrom, Human Resources Charles R. Cantor, Chief Scientific Officer Andreas Braun, Chief Medical Officer

Phone: 858-202-9000 Fax: 858-202-9001 Toll-Free: Address: 3595 John Hopkins Ct., San Diego, CA 92121 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $24,683 ( 9 months) 2002 Profits: $-159,378 ( 9 months) Stock Ticker: SQNM 2001 Sales: $30,700 2001 Profits: $-62,600 Employees: 272 2000 Sales: $10,000 2000 Profits: $-32,900 Fiscal Year Ends: 12/31 1999 Sales: $ 200 1999 Profits: $-21,800 1998 Sales: $ 400 1998 Profits: $-10,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $310,000 Bonus: $155,000 Stock Purch. Plan: Y Second Exec. Salary: $281,000 Bonus: $135,000 ADVANTAGE: Expertise in SNP analysis/Major research partnerships/Growing base of significant customers.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast: Y

International: Y



SEROLOGICALS CORP

www.serologicals.com


Y



Y

TYPES OF BUSINESS:

Profits: 1



Y Y


Drugs-Specialty Human Antibody-Based Products Plasma Collection and Sales Clinical Testing Donor Recruitment and Management Services Monoclonal Antibodies Blood Proteins Biological Products

Serologicals is a leading provider of human antibodies and other blood-related products and services. Through its laboratories, the firm develops specialty antibodies aimed at combating diseases, including Rh incompatibility in newborns, rabies and hepatitis. The company also provides donor recruitment and management services, operating a number of donor centers across the U.S., screening donors and collecting products from them. Furthermore, Serologicals manufactures items for diagnostic products, such as monoclonal antibodies and blood proteins from animal serums that are used in blood typing reagents. The company is also working on the development of new products, including a method to isolate gamma globulin from rabbit serum and a manufacturing process for a form of bovine serum albumin. Both gamma globulin and albumin are plasma proteins that are useful to health care services in the treatment of various diseases. Recently, the company announced intentions to acquire the Intergen Company, a supplier of biological products and technologies to the life sciences industry.

BRANDS/DIVISIONS/AFFILIATES: Pentex EX-CYTE Serologicals Proteins, Inc. Serologicals, Ltd. Intergen Company

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David A. Dodd, CEO David A. Dodd, Pres. Harold W. Ingalls, VP-Finance/CFO Timm M. Hurst, VP-Sales & Mktg. Robert P. Collins, VP-Human Resources M. Dwain Wilcox, VP-Info. Systems Thomas H. Trobaugh, VP-Global Commercial Oper. Jeffrey D. Linton, VP-Bus. Dev. and Legal and Public Affairs Sue Sutton-Jones, VP-Worldwide Regulatory Affairs Keith J. Thompson, VP-Diagnostic Oper.

Phone: 678-728-2000 Fax: 678-728-2299 Toll-Free: 800-842-9099 Address: 5655 Spalding Dr., Norcross, GA 30092 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $100,201 ( 9 months) 2002 Profits: $9,771 ( 9 months) Stock Ticker: SERO 2001 Sales: $109,800 2001 Profits: $17,100 Employees: 703 2000 Sales: $147,800 2000 Profits: $12,900 Fiscal Year Ends: 12/31 1999 Sales: $129,700 1999 Profits: $-15,500 1998 Sales: $123,100 1998 Profits: $16,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $346,684 Stock Purch. Plan: Y Second Exec. Salary: $190,000 ADVANTAGE: Unique services for the pharmaceuticals market.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $245,000 Bonus: $95,000

Northeast: Y

International: Y



SHEFFIELD PHARMACEUTICALS

www.sheffieldpharm.com


Y Y



Profits: 113


TYPES OF BUSINESS:



Drugs-Respiratory Pulmonary Drug Delivery Technologies

Sheffield Pharmaceuticals, Inc., a development-stage company, provides innovative, cost-effective pharmaceutical therapies by combining state-of-the-art pulmonary drug delivery technologies with existing and emerging therapeutic agents. The company is developing a range of products to treat respiratory and systemic diseases in its proprietary delivery systems, including the Premaire delivery system and Tempo inhaler. The Premaire system consists of a reusable inhaler unit and Dosators drug cartridges. In addition, Sheffield has licensed the rights to the UPDAS (ultrasonic pulmonary drug absorption system), a novel disposable unit dose nebulizer system, from Elan Corp. The firm has also licensed Elan's Absorption Enhancing Technology, a therapeutic agent, and NanoCrystal dispersion technology, for use in certain inhaled steroid products. Sheffield's business strategy includes continuing to acquire and inlicense pharmaceutical products, primarily in the area of pulmonary drug delivery. In 1999, the firm and Elan Corp. formed a joint venture, Respiratory Steroid Delivery, Ltd., to develop inhaled steroid products for respiratory disease. The joint venture was 80%-owned by Sheffield. In recent news, this joint venture was ended and Sheffield recovered all rights to the Tempo inhaler and Premaire delivery system for systemic applications.

BRANDS/DIVISIONS/AFFILIATES: Premaire Tempo UPDAS Absorption Enhancing Technology NanoCrystal Respiratory Steroid Delivery, Ltd. Dosators NuChem Pharmaceuticals, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas M. Fitzgerald, CEO Thomas M. Fitzgerald, Pres. Scott A. Hoffman, VP-Finance/CFO Thomas A. Armer, Chief Scientific Officer Scott A. Hoffman, VP-Admin. Scott A. Hoffman, Treas. Thomas A. Armer, VP-Pulmonary Delivery Systems

Phone: 314-579-9899 Fax: 314-579-9799 Toll-Free: Address: 14528 S. Outer Forty Rd., Ste. 205, St. Louis , MO 63017 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 100 ( 9 months) 2002 Profits: $-7,613 ( 9 months) Stock Ticker: SHM 2001 Sales: $ 900 2001 Profits: $-9,500 Employees: 16 2000 Sales: $ 400 2000 Profits: $-5,800 Fiscal Year Ends: 12/31 1999 Sales: $ 400 1999 Profits: $-17,400 1998 Sales: $ 400 1998 Profits: $-18,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $207,276 Stock Purch. Plan: Second Exec. Salary: $207,126 ADVANTAGE: Good list of technologies licensed from other firms/Successful trials.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



SHIRE PHARMACEUTICALS PLC

www.shire.com


Y Y



Profits: 34


TYPES OF BUSINESS:



Drugs-Diversified Drug Delivery Technology

Shire Pharmaceuticals is an international specialty pharmaceutical company with a strategic focus on four therapeutic areas: central nervous system disorders, metabolic diseases, cancer and gastrointestinal disorders. The company's strategy is supported by three technology platforms: lead optimization for small molecules, drug delivery and biologics. The firm operates and manages its business primarily in the United States and Europe, but has operations in other areas of the world as well. Shire’s revenues are derived from sales of products by its own sales and marketing operations, licensing fees, development fees and royalties. Sales and marketing operations are principally in the U.S., Canada, the U.K., the Republic of Ireland, France, Germany, Italy and Spain. Shire’s principal products in the U.S. include Adderall XR and Adderall for the treatment of Attention Deficit Hyperactivity Disorder, Agrylin for the treatment of elevated blood platelets; Pentasa for the treatment of ulcerative colitis; Carbatrol for the treatment of epilepsy; and Proamatine for the treatment of postural hypotension. In addition, the company receives royalties on sales of Reminyl for the treatment of Alzheimer's disease, marketed by Johnson & Johnson. The company has a similar marketing agreement with GlaxoSmithKline for the drugs Epivir, Combivir and Trizivir for the treatment of HIV/AIDS, and Epivir-HBV for the treatment of hepatitis B. In the U.K. and the Republic of Ireland, the Calcichew range (used primarily as adjuncts in the treatment of osteoporosis) and Reminyl are co-promoted by JanssenCilag. Products in Canada include 3TC for the treatment of HIV/AIDS, Combivir and Heptovir (all marketed in partnership with GlaxoSmithKline); Amatine; Second Look, a breast cancer diagnostics product for which the company received FDA approval in 2002; and Fluviral S/F, a vaccine for the prevention of influenza. In recent news, Shire announced that it will construct a vaccine research center in Canada to support its biologics business.

BRANDS/DIVISIONS/AFFILIATES: Adderall XR Carbatrol Shire Laboratories Agrylin Pentasa Reminyl Proamatine 3TC

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Rolf Stahel, CEO Angus Russell, Group Finance Dir. Wilson Totten, Group Research and Dev. Dir. Tatjana May, Corp. Sec. Tatjana May, General Counsel Jeff Devlin, Dir.-Corp. Affairs Jack Khattar, Pres./CEO, Shire Laboratories William Nuerge, Pres./CEO, Shire Richwood Mark Webster, Commercial Dir. James Cavanaugh, Chmn. Richard de Souza, Dir.-International

Phone: +44 1256 894000 Fax: +44 1256 894708 Toll-Free: Address: Hampshire International Business Park/Chineham , Basingstoke, Hampshire RG24 8EP UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $753,588 ( 9 months) 2002 Profits: $179,694 ( 9 months) Stock Ticker: SHPGY 2001 Sales: $877,600 2001 Profits: $38,800 Employees: 1,677 2000 Sales: $517,600 2000 Profits: $76,200 Fiscal Year Ends: 12/31 1999 Sales: $401,500 1999 Profits: $-95,000 1998 Sales: $80,300 1998 Profits: $4,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Rapid sales growth/Delivery technologies.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Bonus: $ Bonus: $

Southeast: Y



Northeast: Y

International: Y



SHIRE-BIOCHEM INC www.bioscorpio.com/shire_biochem_inc.htm Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y




TYPES OF BUSINESS:



Drugs-HIV Influenza Vaccine

Shire BioChem, Inc., formerly known as BioChem Pharma, is a Canada-based company that focuses on research, development and commercialization of innovative products for the prevention and treatment of human diseases. Shire BioChem currently engages in researching cancer and infectious diseases such as HIV and influenza. Shire BioChem’s 3TC is the cornerstone of the therapies that are now standard treatments for HIV and AIDS. 3TC is available in more than 100 countries and is marketed in partnership with GlaxcoSmithKline. Combivir, another of the company’s products, is a treatment that combines 3TC with Retrovir in one tablet. Among other products Shire BioChem currently has on the market are PACIS, a treatment for bladder cancer, and Zeffix, an oral treatment for chronic hepatitis B. The firm also markets Fluviral S/F, an influenza vaccine that is required for annual vaccination programs. In recent news, Shire BioChem entered into a research collaboration with Microbiotix, Inc. to develop a lead antibody compound.

BRANDS/DIVISIONS/AFFILIATES: BioChem ImmunoSystems U.S., Inc. 3TC Combivir PACIS Zeffix Fluvial S/F Biochem Pharma

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph Rus, CEO Joseph Rus, Pres.

Phone: 450-978-7800 Fax: 450-978-7755 Toll-Free: Address: 275 Arman-Frappier Blvd., Laval, Quebec H7V4A7 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $216,800 2000 Profits: $199,700 Fiscal Year Ends: 12/31 1999 Sales: $190,700 1999 Profits: $103,100 1998 Sales: $210,600 1998 Profits: $74,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Very high profit margins.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



SICOR INC

www.gensiasicor.com


Y



Y

TYPES OF BUSINESS:

Profits: 27




Drugs-Oncology Bulk Ingredients for Pharmaceuticals Anesthetics

With operations in Europe, the U.S. and Mexico, Sicor is a vertically integrated company that develops, manufactures and markets injectable pharmaceutical products. The company supplies active pharmaceutical ingredients, finished dosage products and contract manufacturing services to various pharmaceutical and biotechnology companies. Sicor's products are primarily designed for the oncology field, but the firm also manufactures pharmaceuticals for anesthesiology, cardiology and critical care. Injectable products include halioperidol (antipsychotic therapy), amikacin sulfate (for serious infections including meningitis), dipyridamole (for coronary heart disease) and cytarabine (for acute non-lymphocytic leukemia). Among the contract manufacturing services offered by the firm are production of bulk materials, formulation development and scale manufacturing of finished dosage forms. Sicor has concentrated its expansion toward securing marketing approval for new drugs. The company recently received ANDA (Abbreviated New Drug Application) approval for a number of drugs that include Haloperidol Luctate, which is expected to treat psychotic disorders; the Mesna Injection, used in the treatment of testicular cancer; the Thiopeta Injection, a compound that combats carcinoma of the breast, ovaries and bladder, as well as numerous lymphomas; and the Levocarnitine Injection, a treatment geared towards patients with innate metabolism defects. In other news, Sicor acquired Biotechna U.A.B., a Lithuanian company that develops proteins.

BRANDS/DIVISIONS/AFFILIATES: Gensia Sicor Pharmaceuticals Metabasis Therapeutics, Inc. Aramed, Inc. Genchem Pharma, Ltd. Rakepoll Holding B.V. Diaspa Lemery Biotechna U.A.B.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Marvin Samson, CEO Frank C. Becker, Exec. VP/COO Marvin Samson, Pres. Jack Stover, CFO/Exec. VP-Finance Linda Welch, Dir.-Human Resources David C. Dreyer, VP/Chief Acc. Officer/Corp. Controller Wesley N. Fach, VP/Sr. Legal Counsel John W. Sayward, Treas. Gianpaolo Colla, Exec. VP-Italian Oper. Armand J. LeBlanc, Sr. VP-Corp. Scientific Affairs Michael D. Cannon, Exec. VP/Pres.-Biotechnology Armand J. LeBlanc, Pres.-Gensia Sicor Pharmaceuticals

Phone: 949-455-4700 Fax: 949-855-8210 Toll-Free: 800-729-9991 Address: 19 Hughes , Irvine, CA 92618 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $337,343 ( 9 months) 2002 Profits: $73,757 ( 9 months) Stock Ticker: SCRI 2001 Sales: $369,800 2001 Profits: $79,300 Employees: 1,982 2000 Sales: $293,800 2000 Profits: $35,600 Fiscal Year Ends: 12/31 1999 Sales: $229,000 1999 Profits: $11,700 1998 Sales: $178,500 1998 Profits: $-18,700


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $379,382 Stock Purch. Plan: Y Second Exec. Salary: $348,628 ADVANTAGE: Expertise in oncology drugs/Expansion efforts via new drug development.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $253,208 Bonus: $215,353

Northeast:

International: Y



SIGA TECHNOLOGIES INC

www.siga.com


Y



Profits: 82


TYPES OF BUSINESS:

Y



Drugs-Strep Throat Vaccine Vaccines for Sexually Transmitted Diseases Vaccines for Cancer Therapy Antibiotics Bio-Defense Products Veterinary Vaccines

SIGA Technologies is a development-stage biotechnology company focused on the discovery, development and commercialization of vaccines, antibiotics and novel antiinfectives for serious infectious diseases. Its lead vaccine candidate is for the prevention of group A streptococcal pharyngitis, or strep throat. The firm is developing a technology for the mucosal delivery of its vaccines, which may allow them to activate the immune system at the mucus -lined surfaces of the body (such as the mouth, nose and lungs), the sites of entry for most infectious agents. SIGA's anti-infectives programs are aimed at the increasingly serious problem of drug resistance; they are designed to block the ability of bacteria to attach to human tissue, the first step in the infection process. The company is developing genetically engineered commensal bacteria (harmless bacteria that naturally inhabit the body's surfaces) as a means to deliver mucosal vaccines. These commensal vaccines candidates use Gram -positive bacteria. Mucosal vaccines can potentially deliver more complete protection that conventional vaccines; a safety advantage; non-injection administration; the potential for combined vaccine delivery; an elimination of the need for refrigeration; and low-cost production. SIGA is also developing vaccines for sexually transmitted diseases, including chlamydia; broad-spectrum antibiotic technology; veterinary vaccines; and a biological defense program. The company has collaborated with organizations including the National Institutes of Health and Wyeth. In recent news, the firm partnered with TransTech Pharma, Inc. to explore small-molecule therapeutics for the treatment of infectious diseases and the neutralization of potential bio-warfare agents.

BRANDS/DIVISIONS/AFFILIATES: SIGA Research Labs SPEX

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas N. Konatich, Acting CEO Thomas N. Konatich, VP/CFO Dennis E. Hruby, VP/Chief Scientific Officer Thomas N. Konatich, Corp. Sec. Thomas N. Konatich, Treas.

Phone: 212-672-9100 Fax: 212-697-3130 Toll-Free: Address: 420 Lexington Ave., Ste. 620, New York, NY 10170 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,144 ( 9 months) 2002 Profits: $-2,293 ( 9 months) Stock Ticker: SIGA 2001 Sales: $1,200 2001 Profits: $-3,700 Employees: 12 2000 Sales: $ 500 2000 Profits: $-7,800 Fiscal Year Ends: 12/31 1999 Sales: $ 500 1999 Profits: $-3,600 1998 Sales: $ 500 1998 Profits: $-6,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Focus on mucosal delivery of drugs.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:




Northeast: Y

International:



SKYEPHARMA PLC

www.skyepharma.com


Y Y



Profits: 135


TYPES OF BUSINESS:



Drugs-Generic Drug Delivery Technologies

SkyePharma, a London-based company, develops controlled-release drug-delivery systems that reduce side effects and allow for fewer daily doses. The company also develops generic and super-generic drugs (drugs that are difficult to replicate or that are improved versions of offpatent originals). The firm makes the drug-delivery systems, generics and new drugs under the SkyePharma name and under contract to other large pharmaceutical companies, including GlaxoSmithKline and Abbott Laboratories. The company’s growth strategy is to continue to make strategic acquisitions and aggressively add new technologies through these acquisitions. SkyePharma’s five platform technologies include oral, topical, inhalation, injectable and enhanced solubility systems. SkyePharma, Inc., a U.S.-based subsidiary of SkyePharma formerly named DepoTech, develops sustained-release therapeutic products based on DepoFoam, an injectable drug-delivery technology. DepoFoam formulations are capable of releasing drugs over a few days or up to several weeks. In recent news, SkyePharma announced a licensing agreement for the topical therapy Solarase with Meditech Research, Ltd. Through this agreement, the company gains rights to market the product in Australia, New Zealand, Singapore and Malaysia.

BRANDS/DIVISIONS/AFFILIATES: SkyePharma, Inc. DepoTech DepoFoam Solarase

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael Ashton, CEO Donald Nicholson, Dir.-Finance Douglas Parkhill, Corp. Sec. Ian Gowrie-Smith, Chmn.

Phone: +44-20-7491-1777 Fax: +44-20-7491-3338 Toll-Free: Address: 105 Piccadilly, London, W1J 7NJ UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $43,741 ( 6 months) 2002 Profits: $-3,230 ( 6 months) Stock Ticker: SKYE 2001 Sales: $67,900 2001 Profits: $-13,900 Employees: 373 2000 Sales: $36,300 2000 Profits: $-29,400 Fiscal Year Ends: 12/31 1999 Sales: $28,700 1999 Profits: $-31,400 1998 Sales: $18,100 1998 Profits: $-36,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: DepoFoam technology.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



SONUS PHARMACEUTICALS

www.sonuspharma.com


Y Y



Y

TYPES OF BUSINESS:

Profits: 55




Contrast Agents Drug Delivery Systems Blood Substitutes

SONUS Pharmaceuticals, Inc. is engaged in developing proprietary ultrasound contrast agents and drug delivery systems for use in the diagnosis and treatment of heart disease, cancer and other debilitating conditions. Ultrasound imaging is a widely used, non-invasive, costeffective technique used to examine soft tissues, internal body organs and blood flow in the body. While contrast agents are widely used in most imaging modalities, ultrasound imaging is currently performed largely without the use of a contrast agent. The company’s main product under development, EchoGen, is a contrast agent designed to be administered to a patient prior to performing ultrasound studies to improve image quality. EchoGen has been approved for usage in the European Union but has failed to get approval in the U.S. thus far. SONUS is in the process of changing its focus to the development of drug delivery and blood substitute products based on technology similar to that used in EchoGen. TOCOSOL is a novel drug delivery technology platform that is broadly applicable to multiple drugs, diseases and dosage forms, including injectable and oral applications. SONUS is using its TOCOSOL emulsion technology to formulate therapeutic drugs that are highly insoluble in water to deliver them with less toxicity and in a more convenient manner to patients. The firm was recently issued two U.S. patents related to its TOCOSOL drug delivery system. S-8184, the firm's first drug delivery product under development, is an injectable paclitaxel emulsion formulation for the treatment of breast, ovarian and lung cancer. In other news, SONUS entered into a manufacturing and supply agreement with Gensia Sicor Pharmaceuticals, Inc. for TOCOSOL Paclitaxel. Gensia Sicor is a subsidiary of SICOR, Inc., a leading pharmaceutical manufacturer. The firm provides its employees with educational assistance as well as reimbursement for health club and professional association dues. SONUS also offers an employee assistance program.

BRANDS/DIVISIONS/AFFILIATES: EchoGen TOCOSOL S-8184 TOCOSOL Paclitaxel

CONTACTS: Note: Officers with more than one job

title may be

intentionally listed here more than once. Michael A. Martino, CEO Michael A. Martino, Pres. Richard J. Klein, CFO Colleen Dentsey, VP-Human Resources Nagesh Palepu, Chief Science Officer Nagesh Palepu, Chief Tech. Officer Richard J. Klein, Controller John T. Flaherty, Sr. VP/Chief Medical Officer Mark Low , VP-Bus. Dev. Pamela Dull, Mgr.-Investor Rel. Gordon Brandt, VP-Medical and Clinical Affairs

Phone: 425-487-9500 Fax: 425-489-0626 Toll-Free: Address: 22026 20th Ave. SE, Bothell, WA 98021 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 25 ( 9 months) 2002 Profits: $-9,227 ( 9 months) Stock Ticker: SNUS 2001 Sales: $8,700 2001 Profits: $ 500 Employees: 34 2000 Sales: $ 400 2000 Profits: $-2,100 Fiscal Year Ends: 12/31 1999 Sales: $12,100 1999 Profits: $ 400 1998 Sales: $5,100 1998 Profits: $-11,200


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $250,000 Stock Purch. Plan: Y Second Exec. Salary: $150,000 ADVANTAGE: Unique delivery system for cancer therapies.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $426,500 Bonus: $194,500

Northeast:

International:



SPECTRAL DIAGNOSTICS INC www.spectraldiagnostics.com Industry Group Code: 325413 Ranks within this company's industry group: Sales: 16 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:



Y

TYPES OF BUSINESS:

Profits: 11




Blood Diagnostic Test Kits

Toronto-based Spectral Diagnostics manufactures blood test kits used by health care professionals to evaluate chest pain. Marketed under the Cardiac Status name, the kits detect proteins that are sloughed off by the heart during a cardiac incident, such as angina. The test kits give results within minutes and help physicians diagnose the cause of pain and determine the severity of the problem in a timely manner. The firm’s Endotoxin Activity Assay (EAA) is a rapid, whole blood test that can be used to identify patients who are at risk for sepsis (infection). With the development of the EAA test as a rapid indicator of endotoxin, physicians are assisted in stratifying patients into those who are at low risk of severe sepsis and those who require directed anti-sepsis and/or anti-infection therapy. Spectral markets the test kits through a joint venture with Princeton BioMeditech. Spectral’s joint venture with Elan, Sepsis, Inc., develops products to diagnose sepsis. Spectral also has a product development alliance with a Sigma-Aldrich subsidiary and a sales agreement with Biovail. The company recently purchased the remaining 30% interest in its joint venture cardiac point-of-care sales and marketing company, CarePoint Cardiac Corp., from Princeton BioMeditech. CarePoint was established in 1993 to market and sell rapid assay cardiac test kits. In other news, Spectral completed the manufacturing scale-up of its expanded Toronto production facility. Additionally, the firm successfully shipped the first lots of the new and improved generation of the Cardiac Status line of rapid cardiac diagnostics products to customers. Furthermore, Spectral entered into a supply agreement with Allegiance Healthcare, under which Allegiance will distribute its rapid diagnostic products.

BRANDS/DIVISIONS/AFFILIATES: Princeton BioMeditech Sepsis, Inc. Endotoxin Activity Assay CarePoint Cardiac Corp. Status Cardiac Status

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul M. Walker, CEO Paul M. Walker, Pres. Rose Papastamos, CFO Joseph H. Keffer, Chief Medical Officer McCarthy Tetrault, Corp. Sec. McCarthy Tetrault, General Counsel David Ray, VP-Bus. Dev.

Phone: 416-626-3233 Fax: 416-626-1798 Toll-Free: 888-426-4264 Address: 135-2 The West Mall, Toronto, Ontario M9C 1C2 Canada

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Foreign 2001 Sales: $7,000 2001 Profits: $-3,400 Employees: 65 2000 Sales: $6,416 2000 Profits: $-4,970 Fiscal Year Ends: 3/31 1999 Sales: $7,000 1999 Profits: $-6,700 1998 Sales: $3,500 1998 Profits: $-9,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Joint venture with Elan.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest: Y

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



SPECTRUM PHARMACEUTICALS www.neotherapeutics.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 221 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Profits: 179


TYPES OF BUSINESS:



Drugs-Neurological and Psychiatric Diseases Cancer Treatments Genomics Research

Spectrum Pharmaceuticals, formerly NeoTherapeutics, Inc., is a development-stage pharmaceutical company engaged in the pharmaceutical business and functional genomics. The firm engages in the discovery and development of novel technology platforms for therapeutic drugs for the treatment of nervous system disorders and cancer. The company conducts its genomics business through subsidiary NeoGene Technologies. Spectrum's drug candidates, in various stages of development, include Neotrofin for Alzheimer's disease, Parkinson's disease, spinal cord injury and peripheral neuropathy; Neoquin for bladder cancer and radiation sensitization; satraplatin for prostate cancer; elsamitrucin for nonHodgkin's lymphoma; NEO-376 and NEO-392 for schizophrenia; and NEO-339 for mild cognitive impairment and attention deficit. Neotrofin is the company's most extensively studied compound and has been the primary focus of its research efforts. In clinical trials, the drug has been shown to reduce, delay and prevent memory deficits; protect brain cells against neurotoxic injury; cause sprouting of nerve cells; cause proliferation of neural stem cells; and cause production of numerous neurotropic factors. NeoGene maintains a collaborative research agreement with the University of California, Irvine, granting it the exclusive rights to future technology developed by the university through its genomics research. Other partners include GPC Biotech, Inc. and JB Chemical and Pharmaceuticals, Ltd. Recently, Spectrum and GPC signed an agreement to co-develop the firm's lead cancer drug, satraplatin, in Phase III clinical trials.

BRANDS/DIVISIONS/AFFILIATES: NeoTherapeutics, Inc. NeoGene Technologies, Inc. NeoOncoRx Neoquin Neotrofin NEO-339 NEO-376 NEO-392

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Rajesh C. Shrotriya, CEO Rajesh C. Shrotriya, Pres. John McManus, VP-Finance Ashok Gore, VP-Pharmaceutical Oper. and Regulatory Compliance John McManus, VP-Strategic Planning Luigi Lenaz, Pres.-Oncology Shanta Chawla, Dir.-Clinical Dev. and Regulatory Affairs Martyn Gunning, Dir.-Licensing and Corp. Dev. Rajesh C. Shrotriya, Chmn.

Phone: 949-788-6700 Fax: 949-788-6706 Toll-Free: Address: 157 Technology Dr., Irvine, CA 92618 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,219 ( 9 months) 2002 Profits: $-13,798 ( 9 months) Stock Ticker: SPPI 2001 Sales: $ 100 2001 Profits: $-27,800 Employees: 79 2000 Sales: $ 200 2000 Profits: $-46,400 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-26,000 1998 Sales: $ 100 1998 Profits: $-11,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $300,000 Stock Purch. Plan: Second Exec. Salary: $260,000 ADVANTAGE: Therapies with the potential to treat multiple major diseases.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



STEMCELLS, INC

www.stemcellsinc.com


Y



Profits: 2


TYPES OF BUSINESS:



Drugs-Neural, Liver and Pancreas Stem Cell Technologies

StemCells, Inc., formerly CytoTherapeutics, Inc., is a leader in the development of new stem cell therapies designed to treat human diseases and disorders. The firm focuses its operations on the discovery, development and commercialization of its proprietary platform stem cell technologies. The firm's stem cell therapies are directed to and based on the transplantation of human stem cells to repair or repopulate damaged or defective neural, pancreatic or liver tissue that has been damaged or lost as a result of disease or injury. StemCells believes that it has achieved a leadership position in the neural stem cell therapy area with its advancements in its research and development program for the isolation, purification and transplantation of neural stem and progenitor cells. The company has also made advancements in its research programs to discover the stem cells of the pancreas and liver and has established a broad intellectual property position with respect to stem and progenitor cell therapies in all three areas, through both its own patented discoveries and exclusive licensing arrangements. StemCells recently initiated a cost reduction program to curtail expenditures on the company's discovery research activities, in favor of channeling resources into accelerating preclinical development of its proprietary cells for the treatment of neural and liver disease. The company will delay further work on the human neural stem cell until it secures funding from a partner. The firm's plan to scale back operations also included a 25% reduction in staff. StemCells provides an incentive program, a progressive culture and a benefits program designed to attract and retain the best employees.

BRANDS/DIVISIONS/AFFILIATES: CytoTherapeutics, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Martin McGlynn, CEO Martin McGlynn, Pres. Larina Slaughter, VP-Human Resources Ann Tsukamoto, VP-Scientific Oper. George Koshy , Controller Iris Brest, General Counsel Eric Lagasse, Dir.-Liver Stem Cell Discovery Nobuko Uchida, Dir.-Neural Stem Cells

Phone: 650-475-3100 Fax: 650-475-3101 Toll-Free: Address: 3155 Porter Dr., Palo Alto, CA 94304-1213 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 326 ( 9 months) 2002 Profits: $-8,593 ( 9 months) Stock Ticker: STEM 2001 Sales: $ 800 2001 Profits: $-3,400 Employees: 33 2000 Sales: $ 100 2000 Profits: $-11,300 Fiscal Year Ends: 12/31 1999 Sales: $5,000 1999 Profits: $-15,700 1998 Sales: $8,800 1998 Profits: $-12,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $264,423 Stock Purch. Plan: Second Exec. Salary: $183,800 ADVANTAGE: Development of stem cell technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $68,750 Bonus: $50,000

Northeast:

International:



SUPERGEN INC

www.supergen.com


Y



Profits: 209


TYPES OF BUSINESS:



Research & Development-Late-Stage Drug Commercialization Oncology Drugs Anticancer Compounds

SuperGen is a pharmaceutical company dedicated to the development and commercialization of products intended to treat life-threatening diseases, particularly cancer. The company possesses a large portfolio of proprietary oncological drugs that treat a variety of solid tumors and hematological malignancies. Nipent is its chemotherapy agent used in the treatment of hairy cell leukemia. Multiple clinical trials are currently ongoing for other disease states. Mitomycin is the firm’s generic brand of the chemotherapy agent Mutamycin. Surface Safe is a patented two-step application kit used to clean and inactivate anti-cancer drugs on chemotherapy work surfaces. The company’s strategy is to identify, acquire and develop pharmaceutical products that are in the later stages of development. This shortens research and development times and costs, making the process of drug commercialization more efficient. SuperGen also licenses or acquires rights to compounds that are normally at the pre-clinical or early clinical stages of development. In a significant development, the firm recently received approval from the FDA to market Mitozytrex , its proprietary version of the generic drug Mitomycin. The drug may be used in the therapy of disseminated adenocarcinoma of the stomach or pancreas, in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitozytrex becomes the first approved drug based on SuperGen’s patented supergenerics Extra technology platform. The firm provides employees with benefits such as dental and vision coverage, incentive stock options and transportation assistance in the form of a complimentary shuttle between Dublin/Pleasanton Bart and its corporate offices.

BRANDS/DIVISIONS/AFFILIATES: Nipent Rubitecan Cisplatin Extra Dauno Extra Lucanthone Etoposide Extra Mito Extra Mitozytrex

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph Rubinfeld, CEO Joseph Rubinfeld, Pres. Edward Jacobs , CFO Tipp Nelson, VP-Mktg. Christina Wang, Mgr.-Human Resources Craig S. Rosenfeld, Chief Scientific Officer Sam Jason, Controller Karl Mettinger, Sr. VP-Medical Affairs Edward L. Jacobs, Exec. VP-Commercial Oper. Timothy L. Enns, VP-Bus. Dev. Timothy L. Enns, VP-Investor Rel. R. David Lauper, VP-Professional Services Frederick Grab, VP-Compliance Simeon Wrenn, VP-Biotech. Audrey F. Jakubowski, VP-Regulatory Affairs

Phone: 925-560-0100 Fax: 925-560-0101 Toll-Free: Address: 4140 Dublin Blvd., Ste. 200, Dublin, CA 94568 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $8,446 ( 9 months) 2002 Profits: $-43,138 ( 9 months) Stock Ticker: SUPG 2001 Sales: $11,500 2001 Profits: $-55,600 Employees: 115 2000 Sales: $7,100 2000 Profits: $-35,300 Fiscal Year Ends: 12/31 1999 Sales: $4,700 1999 Profits: $-37,000 1998 Sales: $3,000 1998 Profits: $-15,600


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $530,000 Stock Purch. Plan: Second Exec. Salary: $260,000 ADVANTAGE: Continuing success of clinical trials of anticancer drugs.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $466,000 Bonus: $42,300

Northeast:

International:



SYNAPTIC PHARMACEUTICAL

www.synapticcorp.com


Y



Profits: 159


TYPES OF BUSINESS:



Drugs-Human Receptor-Targeted

Synaptic Pharmaceutical Corporation is a leader in the development of pharmaceuticals that target G proteincoupled receptors. These chemicals achieve superior efficacy and safety in the treatment of disorders such as depression, anxiety, diabetes, obesity, pain and incontinence. The firm has developed an innovative human receptor-targeted drug design technology, which involves the use of cloned human receptors as targets for the design of potential drugs. Synaptic’s SNAP Discovery platform identifies the physiological function of receptors, which assists in focusing on receptor targets most likely to produce commercially viable drugs. SNAP Discovery first identifies the specific natural chemical, or ligand, with which a receptor preferentially interacts. Identifying the natural ligand for the receptor provides a wealth of pharmacological insights that help determine whether a given receptor will be a valuable drug discovery target. Accordingly, as part of its operating strategy, the firm has numerous existing licenses and research and development alliances with firms including Grünenthal and Kissei, Novartis, Glaxo, Eli Lilly, Johnson & Johnson, Procter & Gamble and Ranbaxy. These alliances minimize the risks associated with drug development, in addition to generating milestone and royalty payments to the firm. In a significant development, Synaptic recently agreed to be acquired by H. Lundbeck A/S, based in Denmark. H. Lundbeck is an international pharmaceutical company engaged in the research, development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders.

BRANDS/DIVISIONS/AFFILIATES: SNAP Discovery H. Lundbeck A/S

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Errol De Souza, CEO Errol De Souza, Pres. Edmund M. Caviasco, CFO Theresa A. Branchek, VP-Research Edmund M. Caviasco, Controller Richard L. Weinshank, VP-Bus. Dev. Thomas P. Blackburn, VP-Drug Dev. Oper.

Phone: 201-261-1331 Fax: 201-261-0623 Toll-Free: Address: 215 College Rd., Paramus , NJ 07652-1410 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,733 ( 9 months) 2002 Profits: $-22,625 ( 9 months) Stock Ticker: SNAP 2001 Sales: $1,400 2001 Profits: $-21,800 Employees: 101 2000 Sales: $3,800 2000 Profits: $-13,900 Fiscal Year Ends: 12/31 1999 Sales: $1,900 1999 Profits: $-15,100 1998 Sales: $9,400 1998 Profits: $-6,500


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $300,000 Stock Purch. Plan: Second Exec. Salary: $220,000 ADVANTAGE: Innovative biotechnical drug design technology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $150,000 Bonus: $70,000

Northeast: Y

International:



SYNBIOTICS CORP

www.synbiotics.com


Y



Y

TYPES OF BUSINESS:

Profits: 8




Supplies-Animal Health Care Diagnostic Test Kits Internet Portal for Veterinarians Animal Health Vaccines

Synbiotics Corp. is a global company dedicated to delivering innovative animal health products and services to the veterinary market. The firm has evolved from a research and development company to a developer, manufacturer and marketer of veterinary diagnostics, vaccines and other animal health-related products worldwide since its creation in 1982. Synbiotics has discontinued its Internet and chemical analyzer businesses. The firm is the sole provider of the SCA2000, an innovative, patient-side instrument used to measure veterinary blood coagulation factors. The firm’s business strategy in animal health is to grow from its established position in the market through new products and technologies, expanded distribution, enhanced marketing, aquisitions and licensing. Synbiotics plans to combine its ability to generate products through acquisitions, licensing agreements, research and development with its ability to distribute products through established worldwide marketing channels. The company’s CEO and CFO recently resigned unexpectedly to pursue other interests. The firm has operations is San Diego, California and Lyon, France.

BRANDS/DIVISIONS/AFFILIATES: International Canine Genetics Rhone Merieux Diagnostics Prisma Systems SCA2000 Kirkegaard & Perry Laboratories W3Commerce, LLC Capsule Report (The) Witness Ehrlichia

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Keith Butler, CFO Bob Buchanan, VP-Mktg. and Sales Serge Leterme, VP-Research and Dev. Clifford Frank, Dir.-Oper. Gregory A. Soulds , Dir.-Bus. Dev. Francois Guillemin, V P-Animal Health/Pres., Synbiotics Europe

Phone: 858-451-3771 Fax: 858-451-5719 Toll-Free: Address: 11011 Via Frontera, San Diego, CA 92127 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $17,195 ( 9 months) 2002 Profits: $-10,766 ( 9 months) Stock Ticker: SBIO 2001 Sales: $27,500 2001 Profits: $ 400 Employees: 138 2000 Sales: $31,300 2000 Profits: $-18,500 Fiscal Year Ends: 12/31 1999 Sales: $30,800 1999 Profits: $-1,400 1998 Sales: $31,700 1998 Profits: $-1,900


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $227,148 Bonus: $18,750 Stock Purch. Plan: Second Exec. Salary: $185,124 Bonus: $ ADVANTAGE: Sole provider of the SCA2000, a veterinary instrument that measures blood coagulation factors.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Southeast:



Northeast: Y

International: Y



SYNGENTA AG

www.syngenta.com



Y


Profits: 1


TYPES OF BUSINESS:



Agrochemicals Crop Protection Products Field Crop Seeds Vegetable Seeds Flowers

Syngenta AG is the result of the merger and spin-off of the Novartis Agribusiness and Zeneca Agrochemicals units of AstraZeneca and Novartis. Syngenta manufactures a variety of agricultural chemicals including insecticides, herbicides, fungicides, field crop seeds, vegetable seeds and flowers. The global company’s research and manufacturing facilities are located in more than 50 countries worldwide. Products currently in development include cotton and rice herbicides, cornfield crops, bananas, wheat, tomatoes, lettuce, melons and cucumbers. Its leading marketed products include Dual Gold, Bicept II Magnum, Acanto, Score, Amistar, Actara, and Proclaim. Syngenta is involved in research and development collaborations with several universities and companies, including Myraid Genetics, Inc., Maxygen, Inc., Incyte Pharmaceuticals, Inc., the University of California and Wageningen Agricultural University. The University of Basel and Syngenta AG recently successfully sequenced a genetic map of a plant fungus that had never before been analyzed. In other news, Syngenta announced a collaboration with Diversa Corporation to establish a research platform and to discover products.

BRANDS/DIVISIONS/AFFILIATES: Novartis AstraZeneca Dual Gold Bicept II Magnum Acanto Proclaim Score Amistar

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael Patrick Pragnell, CEO John Atkin, COO-Crop Protection Richard Steiblin, CFO John Elias, Human Resources David Lawrence, VP-Research and Tech. Christoph Mader, VP-Legal and Taxes Bruce Bissell, VP-Chemical Oper. & Global Supply David Jones, VP-Planning & Bus. Dev. Jeffrey Beard, COO-Seeds Heinz Imhof, Chmn.

Phone: +41-61-697-1111 Fax: +41-61-323-2424 Toll-Free: Address: Schwarzwaldalle 215, Basel, 4058 Switzerland

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: SYT 2001 Sales: $6,323,000 2001 Profits: $223,000 Employees: 22,791 2000 Sales: $4,876 2000 Profits: $180,000 Fiscal Year Ends: 12/31 1999 Sales: $4,678 1999 Profits: $64,000 1998 Sales: $5,040 1998 Profits: $169,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Ex ec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Worldwide presence/Products already FDA -approved or soon to be.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Bonus: $ Bonus: $

Southeast: Y



Northeast: Y

International: Y



SYNOVIS LIFE TECHNOLOGIES INC

www.biovascular.com




Y

TYPES OF BUSINESS:

Profits: 13



Y


Supplies-Surgery Implantable Biomaterials Grafts Custom Engineering Contract Manufacturing Subassemblies for Medical OEMs

Synovis Life Technologies, Inc., formerly Bio Vascular, Inc., develops, manufactures and markets branded proprietary and patented specialty medical products for use in thoracic, cardiac, neuro, vascular and ophthalmic surgery. The company operates in two business segments: the branded device unit and the contract manufacturing and custom engineering unit. The branded device unit develops implantable biomaterials, and the contract manufacturing and custom engineering unit specializes in custom designed, complex micro-precision wire forms. The company's branded products include the Tissue-Guard product line, the Biograft peripheral vascular graft and surgical productivity tools used in cardiac and vascular surgery. Tissue-Guard products are made from bovine pericardium (the membrane surrounding the hearts of cattle), which is processed using the company's tissuefixation technology. These products, made in various configurations, are used in a wide variety of surgical procedures and are designed to reinforce, reconstruct and repair tissue and prevent leaks of air, blood and other body fluids. The company recently received a patent for its Veritas Collagen Matrix. Veritas provides scaffolding upon which the body lays down its own cells and develops a blood supply in the new tissue. The company's Veritas urethral sling, an implanted device for the treatment of stress urinary incontinence, is its first remodelable biomaterial product. Synovis’s wholly-owned subsidiary, Synovis Interventional Solutions, is a value-added original equipment manufacturer of micro-precision wire-based component products, including precision coils, stylets and guide wire components and subassemblies used in the medical industry. Synovis Life Technologies also owns Micro Companies Alliance, Inc.

BRANDS/DIVISIONS/AFFILIATES: Tissue-Guard Jer-Neen Manufacturing Biograft Bio Vascular, Inc. Veritas Collagen Matrix Synovis Interventional Solutions Micro Companies Alliance, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Karen Gilles Larson, CEO Karen Gilles Larson, Pres. Connie L. Magnuson, CFO/VP-Finance David Buche, VP-Mktg. & Sales Gail Kaleta, VP- Human Resources B. Nicholas Oray, VP-Research and Dev. Karen Gilles Larson, Corp. Sec. Evan Johnston, VP-Oper. James F. Pfau, Pres., Jer-Neen Mfg. Fariborz Boor, COO, Synovis Interventional Solutions

Phone: 651-603-3700 Fax: 651-642-9018 Toll-Free: Address: 2575 University Ave., St. Paul, MN 55114 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $28,192 ( 9 months) 2002 Profits: $2,163 ( 9 months) Stock Ticker: SYNO 2001 Sales: $28,500 2001 Profits: $1,800 Employees: 236 2000 Sales: $21,926 2000 Profits: $ 589 Fiscal Year Ends: 10/31 1999 Sales: $18,904 1999 Profits: $- 520 1998 Sales: $12,017 1998 Profits: $- 483


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $227,885 Bonus: $40,000 Stock Purch. Plan: Second Exec. Salary: $140,000 Bonus: $21,800 ADVANTAGE: Large number of branded products for use in a wide variety of surgical procedures.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:



Northeast:

International:



TANOX INC

www.tanox.com


Y



Profits: 158


TYPES OF BUSINESS:



Drugs-Immunologic and Infectious Disease Monoclonal Antibodies Asthma and Allergy Treatments

Houston, Texas-based Tanox, Inc. identifies and develops therapeutic monoclonal antibodies to address significant unmet medical needs in the areas of asthma, allergies, autoimmune disorders, inflammation and other related diseases. Its products are based on genetically engineered antibodies than target a specific substance or antigen. The firm's most clinically advanced product is Xolair, a humanized monoclonal antibody that blocks IgE, a causative agent in the allergy pathway, thus preventing the onset of allergy and asthma symptoms. Tanox is developing Xolair in collaboration with Novartis Pharma and Genentech, Inc. In addition, the firm is developing a diverse pipeline of monoclonal antibody product candidates, with clinical trials in progress for three antibodies. TNX-901, an anti-IgE antibody distinct from Xolair, is in Phase II trials for patients with severe peanut allergies. TNX-100 is in a Phase I trial for the treatment of Crohn's disease. TNX-355 is in Phase I trials for HIV. Tanox is also conducting research and preclinical studies with TNX-224, an antibody for treating acute inflammatory indications. Tanox also has a European subsidiary, Tanox Pharma, B.V. In recent news, the FDA granted the company fast-track status for its TNX-901 for peanut allergies.

BRANDS/DIVISIONS/AFFILIATES: Tanox Pharma TNX-901 TNX-100 TNX-355 Xolair TNX-224

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Nancy T. Chang, CEO Nancy T. Chang, Pres. Gary M. Glandon, VP-Human Resources Matthew Moyle, VP-Research William R. Shanahan, Chief Medical Officer Seenu V. Srinivasan, VP-Mfg. Oper. Katie-Pat Bowman, VP/Corp. Sec. Katie-Pat Bowman, General Counsel

Phone: 713-578-4000 Fax: 713-578-5002 Toll-Free: Address: 4888 Loop Central Dr., Ste. 820, Houston, TX 770812225 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 409 ( 9 months) 2002 Profits: $-18,692 ( 9 months) Stock Ticker: TNOX 2001 Sales: $ 400 2001 Profits: $-21,400 Employees: 114 2000 Sales: $12,700 2000 Profits: $-1,000 Fiscal Year Ends: 12/31 1999 Sales: $1,400 1999 Profits: $-23,300 1998 Sales: $2,400 1998 Profits: $-10,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $391,250 Stock Purch. Plan: Y Second Exec. Salary: $270,000 ADVANTAGE: Drug development expertise in immunology, infectious disease and cardiology.

OTHER THOUGHTS:



West:

Southwest: Y

Midwest:

Southeast:



Bonus: $44,016 Bonus: $27,540

Northeast:

International: Y



TARGETED GENETICS CORP

www.targetedgenetics.com


Y



Profits: 177


TYPES OF BUSINESS:



Drugs-Acquired and Inherited Disease Cell Therapy Products

Targeted Genetics Corp. (TGC) develops gene therapy products and technologies for treating both acquired and inherited diseases. The firm’s gene therapy product candidates are designed to treat disease by regulating cellular function at a genetic level. This involves inserting genes into target cells and activating the inserted gene in a manner that provides the desired effect. TGC has assembled a broad base of proprietary intellectual property, giving it the potential to address the significant diseases on which it focuses its business. The company has also established expertise and development capabilities in the areas of pre-clinical research and biology, manufacturing process scale-up, quality control and assurance, regulatory affairs and clinical trial design and implementation. Gene therapy products involve the use of delivery vehicles, called vectors. TGC’s vector technologies include viral vectors and synthetic vectors. Viral vectors use modified viruses to deliver genes into cells, focusing primarily on adeno-associated virus, or AAV. The firm’s synthetic vectors deliver genes using lipids, allowing repeated, efficient delivery of therapeutic genes into rapidly dividing cells, such as certain types of tumor cells. The company’s two lead products in development are one for treating cystic fibrosis and another for treating cancer. Other product candidates include treatments for hemophilia, arthritis and lysosomal storage disorders, as well as a vaccine for the prevention of AIDS. TCG recently established a sponsored research agreement with Dr. Daniel Rader of the University of Pennsylvania to advance its dyslipidemia research. In other news, one of the company’s academic collaborators has announced data supporting the use of AAV vectors in AIDS vaccine development.

BRANDS/DIVISIONS/AFFILIATES: Elan Corp. Emerald Gene Systems Genovo Biogen, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. H. Stewart Parker, CEO H. Stewart Parker, Pres. Todd Simpson, CFO/VP- Finance Geoffrey Roach, Dir.-Human Resources Barrie J. Carter, Exec. VP/Chief Scientific Officer Thomas C. Reynolds, VP-Clinical Affairs Todd Simpson, VP-Admin. Todd Simpson, Treas.

Phone: 206-623-7612 Fax: 206-223-0288 Toll-Free: Address: 1100 Olive Way, Ste. 100, Seattle, WA 98101 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $14,785 ( 9 months) 2002 Profits: $-17,677 ( 9 months) Stock Ticker: TGEN 2001 Sales: $18,900 2001 Profits: $-27,200 Employees: 173 2000 Sales: $11,400 2000 Profits: $-47,700 Fiscal Year Ends: 12/31 1999 Sales: $6,800 1999 Profits: $-26,700 1998 Sales: $7,500 1998 Profits: $-8,700


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $350,000 Stock Purch. Plan: Y Second Exec. Salary: $233,000 ADVANTAGE: Capitalizes on basic research discoveries.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $88,200 Bonus: $34,000

Northeast:

International:



TARO PHARMACEUTICAL INDUSTRIES www.taropharma.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 47 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y Y



Profits: 38


TYPES OF BUSINESS:



Drugs-Generic and Proprietary Over-the-Counter Analgesics Vitamins Anti-Cancer Drugs Dermatological Drugs

Taro Pharmaceutical Industries is a multinational sciencebased pharmaceutical company that discovers , develops, manufactures and markets a wide range of health care products, from over-the-counter analgesics to vitamins. The firm’s prescription and over-the-counter medications are mainly used in dermatology, cardiology and neurology, in addition to covering a broad array of indications, from the common cold to cancer. Taro produces more than 200 pharmaceutical products, including topical preparations (creams, ointments, gels, solutions), oral medications (tablets, capsules, powders, liquids) and sterile products (injectables, ophthalmic drops, powders). In recent news, the company received FDA approval for its Ketoconazole Cream 2%, which is bioequivalent to Nizoral Cream. Nizoral, a product of Janssen Pharmaceutica Products, is a prescription product used primarily for the treatment of fungal infections of the skin. Additionally, Taro received approval from the FDA for Econazole Nitrate Cream 1%, a bioequivalent to Ortho Dermatological’s Spectazole Cream. This prescription pharmaceutical is mainly used to treat fungal infections of the skin. Taro was granted the first U.S. approval to manufacture and market a generic equivalent to Spectazole. In other news, Taro filed a new patent application for the use of T2000 as a treatment for essential tremor. T2000 si Taro’s patented, long-acting, non-sedating barbiturate compound. The new patent application was based upon an early Phase II study in patients with essential tremor, whose dysfunction appeared to lessen after taking a short-term course of treatment with T2000. The firm’s U.S. subsidiary, Taro Pharmaceuticals U.S.A., Inc., recently purchased a onethird interest in a building to house its U.S. research and development operations. After renovations, Taro USA will be located in Hawthorne, New York. Taro also recently reported its 27th consecutive quarter of record sales and its 17th consecutive quarter of record net income.

BRANDS/DIVISIONS/AFFILIATES: Taro Pharmaceuticals U.S.A., Inc. Econazole Nitrate Cream 1% Ketoconazole Cream 2% Clobetasol E NonSpil T2000

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Samuel Rubinstein, COO Aaron Levitt, Pres. Kevin Connelly, Sr. VP/CFO Zahava Rafalowicz, VP-Mktg. & Sales Puah Dekel, Dir.-Human Resources Avraham Yacobi, Sr. VP-Research and Dev. Tzvi Tal, VP-IT Mariana Bacalu, VP-Quality Assurance Ilan Ben Cnaan, VP-Oper. Sabar Sasson, VP-Strategy Daniel Saks, VP-Corp. Affairs Yohanan Dichter, VP-Pharmacist Samuel Rubinstein, Sr. VP Roman Kaplan, VP-Tech. Oper. Zalmin Lempert, VP-Regulatory Affairs

Phone: +972-9-971-1800 Fax: +972-9-955-7443 Toll-Free: Address: 14 Hakitor St., Haifa Bay, 26110 Israel

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $149,605 ( 9 months) 2002 Profits: $31,630 ( 9 months) Stock Ticker: TARO 2001 Sales: $150,100 2001 Profits: $26,000 Employees: 750 2000 Sales: $103,800 2000 Profits: $10,000 Fiscal Year Ends: 12/31 1999 Sales: $83,800 1999 Profits: $5,500 1998 Sales: $66,700 1998 Profits: $2,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Multinational company with a wide range of products.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



TECHNE CORP

www.techne-corp.com




Y Y

TYPES OF BUSINESS:

Profits: 6



Y


Supplies-Cytokines, Antibodies and Assay Kits Biotechnology Products Hematology Products Biotechnology Products Distribution Cytokine Testing Service

Techne Corp. is a holding company that operates via two subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) and R&D Systems Europe, Ltd. R&D Systems is a specialty manufacturer of biological products. Its two major operating segments are hematology controls, which are utilized in clinical and hospital laboratories to monitor the accuracy of blood analysis instruments, and biotechnology products, including purified proteins and antibodies that are sold exclusively to the research market. The firm’s biotechnology division was formed in response to a growing need for highly purified biologically active proteins. R&D Europe also distributes biotechnology products and has a German sales subsidiary, R & D Systems GmbH. The company acquired Genzyme Corp.’s research products business and, as a result, became the world’s leading supplier of research and diagnostic cytokine products. The growing interest by researchers in cytokines exists because of the profound effect a tiny amount of a cytokine can have on the cells and tissues of the body. Moreover, the firm recently made equity investments in the preferred stock of ChemoCentryx, Inc., a new technology and drug development company. In addition, the firm has joined in a partnership with Discovery Genomics, a company focused on the discovery of drug targets. Discovery Genomics will apply Techne's Morphanta and Sleeping Beauty Transposona technologies to uncover functions of particular genes in zebrafish. In turn, Techne will be allowed to develop antibodies and immunoassays for proteins that are discovered by its partner.

BRANDS/DIVISIONS/AFFILIATES: Research and Diagnostic Systems, Inc. R&D Systems, Europe Ltd. Sleeping Beauty Transposona Techne Export, Inc. Genzyme ChemoCentryx, Inc. Discovery Genomics, Inc. Morphanta

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas E. Oland, CEO Thomas E. Oland, Pres. Lea Simoane, Dir.-Human Resources Monica Tsang, VP-Research Kathy Backes , Controller Timothy M. Heaney, Corp. Sec. Timothy M. Heaney, General Counsel Thomas E. Oland, Treas. James A. Weatherbee, VP-Chief Scientific Officer Thomas C. Detwiler, VP-Scientific and Regulatory Affairs Marcel Veronneau, VP-Hematology Oper.

Phone: 612-379-8854 Fax: 612-379-6580 Toll-Free: 800-343-7475 Address: 614 McKinley pl. N.E., Minneapolis , MN 55413-2610 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $130,900 (12 months) 2002 Profits: $27,100 (12 months) Stock Ticker: TECH 2001 Sales: $115,400 2001 Profits: $34,000 Employees: 494 2000 Sales: $103,800 2000 Profits: $26,600 Fiscal Year Ends: 6/30 1999 Sales: $90,900 1999 Profits: $16,700 1998 Sales: $67,300 1998 Profits: $15,200


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Y Stock Purch. Plan: ADVANTAGE: Rapid growth potential.

OTHER THOUGHTS:




West:

Southwest:

Midwest: Y

Southeast:



Bonus: $39,820 Bonus: $36,830

Northeast:

International: Y



TELIK INC

www.telik.com


Y



Profits: 151


TYPES OF BUSINESS:



Drugs-Cancer and Diabetes Small-Molecule Drugs

Telik, formerly Terrapin Technologies, is a biopharmaceutical company engaged in the discovery and development of small-molecule pharmaceuticals, mainly for the treatment of diabetes and certain cancers. The company’s proprietary TRAP chemoinformatics technology is used for the rapid identification of promising chemical leads for development. TRAP has the ability to select a small sample from its large compound library and effectively identify small, biologically active molecules. At the moment, the firm has three programs to develop novel biopharmaceutical compounds, including TLK286 for chemotherapy-resistant solid tumors, TLK199 for chemotherapy-induced neutropenia and TLK17411 for Type II diabetes. TLK286, its most advanced drug development candidate, is a novel tumor-activated compound that is currently in Phase II clinical trials for ovarian, non-small cell lung, colorectal and breast cancer. Academic institutions, pharmaceutical and biotechnology companies that Telik has partnered with include Sanwa Kagaku Kenkyusho Co., Ltd., the University of Arizona Cancer Center, the University of California, San Francisco and the Fox Chase Cancer Center. In recent news, the firm initiated two new clinical trials of TLK286 in patients with ovarian cancer.

BRANDS/DIVISIONS/AFFILIATES: Terrapin Technolgies TRAP Technology TLK286 TLK199 TLK17411

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michael M. Wick, CEO Cynthia M. Butitta, COO Michael M. Wick, Pres. Cynthia M. Butitta, CFO Donna Myers, VP-Human Resources David Henner, VP-Clinical Research and Dev. Gail L. Brown, Chief Medical Officer Jay P. Shepard, Sr. VP-Commercial Oper. Marc L. Steuer, Sr. VP-Bus. Dev. Reinaldo F. Gomez, Sr. VP-Product Dev. James G. Keck, VP-Biology Research Robert T. Lum, VP- Preclinical Dev. Steven R. Schow , VP-Chemistry Research

Phone: 650-244-9303 Fax: 650-244-9388 Toll-Free: Address: 750 Gateway Blvd., South San Francisco, CA 94080 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,037 ( 9 months) 2002 Profits: $-22,149 ( 9 months) Stock Ticker: TELK 2001 Sales: $1,900 2001 Profits: $-18,600 Employees: 58 2000 Sales: $2,800 2000 Profits: $-12,600 Fiscal Year Ends: 12/31 1999 Sales: $4,200 1999 Profits: $-7,100 1998 Sales: $3,200 1998 Profits: $-6,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Stock Purch. Plan: Y Second Exec. Salary: $232,387 ADVANTAGE: Proprietary TRAP chemoinformatics technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $100,000 Bonus: $68,750

Northeast:

International:



TEVA PHARMACEUTICAL INDUSTRIES www.tevapharm.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 14 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Y

TYPES OF BUSINESS:

Profits: 13




Drugs-Generic Chemicals Veterinary Products Medical Disposables

Israeli-based Teva Pharmaceutical manufactures generic versions of brand-name drugs, including anti-infectives, heart medication, pain medication and many other drugs. Teva also sells drug ingredients and chemicals, veterinary products and medical disposables. The company was founded in 1901 in Jerusalem and has grown to become one of the top 50 pharmaceutical companies in the world, as well as one of the largest generic pharmaceutical companies in the world. Teva has manufacturing facilities all over the world. One of Teva’s successful pharmaceuticals, Copaxone, is used for the treatment of multiple sclerosis and is currently marketed and sold in countries including the U.S., Canada, Switzerland, Argentina, Israel and Australia to name a few. Teva produces generic drugs in all major therapeutics and steriles in a variety of dosage forms, from tablets and capsules to ointments, creams and liquids. In addition, Teva manufactures innovative drugs in niche markets where it has a relative advantage in research and development. The firm also produces active pharmaceutical ingredients, which are the vital raw materials of the drug manufacturing industry. In addition to supplying some of Teva's own needs, this division is an active competitor in world markets, investing both in the development of new products and manufacturing processes and in the upgrading of production facilities. It also provides an essential link in Teva's strategic marketing chain. In recent news, the FDA approved the company’s ANDA for Amoxicillin for Oral Suspension. Amoxicillin for Oral Suspension is the AB-rated generic equivalent of GlaxoSmithKline’s broad spectrum antibiotic AmoxilÒ for Oral Suspension. Teva also received FDA approval for ANDA for Pergolide Mesylate Tablets, which are the AB-rated generic equivalent of Eli Lilly and Company’s Permax Tablets used in the management of the signs and symptoms of Parkinson’s Disease.

BRANDS/DIVISIONS/AFFILIATES: Copley Pharmaceuticals Teva USA Copaxone Pergolide Mesylate Tablets Amoxicillin for Oral Suspension

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Israel Makov, CEO Israel Makov, Pres. Dan S. Suesskind, CFO Aharon Agmon, VP-Int'l Sales Haim Benjamini, VP-Human Resources Ben Zion Weiner, VP-Research and Dev. Rodney Kasan, VP-Global Product Dev. Uzi Karniel, Corp. Sec. Uzi Karniel, General Counsel Moshe Manor, VP-Strategic Planning William A. Fletcher, Pres., Teva North America Chaim Hurvitz, VP-Israel Pharmaceuticals Meron Mann, VP-Chemicals Aaron Schwartz , VP-Global Product Mktg.

Phone: +972-3-926-7267 Fax: +972-3-923-4050 Toll-Free: Address: 5 Basel St., PO Box 3190, Petach Tikva, 49131 Israel

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,748,400 ( 9 months) 2002 Profits: $273,800 ( 9 months) Stock Ticker: TEVA 2001 Sales: $2,077,400 2001 Profits: $278,200 Employees: 8,982 2000 Sales: $1,749,000 2000 Profits: $46,858 Fiscal Year Ends: 12/31 1999 Sales: $1,282,400 1999 Profits: $117,800 1998 Sales: $1,115,900 1998 Profits: $70,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Manufacturing facilities and distribution worldwide.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



TEXAS BIOTECHNOLOGY CORP

www.tbc.com


Y



Profits: 153


TYPES OF BUSINESS:



Drugs-Vascular Disease Drugs-Small Molecule

Texas Biotechnology Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of a variety of conditions and serious diseases, including thrombosis (abnormal blood clotting), pulmonary hypertension, chronic heart failure, systemic hypertension, asthma and rheumatoid arthritis. The company uses computer-aided small-molecule drug design to create inhibitors of thrombosis, endothelin, cell adhesion, growth factors and apoptosis. Argatroban, the firm’s first approved product, is a direct thrombin inhibitor that selectively binds to and inactivates thrombin in blood plasma. The product is a synthetic small molecule that offers advantages over other market offerings, such as efficacy and safety. MitsubishiTokyo Pharmaceuticals, Inc. markets Argatroban in Japan, where the product is approved as a treatment for ischemic stroke, peripheral arterial occlusion and hemodialysis in patients with anti-thrombin III deficiency, which is a clotting disorder that does not respond to heparin. As a result of the Japanese experience with Argatroban as a treatment for stroke, Texas Biotechnology is conducting preclinical tests to investigate the use of Argatroban in ischemic stroke in the U.S. In addition, the company formed an alliance with drug developer ICOS Corporation to research hypertension and heart failure. In recent news, Texas Biotechnology completed trials that demonstrate the potential of Sitaxsentan for use as daily oral therapy for pulmonary arterial hypertension.

BRANDS/DIVISIONS/AFFILIATES: Argatroban Sitaxsentan

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bruce D. Given, CEO Bruce D. Given, Pres. Stephen L. Mueller, VP-Finance Duane Clark, VP- Mktg. and Sales Pam Mabry, Dir.-Human Resources Richard A.F. Dixon, Sr. VP-Research/Chief Scientific Officer Philip Brown, VP-Clinical Dev. Stephen L. Mueller, VP-Admin. Joseph M. Welch, VP-Bus. Dev. Pamela M. Murphy, VP-Corp. Comm. Stephen L. Mueller, Treas. John M. Pietruski, Chairman Tom Brock, VP-Pharmacology Heather Giles, VP-Strategic Planning

Phone: 713-796-8822 Fax: 713-796-8232 Toll-Free: Address: 7000 Fannin St., Ste. 1920, Houston, TX 77030 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $7,624 ( 9 months) 2002 Profits: $-18,811 ( 9 months) Stock Ticker: TXBI 2001 Sales: $8,900 2001 Profits: $-19,100 Employees: 110 2000 Sales: $15,500 2000 Profits: $-5,700 Fiscal Year Ends: 12/31 1999 Sales: $2,100 1999 Profits: $-15,300 1998 Sales: $2,300 1998 Profits: $-14,500


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $318,387 Stock Purch. Plan: Second Exec. Salary: $263,504 ADVANTAGE: Recent FDA approval of Argatroban/Diversified partnerships.

OTHER THOUGHTS:



West:

Southwest: Y

Midwest:

Southeast:



Bonus: $61,182 Bonus: $33,883

Northeast:

International:



THERAGENICS CORP

www.theragenics.com




Y

TYPES OF BUSINESS:

Profits: 10




Equipment- Implantable Radiation Devices

Theragenics Corp. is the manufacturer of TheraSeed, a rice-sized, FDA-cleared device used primarily in treating localized prostate cancer with a one-time, minimally invasive procedure. The biocompatible seeds emit radiation within the immediate prostate area, killing the tumor while sparing surrounding organs of significant radiation exposure. Theragenics in the world’s leading producer of Palladium -103, the radioactive isotope that supplies the therapeutic radiation for its TheraSeed implants. TheraSeed is utilized by physicians, hospitals and other health care providers located primarily in the United States. The product was previously sold through an exclusive distributor, but it is now sold directly to physicians and non-exclusive third-party distributors. The firm is also involved in the research and development of using the isotope for the treatment of restenosis , macular degeneration and other diseases. A facility in Oak Ridge, Tennessee was constructed to house the equipment, infrastructure and workforce necessary to support the production of isotopes, using unique plasma separation process technology (PSP). Theragenics is also searching for and evaluating external opportunities for diversification, such as partnering and/or acquiring technologies, products or companies. The firm recently announced that it has successfully operated the PSP process, representing the world’s only commercial-scale production of large quantities of a wide range of enriched isotopes and giving Theragenics opportunities in the fields of medical therapeutics, diagnostics, neutron detection, sterilization, nuclear power and national defense. Theragenics offers employees medical, dental and life insurance, as well as an on-site wellness center.

BRANDS/DIVISIONS/AFFILIATES: TheraSeed Indigo Medical, Inc. Johnson & Johnson

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. M. Christine Jacobs, CEO M. Christine Jacobs, Pres. James A. MacLennan, CFO Karen Pfeifer, Dir.-Human Resources Nigel R. Stevenson, VP-Isotope Production and Research Bruce W. Smith, Corp. Sec. James A. MacLennan, Treas. Bruce W. Smith, Exec. VP

Phone: 770-271-0233 Fax: 770-831-4371 Toll-Free: 800-458-4372 Address: 5203 Bristol Industrial Way, Buford, GA 30518 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $32,523 ( 9 months) 2002 Profits: $5,334 ( 9 months) Stock Ticker: TGX 2001 Sales: $50,000 2001 Profits: $15,100 Employees: 160 2000 Sales: $44,000 2000 Profits: $18,700 Fiscal Year Ends: 12/31 1999 Sales: $43,700 1999 Profits: $16,000 1998 Sales: $38,000 1998 Profits: $14,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $399,817 Bonus: $315,000 Stock Purch. Plan: Y Second Exec. Salary: $210,370 Bonus: $17,000 ADVANTAGE: Manufactures products for a type of prostrate cancer therapy that is rapidly gaining popularity.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Northeast:

International:



THIRD WAVE TECHNOLOGIES INC

www.twt.com




Y

TYPES OF BUSINESS:

Profits: 6




Genetic Analysis

Third Wave Technologies, Inc. is a leading developer, manufacturer and marketer of genetic analysis products used in clinical diagnostics and studies. Its patented genetic analysis platform, Invader, offers several advantages over conventional genetic analysis technologies. The Invader platform is accurate, sensitive, easy to use, cost-effective and does not require copying a genetic sample using a complex copying technique known as polymerase chain reaction. Additionally, Third Wave's products are compatible with existing automation processes and detection platforms and are available in ready-to-use formats. These advantages make the Invader platform a simple solution for genetic analysis from disease discovery to the point of patient care, including large-scale disease association studies, drug response marker profiling and molecular diagnostics. In addition to Invader products, Third Wave offers assays for cardiovascular disease and deep-vein thrombosis detection, as well as tests relating to animal and plant genetics. In recent news, Third Wave entered into a license agreement with ACLARA BioSciences under which ACLARA will incorporate Invader assay technology with its eTag chemistry. The resulting eTag Assay System will provide multiple applications for DNA and RNA detection for use by a wide variety of medical specialties.

BRANDS/DIVISIONS/AFFILIATES: Invader ACLARA BioSciences eTag Assay System

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Lance Fors, CEO John J. Puisis, COO John J. Puisis, CFO Bruce Neri, Sr. VP-Research and Dev. John Comerford, Corp. Sec. John Comerford, General Counsel Ivan D. Trifunovich, Sr. VP/Gen. Mgr.-Genomics Alex M. Kaspar, VP-Fin. Lance Fors, Chmn.

Phone: 608-273-8933 Fax: 608-273-8618 Toll-Free: 888-898-2357 Address: 502 S. Rosa Rd., Madison, WI 53719 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: TWTI 2001 Sales: $34,100 2001 Profits: $-36,800 Employees: 273 2000 Sales: $11,400 2000 Profits: $-36,600 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $ 1998 Sales: $ 1998 Profits: $


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $357,512 Stock Purch. Plan: Second Exec. Salary: $232,500 ADVANTAGE: Patented Invader platform which simplifies genetic analysis.

OTHER THOUGHT S:



West:

Southwest:

Midwest: Y

Southeast:



Bonus: $166,800 Bonus: $98,000

Northeast:

International:



TITAN PHARMACEUTICALS

www.titanpharm.com

Industry Group Code : 325412 Ranks within this company's industry group: Sales: 148 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:

Y



Profits: 149


TYPES OF BUSINESS:


GROWTH PLANS/SPECIAL FEAT URES:

Drugs-Schizophrenia Central Nervous System Disorder Therapeutics Cancer Treatments

Titan Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development of proprietary therapeutics for the treatment of central nervous system (CNS) disorders, cancer and other serious and life threatening diseases. Ingenex, Inc. and ProNeura, Inc. are the company’s subsidiaries, primarily engaged in gene therapy. Many of Titan’s development and commercialization activities are supported by partnerships with multinational pharmaceutical companies, government-sponsored research groups and grants received from the National Institutes of Health (NIH). The firm has strategic alliances with Novartis Pharma AG for the development of iloperidone, a novel treatment for schizophrenia; and Schering AG for the development of Spheramine, its treatment for Parkinson’s disease. Titan recently received a license fee from Novartis for the development and commercialization of iloperidone in Japan. The company also received higher grant revenues from NIH in support of the development of Spheramine. Titan currently has 12 products in development including seven in clinical testing, two of which are in Phase III clinical studies. Oncology therapeutic products currently in development include CeaVac, a monoclonal antibody product for the treatment of metastatic colorectal cancer.

BRANDS/DIVISIONS/AFFILIATES: CeaVac Spheramine TriGem Ingenex, Inc. ProNeura, Inc. Zomaril

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Louis R. Bucalo, CEO Sunil Bhonsle, COO Louis R. Bucalo, Pres. Robert E. Farrell, CFO Cindy Lem, Sr. Mgr.-Human Resources Frank H. Valone, Exec. VP-Clinical Dev. Victor J. Bauer, Exec. Dir.-Corp. Dev. Alison Roselli, Dir.-Corp. Comm. Frank H. Valone, Exec. VP-Regulatory Affairs Richard C. Allen, Exec. VP-Cell Therapy

Phone: 650-224-4990 Fax: 650-244-0715 Toll-Free: Address: 400 Oyster Point Blvd., Ste. 505, South San Francisco, CA 94080-1921 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,656 ( 9 months) 2002 Profits: $-19,278 ( 9 months) Stock Ticker: TTP 2001 Sales: $4,600 2001 Profits: $-17,500 Employees: 58 2000 Sales: $1,900 2000 Profits: $-18,800 Fiscal Year Ends: 12/31 1999 Sales: $ 300 1999 Profits: $-11,300 1998 Sales: $ 100 1998 Profits: $-10,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Partnership with Schering AG.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:



Bonus: $67,005 Bonus: $41,280

Northeast: Y

International:



TRANSKARYOTIC THERAPIES

www.tktx.com


Y



Profits: 220


TYPES OF BUSINESS:



Drugs-Anemia Gene Therapy

Transkaryotic Therapies, Inc. is a biopharmaceutical company that develops and commercializes products based on its three proprietary development platforms: gene-activated proteins, niche protein products and gene therapy. The firm’s gene activation technology is based on the activation of genes encoding therapeutic proteins in human cells, as opposed to the traditional methods of cloning and transferring these genes. This positions Transkaryotic to develop and potentially commercialize a large number of therapeutic proteins, including improved versions of many that are currently marketed. Transkaryotic’s niche protein product platform is focused on developing enzyme replacement products to treat patients suffering from certain lysosomal storage disorders and other diseases such as Fabry disease, Gaucher disease, Hunter Syndrome, Hurler Syndrome, Pompe disease and Tay-Sachs disease. The company’s gene therapy is a non-viral, ex vivo, cell-based system that is designed to genetically modify a patient’s own cells in order to produce and deliver therapeutic proteins within the body. Products currently under clinical development include Replagal enzyme replacement therapy, Dynepo Gene-Activated erythropoietin, I2S enzyme replacement therapy, Factor VIII gene therapy and A GA-II. In recent news, the European Commission expanded the summary of product characteristics for Transkaryotic’s Replagal enzyme replacement therapy for Fabry disease to include its use in females. This milestone achievement marks the first time any country has included females in the label of a product to treat Fabry Disease. The expansion increases marketing opportunities for the company to promote its product as prescribed treatment. In other news, Replagal received marketing authorization in Hungary and Slovakia and is now approved for commercial use in 25 countries worldwide. The company provides its employees with reimbursement for health club memberships, discounts on eyewear and domestic partner coverage. Additionally, Transkaryotic offers an educational assistance program, transportation subsidies and parental leave.

BRANDS/DIVISIONS/AFFILIATES: TKT Europe-5S AB Transkaryotic Therapy Dynepo Replagal Aventis Pharma A GA-II

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard F. Selden, CEO Richard F. Selden, Pres. Daniel E. Geffken, CFO Diane Sullivan, Dir.-Human Resources Douglas A. Treco, Sr. VP-Research and Dev. David D. Pendergast, Sr. VP-Quality William E. Aliski, VP- Health Services Renato Fuchs, Sr. VP-Mfg. Michael J. Astrue, General Counsel Michael J. Astrue, Sr. VP-Admin. Justine Koenigsberg, Dir.-Corp. Comm. Renato Fuchs, Sr. VP-Oper. Leanne Torrie, Mgr.-Patient Services

Phone: 617-349-0200 Fax: 617-613-4004 Toll-Free: Address: 700 Main St., Cambridge, MA 02139 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $23,400 ( 9 months) 2002 Profits: $-82,300 ( 9 months) Stock Ticker: TKTX 2001 Sales: $6,200 2001 Profits: $-70,200 Employees: 376 2000 Sales: $7,200 2000 Profits: $-51,000 Fiscal Year Ends: 12/31 1999 Sales: $3,900 1999 Profits: $-44,500 1998 Sales: $5,500 1998 Profits: $-20,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Stock Purch. Plan: Second Exec. Salary: $285,000 ADVANTAGE: Expertise in gene activated proteins and niche protein products.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $150,000 Bonus: $100,000

Northeast: Y

International: Y



TRIANGLE PHARMACEUTICALS

www.tripharm.com


Y



Profits: 224


TYPES OF BUSINESS:



Drugs-Viral Disease Specialty Pharmaceuticals Combination Therapies Small-Molecule Drugs

Triangle Pharmaceuticals develops new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV and AIDS and the hepatitis B virus. Its existing portfolio consists of several licensed drug candidates in clinical trials and others in preclinical stages. The company was founded based in part of its belief that the prolonged use of combination therapy will generate demand for new anti-HIV drugs with favorable activity, resistance, compliance and/or tolerance profiles. The company's HIV candidates are Coviracil, a nucleoside analog, and Amdoxovir, a purine dioxolane nucleoside. These products are in Phase II and III clinical studies. Triangle is also developing emtricitabine and clevudine to treat hepatitis B, currently in Phase II trials. In addition, the company has licensed immunostimulatory sequencing technology from Dynavax Technologies to study as a treatment for hepatitis B. Triangle's business strategy includes focusing on drug development over drug discovery; focusing on small-molecule drugs; and developing drugs for use in combination therapy. In recent news, the firm announced that it signed a definitive agreement to be acquired by Gilead Sciences, Inc. for the purchase price of $464 million.

BRANDS/DIVISIONS/AFFILIATES: Amdoxovir Coviracil Gilead Sciences, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Daniel G. Welch, CEO Chris A. Rallis, COO Chris A. Rallis, Pres. Robert F. Amundsen, Jr., CFO/Exec. VP Franck S. Rousseau, Exec. VP-Medical Affairs/Chief Medical Officer R. Andrew Finkle, Exec. VP/Corp. Sec. R. Andrew Finkle, General Counsel Paul A. Dreyer, Exec. VP-Commercial Oper. Anne F. McKay, VP-Drug Regulatory Affairs

Phone: 919-493-5980 Fax: 919-493-5925 Toll-Free: Address: 4 University Pl., 4611 University Dr., Durham , NC 27707 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $16,625 ( 9 months) 2002 Profits: $-17,775 ( 9 months) Stock Ticker: VIRS 2001 Sales: $5,800 2001 Profits: $-75,900 Employees: 115 2000 Sales: $7,294 2000 Profits: $-109,525 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-104,621 1998 Sales: $ 1998 Profits: $-67,271


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Developing new drugs to fight HIV.

OTHER THOUGHTS:




West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



TRINITY BIOTECH PLC

www.trinitybiotech.com




Y

TYPES OF BUSINESS:

Profits: 16




Diagnostic Testing Kits Immunoassay Technology

Trinity Biotech is engaged in developing, manufacturing and marketing diagnostic products that use immunoassay technologies. The firm markets over 400 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. Trinity sells its products in over 80 countries worldwide through its own sales forces and through a network of international distributors and strategic partners. The company’s product offerings are used for testing and diagnosis in respiratory infections, autoimmune and hormonal disorders, cardiovascular disease, Lyme disease and several infectious diseases including STDs. Its manufactured products are marketed under brand names including Capillus, Recombigen, SeroCard, SalivaCard, MicroTrak and EZ-Bead. Trinity recently acquired the specialty clinical chemistry product line from Sigma Diagnostics, a division of the Sigma Aldrich Corporation. The acquired assets consist of several esoteric products that are clearly differentiated in the marketplace. The product line includes ACE, Bile Acids, Lactate, Oxalate and G6PDH. Many of these are single-source products and will only be available from Trinity Biotech. Also included in the transaction were the HDL, LDL and Lipase product lines. Additionally, the firm gained the rights to an HbA1c product that is FDAcleared but not currently on the market. The addition of these new products will serve to increase the efficiency and effectiveness of its direct sales forces in the U.S., Germany and U.K. and enhance existing distribution channels. The purchase also helps position Trinity as a key provider of esoteric tests across the entire diagnostics market. Manufacturing of these products will be transferred from St. Louis to Trinity’s facility in Dublin. In other news, Trinity received FDA marketing clearance for its new hemostasis analyzer, AMAX Destiny.

BRANDS/DIVISIONS/AFFILIATES: Capillus Recombigen AMAX Destiny SalivaCard HiberGen Sigma Diagnostics MicroTrak EZ-Bead

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ronan O'Caoimh, CEO Jim Walsh, COO Brendan Farrell, Pres. Maurice Hickey, CFO Bonnie Marsh, Dir.-Human Resources Maurice Hickey, Corp. Sec.

Phone: +353-1276-9800 Fax: +353-1276-9888 Toll-Free: 800-603-8076 Address: IDA Business Park, Wicklow, Ireland

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $36,995 ( 9 months) 2002 Profits: $3,505 ( 9 months) Stock Ticker: TRIB 2001 Sales: $37,100 2001 Profits: $1,400 Employees: 306 2000 Sales: $29,700 2000 Profits: $4,800 Fiscal Year Ends: 12/31 1999 Sales: $26,100 1999 Profits: $1,000 1998 Sales: $23,200 1998 Profits: $1,600


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Growth through acquisitions.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast: Y

International: Y



TRIPOS INC

www.tripos.com




Y

TYPES OF BUSINESS:

Profits: 2


Y



Research-Pharmaceuticals Clinical Software Software Consulting Services Chemical Compound Libraries Integrated Data Systems

Tripos, Inc. provides a broad range of drug discovery products and services that are founded on the company’s expertise in cheminformatics. These products and services include discovery software, software consulting services and chemical compound libraries. The company’s software, computer-designed compounds and informatics consulting services advance customers’ productivity in the agrochemical, biotechnology, pharmaceutical and related research industries. The rapid development of certain technologies, including high-throughput screening, have forced many smaller companies to look to outside assistance in providing needed technology, rather than investing in it themselves. Consequently, Tripos has been given the opportunity to offer its expertise to these organizations through compound design, molecular analysis and a complete suite of lead discovery and lead optimization capabilities. Recently, the company signed various agreements to provide its partners with particular services. One such agreement was signed with AstraZeneca, whereby Tripos provides its SYBYL software in order to accelerate the creation of novel therapeutic agents. Molecular Discovery, Ltd. will be utilizing Tripos' VolSurf in order to predict and optimize pharmacokinetic properties of potential drug candidates. The program is expected to reduce development costs by early detection of unproductive candidates. The firm recently signed an agreement with Ionix Pharmaceuticals, Ltd, a European analgesic drug discovery company, to collaborate on the design and synthesis of chemical compounds for evaluation as potential inhibitors of an Ionix drug target. The company also recently announced a strategic chemistry alliance with Pfizer, Inc. Under the agreement, Tripos and Pfizer will collaborate in such fields as library design and analysis and the high-throughput purification and analysis of compounds. Tripos will be engaged in the design, synthesis and purification of these compounds in order to expand Pfizer's compound file collection.

BRANDS/DIVISIONS/AFFILIATES: SYBYL ChemSpace Alchemy 2000 GeneFold LeadQuest VolSurf Tripos Receptor Research ChemCore

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John P. McAlister III, CEO John P. McAlister III, Pres. Jim Rubin, CFO Bruce Frank, VP-Sales, Americas and Asia David Summers, VP-Human Resources Richard D. Cramer III, Chief Scientific Officer/VP-Science John D. Yingling, Controller Edward Hodgkin, VP-Global Bus. Dev. John D. Yingling, Treas. Douglas Danne, Sr. VP/Chief Commercial Officer Peter Hecht, Sr. VP-Discovery Research Oper. Paul L. Weber, Sr. VP-Software Consulting Services Mary Woodward, Sr. VP-Software Consulting Services

Phone: 314-647-1099 Fax: 314-647-9241 Toll-Free: 800-323-2960 Address: 1699 S. Hanley Rd., St. Louis , MO 63144-2913 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $34,887 ( 9 months) 2002 Profits: $- 471 ( 9 months) Stock Ticker: TRPS 2001 Sales: $49,100 2001 Profits: $5,900 Employees: 267 2000 Sales: $29,000 2000 Profits: $-2,100 Fiscal Year Ends: 12/31 1999 Sales: $27,200 1999 Profits: $-2,300 1998 Sales: $25,600 1998 Profits: $ 100


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Expertise in cheminformatics.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest: Y

Southeast:



Bonus: $169,114 Bonus: $125,802

Northeast: Y

International: Y



TULARIK INC

www.tularik.com


Y



Profits: 203


TYPES OF BUSINESS:



Drugs-Small Molecule

Tularik, Inc. is engaged in the discovery and development of a broad range of novel drugs that act through the regulation of gene expression. By resolving how genes are selectively turned on or off, and by recognizing the critical enzymes, regulatory proteins and transcription factors that control this process, the company seeks to develop orally administered, small-molecule drugs to treat a wide range of diseases caused by inappropriate gene expression. The firm’s two subsidiaries, German-based Tularik GmbH and Tularik Texas Corporation, place emphasis on the discovery and development of antibacterial and antifungal drugs. Tularik has established important alliances with Japan Tobacco, Inc., Roche Bioscience and Knoll AG. The firm recently earned a milestone payment from its corporate partner, Eli Lilly and Company. The payment is part of a multi-year collaboration established to design and optimize inhibitors of Factor Xa using Tularik's CAMD technology, as well as to investigate other potential anti-thrombotic targets. In other news, Tularik entered into a collaboration with Sankyo Company, Ltd. The two firms plan to jointly discover and develop human therapeutics that act on orphan G-protein coupled receptors. Tularik provides its employees with a tuition reimbursement program, domestic partner benefits, a casual dress code, subsidized childcare in a local preschool and an employee referral program. Additionally, the firm provides annual flu shots, on-site dry cleaning, commuting assistance, credit union membership, Costco membership and numerous social outings and events. The company also offers employees access to a subsidized cafeteria.

BRANDS/DIVISIONS/AFFILIATES: Tularik GmbH Tularik Texas Corporation CAMD Technology

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David V. Goeddel, CEO Corinne H. Lyle, CFO Chris Smith, Dir.-Human Resources Michael D. Levy, Chief Medical Officer William Rieflin, General Counsel William Rieflin, Exec VP-Admin. Jack M. Anthony, Sr. VP-Bus. Dev. Pieter Timmermans, VP-Pharmacology Andrew J. Perlman, Exec. VP Terry J. Rosen, Exec. VP-Oper.

Phone: 650-825-7000 Fax: 650-825-7303 Toll-Free: Address: 2 Corporate Dr., South San Francisco, CA 94080 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $89,068 ( 9 months) 2002 Profits: $-67,859 ( 9 months) Stock Ticker: TLRK 2001 Sales: $32,600 2001 Profits: $-48,600 Employees: 380 2000 Sales: $25,500 2000 Profits: $-43,300 Fiscal Year Ends: 12/31 1999 Sales: $23,800 1999 Profits: $-25,500 1998 Sales: $21,400 1998 Profits: $-10,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $435,385 Stock Purch. Plan: Y Second Exec. Salary: $312,577 ADVANTAGE: Expertise in gene expression technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $115,296 Bonus: $25,971

Northeast: Y

International: Y



UNIGENE LABORATORIES

www.unigene.com


Y



Profits: 130


TYPES OF BUSINESS:



Drugs-Calcitonin Osteoporosis Treatments

Unigene Laboratories is a biopharmaceutical company engaged in the research, production and delivery of small proteins, referred to as peptides, that have demonstrated or potential medical use. The firm has a patented manufacturing technology for producing many peptides cost-effectively. Unigene also has patented oral delivery technology that has been shown to deliver medically useful amounts of various peptides into the bloodstream. These proprietary technologies form the basis of its business strategy. The firm's primary focus has been on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications. The company's injectable calcitonin product is approved for sale in Switzerland for osteoporosis and in the European Union for two minor indications. Unigene is also engaged in the development of oral and nasal calcitonin products, as well as other peptide products, including parathyroid hormone (PTH) for osteoporosis. The company has completed clinical trials for nasal calcitonin, and a new drug application for the product is in the final stages of preparation. In 2000, Unigene entered into a joint venture with Shijiazhuang Pharmaceutical Group to manufacture and distribute injectable and nasal calcitonin products in China and other Asian markets. The company owns approximately 45% of the joint venture. In recent news, the firm received approval for an osteoporosis related indication of its injectable calcitonin product, Forcaltonin, in the European Union. In addition, Unigene entered into an exclus ive licensing agreement with Upsher-Smith Laboratories, Inc. to market its nasal calcitonin product in the U.S.

BRANDS/DIVISIONS/AFFILIATES: Forcaltonin Shijiazhuang Pharmaceutical Group

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Warren P. Levy, Pres. William J. Steinhauer, Controller Ronald S. Levy, Exec. VP/Corp. Sec. Jay Levy, Treas. James P. Gilligan, VP- Product Dev.

Phone: 973-882-0860 Fax: 973-227-6088 Toll-Free: Address: 110 Little Falls Rd., Fairfield, NJ 07004-2193 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,462 ( 9 months) 2002 Profits: $-4,232 ( 9 months) Stock Ticker: UGNE 2001 Sales: $ 900 2001 Profits: $-12,500 Employees: 60 2000 Sales: $3,300 2000 Profits: $-12,500 Fiscal Year Ends: 12/31 1999 Sales: $9,600 1999 Profits: $-1,600 1998 Sales: $5,100 1998 Profits: $-6,800


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $161,280 Stock Purch. Plan: Second Exec. Salary: $156,626 ADVANTAGE: Cost effective production of peptides/Asian expansion.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International:



UNITED THERAPEUTICS CORP

www.unither.com


Y



Profits: 194


TYPES OF BUSINESS:



Drugs-Pulmonary Hypertension

United Therapeutics Corporation develops pharmaceuticals to treat vascular disease, including pulmonary hypertension and peripheral vascular disease, as well as certain other chronic conditions. The company’s lead product, Uniprost, is currently in pivotal Phase III clinical trials for advanced pulmonary hypertension. United Therapeutics has entered into a strategic alliance with Grupo Ferrer, a leading pharmaceutical company in Europe, for the distribution of Uniprost in Spain, France, Germany, Italy, Portugal, Greece, Belgium, Mexico and all countries in Latin America. In recent news, the Drug Registration Department of the Israeli Ministry of Health approved Remodulin Injection for the treatment of primary pulmonary arterial hypertension, as well as pulmonary arterial hypertension associated with connective tissue disorders. Approximately 25 patients are currently being treated with Remodulin in Israel. The product has also been approved by the U.S. FDA, as well as by the Canadian Therapeutics Products Directorate. United Therapeutics now intends to seek pricing approval for Remodulin from the Canadian provinces. Following approval of the product by the FDA, all four of the United States Medicare Durable Medical Equipment Regional Carriers recently issued policies and procedures allowing for the nationwide reimbursement of Remodulin Injection therapy. In addition to coverage for Remodulin, Medicare will also provide reimbursement for the related infusion pumps and supplies. Generally, Medicare-eligible patients with all forms of pulmonary arterial hypertension for which Remodulin is indicated will be covered under the new policies. In addition, United Therapeutics has submitted marketing applications for Remodulin in France, Switzerland and Australia, with additional European filings to follow approval in France.

BRANDS/DIVISIONS/AFFILIATES: Uniprost Beraprost Remodulin Synergy Unisense Unipeg Medicomp, Inc. Unither Pharmaceuticals, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Martine A. Rothblatt, CEO Roger Jeffs, COO Roger Jeffs, Pres. Fred T. Hadeed, CFO Paul A. Mahon, General Counsel Gilles Cloutier, Treas. Ricardo Balda, CEO, Medicomp, Inc. Barry Kanarek, CEO, Unither Pharmaceuticals David Walsh, Exec. VP-Production

Phone: 301-608-9292 Fax: 301-608-9291 Toll-Free: Address: 1110 Spring St., Silver Spring, MD 20910 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $18,098 ( 9 months) 2002 Profits: $-21,046 ( 9 months) Stock Ticker: UTHR 2001 Sales: $5,700 2001 Profits: $-37,300 Employees: 128 2000 Sales: $2,000 2000 Profits: $-75,600 Fiscal Year Ends: 12/31 1999 Sales: $ 400 1999 Profits: $-33,500 1998 Sales: $ 100 1998 Profits: $-12,800


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $192,308 Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Alliance with Grupo Ferrer opens European and Latin American distribution.

OTHER THOUGHTS:



West:

Southwest:

Midwest: Y

Southeast:




Northeast: Y

International:



UNITED-GUARDIAN INC

www.u-g.com


Y



Profits: 49


TYPES OF BUSINESS:



Drugs-Diversified Pharmaceutical Research and Development Cosmetics Health Care Products Medical Devices Industrial Products Organic Chemical Distribution Research Chemicals

United Guardian, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals, cosmetics, health care products, medical devices and proprietary industrial products. The company is also involved in the distribution of over 3,000 fine organic chemicals, research chemicals, test solutions, indicators, dyes and reagents. The firm operates in two business segments, Eastern Chemical Corporation and the Guardian Laboratories division. United Guardian currently markets its leading product line, Lubrajel, as a component in cosmetics and medical supplies. The company also manufactures Renacidin, Klensoft, AquaThik, Deselex Liquid, Confetti, Hydrajel and DermaSure health care and personal care products. Part of the company’s strategy is focused on forming partnerships with other companies to market, license or purchase personal hygiene products. The firm plans to introduce a new product line to supplement and complement its line of Lubrajel products. Other projects currently under development include an existing antimicrobial product, Clorpactin, for periodontal use, as well as a carrier for an antiviral product designed to prevent sexually transmitted diseases. In other news, United Guardian was granted a U.S. patent for the micoremulsification of silicone into a transparent, water-based gel. The product is stable and has high lubricating and moisturizing characteristics, which should make it suitable for use in the cosmetics industry. The resulting product may also find use as a carrier for active ingredients to treat conditions such as skin irritations, burns and infection.

BRANDS/DIVISIONS/AFFILIATES: Lubrajel Eastern Chemical Corporation Guardian Laboratories Klensoft AquaThik Deselex Liquid Confetti Hydrajel

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Alfred R. Globus, CEO Kenneth H. Globus, Pres. Kenneth H. Globus, CFO Joseph J. Vernice, VP-Technical Services Peter F. Lang, VP-Quality Assurance Mgr. Peter A. Hiltunen, Production Supervisor Robert S. Rubinger, Corp. Sec. Kenneth H. Globus, General Counsel Robert S. Rubinger, Treas. Charles W. Castanza, Sr. VP-Plant Oper. Derek Hampson, VP, Eastern Chemical Corp.

Phone: 631-273-0900 Fax: 631-273-0858 Toll-Free: 800-645-5566 Address: 230 Marcus Blvd., P.O. Box 18050, Hauppauge, NY 11788 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $6,796 ( 9 months) 2002 Profits: $ 258 ( 9 months) Stock Ticker: UG 2001 Sales: $9,600 2001 Profits: $1,900 Employees: 42 2000 Sales: $10,400 2000 Profits: $2,100 Fiscal Year Ends: 12/31 1999 Sales: $9,100 1999 Profits: $1,400 1998 Sales: $8,800 1998 Profits: $1,000


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $188,877 Stock Purch. Plan: Second Exec. Salary: $122,051 ADVANTAGE: Extensive product line may lead to growing revenues.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $37,500 Bonus: $11,000

Northeast: Y

International:



V I TECHNOLOGIES INC

www.vitechnologies.com



Y


Profits: 2


TYPES OF BUSINESS:



Blood Supplies Technology

V.I. Pharmaceuticals (VITEX) is a leading developer and manufacturer of a broad portfolio of blood products that utilize its patented viral inactivation technologies designed to ensure product safety. The technologies offered by the company are tailored for all blood component applications and other blood-derived products, including plasma, plasma derivatives, red blood cells and platelets. VITEX’s lead product is INACTINE Pathogen Inactivation of red blood cells. The firm’s proprietary INACTINE technology is designed to inactivate a wide range of known and as -yetunknown viruses, bacteria and parasites and recently demonstrated its ability to remove prions, while preserving the therapeutic properties of red blood cells. The technology works by binding to the RNA or DNA of the pathogen forming an irreversible bond to the pathogenic nucleic acid and destroying the pathogens. The firm is currently undertaking initiatives to develop the system’s success for commercial viability in the three areas of broad pathogen kill, a wide safety margin for the patient and minimal interference with the function of the red cell. VITEX has partnerships with Pall Corporation, Haemonetics Corporation and Amersham Pharmacia Biotech to support commercialization of the INACTINE portfolio of products. In recent news, VITEX reached an agreement with the FDA to initiate its pivotal Phase III clinical series of trials with the INACTINE system. VITEX was also the first company to successfully achieve inactivation of the West Nile virus in units of red blood cells. The results of preclinical experiments show that the INACTINE process is effective in inactivating the West Nile virus in red blood cells throughout the course of the infection. Benefits that the company offers its employees include a tuition reimbursement plan, dental insurance and incentive bonuses.

BRANDS/DIVISIONS/AFFILIATES: PLAS+SD Universal PLAS+SD INACTINE Pentose Pharmaceuticals

CONTACTS: Note: Officers with more than one job titl e may be intentionally listed here more than once. John R. Barr, CEO John R. Barr, Pres. Thomas T. Higgins, CFO Kurt Andrews, VP-Human Resources Bernadette L. Alford, Exec. VP-Clinical and Regulatory Affairs Thomas T. Higgins, Exec. VP-Oper. Bernadette L. Alford, Exec. VP-Dev. Francesca T. DeVillis, VP-Corp. Comm. Francesca T. DeVillis, Sr. Dir.-Investor Rel. James Hope, VP- Molecular Sciences Andrei Purmal, VP-Biochemical Sciences

Phone: 617-926-1551 Fax: 617-923-2245 Toll-Free: Address: 134 Coolidge Ave., Watertown, MA 02472 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $4,020 ( 9 months) 2002 Profits: $-15,398 ( 9 months) Stock Ticker: VITX 2001 Sales: $26,900 2001 Profits: $-23,400 Employees: 85 2000 Sales: $40,700 2000 Profits: $-15,000 Fiscal Year Ends: 12/31 1999 Sales: $39,700 1999 Profits: $-37,300 1998 Sales: $36,100 1998 Profits: $-6,400


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $371,087 Stock Purch. Plan: Y Second Exec. Salary: $242,230 ADVANTAGE: Technology that deactivates viruses in blood supplies.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $81,000 Bonus: $49,350

Northeast: Y

International:



VALENTIS INC

www.valentis.com


Y



Profits: 197


TYPES OF BUSINESS:



Drugs-Cancer Novel Therapeutics

Valentis, Inc. develops proprietary technologies and applies its preclinical and early clinical development dexterity to develop novel therapeutics. The company’s core technologies include multiple gene delivery and gene expression systems and PEGylation technologies designed to improve the safety, efficacy and dosing characteristics of substances such as genes, antibodies and replicating and non-replicating viruses. PolyMASC Pharmaceuticals, a subsidiary of the company, focuses on the creation of improved biologics through the application of PEGylation technologies, which involves the attachment of the polymer polyethyleneglycol (PEG) to therapeutics to alter their distribution in the body, metabolism and excretion. The firm’s products are covered by a broad patent portfolio of U.S. and European claims. Consequently, the company is capable of pursuing a corporate strategy that involves entering into corporate collaborations for full-scale clinical development and marketing and sales of products. Valentis recently announced that PolyMASC Pharmaceuticals has been granted a European patent covering PEGylated liposomes. In other news, the company has suspended its clinical programs in oncology and significantly reduced its preclinical product development efforts in an effort to reduce expenses. The firm recently closed its facility in The Woodlands, TX, and eliminated 45 jobs.

BRANDS/DIVISIONS/AFFILIATES: PolyMASC Pharmaceuticals Interleukin-2 PEG Technology Roche Diagnostics Glaxo Wellcome Bayer International Eurogene Limited

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Benjamin F. McGraw, III, CEO Benjamin F. McGraw, III, Pres. Joseph Markey, Dir.-Finance Michelle Tolbirt, VP-Human Resources Michael P. Fons, Dir.-Tech. Venturing Alan C. Medelson, Corp. Sec. Margaret M. Snowden, General Counsel Gregory M. McKee, Sr. Dir.-Corp. Dev. Alain Rolland, VP-Research and Dev. Center Head H. Denny Liggitt, VP- Pharmacology and Toxicology J. Tyler Martin, Sr., Sr. VP-Dev.

Phone: 650-697-1900 Fax: 650-652-1980 Toll-Free: Address: 863-A Mitten Rd., Burlingame, CA 94010 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $3,800 (12 months) 2002 Profits: $-33,100 (12 months) Stock Ticker: VLTS 2001 Sales: $4,600 2001 Profits: $-38,200 Employees: 115 2000 Sales: $5,600 2000 Profits: $-47,700 Fiscal Year Ends: 6/30 1999 Sales: $4,100 1999 Profits: $-44,700 1998 Sales: $8,100 1998 Profits: $-8,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $322,081 Stock Purch. Plan: Y Second Exec. Salary: $235,065 ADVANTAGE: Multiple gene delivery and gene expression systems.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $91,155 Bonus: $41,663

Northeast:

International: Y



VAXGEN INC

www.vaxgen.com


Y



Profits: 169


TYPES OF BUSINESS:



Drugs-HIV/AIDS Vaccine Anthrax Vaccine Biologics Manufacturing

VaxGen was formed in 1995 to complete the development and commercialization of AIDSVAX, a vaccine designed to prevent infection or disease caused by HIV, the virus that causes AIDS. The AIDSVAX technology was originally developed by Genentech, Inc. and then licensed exclusively to VaxGen when it was spun off from the company. VaxGen is currently testing the vaccine in humans in two large-scale Phase III clinical trials. These are the first Phase III trials ever to be conducted for a preventative HIV vaccine. AIDSVAX contains synthetic copies of the proteins from the surface of HIV. Since it contains to genetic material, it is incapable of causing HIV infection. Humans vaccinated with AIDSVAX produce antibodies against HIV, which bind to the virus and neutralize its infectivity. Phase III trials are being conducted in North America, Europe and Thailand. Enrollment of more than 5,400 trial volunteers was completed for the North American and European trial in 1999. Enrollment of over 2,500 volunteers in Bangkok was completed in 2000. The firm is also the only U.S. company to be funded by the National Institutes of Health to develop an anthrax vaccine. In 2002, VaxGen formed a joint venture in South Korea, Celltrion, Inc., for the purpose of constructing a cell culture manufacturing facility. The firm owns approximately 44% of Celltrion. VaxGen has also partnered with Aventis Pasteur to codevelop an alternative vaccine regimen. In recent news, the firm cleared final safety review for its Phase III trial in Thailand.

BRANDS/DIVISIONS/AFFILIATES: AIDSVAX Celltrion, Inc. Genentech

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Lance K. Gordon, CEO Donald P. Francis, Pres. Carter A. Lee, Sr. VP-Finance Phillip W. Berman, Sr. VP-Research and Dev. Marc Gurwith, Sr. VP-Medical Affairs/Chief Medical Officer James P. Panek, Sr. VP-Mfg. Oper. Carter A. Lee, Sr. VP-Admin. Piers Whitehead, VP-Corp. and Bus. Dev. Lance Ignon, VP-Corp. Comm. Carmen M. Betancourt, VP-Regulatory Affairs and Quality Systems Seung-Il Shin, Sr. Advisor-Int'l Dev. William L. Heyward, VP-Int'l Clinical Research

Phone: 650-624-1000 Fax: 650-624-1001 Toll-Free: Address: 1000 Marina Blvd., Brisbane, CA 94005 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note : Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 370 ( 9 months) 2002 Profits: $-21,388 ( 9 months) Stock Ticker: VXGN 2001 Sales: $ 900 2001 Profits: $-24,400 Employees: 80 2000 Sales: $ 300 2000 Profits: $-31,800 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-23,300 1998 Sales: $ 100 1998 Profits: $-9,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $325,000 Stock Purch. Plan: Y Second Exec. Salary: $212,000 ADVANTAGE: The only company with an AIDS vaccine in Phase III trials.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $72,000 Bonus: $29,693

Northeast:

International: Y



VERTEX PHARMACEUTICALS INC

www.vpharm.com


Y



Profits: 216


TYPES OF BUSINESS:



Drugs-Viral Disease Neurodegenerative Disease Drugs Hemoglobin Disorder Drugs Autoimmune Disease Drugs Inflammatory Disease Drugs

Vertex Pharmaceuticals, Inc. is a global biotechnology firm that discovers, develops and markets small molecule drugs that address major unmet medical needs. Currently, the company has 12 product candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. The company has developed a variety of advanced and proprietary approaches, including compound screening using NMR SHAPES, virtual screening using computer modeling and combinational chemistry and early incorporation of pharmacological testing to drive the drug discovery process. Compared to industry averages, the company has accelerated drug discovery timelines and increased success rates in early development. Agenerase, the company’s first approved product, is an HIV protease inhibitor that Vertex co-promotes with GlaxoSmithKline. In other product news, due to indications of adverse effects, the company recently decided to suspend clinical development of its VX-745, which was to target rheumatoid arthristis. Instead, h te company will allocate the diverted resources into its potentially successful second-generation oral p38 MAP kinase inhibitors, VX-702 and VX-850. Vertex has collaborative agreements with Eli Lilly, Kissei Pharmaceuticals, Novartis and Schering AG, among others. Recently, Vertex acquired Aurora Biosciences Corporation, a company focused in assay development, screening and cell biology capabilities. The merger is expected to accelerate the company's design and development of new drugs. In other news, Vertex named four new pre-clinical drugs from its research program, which target a broad range of disease areas that include hepatitis C, HIV, sepsis and genetic disorders. Additionally, the firm expanded its gene family research into new gene families and has initiated a multi-target research program in human proteases. The company provides employees with tuition reimbursement and an educational seminar series.

BRANDS/DIVISIONS/AFFILIATES: Altus Biologicals, Inc. Agenerase GlaxoSmithKline Novartis Chemogenomics PanVera Corporation Agenerase Aurora Biosciences Corporation

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joshua S. Boger, CEO Vicki L. Sato, Pres. Ian F. Smith, CFO Michael S. Walsh, VP-Human Resources John C. Pottage, Jr., Dir.-Medical and Antivirals Kenneth S. Boger, General Counsel Iain P.M. Buchanan, VP-European Oper. Jim Feeney, Sr. Dir.-Bus. Dev. Lynne H. Brum, VP-Corp. Comm. Richard H. Aldrich, Sr. VP/Chief Bus. Officer Thomas G. Auchincloss, Jr., Treas. John J. Alam, Sr. VP-Drug Evaluation and Clinical Dev. Thierry Hercend, VP-Research, Europe N. Anthony Coles, Sr. VP-Commercial Oper.

Phone: 617-577-6100 Fax: 617-577-6680 Toll-Free: Address: 130 Waverly St., Cambridge, MA 02139-4242 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $117,301 ( 9 months) 2002 Profits: $-76,538 ( 9 months) Stock Ticker: VRTX 2001 Sales: $167,500 2001 Profits: $-66,300 Employees: 1,000 2000 Sales: $78,127 2000 Profits: $-39,700 Fiscal Year Ends: 12/31 1999 Sales: $50,560 1999 Profits: $-41,000 1998 Sales: $29,055 1998 Profits: $-33,100


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $474,994 Bonus: $150,000 Stock Purch. Plan: Y Second Exec. Salary: $400,010 Bonus: $100,000 ADVANTAGE: A leader in the use of structure-based drug design/Powerful approach to pharmaceutical discovery.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast: Y

International: Y



VICAL INC

www.vical.com


Y



Profits: 109


TYPES OF BUSINESS:



Drugs-Cancer, Infectious Disease and Metabolic Disease DNA Gene Transfer Technologies

Vical develops biopharmaceutical products based on patented naked DNA gene transfer technologies for the prevention and treatment of life-threatening diseases. The company is currently focusing its development on innovative cancer therapies designed to induce an immune response against cancer cells without causing side effects. Allovectin-7 and Leuvectin, the company’s lead candidates, are both in late-stage clinical trials for multiple indications. The firm recently released results from Phase I and Phase II clinical studies concluding that treatment with Allovectin-7 appears to be safe and that further studies are warranted in patients with lessadvanced head and neck cancer. Allovectin-7 contains the HLA-B7 antigen, which alerts the immune system to the presence of foreign tissue and may trigger an immune response against tumor cells. As a result of high public and patient awareness of the need for improved therapies coupled with the limited efficacy of existing treatments, such as chemotherapy, the market for Vical is potentially quite strong. Moreover, the company’s naked DNA gene delivery technology may be useful in developing DNA vaccines to prevent or treat infectious diseases and methods to efficiently deliver human and anim al therapeutic proteins. The innovative technology may also prove to be more cost-effective than therapies that require genetic modification and controlled propagation of viral vectors. Vical was recently awarded a U.S. Government contract to manufacture clinical-grade supplies of an experimental DNA vaccine against Ebola. In other news, Vical partner Centocor, Inc. expanded its earlier license and option agreement to use the firm’s DNA technology to develop and commercialize certain DNA vaccines for the treatment of some types of cancer.

BRANDS/DIVISIONS/AFFILIATES: Allovectin-7 Leuvectin Vaxid

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Vijay B. Samant, CEO Vijay B. Samant, Pres. Martha J. Demski, CFO Sue Bacino, Dir.-Human Resources David C. Kaslow , Chief Scientific Officer Kevin R. Bracken, VP-Mfg. Alan E. Dow , General Counsel George J. Gray, VP-Oper. David J. Pyrce, VP-Bus. Dev. Alan R. Engbring, Dir.-Investor Rel. Martha J. Demski, Treas. Jon A. Norman, VP-Research Alain P. Rolland, VP- Product Dev.

Phone: 858-646-1100 Fax: 858-646-1150 Toll-Free: Address: 9373 Towne Centre Dr., Ste. 100, San Diego, CA 92121-3088 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $6,479 ( 9 months) 2002 Profits: $-20,459 ( 9 months) Stock Ticker: VICL 2001 Sales: $11,400 2001 Profits: $-9,200 Employees: 152 2000 Sales: $7,600 2000 Profits: $-8,500 Fiscal Year Ends: 12/31 1999 Sales: $10,700 1999 Profits: $-6,900 1998 Sales: $5,900 1998 Profits: $-7,500


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $330,000 Stock Purch. Plan: Second Exec. Salary: $207,375 ADVANTAGE: Patented naked DNA gene transfer technology.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $135,000 Bonus: $75,000

Northeast: Y

International:



VION PHARMACEUTICALS INC

www.vionpharm.com


Y Y



Profits: 134


TYPES OF BUSINESS:



Drugs-Cancer Cancer Technology Research Drug Delivery Systems

Vion Pharmaceuticals is a biopharmaceutical company engaged in the research, development and commercialization of cancer treatment technologies. The company's products include a drug delivery platform and three cancer therapeutics, including Triapine and Sulfonyl Hydrazine Prodrugs. The firm’s proprietary drug delivery technology, TAPET (Tumor Amplified Protein Expression Therapy), is focused on the effective delivery of anticancer drugs to tumors without harming normal cells and minimizing the side effects associated with other cancer treatments. It uses genetically altered strains of salmonella bacteria as a vehicle for delivering cancer-fighting drugs to solid tumors. In recent news, the firm announced that the Drug Development Group of the National Cancer Institute's Division of Cancer Treatment and Diagnosis approved a collaboration for the clinical development of Triapine. As part of the collaboration, the Institute’s Cancer Therapy Evaluation Program will sponsor clinical trials of Triapine to further explore its activity as a single agent or in combination with other agents in patients with cancer. In other news, Vion was issued a U.S. patent for TAPET. The company has been studying the product in Phase 1 clinical trials. Vion exclusively licenses TAPET technology from Yale University. The firm offers employees performance bonuses, relocation assistance and education reimbursement.

BRANDS/DIVISIONS/AFFILIATES: Triapine TAPET Sulfonyl Hydrazine Prodrugs

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Alan Kessman, CEO Alan Kessman, Pres. Howard B. Johnson, CFO Daniel Chapman, Dir.-Human Resources Terrence W. Doyle, VP-Research and Dev. Mario Sznol, VP-Clinical Affairs Thomas Mizelle, Corp. Sec. Thomas Mizelle, VP-Oper. Bijan Almassian, VP-Dev. Ivan King, VP-Research

Phone: 203-498-4210 Fax: 203-498-4211 Toll-Free: Address: 4 Science Park, New Haven, CT 06511 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 158 ( 9 months) 2002 Profits: $-9,821 ( 9 months) Stock Ticker: VION 2001 Sales: $ 700 2001 Profits: $-13,800 Employees: 50 2000 Sales: $ 900 2000 Profits: $-14,800 Fiscal Year Ends: 12/31 1999 Sales: $3,200 1999 Profits: $-10,800 1998 Sales: $2,000 1998 Profits: $-10,500


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $412,000 Stock Purch. Plan: Second Exec. Salary: $216,900 ADVANTAGE: Unique TAPET technology delivers drugs to solid tumors.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $6,248 Bonus: $5,935

Northeast: Y

International:



VIRAGEN INC

www.viragen.com


Y



Profits: 124


TYPES OF BUSINESS:



Drugs-Human Interferons Human Immune System Research Cancer Vaccines

Viragen, Inc. is engaged in the research, development and manufacturing of products and technologies that help the human immune system resist viral infections. The firm specializes in natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include Multiferon, a human natural alpha interferon; monoclonal antibodies; peptide drugs; and therapeutic vaccines. The company's proprietary product is Omniferon, a natural interferon product. Omniferon, formed from white blood cells, is only used in clinical trials at this time. The natural interferon stimulates and controls the human immune system. Omniferon is awaiting FDA and European Union approval. Plantation, Florida-based Viragen has manufacturing facilities in Edinburgh, Scotland and Umeå and Ersboda, Sweden. Subsidiary Viragen International recently entered into an exclusive distribution agreement with CJ Pharma, the U.S. pharmaceutical division of Cheil Jedang, to distribute Multiferon in designated Latin American countries. Cheil Jedang conducts business with over 60 different countries through its thirty-two offices around the world. As part of the agreement, CJ Pharma is required to obtain and maintain the appropriate regulatory approvals for Multiferon in the exclusive territories of Brazil, Chile, Uruguay, Peru, Costa Rica, Honduras, Nicaragua, Guatemala and Panama. In a strategy designed to expand Viragen’s presence into the Chinese market, the firm is currently in the process of renegotiating its agreement with U.S.-based Tradeway, Inc. The exclusive distribution rights that Tradeway holds in Taiwan are in the process of being exchanged for the first right to acquire a master distributorship agreement for China.

BRANDS/DIVISIONS/AFFILIATES: Omniferon Zonagen, Inc. Multiferon PolyMASC Pharmaceuticals Cancer Research Campaign Technology Viragen International

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gerald Smith, CEO D. Magnus Nicolson, COO Dennis W. Healey, CFO Maria Rios, Dir. Human Resources Jose I. Ortega, Controller Patrick Yeramian, Chief Medical Officer Dennis W. Healy, Sec. M. Reza Ziai, VP-Research and Dev. Bo Lemar, Dir., ViraNative AB Alan Dickson, Mgr., ViraNative AB Karen Jervis , Dir.-Tech., Projects Coordinator Mel Rothberg, Exec. VP

Phone: 954-233-8746 Fax: 954-233-1414 Toll-Free: Address: 865 SW 78th Ave., Ste. 100, Plantation, FL 33324 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,300 ( 9 months) 2002 Profits: $-11,100 ( 9 months) Stock Ticker: VRA 2001 Sales: $ 717 2001 Profits: $-11,010 Employees: 80 2000 Sales: $ 200 2000 Profits: $-12,300 Fiscal Year Ends: 6/30 1999 Sales: $ 400 1999 Profits: $-10,700 1998 Sales: $1,100 1998 Profits: $-7,900


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $296,333 Stock Purch. Plan: Y Second Exec. Salary: $252,000 ADVANTAGE: Partnership with the Cancer Research Campaign Technology of the UK.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast: Y



Bonus: $ Bonus: $

Northeast:

International: Y



VIRBAC INC

www.virbac.com


Y



Profits: 52


TYPES OF BUSINESS:


GROWTH PLANS/SPECIAL FEAT URES:

Drugs-Animal Health & Pet Care

Virbac is a pharmaceutical company devoted exclusively to veterinary drugs. The company was created in 1999 when the U.S. subsidiary of French veterinary products maker Virbac SA and Agri-Nutrition Group, a former Purina Mills division, finalized a merger agreement. The veterinary pharmaceutical market is divided into two segments: companion animals (household pets) and foodproducing animals (cattle, sheep, poultry and pigs). As a leader in dermatological and oral hygiene products for pets and companion animals, Virbac offers a broad array of health care products to its clients under the C.E.T., Allerderm, St. JON, Zema and Francodex brand names. The company has subsidiaries in 23 countries and production units located in France, the U.S., Australia, Mexico, Brazil and Vietnam. Additionally, Virbac maintains research facilities in France, the U.S., Mexico and Australia. The firm recently reported double-digit growth in its companion animal business. The increase was driven by the successful penetration of new strategic products, including Iverhart (a canine parasiticide) in the U.S., Equimax (an equine parasiticide) in the U.K. and Virbagen Omega (interferon for companion animals) in Europe. The company’s food-producing animal business achieved a lower growth rate mainly because of Virbac’s decision to reduce its presence in the Brazilian market to avoid exposure to economic and monetary risks. Other strongly performing products include the cat vaccine Leucogen, the dog parasiticide Preventic and Suramox, an antibiotic for pigs and poultry. International sales currently represent approximately 75% of the firm’s total sales. In other news, American subsidiary Virbac Corp. recently received FDA approval for Equell Paste, an equine anthelmintic product.

BRANDS/DIVISIONS/AFFILIATES: Iverhart Equimax C.E.T. Dental Products Virbagen Omega Zema Equell Francodex Virbac Corp.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Eric Marée, CEO Pierre Pagès, COO Eric Marée, Pres. Michel Garaudet, CFO Carole Buys-Michela, Mgr.-Human Resources Sophie Favini, VP-Corp. Comm. Christian Karst, Exec. VP Jean-Pierre Dick, VP Thomas L. Bell, CEO, Virbac USA Joseph A . Rougraff, CFO, Virbac USA

Phone: 817-831-5030 Fax: 817-831-8327 Toll-Free: Address: 3200 Meacham Blvd., Fort Worth, TX 76137 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $47,421 ( 9 months) 2002 Profits: $2,393 ( 9 months) Stock Ticker: VBAC 2001 Sales: $60,600 2001 Profits: $1,300 Employees: 278 2000 Sales: $53,000 2000 Profits: $2,900 Fiscal Year Ends: 10/31 1999 Sales: $43,717 1999 Profits: $- 543 1998 Sales: $15,051 1998 Profits: $-1,821


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $195,000 Stock Purch. Plan: Second Exec. Salary: $170,000 ADVANTAGE: Rapidly gaining a strong position in the veterinarian drug market.

OTHER THOUGHTS:



West:

Southwest: Y

Midwest:

Southeast:



Bonus: $19,500 Bonus: $9,734

Northeast:

International: Y



VIROLOGIC INC

www.virologic.com




Y

TYPES OF BUSINESS:




Diagnostics-Viruses

Virologic, Inc. is a biotechnology company that develops and markets innovative products to guide and enhance treatment of viral diseases. The company’s proprietary technology, PhenoSense, is used to test drug resistance in viruses that cause serious diseases, such as AIDS, hepatitis B and hepatitis C. PhenoSense HIV, the company’s initial product, is a test that directly and quantitatively measures resistance of a patient’s HIV to anti-viral drugs. Also, PhenoSense HIV bypasses the need to interpret genotypic mutation patterns, which is the typical, indirect method of evaluating drug resistance. Additional technologies that the firm has developed to assess drug resistance among a number of anti-retroviral therapies include GeneSeq and PhenoScreen. Virologic recently signed a preferred provider agreement with Pfizer for HIV resistance testing technology and services to support Pfizer's HIV drug discovery and development programs. In other news, the firm and Surveillance Data, Inc. signed an agreement to create a new line of HIV market research products based on data collected through Virologic's HIV resistance testing and therapy guidance business. The new products will allow both pharmaceutical and biotech companies to purchase data on drug resistance trends and demographics. Benefits are available to all employees who work for more than 20 hours per week, as well as their domestic partners. Virologic provides dental and vision insurance, transportation assistance, education reimbursement, an employee assistance plan, credit union membership and a business causal environment. Additionally, the company offers its employees a performance bonus plan as well as spot bonuses.

BRANDS/DIVISIONS/AFFILIATES: PhenoSense HIV PhenoSense Assays Therapy Guidance System GeneSeq PhenoScreen

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William D. Young, CEO Martin H. Goldstein, Pres. Karen J. Wilson, CFO Tien Bui, VP-Sales Patricia A. Wray , VP-Human Resources Nicholas S. Hellmann, VP-Clinical Research Frank Barker, CIO/VP-IT Kathy L. Hibbs, General Counsel Sidney S. Ho, Dir.-Public Affairs Christos J. Petropoulos, VP-Research and Dev. Karen E. Hartwig, VP-Mktg.

Phone: 650-635-1100 Fax: 650-635-1111 Toll-Free: Address: 345 Oyster Point Blvd., South San Francisco, CA 94080 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $18,292 ( 9 months) 2002 Profits: $-17,184 ( 9 months) Stock Ticker: VLGC 2001 Sales: $18,300 2001 Profits: $-26,200 Employees: 204 2000 Sales: $7,500 2000 Profits: $-23,200 Fiscal Year Ends: 12/31 1999 Sales: $1,100 1999 Profits: $-17,100 1998 Sales: $ 100 1998 Profits: $-8,100


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: PhenoSense technology.

OTHER THOUGHTS:




West: Y

Southwest:

Midwest:

Southeast:



Bonus: $35,000 Bonus: $30,000

Northeast:

International:



VIROPHARMA INC

www.viropharma.com


Y



Profits: 231


TYPES OF BUSINESS:



Drugs-RNA Virus Illnesses

ViroPharma, Inc. discovers, develops and commercializes antiviral pharmaceuticals made to fight such viral diseases as pneumonia, hepatitis C and influenza. Since there are currently no medicines for most ribonucleic acid (RNA) virus illnesses, the company attempts to provide new and effective treatments for these illnesses in order to help health care providers address a significant medical need. Additionally, the firm is conducting Phase I human clinical trials using VP14637, which is a proprietary small molecule that has been demonstrated to inhibit RSV replication in vitro. This compound is the lead compound in a chemical series discovered and developed by ViroPharma. The company recently announced plans to restructure in order to establish a foundation for future growth. As part of this process, ViroPharma reduced its workforce by approximately 63%, which include transferring its sales force to Aventis Pharmaceuticals, Inc. and reductions in development, commercial operations and administration. Additionally, ViroPharma and Aventis agreed to terminate their collaboration to co-develop and co-promote Picovir. ViroPharma does not intend to fund any additional significant clinical development of Picovir for the treatment of the common cold without a new partner. In other news, ViroPharma extended the screening phase of its hepatitis drug discovery, development and commercialization agreement with Wyeth for up to an additional two years. The two companies are in an alliance designed to discover, develop and commercialize antiviral compounds to treat hepatitis C.

BRANDS/DIVISIONS/AFFILIATES: VP14637 American Home Products Pleconaril

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Michel de Rosen, CEO Michel de Rosen, Pres. Vincent J. Milano, CFO Michael Kelly, Exec. Dir.-Mktg. Richard Farley, VP-Human Resources Marc S. Collett, VP-Discovery Research Thomas F. Doyle, Sec. Thomas F. Doyle, General Counsel Kori Beer, VP-Corp. Comm. Vincent J. Milano, Treas. Jeffrey R. Hincks, VP-Preclinical Dev. Mark A. McKinlay, VP-Research and Dev.

Phone: 610-458-7300 Fax: 610-458-7380 Toll-Free: Address: 405 Eagleview Blvd., Exton, PA 19341 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,846 ( 9 months) 2002 Profits: $-61,653 ( 9 months) Stock Ticker: VPHM 2001 Sales: $3,400 2001 Profits: $-83,000 Employees: 418 2000 Sales: $2,000 2000 Profits: $-41,800 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-29,500 1998 Sales: $1,500 1998 Profits: $-26,400


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Y Top Exec. Salary: $400,000 Stock Purch. Plan: Second Exec. Salary: $244,800 ADVANTAGE: Focus on making a breakthrough in unserved markets.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $185,000 Bonus: $126,456

Northeast: Y

International: Y



VYSIS INC

www.vysis.com




Y

TYPES OF BUSINESS:

Profits: 10


Y



Genetic Diagnostic Products Reagents Microarray Technology

Vysis, Inc., a subsidiary of Abbott Laboratories, began as multiple scientific research units and programs focused on detection of genetic abnormalities. Today, the company is a leading genomic disease management company that develops and markets clinical products providing information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. Fluorescence in Situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH) reagents form the technology base of current Vysis products. The firm provides genomic disease management products and related customer and technical services globally. The firm recently introduced its Breast Aneusomy Probe Set for breast cancer research. This DNA probe set, which incorporates Vysis-patented FISH technology, enables laboratory researchers to detect gains or losses of chromosomes 1, 8, 11 and 17. By utilizing the Breast Aneusomy Probe Set with specimens from cell culture, ductal lavage, fine needle aspirates and nipple aspirates, researchers can study the role of aneusomies and how they relate to breast cancer. In other news, Vysis introduced its LSI MALT1 (18q21) Dual Color, Break Apart Rearrangement Probe. Using FISH technology, this product enables laboratory researchers to detect chromosomal rearrangements (translocations) of the MALT1 gene region on chromosome 18. The firm offers its employees a tuition reimbursement program.

BRANDS/DIVISIONS/AFFILIATES: Fluorescence In Situ Hybridization Comparative Genomic Hybridization Aneu Vysion Amoco Technology Company DNA FISH Breast Aneusomy Probe Set LSI MALT1 Abbott Laboratories

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John L. Bishop, CEO John L. Bishop, Pres. John R. Sluis, CFO Robert J. Koska, VP-Mktg. & Sales Susan Zint, Human Resources Steven A. Seelig, Sr. VP-Research & Dev. Steven A. Seelig, Chief Medical Officer William E. Murray, VP/Sec. William E. Murray, General Counsel R. Scott McKenzie, VP-Oper. Russel K. Enns, VP-Regulatory Affairs

Phone: 630-271-7000 Fax: 630-271-7138 Toll-Free: 800-553-7042 Address: 3100 Woodcreek Dr., Downers Grove, IL 60515-5400 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $24,000 2000 Profits: $- 500 Fiscal Year Ends: 12/31 1999 Sales: $21,700 1999 Profits: $-9,800 1998 Sales: $23,400 1998 Profits: $-16,800


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Unique genomic technology.

OTHER THOUGHTS:




West:

Southwest:

Midwest: Y

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



WARNER CHILCOTT PLC

www.wclabs.com


Y




TYPES OF BUSINESS:



Drugs-Women's Health and Urology

Warner Chilcott PLC develops and markets branded prescription pharmaceutical products in the United States directly to physician specialists, including obstetricians, gynecologists, urologists, cardiologists, dermatologists and general or family practitioners. The company is focused on the growing women's health and urology therapeutic categories. The firm is a subsidiary of Galen Holdings. The firm's primary focus is to strengthen its women's health care business segment and cease its business involvement in cardiology, due to the merger with Galen. In addition, the company will continue its focus on urology and OB/GYN products in the women’s health care segment. Warner Chilcott was previously in agreement with Schering-Plough Corp. to develop a line of cardiovascular products. The agreement was terminated due to the company's new core business focus. Warner Chilcott currently markets women's health care products, including NataFort, NataChew, Estrace Cream, Ovcon 35, Ovcon 50, Doryx, Mandelamine and Pyridium Plus. In recent news, Warner Chilcott announced that it will most likely market the product Menoring in the U.S., developed for the treatment of symptoms of menopause by Galen Holdings.

BRANDS/DIVISIONS/AFFILIATES: NataFort NataChew Estrace Ovcon 35 Ovcon 50 Pyridium Plus Menoring Galen Holdings

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James G. Andress, CEO Roger M. Boissonneault, Pres. Paul S. Herendeen, CFO/Exec. VP Kathleen A. Wickman, VP-Mktg. Elizabeth Greenberg, VP-Human Resources Tina de Vries, Sr. Dir.-Research and Dev. David G. Kelly, Sec./Group VP-Finance Beth P. Hecht, General Counsel/Sr. VP A. Dominick Musacchio, VP-New Bus. Dev. Diane M. Cady, Corp. Comm. Diane M. Cady, Sr. VP-Investor Rel. William J. Poll, V P-Finance/Trade Rel. Norma A. Enders, VP-Regulatory Affairs Robert K. Pallas, VP-Sales Christopher J. Gabanski, VP-Dermatology Sales John A. King, Chmn.

Phone: +353-1-709-4278 Fax: +353-1-662-4950 Toll-Free: 800-521-8813 Address: Lincoln House, Lincoln Pl., Dublin, 2 Ireland

FINANCIALS:



COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Merger with Galen Holdings/Acquisition of Ovcon products.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Bonus: $ Bonus: $

Southeast:



Northeast:

International: Y



WATSON PHARMACEUTICALS INC

www.watsonpharm.com


Y



Profits: 24


TYPES OF BUSINESS:



Drugs-Diversified Proprietary Pharmaceutical Products

Watson Pharmaceuticals, Inc. develops, manufactures and markets over 30 branded and over 140 generic pharmaceutical products. With an emphasis on niche pharmaceuticals, the company offers generic versions of popular brand-name pharmaceuticals such as the asthma drugs Proventil and Ventolin. Watson continues to invest in product development and, consequently, is capable of competing more effectively in the current health care environment. The company owns half of ANCIRC Pharmaceuticals and Somerset Pharmaceuticals. The company markets its proprietary products through its dermatological, women’s health, neuro-psychiatric and primary care divisions in order to foster close professional relationships with physicians in differing fields of medicine. Recently, the U.S. Food and Drug Administration approved Watson’s abbreviated new drug application for Microgestin Fe 1/5/30, an oral contraceptive. Ferrlecit, an injectable iron therapy product used to treat iron deficiency anemia in hemodialysis patients, was also recently approved. The firm acquired the rights to PapSure and Speculite from the Trylon Corporation. PapSure combines the results of a typical Pap smear and a speculoscopy using Speculite, a disposable chemiluminescent light for vaginal illumination, allowing physicians to visually identify possible cervical abnormalities. Combined, the two significantly increase the likelihood of identifying abnormal cells. The PapSure exam is currently the only in-office direct visual cervical exam cleared by the FDA for use in all women. Watson also recently acquired the U.S. rights to Actigall from Novartis Pharmaceuticals Corp. Actigall is used for the dissolution of certain types of gallbladder stones and the prevention of gallstone formation in obese patients experiencing rapid weight loss.

BRANDS/DIVISIONS/AFFILIATES: Schein Pharmaceuticals Watson Laboratories, Inc. ANCIRC Pharmaceuticals Somerset Pharmaceuticals TheraTech, Inc. Pharmacia Corporation Oclassen Dermatologics Monodox

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Allen Y. Chao, CEO Joseph Papa, COO Allen Y. Chao, Pres. Michael E. Boxer, CFO G. Frederick Wilkinson, Exec. VP-Mktg. And Sales Susan Kara, VP-Human Resources David C. Hsia, Sr. VP-Scientific Affairs Maria Chow , Sr. VP-Mfg. Oper. Robert C. Funsten, Corp. Sec. Robert C. Funsten, General Counsel David Lawrence, VP-Bus. Dev. Chato Abad, VP-Finance Donald A. Britt, Sr. VP-Corp. Quality Assurance Charles Ebert, Sr. VP-Research and Dev.

Phone: 909-270-1400 Fax: 909-493-5836 Toll-Free: Address: 311 Bonnie Circle, Corona, CA 92880 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $893,624 ( 9 months) 2002 Profits: $193,193 ( 9 months) Stock Ticker: WPI 2001 Sales: $1,160,700 2001 Profits: $116,400 Employees: 3,416 2000 Sales: $811,500 2000 Profits: $157,500 Fiscal Year Ends: 12/31 1999 Sales: $704,200 1999 Profits: $182,700 1998 Sales: $607,200 1998 Profits: $121,800


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $832,933 Stock Purch. Plan: Second Exec. Salary: $338,569 ADVANTAGE: Expanded niche strategy into the expanding dermatology market.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest: Y

Southeast: Y




Northeast: Y

International: Y



WOMEN FIRST HEALTHCARE

www.womenfirst.com


Y Y



Profits: 80


TYPES OF BUSINESS:



Drugs Health Information Self-Care Products Vitamins Direct Marketing Internet Portal

Women First HealthCare distributes pharmaceutical and self-care products as well as in-depth health information to women and the doctors who care for them in order to ease the transition into menopause. The company is divided into operating divisions in an effort to enhance the partnership between women and their clinicians and to provide women with the tools to make informed decisions about their self-care needs. The pharmaceutical division markets prescription products such as Ortho-Est, OrthoPrefest, Midrin, Bactrim, Synalgos and Equagesic and plans to expand the range of pharmaceutical products currently offered in the near future. The company has a license from Laboratoires Fournier S.A. for the distribution of Esclim in the U.S. and Puerto Rico. These products focus on estrogen replenishment and headache, pain and antibacterial/urinary tract infection management. The consumer business division is responsible for the newly introduced Daily Difference, a line of dietary supplements and health-specific vitamins, as well as the As We Change national mail order catalog and Internet business. The corporate marketing division at Women First HealthCare is responsible for offering access to a network of opinion leaders and practicing clinicians via the integration of continuing medical education programs, database communications, and the Professional Gateway portal of the company’s web site. The educational efforts of the company are guided by the Women First Health Advisory Board and are sponsored by the Mount Sinai School of Medicine and the University of Southern California Keck School of Medicine. Recently, the company announced it acquired the rights to VANIQA Cream from the joint venture between Bristol-Myers Squibb Company and The Gillette Company. VANIQA is a cream used to slow the growth of unwanted facial hair in women.

BRANDS/DIVISIONS/AFFILIATES: Ortho-Est Ortho-Prefest Midrin Bactrim VANIQA Esclim Daily Difference As We Change

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Edward F. Calesa, CEO Edward F. Calesa, Pres. Charles M. Caporale, CFO Charles M. Caporale, Corp. Sec. Charles M. Caporale, Treas. Saundra L. Childs, VP-Pharmaceuticals Randi C. Crawford, VP-Consumer Bus. Edward F. Calesa, Chmn.

Phone: 858-509-1171 Fax: 858-509-1353 Toll-Free: Address: 12220 El Camino Real, Ste. 400, San Diego, CA 92130 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $37,067 ( 9 months) 2002 Profits: $2,497 ( 9 months) Stock Ticker: WFHC 2001 Sales: $28,400 2001 Profits: $-3,400 Employees: 154 2000 Sales: $27,100 2000 Profits: $-22,600 Fiscal Year Ends: 12/31 1999 Sales: $22,500 1999 Profits: $-30,100 1998 Sales: $4,800 1998 Profits: $-9,400


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $396,094 Stock Purch. Plan: Y Second Exec. Salary: $200,000 ADVANTAGE: Focus on products and services related to menopause.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



WYETH

www.wyeth.com


Y



Profits: 7


TYPES OF BUSINESS:



Drugs-Diversified Medical Devices Animal Health Care Products Biologicals Vaccines Over-The-Counter Drugs Pharmaceuticals, Wholesale

Wyeth (formerly American Home Products) discovers, develops, manufacures, distributes and sells a diversified line of health care-based products, which arise from four divisions: Wyeth Pharmaceuticals, Wyeth Research, Wyeth Consumer Healthcare and Fort Dodge Animal Health. The company's name change reflects its shift in focus from holdings in diversified businesses to researchbased pharmaceuticals. The pharmaceuticals segment sells branded and generic pharmaceuticals, biologicals and nutritionals. Products include Premarin, which are estrogen tablets; anti-depressant Effexor; and the vaccine Prevnar. The consumer healthcare segment manufactures well-known over-the-counter products, including Advil, cold medicines Robitussin and Dimetapp and nutritional supplement Centrum. Apart from human care treatments, the firm also makes animal health care products and veterinary drugs, such as Synanthic and Fluvac through its Fort Dodge subsidiary. In recent news, Fort Dodge Animal Health introduced Fel-O-Vax FIV, the first feline vaccine to combat AIDS in cats. All of the company’s products are promoted and sold primarily to wholesalers, pharmacies, hospitals, physicians, retailers, veterinarians and other human and animal health care institutions worldwide. In other news, Wyeth recently sold its share in biotech company Immunex to Amgen. The firm also announced plans to sell some of its ESI Lederle generic human injectable pharmaceuticals business to Baxter Healthcare Corporation. Wyeth offers its employees childcare subsidies, flextime and educational assistance.

BRANDS/DIVISIONS/AFFILIATES: Effexor Premarin Fel-O-Vax FIV Advil Robitussin American Home Products Fort Dodge Scientific Protein Laboratories, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert A. Essner, CEO Robert A. Essner, Pres. Kenneth J. Martin, Sr. VP/CFO Rene R. Lewin, VP-Human Resources L. Patrick Gage, Sr. VP-Science & Tech. Bruce Fadem, VP-Corp. Systems/CIO Eileen M. Lach, Corp. Sec. Louis L. Hoynes, Jr., Exec. VP/General Counsel John B. Adams , VP-Corp. Dev. Marilyn H. Rhudy, VP-Public Affairs Justin R. Victoria, VP-Investor Rel. Jack M. O'Connor, VP/Treas. David M. Olivier, Sr. VP Steven A. Tasher, VP-Envir. Affairs Leo C. Jardot, VP-Gov. Rel. Paul J. Jones, VP/Comptroller

Phone: 973-660-5000 Fax: 973-660-7026 Toll-Free: 800-934-5556 Address: 5 Giralda Farms, Madison, NJ 07940-0874 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $10,770,041 ( 9 months) 2002 Profits: $2,873,178 ( 9 months) Stock Ticker: WYE 2001 Sales: $14,128,000 2001 Profits: $2,285,000 Employees: 52,289 2000 Sales: $13,262,754 2000 Profits: $-2,370,687 Fiscal Year Ends: 12/31 1999 Sales: $11,881,196 1999 Profits: $-1,227,200 1998 Sales: $11,268,570 1998 Profits: $2,474,300


COMPETITIVE

ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $1,760,000 Stock Purch. Plan: Second Exec. Salary: $1,116,667 ADVANTAGE: One of the world's leading health products companies.

OTHER THOUGHTS:



West: Y

Southwest: Y

Midwest: Y

Southeast: Y



Bonus: $1,968,000 Bonus: $1,675,001

Northeast: Y

International: Y



XECHEM INTERNATIONAL

www.xechem.com


Y



Y

TYPES OF BUSINESS:

Profits: 68




Drugs-Generic Biopharmaceutical Development Drug Research and Development Over-the-Counter Products

Xechem International is engaged in the biopharmaceutical industry and focuses on research, development and production of niche generic and proprietary drugs from natural sources. The company uses its extraction, isolation and purification technology to produce and manufacture PAXETOL, a brand of paclitaxel, which is used for the treatment of ovarian, breast and small cell lung cancers and AIDS-related Kaposi sarcomas. The company was recently granted patents for paclitaxel for specific diagnostic microbiological plates. Other generic drugs produced by Xechem include Vancomycin and Bleomycin. Xechem offers contract research services including fermentation, custom synthesis, chemical analysis, biological screening and formulation. The firm's subsidiary, XetaPharm, manufactures natural over-thecounter products including Melatonin, DHEA, GinsengOnce, GinkgoOnce, GarlicOnce and Gugulon, among others. Xechem Pharmaceutical China, Ltd. was established to carry on the business of manufacturing, marketing and distributing pharmaceutical and nutraceutical products in China. Xechem is currently awaiting patents for many new products, both in the United States and internationally. Recently, the company entered into a 20-year product distribution rights agreement with ChemoLab Corporation. Under this agreement, ChemoLab will provide drug distribution services in the United States for all of Xechem’s pharmaceutical products.

BRANDS/DIVISIONS/AF FILIATES: PAXETOL XetaPharm GinsengOnce GinkoOnce GarlicOnce Xechem Pharmaceutical China, Ltd. Vancomycin Bleomycin

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ramesh C. Pandey, CEO Ramesh C. Pandey, Pres. Ramesh C. Pandey, Treas. Ramesh C. Pandey, Chmn.

Phone: 732-247-3300 Fax: 732-247-4090 Toll-Free: Address: 100 Jersey Ave., Bldg. B, Ste. 310, New Brunswick, NJ 08901 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 316 ( 9 months) 2002 Profits: $-1,968 ( 9 months) Stock Ticker: ZKEM 2001 Sales: $ 200 2001 Profits: $-1,700 Employees: 17 2000 Sales: $ 2000 Profits: $-2,000 Fiscal Year Ends: 12/31 1999 Sales: $ 400 1999 Profits: $-2,400 1998 Sales: $ 100 1998 Profits: $-2,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $140,000 Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Use of extraction, isolation and purification technology.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast: Y

International: Y



XENOVA GROUP PLC

www.xenova.co.uk


Y




TYPES OF BUSINESS:



Drugs-Immune System Stimulation Pharmaceutical Treatments-Sexually Transmitted Diseases Drugs-Cancer Drugs-Bovine Herpes

Xenova Group is a biotechnology company with expertise in the development of new drugs for cancer and immunotherapy. In addition, Xenova develops drug therapies to fight cocaine and nicotine addictions and bovine herpes. Multiple drugs are currently in various stages of testing, with one drug, Tariquidar, in Phase III. After the company's merger with Cantab Pharmaceuticals, Xenova's primary focus shifted to cancer research with a secondary interest in immunotherapy. TA-HPV is a product designed to treat cervical cancer. The company has conducted clinical trials with TA-HPV on women with early- and late-stage cervical cancer related to human papillomavirus (HPV) infection. Another drug, TA-CIN, is in development for the treatment of pre-cancerous cervical lesions, known as cervical dysplasia. The drug will be administered for use in the early stages of this disease. The firm is conducting Phase I testing of DISC-GMCSF, a gene therapy product that stimulates a general attack from the immune system on cancer cells anywhere in the body. The drug stimulates the body’s natural defense and reduces the potential for disease recurrence. In recent news, the company's Tariquidar was granted FDA fasttrack review status. As a result, the drug will receive expeditious treatment by the administration in hopes that it will reach the market more quickly. In addition, Xenova is partnering with Millennium Pharmaceuticals to develop and commercialize novel compounds in North America.

BRANDS/DIVISIONS/AFFILIATES: DISC-GMCSF Tariquidar TA-HPV TA-CIN Cantab Pharmaceuticals, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David A. Oxlade, CEO Daniel Abrams , Group Fin. Dir. Michael Moore, Dir.-Research/Chief Scientific Officer John St. Clair Roberts, Dir.-Medical John Waterfall, Dir.-Dev. John B.H. Jackson, Chmn.

Phone: +44-1753 706600 Fax: +44-1753 706607 Toll-Free: Address: 957 Buckingham Ave., Slough, Berkshire SL1 4NL UK

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $- 180 ( months) Stock Ticker: XNVA 2001 Sales: $2,600 2001 Profits: $-22,400 Employees: 144 2000 Sales: $11,800 2000 Profits: $-5,500 Fiscal Year Ends: 12/31 1999 Sales: $8,500 1999 Profits: $-12,200 1998 Sales: $5,500 1998 Profits: $-10,100


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $327,012 Bonus: $110,561 Stock Purch. Plan: Y Second Exec. Salary: $222,680 Bonus: $74,746 ADVANTAGE: Numerous drugs in development/Focus on therapies for cancer and immunotherapy.

OTHER THOUGHTS:



West:

Southwest:

Midwest:

Southeast:



Northeast:

International: Y



XOMA LTD

www.xoma.com


Y



Profits: 181


TYPES OF BUSINESS:



Drugs-Immunologic and Inflammatory Disorder

XOMA develops and manufactures protein and antibodyderived biopharmaceuticals in Santa Monica and Berkeley, California. Infectious diseases, immunologic and inflammatory disorders and cancer are among XOMA’s medical targets. XOMA’s antibody development platform includes products such as bactericidal/permeability-increasing protein (BPI), as well as enabling technologies, including the cell expression system and a patented human engineering method for decreasing antibody immunogenicity. BPI is the company’s infectious disease product development platform, a human protein that includes many anti-infective properties. The company’s other product development programs include Raptiva, ONYX-015, ING-1, NUEPREX, MLN01, CAB-2 and BPI-derived compounds. Through a collaboration with Genetech, XOMA is developing Raptiva for the treatment of psoriasis and rheumatoid arthritis. The company has also entered into an alliance with Onyx Pharmaceuticals, Inc., for the production of ONYX-015 for the treatment of head, neck, lung, colorectal and pancreatic cancer. ING-1 is an antibody in development to target tumor cells. XOMA licensed NUPREX to Baxter Healthcare Corporation to further develop the drug. NUPREX is being tested for the potential use in infectious diseases and inflammatory conditions such as Crohn’s disease. CAB-2 and MLN01 are being developed in collaboration with Millennium Pharmaceuticals, Inc. for use in cardiovascular diseases such as ischemic heart disease, acute myocardial infarcation and aneurisms. Recently, the company entered into a licensing agreement with Dyax Corp. in which its antibody technologies will be used by Dyax to produce antibody products. XOMA offers employees educational assistance, flexible spending accounts for medical and dependent care expenses and a share purchase plan.

BRANDS/DIVISIONS/AFFILIATES: BPI Raptiva ONYX-015 ING-1 NUEPREX MLN01 CAB-2

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John L. Castello, CEO Clarence L. Dellio, COO John L. Castello, Pres. Peter B. Davis, CFO/VP-Finance Chris Wells, VP-Human Resources Patrick J. Scannon, Sr. VP/Chief Scientific Officer Marc D. Better, VP-Tech. Dev. Patrick J. Scannon, Chief Medical Officer Christopher J. Margolin, Corp. Sec. Christopher J. Margolin, General Counsel Clarence L. Dellio, Sr. VP-Oper. Michel Bergh, VP-Bus. Dev. Daniel P. Cafaro, VP-Regulatory Affairs Robert H. Gundel, VP- Preclinical Research Stephen F. Carroll, VP-Scientific and Product Dev. Ronald H. Carlson, VP-Quality John L. Castello, Chmn.

Phone: 510-644-1170 Fax: 510-644-0471 Toll-Free: 800-246-9662 Address: 2910 7th St., Berkeley, CA 94710 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $18,179 ( 9 months) 2002 Profits: $-28,346 ( 9 months) Stock Ticker: XOMA 2001 Sales: $17,300 2001 Profits: $-28,000 Employees: 193 2000 Sales: $6,700 2000 Profits: $-29,400 Fiscal Year Ends: 12/31 1999 Sales: $2,400 1999 Profits: $-45,800 1998 Sales: $6,300 1998 Profits: $-47,200


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $500,000 Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $340,000 Bonus: $ ADVANTAGE: Successful antibody development/Marketing alliances/Has licensed its technologies to more than 20 other firms.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Northeast:

International:



XTRANA INC

www.xtrana.com




Y Y

TYPES OF BUSINESS:

Profits: 9




Diagnostic Kits

Xtrana, Inc., formerly Biopool International, Inc., is engaged in the research, development, manufacture and marketing of technologies to simplify the analysis of DNA and RNA. These diagnostic tests are developed for use in drug discovery, detection of environmental and food contaminants, forensics and identity testing, human and animal diseases and genetic predisposition to disease. The Xtra Amp Extraction System is the company’s initial commercial product. It uses Xtra Bind material technology and provides the user with an extraction kit that is fast and easy to use. These extraction kits are available in three series, each for different applications. The Series I kit removes DNA from whole blood, buccal swab, buffy coat fraction and E. coli cells. The Series II kit removes RNA from tissue culture cells. The Series III kit removes DNA from whole tissue, tissue culture cells, rodent tails, yeast and blood stains. Xtrana distributes its kits in the U.S., Australia, Canada, Italy, Japan and the United Kingdom. Recently, the company announced it was awarded funds from the National Institutes of Health to develop a point-ofcare device for the diagnosis of viral respiratory infections over the next three years.

BRANDS/DIVISIONS/AFFILIATES: Biopool International, Inc. Xtra Amp Extraction System Xtra Bind

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Timothy J. Dahltorp, CEO Timothy J. Dahltorp, CFO John C. Gerdes, Chief Scientific Officer/VP-Research and Dev. Timothy J. Dahltorp, Corp. Sec. Michael D. Bick, Chmn.

Phone: 303-466-4424 Fax: 303-466-3326 Toll-Free: Address: 590 Burbank St., Ste. 205, Broomfield, CO 80020 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $ 700 ( 6 months) 2002 Profits: $-1,200 ( 6 months) Stock Ticker: XTRN 2001 Sales: $ 500 2001 Profits: $-2,900 Employees: 21 2000 Sales: $9,838 2000 Profits: $-1,109 Fiscal Year Ends: 12/31 1999 Sales: $8,842 1999 Profits: $ 714 1998 Sales: $7,870 1998 Profits: $ 414


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $227,659 Stock Purch. Plan: Second Exec. Salary: $184,898 ADVANTAGE: Technology to simplify DNA and RNA analysis.

OTHER THOUGHTS:



West: Y

Southwest:

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:



ZILA INC

www.zila.com


Y



Profits: 97


TYPES OF BUSINESS:

Y



Drugs-Oral Over-the-Counter Drugs

Zila, Inc. is a manufacturer and marketer of pharmaceutical, biomedical, dental and nutritional products. The company’s business is organized into three major product groups: pharmaceutical products, professional products and nutraceutical products. The pharmaceutical products group consists of over-thecounter and prescription products, including the Zilactin family of products, Peridex prescription mouth rinse and OraTest, an oral cancer diagnostic system. The OraTest product is available or approved in 15 countries, and the company is pursuing FDA approval under the management of ILEX Oncology Services, Inc. Subsidiary Zila Pharmaceuticals is part of the pharmaceutical products group. The professional products group operates through the company’s Biodental Technologies Corp. subsidiary. The nutraceutical products group includes Oxycal Laboratories, Inc. and its two subsidiaries Inter-Cal Corporation and Oxycal Export, Inc. Inter-Cal is currently marketing its patented Ester-C, non-acidic vitamin ingredients that are incorporated in combination products to treat eye ailments. Zila recently sold its fullservice dental distribution operations to Henry Schein, Inc. The purchased division will converge with Sullivan-Schein Dental, Schein's U.S.-based dental operations.

BRANDS/DIVISIONS/AFFILIATES: OraTest Ester-C Palmettx Inter-Cal Corporation, Inc. Oxycal Export, Inc. Biodental Technologies Corp. Zila Pharmaceuticals, Inc.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Douglas D. Burkett, CEO Thomas M. Laughlin, COO Douglas D. Burkett, Pres. Bradley C. Anderson, CFO Janice L. Backus, Human Resources Janice L. Backus, Corp. Sec. Bradley C. Anderson, Treas.

Phone: 602-266-6700 Fax: 602-234-2264 Toll-Free: Address: 5227 N. 7th St., Phoenix, AZ 85014 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $34,900 (12 months) 2002 Profits: $-12,000 (12 months) Stock Ticker: ZILA 2001 Sales: $73,700 2001 Profits: $-6,300 Employees: 266 2000 Sales: $77,600 2000 Profits: $2,900 Fiscal Year Ends: 7/31 1999 Sales: $71,300 1999 Profits: $-2,000 1998 Sales: $62,100 1998 Profits: $2,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: ADVANTAGE: Strong over-the-counter drugs group.

OTHER THOUGHTS:




West: Y

Southwest: Y

Midwest: Y

Southeast:



Bonus: $27,859 Bonus: $26,681

Northeast:

International:



ZONAGEN INCORPORATED

www.zonagen.com


Y



Profits: 63


TYPES OF BUSINESS:



Drugs-Fertility and Sexual Dysfunction Human Reproductive System Specialization Reproductive Vaccines Female Health Drugs Male Health Drugs Urological Applications

Zonagen, Inc. is a biopharmaceutical company engaged in the development of products for the human reproductive system, including products for sexual dysfunction, vaccines, products for fertility and female health. The company also develops urological applications, specifically for prostate cancer. Vasomax, its leading product, is an oral formulation of phentolamine, developed for the treatment of male erectile dysfunction. Similarly, the firm is currently in clinical trials with Vasofem, a product developed for the treatment of female sexual dysfunctions. Bimexes and Erxin are also being developed for the treatment of male erectile dysfunction. Zonagen is also conducting trials on Zproxal, which stimulates the human immune system to destroy prostate cancer cells in hormone independent tumors and Gonaxin, which seeks to educe an immune response that neutralizes the hormone signal required for continued tumor growth. Recently, Zonagen announced the FDA is delaying approval of Vasomax in the U.S. until an additional twoyear rodent study is conducted and completed. In other news, Zonagen announced the definitive agreement to merge with Lavipharm Corp., a drug formulation and delivery company. The combined company will change its name to Lavipharm.

BRANDS/DIVISIONS/AFFILIATES: Vasomax Vasofem Bimexes ERxin Zproxal Gonaxin Lavipharm Corp.

CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph S. Podolski, CEO Joseph S. Podolski, Pres. Louis Ploth, CFO Louis Ploth, Corp. Sec. Louis Ploth, VP-Bus. Dev. Paul Lammers, Sr. VP-Clinical and Regulatory Affairs Martin P. Sutter, Chmn.

Phone: 281-719-3400 Fax: 281-719-3446 Toll-Free: Address: 2408 Timberloch Place, Ste. B-4, The Woodlands , TX 77380 US

FINANCIALS:

Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $5,008 ( 9 months) 2002 Profits: $-2,521 ( 9 months) Stock Ticker: ZONA 2001 Sales: $2,300 2001 Profits: $- 800 Employees: 10 2000 Sales: $4,600 2000 Profits: $-11,200 Fiscal Year Ends: 12/31 1999 Sales: $2,400 1999 Profits: $-11,900 1998 Sales: $13,400 1998 Profits: $-12,300


COMPETITIVE

ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $235,000 Stock Purch. Plan: Second Exec. Salary: $139,133 ADVANTAGE: Focus on reproductive system therapies.

OTHER THOUGHTS:



West:

Southwest: Y

Midwest:

Southeast:



Bonus: $ Bonus: $

Northeast:

International:







Appendix Biotech Research Techniques & Genetic Illustrations Editor’s Note: This chapter is based largely on data provided by the Office of Science Education and Outreach, National Human Genome Research Institute , U.S. National Institutes of Health.

CHROMOSOME MICRODISSECTION Chromosome microdissection is a technique that physically removes a large section of DNA from an entire chromosome. The minimum amount of DNA that can be isolated in this manner is 10 million base pairs, which equal hundreds or thousands of individual genes. Scientists who study chromosomes, called cytogeneticists, are able to identify each chromosome based on its unique pattern of dark and light bands. Certain abnormalities, however, cause chromosomes to have unusual banding patterns. For example, one chromosome may have a piece of another chromosome inserted within it, creating extra bands. In another case, a portion of a chromosome may be repeated over and over again, resulting in an unusually wide dark band. Because the chromosomes of many tumor cells exhibit irregular bands, some chromosomal aberrations have been linked to cancer and inherited genetic disorders. Therefore, to understand more about what causes these conditions, scientists wish to determine which genes and DNA

sequences are located in the regions of the chromosomes that contain these unusual bands. Chromosome microdissection is a relatively new way of isolating these regions by removing the DNA from the band and making that area of DNA available for further study. To prepare cells for chromosome microdissection, a scientist first treats them with a chemical that forces them into metaphase, a portion of the cell cycle where the chromosomes are tightly coiled and highly visible. Next, the cells are dropped onto a microscope slide so that the nucleus, which holds all of the genetic material together, breaks apart and releases the chromosomes onto the slide. Then, under a microscope, the scientist locates the specific band of interest, and, using a very fine needle, tears that band away from the rest of the chromosome. After using a procedure called PCR (polymerase chain reaction) to copy the DNA in the band repeatedly, the researcher can use those copies to study the region of the chromosome. DNA CHIP TECHNOLOGY Although scientists know that mutations, or alterations in a gene's DNA, result in certain diseases, it is often difficult for them to identify and characterize these mutations because most large genes have many regions where a mutation could




occur and cause disease. Examples of such genes are BRCA1 and BRCA2, which are believed to cause as many as 60% of all cases of hereditary breast and ovarian cancers. In BRCA1 alone, over 500 different mutations have already been discovered. The DNA microchip is a revolutionary tool used to identify mutations in genes like BRCA1 and BRCA2. The chip, which consists of a small glass plate encased in plastic, is manufactured using a process similar to the one used to make computer microchips. On the surface, each chip contains synthetic single stranded DNA sequences identical to a normal gene. To determine, for example, whether an individual possesses a mutation for BRCA1 or BRCA2, a scientist first obtains a sample of DNA from her blood, as well as a sample that does not contain a mutation in either gene. After denaturing, or separating the samples of DNA into single strands, and cutting them into smaller, more manageable fragments, the researcher labels the fragments with fluorescent dyes. The individual's DNA is labeled with green dye and the normal DNA is labeled with red dye. Both sets of labeled DNA are then inserted into the chip and allowed to hybridize, or bind, to the synthetic BRCA1 or BRCA2 DNA on the chip. If the individual does not have a mutation for the gene, both the red and green samples will hybridize with the sequences on the chip. If the individual does possess a mutation, the red (normal) DNA will still hybridize perfectly with the DNA on the chip, but the green (individual's) DNA will not hybridize properly in the region where the mutation is located. The scientist can then examine this area more closely to confirm that a mutation is present. Scientists hope to be able to use these chips to conduct population studies, for example to determine how often individuals with a particular mutation actually develop breast cancer. In the future, new chips will be generated to help assess individuals' risks for other types of cancer, as well as other diseases, including heart disease and diabetes. DNA MICROARRAY TECHNOLOGY Although all of the cells in the human body contain the same genetic material, the same genes are not active in all of those cells. Studying which genes are active and which are inactive in different kinds of cells helps scientists understand more about how these cells function and about what happens when the genes in a cell don't function properly.

In the past, scientists have only been able to conduct such genetic analyses on a few genes at once. With the development of DNA microarray technology, however, scientists can now examine thousands of genes at the same time, an advance that will help them determine the complex relationships between individual genes. Microarray is based on a database of fragments of genes called expressed sequence tags (ESTs). Minuscule amounts of hundreds or thousands of these ESTs are arranged on a single microscope slide by a robot. Next the genetic messenger molecules, which signal the production of proteins, from a particular cell are labeled with fluorescent tags and allowed to hybridize, or bind, to the ESTs on the slide whose sequences are complementary to the those of the messengers. After a scanner measures the fluorescence of each sample on the slide, scientists can determine how active the genes represented by the ESTs are in the cell. Strong fluorescence indicates that many of the cell's messengers hybridized to the EST and, therefore, that the gene is very active in the cell. Conversely, no fluorescence indicates that none of the messenger molecules hybridized to the EST and that the gene is inactive in the cell. Microarray technology helps researchers learn more about many different diseases-heart disease, mental illness, and infectious disease, to name only a few. One intense area of microarray research at the NIH is the study of cancer. In the past, scientists have classified different types of cancer based on the organs in which the tumors develop. With the help of microarray technology, however, they are able to further classify these types of cancer based on the patterns of gene activity in the tumor cells and then design treatment strategies targeted directly to each specific type of cancer. Additionally, by examining the differences in gene activity between untreated and treated tumor cells, scientists can better understand how different types of cancer therapies affect tumors and can develop more effective treatments. FLUORESCENCE IN SITU HYBRIDIZATION (FISH) FISH involves the preparation of short sequences of single-stranded DNA, called probes, which are complementary to the DNA sequences the researchers wish to paint and examine. These probes hybridize, or bind, to the complementary DNA and, because they are labeled with fluorescent tags, allow researchers to see the location of those sequences of




DNA. Unlike most other techniques used to study chromosomes, which require that the cells be actively dividing, FISH can also be performed on nondividing cells, making it a highly versatile procedure. Scientists use three different types of FISH probes, each of which has a different application: Locus specific probes hybridize to a particular region of a chromosome. This type of probe is useful when scientists have isolated a small portion of a gene and wish to determine which chromosome that gene is located on. They prepare a probe from the piece of the gene and observe which chromosome the probe hybridizes to. Alphoid or centromeric repeat probes are generated from repetitive sequences found at the centromeres of chromosomes. Because each chromosome can be painted in a different color, researchers use this technique to determine whether an individual has the correct number of chromosomes or, for example, whether a person has an extra copy of a chromosome. Whole chromosome probes are actually collections of smaller probes, each of which hybridizes to a different sequence along the length of the same chromosome. Using these libraries of probes, scientists are able to paint an entire chromosome and generate a spectral karyotype. This full color image of the chromosomes allows scientists to distinguish between the chromosomes based on their colors, rather than based on their dark and light banding patterns, viewed in black and white through traditional karyotyping. Whole chromosome probes are particularly useful for examining chromosomal abnormalities, for example, when a piece of one chromosome is attached to the end of another chromosome. POLYMERASE CHAIN REACTION (PCR) Sometimes called "molecular photocopying," the polymerase chain reaction (PCR) is a fast and inexpensive technique used to amplify, or copy, small segments of DNA. Because significant amounts of a sample of DNA are necessary for molecular and genetic analyses, studies of isolated pieces of DNA would be impossible without PCR amplification. Often heralded as one of the most important scientific advances of the decade, PCR so revolutionized the way molecular biologists approach the study of DNA that its creator was awarded the Nobel Prize for Chemistry in 1993. To amplify a segment of DNA using PCR, the sample is first heated so the DNA denatures, or separates into two pieces of single -stranded DNA.

Next, an enzyme called Taq polymerase synthesizes, or makes, two new strands of DNA, using the original strands as templates; this process results in the duplication of the DNA, with each of the new molecules containing one old and one new strand of DNA. The cycle of denaturing and synthesizing new DNA is repeated as many as 30 or 40 times, leading to more than 1 billion exact copies of the original segment of DNA. The entire cycling process of PCR is automated and can be completed in just a few hours. A machine called a thermocycler, which is programmed to alter the temperature of the reaction every few minutes to allow DNA denaturing and synthesis, directs it. Once amplified, PCR products can be used in many different laboratory procedures; for example, most mapping techniques in the Human Genome Project rely on PCR. PCR is also valuable in a number of laboratory and clinical techniques, including DNA fingerprinting, detection of bacteria or viruses (particularly AIDS), and diagnosis of genetic disorders. SPECTRAL KARYOTYPING (SKY) Spectral karyotyping (SKY) is a laboratory technique that allows scientists to visualize all 23 pairs of human chromosomes at one time, with each pair of chromosomes painted in a different fluorescent color. Many diseases are associated with particular chromosomal abnormalities. For example, chromosomes in cancerous cells frequently exhibit aberrations called translocations, where a piece of one chromosome breaks off and attaches to the end of another chromosome. Identifying such chromosome abnormalities and determining their role in disease is an important step in developing new methods for diagnosing many genetic disorders. Traditional karyotyping allows scientists to view the full set of human chromosomes in black and white, a technique that is useful for observing the number and size of the chromosomes. Scientists, however, cannot accurately identify many translocations or other abnormalities using only a black and white karyotype. But by using SKY, they can easily see instances where a chromosome, painted in one color, has a small piece of a different chromosome, painted in another color, attached to it. SKY involves the preparation of a large collection of short sequences of single -stranded DNA called probes. Each of the individual probes in this DNA library is complementary to a unique region of




one chromosome; together, all of the probes make up a network of DNA that is complementary to all of the chromosomes within the human genome. Each probe is labeled with a fluorescent molecule that corresponds to the chromosome to which it is complementary. For example, probes that are complementary to chromosome 1 are labeled with yellow molecules, while those that are complementary to chromosome 2 are labeled with red molecules, and so on. When these probes are mixed with the chromosomes from a human cell, the probes hybridize, or bind, to the DNA in the chromosomes. As they hybridize, the fluorescent probes essentially paint the set of chromosomes in a rainbow of colors. Scientists can then use computers to analyze the painted chromosomes to determine whether any of them exhibit translocations or other structural abnormalities.




ANDENOVIRUS - A group of DNA containing viruses, which cause respiratory disease, including one form of the common cold. Adenoviruses can also be genetically modified and used in gene therapy to treat cystic fibrosis, cancer, and other diseases.




AMINO ACID - A group of 20 different kinds of small molecules that link together in long chains to form proteins. Often referred to as the "building blocks" of proteins.

ANTIBODY - A blood prote in that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop immunity to disease.




BASE PAIR - Two bases, which form a "rung of the DNA ladder." A DNA nucleotide is made of a molecule of sugar, a molecule of phosphoric acid and a molecule called a base. The bases are the "letters" that spell out the genetic code. In DNA, the code letters are A, T, G and C, which stand for the chemicals adenine, thymine, guanine and cytosine, respectively. In base pairing, adenine always pairs with thymine, and guanine always pairs with cytosine.

BASE PAIR (detailed)




BLASTOCYST - A fertilized embryo, aged four to eleven days, which consists of multiplying cells both outside and inside a cavity. It is the blastocyst that embeds itself in the uterine wall and ultimately develops into a fetus. Blastocysts are utilized outside the womb during the process of stem cell cultivation.




CHROMOSOME - One of the threadlike "packages" of genes and other DNA in the nucleus of a cell. Different kinds of organisms have different numbers of chromosomes. Humans have 23 pairs of chromosomes, 46 in all: 44 autosomes and two sex chromosomes. Each parent contributes one chromosome to each pair, so children get half of their chromosomes from their mothers and half from their fathers.




CYTOGENETIC MAP - The visual appearance of a chromosome when stained and examined under a microscope. Particularly important are visually distinct regions, called light and dark bands, which give each of the chromosomes a unique appearance. This feature allows a person's chromosomes to be studied in a clinical test known as a karyotype, which allows scientists to look for chromosomal alterations.




DNA (deoxyribonucleic acid) - The chemical inside the nucleus of a cell that carries the genetic instructions for making living organisms.




DNA REPLICATION - The process by which the DNA double helix unwinds and makes an exact copy of itself.




ENZYME - A protein that encourages a biochemical reaction, usually speeding it up. Organisms could not function if they had no enzymes.

GENE - The functional and physical unit of heredity passed from parent to offspring. Genes are pieces of DNA, and most genes contain the information for making a specific protein.




MICROARRY TECHNOLOGY - A way of studying how large numbers of genes interact with each other and how a cell's regulatory networks control vast batteries of genes simultaneously. The method uses a robot to precisely apply tiny droplets containing functional DNA to glass slides. Researchers then attach fluorescent labels to DNA from the cell they are studying. The labeled probes are allowed to bind to complementary DNA strands on the slides. The slides are put into a scanning microscope that can measure the brightness of each fluorescent dot; brightness reveals how much of a specific DNA fragment is present, an indicator of how active it is.




NUCLEOTIDE - One of the structural components, or building blocks, of DNA and RNA. A nucleotide consists of a base (one of four chemicals: adenine, thymine, guanine and cytosine) plus a molecule of sugar and one of phosphoric acid.




NUCLEOTIDE (detailed)




PROTEIN - A large complex molecule made up of one or more chains of amino acids. Proteins perform a wide variety of activities in the cell.




RIBONUCLEIC ACID (RNA) - A chemical similar to a single strand of DNA. In RNA, the letter U, which stands for uracil, is substituted for T in the genetic code. RNA delivers DNA's genetic message to the cytoplasm of a cell where proteins are made.




RNA (detailed)







ADDITIONAL INDEXES

CONTENTS: Index of Firms Noted as “Hot Spots for Advancement” for Women/Minorities

p. 498

Index by Subsidiaries, Brand Names and Selected Affiliations

p. 500




INDEX OF FIRMS NOTED AS HOT SPOTS FOR ADVANCEMENT FOR WOMEN & MINORITIES ABBOTT LABORATORIES ABGENIX INC ABLE LABORATORIES ADVANCED MAGNETICS INC AFFYMETRIX INC ALEXION PHARMACEUTICALS ALLERGAN INC ALLIANCE PHARMACEUTICAL CORP ALLOS THERAPEUTICS INC ALPHARMA INC ALTEON INC ALZA CORP AMERSHAM PLC AMGEN INC AMYLIN PHARMACEUTICALS INC APHTON CORP APPLERA CORPORATION ARIAD PHARMACEUTICALS ARQULE INC BARR LABORATORIES INC BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BIO TECHNOLOGY GENERAL CORP BIOANALYTICAL SYSTEMS INC BIOGEN INC BIONX IMPLANTS INC BIOPURE CORPORATION BIORA AB BIOSITE INC BIOTRANSPLANT INC BONE CARE INTERNATIONAL BOSTON BIOMEDICA INC BOSTON LIFE SCIENCES INC BRISTOL MYERS SQUIBB CO CARDIOME PHARMACEUTICAL CORP CELL PATHWAYS INC CELL THERAPEUTICS INC CELLTECH GROUP PLC CELSIS INTERNATIONAL PLC CERUS CORPORATION CHARLES RIVER LABORATORIES CORP CHESAPEAKE BIOLOGICAL LAB CHIRON CORP COLLATERAL THERAPEUTICS COLUMBIA LABORATORIES CONNETICS CORPORATION CORIXA CORPORATION CORTEX PHARMACEUTICALS CURAGEN CORPORATION CURIS INC CV THERAPEUTICS INC DIAGNOSTIC PRODUCTS CORPORATION DIGENE CORPORATION

DISCOVERY LABORATORIES DIVERSA CORPORATION DONLAR BIOSYNTREX E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO EMBREX INC ENDO PHARMACEUTICALS HOLDINGS INC ENTREMED INC EPIX MEDICAL INC ESSENTIAL THERAPEUTICS INC EXELIXIS INC E-Z-EM INC FOREST LABORATORIES INC GELTEX PHARMACEUTICALS GENELABS TECHNOLOGIES INC GENENCOR INTERNATIONAL INC GENENTECH INC GENEREX BIOTECHNOLOGY GENSET SA GENTA INC GENZYME CORP GENZYME MOLECULAR ONCOLOGY GERON CORPORATION GILEAD SCIENCES INC GTC BIOTHERAPEUTICS INC GUILFORD PHARMACEUTICALS INC HAUSER INC HEMISPHERX BIOPHARMA INC HUMAN GENOME SCIENCES INC HYSEQ INC ID BIOMEDICAL CORPORATION IDEC PHARMACEUTICALS CORP IDEXX LABORATORIES INC ILLUMINA INC IMCLONE SYSTEMS INC IMMTECH INTERNATIONAL IMMUNEX CORP IMMUNOGEN INC IMS HEALTH INC INCYTE GENOMICS INC INFORMAX INC INKINE PHARMACEUTICAL CO INSITE VISION INC INSPIRE PHARMACEUTICALS INC INTEGRA LIFESCIENCES CORP INTERFERON SCIENCES INC INTERMUNE PHARMACEUTICALS INC INTERNATIONAL ISOTOPES INTRABIOTICS PHARMACEUTICALS INVITROGEN CORPORATION IOMED INC ISIS PHARMACEUTICALS INC JOHNSON & JOHNSON KING PHARMACEUTICALS INC LA JOLLA PHARMACEUTICAL LARGE SCALE BIOLOGY CORP LEXICON GENETICS INC




LIFECORE BIOMEDICAL INC LYNX THERAPEUTICS INC MATRIX PHARMACEUTICAL MDS INC MEDAREX INC MEDICIS PHARMACEUTICAL CORP MEDTOX SCIENTIFIC INC MERCK & CO INC MILLENNIUM PHARMACEUTICALS INC MILLIPORE CORP MOLECULAR DEVICES CORP MONSANTO CO MYLAN LABORATORIES INC NAPRO BIOTHERAPEUTICS INC NEOSE TECHNOLOGIES INC NEUROCRINE BIOSCIENCES INC ONYX PHARMACEUTICALS INC OSI PHARMACEUTICALS INC PACIFIC BIOMETRICS INC PAREXEL INTERNATIONAL PDK LABS INC PFIZER INC PHARMACEUTICAL FORMULATIONS INC PHARMACYCLICS INC PROTEIN DESIGN LABS INC PROTEIN POLYMER TECHNOLOGIES SCIOS INC SEQUENOM INC SONUS PHARMACEUTICALS STEMCELLS, INC SUPERGEN INC SYNOVIS LIFE TECHNOLOGIES INC TANOX INC TECHNE CORP TELIK INC TEXAS BIOTECHNOLOGY CORP THERAGENICS CORP TITAN PHARMACEUTICALS TRANSKARYOTIC THERAPIES V I TECHNOLOGIES INC VALENTIS INC VERTEX PHARMACEUTICALS INC VICAL INC VIRAGEN INC VIRBAC INC VIROLOGIC INC WARNER CHILCOTT PLC WATSON PHARMACEUTICALS INC WOMEN FIRST HEALTHCARE WYETH




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS Brand or subsidiary, followed by the name of the related corporation (R,R)-Formoterol; SEPRACOR INC (S)-Oxybutynin; SEPRACOR INC 3TC; SHIRE-BIOCHEM INC 3TC; SHIRE PHARMACEUTICALS PLC 5G1.1; ALEXION PHARMACEUTICALS A GA-II; TRANSKARYOTIC THERAPIES AAI International; AAIPHARMA INC aaiResearch; AAIPHARMA INC AastromReplicell; AASTROM BIOSCIENCES INC AAV Vectors; AVIGEN INC Abarelix; AMGEN INC Abbott Laboratories; GENSET SA Abbott Laboratories; NAPRO BIOTHERAPEUTICS INC Abbott Laboratories; SEPRACOR INC Abbott Laboratories; VYS IS INC Abelcet; ENZON INC Abgenix, Inc.; CELL GENESYS INC Abgenix, Inc.; AVI BIOPHARMA INC Abgenix, Inc.; SANGSTAT MEDICAL CORP Able Labs; ABLE LABORATORIES Abreva; AVANIR PHARMACEUTICALS Absorption Enhancing Technology; SHEFFIELD PHARMACEUTICALS AC Vaccine; AVAX TECHNOLOGIES INC AC2993; AMYLIN PHARMACEUTICALS INC AC2993 LAR; AMYLIN PHARMACEUTICALS INC AC3056; AMYLIN PHARMACEUTICALS INC Acanto; SYNGENTA AG Accelerated Intelligent Drug Discovery; NEUROGEN CORP Accelerator; ERESEARCH TECHNOLOGY INC Accelrys Software; PHARMACOPEIA INC Access Pharmaceuticals Australia; ACCESS PHARMACEUTICALS Accolate; ASTRAZENECA PLC Accucomp, Ltd.; MALLINCKRODT INC Accufusion, Ltd.; MALLINCKRODT INC Accurun; BOSTON BIOMEDICA INC AccuTrac; COMMONWEALTH BIOTECHNOLOGIES INC ACER/EXCEL, Inc.; KENDLE INTERNATIONAL INC Acidmantle; BRADLEY PHARMACEUTICALS ACLARA BioSciences; THIRD WAVE TECHNOLOGIES INC Acne PDT; DUSA PHARMACEUTICALS INC Acquest System; MOLECULAR DEVICES CORP ACTIMID; CELGENE CORP

Actimmune; INTERMUNE PHARMACEUTICALS INC Actinic Keratoses (AK) PDT; DUSA PHARMACEUTICALS INC Actiq; CEPHALON INC Activase; GENENTECH INC Activase; GENENTECH INC Activelle; NOVO-NORDISK AS Acumedia; NEOGEN CORPORATION Acyclovir; PHARMACEUTICAL RESOURCES INC ADAGEN; ENZON INC ADCON; GLIATECH INC Adderall XR; SHIRE PHARMACEUTICALS PLC Adentri; CV THERAPEUTICS INC Advance Coupe; CELSIS INTERNATIONAL PLC Advance.im; CELSIS INTERNATIONAL PLC Advanced BioScience Laboratories, Inc.; AKZO NOBEL NV Advanced Medical Optics, Inc.; ALLERGAN INC Advantage-S; COLUMBIA LABORATORIES Advicor; KOS PHARMACEUTICALS INC Advil; WYETH AEOL 10113; INCARA PHARMACEUTICALS AEOL 10150; INCARA PHARMACEUTICALS Aeolus Pharmaceuticals, Inc.; INCARA PHARMACEUTICALS Aerobid; FOREST LABORATORIES INC Aeson; HOLLIS -EDEN PHARMACEUTICALS Aeson Therapeutics, Inc.; HOLLIS -EDEN PHARMACEUTICALS AF-1; BOSTON LIFE SCIENCES INC Afferon Corp.; ICOS CORPORATION AFP-Scan; IMMUNOMEDICS INC Afrin; SCHERING-PLOUGH CORP AG-702; ANTIGENICS INC Agdia, Inc.; NEOGEN CORPORATION Agenerase; VERTEX PHARMACEUTICALS INC Agenerase; VERTEX PHARMACEUTICALS INC Agilent 2100 Bioanalyzer; CALIPER TECHNOLOGIES CORP Agilent Technologies; CALIPER TECHNOLOGIES CORP Agrinomics LLC; EXELIXIS PLANT SCIENCES INC Agritope, Inc.; EXELIXIS PLANT SCIENCES INC Agrylin; SHIRE PHARMACEUTICALS PLC AIDSVAX; VAXGEN INC AIMS/PCMS; ARQULE INC AIP-001; ELAN CORP PLC AIR; ALKERMES INC Akineton; PHARMACEUTICAL RESOURCES INC AKuScreen; CELSIS INTERNATIONAL PLC Akzo Nobel INDA; AKZO NOBEL NV Akzo Nobel, Inc.; AKZO NOBEL NV AlaSTAT; DIAGNOSTIC PRODUCTS CORPORATION Albany Research Center; ALBANY MOLECULAR RESEARCH




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Albulast; ALKERMES INC Albuterol; ALKERMES INC Albuterol Sulfate Inhalation Solution; HI TECH PHARMACAL CO INC Alchemy 2000; TRIPOS INC Alcon; ANGIOTECH PHARMACEUTICALS Aldurazyme; BIOMARIN PHARMACEUTICAL Alfenta; AKORN INC ALFERON LDO; INTERFERON SCIENCES INC ALFERON N; INTERFERON SCIENCES INC ALFERON N GEL; INTERFERON SCIENCES INC Algos Pharmaceutical Corporation; ENDO PHARMACEUTICALS HOLDINGS INC Allegra; ALBANY MOLECULAR RESEARCH Allegra/Telfast; AVENTIS SA Allercreme; SENETEK PLC Allerfed; PHARMACEUTICAL FORMULATIONS INC Allergan Ligand Retinoid Therapeutics, Inc.; LIGAND PHARMACEUTICALS INC Alliance Pharmaceutical Corp.; MOLECULAR BIOSYSTEMS INC Alloderm; LIFECELL CORPORATION AlloMune System; BIOTRANSPLANT INC Aloprim; NABI PHARMACEUTICALS Allovectin-7; VICAL INC Alphagan; ALLERGAN INC Alpharma; ASCENT PEDIATRICS INC Alprox-TD; NEXMED INC Alrex; PHARMOS CORPORATION ALT-711; ALTEON INC ALT-744; ALTEON INC Altace; KING PHARMACEUTICALS INC Althexis Company, Inc. (The); ESSENTIAL THERAPEUTICS INC Altropane; BOSTON LIFE SCIENCES INC Altus Biologicals, Inc.; VERTEX PHARMACEUTICALS INC ALX -0600; NPS PHARMACEUTICALS INC ALZA Corporation; DURECT CORP ALZA Corporation; JOHNSON & JOHNSON AMAP Chemistry Operating System; ARQULE INC Amarin Development AB; AMARIN CORPORATION Amarin Pharmaceuticals, Inc.; AMARIN CORPORATION PLC AMAX Destiny; TRINITY BIOTECH PLC AMBI, Inc.; NUTRITION 21 INC AmBisome; GILEAD SCIENCES INC Amdoxovir; TRIANGLE PHARMACEUTICALS AME System; APPLIED MOLECULAR EVOLUTION INC American Home Products; ORAPHARMA INC American Home Products; VIROPHARMA INC American Home Products; PROTEIN DESIGN LABS American Home Products; WYETH American Home Products Corporation; IMMUNEX

Amersham; MOLECULAR BIOSYSTEMS INC Amersham Biosciences; AMERSHAM PLC Amersham Health; AMERSHAM PLC AMEVIVE; BIOGEN INC Amgen; IMMUNEX CORP AMICAR; IMMUNEX CORP AmiGro; DONLAR BIOSYNTREX AmiSorb; DONLAR BIOSYNTREX Amistar; SYNGENTA AG Amlexanox; ACCESS PHARMACEUTICALS AMO Holdings, Inc.; ALLERGAN INC Amoco Technology Company; VYSIS INC Amoxicillin for Oral Suspension; TEVA PHARMACEUTICAL INDUSTRIES AMPAKINE; CORTEX PHARMACEUTICALS Ampersand Medical Corporation; ACCUMED INTERNATIONAL Amphotec; INTERMUNE PHARMACEUTICALS INC Ampligen; HEMISPHERX BIOPHARMA INC AmVet Pharmaceuicals; NEOGEN CORPORATION AMVISC; ANIKA THERAPEUTICS INC Amylin Europe, Ltd.; AMYLIN PHARMACEUTICALS INC Amyloid Inhibitory Peptide; AXONYX INC AN-1792; ELAN CORP PLC Analpram HC; NOVAVAX INC Analyst Bench-top Chemistry System; HEMAGEN DIAGNOSTICS INC Analyst System; MOLECULAR DEVICES CORP ANCIRC Pharmaceuticals; ANDRX CORP ANCIRC Pharmaceuticals; WATSON PHARMACEUTICALS INC Anda, Inc.; ANDRX CORP Androgenics Technologies, Inc.; GENTA INC ANDRO-Ject; NOVAVAX INC ANDROSORB; NOVAVAX INC Andrx Laboratories; ANDRX CORP Andrx Pharmaceuticals; ANDRX CORP Anesta; CEPHALON INC Aneu Vysion; VYSIS INC AngioDynamics, Inc.; E-Z-EM INC Angioprotein-1; REGENERON PHARMACEUTICALS INC Angiostatin; ENTREMED INC Angiozyme; RIBOZYME PHARMACEUTICALS Angle-independent Doppler Blood Flow Technology; NEOPROBE CORPORATION Anipryl; DRAXIS HEALTH INC Ansan Pharmaceuticals, Inc.; DISCOVERY LABORATORIES Antegren; GTC BIOTHERAPEUTICS INC Antegren; ELAN CORP PLC Antex Proteomics; ANTEX BIOLOGICS INC AntexPharma; ANTEX BIOLOGICS INC Antithrombin III; GTC BIOTHERAPEUTICS INC Antivirals, Inc.; AVI BIOPHARMA INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Antizol; ORPHAN MEDICAL INC Antizol-Vet; ORPHAN MEDICAL INC Antrin; PHARMACYCLICS INC Antron; E I DU PONT DE NEMOURS & CO Anusol-HC; KING PHARMACEUTICALS INC AP22594; ARIAD PHARMACEUTICALS AP23451; ARIAD PHARMACEUTICALS AP23573; ARIAD PHARMACEUTICALS Apan; PRAECIS PHARMACEUTICALS Aphthasol; ACCESS PHARMACEUTICALS Apligraph; ORGANOGENESIS INC Apogen Program; ALEXION PHARMACEUTICALS Apokinin; CEPHALON INC Apomate; NORTH AMERICAN SCIENTIFIC Apomine; ILEX ONCOLOGY INC Apoptosis Technology, Inc.; IMMUNOGEN INC Applera Corporation; CELERA GENOMICS GROUP Applied Analytical Industries, Inc.; AAIPHARMA INC Applied Biosystems; APPLERA CORPORATION Applied Biosystems; CELERA GENOMICS GROUP Aptosyn; CELL PATHWAYS INC AquaSite; INSITE VISION INC Aquasol; AAIPHARMA INC AquaThik; UNITED-GUARDIAN INC AQUAVAN Injection; GUILFORD PHARMACEUTICALS INC Aramed, Inc.; SICOR INC Aranesp; AMGEN INC ARASCO; MARTEK BIOSCIENCES CORP Arestin; ORAPHARMA INC Aretas HTS; ACLARA BIOSCIENCES INC Argatroban; TEXAS BIOTECHNOLOGY CORP ARGENT Signaling; ARIAD PHARMACEUTICALS ARGENT Transcription; ARIAD PHARMACEUTICALS Ariad Gene Therapeutics; ARIAD PHARMACEUTICALS Armed Therapeutic Viruses; ONYX PHARMACEUTICALS INC Arnette Optic Illusions, Inc.; BAUSCH & LOMB INC Aronex Pharmaceuticals, Inc.; ANTIGENICS INC Aroplatin; ANTIGENICS INC Array BioPharma, Inc.; ICOS CORPORATION Array of Arrays; ILLUMINA INC ArrayPRO; INFORMAX INC Artemis Pharmaceuticals GmbH; EXELIXIS INC Arthease; BIO TECHNOLOGY GENERAL CORP Aryplase; BIOMARIN PHARMACEUTICAL As We Change; WOMEN FIRST HEALTHCARE Asacard; FLAMEL TECHNOLOGIES SA Ascent Pediatrics; MEDICIS PHARMACEUTICAL CORP ASTA Medica Oncology; BAXTER INTERNATIONAL INC Aston Molecules; OSI PHARMACEUTICALS INC Astral, Inc.; ALLIANCE PHARMACEUTICAL CORP

AstraZeneca; SYNGENTA AG AstraZeneca; NPS PHARMACEUTICALS INC ATL-1251; ALIZYME PLC ATL-2502; ALIZYME PLC ATL-962; ALIZYME PLC Atlantic Pharmaceuticals; ATLANTIC TECHNOLOGY VENTURES Atossa Healthcare, Inc.; NASTECH PHARMACEUTICAL CO INC ATP Bioluminescence; CELSIS INTERNATIONAL PLC ATRA-IV; ANTIGENICS INC Atridox; ATRIX LABORATORIES INC Atridox; COLLAGENEX PHARMACEUTICAL Atrigel; ATRIX LABORATORIES INC Atrionix; JOHNSON & JOHNSON Atrisorb Gtr; ATRIX LABORATORIES INC Atrisorb-Freeflow; COLLAGENEX PHARMACEUTICAL ATS Dermagraft, Inc.; ADVANCED TISSUE SCIENCES ATS Orthopedics, Inc.; ADVANCED TISSUE SCIENCES Atugen; RIBOZYME PHARMACEUTICALS ATV-02; ATLANTIC TECHNOLOGY VENTURES Augmentin; GLAXOSMITHLKINE PLC Aurora Biosciences Corporation; VERTEX PHARMACEUTICALS INC AUTO-LYTE; ORASURE TECHNOLOGIES INC Autoplex T; NABI PHARMACEUTICALS Avadex; MONSANTO CO AVC Cream; NOVAVAX INC Aventis; INTROGEN THERAPEUTICS INC Aventis Behring; AVENTIS SA Aventis CropScience; EXELIXIS PLANT SCIENCES INC Aventis Cropsciences; EXELIXIS INC Aventis Pasteur; AVENTIS SA Aventis Pharma; AVENTIS SA Aventis Pharma; TRANSKARYOTIC THERAPIES AVI-4557; AVI BIOPHARMA INC Avicine; AVI BIOPHARMA INC Avid Bioservices, Inc.; PEREGRINE PHARMACEUTICALS INC Avigen, Inc.; SANGAMO BIOSCIENCES INC Aviron; MEDIMMUNE VACCINES AVONEX; BIOGEN INC Axaron Bioscience AG; LYNX THERAPEUTICS INC Axid; ELI LILLY & CO Axiom Biotechnologies; SEQUENOM INC AXOKINE; REGENERON PHARMACEUTICALS INC Axys Pharmaceuticals, Inc.; CELERA GENOMICS GROUP Azulfidine EN-tabs; MGI PHARMA INC Baby Center; JOHNSON & JOHNSON




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Bactrim; WOMEN FIRST HEALTHCARE Bactrim Pediatric Suspension; HI TECH PHARMACAL CO INC Ban Deodorant; CHATTEM INC Band-Aid; JOHNSON & JOHNSON Bankart Tack; BIONX IMPLANTS INC Barnett International; PAREXEL INTERNATIONAL Barocycler; BOSTON BIOMEDICA INC Barton & Polansky Associates, Inc.; ICON PLC BAS Analytics, Ltd.; BIOANALYTICAL SYSTEMS INC BAS Technicol, Ltd.; BIOANALYTICAL SYSTEMS INC Bausch & Lomb Vision Care; BAUSCH & LOMB INC Baxter Healthcare; ALLIANCE PHARMACEUTICAL CORP Baxter Healthcare Corp.; CERUS CORPORATION Baxter Healthcare Corporation; BAXTER INTERNATIONAL INC Baxter World Trade Corporation; BAXTER INTERNATIONAL INC BAY 43-9006; ONYX PHARMACEUTICALS INC Bayer AG; EXELIXIS INC Bayer CropScience; EXELIXIS PLANT SCIENCES INC Bayer Diagnostics; LUMINEX CORPORATION Bayer International; VALENTIS INC BB-10153; BRITISH BIOTECH PLC BB-10901; BRITISH BIOTECH PLC BB-83698; BRITISH BIOTECH PLC BBI Biotech Research Laboratories; BOSTON BIOMEDICA INC BBI Diagnostics; BOSTON BIOMEDICA INC BBI Source Scientific; BOSTON BIOMEDICA INC BCAM International; ACCUMED INTERNATIONAL BCI-202; BONE CARE INTERNATIONAL BCX-1777; BIOCRYST PHARMACEUTICALS BDNF; REGENERON PHARMACEUTICALS INC BeadArray; ILLUMINA INC BEC2; IMCLONE SYSTEMS INC Befar; NEXMED INC Belmac Corp.; BENTLEY PHARMACEUTICALS INC Belmazol; BENTLEY PHARMACEUTICALS INC Bema; ATRIX LABORATORIES INC Benefen; MACROCHEM CORPORATION Beraprost; UNITED THERAPEUTICS CORP Berlex Laboratories, Inc.; CHIRON CORP Bertek Pharmaceuticals, Inc.; MYLAN LABORATORIES INC Betagan; ALLERGAN INC Betaseron; CHIRON CORP Bicept II Magnum; SYNGENTA AG Bigmar Pharmaceuticals; BIGMAR INC Bigmar Therapeutics; BIGMAR INC Bimexes; ZONAGEN INCORPORATED

Bio Science Contract Production Corp.; CAMBREX CORP Bio Vascular, Inc.; SYNOVIS LIFE TECHNOLOGIES INC Bioadhesive Delivery System; COLUMBIA LABORATORIES Bioanalytical Systems, Ltd.; BIOANALYTICAL SYSTEMS INC BioAstin; CYANOTECH CORPORATION BioChem ImmunoSystems U.S., Inc.; SHIREBIOCHEM INC Biochem Pharma; SHIRE-BIOCHEM INC Biocine S.A.R.L.; CHIRON CORP Biocompatibles Cardiovascular Ireland; BIOCOMPATIBLES INTERNATIONAL PLC Biocompatibles Eyecare, Inc.; BIOCOMPATIBLES INTERNATIONAL PLC BioCuff; BIONX IMPLANTS INC Biodel; SCIOS INC Biodental Technologies Corp.; ZILA INC BiodivYsio Stents; BIOCOMPATIBLES INTERNATIONAL PLC BioEx; BIORA AB BioExpress; GENE LOGIC INC BioFLASH; DYAX CORP Biofluids; BIOSOURCE INTERNATIONAL INC Biogen Japan, Ltd.; BIOGEN INC Biogen, Inc.; ELAN CORP PLC Biogen, Inc.; TARGETED GENETICS CORP Biogen, Inc.; ICOS CORPORATION Biograft; SYNOVIS LIFE TECHNOLOGIES INC Bio-Hep-B; BIO TECHNOLOGY GENERAL CORP Bioinformatics Centre; ASTRAZENECA PLC BIOLON; BIO TECHNOLOGY GENERAL CORP BioLon; BIO TECHNOLOGY GENERAL CORP Biomarker Discovery Center; CIPHERGEN BIOSYSTEMS INC Bio-Metrics Properties, Ltd.; BIO RAD LABORATORIES INC BioMune Corporation; NABI PHARMACEUTICALS Biomune Systems, Inc; DONLAR BIOSYNTREX BioNuvia; ADVANCED TISSUE SCIENCES Biopool International, Inc.; XTRANA INC Bioren; BIGMAR INC BioSepra S.A.; CIPHERGEN BIOSYSTEMS INC Biosite Discovery; BIOSITE INC BioSoftware; IGEN INTERNATIONAL INC Biosonix, Ltd.; NEOPROBE CORPORATION BioSorb; BIONX IMPLANTS INC BioSource Europe, S.A.; BIOSOURCE INTERNATIONAL INC Biospecifics Pharma GmbH; BIOSPECIFICS TECHNOLOGIES CORP Biosphere Medical Japan, Inc.; BIOSPHERE MEDICAL INC BioSphere Medical, Inc.; SEPRACOR INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Biotage, Inc.; DYAX CORP Biotech Australia; ACCESS PHARMACEUTICALS Biotechna U.A.B.; SICOR INC BioTrend; CHARLES RIVER LABORATORIES CORP Bio-Tropin; BIO TECHNOLOGY GENERAL CORP Biovail Pharmaceuticals, Inc.; BIOVAIL CORPORATION Biovail Technologies, Ltd.; BIOVAIL CORPORATION Biowhittake r, Inc.; CAMBREX CORP Bladder Cancer PD; DUSA PHARMACEUTICALS INC Bleomycin; XECHEM INTERNATIONAL Block Drug Company; ACCESS PHARMACEUTICALS Blood Virus Diagnostics, Inc.; BIO RAD LABORATORIES INC BLP25; BIOMIRA INC BLU-U; DUSA PHARMACEUTICALS INC BML Pharmaceuticals, Inc.; ENDO PHARMACEUTICALS HOLDINGS INC BMP-7; CURIS INC Bone Morphogenic Protein; CURIS INC Boost; BRISTOL MYERS SQUIBB CO Boston Scientific; ANGIOTECH PHARMACEUTICALS Botanicals International Extracts; HAUSER INC Bothell Blue; EPOCH BIOSCIENCES Bothell Research Center; ALBANY MOLECULAR RESEARCH BOTOX; ALLERGAN INC BPI; XOMA LTD BrachySeed; CYTOGEN CORPORATION BrachySeed; DRAXIS HEALTH INC Bradycor; CORTECH INC Breast Aneusomy Probe Set; VYSIS INC Brethine; AAIPHARMA INC Bristol-Myers Squibb Company; EXELIXIS INC BRL Screening, Inc.; ARENA PHARMACEUTICALS INC Bruno Biotechnology Development Center; ALBANY MOLECULAR RESEARCH BSMD Ventures, Inc.; BIOSPHERE MEDICAL INC Bull Frog Sunblock; CHATTEM INC Bunsen Rush Laboratories, Inc.; ARENA PHARMACEUTICALS INC Bupropion; IMPAX LABORATORIES INC Bursamune; EMBREX INC Bursaplex; EMBREX INC BusPIRone HCI; PHARMACEUTICAL RESOURCES INC Busulfex; ORPHAN MEDICAL INC BXT-51072; OXIS INTERNATIONAL INC C.E.T. Dental Products; VIRBAC INC C.R. Bard; ANGIOTECH PHARMACEUTICALS C79 Intensive Moisturizer; CELLEGY PHARMACEUTICALS

CAB-2; XOMA LTD Caelyx; ALZA CORP California Biotechnology, Inc.; SCIOS INC California Mastitis Test; IMMUCELL CORPORATION Caliper 250; CALIPER TECHNOLOGIES CORP Caliper 42; CALIPER TECHNOLOGIES CORP Caliper AMS 90 SE; CALIPER TECHNOLOGIES CORP Calydon, Inc.; CELL GENESYS INC Cambridge Antibody Technology, plc; HUMAN GENOME SCIENCES INC Cambridge Discovery Chemistry; MILLENNIUM PHARMACEUTICALS INC CAMD Technology; TULARIK INC Camitro Corporation; ARQULE INC CAMPATH; ILEX ONCOLOGY INC CAMPATH; MILLENNIUM PHARMACEUTICALS INC Camptosar; HYBRIDON INC CAMPYVAX; ANTEX BIOLOGICS INC Cancer Research Campaign Technology; VIRAGEN INC Candex; PENWEST PHARMACEUTICALS CO Cangene; CHESAPEAKE BIOLOGICAL LAB Cantab Pharmaceuticals, Inc.; XENOVA GROUP PLC Capillus; TRINITY BIOTECH PLC CAPSET Calcium Sulfate Barrier; LIFECORE BIOMEDICAL INC Capsule Report (The); SYNBIOTICS CORP Captopril; PHARMACEUTICAL RESOURCES INC Carbatrol; SHIRE PHARMACEUTICALS PLC Cardiac Status; SPECTRAL DIAGNOSTICS INC CardioPass; CARDIOTECH INTERNATIONAL CardioPass; CARDIOTECH INTERNATIONAL Cardiopet Incorporated; IDEXX LABORATORIES INC Cardiosonix Ltd.; NEOPROBE CORPORATION CardioTech International, Ltd.; CARDIOTECH INTERNATIONAL Cardizem CD; BIOVAIL CORPORATION CarePoint Cardiac Corp.; SPECTRAL DIAGNOSTICS INC Carloe, Inc.; CARRINGTON LABORATORIES INC Carmé Cosmeceutical Sciences; SENETEK PLC Carmol 40; BRADLEY PHARMACEUTICALS Carnforth Limited; MALLINCKRODT INC CART Technology; ARENA PHARMACEUTICALS INC Cartia XT; ANDRX CORP Carticel II; GENZYME BIOSURGERY CAT-152; CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC CAT-192; CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC CAT-213; CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC Catalytica, Inc.; DSM PHARMACEUTICALS INC CB-I Therapy Kit; AASTROM BIOSCIENCES INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. CBP-2011; INKINE PHARMACEUTICAL CO CCR5; PRAECIS PHARMACEUTICALS CD39L4; HYSEQ INC CDP 870; CELLTECH GROUP PLC CEA -Cide; IMMUNOMEDICS INC CEA -Scan; IMMUNOMEDICS INC CeaVac; TITAN PHARMACEUTICALS Ceclor; ELI LILLY & CO Cedax; BIOVAIL CORPORATION CEL-1000; CEL-SCI CORPORATION Celebrex; PFIZER INC Celera Diagnostics; CELERA GENOMICS GROUP Celera Diagnostics; APPLERA CORPORATION Celera Genomics; APPLERA CORPORATION Celeris Data Management and Information Systems; CELERIS CORPORATION Celexa; FOREST LABORATORIES INC Celgro, Inc.; CELGENE CORP Cell Genesys; ABGENIX INC CELLEDIRM; CELLEGY PHARMACEUTICALS Cellegesic; CELLEGY PHARMACEUTICALS Cellegy Canada, Inc.; CELLEGY PHARMACEUTICALS CellMetrix; ACCUMED INTERNATIONAL Celltech Chiroscience; PROTEIN DESIGN LABS INC Celltech Medeva; CELLTECH GROUP PLC Celltech Pharmaceuticals; CELLTECH GROUP PLC Celltech R&D; CELLTECH GROUP PLC Celltrion, Inc.; VAXGEN INC Celsior; SANGSTAT MEDICAL CORP Celsis Advance; CELSIS INTERNATIONAL PLC Celsis Laboratory Group; CELSIS INTERNATIONAL PLC Celtrix Pharmaceuticals; INSMED INCORPORATED Centocor, Inc.; GTC BIOTHERAPEUTICS INC Ceplene; MAXIM PHARMACEUTICALS Ceprotin; BAXTER INTERNATIONAL INC Ceregene, Inc.; CELL GENESYS INC Ceres; GENSET SA Cerezyme; GENZYME CORP CG53135; CURAGEN CORPORATION ChemCore; TRIPOS INC Chemdex, Inc.; POLYDEX PHARMACEUTICALS ChemoCentryx, Inc.; TECHNE CORP Chemogenomics; VERTEX PHARMACEUTICALS INC ChemSpace; TRIPOS INC ChemStat; BOSTON BIOMEDICA INC Chiron; ABGENIX INC Chiron Corporation; MATRIX PHARMACEUTICAL Chiron Diagnostics Corp.; BIO RAD LABORATORIES INC Chondrogel; CURIS INC Chromax; NUTRITION 21 INC ChronoFlex; CARDIOTECH INTERNATIONAL CHRONOGESIC; DURECT CORP

Chugai Pharmaceutical; MOLECULAR BIOSYSTEMS INC Chugai Pharmaceutical Co.; GELTEX PHARMACEUTICALS Cialis; ICOS CORPORATION CIBA Vision; NOVARTIS AG Cidecin; CUBIST PHARMACEUTICALS Ciprofloxacin GR; DEPOMED INC Cisplatin Extra; SUPERGEN INC CL McIntosh Regulatory Consulting; CELERIS CORPORATION Clairol, Inc.; BRISTOL MYERS SQUIBB CO Claritin; SCHERING-PLOUGH CORP Clinical and Pharmacologic Research, Inc.; KENDLE INTERNATIONAL INC Clobetasol E; TARO PHARMACEUTICAL INDUSTRIES CLOFAREX; ILEX ONCOLOGY INC C-MAF; BOSTON LIFE SCIENCES INC Code 7228; ADVANCED MAGNETICS INC Codeisan; BENTLEY PHARMACEUTICALS INC CoEase; ANIKA THERAPEUTICS INC Cogent Diagnostics, Ltd.; HYCOR BIOMEDICAL INC Cognizant Technology Solutions; IMS HEALTH INC Cohesion Technologies, Inc.; ANGIOTECH PHARMACEUTICALS COLAL; ALIZYME PLC COLAL-PRED; ALIZYME PLC Colbond Geosynthetics; AKZO NOBEL NV Colcys; FLAMEL TECHNOLOGIES SA Colilert; IDEXX LABORATORIES INC Colirest; INKINE PHARMACEUTICAL CO Collaborative BioAlliance; NABI PHARMACEUTICALS Collagenase ABC; BIOSPECIFICS TECHNOLOGIES CORP Collagenase Santyl Ointment; BIOSPECIFICS TECHNOLOGIES CORP Collateral Targeting Agents; PEREGRINE PHARMACEUTICALS INC Colloral; AUTOIMMUNE INC Colloral, LLC; AUTOIMMUNE INC Columbia Research Laboratories, Inc.; COLUMBIA LABORATORIES Combidex; ADVANCED MAGNETICS INC CombiPatch; NOVEN PHARMACEUTICALS Combivir; SHIRE-BIOCHEM INC Combrestatin; OXIGENE INC Combrestatin A4 Prodrug; OXIGENE INC Comparative Genomic Hybridization; VYSIS INC Compass and Mapping Array Libraries; ARQULE INC Complex Cu3; PROCYTE CORPORATION Compugen; GENOME THERAPEUTICS CORP Comvax; MERCK & CO INC Concell B.V.; CELSIS INTERNATIONAL PLC Confetti; UNITED-GUARDIAN INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Connetics Center for Skin Biology; CONNETICS CORPORATION Consurf; BIOVAIL CORPORATION ConvaTec; BRISTOL MYERS SQUIBB CO Cook Pharmaceutical Solutions; BAXTER INTERNATIONAL INC Cook, Inc.; ANGIOTECH PHARMACEUTICALS Copaxone; TEVA PHARMACEUTICAL INDUSTRIES Copaxone; AUTOIMMUNE INC CoPharma, Inc.; CAMBREX CORP Copley Pharmaceuticals; TEVA PHARMACEUTICAL INDUSTRIES Coppertone; SCHERING-PLOUGH CORP COR Therapeutics, Inc.; MILLENNIUM PHARMACEUTICALS INC Cordycepin; OXIGENE INC CORGENIC; COLLATERAL THERAPEUTICS Corian; E I DU PONT DE NEMOURS & CO Corixa; GENSET SA Corning Glass Works; GENENCOR INTERNATIONAL INC Correctol; SCHERING-PLOUGH CORP Cosan Chemical Corporation; CAMBREX CORP Cotara; PEREGRINE PHARMACEUTICALS INC Coulter Pharmaceutical; CORIXA CORPORATION Covance Central Diagnostics, Inc; COVANCE INC Covance Clinical and Periapproval Services, Inc.; COVANCE INC Covance Clinical Research Unit, Inc.; COVANCE INC Covance Health Economics and Outcomes Services; COVANCE INC Covance Laboratories, Inc.; COVANCE INC Covance Pharmaceutical Packaging Services, Inc.; COVANCE INC Covance Research Products, Inc.; COVANCE INC Coviracil; TRIANGLE PHARMACEUTICALS CP-461; CELL PATHWAYS INC CPX; SCICLONE PHARMACEUTICALS Crescendo Pharmaceuticals; ALZA CORP Crinone; COLUMBIA LABORATORIES CrownPharma, Ltd.; ALLERGAN INC CryptoLight; MARTEK BIOSCIENCES CORP CT Biomaterials; CARDIOTECH INTERNATIONAL CT-2106; CELL THERAPEUTICS INC CT-2584; CELL THERAPEUTICS INC CT-3; ATLANTIC TECHNOLOGY VENTURES CTLA4; REPLIGEN CORPORATION CustomSuites; GENE LOGIC INC CVT-3146; CV THERAPEUTICS INC CVT-510; CV THERAPEUTICS INC Cyanotech Japan YK; CYANOTECH CORPORATION Cyclicons; HYBRIDON INC Cycling Probe Technology; ID BIOMEDICAL CORPORATION Cymetra; LIFECELL CORPORATION

Cyplex Infusible Platelet Membranes; CYPRESS BIOSCIENCE INC Cystadane; ORPHAN MEDICAL INC Cystrin CR; PENWEST PHARMACEUTICALS CO Cytion SA; MOLECULAR DEVICES CORP Cytoclonal Pharmaceutics, Inc.; EXEGENICS INC CytoGam; MEDIMMUNE INC CytoTherapeutics, Inc.; STEMCELLS, INC Cytovia; MAXIM PHARMACEUTICALS D2E7; CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC D2E7; GTC BIOTHERAPEUTICS INC Dacron; E I DU PONT DE NEMOURS & CO Dade Behring, Inc.; DIAGNOSTIC PRODUCTS CORPORATION Daily Difference; WOMEN FIRST HEALTHCARE Dalmane; ICN PHARMACEUTICALS INC Darvocet; AAIPHARMA INC Darvon; AAIPHARMA INC DataSuites; GENE LOGIC INC Dauno Extra; SUPERGEN INC Declopramide; OXIGENE INC DecodeGT; DECODE GENETICS INC Deconamine; BRADLEY PHARMACEUTICALS Degree; MONSANTO CO Delatestryl; BIO TECHNOLOGY GENERAL CORP DelSite Biotechnologies, Inc.; CARRINGTON LABORATORIES INC Deltibant; CORTECH INC Depakote; ABBOTT LABORATORIES DepoFoam; SKYEPHARMA PLC DepoMed Development, Ltd.; DEPOMED INC DepoTech; SKYEPHARMA PLC Deprenyl Animal Health, Inc.; DRAXIS HEALTH INC DerG; CEL-SCI CORPORATION Dermagraft; ADVANCED TISSUE SCIENCES DermEquip, LLC; ADVANCED TISSUE SCIENCES Dermick Laboratories, Inc.; AVENTIS SA Deselex Liquid; UNITED-GUARDIAN INC Deseret Laboratories International; AUTOIMMUNE INC Desloratadine; SCHERING-PLOUGH CORP Detox; CORIXA CORPORATION Dexanabinol; PHARMOS CORPORATION Dexatrim; CHATTEM INC Dextran Products, Ltd.; POLYDEX PHARMACEUTICALS DHA; PROGENICS PHARMACEUTICALS DHASCO; MARTEK BIOSCIENCES CORP Diab II; BIOTECH HOLDINGS LTD DiabetiTussin; HI TECH PHARMACAL CO INC Diachrome; NUTRITION 21 INC diaDexus; INCYTE GENOMICS INC Diagene Europe; DIGENE CORPORATION Diamedix Corporation; IVAX CORPORATION Diamond Animal Health; HESKA CORP Diasorb; COLUMBIA LABORATORIES




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Diaspa; SICOR INC Didronel I.V. Infusion; MGI PHARMA INC DiffGAM; IMMUCELL CORPORATION Digitek; MYLAN LABORATORIES INC Diltia XT; ANDRX CORP Diminishing Viral Gene Expression; INTROGEN THERAPEUTICS INC DioSynth, Inc.; AKZO NOBEL NV Diprivan; ASTRAZENECA PLC DirectAME; APPLIED MOLECULAR EVOLUTION INC Directed Array; ARQULE INC Directed Biosynthesis; CUBIST PHARMACEUTICALS DISC-GMCSF; XENOVA GROUP PLC Discovery Genomics, Inc.; TECHNE CORP Discovery Line; INVITROGEN CORPORATION Dissectron; INTEGRA LIFESCIENCES CORP Ditropan XL; ALZA CORP Diversa Corporation; APPLERA CORPORATION DM1; IMMUNOGEN INC DNA FISH; VYSIS INC DNA Sample Preparation System; ACLARA BIOSCIENCES INC DNA-Binding Technology; GENELABS TECHNOLOGIES INC DNAnchor; EPOCH BIOSCIENCES DNAShuffling; MAXYGEN INC Doak Dermatologics; BRADLEY PHARMACEUTICALS Donlar A-2C; DONLAR BIOSYNTREX Donlar ALC-130; DONLAR BIOSYNTREX Donlar Corporation; DONLAR BIOSYNTREX Dosators; SHEFFIELD PHARMACEUTICALS Dososanal; AVANIR PHARMACEUTICALS Dr. Scholl's; SCHERING-PLOUGH CORP DRAXIMAGE, Inc.; DRAXIS HEALTH INC DRAXIS Pharma, Inc.; DRAXIS HEALTH INC DRAXIS Pharmaceutica; DRAXIS HEALTH INC Drilac Surgical Dressing; ORAPHARMA INC Drixocal; SCHERING-PLOUGH CORP DSM; DSM PHARMACEUTICALS INC DSM Biologics; DSM PHARMACEUTICALS INC DSM Fine Chemicals; DSM PHARMACEUTICALS INC DSM Pharmaceutical Products; DSM PHARMACEUTICALS INC Dual Gold; SYNGENTA AG DuPont Pharmaceuticals; BRISTOL MYERS SQUIBB CO DuraSite; INSITE VISION INC DuraSolv; CIMA LABS INC DURIN; DURECT CORP DUROS; ALZA CORP DUROS Technology; DURECT CORP DVM Pharmaceuticals, Inc.; IVAX CORPORATION DX-88; DYAX CORP

DX-890; DYAX CORP DYNACIN; MEDICIS PHARMACEUTICAL CORP DynaGen, Inc.; ABLE LABORATORIES Dynepo; TRANSKARYOTIC THERAPIES E.R.D.-Screen Urine Test; HESKA CORP Easi-Breathe; IVAX CORPORATION Eastern Chemical Corporation; UNITED-GUARDIAN INC EasyLyte; HEMAGEN DIAGNOSTICS INC EasyVet; HEMAGEN DIAGNOSTICS INC EchoGen; SONUS PHARMACEUTICALS ECLiPS; PHARMACOPEIA INC Eclipse Dark Quencher; EPOCH BIOSCIENCES Eclipse Probe System; EPOCH BIOSCIENCES EcoNail; MACROCHEM CORPORATION Econazole Nitrate Cream 1%; TARO PHARMACEUTICAL INDUSTRIES eData Entry; ERESEARCH TECHNOLOGY INC EDITEK, Inc.; MEDTOX SCIENTIFIC INC Effexor; WYETH Efudex; ICN PHARMACEUTICALS INC Egg Remover; EMBREX INC eHealth Education; ERESEARCH TECHNOLOGY INC Elan Corp.; TARGETED GENETICS CORP Elan Corp.; ATRIX LABORATORIES INC Elan Corporation; ISIS PHARMACEUTICALS INC Elecsys; IGEN INTERNATIONAL INC Elexa; GLYCOGENESYS INC Eligard; ATRIX LABORATORIES INC Eligix CD8-SC; BIOTRANSPLANT INC Eligix HDM Cell Separation System; BIOTRANSPLANT INC Eligix, Inc.; BIOTRANSPLANT INC ELISA; HYCOR BIOMEDICAL INC ELISA Acute Phase Reactant Assays; HEMAGEN DIAGNOSTICS INC Elliotts B Solution; ORPHAN MEDICAL INC Elvetium S.A.; IVAX CORPORATION ELVS System; E-Z-EM INC Embosphere; BIOSPHERE MEDICAL INC Embrex Europe, Ltd.; EMBREX INC Emcocel; PENWEST PHARMACEUTICALS CO Emdex; PENWEST PHARMACEUTICALS CO Emdogain; BIORA AB Emdogain Gel; BIORA AB Emerald Gene Systems; TARGETED GENETICS CORP Emisphere; REGENERON PHARMACEUTICALS INC Enalapril Belmac; BENTLEY PHARMACEUTICALS INC ENBREL; IMMUNEX CORP Encode; DECODE GENETICS INC Endo Pharmaceuticals, Inc.; ENDO PHARMACEUTICALS HOLDINGS INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Endometrial Ablation PDT; DUSA PHARMACEUTICALS INC Endorex Corporation; DOR BIOPHARMA INC Endo-Scan-V; CHARLES RIVER LABORATORIES CORP Endostatin; ENTREMED INC Endotoxin Activity Assay; SPECTRAL DIAGNOSTICS INC ENMD 0995; ENTREMED INC Ensure; ABBOTT LABORATORIES Enteric Products, Inc.; E-Z-EM INC Enterprise Associates, L.L.C.; IMS HEALTH INC Entex PSE; CARACO PHARMACEUTICAL LABORATORIES ENTsol; BRADLEY PHARMACEUTICALS Envision TD; BAUSCH & LOMB INC Enzo Clinical Labs, Inc.; ENZO BIOCHEM INC Enzo Diagnostics, Inc.; ENZO BIOCHEM INC Enzo Therapeutics, Inc.; ENZO BIOCHEM INC EnzyMed; ALBANY MOLECULAR RESEARCH Eos Biotechnology, Inc.; PHARMACOPEIA INC EpiGene Vaccines; EPIMMUNE INC Epi-Guide Periodontal Barrier Matrix; ORAPHARMA INC Epitope Identification System; EPIMMUNE INC Epoch Pharmaceuticals; EPOCH BIOSCIENCES Epogen; AMGEN INC Equell; VIRBAC INC Equimax; VIRBAC INC Erbitux; BRISTOL MYERS SQUIBB CO eResCom; ERESEARCH TECHNOLOGY INC eResearch Network; ERESEARCH TECHNOLOGY INC Erisco Managed Care Technologies; IMS HEALTH INC eRT Operating Company; ERESEARCH TECHNOLOGY INC ERxin; ZONAGEN INCORPORATED Esclim; WOMEN FIRST HEALTHCARE ESOTERICA; MEDICIS PHARMACEUTICAL CORP Estalis; NOVEN PHARMACEUTICALS Ester-C; ZILA INC Esteve Group; DISCOVERY LABORATORIES Estorra; SEPRACOR INC Estrace; WARNER CHILCOTT PLC Estradot; NOVEN PHARMACEUTICALS ESTRASORB; NOVAVAX INC Estrofem; NOVO-NORDISK AS eTag; ACLARA BIOSCIENCES INC eTag Assay System; THIRD WAVE TECHNOLOGIES INC Ethamolin; QUESTCOR PHARMACEUTICALS ETHEX Corporation; K V PHARMACEUTICAL CO Ethrog Biotechnologies; INVITROGEN CORPORATION Ethyol; MEDIMMUNE INC Etoposide Extra; SUPERGEN INC

E-TRANS; ALZA CORP ETRX-101; ESSENTIAL THERAPEUTICS INC Eurogene Limited; VALENTIS INC Evogene; COMPUGEN LTD Excedrin; BRIS TOL MYERS SQUIBB CO EX-CYTE; SEROLOGICALS CORP Exelixis Plant Sciences, Inc.; EXELIXIS INC Exelixis, Inc.; EXELIXIS PLANT SCIENCES INC Exelixis, Inc.; PROTEIN DESIGN LABS INC EXPeRT; ERESEARCH TECHNOLOGY INC ExpressAME; APPLIED MOLECULAR EVOLUTION INC EyeTech Pharmaceuticals, Inc.; GILEAD SCIENCES INC EZ-Bead; TRINITY BIOTECH PLC E-Z-CAT Dry; E-Z-EM INC Ez-Quant; MEDTOX SCIENTIFIC INC Ez-Screen; MEDTOX SCIENTIFIC INC F.H. Faulding & Co., Ltd.; NAPRO BIOTHERAPEUTICS INC F.H. Faulding and Co., Ltd.; ALPHARMA INC Famotidine; PHARMACEUTICAL RESOURCES INC Famoxin; GENSET SA Farma Systems S.A.; LABORATORIO CHILE SA Farmasalud S.A.; LABORATORIO CHILE SA Faslodex; ASTRAZENECA PLC FastTrack 2.0 Kit; INVITROGEN CORPORATION Feelgood; BIOTECH HOLDINGS LTD Fel-O-Vax FIV; WYETH Femcare, Ltd.; PROTEIN POLYMER TECHNOLOGIES Femprox; NEXMED INC Fenofibrate; IMPAX LABORATORIES INC Feridex I.V.; ADVANCED MAGNETICS INC Feverall; ASCENT PEDIATRICS INC Fexofenadine HCL; BARR LABORATORIES INC Fiblast; SCIOS INC First Defense; IMMUCELL CORPORATION FlashDose; BIOVAIL CORPORATION FlavorTech; K V PHARMACEUTICAL CO FlexStation System; MOLECULAR DEVICES CORP FLOCOR; CYTRX CORPORATION Flourous Technologies, Inc.; ALBANY MOLECULAR RESEARCH Fluidic; CEPHEID FluINsure; ID BIOMEDICAL CORPORATIO N FluMist; MEDIMMUNE VACCINES Fluorescence In Situ Hybridization; VYSIS INC Fluorometric Imaging Plate Reader; MOLECULAR DEVICES CORP Fluoxetine; PHARMACEUTICAL RESOURCES INC Fluoxetine Hydrochloride; BARR LABORATORIES INC Flutamide; BARR LABORATORIES INC Fluvial S/F; SHIRE-BIOCHEM INC FMdC; MATRIX PHARMACEUTICAL




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Focalin; CELGENE CORP Forcaltonin; UNIGENE LABORATORIES Formulaid; MARTEK BIOSCIENCES CORP Fort Dodge; WYETH FortaFlex; ORGANOGENESIS INC Fosamax; MERCK & CO INC Francodex; VIRBAC INC Fresenius Medical Care North America; CYPRESS BIOSCIENCE INC Fujisawa Healthcare, Inc.; GILEAD SCIENCES INC Fujisawa Healthcare, Inc.; CV THERAPEUTICS INC FunctionFinder; PARADIGM GENETICS INC Fusion Medical Technologies, Inc.; BAXTER INTERNATIONAL INC Futurebiotics, Inc.; PDK LABS INC G17; APHTON CORP Gabitril; CEPHALON INC Galen Holdings; WARNER CHILCOTT PLC Ganite; GENTA INC GarlicOnce; XECHEM INTERNATIONAL Gastric Retention System; DEPOMED INC GastroMARK; ADVANCED MAGNETICS INC GCS-100; GLYCOGENESYS INC Gelclair; CELL PATHWAYS INC GelPRO; INFORMAX INC GelSponge; IOMED INC GEM 231; HYBRIDON INC Genasense; GENTA INC Gencarta; COMPUGEN LTD Genchem Pharma, Ltd.; SICOR INC Gendux AB; INTROGEN THERAPEUTICS INC Gene Site Saturation Mutagenesis; DIVERSA CORPORATION GeneCalling; CURAGEN CORPORATION GeneChip; AFFYMETRIX INC GeneChip CustomExpress; AFFYMETRIX INC GeneExpress; GENE LOGIC INC GeneFold; TRIPOS INC Genefunction Factory; PARADIGM GENETICS INC GeneMate System; ACLARA BIOSCIENCES INC Genentech; GENENCOR INTERNATIONAL INC Genentech; VAXGEN INC Genentech, Inc.; IDEC PHARMACEUTICALS CORP Genera Pharmaceuticals; IDEXX LABORATORIES INC GENERX; COLLATERAL THERAPEUTICS GeneScape; CURAGEN CORPORATION GeneSeq; VIROLOGIC INC Genesis: The GeneExpress Enterprise System; GENE LOGIC INC GeneSoft, Inc.; BRITISH BIOTECH PLC GeneSolutions, Inc.; HYSEQ INC Genetic MicroSystems, Inc.; AFFYMETRIX INC Genetic Models, Inc.; CHARLES RIVER LABORATORIES CORP Genetics Computer Group; PHARMACOPEIA INC

Gene-Trak DNA; NEOGEN CORPORATION GeneTrove; ISIS PHARMACEUTICALS INC GENEVX; COLLATERAL THERAPEUTICS GENEWARE; LARGE SCALE BIOLOGY CORP GeneXpert; CEPHEID GenFlex Tag Array; AFFYMETRIX INC Gengraf; SANGSTAT MEDICAL CORP Genmab; DECODE GENETICS INC Genmab; MEDAREX INC GenoMax; INFORMAX INC GenomeVision Services; GENOME THERAPEUTICS CORP Genovo; TARGETED GENETICS CORP Genset Oligos; GENSET SA Genset Pacific Pty., Ltd.; GENSET SA Gensia Sicor Pharmaceuticals; SICOR INC Genta Jago Technologies; GENTA INC Genta Pharmaceuticals Europe; GENTA INC GENVASCOR; COLLATERAL THERAPEUTICS Genvir; FLAMEL TECHNOLOGIES SA Genzyme; BIOMARIN PHARMACEUTICAL Genzyme; TECHNE CORP Genzyme Biosurgery; GENZYME CORP Genzyme Corp.; GENZYME BIOSURGERY Genzyme Corp.; GTC BIOTHERAPEUTICS INC Genzyme Corporation; GELTEX PHARMACEUTICALS Genzyme General; GENZYME CORP Genzyme Molecular Oncology; GENZYME CORP Genzyme Surgical Products; GENZYME BIOSURGERY Genzyme Transgenics Corp; GTC BIOTHERAPEUTICS INC Gilead Sciences, Inc.; OSI PHARMACEUTICALS INC Gilead Sciences, Inc.; TRIANGLE PHARMACEUTICALS GinkoOnce; XECHEM INTERNATIONAL GinsengOnce; XECHEM INTERNATIONAL Gish Biomedical, Inc.; CARDIOTECH INTERNATIONAL Glaxo Wellcome; GLAXOSMITHLKINE PLC Glaxo Wellcome; VALENTIS INC GlaxoSmithKline; NPS PHARMACEUTICALS INC GlaxoSmithKline; VERTEX PHARMACEUTICALS INC GlaxoSmithKline plc; EXELIXIS INC Gliadel; SCIOS INC GLIADEL Wafer; GUILFORD PHARMACEUTICALS INC Global Genomics Capital, Inc.; CYTRX CORPORATION Global Pharmaceutical Corp.; IMPAX LABORATORIES INC Glofil-125; QUESTCOR PHARMACEUTICALS GlycoActives; NEOSE TECHNOLOGIES INC GlycoAdvance; NEOSE TECHNOLOGIES INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Glycomed, Inc.; LIGAND PHARMACEUTICALS INC GlycoPEGylation; NEOSE TECHNOLOGIES INC GlycoTherapeutics; NEOSE TECHNOLOGIES INC Glyko Biomedical; BIOMARIN PHARMACEUTICAL GMK; PROGENICS PHARMACEUTICALS GnRH Pharmaccine; APHTON CORP Gold Bond; CHATTEM INC Gold Standard; NORTH AMERICAN SCIENTIFIC Goldcaps, Inc.; IVAX CORPORATION Gonaxin; ZONAGEN INCORPORATED GPI 1485; GUILFORD PHARMACEUTICALS INC Graftpatch; ORGANOGENESIS INC Grand Laboratories, Inc.; NOVARTIS AG Group Lafon; CEPHALON INC Groupe Chauvin; BAUSCH & LOMB INC Growth Analyser; IMS HEALTH INC GS7904L; OSI PHARMACEUTICALS INC GTI 2040; LORUS THERAPEUTICS INC GTI 2501; LORUS THERAPEUTICS INC Guardian Laboratories; UNITED-GUARDIAN INC GVAX Cancer Vaccine; CELL GENESYS INC Gynodiol; NOVAVAX INC H. Lundbeck A/S; FOREST LABORATORIES INC H. Lundbeck A/S; SYNAPTIC PHARMACEUTICAL H-BIG; NABI PHARMACEUTICALS Hair Removal PDT; DUSA PHARMACEUTICALS INC Harness; MONSANTO CO Hauser Chemical Research, Inc.; HAUSER INC Hauser Laboratories; HAUSER INC Hauser Northwest, Inc.; HAUSER INC Hauser Technical Services, Inc.; HAUSER INC Hayashibara Biochemical Laboratories, Inc.; AMARILLO BIOSCIENCES INC HDC Corporation; E-Z-EM INC HE2000; HOLLIS -EDEN PHARMACEUTICALS HE2100; HOLLIS -EDEN PHARMACEUTICALS HE2200; HOLLIS -EDEN PHARMACEUTICALS HE2500; HOLLIS -EDEN PHARMACEUTICALS Heads Up; PDK LABS INC Health Care Communications, Inc.; KENDLE INTERNATIONAL INC Health Pharm; PHARMACEUTICAL FORMULATIONS INC Health+Cross; PHARMACEUTICAL FORMULATIONS INC Healtheon/Web MD; QUINTILES TRANSNATIONAL CORP Heartport; JOHNSON & JOHNSON HeavenlyDoor.com, Inc.; PALIGENT INC Hectorol Capsules; BONE CARE INTERNATIONAL Hectorol Injection; BONE CARE INTERNATIONAL Hedgehog; CURIS INC Heico Chemicals, Inc.; CAMBREX CORP Helinx; CERUS CORPORATION HELIVAX; ANTEX BIOLOGICS INC

Hemagen Diagnosticos Comercio; HEMAGEN DIAGNOSTICS INC HemaSure, Inc.; SEPRACOR INC Hematrol; INKINE PHARMACEUTICAL CO HemoCue; MALLINCKRODT INC Hemopure; BIOPURE CORPORATION HepArrest; COMMONWEALTH BIOTECHNOLOGIES INC HepaSphere SAP; BIOSPHERE MEDICAL INC HepBzyme; RIBOZYME PHARMACEUTICALS Heptazyme; RIBOZYME PHARMACEUTICALS Herbert Laboratories; ALLERGAN INC Herceptin; GENENTECH INC Herzyme; RIBOZYME PHARMACEUTICALS HetaCool; BIOTIME INC HEV Technology; GENELABS TECHNOLOGIES INC Hexalen; MEDIMMUNE INC Hextend; BIOTIME INC HiberGen; TRINITY BIOTECH PLC Hin47; ANTEX BIOLOGICS INC HiSpeed Plasmid Midi Kit; QIAGEN NV Histofreezer; ORASURE TECHNOLOGIES INC Hoffman-La Roche; PROTEIN DESIGN LABS INC Holmium-166 DOTMP; NEORX CORPORATION Hospital for Sick Children (The); CELERA GENOMICS GROUP HP Acthar Gel; QUESTCOR PHARMACEUTICALS HSB Group, Inc.; CURAGEN CORPORATION HuBit Genomix, Inc.; CELERA GENOMICS GROUP Humabid LA; CARACO PHARMACEUTICAL LABORATORIES Human Gene Trap; LEXICON GENETICS INC HuMax-CD4; MEDAREX INC Huperzine A; HI TECH PHARMACAL CO INC HYB 2055; HYBRIDON INC Hybrid Capture Gene Analysis System; DIGENE CORPORATION HyChip; HYSEQ INC Hycor Biomedical GmbH; HYCOR BIO MEDICAL INC Hycor Biomedical, Ltd.; HYCOR BIOMEDICAL INC Hydrajel; UNITED-GUARDIAN INC Hydro-Lac Lotion; PROCYTE CORPORATION HydroThane; CARDIOTECH INTERNATIONAL Hynic-Annexin V; NORTH AMERICAN SCIENTIFIC Hypnostat; QUESTCOR PHARMACEUTICALS Hyseq, Inc.; HYSEQ INC HY-TEC 288; HYCOR BIOMEDICAL INC HY-TEC 480; HYCOR BIOMEDICAL INC HYVISC; ANIKA THERAPEUTICS INC Iamin -Vet Skin Care Gel; PROCYTE CORPORATION IB-863; INTRABIOTICS PHARMACEUTICALS IB-880; INTRABIOTICS PHARMACEUTICALS i-biotech Solution; GENENCOR INTERNATIONAL INC Ibis Therapeutics; ISIS PHARMACEUTICALS INC IBM; LION BIOSCIENCE AG




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. IBStat; INKINE PHARMACEUTICAL CO IBU; PHARMACEUTICAL RESOURCES INC ICAgen; GENOME THERAPEUTICS CORP Icelandic Health Sector Database; DECODE GENETICS INC ICN Biomedicals; ICN PHARMACEUTICALS INC I-CORE; CEPHEID Icy-Hot; CHATTEM INC ID Vaccine; ID BIOMEDICAL CORPORATION Ideal Instruments; NEOGEN CORPORATION IDEXX Veterinary Services, Inc.; IDEXX LABORATORIES INC IDM-1; MEDAREX INC IGFBP-3; INSMED INCORPORATED IL-1Hy1; HYSEQ INC ILEX Oncology Services, Inc.; ILEX ONCOLOGY INC ILX23-7553; ILEX ONCOLOGY INC ILX -295501; ILEX ONCOLOGY INC Imavist; ALLIANCE PHARMACEUTICAL CORP IMC-1C11; IMCLONE SYSTEMS INC IMCB; EXELIXIS INC IMC-C225; IMCLONE SYSTEMS INC IMG Technologies; IMMUNOMEDICS INC Immerge BioTherapeutics; BIOTRANSPLANT INC ImmTech Biologics, Inc.; NOVARTIS AG IMMULITE; DIAGNOSTIC PRODUCTS CORPORATION IMMULITE 2000; DIAGNOSTIC PRODUCTS CORPORATION IMMULITE Turbo; DIAGNOSTIC PRODUCTS CORPORATION Immunex; AMGEN INC Immuno International AG; BAXTER INTERNATIONAL INC Immunol; ENDO PHARMACEUTICALS HOLDINGS INC ImmunoSense; EPIMMUNE INC ImmunoStealth; EPIMMUNE INC IMO Technology; HYBRIDON INC IMPACS; COLLAGENEX PHARMACEUTICAL Impax Pharmaceuticals; IMPAX LABORATORIES INC Implant Support Systems, Inc.; LIFECORE BIOMEDICAL INC Imutec Pharma; LORUS THERAPEUTICS INC INACTINE; V I TECHNOLOGIES INC Incara Cell Technologies, Inc.; INCARA PHARMACEUTICALS Incara Development, Ltd.; INCARA PHARMACEUTICALS INCERT; ANIKA THERAPEUTICS INC indiemed.com; ALPHARMA INC Indigo Medical, Inc.; THERAGENICS CORP Infergen; INTERMUNE PHARMACEUTICALS INC Infergen; AMGEN INC Infinity; GERON CORPORATION InforMax, Inc.; INVITROGEN CORPORATION

ING-1; XOMA LTD Ingenex, Inc.; TITAN PHARMACEUTICALS INGN 201; INTROGEN THERAPEUTICS INC InnoCentive LLC.; ELI LILLY & CO Innovase; DIVERSA CORPORATION Innovex; QUINTILES TRANSNATIONAL CORP Innovex eHealth Solutions Group; QUINTILES TRANSNATIONAL CORP Inosine; BOSTON LIFE SCIENCES INC Inovocox; EMBREX INC Inovoject; EMBREX INC INS-1; INSMED INCORPORATED INS316; INSPIRE PHARMACEUTICALS INC INS365; INSPIRE PHARMACEUTICALS INC INS37217; INSPIRE PHARMACEUTICALS INC Insmed Pharmaceuticals; INSMED INCORPORATED Insta-Glucose; ICN PHARMACEUTICALS INC Integra LifeSciences; INTEGRA LIFESCIENCES CORP Integra NeuroSciences; INTEGRA LIFESCIENCES CORP Integrated Culture Biology Management; CYANOTECH CORPORATION Integrated Medical Systems, Inc.; ELI LILLY & CO Integrilin; MILLENNIUM PHARMACEUTICALS INC Inter-Cal Corporation, Inc.; ZILA INC Intercept; ORASURE TECHNOLOGIES INC INTERCEPT Blood System; CERUS CORPORATION INTERGEL Adhesion Prevention Solution; LIFECORE BIOMEDICAL INC Intergen Company; SEROLOGICALS CORP Interleukin-2; VALENTIS INC International Canine Genetics; SYNBIOTICS CORP International Gene Group, Inc.; GLYCOGENESYS INC International HapMap Project; ILLUMINA INC International Isotopes Idaho, Inc.; INTERNATIONAL ISOTOPES International Isotopes, Inc.; NEORX CORPORATION Intervet, Inc.; AKZO NOBEL NV IntraDose; MATRIX PHARMACEUTICAL IntraEAR; DURECT CORP Inulin; QUESTCOR PHARMACEUTICALS Invader; THIRD WAVE TECHNOLOGIES INC Invantage, Inc.; PAREXEL INTERNATIONAL Investigational Device Exemption (IDE); PROTEIN POLYMER TECHNOLOGIES Invicorp; SENETEK PLC Invitrogen Corp.; INFORMAX INC Inwood Laboratories, Inc.; FOREST LABORATORIES INC IOGEL; IOMED INC IoGold; NORTH AMERICAN SCIENTIFIC Iontocaine; IOMED INC IontoDex; IOMED INC IonWorks; MOLECULAR DEVICES CORP iQLearning; QUINTILES TRANSNATIONAL CORP




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Irofulven; MGI PHARMA INC Iron Chelators; GELTEX PHARMACEUTICALS ISIS 2503; ISIS PHARMACEUTICALS INC ISO-GRID; NEOGEN CORPORATION ISV-401; INSITE VISION INC ISV-403; INSITE VISION INC ISV-900; INSITE VISION INC IV Solutions; BIGMAR INC IV-205; INSITE VISION INC IVAX Corporation; LABORATORIO CHILE SA IVAX Pharmaceuticals, Inc.; IVAX CORPORATION Iverhart; VIRBAC INC Ivomec; MERCK & CO INC J695; CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC Janssen; NPS PHARMACEUTICALS INC Janssen; GENSET SA Japan Pharma Center; QUINTILES TRANSNATIONAL CORP Japan Tobacco; CELL GENESYS INC JCR Pharmaceuticals Co., Ltd.; NAPRO BIOTHERAPEUTICS INC Jer-Neen Manufacturing; SYNOVIS LIFE TECHNOLOGIES INC Johnson & Johnson; THERAGENICS CORP Johnson & Johnson; ORAPHARMA INC Johnson and Johnson; ABGENIX INC Johnson and Johnson; ALZA CORP Jones Pharma, Inc.; KING PHARMACEUTICALS INC JP7; ALLOS THERAPEUTICS INC Kenwood Laboratories; BRADLEY PHARMACEUTICALS Kepler; LARGE SCALE BIOLOGY CORP Kerastick; DUSA PHARMACEUTICALS INC Ketoconazole Cream 2%; TARO PHARMACEUTICAL INDUSTRIES Ketroprofen; ANDRX CORP Kevlar; E I DU PONT DE NEMOURS & CO Keystone Laboratories; BIOSOURCE INTERNATIONAL INC Kiloprep; DYAX CORP Kinetin; SENETEK PLC Kirkegaard & Perry Laboratories; SYNBIOTICS CORP Klensoft; UNITED-GUARDIAN INC Kliogest; NOVO-NORDISK AS KMI; PAREXEL INTERNATIONAL KM-Mouse; MEDAREX INC KnowledGENE.com; NANOGEN INC KnowledgePort; CELERIS CORPORATION KOS-862; KOSAN BIOSCIENCES INC Koss; ABBOTT LABORATORIES KOVA; HYCOR BIOMEDICAL INC Kv1.5; CARDIOME PHARMACEUTICAL CORP LabCard; ACLARA BIOSCIENCES INC LabChile; LABORATORIO CHILE SA LabChip; CALIPER TECHNOLOGIES CORP

LabMAP; LUMINEX CORPORATION LabOnWeb.com; COMPUGEN LTD LabOnWeb.com; GENOME THERAPEUTICS CORP Laboratorios Armstrong; LABORATORIO CHILE SA Laboratorios Belmac; BENTLEY PHARMACEUTICALS INC Laboratorios Davur; BENTLEY PHARMACEUTICALS INC LabShare; INFORMAX INC Large Scale Proteomics Corp.; LARGE SCALE BIOLOGY CORP Larisse; BIOTECH HOLDINGS LTD LaserDerm; ADVANCED TISSUE SCIENCES Lasso; MONSANTO CO Lavipharm Corp.; ZONAGEN INCORPORATED LAX-101; AMARIN CORPORATION PLC LC Resources, Inc.; BIOANALYTICAL SYSTEMS INC LDP-02; MILLENNIUM PHARMACEUTICALS INC LDP-977; MILLENNIUM PHARMACEUTICALS INC LeadQuest; TRIPOS INC LEADS Technology; COMPUGEN LTD Leadtech Corp.; MEDTOX SCIENTIFIC INC LEAP Technology; PRAECIS PHARMACEUTICALS LEAPS; CEL-SCI CORPORATION Leg Ease; PHARMACEUTICAL FORMULATIONS INC Lemery; SICOR INC LeukArrest; ICOS CORPORATION LEUKINE; IMMUNEX CORP LeukoScan; IMMUNOMEDICS INC LeukoSite, Inc.; MILLENNIUM PHARMACEUTICALS INC LeuTech; PALATIN TECHNOLOGIES INC Leuvectin; VICAL INC Levovirin; ICN PHARMACEUTICALS INC Levoxyl; KING PHARMACEUTICALS INC Levulan; DUSA PHARMACEUTICALS INC Lexgen.com; LEXICON GENETICS INC Lexicon Genetics, Inc.; ABGENIX INC Lexicon Pharmaceuticals; LEXICON GENETICS INC LexVision; LEXICON GENETICS INC LIDA; PACIFIC BIOMETRICS INC LIDEX; MEDICIS PHARMACEUTICAL CORP Lidoderm; ENDO PHARMACEUTICALS HOLDINGS INC Liebel-Flarsheim Company; MALLINCKRODT INC Life Sciences Research, Inc.; HUNTINGDON LIFE SCIENCES Life Technologies, Inc.; INVITROGEN CORPORATION LifeExpress; OXFORD GLYCOSCIENCES PLC LifeExpress Database; INCYTE GENOMICS INC LifeProt; INCYTE GENOMICS INC LifeSeq Gold Database; INCYTE GENOMICS INC LifeTools; INCYTE GENOMICS INC Limbitrol; ICN PHARMACEUTICALS INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. LINAC; INTERNATIONAL ISOTOPES LION DiscoveryCenter; LION BIOSCIENCE AG LION Lead Engine; LION BIOSCIENCE AG LION SolutionCenter; LION BIOSCIENCE AG Lipitor; PFIZER INC Liquette; K V PHARMACEUTICAL CO LiquiVent; ALLIANCE PHARMACEUTICAL CORP Lite Bites; NUTRITION 21 INC LJP 1082; LA JOLLA PHARMACEUTICAL LJP 394; LA JOLLA PHARMACEUTICAL LJP 920; LA JOLLA PHARMACEUTICAL LOMUCIN; GENAERA CORPORATION Long SAGE; GENZYME MOLECULAR ONCOLOGY Lopressor; CARACO PHARMACEUTICAL LABORATORIES Lorabid; KING PHARMACEUTICALS INC Loratadine; IMPAX LABORATORIES INC Lotemax; PHARMOS CORPORATION Lovenox/Clexane; AVENTIS SA LPE System; DOR BIOPHARMA INC LPM System; DOR BIOPHARMA INC LR-103; BONE CARE INTERNATIONAL LSI MALT1; VYSIS INC Lubrajel; UNITED-GUARDIAN INC Lucanthone; SUPERGEN INC LumAvidin; LUMINEX CORPORATION Luminex 100; LUMINEX CORPORATION Luminex XYP; LUMINEX CORPORATION LumiTech, Ltd.; CAMBREX CORP Lupron; ABBOTT LABORATORIES Luqix; CONNETICS CORPORATION LUSTRA; MEDICIS PHARMACEUTICAL CORP Lutrin; PHARMACYCLICS INC Luxiq; MGI PHARMA INC Lycra; E I DU PONT DE NEMOURS & CO Lym-1 Technology; PEREGRINE PHARMACEUTICALS INC LymphoCide; IMMUNOMEDICS INC Lymphoglobuline; SANGSTAT MEDICAL CORP LymphoScan; IMMUNOMEDICS INC Lymphoseek; NEOPROBE CORPORATION LymphoStat-B; CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC Lynx; DONLAR BIOSYNTREX Lynx Therapeutics GmbH; LYNX THERAPEUTICS INC Machete; MONSANTO CO MacroDerm; MACROCHEM CORPORATION MacroSweet; LABORATORIO CHILE SA Magainin Pharmaceuticals; GENAERA CORPORATION Magnemax; NUTRITION 21 INC Managed Clinical Solutions, Inc.; ICON PLC Manon Acquisition Corp.; CHIRON CORP Marathon Biopharmaceuticals; CAMBREX CORP

Marco HiTech JV, Ltd.; HI TECH PHARMACAL CO INC Maret Corporation; ESSENTIAL THERAPEUTICS INC Marimastat; BRITISH BIOTECH PLC MARK 5 HSS; DIAGNOSTIC PRODUCTS CORPORATION Maryland Industrial Partnerships; ANTEX BIOLOGICS INC MassARRAY; SEQUENOM INC MassEXTEND; SEQUENOM INC Massively Parallel Signature Sequencing (MPSS); LYNX THERAPEUTICS INC Mastik; IMMUCELL CORPORATION MastOut; IMMUCELL CORPORATION Matritech Europe; MATRITECH INC Matrix Pharmaceutical, Inc.; CHIRON CORP Maverick; MONSANTO CO Mavik; KOS PHARMACEUTICALS INC Max Brand; PDK LABS INC MaxDerm; MAXIM PHARMACEUTICALS Maxline Microplate Readers; MOLECULAR DEVICES CORP MaxyScan; MAXYGEN INC Maxzide; MYLAN LABORATORIES INC MBI 226; MICROLOGIX BIOTECH INC MBI 594AN; MICROLOGIX BIOTECH INC MBP8298; AUTOIMMUNE INC MDS Capital Corp.; MDS INC MDS Laboratory Services; MDS INC MDS Matrix; MDS INC MDS Nordion; MDS INC MDS Pharma Services; MDS INC MDS Proteomics; MDS INC MDS Sciex; MDS INC MDV Technologies, Inc.; ALLIANCE PHARMACEUTICAL CORP MDX-33; MEDAREX INC MDX-44; MEDAREX INC Mead Johnson Nutritionals; BRISTOL MYERS SQUIBB CO Medarex, Inc.; HUMAN GENOME SCIENCES INC Medarex, Inc.; BIOSITE INC Medco Research, Inc.; KING PHARMACEUTICALS INC MEDI-507; BIOTRANSPLANT INC Medical Research Laboratories International BVBA; PHARMACEUTICAL PRODUCT DEVELOPMENT INC Medical Research Laboratories International, Inc.; PHARMACEUTICAL PRODUCT DEVELOPMENT INC Medicomp, Inc.; UNITED THERAPEUTICS CORP MedImmune Oncology, Inc.; MEDIMMUNE INC MedImmune, Inc.; MEDIMMUNE VACCINES Medisorb; ALKERMES INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Medline Industries; CARRINGTON LABORATORIES INC Medusa; FLAMEL TECHNOLOGIES SA Megaclone; LYNX THERAPEUTICS INC Megasort; LYNX THERAPEUTICS INC Megatype; LYNX THERAPEUTICS INC Melacine; CORIXA CORPORATION Melanophore Technology; ARENA PHARMACEUTICALS INC Memantine; NEUROBIOLOGICAL TECHNOLOGIES INC Meniscus Arrow; BIONX IMPLANTS INC Menorest; NOVEN PHARMACEUTICALS Menoring; WARNER CHILCOTT PLC Mentax; MYLAN LABORATORIES INC Mentor Corporation; NORTH AMERICAN SCIENTIFIC Meperidine; BARR LABORATORIES INC Merck KgaA; BIOMIRA INC Merck KGaA; IMCLONE SYSTEMS INC Merck KGaA; HUMAN GENOME SCIENCES INC Merck-Medco Managed Care, L.L. C.; MERCK & CO INC Merial; AVENTIS SA Merz+ Co. GmbH&Co.; NEUROBIOLOGICAL TECHNOLOGIES INC Metabasis Therapeutics, Inc.; SICOR INC Meter Release; K V PHARMACEUTICAL CO Metformin GR; DEPOMED INC Metformin IR; ANDRX CORP MethylGene; MGI PHARMA INC MethylGene Inc.; BRITISH BIOTECH PLC MethyPatch; NOVEN PHARMACEUTICALS Mevacor; MERCK & CO INC MG98; BRITISH BIOTECH PLC MGB Eclipse; EPOCH BIOSCIENCES MGV; PROGENICS PHARMACEUTICALS Micro Companies Alliance, Inc.; SYNOVIS LIFE TECHNOLOGIES INC Micro Release; K V PHARMACEUTICAL CO MicroChem; BOSTON BIOMEDICA INC Microcide Pharmaceuticals; ESSENTIAL THERAPEUTICS INC MICRODUR; DURECT CORP Micromask; K V PHARMACEUTICAL CO MICRO-PLATE; ORASURE TECHNOLOGIES INC Micropump; FLAMEL TECHNOLOGIES SA Microsequencer System; ACLARA BIOSCIENCES INC MicroTrak; TRINITY BIOTECH PLC MIDAS; PALATIN TECHNOLOGIES INC Midrin; WOMEN FIRST HEALTHCARE MiKasome; GILEAD SCIENCES INC Millennium; CALIPER TECHNOLOGIES CORP Millennium Predictive Medicine, Inc.; MILLENNIUM PHARMACEUTICALS INC Millipore Corporation; APPLERA CORPORATION

Millipore MicroElectronics, Inc.; MILLIPORE CORP MinElute PCR Purification and Gel Extraction Kit; QIAGEN NV Minerva Pharmaceuticals; DIAGNOSTIC PRODUCTS CORPORATION Minor Grove Binders; EPOCH BIOSCIENCES Mio Relax; BENTLEY PHARMACEUTICALS INC Mito Extra; SUPERGEN INC Mitozytrex; SUPERGEN INC Mitsubishi Pharma Corporation; IDEC PHARMACEUTICALS CORP MLN01; XOMA LTD MNTX; PROGENICS PHARMACEUTICALS Modafinil; CEPHALON INC Molecular Simulations, Inc.; PHARMACOPEIA INC MolecularBreeding; MAXYGEN INC Mom's Aloe Store; CARRINGTON LABORATORIES INC Monodox; WATSON PHARMACEUTICALS INC Moraxen; AMARIN CORPORATION PLC MorhpiDex; ENDO PHARMACEUTICALS HOLDINGS INC Morphanta; TECHNE CORP Morphelan; LIGAND PHARMACEUTICALS INC MPI 5020 Radiopotentiator; MATRIX PHARMACEUTICAL MS-325; EPIX MEDICAL INC M-SERIES; IGEN INTERNATIONAL INC Multiferon; VIRAGEN INC MultiKine; CEL-SCI CORPORATION MultiScreen; MILLIPORE CORP MV94411; MIRAVANT MEDICAL TECHNOLOGIES M-Vax; AVAX TECHNOLOGIES INC MX126374; MAXIM PHARMACEUTICALS MX2105; MAXIM PHARMACEUTICALS MX2167; MAXIM PHARMACEUTICALS MX8899; MAXIM PHARMACEUTICALS Myelos Corp.; BIO TECHNOLOGY GENERAL CORP Mykrolis Corporation; MILLIPORE CORP Mylan Pharmaceuticals; MYLAN LABORATORIES INC Mylan Technologies; MYLAN LABORATORIES INC Mylanta; JOHNSON & JOHNSON Mylar; E I DU PONT DE NEMOURS & CO Myotrophin; CEPHALON INC MYOVIEW; AMERSHAM PLC Myriad Genetic Laboratories; MYRIAD GENETICS INC Myriad Genetics, Inc.; GENZYME MOLECULAR ONCOLOGY Myriad Pharmaceuticals, Inc.; MYRIAD GENETICS INC NAALADase Inhibitors; GUILFORD PHARMACEUTICALS INC NanoChip; NANOGEN INC NanoCrystal; SHEFFIELD PHARMACEUTICALS




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Nanogen Europe; NANOGEN INC Nanogen Recognomics; NANOGEN INC NaPro 102339; NAPRO BIOTHERAPEUTICS INC NaPro 80239; NAPRO BIOTHERAPEUTICS INC NaPro 80661; NAPRO BIOTHERAPEUTICS INC Nascobal; NASTECH PHARMACEUTICAL CO INC NataChew; WARNER CHILCOTT PLC NataFort; WARNER CHILCOTT PLC NatChem; CUBIST PHARMACEUTICALS NatGen; CUBIST PHARMACEUTICALS Natrecor; SCIOS INC NatuRose; CYANOTECH CORPORATION NBI 6024; NEUROCRINE BIOSCIENCES INC NC 381; LORUS THERAPEUTICS INC neo2000 Gamma Detection System; NEOPROBE CORPORATION NEO -339; SPECTRUM PHARMACEUTICALS NEO -376; SPECTRUM PHARMACEUTICALS NEO -392; SPECTRUM PHARMACEUTICALS NeoGene Technologies, Inc.; SPECTRUM PHARMACEUTICALS Neomorphic; AFFYMETRIX INC NeoOncoRx; SPECTRUM PHARMACEUTICALS Neoquin; SPECTRUM PHARMACEUTICALS NeoSan Pharmaceuticals; AAIPHARMA INC NeoTherapeutics, Inc.; SPECTRUM PHARMACEUTICALS Neotrofin; SPECTRUM PHARMACEUTICALS Neova Therapy; PROCYTE CORPORATION NeovaTherapy; PROCYTE CORPORATION Nepera, Inc.; CAMBREX CORP Nestabs; NOVAVAX INC NetAffx; AFFYMETRIX INC Neupogen; AMGEN INC NeuralStem Biopharmaceuticals; GENZYME MOLECULAR ONCOLOGY NeuroCell-PD; DIACRIN INC Neurodex; AVANIR PHARMACEUTICALS Neurologic Gene Therapeutics; CELL GENESYS INC Neuromins; MARTEK BIOSCIENCES CORP Neurontin; PFIZER INC Neuroscience Pharma; NEUROCRINE BIOSCIENCES INC NeuroSupplies, Inc.; INTEGRA LIFESCIENCES CORP Neutralase; BIOMARIN PHARMACEUTICAL NeuTrexin; ALZA CORP NeuTrexin; MEDIMMUNE INC Newpharm S.A.; LABORATORIO CHILE SA Newplex; EMBREX INC NexACT; NEXMED INC NexMed International, Ltd.; NEXMED INC NeXstar Pharmaceuticals, Inc.; GILEAD SCIENCES INC NGD 97-1; NEUROGEN CORP Niaspan; KOS PHA RMACEUTICALS INC

Nice n' Easy; BRISTOL MYERS SQUIBB CO Nicorette; GLAXOSMITHLKINE PLC Nicostation; KOS PHARMACEUTICALS INC NicVAX; NABI PHARMACEUTICALS Nifedipine XL; PENWEST PHARMACEUTICALS CO Nipent; SUPERGEN INC Nitrek; MYLAN LABORATORIES INC NMP Technology; MATRITECH INC NMP179; MATRITECH INC NMP22 BladderChek; MATRITECH INC NMP22 Test Kit; MATRITECH INC NMP35; MATRITECH INC NMP48; MATRITECH INC NMP66; MATRITECH INC NonSpil; TARO PHARMACEUTICAL INDUSTRIES Norditropin SimpleXx; NOVO-NORDISK AS Norethindrone Acetate; BARR LABORATORIES INC Nortel; BARR LABORATORIES INC Nortran Pharmaceuticals, Inc.; CARDIOME PHARMACEUTICAL CORP Norvir; ABBOTT LABORATORIES NOVANTRONE; IMMUNEX CORP Novartis; SYNGENTA AG Novartis; VERTEX PHARMACEUTICALS INC Novartis Agribusiness; ASTRAZENECA PLC Novartis Institute for Biomedical Research, Inc.; NOVARTIS AG Novartis Pharmaceuticals Corporation; ORGANOGENESIS INC Novation; DIAGNOSTIC PRODUCTS CORPORATION Novavax, Inc.; KING PHARMACEUTICALS INC Novazyme Pharmaceuticals; GENZYME CORP Novex Electrophoresis GmbH; INVITROGEN CORPORATION Novogyne Pharmaceuticals; NOVEN PHARMACEUTICALS NovoPenMate; NOVO-NORDISK AS NovoSeven; NOVO-NORDISK AS NuChem; LORUS THERAPEUTICS INC NuChem Pharmaceuticals, Inc.; SHEFFIELD PHARMACEUTICALS NUEPREX; XOMA LTD Numby Stuff; IOMED INC Nutravail Technologies, Inc.; BIOVAIL CORPORATION Nutrex Hawaii, Inc.; CYANOTECH CORPORATION Nutropin AQ; GENENTECH INC Nutropin Depot; ALKERMES INC Nutropin Depot; GENENTECH INC NUVANCE; IMMUNEX CORP O6-BG; PALIGENT INC OASIS; EXEGENICS INC Ocean-Chill Drying; CYANOTECH CORPORATION Oclassen Dermatologics; WATSON PHARMACEUTICALS INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. OcuGene; INSITE VISION INC OcuPhor; IOMED INC OGT 918; OXFORD GLYCOSCIENCES PLC Oligator; ILLUMINA INC OligoLibraries; COMPUGEN LTD OLUX; CONNETICS CORPORATION OmegaTech, Inc.; MARTEK BIOSCIENCES CORP Omeprazole; IMPAX LABORATORIES INC OmniBank; LEXICON GENETICS INC Omniclonal Phage Display Technology; BIOSITE INC Omniferon; VIRAGEN INC ONC+Mab; ALFACELL CORPORATION ONCASPAR; ENZON INC Oncolym; PEREGRINE PHARMACEUTICALS INC Oncomyc-NG; AVI BIOPHARMA INC Onconase; ALFACELL CORPORATION Oncophage; ANTIGENICS INC OncoScint; CYTOGEN CORPORATION OncoSeed; AMERSHAM PLC Ono Pharmaceutical; CORTECH INC ONTAK; LIGAND PHARMACEUTICALS INC ONYX-015; ONYX PHARMACEUTICALS INC ONYX-015; XOMA LTD ONYX-411; ONYX PHARMACEUTICALS INC ONYX-443; ONYX PHARMACEUTICALS INC OP-1; CURIS INC OP2000; INCARA PHARMACEUTICALS Operon Technologies; QIAGEN NV Optex; ATLANTIC TECHNOLOGY VENTURES Opthalmic Division; AKORN INC Opticap; MILLIPORE CORP Optimized Anti-Sense Inhibitory Sequence; EXEGENICS INC Optimum Lifestyle, Inc.; NUTRITION 21 INC OPTISON; MOLECULAR BIOSYSTEMS INC Optistar MR; MALLINCKRODT INC Optrin; PHARMACYCLICS INC OraDisc; ACCESS PHARMACEUTICALS OragenT; HEMISPHERX BIOPHARMA INC ORALEX; MOLECULAR BIOSYSTEMS INC Oralin; GENEREX BIOTECHNOLOGY Oraphine; DOR BIOPHARMA INC Orapred; ASCENT PEDIATRICS INC OraQuick HIV; ORASURE TECHNOLOGIES INC OraRinse; ACCESS PHARMACEUTICALS OraSolv; CIMA LABS INC OraSure HIV-1; ORASURE TECHNOLOGIES INC OraTest; ZILA INC OraVescent; CIMA LABS INC orBec; DOR BIOPHARMA INC Orbtek; BAUSCH & LOMB INC Orchid Biocomputer; ORCHID BIOSCIENCES INC Orchid Cellmark; ORCHID BIOSCIENCES INC Orchid Diagnostics; ORCHID BIOSCIENCES INC Orchid GeneScreen; ORCHID BIOSCIENCES INC Orchid GeneShield; ORCHID BIOSCIENCES INC

Orchid Life Sciences; ORCHID BIOSCIENCES INC Orex Computed Radiography, Ltd.; IDEXX LABORATORIES INC Organichem Corp.; ALBANY MOLECULAR RESEARCH Organon Teknika Corporation; AKZO NOBEL NV ORIGEN; IGEN INTERNATIONAL INC ORI-TAG; IGEN INTERNATIONAL INC Oritavancin; INTERMUNE PHARMACEUTICALS INC ORI-TWIST; IGEN INTERNATIONAL INC Ortho-Est; WOMEN FIRST HEALTHCARE Ortho-McNeil Pharmaceutical, Inc.; CHIRON CORP Ortho-Prefest; WOMEN FIRST HEALTHCARE ORTHOVISC; ANIKA THERAPEUTICS INC OSI-211; OSI PHARMACEUTICALS INC OSI-760; OSI PHARMACEUTICALS INC OSIC-0961370; OSI PHARMACEUTICALS INC Osmocyte-Vet Pillow Wound Dressings; PROCYTE CORPORATION OsteoPatch; PACIFIC BIOMETRICS INC O-Vax; AVAX TECHNOLOGIES INC Ovcon 35; WARNER CHILCOTT PLC Ovcon 50; WARNER CHILCOTT PLC Oxadrin; BIO TECHNOLOGY GENERAL CORP Oxford Molecular; PHARMACOPEIA INC OxiFirst; MALLINCKRODT INC OXIS Health Products, Inc.; OXIS INTERNATIONAL INC OXIS Therapeutics, Inc.; OXIS INTERNATIONAL INC OxisResearch; OXIS INTERNATIONAL INC Oxycal Export, Inc.; ZILA INC Oxycodone; IMPAX LABORATORIES INC Oxygen Bridge; BIOPURE CORPORATION Oxygent; ALLIANCE PHARMACEUTICAL CORP Oxyglobin; BIOPURE CORPORATION OXYPRIM; ILEX ONCOLOGY INC Oxypurinol; CARDIOME PHARMACEUTICAL CORP OxyScan System; OXIS INTERNATIONAL INC P-32; ALFACELL CORPORATION p38 MAPK ELISA; BIOSOURCE INTERNATIONAL INC Pacific Biometrics Research Foundation; PACIFIC BIOMETRICS INC Pacific Pharma, Inc.; ALLERGAN INC Pacific Research Associates, Inc.; ICON PLC PACIS; SHIRE-BIOCHEM INC Paclitaxel; NAPRO BIOTHERAPEUTICS INC PADRE; EPIMMUNE INC Pafase; ICOS CORPORATION PAGE-4 Plasmid DNA; IDEC PHARMACEUTICALS CORP PakSolv; CIMA LABS INC Palatin Technologies; MOLECULAR BIOSYSTEMS INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Palmettx; ZILA INC Palonosetron; MGI PHARMA INC Palosein; OXIS INTERNATIONAL INC Pamine; BRADLEY PHARMACEUTICALS Panax Pharmaceutical Company, Ltd.; INKINE PHARMACEUTICAL CO Pandel; COLLAGENEX PHARMACEUTICAL PanGenex, Inc.; CELL THERAPEUTICS INC Panistat; QUESTCOR PHARMACEUTICALS Panretin; LIGAND PHARMACEUTICALS INC PanVera Corporation; VERTEX PHARMACEUTICALS INC Panzem; ENTREMED INC Par Pharmaceutical, Inc.; PHARMACEUTICAL RESOURCES INC Paracel; CELERA GENOMICS GROUP Paralex, Inc.; CARDIOME PHARMACEUTICAL CORP Parallex Flex; DYAX CORP Paremyd; AKORN INC PAREXEL Consulting Group; PAREXEL INTERNATIONAL Particle Dynamics, Inc.; K V PHARMACEUTICAL CO Pasadena Research Laboratories, Inc.; AKORN INC Pasteur Sanofi Diagnostics; BIO RAD LABORATORIES INC PathCalling; CURAGEN CORPORATION PATHIGEN; IGEN INTERNATIONAL INC PathoGenome Database; GENOME THERAPEUTICS CORP Pathology Associated International; CHARLES RIVER LABORATORIES CORP PathoSeq Database; INCYTE GENOMICS INC Paxene; IVAX CORPORATION PAXETOL; XECHEM INTERNATIONAL Paxil; GLAXOSMITHLKINE PLC Paxoral; IVAX CORPORATION PBI; NABI PHARMACEUTICALS PCS Health Systems; ELI LILLY & CO PDE 4; CELLTECH GROUP PLC PdGold; NORTH AMERICAN SCIENTIFIC PDK Acquisition Corporation; PDK LABS INC PE Corporation; APPLERA CORPORATION PE Corporation; CELERA GENOMICS GROUP Pedialyte; ABBOTT LABORATORIES PEG Technology; VALENTIS INC PEG-INTRON; ENZON INC PentaLyte; BIOTIME INC Pentasa; SHIRE PHARMACEUTICALS PLC Pentex; SEROLOGICALS CORP Pentose Pharmaceuticals; V I TECHNOLOGIES INC Pepcid; MERCK & CO IN C Perceptive Informatics, Inc.; PAREXEL INTERNATIONAL Percocet; ENDO PHARMACEUTICALS HOLDINGS INC

Percodan; ENDO PHARMACEUTICALS HOLDINGS INC Pergolide Mesylate Tablets; TEVA PHARMACEUTICAL INDUSTRIES Periostat; COLLAGENEX PHARMACEUTICAL Perlegen Sciences, Inc.; AFFYMETRIX INC Permax; AMARIN CORPORATION PLC Personal Products Company; ORAPHARMA INC Pexelizumab; ALEXION PHARMACEUTICALS Pfizer; ABGENIX INC Phage Display Technology; DYAX CORP Pharmacast Therapy Reports; IMS HEALTH INC Pharmacia; AMERSHAM PLC Pharmacia; ELAN CORP PLC Pharmacia; PFIZER INC Pharmacia Corporation; MONSANTO CO Pharmacia Corporation; MIRAVANT MEDICAL TECHNOLOGIES Pharmacia Corporation; WATSON PHARMACEUTICALS INC PharmaKinetics Laboratories; BIOANALYTICAL SYSTEMS INC Pharmax Limited; FOREST LABORATORIES INC Pharmos, Ltd.; PHARMOS CORPORATION Pharmtrade S.A.; LABORATORIO CHILE SA Phenethylnorcymserine; AXONYX INC PhenoScreen; VIROLOGIC INC PhenoSense Assays; VIROLOGIC INC PhenoSense HIV; VIROLOGIC INC Phenserine; AXONYX INC pHisoderm; CHATTEM INC Phoresor System; IOMED INC Photofrin; QLT INC PhotoPoint; MIRAVANT MEDICAL TECHNOLOGIES PhytoDome CCS; CYANOTECH CORPORATION Piccolo; ABAXIS INC Piedmont Research Center; PHARMACEUTICAL PRODUCT DEVELOPMENT INC Pillo Pro Absorbant Dressings; PROCYTE CORPORATION Pimagedine; ALTEON INC Pitocin; KING PHARMACEUTICALS INC PL-2299; PALATIN TECHNOLOGIES INC PLAS+SD; V I TECHNOLOGIES INC Pleconaril; VIROPHARMA INC Plenaxis; PRAECIS PHARMACEUTICALS PLEXION; MEDICIS PHARMACEUTICAL CORP PLP System; DOR BIOPHARMA INC Plurex Multiplexing Card; ACLARA BIOSCIENCES INC PointDX; E-Z-EM INC Polaron Instruments; BIO RAD LABORATORIES INC Polyamines; GELTEX PHARMACEUTICALS Polydex Chemicals, Ltd.; POLYDEX PHARMACEUTICALS




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. PolyFect Transfection Reagent; QIAGEN NV PolyFect Transfection Reagent; QIAGEN NV PolyHeme; NORTHFIELD LABORATORIES PolyMASC Pharmaceuticals; VALENTIS INC PolyMASC Pharmaceuticals; VIRAGEN INC Polymer Technology Corp.; BAUSCH & LOMB INC PolyPeptide Laboratories; INTRABIOTICS PHARMACEUTICALS PPD Development; PHARMACEUTICAL PRODUCT DEVELOPMENT INC PPD Discovery; PHARMACEUTICAL PRODUCT DEVELOPMENT INC PPD Informatics; PHARMACEUTICAL PRODUCT DEVELOPMENT INC PPD Medical Communications; PHARMACEUTICAL PRODUCT DEVELOPMENT INC PPD Virtual; PHARMACEUTICAL PRODUCT DEVELOPMENT INC Pramidin; QUESTCOR PHARMACEUTICALS Pramlintide; AMYLIN PHARMACEUTICALS INC PrefGel; BIORA AB Premaire; SHEFFIELD PHARMACEUTICALS Premarin; WYETH PREOS; NPS PHARMACEUTICALS INC Prestara; GENELABS TECHNOLOGIES INC Pretarget; NEORX CORPORATION Prialt; ELAN CORP PLC Prilosec; ASTRAZENECA PLC PRIMATIZED; IDEC PHARMACEUTICALS CORP Primedica; CHARLES RIVER LABORATORIES CORP Primsol; ASCENT PEDIATRICS INC Princeton BioMeditech; SPECTRAL DIAGNOSTICS INC Princeton Diagnostic Laboratories of America, Inc.; MEDTOX SCIENTIFIC INC Prion Inhibitory Peptide; AXONYX INC Prisma Systems; SYNBIOTICS CORP PRO 140; PROGENICS PHARMACEUTICALS PRO 2000 Gel; PALIGENT INC PRO 542; PROGENICS PHARMACEUTICALS Proamatine; SHIRE PHARMACEUTICALS PLC Procept, Inc.; PALIGENT INC Proclaim; SYNGENTA AG Proclear; BIOCOMPATIBLES INTERNATIONAL PLC Profile; MEDTOX SCIENTIFIC INC Progenics Pharmaceuticals, Inc.; GTC BIOTHERAPEUTICS INC ProGEx; LARGE SCALE BIOLOGY CORP ProLease; ALKERMES INC Proleukin; CHIRON CORP ProNet; MYRIAD GENETICS INC ProNeura, Inc.; TITAN PHARMACEUTICALS ProSolv; PENWEST PHARMACEUTICALS CO Prosorba; CYPRESS BIOSCIENCE INC

Prospera; NORTH AMERICAN SCIENTIFIC ProstaScint; CYTOGEN CORPORATION Protein ProFiler; LYNX THERAPEUTICS INC ProteinChip Systems; CIPHERGEN BIOSYSTEMS INC Proteome; INCYTE GENOMICS INC PROTHECAN; ENZON INC Protocole; ICON PLC PROVAX; IDEC PHARMACEUTICALS CORP ProVax; PROGENICS PHARMACEUTICALS Provigil; CEPHALON INC Prozac; ELI LILLY & CO PR-Q; COLLAGENEX PHARMACEUTICAL Pruv; PENWEST PHARMACEUTICALS CO PSMA; PROGENICS PHARMACEUTICALS PSMA Technology; CYTOGEN CORPORATION PsoriasisSupport.com; BIOGEN INC PT-141; PALATIN TECHNOLOGIES INC PT-15; PALATIN TECHNOLOGIES INC Pulmicort Respules; ASTRAZENECA PLC Pulmospheres; ALLIANCE PHARMACEUTICAL CORP Pulmozyme; GENENTECH INC PULSE; BOSTON BIOMEDICA INC PuraPly; ORGANOGENESIS INC PVAC; CORIXA CORPORATION Pyridium Plus; WARNER CHILCOTT PLC Pyrolase 160 Enzyme; DIVERSA CORPORATION Pyrolase 200 Enzyme; DIVERSA CORPORATION Q.E.D. Saliva Alcohol Test; ORASURE TECHNOLOGIES INC QA Life Sciences; NEOGEN CORPORATION Qiagen Genomics; QIAGEN NV QLT Photo Therapeutics, Inc.; QLT INC QLT0074; QLT INC QS-21; ANTIGENICS INC Quadramet; CYTOGEN CORPORATION Quality Controlled Biochemical; BIOSOURCE INTERNATIONAL INC Quantase, Ltd.; BIO RAD LABORATORIES INC Quantix/ND; NEOPROBE CORPORATION Quantix/OR; NEOPROBE CORPORATION Quantix/TE; NEOPROBE CORPORATION Quantum Core Technology; EXEGENICS INC Quantum Devices, Inc.; PHARMACYCLICS INC Quay Pharmaceuticals; CELLEGY PHARMACEUTICALS QUINTERNET Informatics; QUINTILES TRANSNATIONAL CORP Quintiles Academy; QUINTILES TRANSNATIONAL CORP R&D Systems, Europe Ltd.; TECHNE CORP RadiaCare Gel; CARRINGTON LABORATORIES INC Rakepoll Holding B.V.; SICOR INC Ramoplanin; GENOME THERAPEUTICS CORP




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Ranolazine; CV THERAPEUTICS INC RapidMist Device; GENEREX BIOTECHNOLOGY RapiScreen; CELSIS INTERNATIONAL PLC Raptiva; XOMA LTD Rare Earth Medical; PHARMACYCLICS INC Ravax; IMMUNE RESPONSE CORP (THE) RDP58; SANGSTAT MEDICAL CORP Reach; JOHNSON & JOHNSON Rebeccamycin; EXELIXIS INC Recombigen; TRINITY BIOTECH PLC Redmond Red; EPOCH BIOSCIENCES Reduced Irritation System; DEPOMED INC Regranex Gel; CHIRON CORP RegTech; ARIAD PHARMACEUTICALS Rejuvex; CHATTEM INC Rel-Ease; PRAECIS PHARMACEUTICALS Relafen; GLAXOSMITHLKINE PLC Remicade; GTC BIOTHERAPEUTICS INC Reminyl; SHIRE PHARMACEUTICALS PLC Remitogen; PROTEIN DESIGN LABS INC Remodulin; UNITED THERAPEUTICS CORP Remune; IMMUNE RESPONSE CORP (THE) Renagel; GENZYME CORP Renagel Tablets; GELTEX PHARMACEUTICALS Renaissance Cell Technologies; INCARA PHARMACEUTICALS ReNu; BAUSCH & LOMB INC Renzapride; ALIZYME PLC Replagal; TRANSKARYOTIC THERAPIES Replens; COLUMBIA LABORATORIES Replicase; DIVERSA CORPORATION Repliform; LIFECELL CORPORATION Research and Diagnostic Systems, Inc.; TECHNE CORP Research Medical, Inc.; BAXTER INTERNATIONAL INC Residerm; ACCESS PHARMACEUTICALS RespiGam; MEDIMMUNE INC Respiratory Steroid Delivery, Ltd.; SHEFFIELD PHARMACEUTICALS Restasis; INSPIRE PHARMACEUTICALS INC Resten-NG; AVI BIOPHARMA INC Restoraderm; COLLAGENEX PHARMACEUTICAL REVIMID; CELGENE CORP Rhone Merieux Diagnostics; SYNBIOTICS CORP Ribapharm; ICN PHARMACEUTICALS INC Ribavirin; ICN PHARMACEUTICALS INC Ridaura; MGI PHARMA INC Risperdal Consta; ALKERMES INC Rituxan; IDEC PHARMACEUTICALS CORP Rityxan; GENENTECH INC RNA 6000 Pico; CALIPER TECHNOLOGIES CORP rNAPc2; CORVAS INTERNATIONAL INC Rneasy Protect Kits; QIAGEN NV Robitussin; WYETH Rocephin; CUBIST PHARMACEUTICALS Roche; ALPHARMA INC

Roche Diagnostics; VALENTIS INC Roche Pharmaceuticals; GILEAD SCIENCES INC Rosemont Pharmaceutical Corporation; AKZO NOBEL NV Rosetta Inpharmatics; SANGAMO BIOSCIENCES INC Roslin Biotechnology Centre; GERON CORPORATION Roundup; MONSANTO CO RPD Secretion Technologies; ARIAD PHARMACEUTICALS rProtein A; REPLIGEN CORPORATION RSD1122; CARDIOME PHARMACEUTICAL CORP RSD1235; CARDIOME PHARMACEUTICAL CORP RSR13; ALLOS THERAPEUTICS INC RSR46; ALLOS THERAPEUTICS INC Rubitecan; SUPERGEN INC RWJ-270201; BIOCRYST PHARMACEUTICALS Rx Choice; HI TECH PHARMACAL CO INC Rx Market Monitor; QUINTILES TRANSNATIONAL CORP S.A.R.L.; ICON PLC S.T.E.P.S.; CELGENE CORP S-8184; SONUS PHARMACEUTICALS SAANDS; CELL PATHWAYS INC SABER; DURECT CORP Sabila Industrial, S.A.; CARRINGTON LABORATORIES INC SafeScience Products, Inc.; GLYCOGENESYS INC SafeScience, Inc.; GLYCOGENESYS INC SAGE Database; GENZYME MOLECULAR ONCOLOGY Saigene Corporation; PACIFIC BIOMETRICS INC Salagen; MGI PHARMA INC SaliCept Oral Patch; CARRINGTON LABORATORIES INC SalivaCard; TRINITY BIOTECH PLC SalivaSac; PACIFIC BIOMETRICS INC SangStat Europe; SANGSTAT MEDICAL CORP SangStat, Canada, Ltd.; SANGSTAT MEDICAL CORP Sankyo Company, Ltd.; ARQULE INC Sankyo Pharma, Inc.; GELTEX PHARMACEUTICALS Sanofi-Synthelabo; GENSET SA Satelec Medical; INTEGRA LIFESCIENCES CORP SCA Ventures; ENZON INC SCA2000; SYNBIOTICS CORP Schein Pharmaceuticals; WATSON PHARMACEUTICALS INC Schering AG; COLLATERAL THERAPEUTICS Schering AG; ALLIANCE PHARMACEUTICAL CORP Schering Corporation; HUMAN GENOME SCIENCES INC SC-I Therapy Kit; AASTROM BIOSCIENCES INC SciClone Pharmaceuticals International; SCICLONE PHARMACEUTICALS Scientific Protein Laboratories, Inc.; WYETH SCIO-469; SCIOS INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Scios Nova, Inc.; SCIOS INC Score; SYNGENTA AG ScreenStation System; MOLECULAR DEVICES CORP SCV-07; SCICLONE PHARMACEUTICALS SecreFlo; REPLIGEN CORPORATION Seek Target Validation (S-T-V) Program; LEXICON GENETICS INC Segenix, Inc.; ADVANCED TISSUE SCIENCES SelCIDs; CELGENE CORP SelectAME; APPLIED MOLECULAR EVOLUTION INC Selenomax; NUTRITION 21 INC SelenoPure; NUTRITION 21 INC Selsun Blue; ABBOTT LABORATORIES Selsun Blue; CHATTEM INC Senioral; BENTLEY PHARMACEUTICALS INC SensiLight; MARTEK BIOSCIENCES CORP Sentrix; ILLUMINA INC SEPA; MACROCHEM CORPORATION Seprafilm; GENZYME CORP Sepragel; GENZYME BIOSURGERY Sepsis, Inc.; SPECTRAL DIAGNOSTICS INC SeqCalling; CURAGEN CORPORATION Seragen Inc.; LIGAND PHARMACEUTICALS INC SERM; CELGENE CORP SERMs; PHARMOS CORPORATION Serologicals Proteins, Inc.; SEROLOGICALS CORP Serologicals, Ltd.; SEROLOGICALS CORP Serono SA; BRITISH BIOTECH PLC ShellGel; ANIKA THERAPEUTICS INC Shijiazhuang Pharmaceutical Group; UNIGENE LABORATORIES Shire Laboratories; SHIRE PHARMACEUTICALS PLC Shuster Laboratories; HAUSER INC Sierra Biomedical; CHARLES RIVER LABORATORIES CORP SIGA Research Labs; SIGA TECHNOLOGIES INC Sigma Diagnostics; TRINITY BIOTECH PLC Silver Fox; SENETEK PLC Similac; ABBOTT LABORATORIES Singapore Economic Development Board; ELI LILLY & CO Singular; MERCK & CO INC Siplizumab; BIOTRANSPLANT INC Sitaxsentan; TEXAS BIOTECHNOLOGY CORP Sitaxsentan; ICOS CORPORATION Skeletal Targeted Radiotherapy; NEORX CORPORATION SkyePharma, Inc.; SKYEPHARMA PLC SLAM; ABGENIX INC Sleeping Beauty Transposona; TECHNE CORP SMART Anti-Gamma Interferon Antibody; PROTEIN DESIGN LABS INC Smart Cycler; CEPHEID Smart Cycler II; CEPHEID

Smart Pin; BIONX IMPLANTS INC Smart Screw; BIONX IMPLANTS INC Smart Tack; BIONX IMPLANTS INC SmithKline Beecham; GLAXOSMITHLKINE PLC SMP; ATRIX LABORATORIES INC SNAP Discovery; SYNAPTIC PHARMACEUTICAL SnET2; MIRAVANT MEDICAL TECHNOLOGIES SNPCalling; CURAGEN CORPORATION SNPstream; ORCHID BIOSCIENCES INC SNPware; ORCHID BIOSCIENCES INC Soane BioSciences, Inc.; ACLARA BIOSCIENCES INC Solarase; SKYEPHARMA PLC Solid-Phase Anion-Exchange Technology; QIAGEN NV Solo Step CH Batch Test Strips; HESKA CORP Soltec Research; CONNETICS CORPORATION Somatix Therapy Corporation; CELL GENESYS INC SomatoKine; INSMED INCORPORATED Somerset Pharmaceuticals; WATSON PHARMACEUTICALS INC Source Medical; MDS INC Southern BioSystems, Inc.; DURECT CORP Sparhawk Veterinary Laboratories, Inc.; POLYDEX PHARMACEUTICALS SpectroCHIP; SEQUENOM INC SpectroJET; SEQUENOM INC SpectroTYPER; SEQUENOM INC SPEX; SIGA TECHNOLOGIES INC Spheramine; TITAN PHARMACEUTICALS Spine Wave, Inc.; PROTEIN POLYMER TECHNOLOGIES Spirulina Pacifica; CYANOTECH CORPORATION SportSafe; BIOVAIL CORPORATION Spotted Array Systems; AFFYMETRIX INC Springborn Laboratories, Inc.; CHARLES RIVER LABORATORIES CORP SpyroDerm; CARDIOTECH INTERNATIONAL Squalamine; GENAERA CORPORATION SRS Prisma; LION BIOSCIENCE AG STAARVISC II; ANIKA THERAPEUTICS INC Stadol NS; NASTECH PHARMACEUTICAL CO INC Stainmaster; E I DU PONT DE NEMOURS & CO StaphVAX; NABI PHARMACEUTICALS STA-T Technology; NASTECH PHARMACEUTICAL CO INC STATPROBE; CELERIS CORPORATION Status; SPECTRAL DIAGNOSTICS INC Stemgen; AMGEN INC Steri-Med; HI TECH PHARMACAL CO INC Sterisomes; NOVAVAX INC StreptAvax; ID BIOMEDICAL CORPORATION Striant; COLUMBIA LABORATORIES Sucraid; ORPHAN MEDICAL INC Sufenta; AKORN INC Sulfonyl Hydrazine Prodrugs; VION PHARMACEUTICALS INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Sumitomo; REGENERON PHARMACEUTICALS INC SunAndSkin.com; MEDICIS PHARMACEUTICAL CORP SunPharm Corporation; GELTEX PHARMACEUTICALS Superior Pharmaceutical Co.; ABLE LABORATORIES Superior Supplements; PDK LABS INC SuperVent; DISCOVERY LABORATORIES SureLight; MARTEK BIOSCIENCES CORP Surfaxin; DISCOVERY LABORATORIES Surgical Sling; ORGANOGENESIS INC SweatPatch; PACIFIC BIOMETRICS INC SweetThoughts.com; HI TECH PHARMACAL CO INC SYBYL; TRIPOS INC SYMLIN; AMYLIN PHARMACEUTICALS INC Symphar S.A.; ILEX ONCOLOGY INC Synagis; MEDIMMUNE INC Synavant, Inc.; IMS HEALTH INC Synergy; UNITED THERAPEUTICS CORP SYNERmedica; KENDLE INTERNATIONAL INC Synomics, Ltd.; PHARMACOPEIA INC Synopsys Scientific Systems; PHARMACOPEIA INC Synovis Interventional Solutions; SYNOVIS LIFE TECHNOLOGIES INC Synthelabo S.A.; HUMAN GENOME SCIENCES INC Synvisc II; GENZYME BIOSURGERY Syracuse Research Center; ALBANY MOLECULAR RESEARCH T Cell Sciences; AVANT IMMUNOTHERAPEUTICS T2000; TARO PHARMACEUTICAL INDUSTRIES TA-CIN; XENOVA GROUP PLC TA-HPV; XENOVA GROUP PLC Taisho Pharmaceutical; NEUROCRINE BIOSCIENCES INC Taisho Pharmaceuticals; IDEC PHARMACEUTICALS CORP Takeda Chemical Industries, Ltd.; HUMAN GENOME SCIENCES INC Tamiflu; GILEAD SCIENCES INC Tamoxifen; BARR LABORATORIES INC Tanox Pharma; TANOX INC TAPET; VION PHARMACEUTICALS INC Tarceva; OSI PHARMACEUTICALS INC Targretin; LIGAND PHARMACEUTICALS INC Tariquidar; XENOVA GROUP PLC Tarka; KOS PHARMACEUTICALS INC Taro Pharmaceuticals U.S.A., Inc.; TARO PHARMACEUTICAL INDUSTRIES Taxotere; AVENTIS SA Taylor Pharmaceuticals, Inc.; AKORN INC Tazidime; ELI LILLY & CO TD Acquisition Corp.; IDEXX LABORATORIES INC Techne Export, Inc.; TECHNE CORP Techniclone Corp.; PEREGRINE PHARMACEUTICALS INC

TefGen Regenerative Membranes; LIFECORE BIOMEDICAL INC Teflon; E I DU PONT DE NEMOURS & CO Tegretol; CARACO PHARMACEUTICAL LABORATORIES TeleTrial; COVALENT GROUP INC Tempo; SHEFFIELD PHARMACEUTICALS Tempra FirsTabs; CIMA LABS INC Tenofovir DF; GILEAD SCIENCES INC TerraGen Discovery, Inc.; CUBIST PHARMACEUTICALS Terrapin Technolgies; TELIK INC Testskin II; ORGANOGENESIS INC Teva USA; TEVA PHARMACEUTICAL INDUSTRIES Texas Biotechnology Corporation; ICOS CORPORATION THALOMID; CELGENE CORP Theragenics Corporation; AMERSHAM PLC Therapeutic Discovery Corp.; ALZA CORP Therapy Guidance System; VIROLOGIC INC TheraSeed; THERAGENICS CORP TheraSeed; AMERSHAM PLC TheraTech, Inc.; WATSON PHARMACEUTICALS INC Theratope; BIOMIRA INC ThermalAce; DIVERSA CORPORATION Ther-RX Corporation; K V PHARMACEUTICAL CO Theseus Imaging Corp.; NORTH AMERICAN SCIENTIFIC Thiemann; CELLTECH GROUP PLC THIOPLEX; IMMUNEX CORP Thrombosol; LIFECELL CORPORATION Thrombospondin Technology; INKINE PHARMACEUTICAL CO Thymoglobulin; SANGSTAT MEDICAL CORP Thyrogen; GENZYME CORP Tiazac; FOREST LABORATORIES INC TIMERx; PENWEST PHARMACEUTICALS CO Tinactin; SCHERING-PLOUGH CORP Tip-Test Johne's; IMMUCELL CORPORATION Tissue-Guard; SYNOVIS LIFE TECHNOLOGIES INC TKT Europe-5S AB; TRANSKARYOTIC THERAPIES TLK17411; TELIK INC TLK199; TELIK INC TLK286; TELIK INC TNKase; GENENTECH INC TNT; PEREGRINE PHARMACEUTICALS INC TNX-100; TANOX INC TNX-224; TANOX INC TNX-355; TANOX INC TNX-901; TANOX INC Toagosei; PROTEIN DESIGN LABS INC TOCOSOL; SONUS PHARMACEUTICALS TOCOSOL Paclitaxel; SONUS PHARMACEUTICALS Toho Kagaku Kenkyusho Co., Ltd.; E-Z-EM INC




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Toleragens; LA JOLLA PHARMACEUTICAL Tolerance Technology; LA JOLLA PHARMACEUTICAL Tolserine; AXONYX INC TOPICORT; MEDICIS PHARMACEUTICAL CORP Topiglan; MACROCHEM CORPORATION Topiglan; MACROCHEM CORPORATION TOPO TA Cloning Kit; INVITROGEN CORPORATION Tosara Group; FOREST LABORATORIES INC Tostrelle; CELLEGY PHARMACEUTICALS Tostrex; CELLEGY PHARMACEUTICALS ToxExpress; GENE LOGIC INC ToxScreen Reports; GENE LOGIC INC ToxSuites; GENE LOGIC INC Tramadol; ABLE LABORATORIES TransCyte; ADVANCED TISSUE SCIENCES Transkaryotic Therapy; TRANSKARYOTIC THERAPIES Trans-Phage Technology; BIOSITE INC Trans-Phage Technology; MEDAREX INC TransQ; IOMED INC TRANZFECT; CYTRX CORPORATION TRAP Technology; TELIK INC Trega Biosciences; LION BIOSCIENCE AG Trexal; BARR LABORATORIES INC Triage BNP Test; BIOSITE INC Triage Drugs of Abuse Panel; BIOSITE INC Triage Meter; BIOSITE INC Triage TOX Drug Screen; BIOSITE INC TrialWare; KENDLE INTERNATIONAL INC TrialWeb; KENDLE INTERNATIONAL INC TrialWeb; KENDLE INTERNATIONAL INC Triaminic Softchews; CIMA LABS INC Triapine; VION PHARMACEUTICALS INC TRICORDER; IGEN INTERNATIONAL INC TriGem; TITAN PHARMACEUTICALS Tripos Receptor Research; TRIPOS INC TRISENOX; CELL THERAPEUTICS INC Trisequens; NOVO-NORDISK AS TriZetto Group, Inc., The; IMS HEALTH INC Trodulamine; GENAERA CORPORATION Troponin I; BOSTON LIFE SCIENCES INC Tularik GmbH; TULARIK INC Tularik Texas Corporation; TULARIK INC Tums; GLAXOSMITHLKINE PLC Tunable GeneReassembly; DIVERSA CORPORATION Tyco International; MALLINCKRODT INC Tylenol; JOHNSON & JOHNSON Tzamal Pharma; NAPRO BIOTHERAPEUTICS INC U.S. Bioscience, Inc.; MEDIMMUNE INC UAD Laboratories; FOREST LABORATORIES INC UCT, Inc.; ICON PLC UDL Laboratories, Inc.; MYLAN LABORATORIES INC

U-Gene Reasearch BV; KENDLE INTERNATIONAL INC UHTSS; PANVERA LLC UltiMab Hu man Antibody Development System; MEDAREX INC Unipeg; UNITED THERAPEUTICS CORP Uniprost; UNITED THERAPEUTICS CORP Unisense; UNITED THERAPEUTICS CORP Unither Pharmaceuticals, Inc.; UNITED THERAPEUTICS CORP Universal Gene Recognition; SANGAMO BIOSCIENCES INC Universal GeneTools; SANGAMO BIOSCIENCES INC Universal PLAS+SD; V I TECHNOLOGIES INC Universal Preservation Technologies, Inc.; AVANT IMMUNOTHERAPEUTICS UPDAS; SHEFFIELD PHARMACEUTICALS UPlink; ORASURE TECHNOLOGIES INC Ushercell; POLYDEX PHARMACEUTICALS Vaccine Saver; EMBREX INC Vagifem; NOVO-NORDISK AS Vancomycin; XECHEM INTERNATIONAL VANIQA; WOMEN FIRST HEALTHCARE Vaporizer; COLUMBIA LABORATORIES VARIAGENICS, Inc.; HYSEQ INC Varibar; E-Z-EM INC Vascugel; CURIS INC Vasofem; ZONAGEN INCORPORATED Vasomax; ZONAGEN INCORPORATED Vasotec; MERCK & CO INC Vaxcel, Inc.; CYTRX CORPORATION Vaxid; VICAL INC Vaxis Technologies; CELLEGY PHARMACEUTICALS Vector NTI Advance; INFORMAX INC Vector PathBlazer; INFORMAX INC Vector Xpression; INFORMAX INC Velogene; ID BIOMEDICAL CORPORATION Ventana Medical Systems; ACCUMED INTERNATIONAL Verdict; MEDTOX SCIENTIFIC INC Veritas Collagen Matrix; SYNOVIS LIFE TECHNOLOGIES INC Veritox; NEOGEN CORPORATION Versicor, Inc.; SEPRACOR INC Vertex Pharmaceuticals; PANVERA LLC VetConnect, Inc.; IDEXX LABORATORIES INC Veterinary Laboratories, Inc.; POLYDEX PHARMACEUTICALS VetLife; CYTRX CORPORATION Vetronics; BIOANALYTICAL SYSTEMS INC VetScan; ABAXIS INC VetTest; IDEXX LABORATORIES INC Vevesca; OXFORD GLYCOSCIENCES PLC Viagara; PFIZER INC Vibrilase; BIOMARIN PHARMACEUTICAL




INDEX OF SUBSIDIARIES, BRAND NAMES AND AFFILIATIONS, CONT. Vioxx; COLLAGENEX PHARMACEUTICAL Viracept; PFIZER INC Viragen International; VIRAGEN INC Viratrol; NEXMED INC Virbac Corp.; VIRBAC INC Virbagen Omega; VIRBAC INC ViroTex; ATRIX LABORATORIES INC Virtual HouseCall; COVALENT GROUP INC Virtual Library; NEUROGEN CORP Virtual Screening; NEUROGEN CORP Virulizin; LORUS THERAPEUTICS INC Virus Research Institute; AVANT IMMUNOTHERAPEUTICS Visicol; INKINE PHARMACEUTICAL CO Visudyne; QLT INC VITA Technology; CUBIST PHARMACEUTICALS Vitravene; ISIS PHARMACEUTICALS INC VitriLife; AVANT IMMUNOTHERAPEUTICS Vitrix; ORGANOGENESIS INC Vivelle; NOVEN PHARMACEUTICALS Vivelle -Dot; NOVEN PHARMACEUTICALS Vivitrex; ALKERMES INC VolSurf; TRIPOS INC Volt; DONLAR BIOSYNTREX VP14637; VIROPHARMA INC VSL#3; QUESTCOR PHARMACEUTICALS W3Commerce, LLC; SYNBIOTICS CORP Wash Gel 32; PROCYTE CORPORATION Watson Laboratories, Inc.; WATSON PHARMACEUTICALS INC Wedge, The; BIONX IMPLANTS INC Welchol; GELTEX PHARMACEUTICALS W ilcox Drug Company; HAUSER INC Windamere Venture Partners; PROTEIN POLYMER TECHNOLOGIES Wipe Out Dairy Wipes; IMMUCELL CORPORATION Witness Ehrlichia; SYNBIOTICS CORP Woehlk Contact Lens GmbH; BAUSCH & LOMB INC Women's Health U.S.A., Inc.; CURAGEN CORPORATION WoundCare.com; CARRINGTON LABORATORIES INC Wyeth; ELAN CORP PLC Xactin; AVI BIOPHARMA INC Xcyrin; PHARMACYCLICS INC Xechem Pharmaceutical China, Ltd.; XECHEM INTERNATIONAL Xenerex Biosciences; AVANIR PHARMACEUTICALS XenoMax; ABGENIX INC XenoMouse; ABGENIX INC XenoMune System; BIOTRANSPLANT INC XERECEPT; NEUROBIOLOGICAL TECHNOLOGIES INC XetaPharm; XECHEM INTERNATIONAL xMAP; LUMINEX CORPORATION Xolair; TANOX INC

Xopenex; SEPRACOR INC XTL Pharmaceuticals; AVI BIOPHARMA INC Xtra Amp Extraction System; XTRANA INC Xtra Bind; XTRANA INC XYOTAX; CELL THERAPEUTICS INC Xyrem; ORPHAN MEDICAL INC YRCR, Ltd.; ICON PLC Z3; COMPUGEN LTD Z4000; COMPUGEN LTD ZADAXIN; SCICLONE PHARMACEUTICALS Zantac; GLAXOSMITHLKINE PLC Zavesca; OXFORD GLYCOSCIENCES PLC Zeffix; SHIRE-BIOCHEM INC Zellera; AASTROM BIOSCIENCES INC Zema; VIRBAC INC Zenapax; PROTEIN DESIGN LABS INC Zeneca Group; ASTRAZENECA PLC Zero Blunt PCR Cloning Kit; INVITROGEN CORPORATION ZetaPharm, Inc.; HAUSER INC ZEVALIN; IDEC PHARMACEUTICALS CORP Zila Pharmaceuticals, Inc.; ZILA INC Zoloft; PFIZER INC Zomaril; TITAN PHARMACEUTICALS Zomig-ZMT; CIMA LABS INC Zonagen, Inc.; VIRAGEN INC Zonegran; ELAN CORP PLC ZooSeq Database; INCYTE GENOMICS INC Zproxal; ZONAGEN INCORPORATED Zymetrics, Inc; DIVERSA CORPORATION Zyrtec-D; PFIZER INC


Plunkett's Biotech & Genetics Industry Almanac 2003-2004 (Plunkett's Biotech & Genetics Industry Almanac)

Plunketts Airline Hotel and Travel Industry Almanac

Plunkett's Automobile Industry Almanac

Plunkett's Entertainment & Media Industry Almanac 2002-2003

Plunkett's Real Estate & Construction Industry Almanac 2011

Biotech: The Countercultural Origins of an Industry

Plunkett's Banking, Mortgages & Credit Industry Almanac 2009

Plunkett's Investment & Securities Industry Almanac 2010: The Only Comprehensive Guide to the Investment & Securities Industry (Plunkett's Investment and Securities Industry Almanac)

Plunkett's Retail Industry Almanac 1999-2000

Plunkett's Energy Industry Almanac 2010: Energy Industry Market Research, Statistics, Trends & Leading Companies

Plunkett's Energy Industry Almanac 2009: Energy Industry Market Research, Statistics, Trends & Leading Companies

Biochemisrty & Genetics

Genetics & Hearing Loss

Benford-Biotech

Biotech Industry: A Global, Economic, and Financing Overview

Biotech Industry: A Global, Economic, and Financing Overview

Plunkett's Entertainment & Media Industry Almanac 2000-2001: The Only Complete Guide to the Entertainment & Media Industry

Knowledge Accumulation and Industry Evolution - The Case of Pharma-Biotech

Genetic Engineering (Genetics & Evolution)

Plunkett's E-Commerce & Internet Business Almanac 2010: E-Commerce & Internet Business Industry Market Research, Statistics, Trends & Leading Companies ... E-Commerce and Internet Business Almanac)

Plunkett's Engineering and Research Industry Almanac, 2003-2004

Paint & Coatings Industry 2010,09

Paint & Coatings Industry 2010,04

Paint & Coatings Industry 2010,03

Paint & Coatings Industry 2010,06

Biotech And Nanodreams

Genetics & Hearing Loss (Genetics and Hearing Loss)

Plunkett's Renewable, Alternative & Hydrogen Energy Industry Almanac 2009: Renewable, Alternative & Hydrogen Energy Industry Market Research, Statistics, Trends & Leading Companies

Nutrition Almanac

Stock Trader's Almanac 2010 (Almanac Investor Series)

Stock Trader's Almanac 2011 (Almanac Investor Series)

Plunkett's Biotech & Genetics Industry Almanac 2003-2004 (Plunkett's Biotech & Genetics Industry Almanac)

Plunketts Airline Hotel and Travel Industry Almanac

Plunkett's Automobile Industry Almanac

Plunkett's Entertainment & Media Industry Almanac 2002-2003

Plunkett's Real Estate & Construction Industry Almanac 2011

Biotech: The Countercultural Origins of an Industry

Plunkett's Banking, Mortgages & Credit Industry Almanac 2009

Plunkett's Investment & Securities Industry Almanac 2010: The Only Comprehensive Guide to the Investment & Securities Industry (Plunkett's Investment and Securities Industry Almanac)

Plunkett's Retail Industry Almanac 1999-2000

Plunkett's Energy Industry Almanac 2010: Energy Industry Market Research, Statistics, Trends & Leading Companies

Plunkett's Energy Industry Almanac 2009: Energy Industry Market Research, Statistics, Trends & Leading Companies

Biochemisrty & Genetics

Genetics & Hearing Loss

Benford-Biotech

Biotech Industry: A Global, Economic, and Financing Overview

Biotech Industry: A Global, Economic, and Financing Overview

Plunkett's Entertainment & Media Industry Almanac 2000-2001: The Only Complete Guide to the Entertainment & Media Industry

Knowledge Accumulation and Industry Evolution - The Case of Pharma-Biotech

Genetic Engineering (Genetics & Evolution)

Plunkett's E-Commerce & Internet Business Almanac 2010: E-Commerce & Internet Business Industry Market Research, Statistics, Trends & Leading Companies ... E-Commerce and Internet Business Almanac)

Plunkett's Engineering and Research Industry Almanac, 2003-2004

Paint & Coatings Industry 2010,09

Paint & Coatings Industry 2010,04

Paint & Coatings Industry 2010,03

Paint & Coatings Industry 2010,06

Biotech And Nanodreams

Genetics & Hearing Loss (Genetics and Hearing Loss)

Plunkett's Renewable, Alternative & Hydrogen Energy Industry Almanac 2009: Renewable, Alternative & Hydrogen Energy Industry Market Research, Statistics, Trends & Leading Companies

Nutrition Almanac

Stock Trader's Almanac 2010 (Almanac Investor Series)

Stock Trader's Almanac 2011 (Almanac Investor Series)

Recommend Documents